FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Hamed, HA
Yacoub, A
Park, MA
Eulitt, PJ
Dash, R
Sarkar, D
Dmitriev, IP
Lesniak, MS
Shah, K
Grant, S
Curiel, DT
Fisher, PB
Dent, P
AF Hamed, Hossein A.
Yacoub, Adly
Park, Margaret A.
Eulitt, Patrick J.
Dash, Rupesh
Sarkar, Devanand
Dmitriev, Igor P.
Lesniak, Maciej S.
Shah, Khalid
Grant, Steven
Curiel, David T.
Fisher, Paul B.
Dent, Paul
TI Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery
Enhances mda-7/IL-24 Therapy of Malignant Glioma
SO MOLECULAR THERAPY
LA English
DT Article
ID CANCER-SPECIFIC APOPTOSIS; DIFFERENTIATION-ASSOCIATED GENE-7;
RENAL-CARCINOMA CELLS; HUMAN-MELANOMA CELLS; GLIOBLASTOMA CELLS;
BYSTANDER ACTIVITY; PANCREATIC-CANCER; MDA-7 EXPRESSION; SUPPRESSOR
GENE; PHASE-I
AB We have explored the mechanism by which inhibition of multiple cytoprotective cell-signaling pathways enhance melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) toxicity toward invasive primary human glioblastoma multiforme (GBM) cells, and whether improving adenoviral infectivity/delivery of mda-7/IL-24 enhances therapeutic outcome in animals containing orthotopic xenografted GBM cells. The toxicity of a serotype 5 recombinant adenovirus to express MDA-7/IL-24 (Ad.5-mda-7) was enhanced by combined molecular or small molecule inhibition of mitogen-activated extra-cellular regulated kinase (MEK) 1/2 and phosphatidyl inositol 3-kinase (PI3K) or AKT; inhibition of mammalian target of rapamycin (mTOR) and MEK1/2; and the HSP90 inhibitor 17AAG. Molecular inhibition of mTOR/PI3K/MEK1 signaling in vivo also enhanced Ad.5-mda-7 toxicity. In GBM cells of diverse genetic backgrounds, inhibition of cytoprotective cell-signaling pathways enhanced MDA-7/IL-24-induced autophagy, mitochondrial dysfunction and tumor cell death. Due partly to insufficient adenovirus serotype 5 gene delivery this therapeutic approach has shown limited success in GBM. To address this problem, we employed a recombinant adenovirus that comprises the tail and shaft domains of a serotype 5 virus and the knob domain of a serotype 3 virus expressing MDA-7/IL-24, Ad.5/3-mda-7. Ad.5/3-mda-7 more effectively infected and killed GBM cells in vitro and in vivo than Ad.5-mda-7. Future combinations of these approaches hold promise for developing an effective therapy for GBM.
C1 [Dent, Paul] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Massey Canc Ctr, Sch Med, Richmond, VA 23298 USA.
[Dash, Rupesh; Sarkar, Devanand; Fisher, Paul B.] Virginia Commonwealth Univ, Dept Human Mol Genet, Sch Med, Richmond, VA 23298 USA.
[Sarkar, Devanand; Grant, Steven; Fisher, Paul B.; Dent, Paul] Virginia Commonwealth Univ, VCU Inst Mol Med, Sch Med, Richmond, VA 23298 USA.
[Dmitriev, Igor P.; Curiel, David T.] Univ Alabama, Div Human Gene Therapy, Birmingham, AL USA.
[Lesniak, Maciej S.] Univ Chicago, Brain Tumor Ctr, Chicago, IL 60637 USA.
[Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA USA.
[Grant, Steven] Virginia Commonwealth Univ, Dept Med, Sch Med, Richmond, VA 23298 USA.
[Grant, Steven; Fisher, Paul B.; Dent, Paul] Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, Richmond, VA 23298 USA.
RP Dent, P (reprint author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Massey Canc Ctr, Sch Med, 401 Coll St,Box 980035, Richmond, VA 23298 USA.
EM pdent@vcu.edu
OI dash, rupesh/0000-0001-5740-7053
FU PHS [P01-CA104177, R01-CA108325, R01-DK52825, R01CA63753, R01CA77141,
R01-CA097318, R01-CA134721, P01-NS031492]; Jim Valvano "V" foundation;
Department of Defense [DAMD17-03-1-0262]; Leukemia Society of America
[640597]; Samuel Waxman Cancer Research Foundation (SWCRF)
FX Support for this study was provided to: P.D. from PHS grants
(P01-CA104177, R01-CA108325, R01-DK52825), The Jim Valvano "V"
foundation, and Department of Defense Award (DAMD17-03-1-0262); S. G.
from PHS grants (R01CA63753, R01CA77141) and a Leukemia Society of
America grant 640597; P. B. F. from PHS grants (P01-CA104177,
R01-CA097318, R01-CA134721, P01-NS031492), and the Samuel Waxman Cancer
Research Foundation (SWCRF); D. T. C. from PHS grant (P01-CA104177). P.
D. is The Universal Inc. Professor in Signal Transduction Research. D.
S. is a Harrison Scholar in Cancer Research in the Virginia Commonwealth
University (VCU) Massey Cancer Center, VCU, School of Medicine. P. B. F.
holds the Thelma Newmeyer Corman Chair in Cancer Research at the VCU
Massey Cancer Center, VCU, School of Medicine and an SWCRF Investigator.
NR 50
TC 29
Z9 29
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD JUN
PY 2010
VL 18
IS 6
BP 1130
EP 1142
DI 10.1038/mt.2010.29
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 607ZM
UT WOS:000278545800011
PM 20179672
ER
PT J
AU Lovera, JF
Frohman, E
Brown, TR
Bandari, D
Nguyen, L
Yadav, V
Stuve, O
Karman, J
Bogardus, K
Heimburger, G
Cua, L
Remingon, G
Fowler, J
Monahan, T
Kilcup, S
Courtney, Y
McAleenan, J
Butler, K
Wild, K
Whitham, R
Bourdette, D
AF Lovera, J. F.
Frohman, E.
Brown, T. R.
Bandari, D.
Nguyen, L.
Yadav, V.
Stuve, O.
Karman, J.
Bogardus, K.
Heimburger, G.
Cua, L.
Remingon, G.
Fowler, J.
Monahan, T.
Kilcup, S.
Courtney, Y.
McAleenan, J.
Butler, K.
Wild, K.
Whitham, R.
Bourdette, D.
TI Memantine for cognitive impairment in multiple sclerosis: a randomized
placebo-controlled trial
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE attention; cognition disorders; memantine; memory; multiple sclerosis;
neuropsychological tests; placebo; randomized controlled trial
ID NEUROPSYCHIATRIC INVENTORY; MS PATIENTS; GLUTAMATE; DONEPEZIL; MODERATE;
DISEASE; MEMORY; SCALE
AB Background: Memantine, an NMDA antagonist, is effective for moderate to severe Alzheimer's disease.
Objective: Determine whether memantine improves cognitive performance (CP) among subjects with multiple sclerosis (MS) and cognitive impairment (CI).
Methods: This double-blind, randomized, placebo-controlled trial (Clinicaltrials.gov NCT00300716) compared memantine 10 mg twice a day (4 week titration followed by 12 weeks on the highest tolerated dose) with placebo. The primary outcome was the change from baseline to exit on the Paced Auditory Serial Addition Test (PASAT) and the California Verbal Learning Test-II (CVLT-II) Long Delay Free Recall (LDFR). Secondary outcomes included additional neuropsychological tests; self-report measures of quality of life, fatigue, and depression; and family/caregiver reports of subjects' CI and neuropsychiatric symptoms.
Results: The differences between the groups on the change on the PASAT (placebo-memantine = 0.0 correct responses, 95% CI 3.4, 3.4; p = 0.9) and on CVLT-II LDFR (placebo-memantine = -0.6 words, 95% CI - 2.1, 0.8; p = 0.4) as well as on the other cognitive tests were not significant. Subjects on memantine had no serious adverse events (AEs) but had more fatigue and neurological AEs as well as, per family members' reports, less cognitive improvement and greater neuropsychiatric symptoms than subjects on placebo.
Conclusion: Memantine 10 mg twice a day does not improve CP in subjects with MS, ages 18-65, without major depression, who have subjective cognitive complaints and perform worse than one SD below the mean on the PASAT or on the California Verbal Learning Test-II (total recall or delayed free recall).
C1 [Lovera, J. F.] Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70003 USA.
[Frohman, E.; Stuve, O.; Remingon, G.; Fowler, J.] UT SW, Dallas, TX USA.
[Brown, T. R.; Monahan, T.; Kilcup, S.; Courtney, Y.; McAleenan, J.; Butler, K.] Evergreen Neurosci Inst & Med Ctr, Kirkland, WA USA.
[Bandari, D.; Cua, L.] Univ So Calif, Los Angeles, CA USA.
[Nguyen, L.; Yadav, V.; Karman, J.; Bogardus, K.; Heimburger, G.; Wild, K.; Whitham, R.; Bourdette, D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Whitham, R.; Bourdette, D.] Portland VA Med Ctr, Portland, OR USA.
RP Lovera, JF (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, RM 718,1542 Tulane Ave, New Orleans, LA 70003 USA.
EM jlover@lsuhsc.edu
FU Forest Laboratories
FX Special thanks to: Cynthia Morris, PhD for performing the randomization
and Debbie Griffith, RN, Stacey Moultrie, RN, Lynn Tylkalsky, John
Phillips for entering the data into the database. This study was
supported by an investigator-initiated grant from Forest Laboratories.
NR 27
TC 37
Z9 37
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
J9 MULT SCLER J
JI Mult. Scler. J.
PD JUN
PY 2010
VL 16
IS 6
BP 715
EP 723
DI 10.1177/1352458510367662
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 611OY
UT WOS:000278829800010
PM 20483885
ER
PT J
AU Hugos, CL
Copperman, LF
Fuller, BE
Yadav, V
Lovera, J
Bourdette, DN
AF Hugos, C. L.
Copperman, L. F.
Fuller, B. E.
Yadav, V.
Lovera, J.
Bourdette, D. N.
TI Clinical trial of a formal group fatigue program in multiple sclerosis
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE energy conservation; exercise; fatigue; guideline; multiple sclerosis;
quality of life; rehabilitation; self-efficacy; symptom management
ID RANDOMIZED CONTROLLED-TRIAL; ENERGY-CONSERVATION COURSE; SELF-EFFICACY;
IMPACT SCALE; VALIDATION; DISABILITY; THERAPY; MS
AB Fatigue: Take Control is a novel program to teach fatigue management to people with multiple sclerosis (MS) following recommendations in the Fatigue and Multiple Sclerosis guideline. Fatigue: Take Control includes six 2-hour group sessions with DVD viewing, discussion and homework and accompanying participant and leader workbooks. While many people have participated in Fatigue: Take Control programs, its efficacy has not been determined. The objective of this study was to determine whether participation in Fatigue: Take Control reduces fatigue and increases self-efficacy in people with MS. Thirty participants were randomly assigned to a group who immediately participated in the program (FTC) or a wait-list group (WL). The primary outcome was the Modified Fatigue Impact Scale (MFIS) and secondary outcomes were the Multiple Sclerosis Self-Efficacy Scale (MSSE) and the Fatigue Severity Scale (FSS). The MFIS was administered on 10 occasions. Other measures were administered on four occasions. A mixed model tested the effects using all observations. Compared with the WL, the FTC group had significantly more improvement on the MFIS [F(1, 269) = 7.079, p = 0.008] and the MSSE [F(1, 111) = 5.636, p = 0.019]. No significant effect was found for the FSS. Across all visits, fatigue was significantly lower and self-efficacy was significantly higher for the FTC group compared with the WL group. This pilot study demonstrated significant effects in fatigue and self-efficacy among subjects taking the Fatigue: Take Control program, suggesting that this comprehensive program based on the Fatigue and Multiple Sclerosis guideline may be beneficial in MS.
C1 [Hugos, C. L.] Oregon Hlth & Sci Univ, Dept Rehabil Serv, Dept Neurol, Portland, OR 97239 USA.
[Fuller, B. E.] Portland VA Med Ctr, Div Mental Hlth, Portland, OR USA.
[Lovera, J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA.
[Lovera, J.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA.
[Fuller, B. E.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
RP Hugos, CL (reprint author), Oregon Hlth & Sci Univ, Dept Rehabil Serv, Dept Neurol, 3303 SW Bond Ave,CH3T, Portland, OR 97239 USA.
EM hugosc@ohsu.edu
FU National MS Society Pilot [1327]; NIH [K23 AT003258, UL1 RR024140];
Department of Veterans Affairs
FX The PI would like to acknowledge Laura Mitchell, OTR, for her
contribution as the 'trained substitute' leading two of the Fatigue:
Take Control classes. This study was funded by National MS Society Pilot
Grant 1327 (CLH), NIH K23 AT003258 (VY), the Department of Veterans
Affairs (JL and DNB), Nancy Davis Center Without Walls, and Oregon
Clinical and Translational Research Institute (OCTRI) NIH UL1 RR024140.
NR 27
TC 23
Z9 23
U1 1
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
J9 MULT SCLER J
JI Mult. Scler. J.
PD JUN
PY 2010
VL 16
IS 6
BP 724
EP 732
DI 10.1177/1352458510364536
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 611OY
UT WOS:000278829800011
PM 20375125
ER
PT J
AU David, WS
Goyal, N
Henry, FP
Baldassari, LE
Redmond, RW
AF David, William S.
Goyal, Namita
Henry, Francis P.
Baldassari, Laura E.
Redmond, Robert W.
TI VALIDATION OF AN INCREMENTAL MOTOR UNIT NUMBER ESTIMATION TECHNIQUE IN
RABBITS
SO MUSCLE & NERVE
LA English
DT Article
DE histomorphometry; incremental stimulation; motor unit number estimation;
rabbit; summated single motor unit action potentials
ID AMYOTROPHIC-LATERAL-SCLEROSIS; MULTIPLE POINT STIMULATION;
CLINICAL-TRIAL; ALS; MUSCLE; REPRODUCIBILITY; MICE; MUNE; RELIABILITY;
SURVIVAL
AB Motor unit number estimation (MUNE) allows for quantitative assessment of functional motor units in a nerve. Several techniques have been applied to human studies. Although MUNE has been performed in animals to study neurological disorders, reproducibility has not been addressed. We analyzed the test-retest reproducibility of an incremental MUNE technique in rabbits and performed histological correlation. A peroneal MUNE was performed in 9 rabbits on two occasions separated by 30 days. MUNE was then performed on 18 rabbits prior to euthanize. A count of total fibers and a second count of large myelinated fibers were performed on nerve cross-sections. Test-retest reproducibility revealed an intraclass correlation coefficient (ICC) of 0.75. The average test-retest relative difference was 26.6%. Comparison of MUNE and histomorphometrical counts revealed a correlation coefficient (r) of 0.21 (total fiber counts) and 0.27 (large fibers). Although incremental MUNE has a high degree of reproducibility in rabbits, there is poor correlation with histological fiber counts. Muscle Nerve 41: 794-799, 2010
C1 [David, William S.; Goyal, Namita] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuromuscular Diagnost Ctr, Boston, MA 02114 USA.
[Henry, Francis P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Plast Surg Res Lab, Boston, MA 02114 USA.
[Henry, Francis P.; Redmond, Robert W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Baldassari, Laura E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Goyal, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuromuscular Diagnost Ctr, 165 Cambridge St,Suite 820, Boston, MA 02114 USA.
EM nagoyal@partners.org
OI Henry, Francis P./0000-0003-4170-7806
NR 29
TC 5
Z9 5
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0148-639X
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUN
PY 2010
VL 41
IS 6
BP 794
EP 799
DI 10.1002/mus.21590
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 604NI
UT WOS:000278285300010
PM 20169589
ER
PT J
AU Huang, LY
Terakawa, M
Zhiyentayev, T
Huang, YY
Sawayama, Y
Jahnke, A
Tegos, GP
Wharton, T
Hamblin, MR
AF Huang, Liyi
Terakawa, Mitsuhiro
Zhiyentayev, Timur
Huang, Ying-Ying
Sawayama, Yohei
Jahnke, Ashlee
Tegos, George P.
Wharton, Tim
Hamblin, Michael R.
TI Innovative cationic fullerenes as broad-spectrum light-activated
antimicrobials
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Photodynamic therapy; Functionalized fullerenes; Antimicrobial
photoinactivation; Quantitative structure-function relationships;
Broad-spectrum antimicrobials
ID GRAM-NEGATIVE BACTERIA; PHOTODYNAMIC THERAPY; PSEUDOMONAS-AERUGINOSA;
CANDIDA-ALBICANS; IN-VITRO; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI;
OUTER-MEMBRANE; INACTIVATION; C-60
AB Photodynamic inactivation is a rapidly developing antimicrobial technology that combines a nontoxic photoactivatable dye or photosensitizer in combination with harmless visible light of the correct wavelength to excite the dye to its reactive-triplet state that will then generate reactive oxygen species that are highly toxic to cells. Buckminsterfullerenes are closed-cage molecules entirely composed of sp2-hybridized carbon atoms, and although their main absorption is in the UV, they also absorb visible light and have a long-lived triplet state. When C-60 fullerene is derivatized with cationic functional groups it forms molecules that are more water-soluble and can mediate photodynamic therapy efficiently upon illumination; moreover, cationic fullerenes can selectively bind to microbial cells. In this report we describe the synthesis and characterization of several new cationic fullerenes. Their relative effectiveness as broad-spectrum antimicrobial photosensitizers against gram-positive and gram-negative bacteria, and a fungal yeast was determined by quantitative structure-function relationships.
From the Clinical Editor: Photodynamic inactivation (PDI) is a rapidly developing antimicrobial technology in which a non-toxic photoactivatable dye or photosensitizer is excited with harmless visible light to its reactive state, where it will generate highly toxic reactive oxygen species. Buckminsterfullerenes derivatized with cationic functional groups form molecules that are water-soluble and mediate PDI efficiently. These fullerenes can also selectively bind to microbial cells. Several new cationic fullerenes are presented in this paper, and their efficacy against Gram-positive, Gram-negative bacteria, and a fungal yeast is also demonstrated. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Huang, Liyi; Terakawa, Mitsuhiro; Zhiyentayev, Timur; Huang, Ying-Ying; Sawayama, Yohei; Tegos, George P.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Huang, Liyi; Huang, Ying-Ying; Tegos, George P.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Huang, Liyi] Guangxi Med Univ, Dept Infect Dis, Affiliated Coll & Hosp 1, Nanning, Peoples R China.
[Terakawa, Mitsuhiro] Keio Univ, Dept Elect & Elect Engn, Tokyo 108, Japan.
[Zhiyentayev, Timur] MIT, Dept Chem, Cambridge, MA 02139 USA.
[Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China.
[Sawayama, Yohei] Univ Tokyo, Grad Sch Engn, Tokyo 1138654, Japan.
[Jahnke, Ashlee; Wharton, Tim] Lynntech Inc, College Stn, TX USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
RI Tegos, George/C-8830-2011; Huang, Ying-ying/G-3153-2011; Terakawa,
Mitsuhiro/C-4912-2014;
OI Huang, Ying-ying/0000-0003-3066-6981; Hamblin,
Michael/0000-0001-6431-4605
FU National Institutes of Health [R44AI068400, R44CA103177, R01AI050875]
FX This work was supported by the National Institutes of Health (grants
R44AI068400 and R44CA103177 to T.W. and R01AI050875 to M.R.H.).
NR 48
TC 53
Z9 54
U1 1
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD JUN
PY 2010
VL 6
IS 3
BP 442
EP 452
DI 10.1016/j.nano.2009.10.005
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 603MY
UT WOS:000278213900006
PM 19914400
ER
PT J
AU Rodin, S
Domogatskaya, A
Strom, S
Hansson, EM
Chien, KR
Inzunza, J
Hovatta, O
Tryggvason, K
AF Rodin, Sergey
Domogatskaya, Anna
Strom, Susanne
Hansson, Emil M.
Chien, Kenneth R.
Inzunza, Jose
Hovatta, Outi
Tryggvason, Karl
TI Long-term self-renewal of human pluripotent stem cells on human
recombinant laminin-511
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID FEEDER CELLS; IN-VITRO; EXPRESSION; LINES; DERIVATION; CHAIN;
PURIFICATION; FIBROBLASTS; INTEGRIN; CULTURE
AB We describe a system for culturing human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells on a recombinant form of human laminin-511, a component of the natural hES cell niche. The system is devoid of animal products and feeder cells and contains only one undefined component, human albumin. The hES cells self-renewed with normal karyotype for at least 4 months (20 passages), after which the cells could produce teratomas containing cell lineages of all three germ layers. When plated on laminin-511 in small clumps, hES cells spread out in a monolayer, maintaining cellular homogeneity with approximately 97% OCT4-positive cells. Adhesion of hES cells was dependent on alpha 6 beta 1 integrin. The use of homogeneous monolayer hES or iPS cell cultures provides more controllable conditions for the design of differentiation methods. This xeno-free and feeder-free system may be useful for the development of cell lineages for therapeutic purposes.
C1 [Rodin, Sergey; Domogatskaya, Anna; Tryggvason, Karl] Karolinska Inst, Div Matrix Biol, Dept Med Biochem & Biophys, Stockholm, Sweden.
[Strom, Susanne; Hovatta, Outi] Karolinska Inst, Div Obstet & Gynecol, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.
[Strom, Susanne; Hovatta, Outi] Karolinska Univ Hosp, Stockholm, Sweden.
[Hansson, Emil M.; Chien, Kenneth R.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Chien, Kenneth R.] Dept Stem Cell & Regenerat Biol, Cambridge, MA USA.
[Inzunza, Jose] Karolinska Inst, Novum, Dept Biosci & Nutr, Huddinge, Sweden.
[Inzunza, Jose] Karolinska Hosp, S-10401 Stockholm, Sweden.
RP Tryggvason, K (reprint author), Karolinska Inst, Div Matrix Biol, Dept Med Biochem & Biophys, Stockholm, Sweden.
EM karl.tryggvason@ki.se
RI Domogatskaya, Anna/F-5794-2012;
OI Domogatskaya, Anna/0000-0002-6468-1963; Rodin,
Sergey/0000-0002-6954-1986
FU Knut and Alice Wallenberg Foundation; Novo Nordisk Foundation;
Soderberg's Foundation; Swedish Research Council; Swedish Cancer
Foundation; Harvard Stem Cell Institute; Leducq Foundation
FX We thank A.-S. Nilsson and A.-M. Stromberg for excellent technical
assistance, C. Cowan for collaboration in procuring the iPS cell lines,
F. Holm and R. Bergstrom for their help with the cell cultures and D.
Baker for carrying out karyotyping of hES cells. This work was supported
in part by grants from the Knut and Alice Wallenberg Foundation (K. T.),
the Novo Nordisk Foundation (K. T.), the Soderberg's Foundation (K. T.),
the Swedish Research Council (K. T., O.H.), the Swedish Cancer
Foundation (K. T.), the Harvard Stem Cell Institute (K. R. C.) and the
Leducq Foundation (K. R. C.). E. M. H. is a Wenner-Gren Foundation
fellow. EU: ESTOOLS (O.H.) has not been used for the derivation of new
hES cell lines.
NR 32
TC 234
Z9 239
U1 5
U2 46
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD JUN
PY 2010
VL 28
IS 6
BP 611
EP U102
DI 10.1038/nbt.1620
PG 7
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 611MS
UT WOS:000278820200026
PM 20512123
ER
PT J
AU Abu-Yousif, AO
Hett, EC
Skoczenski, AM
Hasan, T
AF Abu-Yousif, Adnan O.
Hett, Erik C.
Skoczenski, Ann M.
Hasan, Tayyaba
TI The ABC's of industry: a postdoc program provides a sneak peek into
industry careers
SO NATURE BIOTECHNOLOGY
LA English
DT Editorial Material
C1 [Abu-Yousif, Adnan O.; Hett, Erik C.; Skoczenski, Ann M.; Hasan, Tayyaba] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Abu-Yousif, AO (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM aabu-yousif@partners.org
NR 0
TC 1
Z9 1
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD JUN
PY 2010
VL 28
IS 6
BP 625
EP 626
PG 2
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 611MS
UT WOS:000278820200033
PM 20531344
ER
PT J
AU Castoreno, AB
Smurnyy, Y
Torres, AD
Vokes, MS
Jones, TR
Carpenter, AE
Eggert, US
AF Castoreno, Adam B.
Smurnyy, Yegor
Torres, Angelica D.
Vokes, Martha S.
Jones, Thouis R.
Carpenter, Anne E.
Eggert, Ulrike S.
TI Small molecules discovered in a pathway screen target the Rho pathway in
cytokinesis
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article
ID DROSOPHILA S2 CELLS; CONTRACTILE RING; MYOSIN-II; GTPASES; ANILLIN;
MICROTUBULES; PROTEIN; INHIBITOR; SPINDLE; COMPLEX
AB We report the discovery of small molecules that target the Rho pathway, which is a central regulator of cytokinesis-the final step in cell division. We have developed a way of targeting a small molecule screen toward a specific pathway, which should be widely applicable to the investigation of any signaling pathway. In a chemical genetic variant of a classical modifier screen, we used RNA interference (RNAi) to sensitize cells and identified small molecules that suppressed or enhanced the RNAi phenotype. We discovered promising candidate molecules, which we named Rhodblock 1-8, and we identified the target of Rhodblock 6 as Rho kinase. Several Rhodblocks inhibited one function of the Rho pathway in cells: the correct localization of phosphorylated myosin light chain during cytokinesis. Rhodblocks differentially perturb Rho pathway proteins in cells and can be used to dissect the mechanism of the Rho pathway during cytokinesis.
C1 [Castoreno, Adam B.; Smurnyy, Yegor; Torres, Angelica D.; Eggert, Ulrike S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Castoreno, Adam B.; Smurnyy, Yegor; Torres, Angelica D.; Eggert, Ulrike S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Vokes, Martha S.; Jones, Thouis R.; Carpenter, Anne E.] Broad Inst Harvard & MIT, Cambridge, MA USA.
RP Castoreno, AB (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM ulrike_eggert@dfci.harvard.edu
RI Carpenter, Anne/C-4982-2008
OI Carpenter, Anne/0000-0003-1555-8261
FU Life Sciences Research Foundation (Novartis); L'Oreal for Women in
Science; Society for Biomolecular Screening; US National Institutes of
Health (NIH) [5 RL1 CA133834-03]; NIH [R01 GM082834]; Claudia Adams Barr
Program; Dana-Farber Cancer Institute
FX We thank the staff at ICCB-Longwood, the Nikon Imaging Center at Harvard
Medical School and the Broad Institute's Imaging Platform for their
assistance and F. Roth for helpful discussions. We thank C. Field
(Harvard Medical School), R. Saint (Australian National University) and
E. Griffis (University of California, San Francisco) for reagents.
Funding for M.S.V., T.R.J. and A.E.C. was from the Life Sciences
Research Foundation (Novartis), L'Oreal for Women in Science, the
Society for Biomolecular Screening and the US National Institutes of
Health (NIH) 5 RL1 CA133834-03. A.B.C., Y.S., A.D.T. and U.S.E. were
supported by NIH grant R01 GM082834, the Claudia Adams Barr Program and
the Dana-Farber Cancer Institute.
NR 50
TC 31
Z9 31
U1 2
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1552-4450
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD JUN
PY 2010
VL 6
IS 6
BP 457
EP 463
DI 10.1038/nchembio.363
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 597HS
UT WOS:000277748100016
PM 20436488
ER
PT J
AU Stahl, EA
Raychaudhuri, S
Remmers, EF
Xie, G
Eyre, S
Thomson, BP
Li, YH
Kurreeman, FAS
Zhernakova, A
Hinks, A
Guiducci, C
Chen, R
Alfredsson, L
Amos, CI
Ardlie, KG
Barton, A
Bowes, J
Brouwer, E
Burtt, NP
Catanese, JJ
Coblyn, J
Coenen, MJH
Costenbader, KH
Criswell, LA
Crusius, JBA
Cui, J
de Bakker, PIW
De Jager, PL
Ding, B
Emery, P
Flynn, E
Harrison, P
Hocking, LJ
Huizinga, TWJ
Kastner, DL
Ke, XY
Lee, AT
Liu, XD
Martin, P
Morgan, AW
Padyukov, L
Posthumus, MD
Radstake, TRDJ
Reid, DM
Seielstad, M
Seldin, MF
Shadick, NA
Steer, S
Tak, PP
Thomson, W
van der Helm-van Mil, AHM
van der Horst-Bruinsma, IE
van der Schoot, CE
van Riel, PLCM
Weinblatt, ME
Wilson, AG
Wolbink, GJ
Wordsworth, BP
Wijmenga, C
Karlson, EW
Toes, REM
de Vries, N
Begovich, AB
Worthington, J
Siminovitch, KA
Gregersen, PK
Klareskog, L
Plenge, RM
AF Stahl, Eli A.
Raychaudhuri, Soumya
Remmers, Elaine F.
Xie, Gang
Eyre, Stephen
Thomson, Brian P.
Li, Yonghong
Kurreeman, Fina A. S.
Zhernakova, Alexandra
Hinks, Anne
Guiducci, Candace
Chen, Robert
Alfredsson, Lars
Amos, Christopher I.
Ardlie, Kristin G.
Barton, Anne
Bowes, John
Brouwer, Elisabeth
Burtt, Noel P.
Catanese, Joseph J.
Coblyn, Jonathan
Coenen, Marieke J. H.
Costenbader, Karen H.
Criswell, Lindsey A.
Crusius, J. Bart A.
Cui, Jing
de Bakker, Paul I. W.
De Jager, Philip L.
Ding, Bo
Emery, Paul
Flynn, Edward
Harrison, Pille
Hocking, Lynne J.
Huizinga, Tom W. J.
Kastner, Daniel L.
Ke, Xiayi
Lee, Annette T.
Liu, Xiangdong
Martin, Paul
Morgan, Ann W.
Padyukov, Leonid
Posthumus, Marcel D.
Radstake, Timothy R. D. J.
Reid, David M.
Seielstad, Mark
Seldin, Michael F.
Shadick, Nancy A.
Steer, Sophia
Tak, Paul P.
Thomson, Wendy
van der Helm-van Mil, Annette H. M.
van der Horst-Bruinsma, Irene E.
van der Schoot, C. Ellen
van Riel, Piet L. C. M.
Weinblatt, Michael E.
Wilson, Anthony G.
Wolbink, Gert Jan
Wordsworth, B. Paul
Wijmenga, Cisca
Karlson, Elizabeth W.
Toes, Rene E. M.
de Vries, Niek
Begovich, Ann B.
Worthington, Jane
Siminovitch, Katherine A.
Gregersen, Peter K.
Klareskog, Lars
Plenge, Robert M.
CA BIRAC Consortium
YEAR Consortium
TI Genome-wide association study meta-analysis identifies seven new
rheumatoid arthritis risk loci
SO NATURE GENETICS
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; SUSCEPTIBILITY LOCI; CELIAC-DISEASE;
VARIANTS; GENE; COMMON; REGION; POLYMORPHISMS; CONFIRMATION; REPLICATION
AB To identify new genetic risk factors for rheumatoid arthritis, we conducted a genome-wide association study meta-analysis of 5,539 autoantibody-positive individuals with rheumatoid arthritis (cases) and 20,169 controls of European descent, followed by replication in an independent set of 6,768 rheumatoid arthritis cases and 8,806 controls. Of 34 SNPs selected for replication, 7 new rheumatoid arthritis risk alleles were identified at genome-wide significance (P < 5 x 10(-8)) in an analysis of all 41,282 samples. The associated SNPs are near genes of known immune function, including IL6ST, SPRED2, RBPJ, CCR6, IRF5 and PXK. We also refined associations at two established rheumatoid arthritis risk loci (IL2RA and CCL21) and confirmed the association at AFF3. These new associations bring the total number of confirmed rheumatoid arthritis risk loci to 31 among individuals of European ancestry. An additional 11 SNPs replicated at P < 0.05, many of which are validated autoimmune risk alleles, suggesting that most represent genuine rheumatoid arthritis risk alleles.
C1 [Stahl, Eli A.; Raychaudhuri, Soumya; Kurreeman, Fina A. S.; Chen, Robert; Coblyn, Jonathan; Costenbader, Karen H.; Cui, Jing; Shadick, Nancy A.; Weinblatt, Michael E.; Karlson, Elizabeth W.; Plenge, Robert M.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA.
[Stahl, Eli A.; Raychaudhuri, Soumya; Thomson, Brian P.; Kurreeman, Fina A. S.; Guiducci, Candace; Ardlie, Kristin G.; Burtt, Noel P.; de Bakker, Paul I. W.; De Jager, Philip L.; Plenge, Robert M.] Broad Inst, Cambridge, MA USA.
[Raychaudhuri, Soumya] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Remmers, Elaine F.; Kastner, Daniel L.] NIAMSD, Genet & Genom Branch, US NIH, Bethesda, MD 20892 USA.
[Xie, Gang; Liu, Xiangdong; Siminovitch, Katherine A.] Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada.
[Xie, Gang; Liu, Xiangdong; Siminovitch, Katherine A.] Univ Hlth Network, Toronto, ON, Canada.
[Eyre, Stephen; Hinks, Anne; Barton, Anne; Bowes, John; Flynn, Edward; Ke, Xiayi; Martin, Paul; Thomson, Wendy; Worthington, Jane] Univ Manchester, Arthrit Res UK Epidemiol Unit, Manchester, Lancs, England.
[Li, Yonghong; Catanese, Joseph J.; Begovich, Ann B.] Celera, Alameda, CA USA.
[Kurreeman, Fina A. S.; Huizinga, Tom W. J.; van der Helm-van Mil, Annette H. M.; Toes, Rene E. M.] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands.
[Zhernakova, Alexandra; Wijmenga, Cisca] Univ Med Ctr Groningen, Dept Genet, NL-9713 AV Groningen, Netherlands.
[Zhernakova, Alexandra; Brouwer, Elisabeth; Posthumus, Marcel D.; Wijmenga, Cisca] Univ Groningen, Groningen, Netherlands.
[Alfredsson, Lars; Ding, Bo] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden.
[Amos, Christopher I.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Brouwer, Elisabeth; Posthumus, Marcel D.] Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, NL-9713 AV Groningen, Netherlands.
[Coenen, Marieke J. H.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
[Criswell, Lindsey A.] Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA USA.
[Crusius, J. Bart A.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Immunogenet Lab, Amsterdam, Netherlands.
[de Bakker, Paul I. W.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
[De Jager, Philip L.] Brigham & Womens Hosp, Ctr Neurol Dis, Dept Neurol, Boston, MA 02115 USA.
[Emery, Paul; Morgan, Ann W.] Univ Leeds, Leeds Inst Mol Med, Leeds Musculoskeletal Biomed Res Unit, Natl Inst Hlth Res, Leeds, W Yorkshire, England.
[Harrison, Pille; Wordsworth, B. Paul] Univ Oxford, Inst Musculoskeletal Sci, Botnar Res Ctr, Oxford, England.
[Hocking, Lynne J.; Reid, David M.] Univ Aberdeen, Div Appl Med, Musculoskeletal & Genet Sect, Aberdeen, Scotland.
[Lee, Annette T.; Gregersen, Peter K.] N Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA.
[Padyukov, Leonid; Klareskog, Lars] Karolinska Inst, Dept Med, Rheumatol Unit, Stockholm, Sweden.
[Padyukov, Leonid; Klareskog, Lars] Karolinska Univ Hosp Solna, Stockholm, Sweden.
[Radstake, Timothy R. D. J.; van Riel, Piet L. C. M.] Radboud Univ Nijmegen, Med Ctr, Dept Rheumatol, NL-6525 ED Nijmegen, Netherlands.
[Seielstad, Mark] Genome Inst Singapore, Singapore, Singapore.
[Seldin, Michael F.] Univ Calif Davis, Rowe Program Genet, Davis, CA 95616 USA.
[Steer, Sophia] Kings Coll Hosp Natl Hlth Serv Fdn Trust, Clin & Acad Rheumatol, London, England.
[van der Schoot, C. Ellen; Wolbink, Gert Jan] Univ Amsterdam, Acad Med Ctr, Sanquin Res Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands.
[van der Horst-Bruinsma, Irene E.] Vrije Univ Amsterdam, Univ Med Ctr, Dept Rheumatol, Amsterdam, Netherlands.
[Wilson, Anthony G.] Univ Sheffield, Sch Med & Biomed Sci, Sheffield, S Yorkshire, England.
[Wolbink, Gert Jan] Jan van Breemen Inst, Amsterdam, Netherlands.
[Begovich, Ann B.] Roche Diagnost, Pleasanton, CA USA.
RP Plenge, RM (reprint author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.
EM rplenge@partners.org
RI Worthington, Jane/M-9770-2014; Barton, Anne/N-2053-2014; Bowes,
John/B-3472-2015; Hinks, Anne/E-1853-2015; Brouwer,
Elisabeth/A-3198-2015; Coenen, Marieke/A-2159-2010; de Vries,
Niek/J-9348-2013; de Bakker, Paul/B-8730-2009; Wijmenga,
Cisca/D-2173-2009; Siminovitch, Katherine/K-1475-2013; Riel,
P.L.C.M./H-8082-2014;
OI Hocking, Lynne J/0000-0002-2414-2826; Alfredsson,
Lars/0000-0003-1688-6697; Seielstad, Mark/0000-0001-5783-1401; Martin,
Paul/0000-0002-1016-6851; Wijmenga, Cisca/0000-0002-5635-1614;
Klareskog, Lars/0000-0001-9601-6186; Thomson, Wendy/0000-0002-9022-5179;
Eyre, Stephen/0000-0002-1251-6974; Worthington,
Jane/0000-0003-0544-042X; Barton, Anne/0000-0003-3316-2527; Bowes,
John/0000-0003-4659-031X; Hinks, Anne/0000-0001-8843-3967; de Vries,
Niek/0000-0002-6257-8604; de Bakker, Paul/0000-0001-7735-7858;
Zhernakova, Alexandra/0000-0002-4574-0841; Padyukov,
Leonid/0000-0003-2950-5670
FU US National Institutes of Health (NIH) [R01-AR057108, R01-AR056768, U54
RR020278]; Fox Trot Fund; William Randolph Hearst Fund of Harvard
University; Burroughs Wellcome Fund; NIH [1K08AR055688-01A1,
NO1-AR-2-2263, RO1 AR44422, R01 AI065841, 5-M01-RR-00079, P01 CA87969,
CA49449, CA67262, CA50385, AR049880-06, AR47782]; American College of
Rheumatology Bridge Grant; EMBO-UNESCO L'Oreal Fellowship; National
Center for Research Resources [U54 RR020278]; Crescendo; Swedish Medical
Research council; Swedish Council for Working Life and Social Research;
Swedish Rheumatism Foundation; Vinnova; AFA; National Institute of
Arthritis; Musculoskeletal and Skin Diseases of the US National
Institutes of Health; Canadian Institutes for Health Research [MOP79321,
IIN-84042]; Ontario Research Fund [RE01061]; Canada Research Chair;
Arthritis Research campaign arc [17552]; Manchester Biomedical Research
Centre; Manchester Academy of Health Sciences; Netherlands Organization
for Scientific Research (VICI) [918.66.620]; Existing Epidemiological
Data (STAMPEED) genomics research program [R01HL087676]; National Center
for Research Resources; Biogen-Idec; King Gustaf V's 80-year foundation;
US National Institutes of Health and National Heart, Lung, and Blood
Institute; Stockholm County Council
FX R. M. P. is supported by grants from the US National Institutes of
Health (NIH) (R01-AR057108, R01-AR056768 and U54 RR020278), a private
donation from the Fox Trot Fund, the William Randolph Hearst Fund of
Harvard University, the American College of Rheumatology 'Within Our
Reach' campaign and a Career Award for Medical Scientists from the
Burroughs Wellcome Fund. S. R. is supported by an NIH Career Development
Award (1K08AR055688-01A1) and an American College of Rheumatology Bridge
Grant. F. A. S. K. is supported by an EMBO-UNESCO L'Oreal Fellowship.
The Broad Institute Center for Genotyping and Analysis is supported by
grant U54 RR020278 from the National Center for Research Resources. The
BRASS Registry is supported by a grant from Crescendo and Biogen-Idec.
EIRA is supported by grants from the Swedish Medical Research council,
the Swedish Council for Working Life and Social Research, King Gustaf
V's 80-year foundation, the Swedish Rheumatism Foundation, Stockholm
County Council, from Vinnova and the insurance company AFA. NARAC is
supported by the NIH (NO1-AR-2-2263 and RO1 AR44422). L. A. C. is
supported by the NIH (R01 AI065841 and). The Nurses Health Study is
supported by NIH grants P01 CA87969, CA49449, CA67262, CA50385,
AR049880-06 and AR47782. This research was also supported in part by the
Intramural Research Program of the National Institute of Arthritis,
Musculoskeletal and Skin Diseases of the US National Institutes of
Health. This research was also supported in part by grants to K. A. S.
from the Canadian Institutes for Health Research (MOP79321 and
IIN-84042) and the Ontario Research Fund (RE01061) and by a Canada
Research Chair. Genotyping of United Kingdom Rheumatoid Arthritis
Genetics samples was supported by the Arthritis Research campaign arc
grant reference number 17552 and by the Manchester Biomedical Research
Centre and Manchester Academy of Health Sciences. C. W. was funded by
the Netherlands Organization for Scientific Research (VICI grant
918.66.620). We acknowledge the help of B. A. C. Dijkmans, D. van
Schaardenburg, A. Salvador Pena, P. L. Klarenbeek, Z. Zhang, M. T.
Nurmohamed, W. F. Lems, R.R.J. van de Stadt, W. H. Bos, J. Ursum, M. G.
M. Bartelds, D. M. Gerlag, M. G. H. van der Sande, C. A. Wijbrandts and
M. M. J. Herenius in gathering Genetics Network Rheumatology Amsterdam
subject samples and data. We thank the Myocardial Infarction Genetics
Consortium (MIGen) study for the use of genotype data from their healthy
controls in our study. The MIGen study was funded by the US National
Institutes of Health and National Heart, Lung, and Blood Institute's SNP
Typing for Association with Multiple Phenotypes from Existing
Epidemiological Data (STAMPEED) genomics research program R01HL087676
and a grant from the National Center for Research Resources. We thank J.
Seddon, Progression of AMD Study, Age-Related Macular Degeneration (AMD)
Registry Study, Family Study of AMD, The US Twin Study of AMD and the
Age-Related Eye Disease Study (AREDS) for use of genotype data from
their healthy controls in our study. We thank D. Hafler and the Multiple
Sclerosis Collaborative for use of genotype data from their healthy
controls recruited at Brigham and Women's Hospital.
NR 57
TC 600
Z9 609
U1 5
U2 69
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2010
VL 42
IS 6
BP 508
EP U56
DI 10.1038/ng.582
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 601RN
UT WOS:000278081500016
PM 20453842
ER
PT J
AU Colvin, RA
Means, TK
Diefenbach, TJ
Moita, LF
Friday, RP
Sever, S
Campanella, GSV
Abrazinski, T
Manice, LA
Moita, C
Andrews, NW
Wu, DQ
Hacohen, N
Luster, AD
AF Colvin, Richard A.
Means, Terry K.
Diefenbach, Thomas J.
Moita, Luis F.
Friday, Robert P.
Sever, Sanja
Campanella, Gabriele S. V.
Abrazinski, Tabitha
Manice, Lindsay A.
Moita, Catarina
Andrews, Norma W.
Wu, Dianqing
Hacohen, Nir
Luster, Andrew D.
TI Synaptotagmin-mediated vesicle fusion regulates cell migration
SO NATURE IMMUNOLOGY
LA English
DT Article
ID CHEMOKINE RECEPTOR CXCR4; LENTIVIRAL RNAI LIBRARY; MYOSIN HEAVY-CHAIN;
PHOSPHOINOSITIDE-3 KINASE; SIGNAL-TRANSDUCTION; NEUTROPHIL FUNCTION;
LEADING LAMELLA; PLASMA-MEMBRANE; CHEMOTAXIS; FIBROBLASTS
AB Chemokines and other chemoattractants direct leukocyte migration and are essential for the development and delivery of immune and inflammatory responses. To probe the molecular mechanisms that underlie chemoattractant-guided migration, we did an RNA-mediated interference screen that identified several members of the synaptotagmin family of calcium-sensing vesicle-fusion proteins as mediators of cell migration: SYT7 and SYTL5 were positive regulators of chemotaxis, whereas SYT2 was a negative regulator of chemotaxis. SYT7-deficient leukocytes showed less migration in vitro and in a gout model in vivo. Chemoattractant-induced calcium-dependent lysosomal fusion was impaired in SYT7-deficient neutrophils. In a chemokine gradient, SYT7-deficient lymphocytes accumulated lysosomes in their uropods and had impaired uropod release. Our data identify a molecular pathway required for chemotaxis that links chemoattractant-induced calcium flux to exocytosis and uropod release.
C1 [Colvin, Richard A.; Means, Terry K.; Moita, Luis F.; Friday, Robert P.; Campanella, Gabriele S. V.; Abrazinski, Tabitha; Manice, Lindsay A.; Moita, Catarina; Hacohen, Nir; Luster, Andrew D.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
[Colvin, Richard A.; Means, Terry K.; Moita, Luis F.; Friday, Robert P.; Campanella, Gabriele S. V.; Abrazinski, Tabitha; Manice, Lindsay A.; Moita, Catarina; Hacohen, Nir; Luster, Andrew D.] Harvard Univ, Sch Med, Boston, MA USA.
[Diefenbach, Thomas J.] MIT, Ragon Inst MGH, Boston, MA USA.
[Moita, Luis F.; Moita, Catarina] Univ Lisbon, Fac Med, Inst Mol Med, Cell Biol Immune Syst Unit, P-1699 Lisbon, Portugal.
[Sever, Sanja] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
[Andrews, Norma W.] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.
[Wu, Dianqing] Yale Univ, Sch Med, New Haven, CT USA.
[Hacohen, Nir] Broad Inst, Cambridge, MA USA.
RP Luster, AD (reprint author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
EM aluster@mgh.harvard.edu
RI Moita, Luis/L-1296-2013;
OI Moita, Luis/0000-0003-0707-315X; Ferreira Moita,
Catarina/0000-0002-9910-2343
FU US National Institutes of Health [R01 DK074449, R01 GM064625]; Defense
Advanced Research Projects Agency [W81XWH-04-C-0139]; Fundacao
Luso-Americana para o Desenvolvimento; Fundacao para a Ciencia e a
Tecnologia
FX We thank the Immune Circuits and RNAi Platform groups of the Broad
Institute and W. Xu for discussions and the Imaging Core of the Ragon
Institute of MGH, MIT and Harvard. Supported by the US National
Institutes of Health (R01 DK074449 to A. D. L. and R01 GM064625 to
N.W.A.), the Defense Advanced Research Projects Agency (W81XWH-04-C-0139
to N.H.), Fundacao Luso-Americana para o Desenvolvimento (L. F. M.) and
Fundacao para a Ciencia e a Tecnologia (L. F. M.).
NR 59
TC 51
Z9 52
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JUN
PY 2010
VL 11
IS 6
BP 495
EP U60
DI 10.1038/ni.1878
PG 10
WC Immunology
SC Immunology
GA 598FV
UT WOS:000277821300010
PM 20473299
ER
PT J
AU Fan, ZG
Spencer, JA
Lu, Y
Pitsillides, CM
Singh, G
Kim, P
Yun, SH
Toxavidis, V
Strom, TB
Lin, CP
Koulmanda, M
AF Fan, Zhigang
Spencer, Joel A.
Lu, Yan
Pitsillides, Costas M.
Singh, Gurbakhshish
Kim, Pilhan
Yun, Seok H.
Toxavidis, Vasilis
Strom, Terry B.
Lin, Charles P.
Koulmanda, Maria
TI In vivo tracking of 'color-coded' effector, natural and induced
regulatory T cells in the allograft response
SO NATURE MEDICINE
LA English
DT Article
ID TRANSPLANTATION TOLERANCE; INDUCTION; REJECTION; GENERATION; AUTOIMMUNE;
APOPTOSIS; BALANCE; FOXP3
AB Here we present methods to longitudinally track islet allograft-infiltrating T cells in live mice by endoscopic confocal microscopy and to analyze circulating T cells by in vivo flow cytometry. We developed a new reporter mouse whose T cell subsets express distinct, 'color-coded' proteins enabling in vivo detection and identification of effector T cells (T(eff) cells) and discrimination between natural and induced regulatory T cells (nT(reg) and iT(reg) cells). Using these tools, we observed marked differences in the T cell response in recipients receiving tolerance-inducing therapy (CD154-specific monoclonal antibody plus rapamycin) compared to untreated controls. These results establish real-time cell tracking as a powerful means to probe the dynamic cellular interplay mediating immunologic rejection or transplant tolerance.
C1 [Fan, Zhigang; Lu, Yan; Singh, Gurbakhshish; Toxavidis, Vasilis; Strom, Terry B.; Koulmanda, Maria] Harvard Univ, Beth Israel Deaconess Med Ctr, Transplant Inst, Sch Med, Boston, MA 02215 USA.
[Spencer, Joel A.; Pitsillides, Costas M.; Lin, Charles P.] Harvard Univ, Sch Med, Adv Microscopy Program, Ctr Syst Biol, Boston, MA 02215 USA.
[Spencer, Joel A.] Tufts Univ, Dept Biomed Engn, Ctr Sci & Technol, Medford, MA 02155 USA.
[Pitsillides, Costas M.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
[Kim, Pilhan; Yun, Seok H.] Harvard Univ, Sch Med,Adv Microscopy Program, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02215 USA.
RP Strom, TB (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Transplant Inst, Sch Med, Boston, MA 02215 USA.
EM tstrom@bidmc.harvard.edu; lin@helix.mgh.harvard.edu
RI Kim, Pilhan/C-1836-2011; Spencer, Joel/A-4590-2013
OI Kim, Pilhan/0000-0001-8388-1840;
FU US National Institutes of Health [R21 AI081010, R01 EY14106,
P01-AI041521, P01-AI041521-S1]; Juvenile Diabetes Research Foundation
(JDRF) [7-2005-1329]
FX This work was supported by grants from the US National Institutes of
Health (R21 AI081010 to S.H.Y. and R01 EY14106 to C.P.L. and
P01-AI041521 and P01-AI041521-S1 to T.B.S.) and the Juvenile Diabetes
Research Foundation (JDRF 7-2005-1329 to T.B.S. and M.K.).
NR 29
TC 82
Z9 85
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2010
VL 16
IS 6
BP 718
EP U125
DI 10.1038/nm.2155
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 606BA
UT WOS:000278394200040
PM 20495571
ER
PT J
AU Tseng, YH
Cypess, AM
Kahn, CR
AF Tseng, Yu-Hua
Cypess, Aaron M.
Kahn, C. Ronald
TI Cellular bioenergetics as a target for obesity therapy
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Review
ID BROWN ADIPOSE-TISSUE; DIET-INDUCED OBESITY; BONE MORPHOGENETIC
PROTEIN-7; BETA(3)-ADRENERGIC RECEPTOR AGONIST; NONEXERCISE ACTIVITY
THERMOGENESIS; MITOCHONDRIAL UNCOUPLING PROTEIN; PLACEBO-CONTROLLED
TRIAL; PPAR-GAMMA ACTIVATION; HUMAN SKELETAL-MUSCLE; GROWTH-FACTOR-BETA
AB Obesity develops when energy intake exceeds energy expenditure. Although most current obesity therapies are focused on reducing calorific intake, recent data suggest that increasing cellular energy expenditure (bioenergetics) may be an attractive alternative approach. This is especially true for adaptive thermogenesis - the physiological process whereby energy is dissipated in mitochondria of brown fat and skeletal muscle in the form of heat in response to external stimuli. There have been significant recent advances in identifying the factors that control the development and function of these tissues, and in techniques to measure brown fat in human adults. In this article, we integrate these developments in relation to the classical understandings of cellular bioenergetics to explore the potential for developing novel anti-obesity therapies that target cellular energy expenditure.
C1 [Tseng, Yu-Hua; Cypess, Aaron M.; Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Tseng, YH (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM yu-hua.tseng@joslin.harvard.edu; c.ronald.kahn@joslin.harvard.edu
FU National Institutes of Health (NIH) [DK077097, DK082659, DK046200,
DK081604, RR025757]; National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) [P30 DK036836]; Harvard Stem Cell Institute;
Harvard Catalyst/Harvard Clinical and Translational Science Center
[RR025758]
FX We thank L. J. Goodyear for critical reading of the manuscript. This
work was supported in part by National Institutes of Health (NIH) grants
DK077097 (to Y.-H.T.); DK082659 (to C. R. K); and DK046200, DK081604 and
RR025757 (to A. M. C.). And grants to the Joslin Diabetes Center's
Diabetes and Endocrinology Research Center (P30 DK036836 from the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK)). Work was also supported by funding from the Harvard Stem Cell
Institute (to Y.-H.T.); the Harvard Catalyst/Harvard Clinical and
Translational Science Center, RR025758 (to Y.-H.T. and A. M. C.). The
content herein is solely the responsibility of the authors and does not
necessarily represent the official views of the NIDDK or the NIH.
NR 204
TC 202
Z9 212
U1 4
U2 37
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD JUN
PY 2010
VL 9
IS 6
BP 465
EP 481
DI 10.1038/nrd3138
PG 17
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA 603KQ
UT WOS:000278207900023
PM 20514071
ER
PT J
AU Faustman, D
Davis, M
AF Faustman, Denise
Davis, Miriam
TI TNF receptor 2 pathway: drug target for autoimmune diseases
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Review
ID TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
NONOBESE DIABETIC MICE; MONOCLONAL-ANTIBODY HOKT3-GAMMA-1(ALA-ALA);
MAJOR HISTOCOMPATIBILITY COMPLEX; INFLAMMATORY-BOWEL-DISEASE;
ALPHA-INDUCED APOPTOSIS; SIGNALS CELL-DEATH; CD8+ T-CELLS
AB Although drug development has advanced for autoimmune diseases, many current therapies are hampered by adverse effects and the frequent destruction or inactivation of healthy cells in addition to pathological cells. Targeted autoimmune therapies capable of eradicating the rare autoreactive immune cells that are responsible for the attack on the body's own cells are yet to be identified. This Review presents a new emerging approach aimed at selectively destroying autoreactive immune cells by specific activation of tumour necrosis factor receptor 2 (TNFR2), which is found on autoreactive and normal T lymphocytes, with the potential of avoiding or reducing the toxicity observed with existing therapies.
C1 [Faustman, Denise] Massachusetts Gen Hosp, Immunobiol Lab, Charlestown, MA 02129 USA.
Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Faustman, D (reprint author), Massachusetts Gen Hosp, Immunobiol Lab, Room 3602,Bldg 149,13th St, Charlestown, MA 02129 USA.
EM faustman@helix.mgh.harvard.edu
FU Iacocca Foundation
FX We would like to thank the Iacocca Foundation for supporting this work.
NR 147
TC 143
Z9 148
U1 3
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD JUN
PY 2010
VL 9
IS 6
BP 482
EP 493
DI 10.1038/nrd3030
PG 12
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA 603KQ
UT WOS:000278207900024
PM 20489699
ER
PT J
AU Jessen, N
Goodyear, LJ
AF Jessen, Niels
Goodyear, Laurie J.
TI DIABETES Exercise and type 2 diabetes mellitus-good for body and mind?
SO NATURE REVIEWS ENDOCRINOLOGY
LA English
DT Editorial Material
ID HEALTH
C1 [Goodyear, Laurie J.] Harvard Univ, Sch Med, Sect Integrat Physiol & Metab, Joslin Diabet Ctr, Boston, MA 02215 USA.
[Jessen, Niels] Aarhus Univ Hosp, Dept Clin Pharmacol, DK-8000 Aarhus, Denmark.
RP Goodyear, LJ (reprint author), Harvard Univ, Sch Med, Sect Integrat Physiol & Metab, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM laurie.goodyear@joslin.harvard.edu
RI Jessen, Niels/E-1731-2011;
OI Jessen, Niels/0000-0001-5613-7274
NR 9
TC 2
Z9 3
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5029
J9 NAT REV ENDOCRINOL
JI Nat. Rev. Endocrinol.
PD JUN
PY 2010
VL 6
IS 6
BP 303
EP 304
DI 10.1038/nrendo.2010.47
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 601RM
UT WOS:000278081400002
PM 20502463
ER
PT J
AU Almandoz, JED
Yoo, AJ
Stone, MJ
Schaefer, PW
Goldstein, JN
Rosand, J
Oleinik, A
Lev, MH
Gonzalez, RG
Romero, JM
AF Almandoz, Josser E. Delgado
Yoo, Albert J.
Stone, Michael J.
Schaefer, Pamela W.
Goldstein, Joshua N.
Rosand, Jonathan
Oleinik, Alexandra
Lev, Michael H.
Gonzalez, R. Gilberto
Romero, Javier M.
TI Extended analysis of the spot sign score's performance
SO NATURE REVIEWS NEUROLOGY
LA English
DT Letter
ID PRIMARY INTRACEREBRAL HEMORRHAGE; PREDICTS HEMATOMA EXPANSION; CONTRAST
EXTRAVASATION; HIGHEST RISK; IDENTIFIES PATIENTS; MORTALITY
C1 [Almandoz, Josser E. Delgado] Washington Univ, Div Neuroradiol, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA.
[Yoo, Albert J.; Stone, Michael J.; Schaefer, Pamela W.; Lev, Michael H.; Gonzalez, R. Gilberto; Romero, Javier M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neuroradiol,Dept Radiol, Boston, MA 02114 USA.
[Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02114 USA.
[Rosand, Jonathan; Oleinik, Alexandra] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA.
RP Almandoz, JED (reprint author), Washington Univ, Div Neuroradiol, Mallinckrodt Inst Radiol, Campus Box 8131,510 S Kingshighway Blvd, St Louis, MO 63110 USA.
EM delgadoj@mir.wustl.edu
RI Goldstein, Joshua/H-8953-2016
NR 10
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4758
J9 NAT REV NEUROL
JI Nat. Rev. Neurol.
PD JUN
PY 2010
VL 6
IS 6
BP 1
EP 1
DI 10.1038/nrneurol.2009.152-c1
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 608NK
UT WOS:000278590800011
ER
PT J
AU Khurana, V
Lindquist, S
AF Khurana, Vikram
Lindquist, Susan
TI OPINION Modelling neurodegeneration in Saccharomyces cerevisiae: why
cook with baker's yeast?
SO NATURE REVIEWS NEUROSCIENCE
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; ALPHA-SYNUCLEIN TOXICITY; PRPSC-LIKE
CONFORMATION; POLYGLUTAMINE AGGREGATION; HUNTINGTONS-DISEASE;
PARKINSONS-DISEASE; CELLULAR TOXICITY; EXPANDED POLYGLUTAMINE; MUTANT
HUNTINGTIN; TRANSGENIC MOUSE
AB In ageing populations, neurodegenerative diseases increase in prevalence, exacting an enormous toll on individuals and their communities. Multiple complementary experimental approaches are needed to elucidate the mechanisms underlying these complex diseases and to develop novel therapeutics. Here, we describe why the budding yeast Saccharomyces cerevisiae has a unique role in the neurodegeneration armamentarium. As the best-understood and most readily analysed eukaryotic organism, S. cerevisiae is delivering mechanistic insights into cell-autonomous mechanisms of neurodegeneration at an interactome-wide scale.
C1 [Khurana, Vikram; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Lindquist, Susan] MIT, Dept Biol, Cambridge, MA USA.
[Lindquist, Susan] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Khurana, Vikram] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Khurana, Vikram] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA.
RP Lindquist, S (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
EM lindquist_admin@wi.mit.edu
FU HHMI; US National Institutes of Health [NS038372]; Whitehead Institute
Regenerative Biology Initiative
FX We thank members of the Lindquist laboratory for their insightful
comments on the manuscript, and particularly E. Nabieva for her
assistance in the preparation of Table 2. S. L. is an Investigator at
the Howard Hughes Medical Institute (HHMI). This work was supported by
an HHMI Collaborative Innovation Award, US National Institutes of Health
Udall program grant NS038372, and the Whitehead Institute Regenerative
Biology Initiative.
NR 92
TC 83
Z9 85
U1 2
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-0048
J9 NAT REV NEUROSCI
JI Nat. Rev. Neurosci.
PD JUN
PY 2010
VL 11
IS 6
BP 436
EP 449
DI 10.1038/nrn2809
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 598ZN
UT WOS:000277879400013
PM 20424620
ER
PT J
AU Bouwman, P
Aly, A
Escandell, JM
Pieterse, M
Bartkova, J
van der Gulden, H
Hiddingh, S
Thanasoula, M
Kulkarni, A
Yang, QF
Haffty, BG
Tommiska, J
Blomqvist, C
Drapkin, R
Adams, DJ
Nevanlinna, H
Bartek, J
Tarsounas, M
Ganesan, S
Jonkers, J
AF Bouwman, Peter
Aly, Amal
Escandell, Jose M.
Pieterse, Mark
Bartkova, Jirina
van der Gulden, Hanneke
Hiddingh, Sanne
Thanasoula, Maria
Kulkarni, Atul
Yang, Qifeng
Haffty, Bruce G.
Tommiska, Johanna
Blomqvist, Carl
Drapkin, Ronny
Adams, David J.
Nevanlinna, Heli
Bartek, Jiri
Tarsounas, Madalena
Ganesan, Shridar
Jonkers, Jos
TI 53BP1 loss rescues BRCA1 deficiency and is associated with
triple-negative and BRCA-mutated breast cancers
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID CONDITIONAL MOUSE MODEL; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE;
TUMOR-SUPPRESSOR; MAMMARY-TUMORS; CELL-CYCLE; GENOMIC INSTABILITY;
OVARIAN-CANCER; STEM-CELLS; GENE BRCA1
AB Germ-line mutations in breast cancer 1, early onset (BRCA1) result in predisposition to breast and ovarian cancer. BRCA1-mutated tumors show genomic instability, mainly as a consequence of impaired recombinatorial DNA repair. Here we identify p53-binding protein 1 (53BP1) as an essential factor for sustaining the growth arrest induced by Brca1 deletion. Depletion of 53BP1 abrogates the ATM-dependent checkpoint response and G2 cell-cycle arrest triggered by the accumulation of DNA breaks in Brca1-deleted cells. This effect of 53BP1 is specific to BRCA1 function, as 53BP1 depletion did not alleviate proliferation arrest or checkpoint responses in Brca2-deleted cells. Notably, loss of 53BP1 partially restores the homologous-recombination defect of Brca1-deleted cells and reverts their hypersensitivity to DNA-damaging agents. We find reduced 53BP1 expression in subsets of sporadic triple-negative and BRCA-associated breast cancers, indicating the potential clinical implications of our findings.
C1 [Bouwman, Peter; Pieterse, Mark; van der Gulden, Hanneke; Hiddingh, Sanne; Jonkers, Jos] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands.
[Aly, Amal; Kulkarni, Atul; Yang, Qifeng; Haffty, Bruce G.; Ganesan, Shridar] Canc Inst New Jersey, New Brunswick, NJ USA.
[Escandell, Jose M.; Thanasoula, Maria; Tarsounas, Madalena] Canc Res UK MRC Gray Inst Radiat Oncol & Biol, Telomere & Genome Stabil Grp, Oxford, England.
[Bartkova, Jirina; Bartek, Jiri] Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark.
[Bartkova, Jirina; Bartek, Jiri] Danish Canc Soc, Ctr Genotox Stress Res, Copenhagen, Denmark.
[Tommiska, Johanna; Nevanlinna, Heli] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland.
[Blomqvist, Carl] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland.
[Drapkin, Ronny] Dana Farber Canc Inst, Dept Med Oncol, Ctr Mol Oncol Pathol, Boston, MA 02115 USA.
[Adams, David J.] Wellcome Trust Sanger Inst, Cambridge, England.
[Bartek, Jiri] Palacky Univ, Inst Mol & Translat Med, CR-77147 Olomouc, Czech Republic.
RP Jonkers, J (reprint author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
EM madalena.tarsounas@rob.ox.ac.uk; ganesash@umdnj.edu; j.jonkers@nki.nl
RI Bartek, Jiri/G-5870-2014; Drapkin, Ronny/E-9944-2016;
OI Drapkin, Ronny/0000-0002-6912-6977; Jose Miguel, Escandell
Planells/0000-0003-4857-9413; Tommiska, Johanna/0000-0001-7958-8262;
Nevanlinna, Heli/0000-0002-0916-2976
FU Dutch Cancer Society; Netherlands Organization for Scientific Research;
European Community; Cancer Research UK; Breast Cancer Campaign; US
Department of Defense; US National Cancer Institute; Sidney Kimmel
Foundation; Breast Cancer Research Foundation; Danish Cancer Society;
Danish National Research Foundation; Vilhelm Pedersen and Hustrus
Mindelegat; Czech Ministry of Education; Helsinki University Central
Hospital Research Fund; Finnish Cancer Society; Academy of Finland
[132473]; Sigrid Juselius Foundation; Wellcome Trust
FX We wish to thank M. Treur-Mulder for her help with targeting of the
Brca1SCo allele, W. Wang and P. Liu (Wellcome Trust Sanger
Institute) for their kind gift of the piggyBac transposon MSCV 5'-LTR
transposon and the mPB transposase, E. de Bruin, E. Cuppen and M.
Koudijs for help with PCR amplification of the piggyBac insertions, J.
Kong and D. Sie for mapping of piggyBac insertions, K, Szuhai for
multicolor fluorescence in situ hybridization karyotyping, S. Philipsen
(Erasmus Univ.) for providing shRNA vectors, H. te Riele and P. Borst
for their comments on the manuscript, E. Bilal and G. Bhanot for their
help with analysis of microarray data and P. Heikkil and K. Aittom ki
for their help with the Finnish breast cancer data and sample
collection. We are most grateful to the patients who provided clinical
samples that were analyzed in this study. Work in the Jonkers laboratory
is supported by the Dutch Cancer Society, the Netherlands Organization
for Scientific Research and the European Community 7th Framework Program
(EuroSyStem project). Work in the Tarsounas laboratory is supported by
Cancer Research UK and Breast Cancer Campaign. Work in the Ganesan
laboratory is supported by the US Department of Defense (A.A.), the US
National Cancer Institute (S.G.), the Sidney Kimmel Foundation (S.G.)
and the Breast Cancer Research Foundation (S.G.). B. G. H. is supported
by the Breast Cancer Research Foundation and the US National Cancer
Institute. Work in the Bartek laboratory is supported by the Danish
Cancer Society, the Danish National Research Foundation, Vilhelm
Pedersen and Hustrus Mindelegat, the Czech Ministry of Education and the
European Community 7th Framework Program (projects GENICA and
INFLA-CARE). Work in the Nevanlinna laboratory is supported by the
Helsinki University Central Hospital Research Fund, the Finnish Cancer
Society, the Academy of Finland (132473) and the Sigrid Juselius
Foundation. D.J.A. is supported by Cancer Research UK and the Wellcome
Trust.
NR 54
TC 355
Z9 361
U1 3
U2 45
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD JUN
PY 2010
VL 17
IS 6
BP 688
EP U56
DI 10.1038/nsmb.1831
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 606AU
UT WOS:000278393400012
PM 20453858
ER
PT J
AU Chi, LY
Yu, J
Zhu, H
Li, XG
Zhu, SG
Li, ZZ
Pettigrew, LC
Grass, D
Hickman, JJ
Kindy, MS
AF Chi, Lingyi
Yu, Jin
Zhu, Hong
Li, Xingang
Zhu, Shugan
Li, Zhenzhong
Pettigrew, L. Creed
Grass, David
Hickman, James J.
Kindy, Mark S.
TI Dual neuronal response to tumor necrosis factor-alpha following spinal
cord injury
SO NEURAL REGENERATION RESEARCH
LA English
DT Article
DE spinal cord injury; tumor necrosis factor-alpha; rats; inflammation;
motor function; astrocytes; microglia; nerve growth factor;
brain-derived neurotrophic factors
ID NERVE GROWTH-FACTOR; BRAIN-INJURY; TRANSGENIC MICE; GENE-EXPRESSION;
WORKING-MEMORY; CYTOKINES; RATS; APOPTOSIS; SYSTEM; INFLAMMATION
AB BACKGROUND: Numerous studies have shown that tumor necrosis factor a (TNF-alpha) is closely correlated with spinal cord injury (SCI), but the mechanisms of TNF-alpha and therapeutic treatments for SCI are still poorly understood.
OBJECTIVE: To determine the role of TNF-alpha in the pathogenesis of SCI.
DESIGN, TIME AND SETTING: An in vivo experiment based on genetically engineered animals was performed at the Medical University of South Carolina, Charleston, South Carolina, USA, between June 2007 and October 2008.
MATERIALS: TNF-alpha transgenic rats (Xenogen Biosciences in Cranbury, New Jersey, USA) were utilized in this study.
METHODS: TNF-alpha transgenic (tg) and wild-type (WT) rats underwent a complete single-level laminectomy at the 10(th) thoracic vertebra (T(10)).
MAIN OUTCOME MEASURES: Motor function of rat hindlimb was assessed using the Basso, Beattie, and Bresnahan hindlimb locomotor rating scale. Histological evaluation of spinal cord tissue loss was conducted. Immunohistochemistry for astrocytes, microglia/macrophages, and TNF receptors (TNFRs) was performed on spinal cord tissue sections. TNF-alpha mRNA expression was detected by real-time polymerase chain reaction. The concentrations of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in the supernatant were determined using an enzyme-linked immunosorbent assay kit for rat NGF or BDNF, respectively. The rats were injected subcutaneously with etanercept to verify that TNF-alpha was the direct effect of the modulation of behavioral and neurodegenerative outcomes in the TNF-alpha tg rats.
RESULTS: TNF-alpha tg rats showed higher expression of TNF-alpha mRNA in the spinal cord prior to SCI. TNF-alpha tg rats showed worse motor deficits than WT rats in the acute period (<3 days) after SCI (P < 0.01), while in the chronic period, TNF-alpha tg rats exhibited persistent elevated baseline levels of TNF-alpha mRNA and improved recovery in motor function and tissue healing compared to WT rats (P < 0.01). Following SCI, the number of microglia/macrophages in TNF-alpha tg rat was always greater than in WT rat (P < 0.01). There were no significant differences in NGF and BDNF levels in the supernatant of spinal cord homogenates. TNFR1 expression was significantly greater in the TNF-alpha tg rats compared to the WT rats (P < 0.01). However, TNFR2 expression did not reveal a significant increase in the TNF-alpha tg rats compared to the WT rats. Finally, treatment with etanercept reduced injury acutely, but exacerbated the injury chronically.
CONCLUSION: Overexpression of TNF-alpha is deleterious in the acute phase, but beneficial in the chronic phase in the response to SCI. The role of TNF-alpha post-injury may depend on TNF-alpha expression in the spinal cord and its differential binding to TNFR1. Our observations may have clinical relevance that antagonists or inhibitors of TNF-alpha could be administered within the early time window post-injury, and appropriate amounts of TNF-alpha could be administered during the chronic stage, in order to improve the final neurological recovery in patients with SCI.
C1 [Chi, Lingyi; Yu, Jin; Zhu, Hong; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Chi, Lingyi; Li, Xingang; Zhu, Shugan] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan 250012, Shandong, Peoples R China.
[Chi, Lingyi; Li, Xingang] Shandong Univ, Qilu Hosp, Lab Neurosurg, Jinan 250012, Shandong, Peoples R China.
[Li, Zhenzhong; Kindy, Mark S.] Shandong Univ, Sch Med, Dept Anat, Jinan 250012, Shandong, Peoples R China.
[Pettigrew, L. Creed] Univ Kentucky, Sanders Brown Ctr Aging, Stroke Program, Coll Med, Lexington, KY 40536 USA.
[Pettigrew, L. Creed] Dept Vet Affairs Med Ctr, Lexington, KY 40536 USA.
[Grass, David] Xenogen Corp, Cranbury, NJ 08512 USA.
[Hickman, James J.] Univ Cent Florida, NanoSci Technol Ctr, Orlando, FL 32826 USA.
[Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
EM drlixingangneurosurgery@yahoo.com.cn; kindyms@musc.edu
FU VA [ES016774-01A1]; National Science Foundation [EPS-0132573,
EPS-0447660, NS050452-05]
FX Supported by: the ES016774-01A1*, VA Merit Award and National Science
Foundation EPSCoR grant, No. EPS-0132573* and EPS-0447660 (MSK)* and
NS050452-05 (JJH)*
NR 56
TC 2
Z9 2
U1 1
U2 7
PU SHENYANG EDITORIAL DEPT NEURAL REGENERATION RES
PI SHENYANG
PA PO BOX 1234, SHENYANG, LIAONING 110004, PEOPLES R CHINA
SN 1673-5374
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD JUN
PY 2010
VL 5
IS 12
BP 917
EP 926
DI 10.3969/j.issn.1673-5374.2010.12.007
PG 10
WC Cell Biology; Neurosciences
SC Cell Biology; Neurosciences & Neurology
GA 625LC
UT WOS:000279895700007
ER
PT J
AU Scott, BJ
Quant, EC
McNamara, MB
Ryg, PA
Batchelor, TT
Wen, PY
AF Scott, Brian J.
Quant, Eudocia C.
McNamara, Margaret B.
Ryg, Peter A.
Batchelor, Tracy T.
Wen, Patrick Y.
TI Bevacizumab salvage therapy following progression in high-grade glioma
patients treated with VEGF receptor tyrosine kinase inhibitors
SO NEURO-ONCOLOGY
LA English
DT Article
DE bevacizumab; recurrent glioblastoma; tyrosine kinase inhibitor; vascular
endothelial growth factor
ID MALIGNANT GLIOMA; PLUS IRINOTECAN; RECURRENT GLIOBLASTOMA;
ANTIANGIOGENIC THERAPY; TUMOR VASCULATURE; PHASE-II; ANGIOGENESIS;
ANTITUMOR; EFFICACY; INVASION
AB Agents targeting the vascular endothelial growth factor (VEGF) pathway are being used with increasing frequency in patients with recurrent high-grade glioma. The effect of more than one antiangiogenic therapy given in succession has not been established. We reviewed the efficacy of bevacizumab, a VEGF-A monoclonal antibody, in patients who progressed following prior therapy with VEGF receptor tyrosine kinase inhibitors (R-TKi). Seventy-three patients with recurrent high-grade gliomas received VEGF R-TKi (cediranib, sorafenib, pazopanib, or sunitinib) as part of phase I or II clinical trials. Twenty-four of these patients with glioblastoma progressed and received bevacizumab-containing regimens immediately after R-TKi. Those who stopped R-TKi therapy for reasons other than disease progression, or received a treatment that did not include bevacizumab, were excluded from the analysis. The efficacy of bevacizumab-containing regimens in these 24 patients was evaluated. During R-TKi therapy, 6 of 24 patients (25%) had a partial response (PR) to treatment. The 6-month progression-free survival (APF6) was 16.7% and median time-to-progression (TTP) was 14.3 weeks. Grade III/IV toxicities were seen in 13 of 24 patients (54%). Subsequently with bevacizumab salvage therapy, 5 of 24 patients (21%) had a PR, the APF6 was 12.5%, and the median TIP was 8 weeks. Five of 24 patients had grade III/IV toxicities (21%). The median overall survival (OS) from the start of R-TKi therapy was 9.2 months (range: 2.8-34.1+), whereas the median OS after bevacizumab was 5.2 months (range: 1.3-28.9+). Bevacizumab retains modest activity in high-grade glioma patients who progress on R-TKi. However, the APF6 of 12.5% in this cohort of patients indicates that durable tumor control is not achieved for most patients.
C1 [Scott, Brian J.; Quant, Eudocia C.; Ryg, Peter A.; Batchelor, Tracy T.] Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Boston, MA 02114 USA.
[Scott, Brian J.; Quant, Eudocia C.; McNamara, Margaret B.; Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA.
RP Scott, BJ (reprint author), Lahey Clin Med Ctr, Dept Neurol, 41 Mall Rd, Burlington, MA 01805 USA.
EM brian.j.scott@lahey.org
FU NIH [R21-CA117079, K24-CA125440, R01-CA129371]; Harvard Clinical and
Translational Science Center, the National Center for Research Resources
FX This work was supported by NIH grant R21-CA117079, and in part by NIH
grants K24-CA125440 and R01-CA129371 and the Harvard Clinical and
Translational Science Center, from the National Center for Research
Resources. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National Center
for Research Resources or the National Institutes of Health.
NR 23
TC 36
Z9 37
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP 603
EP 607
DI 10.1093/neuonc/nop073
PG 5
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700010
PM 20156808
ER
PT J
AU Cho, Y
Tamayo, P
Tsherniak, A
Greulich, H
Lu, J
Kool, M
Zhou, T
Eberhart, CG
Olson, JM
Lau, CC
Meyerson, M
Mesirov, JP
Pomeroy, SL
AF Cho, Y.
Tamayo, P.
Tsherniak, A.
Greulich, H.
Lu, J.
Kool, M.
Zhou, T.
Eberhart, C. G.
Olson, J. M.
Lau, C. C.
Meyerson, M.
Mesirov, J. P.
Pomeroy, S. L.
TI INTEGRATIVE GENOMIC ANALYSIS OF MEDULLOBLASTOMA IDENTIFIES A MOLECULAR
SUBGROUP THAT DRIVES POOR CLINICAL OUTCOME
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Cho, Y.; Pomeroy, S. L.] Childrens Hosp, Boston, MA 02115 USA.
[Cho, Y.; Meyerson, M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tamayo, P.; Tsherniak, A.; Greulich, H.; Meyerson, M.; Mesirov, J. P.] MIT, Broad Inst, Cambridge, MA 02139 USA.
[Lu, J.] Yale Univ, Med Ctr, New Haven, CT USA.
[Kool, M.] Acad Med Ctr, Amsterdam, Netherlands.
[Zhou, T.] Childrens Oncol Grp, Acadia, CA USA.
[Eberhart, C. G.] Johns Hopkins Med Ctr, Baltimore, MD USA.
[Olson, J. M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Lau, C. C.] Texas Childrens Hosp, Houston, TX 77030 USA.
RI Meyerson, Matthew/E-7123-2012; Kool, Marcel/H-2541-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II1
EP II1
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700015
ER
PT J
AU Chordas, C
Zimmerman, M
Kieran, MW
Chi, SN
Lee, M
Robison, N
Stratton, N
Goumnerova, L
Ullrich, NJ
Marcus, KJ
Manley, PE
AF Chordas, C.
Zimmerman, M.
Kieran, M. W.
Chi, S. N.
Lee, M.
Robison, N.
Stratton, N.
Goumnerova, L.
Ullrich, N. J.
Marcus, K. J.
Manley, P. E.
TI ECHOCARDIOGRAPHIC FINDINGS FOLLOWING TREATMENT FOR CHILDHOOD
MEDULLOBLASTOMA: A SINGLE CENTER'S EXPERIENCE
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Chordas, C.; Zimmerman, M.; Kieran, M. W.; Chi, S. N.; Lee, M.; Robison, N.; Stratton, N.; Goumnerova, L.; Ullrich, N. J.; Marcus, K. J.; Manley, P. E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kieran, M. W.; Chi, S. N.; Lee, M.; Robison, N.; Goumnerova, L.; Ullrich, N. J.; Marcus, K. J.; Manley, P. E.] Childrens Hosp Boston, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II114
EP II114
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700527
ER
PT J
AU Chordas, C
Liptak, C
Delaney, B
Barnes, J
Chabot, J
Northman, L
Morris, M
Gambhir, R
Rey-Casserly, C
Diver, T
Manley, PE
AF Chordas, C.
Liptak, C.
Delaney, B.
Barnes, J.
Chabot, J.
Northman, L.
Morris, M.
Gambhir, R.
Rey-Casserly, C.
Diver, T.
Manley, P. E.
TI RESOURCE AND INFORMATION NEEDS OF BRAIN TUMOR SURVIVORS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Chordas, C.; Liptak, C.; Delaney, B.; Barnes, J.; Chabot, J.; Northman, L.; Morris, M.; Gambhir, R.; Rey-Casserly, C.; Manley, P. E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rey-Casserly, C.; Manley, P. E.] Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II110
EP II110
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700506
ER
PT J
AU Chordas, C
Manley, P
Medeiros-Nancarrow, C
Merport, A
Zwemer, E
Liptak, C
Recklitis, C
AF Chordas, C.
Manley, P.
Medeiros-Nancarrow, C.
Merport, A.
Zwemer, E.
Liptak, C.
Recklitis, C.
TI PREVALENCE OF AND FACTORS ASSOCIATED WITH POST-CANCER PAIN IN A COHORT
OF CHILDHOOD BRAIN TUMOR SURVIVORS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Chordas, C.; Manley, P.; Medeiros-Nancarrow, C.; Merport, A.; Zwemer, E.; Liptak, C.; Recklitis, C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Manley, P.; Zwemer, E.; Liptak, C.; Recklitis, C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II108
EP II108
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700497
ER
PT J
AU Diver, T
Manley, P
Kieran, MW
Chi, S
Goumnerova, L
Scott, R
Marcus, KJ
Ullrich, N
Liptak, C
Chordas, C
Zimmerman, M
Delaney, B
Rey-Casserly, C
AF Diver, T.
Manley, P.
Kieran, M. W.
Chi, S.
Goumnerova, L.
Scott, R.
Marcus, K. J.
Ullrich, N.
Liptak, C.
Chordas, C.
Zimmerman, M.
Delaney, B.
Rey-Casserly, C.
TI AGE AT DIAGNOSIS AND CRANIOSPINAL RADIATION DOSE EFFECTS ON INTELLECTUAL
OUTCOME IN CHILDREN/ADOLESCENTS TREATED FOR MEDULLOBLASTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Diver, T.; Rey-Casserly, C.] Childrens Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Diver, T.; Manley, P.; Kieran, M. W.; Chi, S.; Goumnerova, L.; Scott, R.; Marcus, K. J.; Ullrich, N.; Liptak, C.; Chordas, C.; Zimmerman, M.; Delaney, B.; Rey-Casserly, C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II7
EP II8
PG 2
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700040
ER
PT J
AU Gruber-Olipitz, M
Dabral, SK
Ligon, KL
Segal, RA
AF Gruber-Olipitz, M.
Dabral, S. K.
Ligon, K. L.
Segal, R. A.
TI DASATINIB ACTIVITY ON GLIOBLASTOMA CELLS IS DUE TO ANOIKIS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Gruber-Olipitz, M.; Dabral, S. K.; Segal, R. A.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA USA.
[Ligon, K. L.] Dept Med Oncol, Boston, MA USA.
[Ligon, K. L.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA.
[Ligon, K. L.] Childrens Hosp Boston, Dept Pathol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II88
EP II88
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700402
ER
PT J
AU Kieran, MW
Rich, BE
Santagata, S
Chan, JA
MacConaill, L
Goff, D
Stiles, C
Garraway, L
Golub, T
Golub, T
Ligon, KL
AF Kieran, M. W.
Rich, B. E.
Santagata, S.
Chan, J. A.
MacConaill, L.
Goff, D.
Stiles, C.
Garraway, L.
Golub, T.
Golub, T.
Ligon, K. L.
TI GANGLIOGLIOMAS AND V600E STATUS IDENTIFIED BY EXTENDED MUTATIONAL
ANALYSIS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Kieran, M. W.; Rich, B. E.; MacConaill, L.; Goff, D.; Stiles, C.; Garraway, L.; Golub, T.; Golub, T.; Ligon, K. L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA.
[Santagata, S.; Chan, J. A.; MacConaill, L.; Garraway, L.; Golub, T.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Santagata, S.; Chan, J. A.; Ligon, K. L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II92
EP II92
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700421
ER
PT J
AU Kieran, MW
Rich, BE
MacConaill, L
Chan, JA
Santagata, S
Goff, D
Stiles, C
Golub, T
Garraway, L
Ligon, KL
AF Kieran, M. W.
Rich, B. E.
MacConaill, L.
Chan, J. A.
Santagata, S.
Goff, D.
Stiles, C.
Golub, T.
Garraway, L.
Ligon, K. L.
TI MOLECULAR CHARACTERIZATION BY AGE OF PEDIATRIC PILOCYTIC ASTROCYTOMAS IN
THE PRESENCE OR ABSENCE OF BRAF MUTATION OR DUPLICATION
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Kieran, M. W.; Rich, B. E.; MacConaill, L.; Goff, D.; Stiles, C.; Ligon, K. L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA.
[Rich, B. E.; Chan, J. A.; Santagata, S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[MacConaill, L.; Chan, J. A.; Santagata, S.; Golub, T.; Garraway, L.] MIT, Broad Inst, Cambridge, MA 02139 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II23
EP II23
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700109
ER
PT J
AU Kieran, MW
Mehta, S
Huillard, E
Rowitch, DH
Saad, A
Stiles, CD
Ligon, KL
AF Kieran, M. W.
Mehta, S.
Huillard, E.
Rowitch, D. H.
Saad, A.
Stiles, C. D.
Ligon, K. L.
TI REMISSION AND RELAPSE IN PEDIATRIC LOW GRADE ASTROCYTOMA: AN
OPPOSITIONAL RELATIONSHIP BETWEEN STEMNESS AND P53?
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Kieran, M. W.; Mehta, S.; Stiles, C. D.; Ligon, K. L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA.
[Huillard, E.; Rowitch, D. H.] UCSF, San Francisco, CA USA.
[Saad, A.; Ligon, K. L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II24
EP II24
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700113
ER
PT J
AU Kieran, MW
MacConaill, L
Chan, JA
Santagata, S
Goff, D
Stiles, C
Garraway, L
Ligon, KL
AF Kieran, M. W.
MacConaill, L.
Chan, J. A.
Santagata, S.
Goff, D.
Stiles, C.
Garraway, L.
Ligon, K. L.
TI INTEGRATIVE MOLECULAR PROFILING OF PEDIATRIC LOW-GRADE ASTROCYTOMAS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Kieran, M. W.; MacConaill, L.; Chan, J. A.; Goff, D.; Stiles, C.; Garraway, L.; Ligon, K. L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA.
[MacConaill, L.; Chan, J. A.; Santagata, S.; Garraway, L.] MIT, Broad Inst, Cambridge, MA USA.
[Santagata, S.; Ligon, K. L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II23
EP II24
PG 2
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700111
ER
PT J
AU Kuhlthau, KA
Pulsifer, M
Delahaye, J
MacDonald, SM
Tarbell, NJ
Yock, TI
AF Kuhlthau, K. A.
Pulsifer, M.
Delahaye, J.
MacDonald, S. M.
Tarbell, N. J.
Yock, T. I.
TI HEALTH-RELATED QUALITY OF LIFE OF PEDIATRIC BRAIN TUMOR PATIENTS ON
PROTON TREATMENT
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Kuhlthau, K. A.; Pulsifer, M.; Delahaye, J.; MacDonald, S. M.; Tarbell, N. J.; Yock, T. I.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II111
EP II111
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700513
ER
PT J
AU Liptak, C
Zwemer, E
Merport, A
Manley, P
Recklitis, CJ
AF Liptak, C.
Zwemer, E.
Merport, A.
Manley, P.
Recklitis, C. J.
TI ASSESSMENT OF PSYCHOLOGICAL DISTRESS IN ADOLESCENT AND YOUNG ADULT BRAIN
TUMOR SURVIVORS: THE VALUE OF PARENT AND SURVIVOR SELF-REPORT
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Liptak, C.; Zwemer, E.; Merport, A.; Manley, P.; Recklitis, C. J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Liptak, C.; Zwemer, E.; Manley, P.; Recklitis, C. J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II109
EP II109
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700500
ER
PT J
AU Liptak, C
Brinkman, T
Ing, J
Chordas, C
Delaney, B
Manley, PE
AF Liptak, C.
Brinkman, T.
Ing, J.
Chordas, C.
Delaney, B.
Manley, P. E.
TI QUALITATIVE ASSESSMENT OF A SOCIAL PROGRAM FOR ADOLESCENT AND YOUNG
ADULT BRAIN TUMOR SURVIVORS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Liptak, C.; Brinkman, T.; Ing, J.; Delaney, B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Manley, P. E.] Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II110
EP II110
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700508
ER
PT J
AU MacDonald, SM
Lavally, B
Yeap, BY
Marcus, K
Ebb, D
Yock, TI
Tarbell, NJ
AF MacDonald, S. M.
Lavally, B.
Yeap, B. Y.
Marcus, K.
Ebb, D.
Yock, T. I.
Tarbell, N. J.
TI PROTON THERAPY FOR CHILDHOOD CNS EPENDYMOMA: CLINICAL OUTCOMES IN A
COHORT OF 49 PATIENTS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [MacDonald, S. M.; Lavally, B.; Yeap, B. Y.; Ebb, D.; Yock, T. I.; Tarbell, N. J.] Massachusetts Gen Hosp, Boston, MA USA.
[Marcus, K.] Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II27
EP II27
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700124
ER
PT J
AU Manley, PE
Pietrantonio, J
Chi, SN
Lee, M
Robison, N
Ullrich, NJ
Zimmerman, M
Chordas, C
Goumnerova, L
Kieran, MW
AF Manley, P. E.
Pietrantonio, J.
Chi, S. N.
Lee, M.
Robison, N.
Ullrich, N. J.
Zimmerman, M.
Chordas, C.
Goumnerova, L.
Kieran, M. W.
TI A PHASE II PILOT STUDY OF THALIDOMIDE AND TEMOZOLOMIDE IN PATIENTS WITH
RELAPSED OR PROGRESSIVE BRAIN TUMORS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Manley, P. E.; Pietrantonio, J.; Chi, S. N.; Lee, M.; Robison, N.; Ullrich, N. J.; Zimmerman, M.; Chordas, C.; Goumnerova, L.; Kieran, M. W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Manley, P. E.; Chi, S. N.; Lee, M.; Robison, N.; Ullrich, N. J.; Goumnerova, L.; Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II89
EP II90
PG 2
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700410
ER
PT J
AU Manley, PE
McKendrick, K
Chi, SN
Kieran, MW
Marcus, KJ
Cohen, LE
Goumnerova, L
Lee, M
Robison, N
Pomeroy, S
Ullrich, NJ
AF Manley, P. E.
McKendrick, K.
Chi, S. N.
Kieran, M. W.
Marcus, K. J.
Cohen, L. E.
Goumnerova, L.
Lee, M.
Robison, N.
Pomeroy, S.
Ullrich, N. J.
TI SLEEP DYSFUNCTION IN LONG TERM SURVIVORS OF CRANIOPHARYNGIOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Manley, P. E.; McKendrick, K.; Chi, S. N.; Kieran, M. W.; Marcus, K. J.; Goumnerova, L.; Lee, M.; Robison, N.; Pomeroy, S.; Ullrich, N. J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Manley, P. E.; Chi, S. N.; Kieran, M. W.; Marcus, K. J.; Cohen, L. E.; Goumnerova, L.; Lee, M.; Robison, N.; Pomeroy, S.; Ullrich, N. J.] Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II39
EP II39
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700177
ER
PT J
AU Manley, PE
Jones, I
Chordas, C
Zimmerman, M
Kieran, MV
Chi, SN
Lee, M
Robison, N
Stratton, N
Goumnerova, L
Ullrich, NJ
Marcus, KJ
Cohen, LE
AF Manley, P. E.
Jones, I.
Chordas, C.
Zimmerman, M.
Kieran, M. V.
Chi, S. N.
Lee, M.
Robison, N.
Stratton, N.
Goumnerova, L.
Ullrich, N. J.
Marcus, K. J.
Cohen, L. E.
TI ABNORMAL TIMING OF PUBERTAL ONSET IN FEMALE SURVIVORS OF MEDULLOBLASTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Manley, P. E.; Chordas, C.; Zimmerman, M.; Kieran, M. V.; Chi, S. N.; Lee, M.; Robison, N.; Stratton, N.; Goumnerova, L.; Ullrich, N. J.; Marcus, K. J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Manley, P. E.; Jones, I.; Kieran, M. V.; Chi, S. N.; Lee, M.; Robison, N.; Goumnerova, L.; Ullrich, N. J.; Marcus, K. J.; Cohen, L. E.] Childrens Hosp Boston, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II31
EP II31
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700143
ER
PT J
AU Paugh, BS
Jones, C
Qu, C
Liu, Z
Adamowicz-Brice, M
Zhang, J
Bax, DA
Coyle, B
Barrow, J
Hargrave, D
Lowe, J
Zhao, W
Geyer, JR
Chi, S
da Silva, NS
Baker, J
Gajjar, A
Grundy, R
Ellison, DW
Broniscer, A
Baker, SJ
AF Paugh, B. S.
Jones, C.
Qu, C.
Liu, Z.
Adamowicz-Brice, M.
Zhang, J.
Bax, D. A.
Coyle, B.
Barrow, J.
Hargrave, D.
Lowe, J.
Zhao, W.
Geyer, J. R.
Chi, S.
da Silva, N. Saba
Baker, J.
Gajjar, A.
Grundy, R.
Ellison, D. W.
Broniscer, A.
Baker, S. J.
TI INTEGRATED MOLECULAR GENETIC PROFILING OF PEDIATRIC HIGH-GRADE GLIOMAS
AND DIFFUSE INTRINSIC PONTINE GLIOMAS REVEALS KEY DIFFERENCES WITH ADULT
GLIOMAS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Paugh, B. S.; Qu, C.; Liu, Z.; Zhang, J.; Zhao, W.; Baker, J.; Gajjar, A.; Ellison, D. W.; Broniscer, A.; Baker, S. J.] St Jude Childrens Hosp, Memphis, TN 38105 USA.
[Jones, C.; Bax, D. A.] Inst Canc Res, Surrey, England.
[Adamowicz-Brice, M.; Coyle, B.; Barrow, J.; Lowe, J.; Grundy, R.] Univ Nottingham, Nottingham NG7 2RD, England.
[Hargrave, D.] Royal Marsden NHS Fdn Trust, Surrey, England.
[Geyer, J. R.] Univ Washington, Seattle, WA 98195 USA.
[Chi, S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[da Silva, N. Saba] Univ Fed Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II10
EP II10
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700052
ER
PT J
AU Peyrl, A
Heinrich, M
Azizi, AA
Reismueller, B
Kieran, MV
Woehrer, A
Prayer, D
Slavc, I
AF Peyrl, A.
Heinrich, M.
Azizi, A. A.
Reismueller, B.
Kieran, M. V.
Woehrer, A.
Prayer, D.
Slavc, I.
TI OBJECTIVE RESPONSE TO ANTIANGIOGENIC METRONOMIC THERAPY INCLUDING
BEVACIZUMAB AND IMATINIB IN TWO PATIENTS WITH MULTIPLY RECURRENT
SECRETING INTRACRANIAL NONGERMINOMATOUS GERM CELL TUMORS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Peyrl, A.; Heinrich, M.; Azizi, A. A.; Reismueller, B.; Slavc, I.] Med Univ Vienna, Dept Pediat, Vienna, Austria.
[Kieran, M. V.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Kieran, M. V.] Childrens Hosp, Boston, MA 02115 USA.
[Woehrer, A.] Med Univ Vienna, Inst Neurol, Vienna, Austria.
[Prayer, D.] Med Univ Vienna, Dept Radiol, Vienna, Austria.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II107
EP II107
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700492
ER
PT J
AU Peyrl, A
Azizi, AA
Reismueller, B
Kieran, NV
Heinrich, M
Czech, T
Dieckmann, K
Slave, I
AF Peyrl, A.
Azizi, A. A.
Reismueller, B.
Kieran, N. V.
Heinrich, M.
Czech, T.
Dieckmann, K.
Slave, I.
TI ANTIANGIOGENIC METRONOMIC CHEMOTHERAPY FOR PATIENTS WITH RECURRENT
EMBRYONAL AND EPENDYMAL BRAIN TUMORS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Peyrl, A.; Azizi, A. A.; Reismueller, B.; Heinrich, M.; Slave, I.] Med Univ Vienna, Dept Pediat, Vienna, Austria.
[Kieran, N. V.] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Czech, T.] Med Univ Vienna, Dept Neurosurg, Vienna, Austria.
[Dieckmann, K.] Med Univ Vienna, Dept Radiotherapy, Vienna, Austria.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II44
EP II44
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700201
ER
PT J
AU Robison, NJ
Chi, SN
Kieran, MW
Manley, P
Cohen, LE
Goumnerova, L
Smith, E
Scott, M
Ullrich, NJ
AF Robison, N. J.
Chi, S. N.
Kieran, M. W.
Manley, P.
Cohen, L. E.
Goumnerova, L.
Smith, E.
Scott, M.
Ullrich, N. J.
TI EVALUATION OF PATIENTS WITH PITUITARY STALK ENLARGEMENT
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Robison, N. J.; Chi, S. N.; Kieran, M. W.; Manley, P.; Goumnerova, L.; Smith, E.; Scott, M.; Ullrich, N. J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Robison, N. J.; Chi, S. N.; Kieran, M. W.; Manley, P.] Childrens Hosp Boston, Dept Hematol Oncol, Boston, MA USA.
[Cohen, L. E.] Childrens Hosp Boston, Div Endocrinol, Boston, MA USA.
[Goumnerova, L.; Smith, E.; Scott, M.] Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
[Ullrich, N. J.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II29
EP II29
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700135
ER
PT J
AU Shiers, D
Sheehan, K
Gregory, M
AF Shiers, D.
Sheehan, K.
Gregory, M.
TI NURSING CARE OF THE CHILD AFTER CRANIOTOMY FOR BRAIN TUMOR RESECTION IN
A STEP-UP UNIT SETTING
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Shiers, D.; Sheehan, K.; Gregory, M.] Childrens Hosp, Boston, MA 02115 USA.
[Shiers, D.; Sheehan, K.; Gregory, M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II82
EP II82
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700372
ER
PT J
AU Turner, CD
Chi, SN
Chordas, CA
Zimmerman, MA
Ullrich, N
Goumnerova, L
Kieran, MW
AF Turner, C. D.
Chi, S. N.
Chordas, C. A.
Zimmerman, M. A.
Ullrich, N.
Goumnerova, L.
Kieran, M. W.
TI INTRATHECAL LIPOSOMAL CYTARABINE IN COMBINATION WITH SYSTEMIC
CHEMOTHERAPY IN CHILDREN WITH DISSEMINATED LEPTOMENINGEAL
MEDULLOBLASTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Turner, C. D.; Chi, S. N.; Chordas, C. A.; Zimmerman, M. A.; Ullrich, N.; Goumnerova, L.; Kieran, M. W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Turner, C. D.; Chi, S. N.; Ullrich, N.; Goumnerova, L.; Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II60
EP II60
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700272
ER
PT J
AU Ullrich, NJ
Pomeroy, SL
Manley, P
Chordas, C
Looddenkemper, T
AF Ullrich, N. J.
Pomeroy, S. L.
Manley, P.
Chordas, C.
Looddenkemper, T.
TI OUTCOME OF AND PREDICTORS OF SEIZURES IN LONG-TERM SURVIVORS OF
PEDIATRIC BRAIN TUMORS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Ullrich, N. J.; Pomeroy, S. L.; Looddenkemper, T.] Childrens Hosp Boston, Dept Neurol, Boston, MA USA.
[Ullrich, N. J.; Pomeroy, S. L.; Manley, P.; Chordas, C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Manley, P.] Childrens Hosp Boston, Dept Hematol & Oncol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II114
EP II114
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700524
ER
PT J
AU Ullrich, NJ
Zimmerman, M
Smith, E
Irons, MB
Marcus, KJ
Kieran, MW
AF Ullrich, N. J.
Zimmerman, M.
Smith, E.
Irons, M. B.
Marcus, K. J.
Kieran, M. W.
TI RAPID PROGRESSION OF NEUROFIBROMATOSIS-ASSOCIATED MOYAMOYA AFTER
BEVACIZUMAB FOR GLIOBLASTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Ullrich, N. J.] Childrens Hosp Boston, Dept Neurol, Boston, MA USA.
[Ullrich, N. J.; Zimmerman, M.; Marcus, K. J.; Kieran, M. W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Smith, E.] Childrens Hosp Boston, Dept Neurosurg, Boston, MA USA.
[Irons, M. B.] Childrens Hosp Boston, Dept Genet, Boston, MA USA.
[Marcus, K. J.] Childrens Hosp Boston, Dept Radiat Oncol, Boston, MA USA.
[Kieran, M. W.] Childrens Hosp Boston, Dept Hematol Oncol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II85
EP II85
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700390
ER
PT J
AU Ullrich, NJ
McGowan, C
Porter, A
Miller, D
Kieran, M
Korf, B
Irons, MB
AF Ullrich, N. J.
McGowan, C.
Porter, A.
Miller, D.
Kieran, M.
Korf, B.
Irons, M. B.
TI DOES SURVEILLANCE NEUROIMAGING CHANGE MANAGEMENT OF OPTIC PATHWAY
GLIOMAS IN NEUROFIBROMATOSIS TYPE 1?
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Ullrich, N. J.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Ullrich, N. J.; Kieran, M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[McGowan, C.; Miller, D.] Childrens Hosp, Div Genet, Boston, MA 02115 USA.
[Kieran, M.] Childrens Hosp, Dept Hematol Oncol, Boston, MA 02115 USA.
[Korf, B.] Univ Alabama, Dept Genet, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II22
EP II22
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700103
ER
PT J
AU Van Vuurden, DG
Hulleman, E
Van der Stoop, PM
Gupta, R
Wedekind, LE
Badr, CE
Meijer, DH
Noske, DP
Wurdinger, T
Kaspers, GJL
Cloos, J
AF Van Vuurden, D. G.
Hulleman, E.
Van der Stoop, P. M.
Gupta, R.
Wedekind, L. E.
Badr, C. E.
Meijer, D. H.
Noske, D. P.
Wurdinger, T.
Kaspers, G. J. L.
Cloos, J.
TI DEREGULATION AND POTENTIAL THERAPEUTIC TARGETING OF THE NF-kappa B
PATHWAY IN HIGH-GRADE CHILDHOOD BRAIN TUMORS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Van Vuurden, D. G.; Kaspers, G. J. L.; Cloos, J.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat, Amsterdam, Netherlands.
[Van Vuurden, D. G.; Hulleman, E.; Van der Stoop, P. M.; Gupta, R.; Wedekind, L. E.; Badr, C. E.; Meijer, D. H.; Noske, D. P.; Wurdinger, T.] Vrije Univ Amsterdam, Med Ctr, Ctr Canc, Neuro Oncol Res Grp, Amsterdam, Netherlands.
[Hulleman, E.; Van der Stoop, P. M.; Wedekind, L. E.; Noske, D. P.] Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, Amsterdam, Netherlands.
[Badr, C. E.; Wurdinger, T.] Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA.
[Badr, C. E.; Wurdinger, T.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Badr, C. E.; Wurdinger, T.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Cloos, J.] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II50
EP II50
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700226
ER
PT J
AU Vanan, I
Redner, AS
Quinlan, A
Mittler, M
Schneider, S
Leibsch, NJ
Atlas, MP
AF Vanan, I.
Redner, A. S.
Quinlan, A.
Mittler, M.
Schneider, S.
Leibsch, N. J.
Atlas, M. P.
TI MULTI-MODALITY MANAGEMENT OF CLIVAL CHORDOMAS - EXPERIENCE FROM A
TERTIARY CARE CENTER
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Vanan, I.; Redner, A. S.; Quinlan, A.; Mittler, M.; Schneider, S.; Atlas, M. P.] Schneider Childrens Hosp, New Hyde Pk, NY USA.
[Leibsch, N. J.] Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr, Massachusetts, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II125
EP II125
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700578
ER
PT J
AU Winkfield, KM
Tsai, HK
Yao, X
Neuberg, D
Larson, E
Pomeroy, SL
Ullrich, N
Cohen, LE
Kieran, MW
Scott, RM
Goumnerova, LL
Marcus, KS
AF Winkfield, K. M.
Tsai, H. K.
Yao, X.
Neuberg, D.
Larson, E.
Pomeroy, S. L.
Ullrich, N.
Cohen, L. E.
Kieran, M. W.
Scott, R. M.
Goumnerova, L. L.
Marcus, K. S.
TI LONG-TERM CLINICAL OUTCOMES FOLLOWING TREATMENT OF CHILDHOOD
CRANIOPHARYNGIOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Winkfield, K. M.; Tsai, H. K.] Harvard Radiat Oncol Program, Boston, MA USA.
[Winkfield, K. M.; Tsai, H. K.; Marcus, K. S.] Childrens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
[Yao, X.; Neuberg, D.] Dana Farber Canc Inst, Dept Biostatist & Computat Biol, Boston, MA 02115 USA.
[Larson, E.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
[Pomeroy, S. L.; Ullrich, N.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Cohen, L. E.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Kieran, M. W.] Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
[Kieran, M. W.] Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA.
[Scott, R. M.; Goumnerova, L. L.] Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II38
EP II38
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700174
ER
PT J
AU Zimmerman, M
Marcus, KJ
Cohen, LE
Chordas, C
Chi, SN
Lee, M
Manley, PE
Robison, N
Ullrich, NJ
Goumnerova, L
Kieran, MW
AF Zimmerman, M.
Marcus, K. J.
Cohen, L. E.
Chordas, C.
Chi, S. N.
Lee, M.
Manley, P. E.
Robison, N.
Ullrich, N. J.
Goumnerova, L.
Kieran, M. W.
TI ENDOCRINOLOGIC ASSESSMENT IN PATIENTS WITH DIFFUSE INTRINSIC PONTINE
GLIOMA (DIPG)
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 14th International Symposium on Pediatric Neuro-Oncology
CY JUN 20-23, 2010
CL Vienna, AUSTRIA
C1 [Zimmerman, M.; Marcus, K. J.; Chordas, C.; Chi, S. N.; Lee, M.; Manley, P. E.; Robison, N.; Ullrich, N. J.; Goumnerova, L.; Kieran, M. W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Marcus, K. J.; Cohen, L. E.; Chi, S. N.; Lee, M.; Manley, P. E.; Robison, N.; Ullrich, N. J.; Goumnerova, L.; Kieran, M. W.] Childrens Hosp Boston, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2010
VL 12
IS 6
BP II123
EP II123
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 611LW
UT WOS:000278817700566
ER
PT J
AU Coma, M
Sereno, L
Da Rocha-Souto, B
Scotton, TC
Espana, J
Sanchez, MB
Rodriguez, M
Agullo, J
Guardia-Laguarta, C
Garcia-Alloza, M
Borrelli, LA
Clarimon, J
Lleo, A
Bacskai, BJ
Saura, CA
Hyman, BT
Gomez-Isla, T
AF Coma, M.
Sereno, L.
Da Rocha-Souto, B.
Scotton, T. C.
Espana, J.
Sanchez, M. B.
Rodriguez, M.
Agullo, J.
Guardia-Laguarta, C.
Garcia-Alloza, M.
Borrelli, L. A.
Clarimon, J.
Lleo, A.
Bacskai, B. J.
Saura, C. A.
Hyman, B. T.
Gomez-Isla, T.
TI Triflusal reduces dense-core plaque load, associated axonal alterations
and inflammatory changes, and rescues cognition in a transgenic mouse
model of Alzheimer's disease
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Alzheimer's disease; Transgenic mice; Triflusal; Amyloid;
Neuroinflammation; Cytokines; Cognition; CREB; c-fos; BDNF
ID FACTOR-KAPPA-B; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LONG-TERM-MEMORY;
ANIMAL-MODEL; 4-TRIFLUOROMETHYL DERIVATIVES; AMYLOID PLAQUES; IN-VIVO;
2-HYDROXY-4-TRIFLUOROMETHYLBENZOIC ACID; MICROGLIAL PHAGOCYTOSIS;
SYNAPTIC PLASTICITY
AB Inflammation has been associated with the two classic lesions in the Alzheimer's (AD) brain, amyloid deposits and neurofibrillary tangles. Recent data suggest that Triflusal, a compound with potent anti-inflammatory effects in the central nervous system in vivo, might delay the conversion from amnestic mild cognitive impairment to a fully established clinical picture of dementia. In the present study, we investigated the effect of Triflusal on brain A beta accumulation, neuroinflammation, axonal curvature and cognition in an AD transgenic mouse model (Tg2576). Triflusal treatment did not alter the total brain A beta accumulation but significantly reduced dense-cored plaque load and associated glial cell proliferation, proinflammatory cytokine levels and abnormal axonal curvature, and rescued cognitive deficits in Tg2576 mice. Behavioral benefit was found to involve increased expression of c-fos and BDNF, two of the genes regulated by CREB, as part of the signal transduction cascade underlying the molecular basis of long-term potentiation. These results add preclinical evidence of a potentially beneficial effect of Triflusal in AD. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Coma, M.; Sereno, L.; Da Rocha-Souto, B.; Sanchez, M. B.; Rodriguez, M.; Agullo, J.; Guardia-Laguarta, C.; Clarimon, J.; Lleo, A.; Gomez-Isla, T.] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, Barcelona 08025, Spain.
[Coma, M.; Da Rocha-Souto, B.; Scotton, T. C.; Garcia-Alloza, M.; Borrelli, L. A.; Bacskai, B. J.; Hyman, B. T.; Gomez-Isla, T.] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA.
[Espana, J.; Saura, C. A.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Inst Neurociencies, Barcelona 08025, Spain.
RP Gomez-Isla, T (reprint author), Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, C St Antoni Ma Claret 167, Barcelona 08025, Spain.
EM mgomezi@santpau.es
RI Saura, Carlos/D-2727-2011;
OI Saura, Carlos/0000-0003-3692-5657; Clarimon, Jordi/0000-0002-6824-6942;
Guardia-Laguarta, Cristina/0000-0003-0811-9068; Garcia-Alloza,
Monica/0000-0003-1610-4114
FU FIS [PI041887]; CIBERNED; NIH [AG020570]; Marato [072610]
FX This project was funded in part by FIS PI041887, CIBERNED, NIH AG020570
and Marato 072610.
NR 58
TC 21
Z9 21
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD JUN
PY 2010
VL 38
IS 3
SI SI
BP 482
EP 491
DI 10.1016/j.nbd.2010.01.019
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 595XU
UT WOS:000277648200019
PM 20149872
ER
PT J
AU Klein, JC
Rushworth, MFS
Behrens, TEJ
Mackay, CE
de Crespigny, AJ
D'Arceuil, H
Johansen-Berg, H
AF Klein, Johannes C.
Rushworth, Matthew F. S.
Behrens, Timothy E. J.
Mackay, Clare E.
de Crespigny, Alex J.
D'Arceuil, Helen
Johansen-Berg, Heidi
TI Topography of connections between human prefrontal cortex and
mediodorsal thalamus studied with diffusion tractography
SO NEUROIMAGE
LA English
DT Article
DE Anatomy; DTI; Human; Macaque; Thalamus
ID COMPARATIVE CYTOARCHITECTONIC ANALYSIS; MACAQUE MONKEYS; CORTICAL
PROJECTIONS; FRONTAL-CORTEX; ORBITOFRONTAL CORTEX; SOCIAL-BEHAVIOR;
BRAIN IMAGES; FUNCTIONAL SPECIALIZATION; DIFFERENTIAL CONNECTIONS;
LONGITUDINAL COLUMNS
AB Studies in monkeys show clear anatomical and functional distinctions among networks connecting with subregions within the prefrontal cortex. Three such networks are centered on lateral orbitofrontal cortex, medial frontal and cingulate cortex, and lateral prefrontal cortex and all have been identified with distinct cognitive roles. Although these areas differ in a number of their cortical connections, some of the first anatomical evidence for these networks came from tracer studies demonstrating their distinct patterns of connectivity with the mediodorsal (MD) nucleus of the thalamus. Here, we present evidence for a similar topography of MD thalamus prefrontal connections, using non-invasive imaging and diffusion tractography (DWI-DT) in human and macaque. DWI-DT suggested that there was a high probability of interconnection between medial MD and lateral orbitofrontal cortex, between caudodorsal MD and medial frontal/cingulate cortex, and between lateral MD and lateral prefrontal cortex, in both species. Within the lateral prefrontal cortex a dorsolateral region (the principal sulcus in the macaque and middle frontal gyrus in the human) was found to have a high probability of interconnection with the MD region between the regions with a high probability of interconnection with other parts of the lateral prefrontal cortex and with the lateral orbitofrontal cortex. In addition to suggesting that the thalamic connectivity in the macaque is a good guide to human prefrontal cortex, and therefore that there are likely to be similarities in the cognitive roles played by the prefrontal areas in both species, the present results are also the first to provide insight into the topography of projections of an individual thalamic nucleus in the human brain. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Klein, Johannes C.; Rushworth, Matthew F. S.; Behrens, Timothy E. J.; Mackay, Clare E.; Johansen-Berg, Heidi] Univ Oxford, Ctr Funct MRI Brain, Oxford OX3 9DU, England.
[Klein, Johannes C.] Goethe Univ Frankfurt, Dept Neurol, Frankfurt, Germany.
[Rushworth, Matthew F. S.; Behrens, Timothy E. J.] Univ Oxford, Dept Expt Psychol, Oxford OX3 9DU, England.
[Mackay, Clare E.] Univ Oxford, Dept Psychiat, Oxford OX3 9DU, England.
[de Crespigny, Alex J.; D'Arceuil, Helen] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP Johansen-Berg, H (reprint author), Univ Oxford, FMRIB Ctr, Oxford OX3 9DU, England.
EM heidi@fmrib.ox.ac.uk
OI Johansen-Berg, Heidi/0000-0002-4134-9730; Mackay,
Clare/0000-0001-6111-8318
FU Biotechnology and Biological Sciences Research Council UK; Wellcome
Trust; Medical Research Council UK; A. A. Martinos Center (NIH)
[P41RR14075, 1S10RR016811-01]
FX This work was supported by the Biotechnology and Biological Sciences
Research Council UK (to JK, HJB, and TEJB). We are grateful for personal
support from the Wellcome Trust (to HJB) and Medical Research Council UK
(to TEJB, MFSR, and FMRIB core grant) and the A. A. Martinos Center
(NIH: P41RR14075, 1S10RR016811-01).
NR 80
TC 76
Z9 76
U1 1
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD JUN
PY 2010
VL 51
IS 2
BP 555
EP 564
DI 10.1016/j.neuroimage.2010.02.062
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 589IT
UT WOS:000277141200006
PM 20206702
ER
PT J
AU Wang, L
LaViolette, P
O'Keefe, K
Putcha, D
Bakkour, A
Van Dijk, KRA
Pihlajamaki, M
Dickerson, BC
Sperling, RA
AF Wang, Liang
LaViolette, Peter
O'Keefe, Kelly
Putcha, Deepti
Bakkour, Akram
Van Dijk, Koene R. A.
Pihlajamaeki, Maija
Dickerson, Bradford C.
Sperling, Reisa A.
TI Intrinsic connectivity between the hippocampus and posteromedial cortex
predicts memory performance in cognitively intact older individuals
SO NEUROIMAGE
LA English
DT Article
ID MEDIAL TEMPORAL-LOBE; RESTING HUMAN BRAIN; FUNCTIONAL CONNECTIVITY;
ALZHEIMERS-DISEASE; DEFAULT-MODE; PARIETAL DEACTIVATION; ACTIVITY
FLUCTUATIONS; MOTOR CORTEX; NETWORK; MRI
AB Coherent fluctuations of spontaneous brain activity are present in distinct functional-anatomic brain systems during undirected wakefulness. However, the behavioral significance of this spontaneous activity has only begun to be investigated. Our previous studies have demonstrated that successful memory formation requires coordinated neural activity in a distributed memory network including the hippocampus and posteromedial cortices, specifically the precuneus and posterior cingulate (PPC), thought to be integral nodes of the default network. In this study, we examined whether intrinsic connectivity during the resting state between the hippocampus and PPC can predict individual differences in the performance of an associative memory task among cognitively intact older individuals. The intrinsic connectivity, between regions within the hippocampus and PPC that were maximally engaged during a subsequent memory fMRI task, was measured during a period of rest prior to the performance of the memory paradigm. Stronger connectivity between the hippocampal and posteromedial regions during rest predicted better performance on the memory task. Furthermore, hippocampal-PPC intrinsic connectivity was also significantly correlated with episodic memory measures on neuropsychological tests, but not with performance in non-memory domains. Whole-brain exploratory analyses further confirmed the spatial specificity of the relationship between hippocampal-default network posteromedial cortical connectivity and memory performance in older subjects. Our findings provide support for the hypothesis that one of the functions of this large-scale brain network is to subserve episodic memory processes. Research is ongoing to determine if impaired connectivity between these regions may serve as a predictor of memory decline related to early Alzheimer's disease. (C) 2010 Elsevier Inc. All rights reserved.
C1 [O'Keefe, Kelly; Putcha, Deepti; Pihlajamaeki, Maija; Sperling, Reisa A.] Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Dept Neurol, Boston, MA 02115 USA.
[Wang, Liang; LaViolette, Peter] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
[Wang, Liang; LaViolette, Peter; Bakkour, Akram; Van Dijk, Koene R. A.; Dickerson, Bradford C.; Sperling, Reisa A.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Bakkour, Akram; Dickerson, Bradford C.; Sperling, Reisa A.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA.
[Van Dijk, Koene R. A.; Dickerson, Bradford C.; Sperling, Reisa A.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP Sperling, RA (reprint author), Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Dept Neurol, 221 Longwood Ave, Boston, MA 02115 USA.
EM reisa@rics.bwh.harvard.edu
RI Wang, Liang/E-8652-2011; Van Dijk, Koene/G-3317-2012;
OI Van Dijk, Koene/0000-0001-6137-4282; Bakkour, Akram/0000-0002-6070-4945
FU NIA NIH HHS [K24 AG035007, P50 AG005134, P50 AG005134-268381, R01
AG027435, R01 AG027435-04, R01 AG027435-05, R01 AG029411]
NR 48
TC 97
Z9 98
U1 1
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD JUN
PY 2010
VL 51
IS 2
BP 910
EP 917
DI 10.1016/j.neuroimage.2010.02.046
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 589IT
UT WOS:000277141200042
PM 20188183
ER
PT J
AU De Grauwe, S
Swain, A
Holcomb, PJ
Ditman, T
Kuperberg, GR
AF De Grauwe, Sophie
Swain, Abigail
Holcomb, Phillip J.
Ditman, Tali
Kuperberg, Gina R.
TI Electrophysiological insights into the processing of nominal metaphors
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Language; Semantic; Metaphor; ERP; N400; LPC; P600
ID EVENT-RELATED POTENTIALS; BRAIN POTENTIALS; RIGHT-HEMISPHERE;
TIME-COURSE; LANGUAGE COMPREHENSION; SENTENCE COMPREHENSION; AMBIGUOUS
WORDS; THEMATIC RELATIONSHIPS; INDIVIDUAL-DIFFERENCES; SYNTACTIC
ANOMALIES
AB We used event-related potentials (ERPs) to examine the time-course of processing metaphorical and literal sentences in the brain. ERPs were measured to sentence-final (Experiment 1) and mid-sentence (Experiment 2) critical words (CWs) as participants read and made plausibility judgments about familiar nominal metaphors ("A is a B") as well as literal and semantically anomalous sentences of the same form. Unlike the anomalous words, which evoked a robust N400 effect (on the CW in experiments 1 and 2 as well as on the sentence-final word in experiment 2), CWs in the metaphorical, relative to the literal, sentences only evoked an early, localized N400 effect that was over by 400 ms after CW onset, suggesting that, by this time, their metaphorical meaning had been accessed. CWs in the metaphorical sentences also evoked a significantly larger LPC (Late Positive Component) than in the literal sentences. We suggest that this LPC reflected additional analysis that resolved a conflict between the implausibility of the literal sentence interpretation and the match between the metaphorical meaning of the CW, the context and stored information within semantic memory, resulting from early access to both literal and figurative meanings of the CWs. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [De Grauwe, Sophie] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit, NL-6500 HE Nijmegen, Netherlands.
[De Grauwe, Sophie; Swain, Abigail; Holcomb, Phillip J.; Ditman, Tali; Kuperberg, Gina R.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA.
[Ditman, Tali; Kuperberg, Gina R.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Ditman, Tali; Kuperberg, Gina R.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[De Grauwe, Sophie] Katholieke Univ Leuven, Lab Cognit Neurol, Louvain, Belgium.
[De Grauwe, Sophie] Univ Groningen, Groningen, Netherlands.
RP De Grauwe, S (reprint author), Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit, POB 9104, NL-6500 HE Nijmegen, Netherlands.
EM s.degrauwe@donders.ru.nl
RI De Grauwe, Sophie/D-9450-2012
FU NIMH [R01 MH071635]; NARSAD (with the Sidney Baer Trust); NICHD
[HD25889, HD043251]; Marco Polo grant; Groninger Universiteitsfonds
grant
FX We are very grateful to Laurie Stowe, Martin Paczynski, Courtney Brown,
and Laura Davis for their help with design and to Mante Nieuwland and
Herman Kolk for their helpful comments on the manuscript. This research
was supported by NIMH (R01 MH071635), NARSAD (with the Sidney Baer
Trust) to GRK, NICHD (HD25889 and HD043251) to PJH and a Marco Polo
grant and a Groninger Universiteitsfonds grant to SDG.
NR 92
TC 34
Z9 34
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD JUN
PY 2010
VL 48
IS 7
BP 1965
EP 1984
DI 10.1016/j.neuropsychologia.2010.03.017
PG 20
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 613ZD
UT WOS:000279023100011
PM 20307557
ER
PT J
AU Filley, CM
AF Filley, Christopher M.
TI White Matter: Organization and Functional Relevance
SO NEUROPSYCHOLOGY REVIEW
LA English
DT Review
DE White matter; Geschwind; Disconnection; Distributed neural networks;
White matter dementia
ID CENTRAL-NERVOUS-SYSTEM; AIDS DEMENTIA COMPLEX; NORMAL-PRESSURE
HYDROCEPHALUS; CHRONIC TOLUENE ABUSE; MULTIPLE-SCLEROSIS; COGNITIVE
IMPAIRMENT; BINSWANGERS-DISEASE; VASCULAR DEMENTIA; DISCONNECTION
SYNDROMES; LUPUS-ERYTHEMATOSUS
AB Norman Geschwind's landmark paper in 1965, "Disconnexion Syndromes in Animals and Man," inspired a generation of investigators to consider the effects of focal brain lesions disrupting higher brain functions. Although Geschwind viewed disconnection as resulting from either white or gray matter lesions, his signature article drew upon the insights of 19th century neurologists and firmly established white matter within the vocabulary of behavioral neurology, neuropsychology, and cognitive neuroscience. This influence, and the advent of sensitive neuroimaging techniques later in the 20th century, led to white matter gradually gaining more attention as an essential component of distributed neural networks subserving cognition and emotion. Today, whereas focal white matter lesions remain central to the pathogenesis of classic neurobehavioral syndromes, diffuse white matter involvement is regarded as increasingly relevant to a wide variety of dementia syndromes and a host of neuropsychiatric disorders as well. In parallel, better understanding of the neurobiology of brain white matter at all ages has been achieved. While much remains to be explored, a general conceptual formulation is that white matter supports information transfer to complement the information processing carried out by gray matter. As knowledge of the organization and functional relevance of white matter continues to advance, improved understanding of the role of myelinated tracts in higher function can be anticipated, and with it many clinical benefits.
C1 [Filley, Christopher M.] Behav Neurol Sect, Aurora, CO 80045 USA.
[Filley, Christopher M.] Univ Colorado, Sch Med, Behav Neurol Sect, Denver, CO USA.
[Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Filley, CM (reprint author), Behav Neurol Sect, 12631 E 17th Ave,MS B185,POB 6511, Aurora, CO 80045 USA.
EM christopher.filley@ucdenver.edu
FU National Institutes of Health [R01 AR049152-02S1, R01 AR049152-01A2]
FX Preparation of this article was supported by National Institutes of
Health research grants R01 AR049152-02S1 and R01 AR049152-01A2.
NR 119
TC 29
Z9 30
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1040-7308
J9 NEUROPSYCHOL REV
JI Neuropsychol. Rev.
PD JUN
PY 2010
VL 20
IS 2
SI SI
BP 158
EP 173
DI 10.1007/s11065-010-9127-9
PG 16
WC Psychology, Clinical; Neurosciences
SC Psychology; Neurosciences & Neurology
GA 607AK
UT WOS:000278470400005
PM 20352350
ER
PT J
AU Eygenov, OV
AF Eygenov, Olee V.
TI Soluble guanylate cyclase as a therapeutic target in pulmonary
hypertension
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Meeting Abstract
CT 6th Int Conf on Biol, Chemistry, and Therapeutic Applications of Nitric
Oxide/2nd Int Conf NO and Cancer/10th Annual Meeting of the
Nitric-Oxide-Soc-Japan
CY JUN 14-18, 2010
CL Kyoto, JAPAN
SP Nitr Oxide Soc Japan
C1 [Eygenov, Olee V.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD JUN
PY 2010
VL 22
SU S
BP S32
EP S32
DI 10.1016/j.niox.2010.05.091
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 606PZ
UT WOS:000278440700088
ER
PT J
AU Ichinose, F
AF Ichinose, Fumito
TI Surviving cardiac arrest with hydrogen sulfide
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Meeting Abstract
CT 6th Int Conf on Biol, Chemistry, and Therapeutic Applications of Nitric
Oxide/2nd Int Conf NO and Cancer/10th Annual Meeting of the
Nitric-Oxide-Soc-Japan
CY JUN 14-18, 2010
CL Kyoto, JAPAN
SP Nitr Oxide Soc Japan
C1 [Ichinose, Fumito] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD JUN
PY 2010
VL 22
SU S
BP S28
EP S28
DI 10.1016/j.niox.2010.05.078
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 606PZ
UT WOS:000278440700075
ER
PT J
AU Rane, S
Nair, G
Duong, TQ
AF Rane, Swati
Nair, Govind
Duong, Timothy Q.
TI DTI at long diffusion time improves fiber tracking
SO NMR IN BIOMEDICINE
LA English
DT Article
DE diffusion tensor imaging; STEAM sequence; rhesus macaques; cross-terms;
formalin fixation; fractional anisotropy; white matter tracking
ID HUMAN BRAIN; SPIN-ECHO; SELF-DIFFUSION; TENSOR; MRI; TISSUE; WATER; NMR;
COEFFICIENT; PRINCIPLES
AB While diffusion-tensor-imaging tractography provides remarkable in vivo anatomical connectivity of the central nervous system, the majority of DTI studies to date are predominantly limited to tracking large white-matter fibers. This study investigated DTI tractography using long diffusion time (t(diff)) to improve tracking of thinner fibers in fixed rhesus monkey brains. Stimulated Echo Acquisition Mode (STEAM) sequence on a 3T Siemens TRIO was modified to include a diffusion module. DTI was acquired using STEAM with t(diff) of 48 and 192 ms with matched signal-to-noise ratios (SNR). Comparisons were also made with the conventional double-spin echo (DSE) at a short t(diff) of 45 ms. Not only did the fractional anisotropy increase significantly with the use of long diffusion time, but directional entropy measures indicated that there was an increased coherence amongst neighboring tensors. Further, the magnitude of the major eigenvector was larger at the t(diff) = 192 ms as compared to the short t(diff). Probabilistic connectivity maps at long t(diff) showed larger areas of connectivity with the use of long diffusion time, which traversed deeper into areas of low anisotropy. With tractography, it was found that the length of the fibers, increased by almost 10% in the callosal fibers that branch into the paracentral gyrus, the precentral gyrus and the post central gyrus. A similar increase of about 20% was observed in the fibers of the internal capsule. These findings offer encouraging data that DTI at long diffusion time could improve tract tracing of small fibers in areas of low fractional anisotropy (FA), such as at the interfaces of white matter and grey matter. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Physiol, San Antonio, TX 78229 USA.
[Rane, Swati] Georgia Inst Technol, Atlanta, GA 30332 USA.
[Rane, Swati; Nair, Govind] Emory Univ, Atlanta, GA 30322 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Duong, Timothy Q.] SW Natl Primate Res Ctr, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008
FU NIH [R01NS45879]; Center for Behavioral Neuroscience, NSF [IBN-9876754]
FX Contract/grant sponsor: NIH; contract/grant number: R01NS45879.;
Contract/grant sponsor: The Center for Behavioral Neuroscience;
contract/grant number: NSF, IBN-9876754.
NR 38
TC 8
Z9 8
U1 0
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0952-3480
J9 NMR BIOMED
JI NMR Biomed.
PD JUN
PY 2010
VL 23
IS 5
BP 459
EP 465
DI 10.1002/nbm.1482
PG 7
WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
GA 620UQ
UT WOS:000279526300003
PM 20175137
ER
PT J
AU Goren, A
Kim, E
Amit, M
Vaknin, K
Kfir, N
Ram, O
Ast, G
AF Goren, Amir
Kim, Eddo
Amit, Maayan
Vaknin, Keren
Kfir, Nir
Ram, Oren
Ast, Gil
TI Overlapping splicing regulatory motifs-combinatorial effects on splicing
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID BINDING-SITES; TRANSCRIPTION FACTORS; PROTEIN-COMPOSITION; SEQUENCE
MOTIFS; GENE PROMOTER; HUMAN GENOME; ENHANCERS; IDENTIFICATION;
RECOGNITION; SELECTION
AB Regulation of splicing in eukaryotes occurs through the coordinated action of multiple splicing factors. Exons and introns contain numerous putative binding sites for splicing regulatory proteins. Regulation of splicing is presumably achieved by the combinatorial output of the binding of splicing factors to the corresponding binding sites. Although putative regulatory sites often overlap, no extensive study has examined whether overlapping regulatory sequences provide yet another dimension to splicing regulation. Here we analyzed experimentally-identified splicing regulatory sequences using a computational method based on the natural distribution of nucleotides and splicing regulatory sequences. We uncovered positive and negative interplay between overlapping regulatory sequences. Examination of these overlapping motifs revealed a unique spatial distribution, especially near splice donor sites of exons with weak splice donor sites. The positively selected overlapping splicing regulatory motifs were highly conserved among different species, implying functionality. Overall, these results suggest that overlap of two splicing regulatory binding sites is an evolutionary conserved widespread mechanism of splicing regulation. Finally, over-abundant motif overlaps were experimentally tested in a reporting minigene revealing that overlaps may facilitate a mode of splicing that did not occur in the presence of only one of the two regulatory sequences that comprise it.
C1 [Goren, Amir; Kim, Eddo; Amit, Maayan; Vaknin, Keren; Kfir, Nir; Ram, Oren; Ast, Gil] Tel Aviv Univ, Sackler Fac Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel.
[Ram, Oren] Massachusetts Gen Hosp, Pathol & Canc Ctr, Boston Harvard Med Sch, Boston Broad Inst, Cambridge, MA USA.
RP Ast, G (reprint author), Tel Aviv Univ, Sackler Fac Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel.
EM gilast@post.tau.ac.il
FU Israel Science Foundation (ISF) [61/09]; Joint Germany-Israeli Research
Program [ca-139]; Deutsche-Israel Project (DIP) [MI-1317]; European
Alternative Splicing Network (EURASNET); Israel Academy of Sciences and
Humanities
FX FUNDING; Israel Science Foundation (ISF 61/09), Joint Germany-Israeli
Research Program (ca-139), Deutsche-Israel Project (DIP MI-1317) and
European Alternative Splicing Network (EURASNET). AG is supported by the
Adams Fellowship Program of the Israel Academy of Sciences and
Humanities and EK is a fellow of the Clore Scholars Program. Funding for
open access charge: EURASNET.
NR 45
TC 8
Z9 8
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUN
PY 2010
VL 38
IS 10
BP 3318
EP 3327
DI 10.1093/nar/gkq005
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 606QQ
UT WOS:000278442600022
PM 20110253
ER
PT J
AU Henderson, GC
Nadeau, D
Horton, ES
Nair, KS
AF Henderson, Gregory C.
Nadeau, Daniel
Horton, Edward S.
Nair, K. Sreekumaran
TI Effects of Adiposity and 30 Days of Caloric Restriction Upon Protein
Metabolism in Moderately vs. Severely Obese Women
SO OBESITY
LA English
DT Article
ID HEALTHY-HUMAN SUBJECTS; WHOLE-BODY; LEUCINE TURNOVER; WEIGHT-LOSS;
INSULIN-SECRETION; AMINO-ACIDS; GLUCOSE; HUMANS; OXIDATION; KINETICS
AB Protein metabolism adapts during caloric restriction (CR) to minimize protein loss, and it is unclear whether greater fat stores favorably affect this response. We sought to determine whether protein metabolism is related to degree of obesity and whether the response to CR is impacted by pre-CR adiposity level. Whole body protein metabolism was studied in 12 obese women over a wide range of BMI (30-53 kg/m(2)) as inpatients using [1-(13)C] leucine as a tracer following 5 days of a weight-maintaining diet and then after 30 days of CR (1,400 kcal deficit with maintained protein intake). When expressed as total rates, per body weight (BW) or per fat-free mass (FFM), leucine rate of appearance (Ra), and nonoxidative leucine disposal (NOLD) were significantly higher in the individuals with a greater degree of obesity (P < 0.05). Leucine oxidation (Rox) was also higher in more highly obese women when expressed as a total rate (P < 0.05) but not if expressed per BW or FFM. CR reduced BW, FFM, and fat mass (P < 0.001), and declines were relatively similar between individuals. CR reduced Ra (P < 0.001), NOLD (P < 0.01), and Rox (P < 0.05), and the relative decline was not affected by differences in fat mass. CR-induced declines were significant even when Ra and NOLD were normalized to BW or FFM. We conclude that fat mass, like FFM, is a key determinant of protein turnover. However, during CR, higher fat mass does not favorably alter the response of protein metabolism and does not mitigate the loss of FFM.
C1 [Henderson, Gregory C.; Nair, K. Sreekumaran] Mayo Clin, Div Endocrinol, Rochester, MN 55905 USA.
[Nadeau, Daniel] Univ Vermont, Dept Med, Burlington, VT USA.
[Horton, Edward S.] Harvard Univ, Joslin Diabet Ctr, Boston, MA 02115 USA.
RP Nair, KS (reprint author), Mayo Clin, Div Endocrinol, Rochester, MN 55905 USA.
EM nair.sree@mayo.edu
RI Biguzzi, Felipe/E-4724-2015
FU Univite Corporation; NIH [RO1 DK412973, UL1 RR024150-01, GCRC RR109, T32
DK07352]
FX We thank the study participants for their time and compliance with the
protocol. We additionally thank Dr Basu, and members of the University
of Vermont GCRC nursing and dietetic staff. This work was supported by
funding from Univite Corporation, NIH grant RO1 DK412973 to K.S.N., NIH
grants UL1 RR024150-01 and GCRC RR109, and G.C.H. was supported by NIH
grant T32 DK07352.
NR 42
TC 5
Z9 5
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD JUN
PY 2010
VL 18
IS 6
BP 1135
EP 1142
DI 10.1038/oby.2009.505
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 600RQ
UT WOS:000278005300012
PM 20134416
ER
PT J
AU Barth, WH
AF Barth, William H., Jr.
TI Familial Spontaneous Preterm Birth Further Evidence of a Complex Genetic
Disease
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Editorial Material
ID GENOMEWIDE ASSOCIATION; RISK
C1 [Barth, William H., Jr.] Massachusetts Gen Hosp, Div Maternal Fetal Med, Boston, MA 02114 USA.
[Barth, William H., Jr.] Harvard Univ, Sch Med, Boston, MA USA.
RP Barth, WH (reprint author), Massachusetts Gen Hosp, Div Maternal Fetal Med, Boston, MA 02114 USA.
EM wbarthjr@partners.org
NR 12
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD JUN
PY 2010
VL 115
IS 6
BP 1114
EP 1115
DI 10.1097/AOG.0b013e3181e15e1f
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 603VD
UT WOS:000278235300002
PM 20502278
ER
PT J
AU Wylie, BJ
Gilbert, S
Landon, MB
Spong, CY
Rouse, DJ
Leveno, KJ
Varner, MW
Caritis, SN
Meis, PJ
Wapner, RJ
Sorokin, Y
Miodovnik, M
O'Sullivan, MJ
Sibai, BM
Langer, O
AF Wylie, Blair J.
Gilbert, Sharon
Landon, Mark B.
Spong, Catherine Y.
Rouse, Dwight J.
Leveno, Kenneth J.
Varner, Michael W.
Caritis, Steve N.
Meis, Paul J.
Wapner, Ronald J.
Sorokin, Yoram
Miodovnik, Menachem
O'Sullivan, Mary J.
Sibai, Baha M.
Langer, Oded
CA Eunice Kennedy Shriver NICHD
TI Comparison of Transverse and Vertical Skin Incision for Emergency
Cesarean Delivery
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID OUTCOMES
AB OBJECTIVE: To compare incision-to-delivery intervals and related maternal and neonatal outcomes by skin incision in primary and repeat emergent cesarean deliveries.
METHODS: From 1999 to 2000, a prospective cohort study of all cesarean deliveries was conducted at 13 hospitals comprising the Eunice Kennedy Shriver National Institute of Child Health and Human Development's Maternal-Fetal Medicine Units Network. This secondary analysis was limited to emergent procedures, defined as those performed for cord prolapse, abruption, placenta previa with hemorrhage, nonreassuring fetal heart rate tracing, or uterine rupture. Incision-to-delivery intervals, incision-to-closure intervals, and maternal outcomes were compared by skin-incision type (transverse compared with vertical) after stratifying for primary compared with repeat singleton cesarean delivery. Neonatal outcomes were compared by skin-incision type.
RESULTS: Of the 37,112 live singleton cesarean deliveries, 3,525 (9.5%) were performed for emergent indications of which 2,498 (70.9%) were performed by transverse and the remaining 1,027 (29.1%) by vertical incision. Vertical skin incision shortened median incision-to-delivery intervals by 1 minute (3 compared with 4 minutes, P<.001) in primary and 2 minutes (3 compared with 5 minutes, P<.001) in repeat cesarean deliveries. Total median operative time was longer after vertical skin incision by 3 minutes in primary (46 compared with 43 minutes, P<.001) and 4 minutes in repeat cesarean deliveries (56 compared with 52 minutes, P<.001). Neonates delivered through a vertical incision were more likely to have an umbilical artery pH of less than 7.0 (10% compared with 7%, P=.02), to be intubated in the delivery room (17% compared with 13%, P=.001), or to be diagnosed with hypoxic ischemic encephalopathy (3% compared with 1%, P<.001).
CONCLUSION: In emergency cesarean deliveries, neonatal delivery occurred more quickly after a vertical skin incision, but this was not associated with improved neonatal outcomes. (Obstet Gynecol 2010; 115: 1134-40)
C1 Columbia Univ, Dept Obstet & Gynecol, New York, NY USA.
Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA.
Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA.
Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA.
Univ Utah, Dept Obstet & Gynecol, Salt Lake City, UT USA.
Univ Pittsburgh, Dept Obstet & Gynecol, Pittsburgh, PA USA.
Wake Forest Univ Hlth Sci, Dept Obstet & Gynecol, Winston Salem, NC USA.
Thomas Jefferson Univ, Dept Obstet & Gynecol, Philadelphia, PA 19107 USA.
Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA.
Univ Cincinnati, Dept Obstet & Gynecol, Cincinnati, OH USA.
Univ Miami, Dept Obstet & Gynecol, Miami, FL USA.
Univ Tennessee, Dept Obstet & Gynecol, Memphis, TN 38103 USA.
Univ Texas San Antonio, Dept Obstet & Gynecol, San Antonio, TX USA.
George Washington Univ, Dept Obstet & Gynecol, Ctr Biostat, Washington, DC USA.
Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
RP Wylie, BJ (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, 55 Fruit St, Boston, MA 02114 USA.
EM bwylie@partners.org
RI Varner, Michael/K-9890-2013
OI caritis, steve/0000-0002-2169-0712; Varner, Michael/0000-0001-9455-3973
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development [HD21410, HD21414, HD27860, HD27861, HD27869, HD27905,
HD27915, HD27917, HD34116, HD34122, HD34136, HD34208, HD34210, HD36801];
National Institute of Child Health and Human Development (NICHD); NICHD
Maternal-Fetal Medicine Units Network; NIH-NICHD [HD-27905-05]; National
Heart, Lung and Blood Institute; National Institutes of Health
FX Supported by grants from the Eunice Kennedy Shriver National Institute
of Child Health and Human Development (HD21410, HD21414, HD27860,
HD27861, HD27869, HD27905, HD27915, HD27917, HD34116, HD34122, HD34136,
HD34208, HD34210, HD36801).; Dr. Landon received honoraria for doing
grand rounds at various institutions and travel and accommodation
expenses covered or reimbursed for grand rounds. Dr. Leveno received
royalties for the Williams Obstetrics textbook. Dr. Varner received
grants or grants pending from the National Institute of Child Health and
Human Development (NICHD) for research conducted with funding from the
NICHD Maternal-Fetal Medicine Units Network. Dr. Miodovnik received a
grant, NIH-NICHD HD-27905-05 (until 2003). Dr. O'Sullivan was reimbursed
for travel expenses related to this study by the NICHD; participated in
the data monitoring committee after no longer a member of the study
group and the compensation for travel and hotel was reimbursed by the
NICHD; received a grant or has grants pending from the National Heart,
Lung and Blood Institute for The Women's Health Initiative (WHI; The
National Children's Study, sponsored by the National Institutes of
Health); travel and accommodation expenses were reimbursed by NHLBI for
the WHI annual meeting. The other authors did not report any potential
conflicts of interest.
NR 9
TC 12
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD JUN
PY 2010
VL 115
IS 6
BP 1134
EP 1140
DI 10.1097/AOG.0b013e3181df937f
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 603VD
UT WOS:000278235300006
PM 20502282
ER
PT J
AU Delaney, S
Shaffer, BL
Cheng, YW
Vargas, J
Sparks, TN
Paul, K
Caughey, AB
AF Delaney, Shani
Shaffer, Brian L.
Cheng, Yvonne W.
Vargas, Juan
Sparks, Teresa N.
Paul, Kathleen
Caughey, Aaron B.
TI Labor Induction With a Foley Balloon Inflated to 30 mL Compared With 60
mL A Randomized Controlled Trial
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID ORAL MISOPROSTOL; CATHETER; GEL; DINOPROSTONE; OXYTOCIN; 30-ML; RISK
AB OBJECTIVE: To compare 30-mL and 60-mL Foley balloon inflation for labor induction and the effect on length of labor and mode of delivery.
METHODS: Women with term, vertex, singleton pregnancies (n = 192) and a Bishop score less than 5 were assigned randomly to receive a transcervical Foley balloon inflated to either 30 mL or 60 mL. Exclusion criteria were painful, regular contractions on admission, ruptured membranes, low-lying placenta, or prior hysterotomy. Randomization was stratified by parity, and health care providers were blinded to Foley balloon size. Primary outcome was delivery within 24 hours of Foley balloon placement. Secondary outcomes included delivery within 12 hours, time from Foley balloon placement to expulsion, cervical dilation after Foley balloon expulsion, maximum oxytocin dose, method of delivery, wchorioamnionitis, meconium, cervical laceration, abruption, 5-minute Apgar score, and umbilical cord gases.
RESULTS: A higher proportion of women randomly assigned to the 60-mL Foley balloon achieved delivery within 12 hours of placement compared with the 30-mL Foley balloon group (26% compared with 14%, P=.04). This difference was more pronounced among nulliparous women. There was no difference in median time interval to delivery or proportion of women who achieved delivery within 24 hours. Median cervical dilation after Foley balloon expulsion was higher in the 60-mL Foley balloon group (4 cm compared with 3 cm, P<.01). There were no differences in the frequencies of cesarean delivery, maternal morbidity, or neonatal outcomes.
CONCLUSION: Labor induction using Foley balloons inflated to 60 mL was more likely to achieve delivery within 12 hours compared with 30-mL inflation. There were no differences in delivery within 24 hours, cesarean delivery, labor complications, or neonatal outcomes.
C1 Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Ctr Clin & Policy Perinatal Res, San Francisco, CA 94143 USA.
Massachusetts Gen Hosp, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Boston, MA 02114 USA.
RP Delaney, S (reprint author), 1959 NE Pacific St,Box 356460, Seattle, WA 98195 USA.
EM delaneys@u.washington.edu
FU Robert Wood Johnson Physician Faculty Scholar [RWJF-61535]
FX Dr. Caughey was funded as a Robert Wood Johnson Physician Faculty
Scholar (RWJF-61535). The other authors did not report any potential
conflicts of interest.
NR 19
TC 32
Z9 35
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD JUN
PY 2010
VL 115
IS 6
BP 1239
EP 1245
DI 10.1097/AOG.0b013e3181dec6d0
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 603VD
UT WOS:000278235300020
PM 20502296
ER
PT J
AU Panda, B
Panda, A
Riley, LE
AF Panda, Britta
Panda, Alexander
Riley, Laura E.
TI Selected Viral Infections in Pregnancy
SO OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Influenza; Hepatitis A; Hepatitis B; Hepatitis C
ID HEPATITIS-C VIRUS; IMMUNIZATION PRACTICES ACIP; TO-INFANT TRANSMISSION;
VERTICAL TRANSMISSION; ADVISORY-COMMITTEE; MATERNAL INFLUENZA; H1N1
INFLUENZA; WOMEN; RISK; RECOMMENDATIONS
AB This article reviews the impact of seasonal influenza on pregnancy with particular emphasis on the 2009 novel H1N1 pandemic. Antiviral therapy for influenza, as well as recommendations and safety data on vaccination are discussed. In addition, the impact of hepatitis A, B, and C in pregnancy is addressed with a focus on prevention and treatment strategies for hepatitis B and C.
C1 [Riley, Laura E.] Massachusetts Gen Hosp, Div Maternal Fetal Med, Boston, MA 02114 USA.
[Panda, Britta] Massachusetts Gen Hosp, Div Maternal Fetal Med, Boston, MA 02210 USA.
[Panda, Alexander] Yale Univ, Div Pulm & Crit Care Med, New Haven, CT 06512 USA.
[Panda, Alexander] Yale Univ, Div Infect Dis, New Haven, CT 06512 USA.
RP Riley, LE (reprint author), Massachusetts Gen Hosp, Div Maternal Fetal Med, Founders 4-414, Boston, MA 02114 USA.
EM lriley@partners.org
NR 55
TC 4
Z9 4
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8545
J9 OBSTET GYN CLIN N AM
JI Obstet. Gynecol. Clin. N. Am.
PD JUN
PY 2010
VL 37
IS 2
BP 321
EP +
DI 10.1016/j.ogc.2010.02.009
PG 12
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 618DK
UT WOS:000279331400014
PM 20685556
ER
PT J
AU Shin, H
Sampat, MP
Koomen, JM
Markey, MK
AF Shin, Hyunjin
Sampat, Mehul P.
Koomen, John M.
Markey, Mia K.
TI Wavelet-Based Adaptive Denoising and Baseline Correction for MALDI TOF
MS
SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
LA English
DT Article
ID MASS-SPECTROMETRY DATA; ENHANCED LASER-DESORPTION; IMPROVED PEAK
DETECTION; DISEASE CLASSIFICATION; SERUM; QUANTIFICATION; IONIZATION;
TRANSFORM; SHRINKAGE; SPECTRUM
AB Proteomic profiling by MALDI TOF mass spectrometry (MS) is an effective method for identifying biomarkers from human serum/plasma, but the process is complicated by the presence of noise in the spectra. In MALDI TOF MS, the major noise source is chemical noise, which is defined as the interference from matrix material and its clusters. Because chemical noise is nonstationary and nonwhite, wavelet-based denoising is more effective than conventional noise reduction schemes based on Fourier analysis. However, current wavelet-based denoising methods for mass spectrometry do not fully consider the characteristics of chemical noise. In this article, we propose new wavelet-based high-frequency noise reduction and baseline correction methods that were designed based on the discrete stationary wavelet transform. The high-frequency noise reduction algorithm adaptively estimates the time-varying threshold for each frequency subband from multiple realizations of chemical noise and removes noise from mass spectra of samples using the estimated thresholds. The baseline correction algorithm computes the monotonically decreasing baseline in the highest approximation of the wavelet domain. The experimental results demonstrate that our algorithms effectively remove artifacts in mass spectra that are due to chemical noise while preserving informative features as compared to commonly used denoising methods.
C1 [Markey, Mia K.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA.
[Shin, Hyunjin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol,Dept Biostat, Boston, MA 02115 USA.
[Sampat, Mehul P.] Univ Calif San Francisco, Dept Neurol, Adv Imaging Multiple Sclerosis Lab, San Francisco, CA 94143 USA.
[Koomen, John M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol Prote, Tampa, FL 33612 USA.
RP Markey, MK (reprint author), Univ Texas Austin, Dept Biomed Engn, 1 Univ Stn C0800, Austin, TX 78712 USA.
EM mia.markey@mail.utexas.edu
RI Koomen, John/D-1844-2013;
OI Markey, Mia/0000-0001-8186-4959
NR 27
TC 10
Z9 10
U1 0
U2 8
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1536-2310
J9 OMICS
JI OMICS
PD JUN
PY 2010
VL 14
IS 3
BP 283
EP 295
DI 10.1089/omi.2009.0119
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 614HS
UT WOS:000279046800007
PM 20455751
ER
PT J
AU Fingert, JH
Roos, B
Eyestone, ME
Pham, JD
Mellot, ML
Stone, E
AF Fingert, John H.
Roos, Ben
Eyestone, Mari E.
Pham, Joshua D.
Mellot, Mei L.
Stone, Edwin
TI Novel Intragenic FRMD7 Deletion in a Pedigree with Congenital X-Linked
Nystagmus
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Nystagmus; Genetics; Mutation
ID MOTOR NYSTAGMUS; INFANTILE NYSTAGMUS; CHINESE FAMILIES; GENE; MUTATIONS;
HEREDITARY; LINKAGE
AB Objective: To identify the disease-causing mutation in a large 3 generation pedigree of X-linked congenital nystagmus.
Methods: Twenty-three members of a single pedigree, including 7 affected males, 2 affected females, 5 obligate carriers, and 9 unaffected family members were tested for mutations in the FRMD7 gene using PCR-based DNA sequencing assays and multiplex PCR assays for deletions.
Results: A hemizygous deletion of exons 2, 3, and 4 of FRMD7 was detected in all affected males in the family and was absent from 40 control subjects.
Conclusions: A range of missense, nonsense, frameshift, and splicing mutations in FRMD7 have been shown to cause X-linked congenital nystagmus. Here we show for the first time that large intragenic deletions of FRMD7 can also cause this form of nystagmus.
C1 [Fingert, John H.; Roos, Ben; Eyestone, Mari E.; Pham, Joshua D.; Stone, Edwin] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
[Mellot, Mei L.] Massachusetts Eye & Ear Infirm, Cambridge, MA USA.
[Stone, Edwin] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
RP Fingert, JH (reprint author), Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA.
EM john-fingert@uiowa.edu
RI Fingert, John/F-8787-2012
OI Fingert, John/0000-0002-0377-0479
FU Research to Prevent Blindness
FX Dr. Fingert is supported by a Research to Prevent Blindness Career
Development Award.
NR 22
TC 11
Z9 13
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1381-6810
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD JUN
PY 2010
VL 31
IS 2
BP 77
EP 80
DI 10.3109/13816810903584989
PG 4
WC Genetics & Heredity; Ophthalmology
SC Genetics & Heredity; Ophthalmology
GA 613VA
UT WOS:000279009200004
PM 20450309
ER
PT J
AU Jones-Jordan, LA
Walline, JJ
Mutti, DO
Rah, MJ
Nichols, KK
Nichols, JJ
Zadnik, K
AF Jones-Jordan, Lisa A.
Walline, Jeffrey J.
Mutti, Donald O.
Rah, Marjorie J.
Nichols, Kelly K.
Nichols, Jason J.
Zadnik, Karla
TI Gas Permeable and Soft Contact Lens Wear in Children
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE pediatric; gas permeable contact lenses; soft contact lenses; myopia;
refractive error; children
ID MYOPIA PROGRESSION CLAMP; RANDOMIZED-TRIAL; SPECTACLES
AB Purpose. To compare children's reports of comfort, vision, and contact lens-related issues in gas permeable (GP) and soft (SCL) contact lens wearers.
Methods. Subjects were 116 8-to 11-year old children in the Contact Lenses and Myopia Progression Study. Aspects of contact lens wear were compared for children remaining in their original treatment group (either GPs or SCLs) for 3 years. Questionnaires were completed at every visit, as was visual acuity. Comparisons were made between the two groups using logistic regression or mixed linear models analyses as appropriate to examine the contact lens wearing experience. Additionally, children crossing over from GP wear to SCLs were compared with children remaining in GP lenses to determine the potential factors related to GP dissatisfaction.
Results. Seventy percent of GP wearers and 93% of SCL wearers wore their assigned lenses every visit. GP wearers wore their lenses significantly fewer hours per week than the SCL wearers (76.2 h/week vs. 86.8 h/week, respectively, p = 0.003). GP wearers had statistically significantly better visual acuity though the difference was not clinically meaningful (p < 0.001). Comfort was poorer among the GP wearers using the Ocular Pain subscale (p < 0.001) but did not differ using a subjective question about comfort. Symptoms were more frequent in GP wearers than SCL wearers (p = 0.002) and were related to reports of discomfort. Significant factors relating to crossing over from GPs to SCLs were lower wearing time with GPs and itching.
Conclusions. Children are able to successfully wear GP and soft contact lenses. Long-term adaptation occurred more frequently to SCLs than to GPs. The amount of time GP lens wearers are able to comfortably wear their contact lenses and the amount of itching may help determine whether they will remain in that modality. (Optom Vis Sci 2010; 87: 414-420)
C1 [Jones-Jordan, Lisa A.; Walline, Jeffrey J.; Mutti, Donald O.; Nichols, Kelly K.; Nichols, Jason J.; Zadnik, Karla] Ohio State Univ, Coll Optometry, Columbus, OH 43210 USA.
[Rah, Marjorie J.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Jones-Jordan, LA (reprint author), Ohio State Univ, Coll Optometry, 338 W 10Th Ave, Columbus, OH 43210 USA.
EM ljordan@optometry.osu.edu
OI Nichols, Jason/0000-0003-1519-7734
FU National Eye Institute, National Institutes of Health, Bethesda, MD
[K23-EY00383, T35-EY07151, R21-EY12273, R24-014792]; Menicon Co, Ltd,
Nagoya, Japan; CIBAVision Corporation, Duluth, GA; SOLA Optical, U.S.,
Petaluma, CA; American Optometric Foundation
FX This study was supported by grants K23-EY00383, T35-EY07151,
R21-EY12273, and R24-014792 from the National Eye Institute, National
Institutes of Health, Bethesda, MD; Menicon Co, Ltd, Nagoya, Japan;
CIBAVision Corporation, Duluth, GA; SOLA Optical, U.S., Petaluma, CA;
and an American Optometric Foundation William C. Ezell Fellowship,
sponsored by Essilor, Dallas, TX (to JJW).
NR 32
TC 9
Z9 9
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JUN
PY 2010
VL 87
IS 6
BP 414
EP 420
DI 10.1097/OPX.0b013e3181dc9a04
PG 7
WC Ophthalmology
SC Ophthalmology
GA 622EC
UT WOS:000279642200006
PM 20386349
ER
PT J
AU Eckstein, F
Wirth, W
Hunter, DJ
Guermazi, A
Kwoh, CK
Nelson, DR
Benichou, O
AF Eckstein, F.
Wirth, W.
Hunter, D. J.
Guermazi, A.
Kwoh, C. K.
Nelson, D. R.
Benichou, O.
CA OAI Investigators
TI Magnitude and regional distribution of cartilage loss associated with
grades of joint space narrowing in radiographic osteoarthritis - data
from the Osteoarthritis Initiative (OAI)
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Joint space narrowing; Radiographic osteoarthritis; Cartilage loss;
Magnetic resonance imaging; Side comparison
ID KNEE-JOINT; ARTICULAR-CARTILAGE; SURFACE-AREA; STANDING ANTEROPOSTERIOR;
TIBIOFEMORAL COMPARTMENT; 3 TESLA; RESONANCE; BONE; MORPHOLOGY;
PRECISION
AB Objective Clinically, radiographic joint space narrowing (JSN) is regarded a surrogate of cartilage loss in osteoarthritis (OA) Using magnetic resonance imaging (MRI), we explored the magnitude and regional distribution of differences in cartilage thickness and subchondral bone area associated with specific Osteoarthritis Research Society International (OARSI) JSN grades
Method Seventy-three participants with unilateral medial JSN were selected from the first half (2678 cases) of the OA Initiative cohort (45, 21, and 7 with OARSI JSN grades 1, 2, and 3, respectively, no medial JSN in the contra-lateral knee) Bilateral sagittal baseline DESSwe MRIs were segmented by experienced operators Intra-person between-knee differences in cartilage thickness and subchondral bone areas were determined in medial femorotibial subregions
Results Knees with medial OARSI JSN grades 1, 2, and 3 displayed a 190 mu m (5 2%), 630 mu m (18%), and 1560 mu m (44%) smaller cartilage thickness in weight-bearing medial femorotibial compartments compared to knees without JSN, respectively. The weight-bearing femoral condyle displayed relatively greater differences than the posterior femoral condyle or the medial tibia (MT) The central subregion within the weight-bearing medial femur (cMF) of the femoral condyle (30-75 degrees), and the external and central subregions within the tibia displayed relatively greater JSN-associated differences compared to other medial femorotibial subregions Knees with higher JSN grades also displayed larger than contralateral femorotibial subchondral bone areas
Conclusions This study provides quantitative estimates of JSN-related cartilage loss, with the central part of the weight-bearing femoral condyle being most strongly affected Knees with higher JSN grades displayed larger subchondral bone areas, suggesting that an increase in subchondral bone area occurs in advanced OA (C) 2010 Osteoarthritis Research Society International Published by Elsevier Ltd All rights reserved
C1 [Eckstein, F.; Wirth, W.] PMU, Inst Anat, A-5020 Salzburg, Austria.
[Eckstein, F.; Wirth, W.] Chondrometrics GmbH, Ainring, Germany.
[Hunter, D. J.] New England Baptist Hosp, Div Res, Boston, MA USA.
[Guermazi, A.] Boston Univ, Med Ctr, Dept Radiol, Boston, MA 02118 USA.
[Kwoh, C. K.] Univ Pittsburgh, Div Clin Immunol & Rheumatol, Pittsburgh, PA USA.
[Kwoh, C. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Nelson, D. R.; Benichou, O.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
RP Eckstein, F (reprint author), PMU, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria.
RI Eckstein, Felix/E-1585-2011; Hunter, David/A-4622-2010; Wirth,
Wolfgang/C-8724-2011
OI Hunter, David/0000-0003-3197-752X; Wirth, Wolfgang/0000-0002-2297-8283
FU Eli Lilly Co, IN; National Institute of Health, Department of Health and
Human Services [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260,
N01-AR-2-2261, N01-AR-22262]; OAI include Merck Research Laboratories;
Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Pfizer, Inc.
FX Funding sources The image analysis of this study was funded by Eli Lilly
& Co, IN. The images were acquired by the OAI, a public private
partnership comprised five contracts (N01-AR-2-2258, N01-AR-2-2259;
N01-AR-2-2260, N01-AR-2-2261; N01-AR-22262) funded by the National
Institute of Health, a branch of the Department of Health and Human
Services, and conducted by the OAI Study Investigators. Private funding
partners of the OAI include Merck Research Laboratories; Novartis
Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer, Inc. Private
sector funding for the OAI is managed by the Foundation for the National
Institute of Health This manuscript has received the approval of the OAI
Publications Committee based on a review of its scientific content and
data interpretation
NR 43
TC 31
Z9 31
U1 0
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD JUN
PY 2010
VL 18
IS 6
BP 760
EP 768
DI 10.1016/j.joca.2009.12.009
PG 9
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 609FX
UT WOS:000278642400005
PM 20171298
ER
PT J
AU Perkins, JA
Manning, SC
Tempero, RM
Cunningham, MJ
Edmonds, JL
Hoffer, FA
Egbert, MA
AF Perkins, Jonathan A.
Manning, Scott C.
Tempero, Richard M.
Cunningham, Michael J.
Edmonds, Joseph L., Jr.
Hoffer, Fredric A.
Egbert, Mark A.
TI Lymphatic malformations: Current cellular and clinical investigations
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
ID VASCULAR MALFORMATIONS; ENDOTHELIAL-CELLS; OUTCOMES RESEARCH; VEGF-C;
LYMPHANGIOMAS; HEMANGIOMAS; INFANTS; DISEASE; SYSTEM; TUMORS
AB OBJECTIVE: Summarize current knowledge of lymphatic malformation development, biology, and clinical outcome measures.
METHODS: Panel presentation of lymphatic malformation biology and measurement of head and neck malformation treatment outcomes.
RESULTS: Characterization of lymphatic malformation endothelial and stromal cells may lead to biologically based treatment. Traditionally, lymphatic malformation treatment outcomes have been measured according to reduction of malformation size. Currently, methods to measure functional outcomes following lymphatic malformation treatment are lacking. This is particularly apparent when the malformation directly involves the upper aero-digestive tract.
CONCLUSIONS: The etiology and pathogenesis of head and neck lymphatic malformations are poorly understood, but understanding is improving through ongoing investigation. Reduction of lymphatic malformation size is generally possible, but further work is necessary to optimize methods for measuring therapeutic outcomes in problematic areas. (C) 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved.
C1 [Perkins, Jonathan A.; Manning, Scott C.] Seattle Childrens Hosp, Div Pediat Otolaryngol Head & Neck Surg, Seattle, WA 98105 USA.
[Perkins, Jonathan A.; Manning, Scott C.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
[Tempero, Richard M.] Boys Town Natl Res Hosp, Omaha, NE 68131 USA.
[Cunningham, Michael J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol, Boston, MA USA.
[Cunningham, Michael J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Edmonds, Joseph L., Jr.] Childrens ENT Houston, Houston, TX USA.
[Hoffer, Fredric A.] Univ Washington, Dept Radiol, Seattle Childrens Hosp, Seattle, WA 98195 USA.
[Egbert, Mark A.] Univ Washington, Dept Oral & Maxillofacial Surg, Seattle Childrens Hosp, Seattle, WA 98195 USA.
[Edmonds, Joseph L., Jr.] Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA.
[Edmonds, Joseph L., Jr.] Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA.
[Edmonds, Joseph L., Jr.] Weill Cornell Coll Med, Dept Otolaryngol, New York, NY USA.
[Edmonds, Joseph L., Jr.] Univ Texas Houston, Sch Med, Dept Otolaryngol, Houston, TX USA.
RP Perkins, JA (reprint author), Seattle Childrens Hosp, Div Otolaryngol Head & Neck Surg, 4800 Sand Point Way NE,Mailstop W-7729, Seattle, WA 98105 USA.
EM jonathan.perkins@seattlechildrens.org
FU Arthrocare
FX Arthrocare: approval of manuscript.
NR 32
TC 36
Z9 37
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD JUN
PY 2010
VL 142
IS 6
BP 789
EP 794
DI 10.1016/j.otohns.2010.02.025
PG 6
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 601EQ
UT WOS:000278041400003
PM 20493347
ER
PT J
AU Perkins, JA
Manning, SC
Tempero, RM
Cunningham, MJ
Edmonds, JL
Hoffer, FA
Egbert, MA
AF Perkins, Jonathan A.
Manning, Scott C.
Tempero, Richard M.
Cunningham, Michael J.
Edmonds, Joseph L., Jr.
Hoffer, Fredric A.
Egbert, Mark A.
TI Lymphatic malformations: Review of current treatment
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Review
ID CYSTIC HYGROMA; PERCUTANEOUS SCLEROTHERAPY; VASCULAR MALFORMATIONS;
CHILDREN; OK-432; LYMPHANGIOMAS; MANAGEMENT; INJECTION; HEAD; NECK
AB OBJECTIVE: Summarize current knowledge of lymphatic malformation medical, sclerotherapy, and surgical treatment; and highlight areas of treatment controversy and treatment difficulty that need improvement.
METHODS: Panel presentation of various aspects of lymphatic malformation treatment.
RESULTS: The mainstay of lymphatic malformation treatment has been surgical resection, which has been refined through lesion staging and radiographic characterization. Intralesional sclerotherapy in macrocystic lymphatic malformations is effective. Suprahyoid microcystic lymphatic malformations are more difficult to treat than macrocystic lymphatic malformations in the infrahyoid and posterior cervical regions. Bilateral suprahyoid lymphatic malformations require staged treatment to prevent complications, Lymphatic malformation treatment planning is primarily determined by the presence or possibility of functional compromise. Problematic areas include chronic lymphatic malformation inflammation, dental health maintenance, macroglossia, airway obstruction, and dental malocclusion.
CONCLUSIONS: Lymphatic malformation treatment improvements have been made through radiographic characterization and staging of lymphatic malformations. Direct malformation involvement of the upper aerodigestive tract can cause significant functional compromise that is difficult to treat. (C) 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved.
C1 [Perkins, Jonathan A.; Manning, Scott C.] Seattle Childrens Hosp, Div Pediat Otolaryngol Head & Neck Surg, Seattle, WA 98105 USA.
[Perkins, Jonathan A.; Manning, Scott C.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
[Tempero, Richard M.] Boys Town Natl Res Hosp, Omaha, NE 68131 USA.
[Cunningham, Michael J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol, Boston, MA USA.
[Cunningham, Michael J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Edmonds, Joseph L., Jr.] Childrens ENT Houston, Houston, TX USA.
[Hoffer, Fredric A.] Univ Washington, Dept Radiol, Seattle Childrens Hosp, Seattle, WA 98195 USA.
[Egbert, Mark A.] Univ Washington, Dept Oral & Maxillofacial Surg, Seattle Childrens Hosp, Seattle, WA 98195 USA.
[Edmonds, Joseph L., Jr.] Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA.
[Edmonds, Joseph L., Jr.] Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA.
[Edmonds, Joseph L., Jr.] Weill Cornell Coll Med, Dept Otolaryngol, New York, NY USA.
[Edmonds, Joseph L., Jr.] Univ Texas Houston, Sch Med, Dept Otolaryngol, Houston, TX USA.
RP Perkins, JA (reprint author), Seattle Childrens Hosp, Div Otolaryngol Head & Neck Surg, 4800 Sand Point Way NE,Mailstop W-7729, Seattle, WA 98105 USA.
EM jonathan.perkins@seattlechildrens.org
FU Arthrocare
FX Arthrocare: approval of manuscript.
NR 51
TC 62
Z9 69
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD JUN
PY 2010
VL 142
IS 6
BP 795
EP 803
DI 10.1016/j.otohns.2010.02.026
PG 9
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 601EQ
UT WOS:000278041400004
PM 20493348
ER
PT J
AU Miller, ME
Makary, C
Lopez, IA
Ishiyama, A
AF Miller, Mia E.
Makary, Chadi
Lopez, Ivan A.
Ishiyama, Akira
TI Endolymphatic Hydrops in Otologic Syphilis: A Temporal Bone Study
SO OTOLOGY & NEUROTOLOGY
LA English
DT Article
DE Endolymphatic hydrops; Gumma; Microgummata; Osteitis; Otologic syphilis;
Otosyphilis; Syphilis
ID HEARING-LOSS; SAC; OBLITERATION; DUCT
AB Hypothesis: Endolymphatic hydrops in temporal bones with otologic syphilis directly relates to osteitis, new bone formation, and/or resorption along the course of the endolymphatic system.
Background: Meniere's disease and otosyphilis both cause progressive endolymphatic hydrops, and the mechanism of hydrops formation in each disease process remains unclear. Traditionally, osteitic changes of the labyrinthine capsule were thought to lead to endolymphatic hydrops in syphilitic temporal bones. More recently, authors have suggested that microgummata and inflammatory change obliterating the endolymphatic duct and sac may cause endolymphatic hydrops in otosyphilis.
Methods: This is a histopathologic study of 11 temporal bones from patients with otosyphilis. Gathered data include presence/absence of endolymphatic hydrops of the cochlea, saccule, and utricle; bony changes involving the endolymphatic duct and sac; a description of bony changes throughout the temporal bone; and the degree of atrophy of the organ of Corti, spiral ganglion, and stria vascularis.
Results: The presence of osteitic changes surrounding the endolymphatic duct and sac and whether the endolymphatic system was obliterated did not directly correlate with the presence of endolymphatic hydrops in this study.
Conclusion: We reject the hypothesis that otologic syphilis is directly related to osteitis, new bone formation, and/or resorption along the course of the endolymphatic duct and sac. Although a change in the endolymphatic system may contribute to the formation of endolymphatic hydrops in otologic syphilis, it is not the only cause. Whether otosyphilis and Meniere's disease share a common mechanism of endolymphatic hydrops formation remains unclear, and the relationship between these causes of hydrops should be investigated further.
C1 [Miller, Mia E.; Lopez, Ivan A.; Ishiyama, Akira] Univ Calif Los Angeles, Div Head & Neck Surg, Los Angeles, CA 90095 USA.
[Makary, Chadi] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Ishiyama, A (reprint author), Univ Calif Los Angeles, Div Head & Neck Surg, 10833 Le Conte Ave,CHS 62-158, Los Angeles, CA 90095 USA.
EM ishiyama@ucla.edu
OI Lopez, Ivan/0000-0001-5205-7293
FU National Institute on Deafness and Other Communication Disorders
Temporal Bone, Hearing and Balance Pathology Resource Registry; National
Institutes of Health [NIDCD R01 DC-06-001, DC 008635, DC 005028, DC
005187]; Temporal Bone Registry at the Massachusetts Eye and Ear
Infirmary
FX This work was supported in part by the Otopathology Mini-Travel
Fellowship Program of the National Institute on Deafness and Other
Communication Disorders Temporal Bone, Hearing and Balance Pathology
Resource Registry. This also was funded in part by the National
Institutes of Health Grants NIDCD R01 DC-06-001, DC 008635, DC 005028,
and DC 005187.; The authors thank Dr. Saumil Merchant and the Temporal
Bone Registry at the Massachusetts Eye and Ear Infirmary for help and
support.
NR 16
TC 8
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1531-7129
J9 OTOL NEUROTOL
JI Otol. Neurotol.
PD JUN
PY 2010
VL 31
IS 4
BP 681
EP 686
DI 10.1097/MAO.0b013e3181dbb7e4
PG 6
WC Clinical Neurology; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA 604CF
UT WOS:000278254200023
PM 20431499
ER
PT J
AU Goebel, JR
Sherbourne, CD
Asch, SM
Meredith, L
Cohen, AB
Hagenmaier, E
Lanto, AB
Simon, B
Rubenstein, LV
Shugarman, LR
Lorenz, KA
AF Goebel, Joy R.
Sherbourne, Cathy D.
Asch, Steven M.
Meredith, Lisa
Cohen, Angela B.
Hagenmaier, Emily
Lanto, Andy B.
Simon, Barbara
Rubenstein, Lisa V.
Shugarman, Lisa R.
Lorenz, Karl A.
TI Addressing Patients' Concerns about Pain Management and Addiction Risks
SO PAIN MANAGEMENT NURSING
LA English
DT Article
ID NURSES; QUALITY; KNOWLEDGE; VIGNETTES; BARRIERS
AB Fear of engendering addiction is frequently reported as both a provider and a patient barrier to effective pain management. In this study, a clinical scenario ascertained nursing staff members' usual practice in addressing addiction fears for patients with concerns about the addictive potential of pain medication. One hundred forty-five Veterans Health Administration nursing staff members from eight ambulatory care sites were queried to identify variables associated with proclivity to address patient fears about addiction risks in a population where pain is prevalent and the risk for substance abuse is high. Regarding addressing addiction concerns, 66% of nursing staff were very likely, 16% somewhat likely, 9% unsure, 6% somewhat unlikely, and 2% very unlikely to take action. Health technicians were less likely to address addiction concerns than registered or licensed vocational nurses (odds ratio [OR] 0.116; p=.004). Nursing staff with more years' experience (OR 1.070; p=.005) and higher levels of self-efficacy/confidence (OR 1.380; p=.001) were more likely to engage in discussions related to addiction risks. Targeted efforts to improve pain management activities should focus on retaining experienced nursing staff in initial assessment positions and improving the skills and confidence of less experienced and less skilled staff. (C) 2010 by the American Society for Pain Management Nursing
C1 [Goebel, Joy R.] Calif State Univ Long Beach, Dept Nursing, Long Beach, CA 90840 USA.
[Sherbourne, Cathy D.; Asch, Steven M.; Meredith, Lisa; Rubenstein, Lisa V.; Shugarman, Lisa R.; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA.
[Asch, Steven M.; Meredith, Lisa; Rubenstein, Lisa V.; Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Asch, Steven M.; Cohen, Angela B.; Hagenmaier, Emily; Lanto, Andy B.; Simon, Barbara; Rubenstein, Lisa V.; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Goebel, JR (reprint author), Calif State Univ Long Beach, Dept Nursing, 1250 Bellflower Blvd, Long Beach, CA 90840 USA.
NR 36
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1524-9042
EI 1532-8635
J9 PAIN MANAG NURS
JI Pain Manag. Nurs.
PD JUN
PY 2010
VL 11
IS 2
BP 92
EP 98
DI 10.1016/j.pmn.2009.03.009
PG 7
WC Nursing
SC Nursing
GA 610QH
UT WOS:000278748700005
PM 20510839
ER
PT J
AU Arnstein, P
AF Arnstein, Paul
TI Balancing Analgesic Efficacy with Safety Concerns in the Older Patient
SO PAIN MANAGEMENT NURSING
LA English
DT Article
ID LIDOCAINE PATCH 5-PERCENT; INAPPROPRIATE MEDICATION USE; ADVERSE DRUG
EVENTS; OF-THE-LITERATURE; NEUROPATHIC PAIN; TOPICAL NSAIDS;
DOUBLE-BLIND; EXPLICIT CRITERIA; HIGH-RISK; PREVENTION
AB The rapidly expanding number of aged Americans and the increasing prevalence of persistent pain in older adults create an urgent need to unravel the complexities of chronic pain management in this population. This requires health professionals to understand both normal and pathologic changes that occur within the aging body and mind, as well as how those factors affect responses to pain and pain-relieving treatments. The medical management of pharmacologic treatment for pain in older adults is often suboptimal, ranging from failing to use analgesics for patients with considerable pain to exposing older adults to potentially life-threatening toxicities, overdoses, or drug interactions. Models for safe and effective approaches to treating pain in older adults exist, but treatments must still be tailored for each individual's needs. A growing array of targeted therapies are available for managing pain, yet two or three trials of different agents within the same drug class are often needed to optimize treatment because of the considerable variability in responses to the effects of particular medications. Older adults tend to be more vulnerable to side effects and drug interactions than their younger counterparts, owing to differences in drug distribution, metabolism, and elimination. This review delineates these vulnerabilities and informs clinicians of the strategies needed to promote safe and effective use of medications to treat pain in older adults. The goal of this paper was to review specific considerations for balancing efficacy and safety in the pharmacologic treatment of persistent pain in older adults. (C) 2010 by the American Society for Pain Management Nursing
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Arnstein, P (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM pmarnstein@partners.org
NR 65
TC 7
Z9 7
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1524-9042
EI 1532-8635
J9 PAIN MANAG NURS
JI Pain Manag. Nurs.
PD JUN
PY 2010
VL 11
IS 2
SU 1
BP S11
EP S22
DI 10.1016/j.pmn.2010.03.003
PG 12
WC Nursing
SC Nursing
GA 610QJ
UT WOS:000278748900002
PM 20510845
ER
PT J
AU Rodriguez, KL
Bayliss, NK
Jaffe, E
Zickmund, S
Sevick, MA
AF Rodriguez, Keri L.
Bayliss, Nichole K.
Jaffe, Emily
Zickmund, Susan
Sevick, Mary Ann
TI Factor analysis and internal consistency evaluation of the FAMCARE Scale
for use in the long-term care setting
SO PALLIATIVE & SUPPORTIVE CARE
LA English
DT Article
DE Long-term care; Nursing homes; Consumer satisfaction; Family;
Psychometrics
AB Objective: The FAMCARE Scale was originally designed to measure family satisfaction with advanced cancer care. The current study evaluated the instrument's psychometric qualities when used in the long-term care (LTC) setting.
Method: In a prospective cohort study in 2004, the 20-item instrument was administered via telephone to family members of 51 patients receiving LTC in Veterans Affairs facilities. Satisfaction scores on a 5-point Likert scale were used for factor analysis and internal consistency evaluation.
Results: Although 16 patients were in geriatric palliative care and 35 were in nursing home care, scores of their family members did not vary based on care unit. The total satisfaction score was high, with a mean (SD) of 44.7 (11.9) and a Cronbach alpha of 0.94. Inter-item correlations were low for care availability items (range, 0.01-0.59). Two items-availability of a hospital bed and availability of nurses to the family-had low eigenvalues (0.26 and 0.18, respectively) and weak correlations with the total score (0.23 and 0.16, respectively).
Significance of results: In the LTC setting, FAMCARE appears to have good internal consistency, but it may be preferable to exclude the two items with weak correlations and to use a 10-point visual analog scale.
C1 [Rodriguez, Keri L.; Bayliss, Nichole K.; Zickmund, Susan; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Rodriguez, Keri L.; Zickmund, Susan; Sevick, Mary Ann] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Rodriguez, Keri L.; Jaffe, Emily; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA.
[Bayliss, Nichole K.] Univ Pittsburgh, Sociol Dept, Pittsburgh, PA USA.
[Jaffe, Emily] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA USA.
[Sevick, Mary Ann] Univ Pittsbsburg, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA.
RP Rodriguez, KL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Bldg 2,Room 4083E,151C-H, Pittsburgh, PA 15206 USA.
EM keri.rodriguez@va.gov
NR 25
TC 10
Z9 10
U1 1
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1478-9515
J9 PALLIAT SUPPORT CARE
JI Palliat. Support Care
PD JUN
PY 2010
VL 8
IS 2
BP 169
EP 176
DI 10.1017/S1478951509990927
PG 8
WC Health Policy & Services
SC Health Care Sciences & Services
GA V25ON
UT WOS:000208487400009
PM 20331914
ER
PT J
AU Lando, HA
Hipple, BJ
Muramoto, M
Klein, JD
Prokhorov, AV
Ossip, DJ
Winickoff, JP
AF Lando, Harry A.
Hipple, Bethany J.
Muramoto, Myra
Klein, Jonathan D.
Prokhorov, Alexander V.
Ossip, Deborah J.
Winickoff, Jonathan P.
TI Tobacco Control and Children: An International Perspective
SO PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY
LA English
DT Article
ID DEVELOPING-COUNTRIES; SMOKING; HEALTH; WORKING; YOUTH; TUBERCULOSIS;
CARCINOGEN; EXPOSURE; IMPACT; HIV
AB Tobacco use currently claims >5 million deaths per year worldwide and this number is projected to increase dramatically by 2030. The burden of death and disease is shifting to low- and middle-income countries. Tobacco control initiatives face numerous challenges including not being a high priority in many countries, government dependence upon immediate revenue from tobacco sales and production, and opposition of the tobacco industry. Tobacco leads to environmental harms, exploitation of workers in tobacco farming, and increased poverty. Children are especially vulnerable. Not only do they initiate tobacco use themselves, but also they are victimized by exposure to highly toxic secondhand smoke. Awareness of tobacco adverse health effects is often superficial even among health professionals. The tobacco industry continues to aggressively promote its products and recognizes that children are its future. The tools and knowledge exist, however, to dramatically reduce the global burden of tobacco. In 2003 the World Health Organization adopted the Framework Convention on Tobacco Control. Aggressive tobacco control initiatives have been undertaken not only in high-income countries but also in less-wealthy countries such as Uruguay and Thailand. Stakeholders must come together in coordinated efforts and there must be a broad and sustained investment in global tobacco control.
C1 [Lando, Harry A.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA.
[Hipple, Bethany J.; Winickoff, Jonathan P.] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Policy, Boston, MA 02114 USA.
[Hipple, Bethany J.] Erasmus Univ, Inst Hlth Policy & Management, Rotterdam, Netherlands.
[Muramoto, Myra] Univ Arizona, Tucson, AZ USA.
[Klein, Jonathan D.] Amer Acad Pediat, Elk Grove Village, IL USA.
[Prokhorov, Alexander V.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Ossip, Deborah J.] Univ Rochester, Rochester, NY USA.
RP Lando, HA (reprint author), Univ Minnesota, Div Epidemiol & Community Hlth, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.
EM lando001@umn.edu
FU NIH [R01 CA132950]
FX This article was written on behalf of the American Academy of Pediatrics
Tobacco Consortium and the Julius B. Richmond Center of Excellence. Some
content overlaps with an editorial in the Bulletin of the World Health
Organization 4 by the current authors. Additional content was taken from
a longer unpublished draft of that editorial. This study was supported
in part by an NIH grant R01 CA132950 (Principal Investigator: Deborah J.
Ossip).
NR 42
TC 5
Z9 5
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2151-321X
J9 PEDIAT ALLER IMM PUL
JI Pediatr. Allergy Immunol. Pulmonol.
PD JUN
PY 2010
VL 23
IS 2
BP 99
EP 103
DI 10.1089/ped.2010.0012
PG 5
WC Allergy; Immunology; Pediatrics; Respiratory System
SC Allergy; Immunology; Pediatrics; Respiratory System
GA 645DX
UT WOS:000281432200002
PM 22375275
ER
PT J
AU Gutierrez, A
Grebliunaite, R
Feng, H
Den Hertog, J
Prochownik, E
Testa, J
Kanki, J
Look, T
AF Gutierrez, Alejandro
Grebliunaite, Ruta
Feng, Hui
Den Hertog, Jeroen
Prochownik, Edward
Testa, Joseph
Kanki, John
Look, Thomas
TI Pten INACTIVATION PROMOTES LOSS OF MYC "ONCOGENE ADDICTION" IN A
CONDITIONAL ZEBRAFISH MODEL OF T-ALL
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Gutierrez, Alejandro; Grebliunaite, Ruta; Feng, Hui; Den Hertog, Jeroen; Prochownik, Edward; Testa, Joseph; Kanki, John; Look, Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2010
VL 54
IS 6
BP 787
EP 787
PG 1
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 578JT
UT WOS:000276290300003
ER
PT J
AU Gutierrez, A
Dahlberg, S
Neuberg, D
Zhang, JH
Grebliunaite, R
Sanda, T
Protopopov, A
Kutok, J
Winter, S
Larson, R
Borowitz, M
Loh, M
Silverman, L
Chin, L
Hunger, S
Sallan, S
Look, T
AF Gutierrez, Alejandro
Dahlberg, Suzanne
Neuberg, Donna
Zhang, Jianhua
Grebliunaite, Ruta
Sanda, Takaomi
Protopopov, Alexei
Kutok, Jeffrey
Winter, Stuart
Larson, Richard
Borowitz, Michael
Loh, Mignon
Silverman, Lewis
Chin, Lynda
Hunger, Stephen
Sallan, Stephen
Look, Thomas
TI ABSENCE OF BIALLELIC TCR gamma DELETIONS (ABGD) PREDICTS INDUCTION
FAILURE IN PEDIATRIC T-ALL
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Gutierrez, Alejandro; Dahlberg, Suzanne; Neuberg, Donna; Zhang, Jianhua; Grebliunaite, Ruta; Sanda, Takaomi; Protopopov, Alexei; Kutok, Jeffrey; Winter, Stuart; Larson, Richard; Borowitz, Michael; Loh, Mignon; Silverman, Lewis; Chin, Lynda; Hunger, Stephen; Sallan, Stephen; Look, Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2010
VL 54
IS 6
BP 812
EP 812
PG 1
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 578JT
UT WOS:000276290300090
ER
PT J
AU Narla, A
Bernt, K
Gordon, P
Hettmer, S
Hoffman, I
Lee, M
Billett, A
AF Narla, Anu
Bernt, Kathrin
Gordon, Peter
Hettmer, Simone
Hoffman, Inga
Lee, Michelle
Billett, Amy
TI MAXIMIZING THE USE OF TMP-SMZ FOR PCP PROPHYLAXIS IN PEDIATRIC ONCOLOGY
PATIENTS
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Narla, Anu; Bernt, Kathrin; Gordon, Peter; Hettmer, Simone; Hoffman, Inga; Lee, Michelle; Billett, Amy] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 2
TC 0
Z9 0
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2010
VL 54
IS 6
BP 829
EP 829
PG 1
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 578JT
UT WOS:000276290300151
ER
PT J
AU Benor, S
Russell, GH
Silver, M
Israel, EJ
Yuan, Q
Winter, HS
AF Benor, Shira
Russell, George H.
Silver, Michael
Israel, Esther J.
Yuan, Qian
Winter, Harland S.
TI Shortcomings of the Inflammatory Bowel Disease Serology 7 Panel
SO PEDIATRICS
LA English
DT Article
DE inflammatory bowel disease; serological testing; Crohn disease;
ulcerative colitis; indeterminate colitis; thrombocytosis; erythrocyte
sedimentation rate; anemia
ID CROHNS-DISEASE; ULCERATIVE-COLITIS; SACCHAROMYCES-CEREVISIAE;
DIAGNOSTIC-ACCURACY; LABORATORY TESTS; CHILDREN; MARKERS; ANTIBODIES;
ASCA; RESPONSES
AB OBJECTIVE: The goal was to compare the predictive values of the Prometheus Inflammatory Bowel Disease (IBD) Serology 7 (IBD7) panel (Prometheus Laboratories, San Diego, CA) with the predictive values of routine blood tests in a population of children referred for initial evaluation of suspected IBD.
METHODS: Medical records of pediatric patients referred for evaluation of IBD for whom IBD7 testing was performed at Prometheus Laboratories between January 2006 and November 2008 were reviewed. Patients underwent diagnosis by pediatric gastroenterologists on the basis of clinical, radiologic, endoscopic, and pathologic evaluations.
RESULTS: A total of 394 records were identified. We excluded 90 records on the basis of age of >21 years, previous diagnosis of IBD, or unclear diagnosis. The prevalence of IBD in this cohort was 38%. The sensitivity, specificity, positive predictive value, negative predictive value, and kappa value for the serological panel were 67%, 76%, 63%, 79%, and 42%, respectively, compared with values for a combination of 3 abnormal routine laboratory test results of 72%, 94%, 85%, 79%, and 47%. The antiflagellin antibody assay, the newest assay added to the panel, had sensitivity of 50% and specificity of 53%. Repeat serological testing failed to produce consistent results for 4 of 10 patients.
CONCLUSION: Despite its recent inclusion of the antiflagellin assay, the IBD7 panel has lower predictive values than routine laboratory tests in pediatric screening for IBD. Pediatrics 2010; 125: 1230-1236
C1 [Benor, Shira; Russell, George H.; Israel, Esther J.; Yuan, Qian; Winter, Harland S.] Massachusetts Gen Hosp Children, Dept Pediat Gastroenterol & Nutr, Boston, MA USA.
[Silver, Michael] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Biostat, Boston, MA USA.
RP Benor, S (reprint author), Dana Hosp Children, Tel Aviv Sourasky Med Ctr, Dept Pediat, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM shirabenor@yahoo.com
FU Advanced IBD Fellowship
FX This study was supported by an Advanced IBD Fellowship grant provided by
Martin Schlaff.
NR 29
TC 20
Z9 21
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2010
VL 125
IS 6
BP 1230
EP 1236
DI 10.1542/peds.2009-1936
PG 7
WC Pediatrics
SC Pediatrics
GA 604GX
UT WOS:000278268600018
PM 20439597
ER
PT J
AU Pekary, AE
Stevens, SA
Blood, JD
Sattin, A
AF Pekary, Albert Eugene
Stevens, Schetema A.
Blood, James D.
Sattin, Albert
TI Rapid modulation of TRH and TRH-like peptide release in rat brain,
pancreas, and testis by a GSK-3 beta inhibitor
SO PEPTIDES
LA English
DT Article
DE GSK-3 beta; Thyrotropin-releasing hormone; Limbic system; Testis; HPLC;
Radioimmunoassay
ID GLYCOGEN-SYNTHASE KINASE-3-BETA; PGLU-GLU-PRO-NH2 EEP;
TAU-PHOSPHORYLATION; PERIPHERAL-TISSUES; INSULIN-SECRETION; LIGHT-CHAIN;
HORMONE TRH; IN-VITRO; KINESIN; GSK3
AB Antidepressants have been shown to be neuroprotective and able to reverse damage to glia and neurons. Thyrotropin-releasing hormone (TRH) is an endogenous antidepressant-like neuropeptide that reduces the expression of glycogen synthase kinase-3 beta (GSK-3 beta), an enzyme that hyperphosphorylates tau and is implicated in bipolar disorder, diabetes and Alzheimer's disease. In order to understand the potential role of GSK-3 beta in the modulation of depression by TRH and TRH-like peptides and the therapeutic potential of GSK-3 beta inhibitors for neuropsychiatric and metabolic diseases, young adult male Sprague-Dawley (SD) rats were (a) injected ip with 1.8 mg/kg of GSK-3 beta inhibitor VIII (GSKI) and sacrificed 0, 2, 4, 6, and 8 h later or (b) injected with 0, 0.018, 0.18 or 1.8 mg/kg GSKI and bled 4 h later. Levels of TRH and TRH-like peptides were measured in various brain regions involved in mood regulation, pancreas and reproductive tissues. Large, 3-15-fold, increases of TRH and TRH-like peptide levels in cerebellum, for example, as well as other brain regions were noted at 2 and 4 h. In contrast, a nearly complete loss of TRH and TRH-like peptides from testis within 2 h and pancreas by 4 h following GSKI injection was observed. We have previously reported similar acute effects of corticosterone in brain and peripheral tissues. Incubation of a decapsulated rat testis with either GSKI or corticosterone accelerated release of TRH, and TRH-like peptides. Glucocorticoids, via inhibition of GSK3-beta activity, may thus be involved in the inhibition of TRH and TRH-like peptide release in brain, thereby contributing to the depressogenic effect of this class of steroids. Corticosterone-induced acceleration of release of these peptides from testis may contribute to the decline in reproductive function and redirection of energy needed during life-threatening emergencies. These contrasting effects of glucocorticoid on peptide release appear to be mediated by GSK-3 beta. Published by Elsevier Inc.
C1 [Pekary, Albert Eugene; Stevens, Schetema A.; Blood, James D.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
[Sattin, Albert] VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA.
[Pekary, Albert Eugene] VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA.
[Pekary, Albert Eugene] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA.
[Sattin, Albert] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA.
[Sattin, Albert] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA.
RP Pekary, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM Eugene.Pekary@va.gov
FU Veterans Administration Medical Research Funds; Pekary Family Trust
FX This work was supported by Veterans Administration Medical Research
Funds (AEP and AS) and the Pekary Family Trust.
NR 63
TC 6
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD JUN
PY 2010
VL 31
IS 6
BP 1083
EP 1093
DI 10.1016/j.peptides.2010.03.020
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 676SN
UT WOS:000283939000013
PM 20338209
ER
PT J
AU Peter, L
Stengel, A
Noetzel, S
Inhoff, T
Goebel, M
Tache, Y
Veh, RW
Bannert, N
Grotzinger, C
Wiedenmann, B
Klapp, BF
Monnikes, H
Kobelt, P
AF Peter, Lisa
Stengel, Andreas
Noetzel, Steffen
Inhoff, Tobias
Goebel, Miriam
Tache, Yvette
Veh, Ruediger W.
Bannert, Norbert
Groetzinger, Carsten
Wiedenmann, Bertram
Klapp, Burghard F.
Moennikes, Hubert
Kobelt, Peter
TI Peripherally injected CCK-8S activates CART positive neurons of the
paraventricular nucleus in rats
SO PEPTIDES
LA English
DT Article
DE CCK; CART; c-Fos; Food intake; PVN
ID C-FOS EXPRESSION; CORTICOTROPIN-RELEASING HORMONE; DORSAL VAGAL COMPLEX;
FOOD-INTAKE; SOLITARY TRACT; HYPOTHALAMIC NEUROENDOCRINE;
CHOLECYSTOKININ-OCTAPEPTIDE; GENE-EXPRESSION; BRAIN-STEM; PEPTIDE
AB Cholecystokinin (CCK) plays a role in the short-term inhibition of food intake. Cocaine-and amphetamine-regulated transcript (CART) peptide has been observed in neurons of the paraventricular nucleus (PVN). It has been reported that intracerebroventricular injection of CART peptide inhibits food intake in rodents. The aim of the study was to determine whether intraperitoneally (ip) injected CCK-8S affects neuronal activity of PVN-CART neurons. Ad libitum fed male Sprague-Dawley rats received 6 or 10 mu g/kg CCK-8S or 0.15M NaCl ip (n = 4/group). The number of c-Fos-immunoreactive neurons was determined in the PVN, arcuate nucleus (ARC), and the nucleus of the solitary tract (NTS). CCK-8S dose-dependently increased the number of c-Fos-immunoreactive neurons in the PVN (mean +/- SEM: 102 +/- 6 vs. 150 +/- 5 neurons/section, p < 0.05) and compared to vehicle treated rats (18 +/- 7, p < 0.05 vs. 6 and 10 mu g/kg CCK-8S). CCK-8S at both doses induced an increase in the number of c-Fos-immunoreactive neurons in the NTS (65 +/- 13, p < 0.05, and 182 +/- 16, p < 0.05). No effect on the number of c-Fos neurons was observed in the ARC. Immunostaining for CART and c-Fos revealed a dose-dependent increase of activated CART neurons (19 +/- 3 vs. 29 +/- 7; p < 0.05), only few activated CART neuron were observed in the vehicle group (1 +/- 0). The present observation shows that CCK-8S injected ip induces an increase in neuronal activity in PVN-CART neurons and suggests that CART neurons in the PVN may play a role in the mediation of peripheral CCK-8S's anorexigenic effects. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Klapp, Burghard F.; Kobelt, Peter] Charite, Dept Med, Div Psychosomat Med & Psychotherapy, D-10117 Berlin, Germany.
[Peter, Lisa; Noetzel, Steffen; Inhoff, Tobias; Groetzinger, Carsten; Wiedenmann, Bertram; Kobelt, Peter] Charite, Dept Med, Div Hepatol Gastroenterol & Endocrinol, D-10117 Berlin, Germany.
[Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA.
[Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Univ Calif Los Angeles, Ctr Neurobiol Stress, Los Angeles, CA USA.
[Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Veh, Ruediger W.] Charite, Inst Integrat Neuroanat, D-10117 Berlin, Germany.
[Bannert, Norbert] Robert Koch Inst, D-1000 Berlin, Germany.
[Moennikes, Hubert] Martin Luther Hosp, Dept Med, Berlin, Germany.
[Moennikes, Hubert] Martin Luther Hosp, Inst Neurogastroenterol, Berlin, Germany.
RP Kobelt, P (reprint author), Charite, Dept Med, Div Psychosomat Med & Psychotherapy, Campus Mitte,Luisenstr 13 A, D-10117 Berlin, Germany.
EM peter.kobelt@charite.de
OI Grotzinger, Carsten/0000-0001-9872-3087
FU German Research Foundation [DFG KO 3864/2-1];
Charite-Universitatsmedizin Berlin [UFF 09/41730, 09/42458]; Veterans
Administration; NIHDK [33061]; [DK-41301]
FX This work was supported by grants from the German Research Foundation to
P.K (DFG KO 3864/2-1), and from Charite-Universitatsmedizin Berlin to
P.K (UFF 09/41730 and 09/42458) as well as Veterans Administration
Research Career Scientist Award (Y.T), Veterans Administration Merit
Award (Y.T), NIHDK 33061 (Y.T), Center Grant DK-41301 (Animal Core)
(Y.T.).
NR 44
TC 10
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD JUN
PY 2010
VL 31
IS 6
BP 1118
EP 1123
DI 10.1016/j.peptides.2010.03.013
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 676SN
UT WOS:000283939000018
PM 20307613
ER
PT J
AU Sharma, SD
Katiyar, SK
AF Sharma, Som D.
Katiyar, Santosh K.
TI Dietary Grape Seed Proanthocyanidins Inhibit UVB-Induced
Cyclooxygenase-2 Expression and Other Inflammatory Mediators in
UVB-Exposed Skin and Skin Tumors of SKH-1 Hairless Mice
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE chemoprevention; COX-2; grape seed proanthocyanidins; skin cancer;
ultraviolet radiation
ID INDUCED OXIDATIVE STRESS; NF-KAPPA-B; MOUSE SKIN; GREEN TEA; DNA-REPAIR;
PREVENTS PHOTOCARCINOGENESIS; ULTRAVIOLET-LIGHT; COX-2 EXPRESSION;
CARCINOMA-CELLS; IN-VIVO
AB The purpose of this study was to determine the chemopreventive mechanism of dietary grape seed proanthocyanidins (GSPs) against ultraviolet (UV) radiation-induced skin tumor development in mice.
Six-to-seven-week-old SKH-1 hairless mice were subjected to photocarcinogenesis protocol, and exposed to UVB radiation (180 mJ/cm(2)) three times/week for 24 weeks. Mice were fed a standard AIN76A control diet with or without supplementation with grape seed proanthocyanidins (GSPs; 0.2% or 0.5%, w/w). At the termination of the experiment, mice were sacrificed, and skin and skin tumor samples were harvested and subjected to the analysis of biomarkers related to inflammation using immunostaining, western blot analysis, ELISA and real-time PCR.
Dietary GSPs inhibited UVB-induced infiltration of proinflammatory leukocytes and the levels of myeloperoxidase, cyclooxygenase-2 (COX-2), prostaglandin (PG) E-2, cyclin D1 and proliferating cell nuclear antigen (PCNA) in the skin and skin tumors compared to non-GSPs-treated UVB irradiated mouse skin and skin tumors. GSPs also significantly inhibited the levels of proinflammatory cytokines, tumor necrosis factor-alpha (P < 0.01), IL-1 beta (P < 0.001) and IL-6 (P < 0.001), in UVB-exposed skin and skin tumors.
The results from this study clearly suggest that dietary GSPs inhibit photocarcinogenesis in mice through the inhibition of UVB-induced inflammation and mediators of inflammation in mouse skin.
C1 [Sharma, Som D.; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration Merit Review Award
FX This work was financially supported by the Veterans Administration Merit
Review Award (S.K.K.).
NR 42
TC 40
Z9 43
U1 1
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUN
PY 2010
VL 27
IS 6
BP 1092
EP 1102
DI 10.1007/s11095-010-0050-9
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 597VW
UT WOS:000277791300016
PM 20143255
ER
PT J
AU Luttrell, LM
Gesty-Palmer, D
AF Luttrell, Louis M.
Gesty-Palmer, Diane
TI Beyond Desensitization: Physiological Relevance of Arrestin-Dependent
Signaling
SO PHARMACOLOGICAL REVIEWS
LA English
DT Review
ID PROTEIN-COUPLED RECEPTOR; BETA-ADRENERGIC-RECEPTOR; PARATHYROID-HORMONE
PTH; CLATHRIN-MEDIATED ENDOCYTOSIS; ANGIOTENSIN-II RECEPTOR;
GROWTH-FACTOR RECEPTOR; TERNARY COMPLEX MODEL; CHRONIC HEART-FAILURE;
FAILING HUMAN HEART; BETA(2)-ADRENERGIC RECEPTOR
AB Heptahelical G protein-coupled receptors are the most diverse and therapeutically important family of receptors in the human genome. Ligand binding activates heterotrimeric G proteins that transmit intracellular signals by regulating effector enzymes or ion channels. G protein signaling is terminated, in large part, by arrestin binding, which uncouples the receptor and G protein and targets the receptor for internalization. It is clear, however, that heptahelical receptor signaling does not end with desensitization. Arrestins bind a host of catalytically active proteins and serve as ligand-regulated scaffolds that recruit protein and lipid kinase, phosphatase, phosphodiesterase, and ubiquitin ligase activity into the receptor-arrestin complex. Although many of these arrestin-bound effectors serve to modulate G protein signaling, degrading second messengers and regulating endocytosis and trafficking, other signals seem to extend beyond the receptor-arrestin complex to regulate such processes as protein translation and gene transcription. Although these findings have led to a re-envisioning of heptahelical receptor signaling, little is known about the physiological roles of arrestin-dependent signaling. In vivo, the duality of arrestin function makes it difficult to dissociate the consequences of arrestin-dependent desensitization from those that might be ascribed to arrestin-mediated signaling. Nonetheless, recent evidence generated using arrestin knockouts, G protein-uncoupled receptor mutants, and arrestin pathway-selective "biased agonists" is beginning to reveal that arrestin signaling plays important roles in the retina, central nervous system, cardiovascular system, bone remodeling, immune system, and cancer. Understanding the signaling roles of arrestins may foster the development of pathway-selective drugs that exploit these pathways for therapeutic benefit.
C1 [Gesty-Palmer, Diane] Duke Univ, Med Ctr, Div Endocrinol & Metab, Dept Med, Durham, NC 27710 USA.
[Gesty-Palmer, Diane] Durham Vet Affairs Med Ctr, Durham, NC USA.
[Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Gesty-Palmer, D (reprint author), Duke Univ, Med Ctr, Div Endocrinol & Metab, Dept Med, Box 103015, Durham, NC 27710 USA.
EM gesty001@mc.duke.edu
FU National Institutes of Health National Institute of Diabetes and
Digestive and Kidney Diseases [DK64353, DK55524]; National Institutes of
Health National Institute of Child Health & Human Development
[HD043446]; Arthritis Foundation; Research Services of the Charleston,
SC, and Durham, NC, Veterans Affairs Medical Centers
FX This work was supported by the National Institutes of Health National
Institute of Diabetes and Digestive and Kidney Diseases [Grants DK64353,
DK55524 (to L. M. L.)]; the National Institutes of Health National
Institute of Child Health & Human Development [Grant HD043446 (to
D.G.-P.)]; the Arthritis Foundation (to D.G.-P.); and the Research
Services of the Charleston, SC, and Durham, NC, Veterans Affairs Medical
Centers. We offer our sincere apologies to the many outstanding
researchers whose work has been omitted because of space and topic
constraints. There is no intent to diminish or downplay the significance
of their contributions to this rapidly expanding field.
NR 224
TC 181
Z9 188
U1 1
U2 12
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0031-6997
J9 PHARMACOL REV
JI Pharmacol. Rev.
PD JUN
PY 2010
VL 62
IS 2
BP 305
EP 330
DI 10.1124/pr.109.002436
PG 26
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 596QB
UT WOS:000277698900005
PM 20427692
ER
PT J
AU Hamblin, MR
Dai, TH
AF Hamblin, Michael R.
Dai, Tianhong
TI Can surgical site infections be treated by photodynamic therapy?
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Letter
ID ANTIMICROBIAL PHOTOINACTIVATION; METHYLENE-BLUE; PHOTOSENSITIZER;
DELIVERY; PUMPS
C1 [Hamblin, Michael R.; Dai, Tianhong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Hamblin, MR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Wellman Ctr Photomed, BAR 414,40 Blossom St, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU NIAID NIH HHS [R01 AI050875, R01 AI050875-07]
NR 21
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1572-1000
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD JUN
PY 2010
VL 7
IS 2
BP 134
EP 136
DI 10.1016/j.pdpdt.2010.04.004
PG 3
WC Oncology
SC Oncology
GA 613NR
UT WOS:000278986500011
PM 20510311
ER
PT J
AU Ferry, AT
Graves, T
Theodore, GH
Gill, TJ
AF Ferry, Amon T.
Graves, Timothy
Theodore, George H.
Gill, Thomas J.
TI Stress Fractures in Athletes
SO PHYSICIAN AND SPORTSMEDICINE
LA English
DT Article
DE stress fracture; athlete; return to play; treatment
ID FEMALE ARMY RECRUITS; PNEUMATIC LEG BRACE; OVERUSE INJURIES;
ELECTROMAGNETIC-FIELDS; MILITARY RECRUITS; PULSED ULTRASOUND;
CONTROLLED-TRIAL; RISK-FACTORS; BONE; RUNNERS
AB Stress fractures that occur in the young active population typically represent an overuse injury, and may lead to prolonged periods of restriction from play if they are not treated appropriately. Several risk factors have been identified and must be addressed when treating these patients. Low-risk stress fractures can be successfully treated with activity restriction and a stepwise return to sport. Several pharmacologic and nonoperative treatment modalities have been described. However, high-risk stress fractures are more difficult to treat because they may have an increased rate of delay and nonunion, and oft en require surgical stabilization. When treating an athlete with a stress fracture, the objective is a safe and quick return to sport; therefore, special considerations must be made in this population, particularly when dealing with the in-season athlete.
C1 [Ferry, Amon T.; Graves, Timothy; Theodore, George H.; Gill, Thomas J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Sports Med Serv, Boston, MA 02114 USA.
RP Gill, TJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Sports Med Serv, 175 Cambridge St, Boston, MA 02114 USA.
EM tgill@partners.org
NR 66
TC 3
Z9 3
U1 4
U2 14
PU JTE MULTIMEDIA
PI BERWYN
PA 1235 WESTLAKES DR, STE 220, BERWYN, PA 19312 USA
SN 0091-3847
J9 PHYSICIAN SPORTSMED
JI Physician Sportsmed.
PD JUN
PY 2010
VL 38
IS 2
BP 109
EP 116
PG 8
WC Primary Health Care; Orthopedics; Sport Sciences
SC General & Internal Medicine; Orthopedics; Sport Sciences
GA 766SY
UT WOS:000290808000020
PM 20631470
ER
PT J
AU Barabasi, AL
AF Barabasi, Albert-Laszlo
TI You're so predictable
SO PHYSICS WORLD
LA English
DT Article
C1 [Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA.
[Barabasi, Albert-Laszlo] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA.
[Barabasi, Albert-Laszlo] Dana Farber Canc Inst, Boston, MA USA.
RP Barabasi, AL (reprint author), Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA.
EM barabasi@gmail.com
NR 0
TC 1
Z9 1
U1 0
U2 7
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 0953-8585
J9 PHYS WORLD
JI Phys. World
PD JUN
PY 2010
VL 23
IS 6
BP 22
EP 26
PG 5
WC Physics, Multidisciplinary
SC Physics
GA 613FY
UT WOS:000278965900016
ER
PT J
AU Pedersen, ME
Baldwin, RA
Niquet, J
Stafford, GI
van Staden, J
Wasterlain, CG
Jager, AK
AF Pedersen, Mikael E.
Baldwin, Roger A.
Niquet, Jerome
Stafford, Gary I.
van Staden, Johannes
Wasterlain, Claude G.
Jager, Anna K.
TI Anticonvulsant Effects of Searsia dentata (Anacardiaceae) Leaf Extract
in Rats
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE traditional medicine; epilepsy; NMDA receptor antagonists
AB Searsia species are used in South Africa to treat epilepsy. Previous studies have demonstrated an in vitro N-methyl-D-aspartic acid (NMDA) receptor antagonistic effect of the ethanolic leaf extract. The aim of this study was to evaluate the potential anticonvulsant properties of the ethanolic extract of S. dentata in various animal models of epilepsy. The extract was submitted to a screening in anticonvulsant assays including NMDA-, kainic acid (KA)-, pentylenetetrazol (PTZ)- and bicuculline (BIC)-induced seizures in rats. The extract protected 47% of the PN 18 Wistar pups (postnatal day 18, date of birth PN 0) (p < 0.05, n > 10) against NMDA-induced seizures and significantly delayed the onset of PTZ-induced seizures (p < 0.05, n > 8) at a dose of 250 mg/kg. A dose optimum was detected at 500 mg/kg for protection against KA-(63% protection, p < 0.05, n > 8) and BIC-induced seizures (50% protection, p < 0.05, n > 8) in young adult and PN 18 rats, respectively. The ethanolic extract of S. dentata showed anticonvulsive properties in several models of epilepsy. These results are compatible with previous findings of NMDA receptor antagonism. Due to the complex composition of the extract, the effect might be caused by more than one compound. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Pedersen, Mikael E.; Jager, Anna K.] Univ Copenhagen, Fac Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen O, Denmark.
[Pedersen, Mikael E.; Stafford, Gary I.; van Staden, Johannes] Univ KwaZulu Natal Pietermaritzburg, Sch Biol & Conservat Sci, Res Ctr Plant Growth & Dev, ZA-3209 Scottsville, South Africa.
[Pedersen, Mikael E.; Baldwin, Roger A.; Niquet, Jerome; Wasterlain, Claude G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Jager, AK (reprint author), Univ Copenhagen, Fac Pharmaceut Sci, Dept Med Chem, 2 Univ Pk, DK-2100 Copenhagen O, Denmark.
EM ankj@farma.ku.dk
RI Stafford, Gary/E-8668-2011; Pedersen, Mikael/F-9158-2011
OI Stafford, Gary/0000-0003-0198-0955;
FU National Research Foundation (South Africa)
FX The National Research Foundation (South Africa) is thanked for financial
assistance.
NR 11
TC 5
Z9 5
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0951-418X
J9 PHYTOTHER RES
JI Phytother. Res.
PD JUN
PY 2010
VL 24
IS 6
BP 924
EP 927
DI 10.1002/ptr.3016
PG 4
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 614OS
UT WOS:000279070200021
PM 19953526
ER
PT J
AU Salvatori, R
Nachtigall, LB
Cook, DM
Bonert, V
Molitch, ME
Blethen, S
Chang, S
AF Salvatori, Roberto
Nachtigall, Lisa B.
Cook, David M.
Bonert, Vivien
Molitch, Mark E.
Blethen, Sandra
Chang, Stephen
CA SALSA Study Grp
TI Effectiveness of self- or partner-administration of an extended-release
aqueous-gel formulation of lanreotide in lanreotide-naive patients with
acromegaly
SO PITUITARY
LA English
DT Article
DE Acromegaly; Self-administration; Somatostatin analogue; Lanreotide;
Octreotide
ID OCTREOTIDE; THERAPY; AUTOGEL(R); MANAGEMENT; DIAGNOSIS
AB Surgical resection is often not curative in patients with acromegaly and long-acting somatostatin analogues (lanreotide or octreotide) are often needed. This study assessed the efficacy and safety of self- or partner-administration of lanreotide in patients with acromegaly. This was a six-month, single-arm, open-label study conducted at 13 endocrinology clinics. Fifty-nine patients received deep subcutaneous lanreotide injections every 28 days. Twelve patients started on 120 mg lanreotide and forty-seven started on 90 mg lanreotide. At week 16, the dose was adjusted to 60, 90 or 120 mg based on insulin-like growth factor-1 (IGF-1) levels at week 12. Fifty-nine patients with acromegaly either switched from long-acting octreotide (switch; n = 33) or were somatostatin analogue treatment-na < ve or not currently taking long-acting octreotide ("other"; n = 26). The key endpoints included the percentage of patients/partners able to self- or partner-inject lanreotide and those with normal IGF-1 or growth hormone (GH) levels at week 24/early termination. 100% of patients/partners correctly self- (n = 41) or partner-injected (n = 18) lanreotide by week 4. By week 24/early termination, IGF-1 levels were controlled in 93.7% of switch and 46.2% of "other" patients, while GH levels were controlled in 76.9% and 39.1% of patients, respectively. Both IGF-1 and GH were controlled in 73.1% of switch and 30.4% of "other" patients. Most switch patients (81%) reported they preferred lanreotide over long-acting octreotide for future use (P = 0.0001). Self- or partner-administration of lanreotide is generally well tolerated and associated with IGF-1 and GH control in many lanreotide-na < ve patients with acromegaly.
C1 [Salvatori, Roberto] Johns Hopkins Univ, Sch Med, Div Endocrinol, Baltimore, MD 21287 USA.
[Nachtigall, Lisa B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cook, David M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Bonert, Vivien] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Bonert, Vivien] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Molitch, Mark E.] Northwestern Univ, Chicago, IL 60611 USA.
[Blethen, Sandra; Chang, Stephen] Tercica Inc, Brisbane, CA USA.
RP Salvatori, R (reprint author), Johns Hopkins Univ, Sch Med, Div Endocrinol, 1830 E Monument St 333, Baltimore, MD 21287 USA.
EM salvator@jhmi.edu
FU Tercica, Inc.
FX This study was sponsored by Tercica, Inc., a subsidiary of the Ipsen
Group; the sponsor participated in the study design as well as the data
collection, analysis and interpretation. Medical writing support for the
preparation of this manuscript was provided by Jessica Mendoza, PhD, who
is a full-time employee of Tercica, Inc., a subsidiary of the Ipsen
Group.
NR 13
TC 27
Z9 27
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1386-341X
J9 PITUITARY
JI Pituitary
PD JUN
PY 2010
VL 13
IS 2
BP 115
EP 122
DI 10.1007/s11102-009-0207-x
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 584RS
UT WOS:000276770900004
PM 19898989
ER
PT J
AU Yueh, JH
Slavin, SA
Adesiyun, T
Nyame, TT
Gautam, S
Morris, DJ
Tobias, AM
Lee, BT
AF Yueh, Janet H.
Slavin, Sumner A.
Adesiyun, Tolulope
Nyame, Theodore T.
Gautam, Shiva
Morris, Donald J.
Tobias, Adam M.
Lee, Bernard T.
TI Patient Satisfaction in Postmastectomy Breast Reconstruction: A
Comparative Evaluation of DIEP, TRAM, Latissimus Flap, and Implant
Techniques
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article; Proceedings Paper
CT 39th Annual Fall Scientific Symposium of the
American-Society-of-Ophthalmic-Plastic-and-Reconstructive-Surgery
CY NOV, 2008
CL Atlanta, GA
SP Amer Soc Ophthalm Plast & Reconstruct Surg
ID EPIGASTRIC PERFORATOR FLAPS; QUALITY-OF-LIFE; RETROSPECTIVE ANALYSIS;
OUTCOMES; DETERMINANTS; EXPERIENCE
AB Background: Despite a growing literature on patient satisfaction in breast reconstruction, few studies have compared perforator flaps with the more commonly practiced methods. The authors compared four reconstructive techniques and identified factors influencing patient satisfaction.
Methods: All patients undergoing postmastectomy breast reconstruction between 1999 and 2006 at a single academic institution were included in our study. A total of 583 patients with tissue expander/implant, latissimus, pedicle transverse rectus abdominis muscle (TRAM), and deep inferior epigastric perforator (DIEP) flap reconstructions received a validated questionnaire on satisfaction, health-related quality of life, and sociodemographic data.
Results: Patient response was 75 percent, with 439 completed questionnaires including 87 tissue expander/implant, 116 latissimus, and 119 pedicle TRAM and 117 DIEP flap patients. DIEP patients had the highest level of general satisfaction at 80 percent, and pedicle TRAM patients had the highest level of aesthetic satisfaction at 77 percent (p < 0.001 and p < 0.001, respectively). Health-related quality of life and length of time since surgery were identified as significant covariates influencing patient satisfaction. After logistic regression analysis, autologous reconstruction had significantly higher generalandaesthetic satisfaction than implant-based reconstruction (p = 0.017 and p < 0.001). Among the autologous reconstructions, abdominal-based flaps had significantly higher general and aesthetic satisfaction than latissimus flaps (p = 0.011 and p = 0.016). When comparing the abdominal-based reconstructions, general and aesthetic satisfaction were no longer statistically significant between pedicle TRAM and DIEP flaps (p = 0.659 and p = 0.198).
Conclusions: Autologous, abdominal-based reconstructions had the highest satisfaction rates across all four groups. After logistic regression analysis, differences in patient satisfaction between pedicle TRAM and DIEP flap reconstruction were no longer observed. Discussing satisfaction outcomes with patients will help them make educated decisions about breast reconstruction. (Plast. Reconstr. Surg. 125:1585,2010.)
C1 [Lee, Bernard T.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Plast & Reconstruct Surg, Dept Surg,Med Sch,Harvard Thorndike Gen Clin Res, Boston, MA 02215 USA.
Harvard Univ, Beth Israel Deaconess Med Ctr, Harvard Thorndike Gen Clin Res, Sch Med,Biostat Program, Boston, MA 02215 USA.
RP Lee, BT (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Plast & Reconstruct Surg, Dept Surg,Med Sch,Harvard Thorndike Gen Clin Res, 110 Francis St,Suite 5A, Boston, MA 02215 USA.
EM blee3@bidmc.harvard.edu
RI Lee, Bernard/K-1106-2016
OI Lee, Bernard/0000-0002-5533-3166
NR 36
TC 108
Z9 112
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD JUN
PY 2010
VL 125
IS 6
BP 1585
EP 1595
DI 10.1097/PRS.0b013e3181cb6351
PG 11
WC Surgery
SC Surgery
GA 605XC
UT WOS:000278380700001
PM 20517080
ER
PT J
AU Murphy, AD
McCormack, MC
Bichara, DA
Nguyen, JT
Randolph, MA
Watkins, MT
Lee, RC
Austen, WG
AF Murphy, Adrian D.
McCormack, Michael C.
Bichara, David A.
Nguyen, John T.
Randolph, Mark A.
Watkins, Michael T.
Lee, Raphael C.
Austen, William G., Jr.
TI Poloxamer 188 Protects against Ischemia-Reperfusion Injury in a Murine
Hind-Limb Model
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article; Proceedings Paper
CT 54th Annual Meeting of the Plastic-Surgery-Research-Council
CY MAY 27-30, 2009
CL Pittsburgh, PA
SP Plast Surg Res Council
ID ACUTE MYOCARDIAL-INFARCTION; EXPERIMENTAL FREE FLAPS; NO-REFLOW
PHENOMENON; SKELETAL-MUSCLE; ISCHEMIA/REPERFUSION INJURY; FUNCTIONAL
RECOVERY; LIPID MONOLAYERS; IN-VIVO; IGM; COMPLEMENT
AB Background: Ischemia-reperfusion injury can activate pathways generating reactive oxygen species, which can injure cells by creating holes in the cell membranes. Copolymer surfactants such as poloxamer 188 are capable of sealing defects in cell membranes. The authors postulated that a single-dose administration of poloxamer 188 would decrease skeletal myocyte injury and mortality following ischemia-reperfusion injury.
Methods: Mice underwent normothermic hind-limb ischemia for 2 hours. Animals were treated with 150 mu l of poloxamer 188 or dextran at three time points: (1) 10 minutes before ischemia; (2) 10 minutes before reperfusion; and (3) 2 or 4 hours after reperfusion. After 24 hours of reperfusion, tissues were analyzed for myocyte injury (histology) and metabolic dysfunction (muscle adenosine 5'-triphosphate). Additional groups of mice were followed for 7 days to assess mortality.
Results: When poloxamer 188 treatment was administered 10 minutes before ischemia, injury was reduced by 84 percent, from 50 percent injury in the dextran group to 8 percent injury in the poloxamer 188 group (p < 0.001). When administered 10 minutes before reperfusion, poloxamer 188 animals demonstrated a 60 percent reduction in injury compared with dextran controls (12 percent versus 29 percent). Treatment at 2 hours, but not at 4 hours, postinjury prevented substantial myocyte injury. Preservation of muscle adenosine 5'-triphosphate paralleled the decrease in myocyte injury in poloxamer 188-treated animals. Poloxamer 188 treatment significantly reduced mortality following injury (10 minutes before, 75 percent versus 25 percent survival, p = 0.0077; 2 hours after, 50 percent versus 8 percent survival, p = 0.032).
Conclusion: Poloxamer 188 administered to animals decreased myocyte injury, preserved tissue adenosine 5'-triphosphate levels, and improved survival following hind-limb ischemia-reperfusion injury. (Plast. Reconstr. Surg. 125: 1651, 2010.)
C1 [Austen, William G., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Vasc & Endovasc Surg, Boston, MA 02114 USA.
Univ Chicago, Dept Surg, Comm Mol Med, Chicago, IL 60637 USA.
Univ Chicago, Dept Med, Comm Mol Med, Chicago, IL 60637 USA.
Univ Chicago, Dept Organismal Biol & Anat, Comm Mol Med, Chicago, IL 60637 USA.
RP Austen, WG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, 15 Parkman St,Suite WAC 435, Boston, MA 02114 USA.
EM wausten@partners.org
FU NIGMS NIH HHS [R01 GM064757, GM 5R01GM064757-07]
NR 46
TC 13
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD JUN
PY 2010
VL 125
IS 6
BP 1651
EP 1660
DI 10.1097/PRS.0b013e3181ccdbef
PG 10
WC Surgery
SC Surgery
GA 605XC
UT WOS:000278380700010
PM 20517088
ER
PT J
AU Gold, MC
Cerri, S
Smyk-Pearson, S
Cansler, ME
Vogt, TM
Delepine, J
Winata, E
Swarbrick, GM
Chua, WJ
Yu, YYL
Lantz, O
Cook, MS
Null, MD
Jacoby, DB
Harriff, MJ
Lewinsohn, DA
Hansen, TH
Lewinsohn, DM
AF Gold, Marielle C.
Cerri, Stefania
Smyk-Pearson, Susan
Cansler, Meghan E.
Vogt, Todd M.
Delepine, Jacob
Winata, Ervina
Swarbrick, Gwendolyn M.
Chua, Wei-Jen
Yu, Yik Y. L.
Lantz, Olivier
Cook, Matthew S.
Null, Megan D.
Jacoby, David B.
Harriff, Melanie J.
Lewinsohn, Deborah A.
Hansen, Ted H.
Lewinsohn, David M.
TI Human Mucosal Associated Invariant T Cells Detect Bacterially Infected
Cells
SO PLOS BIOLOGY
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS INFECTION; MR1 ANTIGEN PRESENTATION;
ALPHA-CHAIN; MAIT CELLS; RECOGNITION; LYMPHOCYTES; RESPONSES; RECEPTOR;
PROTEIN; INNATE
AB Control of infection with Mycobacterium tuberculosis (Mtb) requires Th1-type immunity, of which CD8(+) T cells play a unique role. High frequency Mtb-reactive CD8(+) T cells are present in both Mtb-infected and uninfected humans. We show by limiting dilution analysis that nonclassically restricted CD8(+) T cells are universally present, but predominate in Mtb-uninfected individuals. Interestingly, these Mtb-reactive cells expressed the V alpha 7.2 T-cell receptor (TCR), were restricted by the nonclassical MHC (HLA-Ib) molecule MR1, and were activated in a transporter associated with antigen processing and presentation (TAP) independent manner. These properties are all characteristics of mucosal associated invariant T cells (MAIT), an "innate'' T-cell population of previously unknown function. These MAIT cells also detect cells infected with other bacteria. Direct ex vivo analysis demonstrates that Mtb-reactive MAIT cells are decreased in peripheral blood mononuclear cells (PBMCs) from individuals with active tuberculosis, are enriched in human lung, and respond to Mtb-infected MR1-expressing lung epithelial cells. Overall, these findings suggest a generalized role for MAIT cells in the detection of bacterially infected cells, and potentially in the control of bacterial infection.
C1 [Gold, Marielle C.; Cerri, Stefania; Smyk-Pearson, Susan; Delepine, Jacob; Winata, Ervina; Swarbrick, Gwendolyn M.; Cook, Matthew S.; Jacoby, David B.; Harriff, Melanie J.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
[Gold, Marielle C.; Delepine, Jacob; Swarbrick, Gwendolyn M.; Harriff, Melanie J.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR USA.
[Smyk-Pearson, Susan; Cansler, Meghan E.; Vogt, Todd M.; Swarbrick, Gwendolyn M.; Cook, Matthew S.; Null, Megan D.; Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA.
[Chua, Wei-Jen; Yu, Yik Y. L.; Hansen, Ted H.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[Lantz, Olivier] Inst Curie Paris, Inserm 932, Lab Immunol & Unite, Paris, France.
[Lewinsohn, Deborah A.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
RP Gold, MC (reprint author), Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
EM goldm@ohsu.edu; lewinsod@ohsu.edu
RI Lantz, Olivier/J-4960-2012; Cerri, Stefania/N-9701-2016; Lewinsohn,
David/I-4936-2013;
OI Lantz, Olivier/0000-0003-3161-7719; Cerri, Stefania/0000-0003-4612-1580;
Jacoby, David/0000-0003-2195-9512; Lewinsohn, David/0000-0001-9906-9494;
Gold, Marielle/0000-0003-2505-3291
FU Department of Veterans Affairs; National Institutes of Health (NIH)
[AI48090, HHSN266200400081C]
FX Funding was provided in part by the Department of Veterans Affairs and
with resources and the use of facilities at the Portland VA Medical
Center, National Institutes of Health (NIH) grant AI48090, and NIH
contract HHSN266200400081C. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 52
TC 192
Z9 192
U1 4
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1544-9173
J9 PLOS BIOL
JI PLoS. Biol.
PD JUN
PY 2010
VL 8
IS 6
AR e1000407
DI 10.1371/journal.pbio.1000407
PG 14
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics
GA 618LK
UT WOS:000279355600019
PM 20613858
ER
PT J
AU Sepulcre, J
Liu, HS
Talukdar, T
Martincorena, I
Yeo, BTT
Buckner, RL
AF Sepulcre, Jorge
Liu, Hesheng
Talukdar, Tanveer
Martincorena, Inigo
Yeo, B. T. Thomas
Buckner, Randy L.
TI The Organization of Local and Distant Functional Connectivity in the
Human Brain
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID DEFAULT MODE NETWORK; MEDIAL PREFRONTAL CORTEX; RESTING HUMAN BRAIN;
CEREBRAL-CORTEX; WHITE-MATTER; NEUROCOGNITIVE NETWORKS; AUTOBIOGRAPHICAL
MEMORY; CORTICAL CONNECTIONS; MACAQUE MONKEYS; LOW-FREQUENCY
AB Information processing in the human brain arises from both interactions between adjacent areas and from distant projections that form distributed brain systems. Here we map interactions across different spatial scales by estimating the degree of intrinsic functional connectivity for the local (<= 14 mm) neighborhood directly surrounding brain regions as contrasted with distant (>14 mm) interactions. The balance between local and distant functional interactions measured at rest forms a map that separates sensorimotor cortices from heteromodal association areas and further identifies regions that possess both high local and distant cortical-cortical interactions. Map estimates of network measures demonstrate that high local connectivity is most often associated with a high clustering coefficient, long path length, and low physical cost. Task performance changed the balance between local and distant functional coupling in a subset of regions, particularly, increasing local functional coupling in regions engaged by the task. The observed properties suggest that the brain has evolved a balance that optimizes information-processing efficiency across different classes of specialized areas as well as mechanisms to modulate coupling in support of dynamically changing processing demands. We discuss the implications of these observations and applications of the present method for exploring normal and atypical brain function.
C1 [Sepulcre, Jorge; Buckner, Randy L.] Howard Hughes Med Inst, Cambridge, MA USA.
[Sepulcre, Jorge; Liu, Hesheng; Yeo, B. T. Thomas; Buckner, Randy L.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Sepulcre, Jorge; Liu, Hesheng; Yeo, B. T. Thomas; Buckner, Randy L.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA.
[Sepulcre, Jorge; Liu, Hesheng; Talukdar, Tanveer; Yeo, B. T. Thomas; Buckner, Randy L.] Athinioula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA.
[Martincorena, Inigo] Univ Cambridge, European Bioinformat Inst, Cambridge, England.
[Buckner, Randy L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Buckner, Randy L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Sepulcre, J (reprint author), Howard Hughes Med Inst, Cambridge, MA USA.
EM sepulcre@nmr.mgh.harvard.edu
OI Liu, Hesheng/0000-0002-7233-1509; Yeo, B.T. Thomas/0000-0002-0119-3276
FU Howard Hughes Medical Institute; NIA [R01-AG21910]
FX Grants support: Howard Hughes Medical Institute, NIA R01-AG21910 and
Martinos Ctr 5R90DA023427. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 81
TC 125
Z9 129
U1 3
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-734X
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD JUN
PY 2010
VL 6
IS 6
AR e1000808
DI 10.1371/journal.pcbi.1000808
PG 15
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 618HA
UT WOS:000279341000014
PM 20548945
ER
PT J
AU Lim, SY
Chan, T
Gelman, RS
Whitney, JB
O'Brien, KL
Barouch, DH
Goldstein, DB
Haynes, BF
Letvin, NL
AF Lim, So-Yon
Chan, Tiffany
Gelman, Rebecca S.
Whitney, James B.
O'Brien, Kara L.
Barouch, Dan H.
Goldstein, David B.
Haynes, Barton F.
Letvin, Norman L.
TI Contributions of Mamu-A*01 Status and TRIM5 Allele Expression, But Not
CCL3L Copy Number Variation, to the Control of SIVmac251 Replication in
Indian-Origin Rhesus Monkeys
SO PLOS GENETICS
LA English
DT Article
ID SIMIAN IMMUNODEFICIENCY; HIV-1 INFECTION; SEGMENTAL DUPLICATIONS;
SUSCEPTIBILITY; PROGRESSION; GENE; AIDS; GENOME; CELLS
AB CCL3 is a ligand for the HIV-1 co-receptor CCR5. There have recently been conflicting reports in the literature concerning whether CCL3-like gene (CCL3L) copy number variation (CNV) is associated with resistance to HIV-1 acquisition and with both viral load and disease progression following infection with HIV-1. An association has also been reported between CCL3L CNV and clinical sequelae of the simian immunodeficiency virus (SIV) infection in vivo in rhesus monkeys. The present study was initiated to explore the possibility of an association of CCL3L CNV with the control of virus replication and AIDS progression in a carefully defined cohort of SIVmac251-infected, Indian-origin rhesus monkeys. Although we demonstrated extensive variation in copy number of CCL3L in this cohort of monkeys, CCL3L CNV was not significantly associated with either peak or set-point plasma SIV RNA levels in these monkeys when MHC class I allele Mamu-A*01 was included in the models or progression to AIDS in these monkeys. With 66 monkeys in the study, there was adequate power for these tests if the correlation of CCL3L and either peak or set-point plasma SIV RNA levels was 0.34 or 0.36, respectively. These findings call into question the premise that CCL3L CNV is important in HIV/SIV pathogenesis.
C1 [Lim, So-Yon; Chan, Tiffany; Whitney, James B.; O'Brien, Kara L.; Barouch, Dan H.; Letvin, Norman L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Haynes, Barton F.] Duke Univ, Duke Human Vaccine Inst, Durham, NC USA.
[Goldstein, David B.] Duke Univ, Duke Inst Genome Sci & Policy, Ctr Populat Genom & Pharmacogenet, Durham, NC USA.
[Gelman, Rebecca S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Lim, SY (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
EM nletvin@bidmc.harvard.edu
FU NIAID Center for HIV/AIDS Vaccine Immunology [AI067854, AI078526]
FX This work was supported by the NIAID Center for HIV/AIDS Vaccine
Immunology grant AI067854 (NLL) and AI078526 (DHB). The funder had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 26
TC 25
Z9 26
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7390
J9 PLOS GENET
JI PLoS Genet.
PD JUN
PY 2010
VL 6
IS 6
AR e1000997
DI 10.1371/journal.pgen.1000997
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 624GN
UT WOS:000279805200026
PM 20585621
ER
PT J
AU Cohen, T
Murray, M
Wallengren, K
Alvarez, GG
Samuel, EY
Wilson, D
AF Cohen, Ted
Murray, Megan
Wallengren, Kristina
Alvarez, Gonzalo G.
Samuel, Elizabeth Y.
Wilson, Douglas
TI The Prevalence and Drug Sensitivity of Tuberculosis among Patients Dying
in Hospital in KwaZulu-Natal, South Africa: A Postmortem Study
SO PLOS MEDICINE
LA English
DT Article
ID NEGATIVE PULMONARY TUBERCULOSIS; HIV-POSITIVE PATIENTS; DIAGNOSIS;
AUTOPSY; SPUTUM; DEATH; MICROSCOPY; ANTIBODIES; SETTINGS; BOTSWANA
AB Background: Tuberculosis is the leading cause of death in South Africa by death notification, but accurate diagnosis of tuberculosis is challenging in this setting of high HIV prevalence. We conducted limited autopsies on young adults dying in a single public hospital in the province of KwaZulu-Natal between October 2008 and August 2009 in order to estimate the magnitude of deaths attributable to tuberculosis.
Methods and Findings: We studied a representative sample of 240 adult inpatients (aged 20-45 years) dying after admission to Edendale Hospital. Limited autopsies included collection of respiratory tract secretions and tissue by needle core biopsies of lung, liver, and spleen. Specimens were examined by fluorescent microscopy for acid-fast bacilli and cultured in liquid media; cultures positive for M. tuberculosis were tested for drug susceptibility to first-and second-line antibiotics. Ninety-four percent of our study cohort was HIV seropositive and 50% of decedents had culture-positive tuberculosis at the time of death. Fifty percent of the participants were on treatment for tuberculosis at the time of death and 58% of these treated individuals remained culture positive at the time of death. Of the 50% not receiving tuberculosis treatment, 42% were culture positive. Seventeen percent of all positive cultures were resistant to both isoniazid and rifampin (i.e., multidrug resistant); 16% of patients dying during the initiation phase of their first ever course of tuberculosis treatment were infected with multidrug-resistant bacilli.
Conclusions: Our findings reveal the immense toll of tuberculosis among HIV-positive individuals in KwaZulu-Natal. The majority of decedents who remained culture positive despite receiving tuberculosis treatment were infected with pansusceptible M. tuberculosis, suggesting that the diagnosis of tuberculosis was made too late to alter the fatal course of the infection. There is also a significant burden of undetected multidrug-resistant tuberculosis among HIV-coinfected individuals dying in this setting. New public health approaches that improve early diagnosis of tuberculosis and accelerate the initiation of treatment are urgently needed in this setting.
C1 [Cohen, Ted; Murray, Megan] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA.
[Cohen, Ted; Murray, Megan; Wallengren, Kristina] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Murray, Megan] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA.
[Alvarez, Gonzalo G.] Univ Ottawa, Dept Med, Ottawa Hosp, Ottawa, ON, Canada.
[Samuel, Elizabeth Y.] Inkosi Albert Luthuli Cent Hosp, Natl Hlth Lab Serv, Mayville, South Africa.
[Wilson, Douglas] Univ KwaZulu Natal, Dept Med, Edendale Hosp, Durban, South Africa.
RP Cohen, T (reprint author), Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA.
EM tcohen@hsph.harvard.edu
RI Cohen, Ted/G-8101-2011
FU Massachusetts General Hospital; BMS Secure the Future; Edendale
Hospital; Harvard University CFAR; Ragon Institute; Gary and Lauren
Cohen; Mark and Lisa Schwartz Foundation; Witten Family Foundation; US
National Institutes Of Health [DP2OD006663]; KwaZulu-Natal Department of
Health
FX This work was made possible through funding provided by Massachusetts
General Hospital, BMS Secure the Future, and Edendale Hospital. We also
thank the Harvard University CFAR, the Ragon Institute, Gary and Lauren
Cohen, the Mark and Lisa Schwartz Foundation, and the Witten Family
Foundation for additional support. TC received support through Award
Number DP2OD006663 from the Office of the Director, US National
Institutes Of Health. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
Office of the Director of the US NIH, or the NIH. The funders had no
role in the study design, data collection and analysis, decision to
publish, or preparation of the manuscript.; We appreciate the
contributions of Mary-Jane Khumalo, Robin Draper, Keith Rasmussen, Langa
Ngubane, Stanley Carries, Shaakir Khader, Matanja Coetzee, Molly Franke,
Krista Dong, Rocio Hurtado, and Bruce Walker. We acknowledge the support
of the KwaZulu-Natal Department of Health.
NR 37
TC 64
Z9 64
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD JUN
PY 2010
VL 7
IS 6
AR e1000296
DI 10.1371/journal.pmed.1000296
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 619AV
UT WOS:000279400000016
PM 20582324
ER
PT J
AU Figoni, SF
Kunkel, CF
Scremin, AME
Scremin, OU
Cohen, B
AF Figoni, Stephen F.
Kunkel, Charles F.
Scremin, A. M. Erika
Scremin, Oscar U.
Cohen, Babak
TI Ergometric Performance During Exercise Training in Men With Intermittent
Claudication
SO PM&R
LA English
DT Article
AB Objective: To determine and describe changes in weekly work, power, exercise times, and recovery times during an exercise training intervention in men with peripheral arterial disease (PAD) and intermittent calf claudication.
Design: Tracking of weekly exercise training parameters involved repeated measures over time in one group of participants. Other outcomes of this pilot study used a one-group, pretest-posttest design.
Setting: Tertiary-care medical center.
Participants: Fifteen male veterans (mean age, 69 years) with Fontaine stage ha PAD and classic intermittent calf claudication.
Main Outcome Measurements: Participants completed graded treadmill exercise tests before and after intervention from which maximal walking power was calculated. Work, power, and exercise and recovery times for each exercise training session were computed and averaged for each week.
Intervention: The intervention consisted of an intensive 3-month exercise training program involving walking and calf muscle exercises: 3 sessions per week at the clinic (treadmill walking and calf ergometry) and 2 sessions per week at home (free walking and standing heel raises).
Results: After training, participants increased treadmill maximal walking power from 220 to 414 W (by 87%). Treadmill and calf exercise work, power, and exercise time per session increased linearly during 13 weeks of training, whereas recovery time per session of treadmill exercise decreased. During the same period, treadmill and calf exercise training power outputs increased by averages of 227% and 92%, respectively.
Conclusion: Calculation of work and power during exercise training can be used to track progress quantitatively at short intervals. Weekly linear increases in training work and power per exercise session suggest that optimal intervention duration may be longer than 3 months for men with PAD and intermittent calf claudication. PM R 2010;2:528-536
C1 [Figoni, Stephen F.; Kunkel, Charles F.; Scremin, A. M. Erika; Cohen, Babak] VA Greater Los Angeles Healthcare Syst, Phys Med & Rehabil Serv, Los Angeles, CA 90073 USA.
[Kunkel, Charles F.; Scremin, A. M. Erika] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Scremin, Oscar U.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
[Scremin, Oscar U.; Cohen, Babak] VA Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA.
RP Figoni, SF (reprint author), VA Greater Los Angeles Healthcare Syst, Phys Med & Rehabil Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM sfigoni@gmail.com
FU Rehabilitation Research and Development Service, Department of Veterans
Affairs [B3644P]
FX Disclosure: 8, Rehabilitation Research and Development Service,
Department of Veterans Affairs grant #B3644P
NR 18
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD JUN
PY 2010
VL 2
IS 6
BP 528
EP 536
DI 10.1016/j.pmrj.2010.03.009
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA V24LQ
UT WOS:000208412300008
PM 20630439
ER
PT J
AU Zhou, BY
Xu, WH
Herndon, D
Tompkins, R
Davis, R
Xiao, WZ
Wong, WH
AF Zhou, Baiyu
Xu, Weihong
Herndon, David
Tompkins, Ronald
Davis, Ronald
Xiao, Wenzhong
Wong, Wing Hung
CA Inflammation Host Response Injury
TI Analysis of factorial time-course microarrays with application to a
clinical study of burn injury
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE factorial design; longitudinal data; analysis of variance
ID GENE-EXPRESSION DATA; IDENTIFICATION; CHILDREN; MODEL
AB Time-course microarray experiments are capable of capturing dynamic gene expression profiles. It is important to study how these dynamic profiles depend on the multiple factors that characterize the experimental condition under which the time course is observed. Analytic methods are needed to simultaneously handle the time course and factorial structure in the data. We developed a method to evaluate factor effects by pooling information across the time course while accounting for multiple testing and non-normality of the microarray data. The method effectively extracts gene-specific response features and models their dependency on the experimental factors. Both longitudinal and cross-sectional time-course data can be handled by our approach. The method was used to analyze the impact of age on the temporal gene response to burn injury in a large-scale clinical study. Our analysis reveals that 21% of the genes responsive to burn are age-specific, among which expressions of mitochondria and immunoglobulin genes are differentially perturbed in pediatric and adult patients by burn injury. These new findings in the body's response to burn injury between children and adults support further investigations of therapeutic options targeting specific age groups. The methodology proposed here has been implemented in R package "TANOVA" and submitted to the Comprehensive R Archive Network at http://www.r-project.org/. It is also available for download at http://gluegrant1.stanford.edu/TANOVA/.
C1 [Xu, Weihong; Davis, Ronald; Xiao, Wenzhong] Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA.
[Xu, Weihong; Davis, Ronald; Xiao, Wenzhong] Stanford Univ, Dept Biochem, Palo Alto, CA 94304 USA.
[Zhou, Baiyu; Wong, Wing Hung] Stanford Univ, Dept Stat, Stanford, CA 94305 USA.
[Herndon, David] Univ Texas Galveston, Med Branch, Dept Surg, Galveston, TX 77550 USA.
[Tompkins, Ronald; Xiao, Wenzhong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Hosp Children, Boston, MA 02114 USA.
[Wong, Wing Hung] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA.
RP Xiao, WZ (reprint author), Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA.
EM wxiao1@partners.org; whwong@stanford.edu
RI Zhou, Baiyu/H-3506-2012; Xu, Weihong/C-4175-2012;
OI xiao, wenzhong/0000-0003-4944-6380; Remick, Daniel/0000-0002-2615-3713
FU NIH [U54 GM-062119, SHC 86400]
FX We thank Ted Anderson for helpful discussions. In particular, we wish to
acknowledge the efforts of many individuals at participating
institutions of the Glue Grant Program that generated the clinical and
genomic data reported here. This study was supported by NIH U54
GM-062119 and SHC 86400.
NR 21
TC 33
Z9 35
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 1
PY 2010
VL 107
IS 22
BP 9923
EP 9928
DI 10.1073/pnas.1002757107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 603ZD
UT WOS:000278246000005
PM 20479259
ER
PT J
AU Wolk, DA
Dickerson, BC
AF Wolk, David A.
Dickerson, Bradford C.
CA Alzheimer's Dis Neuroimaging
TI Apolipoprotein E (APOE) genotype has dissociable effects on memory and
attentional-executive network function in Alzheimer's disease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE cognition; neuroimaging; dementia; cortical thickness; medial temporal
lobe
ID NINCDS-ADRDA CRITERIA; E EPSILON-4 ALLELE; MILD AD DEMENTIA;
FRONTOTEMPORAL DEMENTIA; CORTICAL SIGNATURE; ENTORHINAL CORTEX;
TRANSGENIC MICE; E POLYMORPHISM; BRAIN ATROPHY; SURFACE-AREA
AB The epsilon 4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for Alzheimer's disease (AD), but limited work has suggested that APOE genotype may modulate disease phenotype. Carriers of the e4 allele have been reported to have greater medial temporal lobe (MTL) pathology and poorer memory than noncarriers. Less attention has focused on whether there are domains of cognition and neuroanatomical regions more affected in noncarriers. Further, a major potential confound of prior in vivo studies is the possibility of different rates of clinical misdiagnosis for carriers vs. noncarriers. We compared phenotypic differences in cognition and topography of regional cortical atrophy of e4 carriers (n = 67) vs. noncarriers (n = 24) with mild AD from the Alzheimer's Disease Neuroimaging Initiative, restricted to those with a cerebrospinal fluid (CSF) molecular pro. le consistent with AD. Between-group comparisons were made for psychometric tests and morphometric measures of cortical thickness and hippocampal volume. Carriers displayed significantly greater impairment on measures of memory retention, whereas noncarriers were more impaired on tests of working memory, executive control, and lexical access. Consistent with this cognitive dissociation, carriers exhibited greater MTL atrophy, whereas noncarriers had greater frontoparietal atrophy. Performance deficits in particular cognitive domains were associated with disproportionate regional brain atrophy within nodes of cortical networks thought to subserve these cognitive processes. These convergent cognitive and neuroanatomic findings in individuals with a CSF molecular pro. le consistent with AD support the hypothesis that APOE genotype modulates the clinical phenotype of AD through influence on specific large-scale brain networks.
C1 [Wolk, David A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Wolk, David A.] Univ Penn, Alzheimers Dis Core Ctr, Philadelphia, PA 19104 USA.
[Wolk, David A.] Univ Penn, Penn Memory Ctr, Philadelphia, PA 19104 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Frontotemporal Dementia Unit, Boston, MA 02115 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02115 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Wolk, DA (reprint author), Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
EM david.wolk@uphs.upenn.edu
RI Scharre, Douglas/E-4030-2011; Preda, Adrian /K-8889-2013; Saykin,
Andrew/A-1318-2007; Beversdorf, David/M-2786-2016
OI Preda, Adrian /0000-0003-3373-2438; Saykin, Andrew/0000-0002-1376-8532;
Beversdorf, David/0000-0002-0298-0634
FU ADNI; National Institutes of Health [U01 AG024904]; National Institute
on Aging (NIA); National Institute of Biomedical Imaging and
Bioengineering; Northern California Institute for Research and
Education; NIA [R01-AG29411, R21-AG29840, P50-AG005134, K23-AG028018,
P30-AG010124]; Alzheimer's Association
FX This work was primarily funded by the ADNI (Principal Investigator:
Michael Weiner; National Institutes of Health Grant U01 AG024904). ADNI
is funded by the National Institute on Aging (NIA), National Institute
of Biomedical Imaging and Bioengineering, and the with participation
from the US Food and Drug Administration. The grantee organization is
the Northern California Institute for Research and Education, and the
study is coordinated by the Alzheimer's Disease Cooperative Study at the
University of California, San Diego. This analysis was also supported by
NIA Grants R01-AG29411, R21-AG29840, P50-AG005134, K23-AG028018, and
P30-AG010124 and the Alzheimer's Association.
NR 60
TC 89
Z9 90
U1 0
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 1
PY 2010
VL 107
IS 22
BP 10256
EP 10261
DI 10.1073/pnas.1001412107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 603ZD
UT WOS:000278246000063
PM 20479234
ER
PT J
AU Banez, LL
Loftis, RM
Freedland, SJ
Presti, JC
Aronson, WJ
Amling, CL
Kane, CJ
Terris, MK
AF Banez, L. L.
Loftis, R. M.
Freedland, S. J.
Presti, J. C., Jr.
Aronson, W. J.
Amling, C. L.
Kane, C. J.
Terris, M. K.
TI The influence of hepatic function on prostate cancer outcomes after
radical prostatectomy
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
DE prostate neoplasm; staging; pathology; PSA recurrence; radical
prostatectomy; liver function tests
ID HORMONE-BINDING GLOBULIN; LIVER-CIRRHOSIS; ALCOHOL-CONSUMPTION; RISK;
ANTIGEN; FINASTERIDE; OBESITY; COHORT; MALES; MEN
AB Prostate growth is dependent on circulating androgens, which can be influenced by hepatic function. Liver disease has been suggested to influence prostate cancer (CaP) incidence. However, the effect of hepatic function on CaP outcomes has not been investigated. A total of 1181 patients who underwent radical prostatectomy (RP) between 1988 and 2008 at four Veterans Affairs hospitals that comprise the Shared Equal Access Regional Cancer Hospital database and had available liver function test (LFT) data were included in the study. Independent associations of LFTs with unfavorable pathological features and biochemical recurrence were determined using logistic and Cox regression analyses. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) levels were elevated in 8.2 and 4.4% of patients, respectively. After controlling for CaP features, logistic regression revealed a significant association between SGOT levels and pathological Gleason sum >= 7(4 + 3) cancer (odds ratio = 2.12; 95% confidence interval = 1.11-4.05; P = 0.02). Mild hepatic dysfunction was significantly associated with adverse CaP grade, but was not significantly associated with other adverse pathological features or biochemical recurrence in a cohort of men undergoing RP. The effect of moderate-to-severe liver disease on disease outcomes in CaP patients managed non-surgically remains to be investigated. Prostate Cancer and Prostatic Diseases (2010) 13, 173-177; doi:10.1038/pcan.2010.3; published online 2 March 2010
C1 [Banez, L. L.; Freedland, S. J.] Duke Univ, Div Urol Surg, Dept Surg, Med Ctr, Durham, NC 27710 USA.
[Banez, L. L.; Freedland, S. J.] Duke Univ, Duke Prostate Ctr, Dept Surg, Med Ctr, Durham, NC 27710 USA.
[Banez, L. L.; Freedland, S. J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA.
[Loftis, R. M.; Terris, M. K.] Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA.
[Loftis, R. M.; Terris, M. K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
[Freedland, S. J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Presti, J. C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA.
[Presti, J. C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA.
[Aronson, W. J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Aronson, W. J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA.
[Amling, C. L.] Oregon Hlth & Sci Univ, Dept Surg, Div Urol, Portland, OR 97201 USA.
[Kane, C. J.] Univ Calif San Diego, Dept Urol, San Diego, CA 92103 USA.
[Kane, C. J.] Vet Affairs Med Ctr, Urol Sect, San Diego, CA 92161 USA.
RP Banez, LL (reprint author), Duke Univ, Div Urol Surg, Dept Surg, Med Ctr, Box 2626,571 Res Dr, Durham, NC 27710 USA.
EM lionel.banez@duke.edu
OI Terris, Martha/0000-0002-3843-7270
FU Department of Veterans Affairs; Department of Defense; Georgia Cancer
Coalition; American Urological Association Foundation; National
Institutes of Health [R01 CA100938, P50 CA921310-1A1]
FX This study was supported by the Department of Veterans Affairs,
Department of Defense Prostate Cancer Research Program, the Georgia
Cancer Coalition, the American Urological Association
Foundation/Astellas Rising Star in Urology Award, National Institutes of
Health R01 CA100938, and National Institutes of Health Specialized
Programs of Research Excellence Grant P50 CA921310-1A1.
NR 24
TC 9
Z9 9
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD JUN
PY 2010
VL 13
IS 2
BP 173
EP 177
DI 10.1038/pcan.2010.3
PG 5
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 595QC
UT WOS:000277626300011
PM 20195294
ER
PT J
AU Cohen, LS
Wang, B
Nonacs, R
Viguera, AC
Lemon, EL
Freeman, MP
AF Cohen, Lee S.
Wang, Betty
Nonacs, Ruta
Viguera, Adele C.
Lemon, Elizabeth L.
Freeman, Marlene P.
TI Treatment of Mood Disorders During Pregnancy and Postpartum
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Mood disorders; Pregnancy; Postpartum
ID SEROTONIN-REUPTAKE INHIBITORS; PERSISTENT PULMONARY-HYPERTENSION;
IN-UTERO EXPOSURE; DEFICIT HYPERACTIVITY DISORDER; OBSESSIVE-COMPULSIVE
DISORDER; PSYCHOTROPIC-DRUG USE; BIPOLAR DISORDER; PANIC DISORDER;
POSTNATAL DEPRESSION; MAJOR DEPRESSION
AB Studies suggest that pregnancy does not protect women from the emergence or persistence of mood disorders. Mood and anxiety disorders are prevalent in women during the childbearing years and, for many women, these mood disorders are chronic or recurrent. Maintenance antidepressant therapy is often indicated during the reproductive years and women face difficult treatment decisions regarding psychotropic medications and pregnancy. Treatment of psychiatric disorders during pregnancy involves a thoughtful weighing of the risks and benefits of proposed interventions and the documented and theoretical risks associated with untreated psychiatric disorders such as depression. Collaborative decision-making that incorporates patient treatment preferences is optimal for women trying to conceive or who are pregnant. This article reviews the diagnosis and treatment guidelines of mood disorders during pregnancy and postpartum, with specific reference to the use of psychotropic medications during this critical time.
C1 [Cohen, Lee S.; Wang, Betty; Nonacs, Ruta; Viguera, Adele C.; Lemon, Elizabeth L.; Freeman, Marlene P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
RP Cohen, LS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 185 Cambridge St, Boston, MA 02114 USA.
EM lcohen2@partners.org
NR 138
TC 29
Z9 29
U1 6
U2 15
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD JUN
PY 2010
VL 33
IS 2
BP 273
EP +
DI 10.1016/j.psc.2010.02.001
PG 22
WC Psychiatry
SC Psychiatry
GA 591FN
UT WOS:000277285300003
PM 20385337
ER
PT J
AU Deligiannidis, KM
Freeman, MP
AF Deligiannidis, Kristina M.
Freeman, Marlene P.
TI Complementary and Alternative Medicine for the Treatment of Depressive
Disorders in Women
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Complementary/alternative treatment; S-Adenosylmethionine; Omega-3 fatty
acids; St John's wort; Acupuncture; Depression; Women
ID ST-JOHNS-WORT; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL;
ADENOSYL-L-METHIONINE; PHASE DYSPHORIC DISORDER; DECREASES PREMENSTRUAL
SYMPTOMS; POLYUNSATURATED FATTY-ACIDS; POSTMENOPAUSAL HOT FLASHES;
BRIGHT LIGHT TREATMENT; MIDDLE-AGED WOMEN
AB Complementary and alternative medicine (CAM) therapies are commonly practiced in the United States and are used more frequently among women than men. This article reviews several CAM treatments for depressive disorders in women, with a focus on major depressive disorder across the reproductive life cycle. The CAM therapies selected for this review (ie, S-adenosylmethionine, omega-3 fatty acids, St John's wort, bright light therapy, acupuncture, and exercise) were based on their prevalence of use and the availability of randomized, placebo-controlled data. Further study is necessary to delineate the role of specific CAM therapies in premenstrual syndrome, premenstrual dysphoric disorder, antepartum and postpartum depression, lactation, and the menopausal transition.
C1 [Deligiannidis, Kristina M.] Univ Massachusetts, Sch Med, Ctr Psychopharmacol Res & Treatment, Worcester, MA 01605 USA.
[Deligiannidis, Kristina M.] Univ Massachusetts, Sch Med, Depress Specialty Clin, UMass Mem Med Ctr, Worcester, MA 01605 USA.
[Deligiannidis, Kristina M.] Univ Massachusetts, Sch Med, Womens Mental Hlth Specialty Clin, UMass Mem Med Ctr, Worcester, MA 01605 USA.
[Freeman, Marlene P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Perinatal & Reprod Psychiat Program, Boston, MA 02114 USA.
RP Deligiannidis, KM (reprint author), Univ Massachusetts, Sch Med, Ctr Psychopharmacol Res & Treatment, 361 Plantat St, Worcester, MA 01605 USA.
EM kristina.deligiannidis@umassmemorial.org
RI Deligiannidis, Kristina/C-3654-2014
OI Deligiannidis, Kristina/0000-0001-7439-2236
NR 182
TC 17
Z9 17
U1 10
U2 23
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD JUN
PY 2010
VL 33
IS 2
BP 441
EP +
DI 10.1016/j.psc.2010.01.002
PG 24
WC Psychiatry
SC Psychiatry
GA 591FN
UT WOS:000277285300012
PM 20385346
ER
PT J
AU Pratchett, LC
Pelcovitz, MR
Yehuda, R
AF Pratchett, Laura C.
Pelcovitz, Michelle R.
Yehuda, Rachel
TI Trauma and Violence: Are Women the Weaker Sex?
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Trauma; Gender; Risk; Prevalence
ID POSTTRAUMATIC-STRESS-DISORDER; BORDERLINE PERSONALITY-DISORDER;
NATIONAL-COMORBIDITY-SURVEY; PSYCHOLOGICAL RISK-FACTORS;
GENDER-DIFFERENCES; CHILDHOOD EXPERIENCES; GENERAL-POPULATION;
FEMALE-PATIENTS; MENTAL-HEALTH; LIFE EVENTS
AB Posttraumatic stress disorder (PTSD) as a response to trauma is repeatedly found to be more common among women than men. This article explores prevalence rates and gender differences. Explanations for this gender bias and examined and the literature on trauma types and resulting PTSD is reviewed. Other disorders that may result from trauma that also have gender biases are considered as a potential way to understand this difference. Risk and resilience can perhaps more appropriately be considered specific to symptom picture rather than merely development of pathology.
C1 [Pratchett, Laura C.; Pelcovitz, Michelle R.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Pratchett, Laura C.; Pelcovitz, Michelle R.; Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
RP Pratchett, LC (reprint author), James J Peters Vet Affairs Med Ctr, 526 OOMH 116-A,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM laura.pratchett@va.gov
NR 62
TC 30
Z9 31
U1 1
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD JUN
PY 2010
VL 33
IS 2
BP 465
EP +
DI 10.1016/j.psc.2010.01.010
PG 12
WC Psychiatry
SC Psychiatry
GA 591FN
UT WOS:000277285300013
PM 20385347
ER
PT J
AU Kettl, P
AF Kettl, Paul
TI State Hospitals and Getting Stuck in a Train
SO PSYCHIATRIC SERVICES
LA English
DT Editorial Material
C1 Philadelphia Dept Vet Affairs Med Ctr, Behav Hlth Serv, Philadelphia, PA 19104 USA.
RP Kettl, P (reprint author), Philadelphia Dept Vet Affairs Med Ctr, Behav Hlth Serv, Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM paul.kettl@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUN
PY 2010
VL 61
IS 6
BP 552
EP 553
PG 2
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 602UT
UT WOS:000278165100004
PM 20513676
ER
PT J
AU Perron, BE
Grahovac, ID
Parrish, D
AF Perron, Brian E.
Grahovac, Ivana D.
Parrish, Diana
TI Students for Recovery: A Novel Way to Support Students on Campus
SO PSYCHIATRIC SERVICES
LA English
DT Editorial Material
C1 [Perron, Brian E.] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA.
[Grahovac, Ivana D.] Univ Texas Austin, Ctr Students Recovery, Austin, TX 78712 USA.
[Parrish, Diana] US Dept Vet Affairs, Ann Arbor, MI USA.
RP Perron, BE (reprint author), Univ Michigan, Sch Social Work, 1080 S Univ Ave, Ann Arbor, MI 48109 USA.
EM beperron@umich.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUN
PY 2010
VL 61
IS 6
BP 633
EP 633
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 602UT
UT WOS:000278165100019
PM 20513691
ER
PT J
AU Moore, SA
Varra, AA
Michael, ST
Simpson, TL
AF Moore, Sally A.
Varra, Alethea A.
Michael, Scott T.
Simpson, Tracy L.
TI Stress-Related Growth, Positive Reframing, and Emotional Processing in
the Prediction of Post-Trauma Functioning Among Veterans in Mental
Health Treatment
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE stress-related growth; emotional processing; reappraisal; positive
reframing; posttraumatic stress disorder
ID BREAST-CANCER; TRAUMA; ADJUSTMENT; DEPRESSION; VALIDATION
AB The role of stress related growth (SRG) in posttrauma functioning is currently uncertain and may be obscured by the overlap between SRG and key coping strategies. Utilizing a veteran sample in mental health treatment, the current study examined whether SRG accounts for unique variance in the severity of posttraumatic stress disorder (PTSD), depression, and Disorders of Extreme Stress Not Otherwise Specified (DESNOS) beyond the effects of two general coping strategies, emotional processing and positive reframing. Curvilinear relationships were evident between SRG and outcome measures, such that individuals with moderate SRG reported the greatest distress, and individuals with the lowest and highest SRG scores reported lower distress. In regression analyses. SRG accounted for significant variance in lower PTSD, depression, and DESNOS while accounting for demographics, trauma type, emotional processing, and positive reframing. The results suggest that SRG captures variance in posttrauma functioning that may be distinct from general emotional processing and positive refraining coping and provides further evidence for a curvilinear relationship between SRG and measures of psychological distress.
C1 [Moore, Sally A.] Dept Vet Affairs Med Ctr, MIRECC, Seattle, WA USA.
[Moore, Sally A.; Varra, Alethea A.; Michael, Scott T.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Varra, Alethea A.; Michael, Scott T.; Simpson, Tracy L.] Dept Vet Affairs Med Ctr, Mental Hlth Serv, Seattle, WA USA.
RP Moore, SA (reprint author), VA Puget Sound Hlth Care Syst, Mail Stop S116-WTRC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM sally.moore2@va.gov
NR 15
TC 6
Z9 6
U1 1
U2 2
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD JUN
PY 2010
VL 2
IS 2
BP 93
EP 96
DI 10.1037/a0018975
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 742CD
UT WOS:000288914800004
ER
PT J
AU Boscarino, JA
Forsberg, CW
Goldberg, J
AF Boscarino, Joseph A.
Forsberg, Christopher W.
Goldberg, Jack
TI A Twin Study of the Association Between PTSD Symptoms and Rheumatoid
Arthritis
SO PSYCHOSOMATIC MEDICINE
LA English
DT Article
DE posttratimatic stress disorder; rheumatoid arthritis; autoimmune
disease; inflammation; zygosity; co-twin study
ID POSTTRAUMATIC-STRESS-DISORDER; CORONARY-HEART-DISEASE; TRADE-CENTER
DISASTER; VIETNAM VETERANS; CLINICAL-RESEARCH; COMBAT EXPOSURE;
CHILDHOOD ABUSE; PHYSICAL HEALTH; MORTALITY; TRAUMA
AB Objectives: To assess the association between posttraumatic stress disorder (PTSD) and rheumatoid arthritis (RA) and to determine if this was due to PTSD or confounding by environmental and genetic factors. Methods: Data were obtained from 3143 twin pairs in the Vietnam Era Twin Registry, which included male twin pairs who served during the Vietnam War era (mean age, 40.6 years; standard deviation, 2.9). Measurements included a PTSD symptom scale, history of physician-diagnosed RA, sociodemographics, and health confounding factors. Co-twin control analytic methods used generalized estimating equation logistic regression to account for the paired twin data and to examine the association between PTSD symptoms and RA in all twins. Separate analyses were conducted within twin pairs. Results: The prevalence of RA among this population was 1.9% (95% confidence interval, 1.6-2.3) and the mean PTSD symptom level was 25.5 (standard deviation, 9.6). PTSD symptoms were associated with an increased likelihood of adult RA even after adjustment for confounding (p(trend) < .001). Among all twins, those in the highest PTSD symptom quartile were 3.8 times more likely (95% confidence interval, 2.1-6.1) to have RA compared with those in the lowest. These findings also persist when examined within twin pairs (p(trend) < .022). Conclusions: PTSD symptoms were associated with adult RA onset. Even after adjustment for familial/genetic factors and other confounders, an association between PTSD symptoms and RA remained. This is one of the first studies to demonstrate a link between PTSD and RA onset among a community-based population sample, independent of familial and genetic factors.
C1 [Boscarino, Joseph A.] Geisinger Med Clin, Ctr Hlth Res, Danville, PA 17822 USA.
[Boscarino, Joseph A.] Mt Sinai Sch Med, Dept Internal Med, New York, NY USA.
[Boscarino, Joseph A.] Mt Sinai Sch Med, Dept Pediat, New York, NY USA.
[Forsberg, Christopher W.; Goldberg, Jack] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Goldberg, Jack] Univ Washington, Dept Epidemiol, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA.
RP Boscarino, JA (reprint author), Geisinger Med Clin, Ctr Hlth Res, 100 N Acad Ave, Danville, PA 17822 USA.
EM jaboscarino@geisinger.edu
FU VA Puget Sound Health Care System, Seattle, Washington; U.S. Department
of Veterans Affairs
FX This study was supported, in part, by the VA Puget Sound Health Care
System, Seattle, Washington. The U.S. Department of Veterans Affairs
provided financial support for the development and maintenance of the
VET Registry.
NR 49
TC 40
Z9 40
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0033-3174
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD JUN
PY 2010
VL 72
IS 5
BP 481
EP 486
DI 10.1097/PSY.0b013e3181d9a80c
PG 6
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 613UB
UT WOS:000279005800007
PM 20410244
ER
PT J
AU Schwarzschild, M
AF Schwarzschild, Michael
TI Targeting purines in Parkinson's: From adenosine to caffeine to urate
SO PURINERGIC SIGNALLING
LA English
DT Meeting Abstract
C1 [Schwarzschild, Michael] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1573-9538
J9 PURINERG SIGNAL
JI Purinergic Signal.
PD JUN
PY 2010
VL 6
SU 1
BP 21
EP 21
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 630AA
UT WOS:000280241700044
ER
PT J
AU Holden, LM
Watts, DD
Walker, PH
AF Holden, L. M.
Watts, D. D.
Walker, P. H.
TI Communication and collaboration: it's about the pharmacists, as well as
the physicians and nurses
SO QUALITY & SAFETY IN HEALTH CARE
LA English
DT Article
ID SAFETY ATTITUDES QUESTIONNAIRE; GENERAL-PRACTICE; MEDICAL ERRORS;
MALPRACTICE CLAIMS; ADVERSE EVENTS; TEAMWORK; CLIMATE; CARE
AB Objective Collaboration and communication as dimensions of patient safety climate have been measured in acute care hospital units, and discrepant viewpoints have been documented between different professional groups, particularly between physicians and nurses. In the ambulatory care setting, these groups often work more closely together throughout the day than in acute care settings, thereby enhancing effective collaboration and communication. This study sought to determine if the communication differences that are known to impact patient safety, which are found in acute care, also exist in ambulatory care.
Methods The Safety Attitudes Questionnaire, a 77-item survey of collaboration, communication and safety attitudes, was administered to the primary care staff at four Midwestern military ambulatory care clinics.
Results There were 107 participants consisting of nurses (n=46), nurse practitioners (n=12), pharmacists (n=10) and physicians (n=39), yielding an overall response rate of 65%. All groups rated their peer group higher than other professional groups. The ratings of nurses and physicians were very similar: 85.0% of nurses rated physicians, and 85.7% of physicians rated nurses as high or very high in communication and collaboration. Pharmacists were rated the lowest by each of the other professional groups. Only 60% of pharmacists rated physicians as high or very high.
Conclusions Collaboration and communication ratings among physicians and nurses appear to be higher in the ambulatory care setting than in the acute care. However, interactions with pharmacists are more problematic, perceived as adversarial. Teamwork training that focuses on specific interactions among professional groups should target these concerns.
C1 [Holden, L. M.] Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA 02114 USA.
[Holden, L. M.] United States AF Nurse Corps, Offutt AFB, NE USA.
[Watts, D. D.; Walker, P. H.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.
RP Holden, LM (reprint author), Massachusetts Gen Hosp, Ctr Qual & Safety, 55 Fruit St,BUL 280, Boston, MA 02114 USA.
EM LMHolden@Partners.org
NR 24
TC 5
Z9 5
U1 1
U2 5
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1475-3898
J9 QUAL SAF HEALTH CARE
JI Qual. Saf. Health Care
PD JUN
PY 2010
VL 19
IS 3
BP 169
EP 172
DI 10.1136/qshc.2008.026435
PG 4
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 618LL
UT WOS:000279355700003
PM 20123760
ER
PT J
AU Pomerantz, SR
Choy, G
AF Pomerantz, Stuart R.
Choy, Garry
TI Net Assets: PowerPoint Pearls for Radiology Presentations. Part II
SO RADIOLOGY
LA English
DT Editorial Material
ID MOVIE CLIPS
C1 [Pomerantz, Stuart R.] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA.
[Choy, Garry] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Pomerantz, SR (reprint author), Massachusetts Gen Hosp, Dept Neuroradiol, 55 Fruit St,Gray 2-B285, Boston, MA 02114 USA.
EM netassets@rsna.org
NR 5
TC 2
Z9 2
U1 0
U2 1
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JUN
PY 2010
VL 255
IS 3
BP 687
EP 691
DI 10.1148/radiol.10100479
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 601DO
UT WOS:000278038500006
PM 20501709
ER
PT J
AU Vartanians, VM
Sistrom, CL
Weilburg, JB
Rosenthal, DI
Thrall, JH
AF Vartanians, Vartan M.
Sistrom, Christopher L.
Weilburg, Jeffrey B.
Rosenthal, Daniel I.
Thrall, James H.
TI Increasing the Appropriateness of Outpatient Imaging: Effects of a
Barrier to Ordering Low-Yield Examinations
SO RADIOLOGY
LA English
DT Article
ID CLINICAL DECISION-SUPPORT; PATIENT OUTCOMES; CHEST PAIN; EDUCATION;
PROGRAM; SYSTEMS; CARE; INTERVENTION; INFORMATION; MANAGEMENT
AB Purpose: To determine the effect of a computerized radiology order entry system rule that prevented nonclinician support staff from completing orders for outpatient computed tomographic, magnetic resonance imaging, and nuclear medicine examinations that received initial low-yield decision support scores in the order entry system.
Materials and Methods: This retrospective HIPAA-compliant study was approved by the institutional review board; the requirement for informed consent was waived. The control group consisted of 42 737 consecutive orders for examinations in which decision support was provided that were placed from April to December 2006. The study group consisted of 76 238 consecutive orders that were placed from April to December 2007. During the latter time period, a new rule in the order entry system was implemented: Examinations that had low-yield decision support scores could not be scheduled when the orders were placed by nonclinician support staff. To schedule the blocked examinations, the responsible clinician was required to personally log in to complete the process. System event logs and records of outpatient imaging procedures were extracted, counted, and analyzed to determine which ordering sessions resulted in examinations being scheduled and performed and which sessions resulted in modified or cancelled examinations. Results were correlated with user status and decision support scores. The Cochran-Mantel-Haenszel technique was used to control for the status of the order initiator and to allow testing for significance of the effect of the intervention on the "fate" of ordering events.
Results: After the intervention, the proportion of total examination requests initiated by clinicians directly logging in almost doubled: from 11 243 (26.31%) of 42 737 to 41 450 (54.37%) of 76 238 examinations (P < .001). The fraction of low-yield (decision support score, 1-3) examinations requested through the order entry system that were later scheduled and performed decreased from 2106 (5.43%) of 38 801 to 1261 (1.92%) of 65 765 (P < .001). This is in contrast to requests for examinations with higher initial decision support scores that were not affected by the policy change and were scheduled at the same rate (relative risk, 0.988) before and after the change.
Conclusion: A simple change in the business logic of the order entry system resulted in a substantially decreased rate of low-yield imaging examinations and a markedly increased percentage of tests personally ordered by clinicians.
C1 [Vartanians, Vartan M.; Rosenthal, Daniel I.; Thrall, James H.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Weilburg, Jeffrey B.] Harvard Univ, Sch Med, Massachusetts Gen Phys Org, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sistrom, Christopher L.] Univ Florida, Dept Radiol, Gainesville, FL 32610 USA.
RP Vartanians, VM (reprint author), Harvard Univ, Sch Med, Dept Radiol, 25 New Chardon St,Suite 427B, Boston, MA 02114 USA.
EM vvartanians@partners.org
NR 21
TC 47
Z9 50
U1 1
U2 3
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JUN
PY 2010
VL 255
IS 3
BP 842
EP 849
DI 10.1148/radiol.10091228
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 601DO
UT WOS:000278038500023
PM 20501721
ER
PT J
AU Almandoz, JED
Schaefer, PW
Kelly, HR
Lev, MH
Gonzalez, RG
Romero, JM
AF Almandoz, Josser E. Delgado
Schaefer, Pamela W.
Kelly, Hillary R.
Lev, Michael H.
Gonzalez, R. Gilberto
Romero, Javier M.
TI CT Angiography in Head and Neck Trauma Response
SO RADIOLOGY
LA English
DT Letter
C1 [Almandoz, Josser E. Delgado; Schaefer, Pamela W.; Kelly, Hillary R.; Lev, Michael H.; Gonzalez, R. Gilberto; Romero, Javier M.] Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA.
[Almandoz, Josser E. Delgado] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Div Neuroradiol, St Louis, MO 63110 USA.
RP Almandoz, JED (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA.
EM delgadoj@mir.wustl.edu
NR 2
TC 0
Z9 0
U1 0
U2 0
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JUN
PY 2010
VL 255
IS 3
BP 1009
EP 1009
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 601DO
UT WOS:000278038500041
ER
PT J
AU Ling, CC
Gerweck, LE
Zaider, M
Yorke, E
AF Ling, C. Clifton
Gerweck, Leo E.
Zaider, Marco
Yorke, Ellen
TI Dose-rate effects in external beam radiotherapy redux
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Review
DE Dose-rate effect; External beam radiotherapy
ID POTENTIALLY LETHAL DAMAGE; LINEAR-QUADRATIC MODEL; PLATEAU-PHASE
CULTURES; CHINESE-HAMSTER CELLS; MAMMALIAN-CELLS; RADIATION-DAMAGE;
SUBLETHAL DAMAGE; SPINAL-CORD; INTERFRACTION INTERVAL;
CHROMOSOME-ABERRATIONS
AB Recent developments in external beam radiotherapy, both in technical advances and in clinical approaches, have prompted renewed discussions on the potential influence of dose-rate on radio-response in certain treatment scenarios. We consider the multiple factors that influence the dose-rate effect, e.g. radical recombination, the kinetics of sublethal damage repair for tumors and normal tissues, the difference in alpha/beta ratio for early and late reacting tissues, and perform a comprehensive literature review. Based on radiobiological considerations and the linear-quadratic (LQ) model we estimate the influence of overall treatment time on radio-response for specific clinical situations. As the influence of dose-rate applies to both the tumor and normal tissues, in oligo-fractionated treatment using large doses per fraction, the influence of delivery prolongation is likely important, with late reacting normal tissues being generally more sensitive to the dose-rate effect than tumors and early reacting tissues. In conventional fractionated treatment using 1.8-2 Gy per fraction and treatment times of 2-10 min, the influence of dose-rate is relatively small. Lastly, the dose-rate effect in external beam radiotherapy is governed by the overall beam-on-time, not by the average linac dose-rate, nor by the instantaneous dose-rate within individual linac pulses which could be as high as 3 x 10(6) MU/min. (C) 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 95 (2010) 261-268
C1 [Ling, C. Clifton] Varian Med Syst, Palo Alto, CA USA.
[Ling, C. Clifton; Zaider, Marco; Yorke, Ellen] Mem Hosp, Dept Med Phys, New York, NY USA.
[Gerweck, Leo E.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Ling, CC (reprint author), Varian Med Syst, Palo Alto, CA USA.
EM lingc@mskcc.org; lgerweck@partners.org
OI Zaider, Marco/0000-0002-5113-7862
NR 66
TC 42
Z9 43
U1 2
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-8140
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUN
PY 2010
VL 95
IS 3
BP 261
EP 268
DI 10.1016/j.radonc.2010.03.014
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 614EO
UT WOS:000279038400001
PM 20363041
ER
PT J
AU Hurwitz, MD
Kaur, P
Nagaraja, GM
Bausero, MA
Manola, J
Asea, A
AF Hurwitz, Mark D.
Kaur, Punit
Nagaraja, Ganachari M.
Bausero, Maria A.
Manola, Judith
Asea, Alexzander
TI Radiation therapy induces circulating serum Hsp72 in patients with
prostate cancer
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
DE Androgen suppressive therapy; Chaperokine; Heat shock proteins; Prostate
cancer; Radiation
ID HEAT-SHOCK-PROTEIN; CELL-DERIVED EXOSOMES; IMMUNE-RESPONSE; CHAPEROKINE
ACTIVITY; EXTRACELLULAR HSP72; STRESS-PROTEINS; T-CELLS; IN-VIVO;
HEAT-SHOCK-PROTEIN-70; PATHWAY
AB Background and purpose: Hsp72 found in the extracellular milieu has been shown to play an important role in immune regulation. The impact of common cancer therapies on extracellular release of Hsp72 however, has been to date undefined.
Materials and methods: Serum from 13 patients undergoing radiation therapy (XRT) for prostate cancer with or without hormonal therapy (ADT) was measured for levels of circulating serum Hsp72 and pro-inflammatory cytokines (IL-6 and TNF-alpha) using the classical sandwich ELISA technique and the relative expression of CD8(+) T lymphocytes and natural killer (NK) cells was measured using flow cytometry. Mouse orthotopic xenograft of human prostate cancer tumors (DU-145 and PC-3) were used to validate and further characterize the response noted in the clinical setting. The biological significance of tumor released Hsp72 was studied in human dendritic cells (DC) in vitro.
Results: Circulating serum Hsp72 levels increased an average of 3.5-fold (median per patient 4.8-fold) with XRT but not with ADT (p = 0.0002). Increases in IL-6 (3.3-fold), TNF-alpha (1.8-fold), CD8(+) CTL (2.1-fold) and NK cells (3.2-fold) also occurred. Using PC-3 and DU-145 human prostate cancer xenograft models in mice, we confirmed that XRT induces Hsp72 release primarily from implanted tumors. In vitro studies using supernatant recovered from irradiated human prostate cancer cells point to exosomes containing Hsp72 as a possible stimulator of pro-inflammatory cytokine production and costimulatory molecules expression in human DC.
Conclusions: The current study confirms for the first time in an actual clinical setting elevation of circulating serum Hsp72 with XRT. The accompanying studies in mice and in vitro identify the released exosomes containing Hsp72 as playing a pivotal role in stimulating pro-inflammatory immune responses. These findings, if validated, may lead to new treatment paradigms for common human malignancies. (C) 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 95 (2010) 350-358
C1 [Kaur, Punit; Nagaraja, Ganachari M.; Bausero, Maria A.; Asea, Alexzander] Scott & White Mem Hosp & Clin, Dept Pathol, Temple, TX 76504 USA.
[Kaur, Punit; Nagaraja, Ganachari M.; Bausero, Maria A.; Asea, Alexzander] Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX 76504 USA.
[Hurwitz, Mark D.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA.
[Hurwitz, Mark D.; Manola, Judith] Harvard Univ, Sch Med, Boston, MA USA.
[Manola, Judith] Dana Farber Brigham & Womens Canc Ctr, Dept Biostat Sci, Boston, MA USA.
RP Asea, A (reprint author), Scott & White Mem Hosp & Clin, Div Investigat Pathol, 1901 S 1st St, Temple, TX 76504 USA.
EM asea@medicine.tamhsc.edu
RI Asea, Alexzander/I-4112-2013
OI Asea, Alexzander/0000-0003-3592-3481
FU National Institute of Health [RO1CA91889]; Scott White Clinic; Texas A&M
Health Science Center, College of Medicine; Central Texas Veterans
Health Administration; Cain Foundation
FX Research in this study was supported in part by the National Institute
of Health grant RO1CA91889, Scott & White Clinic, the Texas A&M Health
Science Center, College of Medicine, the Central Texas Veterans Health
Administration and an Endowment from the Cain Foundation to A.A. The
authors thank Edwina E. Asea, Department of Pathology, Scott and White
Hospital and Clinic, Temple, Texas, USA for expert technical assistance.
NR 35
TC 27
Z9 27
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-8140
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUN
PY 2010
VL 95
IS 3
BP 350
EP 358
DI 10.1016/j.radonc.2010.03.024
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 614EO
UT WOS:000279038400017
PM 20430459
ER
PT J
AU Schmidt, UH
Hess, DR
AF Schmidt, Ulrich H.
Hess, Dean R.
TI Does Spontaneous Breathing Produce Harm in Patients With the Acute
Respiratory Distress Syndrome?
SO RESPIRATORY CARE
LA English
DT Editorial Material
ID ACUTE LUNG INJURY; MECHANICALLY VENTILATED PATIENTS; ESOPHAGEAL
PRESSURE; AIRWAY PRESSURE; TIDAL VOLUMES; CARE; FEASIBILITY; SEDATION;
PROTOCOL; STRESS
C1 [Schmidt, Ulrich H.; Hess, Dean R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
RP Schmidt, UH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
NR 22
TC 9
Z9 11
U1 0
U2 0
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
J9 RESP CARE
JI Respir. Care
PD JUN
PY 2010
VL 55
IS 6
BP 784
EP 786
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 616TJ
UT WOS:000279232200019
PM 20507667
ER
PT J
AU Grudzen, CR
Hoffman, JR
Koenig, WJ
Boscardin, J
Lorenz, KA
Asch, SM
AF Grudzen, Corita R.
Hoffman, Jerome R.
Koenig, William J.
Boscardin, John
Lorenz, Karl A.
Asch, Steven M.
TI The LA story: What happened after a new policy allowing paramedics to
forgo resuscitation attempts in prehospital cardiac arrest
SO RESUSCITATION
LA English
DT Article
DE Prehospital care; Cardiopulmonary resuscitation; Ethics
ID EMERGENCY MEDICAL-SERVICES; OF-LIFE CARE; PATIENT PREFERENCES; DEATH;
SURVIVAL; PLACE; FATES; WORSE
AB Background: Despite potential harm to patients, families, and emergency personnel, a low survival rate, and high costs and intensity of care, attempting resuscitation after prehospital cardiac arrest is the norm, unless there are signs of irreversible death or the presence of a valid, state-issued DNR.
Objective: To determine whether there was a change in the rate of forgoing resuscitation attempts in prehospital cardiac arrest after implementation of a new policy allowing paramedics to forgo resuscitation based on a verbal family request or the presence of certain arrest characteristics.
Methods and results: All prehospital run sheets for cardiac arrest in Los Angeles County were reviewed for the first seven days of each month August 2006-January 2007 (pre-policy) and January-June 2008 (post-policy). Paramedics were more likely to forgo resuscitation attempts after the policy change (13.3% vs. 8.5%, p < 0.01). In addition, the percentage of patients with documented signs of irreversible death decreased post-policy, from 50.4% to 35.8%, p < 0.01. After adjustment for potential confounders (patient demographics, clinical characteristics and EMS factors), as well as exclusion of patients with signs of irreversible death, paramedics are significantly more likely to forgo a resuscitation, and less likely to attempt resuscitation, after the policy change (OR 1.67 [95% CI 1.07, 2.61], p = 0.024).
Conclusions: Paramedics are more likely to forgo, and less likely to attempt, resuscitation in victims of cardiac arrest after implementation of a new policy. There was also an associated decrease in the percentage of patients who had signs of irreversible death, which might reflect a change in paramedic behavior. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Grudzen, Corita R.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA.
[Grudzen, Corita R.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Hoffman, Jerome R.] Univ Calif Los Angeles, Dept Emergency Med, Los Angeles, CA USA.
[Koenig, William J.] Los Angeles Cty Emergency Med Serv Agcy, Los Angeles, CA USA.
[Boscardin, John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Boscardin, John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Lorenz, Karl A.; Asch, Steven M.] VA Greater Los Angeles, Los Angeles, CA USA.
RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, 1 Gustave L Levy Pl,Box 1620, New York, NY 10029 USA.
EM corita.grudzen@mssm.edu
OI Grudzen, Corita/0000-0003-3039-8497
FU California HealthCare Foundation; Los Angeles County EMS
FX We would like to thank Nui Brown and Jacqueline Torres for their help
collecting the data as well as Susan Mori, Richard Taddeo, Maureen
Hasbrouck, and Robin Smilor at Los Angeles County EMS for support of the
project and help in acquiring the run sheets.; Funding sources: This
project was supported by the California HealthCare Foundation.
NR 17
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0300-9572
J9 RESUSCITATION
JI Resuscitation
PD JUN
PY 2010
VL 81
IS 6
BP 685
EP 690
DI 10.1016/j.resuscitation.2010.02.011
PG 6
WC Critical Care Medicine; Emergency Medicine
SC General & Internal Medicine; Emergency Medicine
GA 614VM
UT WOS:000279087900012
PM 20236748
ER
PT J
AU Ceranoglu, TA
AF Ceranoglu, T. Atilla
TI Video Games in Psychotherapy
SO REVIEW OF GENERAL PSYCHOLOGY
LA English
DT Article
DE child and adolescent psychotherapy; video games; media
ID TREASURE HUNT; CHILDREN; DISTRACTION; ADOLESCENTS; THERAPY; CANCER
AB Video games have found their way into the clinical care of youth in most medical fields, and academic interest in their use is increasing steadily. The popularity of video games among youth may qualify them as a useful tool in psychotherapy tor children and adolescents. Limited literature on use of video games in mental health care suggests that they can help young patients become more cooperative and enthusiastic about psychotherapy. Recent experience suggests that video games may facilitate therapeutic relationships, complement the psychological assessment of youth by evaluating cognitive skills, and elaborate and clarify conflicts during the therapy process. Concerns about video game content, perceived effects on youth. and lack of familiarity with this medium may form a barrier in their use in therapy offices. Further research on the benefits of video game use in psychotherapy, including patient characteristics that may moderate outcomes, is needed. Finally, future collaborations between clinicians and video game developers may produce specific games to be used in psychotherapy.
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Ceranoglu, TA (reprint author), Massachusetts Gen Hosp, 55 Fruit St,YAW 6A, Boston, MA 02114 USA.
EM aceranoglu@partners.org
NR 40
TC 29
Z9 33
U1 1
U2 22
PU EDUCATIONAL PUBLISHING FOUNDATION
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1089-2680
J9 REV GEN PSYCHOL
JI Rev. Gen. Psychol.
PD JUN
PY 2010
VL 14
IS 2
SI SI
BP 141
EP 146
DI 10.1037/a0019439
PG 6
WC Psychology, Multidisciplinary
SC Psychology
GA 612GY
UT WOS:000278886000009
ER
PT J
AU Olson, CK
AF Olson, Cheryl K.
TI Children's Motivations for Video Game Play in the Context of Normal
Development
SO REVIEW OF GENERAL PSYCHOLOGY
LA English
DT Article
DE video games; child development; adolescence; motivation
ID VIOLENCE; PERSPECTIVES; EXPERIENCES; ENJOYMENT; BEHAVIOR; PARENTS; BOYS;
FLOW; FEAR
AB Electronic games are now an everyday part of childhood and adolescence. The debate has moved from whether children should play video games to how to maximize potential benefits and to identify and minimize potential harms. To do this, we must understand what motivates children to play electronic games and what needs the games meet. Drawing on a survey of 1,254 middle school children, focus groups with boys and their parents, and findings from other quantitative and qualitative research, the author describes a variety of motivations for video game play (including games with violent content) and how these may vary based on factors such as mood, environment. personality, and developmental stage. The findings are put into the context of normal development, and suggestions are given for parents, educators, and researchers.
C1 Massachusetts Gen Hosp, Dept Psychiat, Ctr Mental Hlth & Media, Boston, MA 02114 USA.
RP Olson, CK (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Mental Hlth & Media, Wang 812,15 Parkman St, Boston, MA 02114 USA.
EM colson@hms.harvard.edu
NR 57
TC 102
Z9 103
U1 4
U2 45
PU EDUCATIONAL PUBLISHING FOUNDATION
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1089-2680
J9 REV GEN PSYCHOL
JI Rev. Gen. Psychol.
PD JUN
PY 2010
VL 14
IS 2
SI SI
BP 180
EP 187
DI 10.1037/a0018984
PG 8
WC Psychology, Multidisciplinary
SC Psychology
GA 612GY
UT WOS:000278886000013
ER
PT J
AU Waheed, S
Cannon, CP
AF Waheed, Salman
Cannon, Christopher P.
TI Cardiac Rehabilitation Reduces the Long-Term Risk of Death and
Cardiovascular Complications
SO REVIEWS IN CARDIOVASCULAR MEDICINE
LA English
DT Editorial Material
ID CORONARY-ARTERY-DISEASE; PROGRAMS
C1 [Waheed, Salman] UMass Mem Med Ctr, Worcester, MA USA.
[Cannon, Christopher P.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
RP Waheed, S (reprint author), UMass Mem Med Ctr, Worcester, MA USA.
NR 11
TC 0
Z9 0
U1 0
U2 0
PU MEDREVIEWS, LLC
PI NEW YORK
PA 1370 BROADWAY, STE 900, NEW YORK, NY 10018 USA
SN 1530-6550
J9 REV CARDIOVASC MED
JI Rev. Cardiovasc. Med.
PD SUM
PY 2010
VL 11
IS 3
BP E181
EP E184
DI 10.3909/ricm0543
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 690GH
UT WOS:000284990000007
PM 21045772
ER
PT J
AU Olincy, A
Braff, DL
Adler, LE
Cadenhead, KS
Calkins, ME
Dobie, DJ
Green, MF
Greenwood, TA
Gur, RE
Gur, RC
Light, GA
Mintz, J
Nuechterlein, KH
Radant, AD
Schork, NJ
Seidman, LJ
Siever, LJ
Silverman, JM
Stone, WS
Swerdlow, NR
Tsuang, DW
Tsuang, MT
Turetsky, BI
Wagner, BD
Freedman, R
AF Olincy, Ann
Braff, David L.
Adler, Lawrence E.
Cadenhead, Kristin S.
Calkins, Monica E.
Dobie, Dorcas J.
Green, Michael F.
Greenwood, Tiffany A.
Gur, Raquel E.
Gur, Reuben C.
Light, Gregory A.
Mintz, James
Nuechterlein, Keith H.
Radant, Allen D.
Schork, Nicholas J.
Seidman, Larry J.
Siever, Larry J.
Silverman, Jeremy M.
Stone, William S.
Swerdlow, Neal R.
Tsuang, Debby W.
Tsuang, Ming T.
Turetsky, Bruce I.
Wagner, Brandie D.
Freedman, Robert
TI Inhibition of the P50 cerebral evoked response to repeated auditory
stimuli: Results from the Consortium on Genetics of Schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Evoked potentials auditory; Inhibition; Genetics
ID SENSORY-GATING DEFICIT; REM-SLEEP; HIPPOCAMPUS; SUPPRESSION;
ABNORMALITIES; HERITABILITY; POLYMORPHISM; RELATIVES; P300
AB Inhibitiion of the P50 evoked electroencephalographic response to the second of paired auditory stimuli has been frequently examined as a neurophysiological deficit in schizophrenia. The Consoritum on the Genetics of Schizophrenia (COGS), a 7-site study funded by the National Institute of Mental Health, examined this endophenotype in recording from 181 probands with schizophrenia, 429 of their first degree relatives, and 333 community comparison control subjects. Most probands were treated with second generation antipsychotic medications. Highly significant differnces in P50 inhibtion, measured as either the ratio of amplitudes or their difference in response to the two stimuli, were found between the probands and the community comparison sample. There were no differences between the COGS sites for these findings. For the ratio parameter, an admixture analysis found that nearly 40% of the relatives demonstrated deficiencies in P50 inhibition that are comparable to the deficit found in the probands. These results indicate that P50 auditory evoked potentials can be recorded across multiple sites and reliably demonstrate a physiological abnormality in schizophrenia. The appearance of the physicological abnormality in a substantial proporition of clinically unaffected first degree relatives is consisten with the hypothesis that deficits in cerebral inhibition are a familial neurobiological risk factor for the illness. Published by Elsevier B.V.
C1 [Olincy, Ann] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA.
[Olincy, Ann; Adler, Lawrence E.; Freedman, Robert] Vet Affairs Denver Med Ctr VISN 19 MIRECC, Dept Psychiat, Denver, CO USA.
[Braff, David L.; Cadenhead, Kristin S.; Greenwood, Tiffany A.; Light, Gregory A.; Swerdlow, Neal R.; Tsuang, Ming T.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Calkins, Monica E.; Gur, Raquel E.; Gur, Reuben C.; Turetsky, Bruce I.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Dobie, Dorcas J.; Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Green, Michael F.; Mintz, James; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA.
[Green, Michael F.; Mintz, James] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Schork, Nicholas J.] Scripps Genome Med, La Jolla, CA USA.
[Schork, Nicholas J.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.
[Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med,Publ Psychiat Div,Beth Israel Deaconess M, Dept Psychiat,Massachusetts Mental Hlth Ctr, Harvard Inst Psychiat Epidemiol & Genet, Boston, MA 02115 USA.
[Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Siever, Larry J.; Silverman, Jeremy M.] James J Peters VA Med Ctr, Bronx, NY USA.
[Siever, Larry J.; Silverman, Jeremy M.] VISN 3 MIRECC, Bronx, NY USA.
[Wagner, Brandie D.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO 80045 USA.
RP Olincy, A (reprint author), Univ Colorado Denver, Dept Psychiat, Mail Stop F546,13001 E 17th Pl, Aurora, CO 80045 USA.
EM Ann.olincy@ucdenver.edu
RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016
OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang,
Debby/0000-0002-4716-1894
FU NIMH [R01]
FX Funding for this study was provided by the NIMH Collaborative R01 Grants
to each of the 7 sites; the NIMH had no further role in study design; in
the collection, analysis and interpretation of data; in the writing of
the report; and in the decisiion to submit the paper for publication.
NR 37
TC 48
Z9 50
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD JUN
PY 2010
VL 119
IS 1-3
BP 175
EP 182
DI 10.1016/j.schres.2010.03.004
PG 8
WC Psychiatry
SC Psychiatry
GA 631JC
UT WOS:000280341700026
PM 20382002
ER
PT J
AU Ogg, JA
Brinkman, TM
Dedrick, RF
Carlson, JS
AF Ogg, Julia A.
Brinkman, Tara M.
Dedrick, Robert F.
Carlson, John S.
TI Factor Structure and Invariance Across Gender of the Devereux Early
Childhood Assessment Protective Factor Scale
SO SCHOOL PSYCHOLOGY QUARTERLY
LA English
DT Article
DE DECA; strength-based assessment; Head Start; differential item
functioning
ID HEAD-START; PRESCHOOL-CHILDREN; BEHAVIOR PROBLEMS; LANGUAGE DELAYS;
RISK; PSYCHOPATHOLOGY; MODEL; BOYS
AB Early childhood social emotional assessment has traditionally focused on risk factors or psychopathology, and has less frequently examined protective factors that may serve to promote positive developmental outcomes for children. To advance conceptual models that include protective factors as key explanatory constructs, there is a need for quantitative measures of protective factors that are psychometrically sound and function similarly across different subgroups, including gender. This study examined the factor structure and factorial invariance across gender of the Devereux Early Childhood Assessment (DECA), one of the few measures to focus on protective behaviors. A total of 1,344 parents completed the DECA for a group of developmentally and economically at-risk children ages 2 to 5 years. Results of the confirmatory factor analysis, the first to be conducted on the DECA, revealed that the factor structure proposed by the authors of the DECA was adequate with some modifications. Multigroup comparisons by gender supported the invariance of the factor pattern coefficients and 26 of the 27 item intercepts, indicating that the items were functioning similarly across boys and girls. Suggestions for improving problematic item pairs and content are provided. This study can be viewed as part of the ongoing validation of the DECA and an important contribution to the strength-based assessment literature.
C1 [Ogg, Julia A.] Univ S Florida, Dept Psychol & Social Fdn, Tampa, FL 33620 USA.
[Brinkman, Tara M.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA USA.
[Dedrick, Robert F.] Univ S Florida, Dept Measurement & Res, Tampa, FL 33620 USA.
[Carlson, John S.] Michigan State Univ, Dept Educ Psychol Counseling & Special Educ, E Lansing, MI 48824 USA.
RP Ogg, JA (reprint author), 4202 E Fowler Ave,Stop EDU 105, Tampa, FL 33620 USA.
EM jogg@usf.edu
NR 35
TC 5
Z9 5
U1 0
U2 8
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1045-3830
J9 SCHOOL PSYCHOL QUART
JI Sch. Psychol. Q.
PD JUN
PY 2010
VL 25
IS 2
BP 107
EP 118
DI 10.1037/a0020251
PG 12
WC Psychology, Educational
SC Psychology
GA 629XY
UT WOS:000280235700005
ER
PT J
AU Feramisco, JD
Tsao, H
Siegel, DH
AF Feramisco, Jamison D.
Tsao, Hensin
Siegel, Dawn H.
TI Genetics for the Practicing Dermatologist
SO SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; IDENTIFIES SUSCEPTIBILITY VARIANTS;
FACIO-CUTANEOUS SYNDROME; MUCKLE-WELLS-SYNDROME; ATOPIC-DERMATITIS;
LUPUS-ERYTHEMATOSUS; GERMLINE MUTATIONS; DNA METHYLATION;
CROHNS-DISEASE; SKIN DISEASES
AB In the era of robust genome sequencing, a working understanding of genetics has become important for the clinician. For the dermatologist, understanding the flow of genetic information from genotype to phenotype can aid in the delivery of effective patient care. In this article, we will review concepts in genetics and the human genome and how they contribute to clinical dermatology. Semin Cutan Med Surg 29:127-136 (C) 2010 Published by Elsevier Inc.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
RP Siegel, DH (reprint author), Oregon Hlth & Sci Univ, Dept Dermatol & Pediat, 3303 SW Bond Ave,CH16D, Portland, OR 97239 USA.
EM siegeld@ohsu.edu
NR 95
TC 4
Z9 4
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1085-5629
J9 SEMIN CUTAN MED SURG
JI Semin. Cutan. Med. Surg.
PD JUN
PY 2010
VL 29
IS 2
BP 127
EP 136
DI 10.1016/j.sder.2010.04.006
PG 10
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 619IU
UT WOS:000279424600009
PM 20579602
ER
PT J
AU Hough, S
AF Hough, Sigmund
TI The Psychology of Spinal Surgery
SO SEXUALITY AND DISABILITY
LA English
DT Book Review
C1 [Hough, Sigmund] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Hough, Sigmund] Boston Sch Med, Boston, MA USA.
[Hough, Sigmund] VA Boston Healthcare Syst, Spinal Cord Injury Serv, W Roxbury, MA USA.
RP Hough, S (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
EM sigmund_hough@hms.harvard.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0146-1044
J9 SEX DISABIL
JI Sex. Disabil.
PD JUN
PY 2010
VL 28
IS 2
BP 141
EP 142
DI 10.1007/s11195-010-9151-y
PG 2
WC Rehabilitation
SC Rehabilitation
GA 593JM
UT WOS:000277450000007
ER
PT J
AU Sumi, Y
Chen, Y
Yao, Y
Woehrle, T
El Khal, A
Junger, WG
AF Sumi, Y.
Chen, Y.
Yao, Y.
Woehrle, T.
El Khal, A.
Junger, W. G.
TI PLASMA ATP CONCENTRATIONS CORRELATE WITH NEUTROPHIL ACTIVATION AFTER
SEPSIS
SO SHOCK
LA English
DT Meeting Abstract
CT 33rd Annual Conference on Shock
CY JUN 12-15, 2010
CL Portland, OR
SP Shock Soc
C1 [Sumi, Y.; Chen, Y.; Yao, Y.; Woehrle, T.; El Khal, A.; Junger, W. G.] Harvard Univ, Sch Med, Dept Surg, BIDMC, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD JUN
PY 2010
VL 33
SU 1
BP 10
EP 10
PG 1
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 598IC
UT WOS:000277828000034
ER
PT J
AU Chen, Y
Yao, Y
Sumi, Y
Woehrle, T
ElKhal, A
Junger, WG
AF Chen, Y.
Yao, Y.
Sumi, Y.
Woehrle, T.
ElKhal, A.
Junger, W. G.
TI ATP RELEASE VIA PANNEXIN 1 HEMI-CHANNELS CONTROLS NEUTROPHIL CHEMOTAXIS
SO SHOCK
LA English
DT Meeting Abstract
CT 33rd Annual Conference on Shock
CY JUN 12-15, 2010
CL Portland, OR
SP Shock Soc
C1 [Chen, Y.; Yao, Y.; Sumi, Y.; Woehrle, T.; ElKhal, A.; Junger, W. G.] Harvard Univ, Sch Med, Dept Surg, BIDMC, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD JUN
PY 2010
VL 33
SU 1
BP 27
EP 27
PG 1
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 598IC
UT WOS:000277828000089
ER
PT J
AU Li, Y
Xiang, M
Wilson, M
Fan, J
AF Li, Y.
Xiang, M.
Wilson, M.
Fan, J.
TI TLR4-IL-1RI CROSS-TALK MEDIATES HEMORRHAGIC SHOCK-PRIMED CASPASE-1
ACTIVATION IN LUNG ENDOTHELIAL CELLS
SO SHOCK
LA English
DT Meeting Abstract
CT 33rd Annual Conference on Shock
CY JUN 12-15, 2010
CL Portland, OR
SP Shock Soc
C1 [Li, Y.; Xiang, M.; Wilson, M.; Fan, J.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15240 USA.
[Li, Y.; Xiang, M.; Wilson, M.; Fan, J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
NR 0
TC 0
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD JUN
PY 2010
VL 33
SU 1
BP 36
EP 37
PG 2
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 598IC
UT WOS:000277828000122
ER
PT J
AU Junger, WG
Rhind, SG
Rizoli, SB
Cuschieri, J
Hoyt, DB
Baker, AJ
Shek, PN
Bulger, EM
AF Junger, W. G.
Rhind, S. G.
Rizoli, S. B.
Cuschieri, J.
Hoyt, D. B.
Baker, A. J.
Shek, P. N.
Bulger, E. M.
TI HYPERTONIC RESUSCITATION OF SHOCK PATIENTS DOWNREGULATES NEUTROPHIL
ACTIVATION
SO SHOCK
LA English
DT Meeting Abstract
CT 33rd Annual Conference on Shock
CY JUN 12-15, 2010
CL Portland, OR
SP Shock Soc
C1 [Junger, W. G.; Rhind, S. G.; Rizoli, S. B.; Cuschieri, J.; Hoyt, D. B.; Baker, A. J.; Shek, P. N.; Bulger, E. M.] Harvard Univ, Sch Med, BIDMC, Dept Surg, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD JUN
PY 2010
VL 33
SU 1
BP 50
EP 50
PG 1
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 598IC
UT WOS:000277828000163
ER
PT J
AU Elkhal, A
Sumi, Y
Bhate, M
Chen, Y
Yao, Y
Woehrle, T
Junger, WG
AF Elkhal, A.
Sumi, Y.
Bhate, M.
Chen, Y.
Yao, Y.
Woehrle, T.
Junger, W. G.
TI TH17 TYPE CYTOKINES ARE INCREASED LOCALLY AND SYSTEMICALLY IN A MOUSE
SEPSIS MODEL
SO SHOCK
LA English
DT Meeting Abstract
CT 33rd Annual Conference on Shock
CY JUN 12-15, 2010
CL Portland, OR
SP Shock Soc
C1 [Elkhal, A.; Sumi, Y.; Bhate, M.; Chen, Y.; Yao, Y.; Woehrle, T.; Junger, W. G.] Harvard Univ, BIDMC, Sch Med, Dept Surg, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD JUN
PY 2010
VL 33
SU 1
BP 80
EP 81
PG 2
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 598IC
UT WOS:000277828000265
ER
PT J
AU Gutchess, AH
Hedden, T
Ketay, S
Aron, A
Gabrieli, JDE
AF Gutchess, Angela H.
Hedden, Trey
Ketay, Sarah
Aron, Arthur
Gabrieli, John D. E.
TI Neural differences in the processing of semantic relationships across
cultures
SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE
LA English
DT Article
DE cognition; culture; executive function; fMRI; semantic
ID THEMATIC CONCEPTUAL RELATIONS; EVENT-RELATED FMRI; COGNITIVE CONTROL;
CHINESE; BRAIN; CATEGORIES; OBJECT; AMERICAN; CONTEXT; WORDS
AB The current study employed functional MRI to investigate the contribution of domain-general (e. g. executive functions) and domain-specific (e. g. semantic knowledge) processes to differences in semantic judgments across cultures. Previous behavioral experiments have identified cross-cultural differences in categorization, with East Asians preferring strategies involving thematic or functional relationships (e. g. cow-grass) and Americans preferring categorical relationships (e. g. cow-chicken). East Asians and American participants underwent functional imaging while alternating between categorical or thematic strategies to sort triads of words, as well as matching words on control trials. Many similarities were observed. However, across both category and relationship trials compared to match (control) trials, East Asians activated a frontal-parietal network implicated in controlled executive processes, whereas Americans engaged regions of the temporal lobes and the cingulate, possibly in response to conflict in the semantic content of information. The results suggest that cultures differ in the strategies employed to resolve conflict between competing semantic judgments.
C1 [Gutchess, Angela H.] Brandeis Univ, Dept Psychol, Waltham, MA 02454 USA.
[Hedden, Trey] Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
[Hedden, Trey; Gabrieli, John D. E.] MIT, Cambridge, MA 02139 USA.
[Ketay, Sarah] Mt Sinai Sch Med, New York, NY 10029 USA.
[Aron, Arthur] SUNY Stony Brook, Stony Brook, NY 11794 USA.
RP Gutchess, AH (reprint author), Brandeis Univ, Dept Psychol, 415 South St,MS 062, Waltham, MA 02454 USA.
EM gutchess@brandeis.edu
FU National Institutes of Health; McGovern Institute for Brain Research at
MIT
FX This work was supported by the National Institutes of Health [to
J.D.E.G.] and the McGovern Institute for Brain Research at MIT.
NR 48
TC 18
Z9 18
U1 3
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1749-5016
J9 SOC COGN AFFECT NEUR
JI Soc. Cogn. Affect. Neurosci.
PD JUN
PY 2010
VL 5
IS 2-3
BP 254
EP 263
DI 10.1093/scan/nsp059
PG 10
WC Neurosciences; Psychology; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA 653EU
UT WOS:000282071900017
PM 20139116
ER
PT J
AU Kilzieh, N
Rastam, S
Ward, KD
Maziak, W
AF Kilzieh, Nael
Rastam, Samer
Ward, Kenneth D.
Maziak, Wasim
TI Gender, depression and physical impairment: an epidemiologic perspective
from Aleppo, Syria
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE Physical impairment; Gender; Depression; Epidemiologic studies; Syria
ID GENERAL-POPULATION; MENTAL-DISORDERS; MAJOR DEPRESSION; PRIMARY-CARE;
HEALTH; DISABILITY; ILLNESS; DETERMINANTS; OUTCOMES; ADHERENCE
AB Examine the association of physical impairment with gender, depression, and socio-demographics in the community in Aleppo, Syria.
We conducted a cross-sectional, population-based study in Aleppo on adults aged 18-65 (N = 2,038). We used a computerized interviewer-administered structured questionnaire. Physical impairment was measured via an adapted 12-item World Health Organization, Health State Description Individual Questionnaire which includes both physical and emotional items. We used physical impairment items score to classify individuals into low, middle, and high physical impairment category. Self-report of physician-diagnosed depression and chronic diseases active in the past year and their current treatment status were obtained.
Sample mean age (SD) was 35.3 (12.1) years, 55% were female, and 4.5% had depression. Female gender, low socioeconomic status (SES), and depression were associated with high physical impairment. Women had more impairment (OR = 3.35, 95% CI: 2.15-5.21) with little change after controlling for depression and chronic diseases, but significantly decreased after controlling for socio-demographics (OR = 1.51, 95% CI: 0.84-2.73). The association with low (vs. high) SES was prominent (OR = 2.48, 95% CI: 1.32-4.67) after controlling for all variables. Depression's association (OR = 4.85, 95% CI: 1.93-12.15) lost significance after controlling for chronic diseases (OR = 2.81, 95% CI: 0.96-8.25), but further adjustment for socio-demographics had little effect.
Women and individuals of low SES appear more vulnerable to physical impairment in the community in Aleppo. Depression's association with physical impairment may be mediated through co-existing chronic diseases. Public health planning regarding physical impairment in Syria should encompass these as putative risk factors.
C1 [Kilzieh, Nael] VA Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA 98493 USA.
[Kilzieh, Nael] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Rastam, Samer; Maziak, Wasim] Syrian Ctr Tobacco Studies, Aleppo, Syria.
[Ward, Kenneth D.; Maziak, Wasim] Univ Memphis, Dept Hlth & Sport Sci, Memphis, TN 38152 USA.
[Ward, Kenneth D.; Maziak, Wasim] Univ Memphis, Ctr Community Hlth, Memphis, TN 38152 USA.
RP Kilzieh, N (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div, 9600 Vet Dr,A-116, Tacoma, WA 98493 USA.
EM nael.kilzieh@va.gov
OI Rastam, Samer/0000-0002-4004-7773
FU US Public Health Service [R01 TW05962, R21 TW006545]; NIDA
[R01DA024876-01]; Fulbright Scholar Grant, Bureau of Cultural and
Educational Affairs, US Department of State; Veterans Affairs Mental
Illness Research, Education, and Clinical Center (MIRECC); VISN 20
FX This work is supported by US Public Health Service grants R01 TW05962
and R21 TW006545; and NIDA grant R01DA024876-01. Nael Kilzieh is
supported by The Fulbright Scholar Grant, Bureau of Cultural and
Educational Affairs, US Department of State and the Veterans Affairs
Mental Illness Research, Education, and Clinical Center (MIRECC), VISN
20.
NR 32
TC 3
Z9 3
U1 2
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0933-7954
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD JUN
PY 2010
VL 45
IS 6
BP 595
EP 602
DI 10.1007/s00127-009-0076-7
PG 8
WC Psychiatry
SC Psychiatry
GA 599VS
UT WOS:000277942500001
PM 20195569
ER
PT J
AU Krause, JS
Terza, JV
Saunders, LL
Dismuke, CE
AF Krause, J. S.
Terza, J. V.
Saunders, L. L.
Dismuke, C. E.
TI Delayed entry into employment after spinal cord injury: factors related
to time to first job
SO SPINAL CORD
LA English
DT Article
DE spinal cord injury; employment; vocational rehabilitation;
participation; psychosocial
ID LIFE; ADJUSTMENT; EARNINGS; RETURN; GENDER; WORK
AB Study design: Data were cross-sectional and were collected by survey methodology.
Objectives: To investigate factors predictive of length of time between spinal cord injury (SCI) onset and start of first post-injury employment and full-time employment.
Setting: A large specialty hospital in the Southeastern United States, with additional participant samples from two hospitals in the Midwestern United States.
Methods: Participants were identified from patient records at the participating hospitals. They met the following three exclusion/inclusion criteria: traumatic SCI, at least 18 years of age at time of survey, and a minimum of 1-year after SCI. Outcome measures were years from injury onset to beginning first post-injury job and years to first full-time post-injury job. Two separate models were developed for each outcome using a regression analysis. All those 10 years and more post-injury were censored (that is eliminated) in the analysis.
Results: Having a higher level of education, less severe injury, being Caucasian, and returning to the pre-injury employer were associated with a shorter interval to initiation of employment with 10-year censoring. In addition to these variables, gender was associated with time to return to first full-time job.
Conclusion: The findings underscore the importance of using pre-injury education and opportunities to return to the pre-injury employer to minimize the length of time until initiation of employment after SCI. Spinal Cord (2010) 48, 487-491; doi: 10.1038/sc.2009.157; published online 24 November 2009
C1 [Krause, J. S.; Saunders, L. L.; Dismuke, C. E.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA.
[Terza, J. V.] Univ N Carolina, Bryan Sch Business & Econ, Greensboro, NC 27412 USA.
[Dismuke, C. E.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Krause, JS (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Suite 117,MSC 700, Charleston, SC 29425 USA.
EM krause@musc.edu
FU National Institute for Disability and Rehabilitation Research (NIDRR) of
the Office of Special Education and Rehabilitative Services (OSERS)
[H133G020239, H133G060126]; United States Department of Education
FX This research was supported by field initiated grants (H133G020239,
H133G060126) from the National Institute for Disability and
Rehabilitation Research (NIDRR) of the Office of Special Education and
Rehabilitative Services (OSERS), the United States Department of
Education. The opinions expressed here are those of the grantee and not
the funding agency. We thank the following people whose contributions
made completion of this article possible: Richard Aust, Dr Rickey E
Carter Jennifer Coker, Karla Reed, and Yusheng Zhai, and Sarah Lottes
and Christina McCleery of the Shepherd Center.
NR 18
TC 18
Z9 18
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD JUN
PY 2010
VL 48
IS 6
BP 487
EP 491
DI 10.1038/sc.2009.157
PG 5
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 605BI
UT WOS:000278321900009
PM 19935754
ER
PT J
AU Yang, C
Hornicek, FJ
Wood, KB
Schwab, JH
Choy, E
Iafrate, J
Rosenberg, A
Nielsen, GP
Xavier, RJ
Mankin, H
Duan, ZF
AF Yang, Cao
Hornicek, Francis J.
Wood, Kirkham B.
Schwab, Joseph H.
Choy, Edwin
Iafrate, John
Rosenberg, Andrew
Nielsen, G. Petur
Xavier, Ramnik J.
Mankin, Henry
Duan, Zhenfeng
TI Characterization and Analysis of Human Chordoma Cell Lines
SO SPINE
LA English
DT Article
DE chordoma; characteristics; 3D cell culture; chemotherapy
ID TUMOR-SUPPRESSOR PROTEIN; BREAST-CARCINOMA CELLS; TERM-FOLLOW-UP;
PROGNOSTIC-FACTORS; MOBILE SPINE; CANCER CELLS; V COLLAGEN; I-TRIMER;
HYPOXIA; GROWTH
AB Study Design. An experimental study to investigate the characterization of 3 chordoma cell lines.
Objective. To characterize chordoma cell lines and generate hypothesis for further chordoma studies.
Summary of Background Data. Three cultured human chordoma cell lines have been successfully generated; however, their characterization is incomplete. Complete characterization of chordoma cell lines is necessary for these reagents to be a useful preclinical model.
Methods. Three chordoma cell lines, CH 8, U-CH1, and GP 60, were cultured in different commercially available tissue culture media. They were also cultured in different environments, which included collagen substrate, various concentrations of glucose, and various levels of hypoxic conditions. The rate of cell proliferation was assessed by either MTT or numeration assay. A 3-dimensional (3D) cell culture model of these chordoma cell lines was also studied, and the expression of vimentin and cytokeratin was measured by immunofluorescence and Western blot. Additionally, the sensitivity of the 3 chordoma cell lines to 6 chemotherapeutic drugs was analyzed.
Results. CH 8, GP 60, and U-CH1 cells proliferate more actively in Iscove Modified Dulbecco Medium or Dulbecco modified Eagle Medium and less actively in RPMI medium. All 3 chordoma cell lines universally grow better in collagen substrate and survive in hypoxic conditions, whereas glucose concentration has no significant influence on their growth properties. Chordoma cell lines grew well in 3D culture systems and formed acini-like spheroids and retained the expression of vimentin and cytokeratin. MTT analysis indicates that all 3 chordoma cell lines are sensitive to doxorubicin, yondelis, zalypsis, and cisplatin.
Conclusion. We characterized 3 chordoma cell lines for differential growth properties in a variety of media and response to chemotherapeutic agents.
C1 [Yang, Cao; Hornicek, Francis J.; Wood, Kirkham B.; Schwab, Joseph H.; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Yang, Cao; Hornicek, Francis J.; Schwab, Joseph H.; Choy, Edwin; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Yang, Cao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed Surg, Wuhan 430074, Peoples R China.
[Choy, Edwin] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA.
[Iafrate, John; Rosenberg, Andrew; Nielsen, G. Petur; Xavier, Ramnik J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Duan, ZF (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, 70 Blossom St,GRJ 1115, Boston, MA 02114 USA.
EM zduan@partners.org
OI Choy, Edwin/0000-0001-9896-8084
FU NIDDK NIH HHS [P30 DK040561-15, P30 DK040561]
NR 38
TC 17
Z9 19
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-2436
J9 SPINE
JI SPINE
PD JUN 1
PY 2010
VL 35
IS 13
BP 1257
EP 1264
DI 10.1097/BRS.0b013e3181c2a8b0
PG 8
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 602TZ
UT WOS:000278163000002
PM 20461036
ER
PT J
AU Kim, DS
Lee, JS
Leem, JW
Huh, YJ
Kim, JY
Kim, HS
Park, IH
Daley, GQ
Hwang, DY
Kim, DW
AF Kim, Dae-Sung
Lee, Jae Souk
Leem, Joong Woo
Huh, Yong Jun
Kim, Ji Young
Kim, Han-Soo
Park, In-Hyun
Daley, George Q.
Hwang, Dong-Youn
Kim, Dong-Wook
TI Robust Enhancement of Neural Differentiation from Human ES and iPS Cells
Regardless of their Innate Difference in Differentiation Propensity
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Pluripotent stem cell; Differentiation propensity; Neural induction;
Cell signaling; Small molecule
ID HUMAN EMBRYONIC STEM; HIGHLY EFFICIENT; GROWTH-FACTOR; PLURIPOTENCY;
INDUCTION; SUPPRESSION; PRECURSORS; PATHWAYS; SIGNALS; ABSENCE
AB Our analyses of three human induced pluripotent stem cell (hiPSC) and six human embryonic stem cell (hESC) lines showed marked variability in differentiation potential into specific lineages, which often hampers their differentiation into specific cell types or cell lineages of interest. Simultaneous inhibition of both Activin/Nodal and BMP pathways with small molecules, SB431542 and dorsomorphin (DM), respectively, promoted significant neural differentiation from all human pluripotent stem cell (hPSC) lines tested, regardless of their differentiation propensity. On the contrary, differentiation into other cell lineages and the number of undifferentiated cells were significantly reduced after differentiation by the dual inhibition. These results demonstrate that innate differentiation propensity of hPSCs could be overcome, at least in part, by modulation of intracellular signaling pathways, resulting in efficient generation of desirable cell types, such as neural cells.
C1 [Hwang, Dong-Youn] CHA Univ, Coll Med, CHA Stem Cell Inst, Seoul, South Korea.
[Kim, Dong-Wook] Yonsei Univ, Coll Med, Dept Physiol, Ctr Cell Therapy, Seoul, South Korea.
[Kim, Dae-Sung; Lee, Jae Souk; Leem, Joong Woo; Huh, Yong Jun; Kim, Ji Young; Kim, Dong-Wook] Brain Korea 21 Project Med Sci, Dept Physiol, Seoul 120752, South Korea.
[Kim, Han-Soo] Yonsei Univ, Coll Med, Dept Lab Med, Seoul 120752, South Korea.
[Park, In-Hyun; Daley, George Q.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Med,Div Pediat Hematol Oncol, Boston, MA 02115 USA.
[Park, In-Hyun; Daley, George Q.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
RP Hwang, DY (reprint author), CHA Univ, Coll Med, CHA Stem Cell Inst, 606-16 Vis Bldg,4th Floor, Seoul, South Korea.
EM hdy@cha.ac.kr; dwkim2@yuhs.ac
RI Kim, Dae-Sung/H-1116-2015
OI Kim, Dae-Sung/0000-0002-3835-4803
FU Ministry of Education, Science and Technology, Republic of Korea
[SC1110, SC4140, SC5170]
FX This research was supported by grants (code: SC1110, SC4140 and SC5170)
from the Stem Cell Research Center of the 21th Century Frontier Research
Program funded by the Ministry of Education, Science and Technology,
Republic of Korea.
NR 25
TC 111
Z9 113
U1 2
U2 26
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1550-8943
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD JUN
PY 2010
VL 6
IS 2
BP 270
EP 281
DI 10.1007/s12015-010-9138-1
PG 12
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
Experimental
SC Cell Biology; Research & Experimental Medicine
GA 613CG
UT WOS:000278953100013
PM 20376579
ER
PT J
AU Sauerwein, W
Wittig, A
Matsumttra, A
Nakagawa, Y
Mauri, P
Zonta, A
Busse, P
Moss, R
AF Sauerwein, W.
Wittig, A.
Matsumttra, A.
Nakagawa, Y.
Mauri, P.
Zonta, A.
Busse, P.
Moss, R.
TI Clinical applications for Boron Neutron Capture Therapy (BNCT)
SO STRAHLENTHERAPIE UND ONKOLOGIE
LA English
DT Meeting Abstract
CT 16th Annual Meeting of the German-Society-of-Radiooncology
CY JUN 03-03, 2010
CL Magdenburg, GERMANY
SP German Soc Radiooncol
C1 [Sauerwein, W.; Wittig, A.] Univ Duisburg Essen, Strahlen Klin, Essen, Germany.
[Matsumttra, A.] Univ Tsukuba, Ibaraki, Japan.
[Nakagawa, Y.] Natl Kagawa Childrens Hosp, Dept Neurosurg, Zentsuji, Japan.
[Mauri, P.] CNR, Ist Tecnol Biomed, Segrate, Italy.
[Zonta, A.] Univ Studi Pavia, Dept Surg Sci, Pavia, Italy.
[Busse, P.] Massachusetts Gen Hosp, Head & Neck Canc Ctr, Boston, MA 02114 USA.
[Moss, R.] European Commiss Joint Res Ctr, Inst Energy, Petten, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU URBAN & VOGEL
PI MUNICH
PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY
SN 0179-7158
J9 STRAHLENTHER ONKOL
JI Strahlenther. Onkol.
PD JUN
PY 2010
VL 186
SU 1
BP 56
EP 56
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 601OK
UT WOS:000278071200145
ER
PT J
AU Hachinski, V
Donnan, GA
Gorelick, PB
Hacke, W
Cramer, SC
Kaste, M
Fisher, M
Brainin, M
Buchan, AM
Lo, EH
Skolnick, BE
Furie, KL
Hankey, GJ
Kivipelto, M
Morris, J
Rothwell, PM
Sacco, RL
Smith, SC
Wang, YL
Bryer, A
Ford, GA
Iadecola, C
Martins, SCO
Saver, J
Skvortsova, V
Bayley, M
Bednar, MM
Duncan, P
Enney, L
Finklestein, S
Jones, TA
Kalra, L
Kleim, J
Nitkin, R
Teasell, R
Weiller, C
Desai, B
Goldberg, MP
Heiss, WD
Saarelma, O
Schwamm, LH
Shinohara, Y
Trivedi, B
Wahlgren, N
Wong, LK
Hakim, A
Norrving, B
Prudhomme, S
Bornstein, NM
Davis, SM
Goldstein, LB
Leys, D
Tuomilehto, J
AF Hachinski, Vladimir
Donnan, Geoffrey A.
Gorelick, Philip B.
Hacke, Werner
Cramer, Steven C.
Kaste, Markku
Fisher, Marc
Brainin, Michael
Buchan, Alastair M.
Lo, Eng H.
Skolnick, Brett E.
Furie, Karen L.
Hankey, Graeme J.
Kivipelto, Miia
Morris, John
Rothwell, Peter M.
Sacco, Ralph L.
Smith, Sidney C., Jr.
Wang, Yulun
Bryer, Alan
Ford, Gary A.
Iadecola, Costantino
Martins, Sheila C. O.
Saver, Jeff
Skvortsova, Veronika
Bayley, Mark
Bednar, Martin M.
Duncan, Pamela
Enney, Lori
Finklestein, Seth
Jones, Theresa A.
Kalra, Lalit
Kleim, Jeff
Nitkin, Ralph
Teasell, Robert
Weiller, Cornelius
Desai, Bhupat
Goldberg, Mark P.
Heiss, Wolf-Dieter
Saarelma, Osmo
Schwamm, Lee H.
Shinohara, Yukito
Trivedi, Bhargava
Wahlgren, Nils
Wong, Lawrence K.
Hakim, Antoine
Norrving, Bo
Prudhomme, Stephen
Bornstein, Natan M.
Davis, Stephen M.
Goldstein, Larry B.
Leys, Didier
Tuomilehto, Jaakko
TI Stroke: Working Toward a Prioritized World Agenda
SO STROKE
LA English
DT Article
DE prevention; rehabilitation; stroke; translational; treatment
ID VASCULAR COGNITIVE IMPAIRMENT; TISSUE-PLASMINOGEN ACTIVATOR; TRANSIENT
ISCHEMIC ATTACK; HEALTHY LIFE-STYLE; PRIMARY PREVENTION; POLICY
STATEMENT; CARE; RECOMMENDATIONS; PROGRESS; BRAIN
AB Background and Purpose-The aim of the Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke.
Methods-Preliminary work was performed by 7 working groups of stroke leaders followed by a synergium (a forum for working synergistically together) with approximately 100 additional participants. The resulting draft document had further input from contributors outside the synergium.
Results-Recommendations of the Synergium are:
Basic Science, Drug Development and Technology: There is a need to develop: (1) New systems of working together to break down the prevalent "silo" mentality; (2) New models of vertically integrated basic, clinical, and epidemiological disciplines; and (3) Efficient methods of identifying other relevant areas of science.
Stroke Prevention: (1) Establish a global chronic disease prevention initiative with stroke as a major focus. (2) Recognize not only abrupt clinical stroke, but subtle subclinical stroke, the commonest type of cerebrovascular disease, leading to impairments of executive function. (3) Develop, implement and evaluate a population approach for stroke prevention. (4) Develop public health communication strategies using traditional and novel (eg, social media/marketing) techniques.
Acute Stroke Management: Continue the establishment of stroke centers, stroke units, regional systems of emergency stroke care and telestroke networks.
Brain Recovery and Rehabilitation: (1) Translate best neuroscience, including animal and human studies, into poststroke recovery research and clinical care. (2) Standardize poststroke rehabilitation based on best evidence. (3) Develop consensus on, then implementation of, standardized clinical and surrogate assessments. (4) Carry out rigorous clinical research to advance stroke recovery.
Into the 21st Century: Web, Technology and Communications: (1) Work toward global unrestricted access to stroke-related information. (2) Build centralized electronic archives and registries.
Foster Cooperation Among Stakeholders (large stroke organizations, nongovernmental organizations, governments, patient organizations and industry) to enhance stroke care.
Educate and energize professionals, patients, the public and policy makers by using a "Brain Health" concept that enables promotion of preventive measures.
Conclusions-To accelerate progress in stroke, we must reach beyond the current status scientifically, conceptually, and pragmatically. Advances can be made not only by doing, but ceasing to do. Significant savings in time, money, and effort could result from discontinuing practices driven by unsubstantiated opinion, unproven approaches, and financial gain. Systematic integration of knowledge into programs coupled with careful evaluation can speed the pace of progress.
C1 [Hachinski, Vladimir] Univ Western Ontario, Dept Clin Neurol Sci, London Hlth Sci Ctr, London, ON N6A 5A5, Canada.
[Donnan, Geoffrey A.] Florey Neurosci Inst, Carlton, Vic, Australia.
[Gorelick, Philip B.] Univ Illinois, Chicago, IL USA.
[Hacke, Werner] Univ Heidelberg, Heidelberg, Germany.
[Cramer, Steven C.] Univ Calif Irvine, Orange, CA 92668 USA.
[Kaste, Markku] Univ Helsinki, Helsinki Univ Cent Hosp, Helsinki, Finland.
[Fisher, Marc] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Brainin, Michael] Univ Donau Univ Krems, Krems, Austria.
[Buchan, Alastair M.] Univ Oxford, Oxford, England.
[Lo, Eng H.; Furie, Karen L.; Schwamm, Lee H.] Massachusetts Gen Hosp, Charlestown, MA USA.
[Skolnick, Brett E.] Novo Nordisk, Princeton, NJ USA.
[Hankey, Graeme J.] Royal Perth Hosp, Perth, WA, Australia.
[Kivipelto, Miia; Wahlgren, Nils] Karolinska Inst, Stockholm, Sweden.
[Morris, John; Goldberg, Mark P.] Washington Univ, Sch Med, St Louis, MO USA.
[Rothwell, Peter M.] John Radcliffe Hosp, Oxford OX3 9DU, England.
[Sacco, Ralph L.] Univ Miami, AHA, Miami, FL USA.
[Smith, Sidney C., Jr.] Univ N Carolina, Ctr Cardiovasc Sci & Med, Chapel Hill, NC USA.
World Heart Federat, Geneva, Switzerland.
[Wang, Yulun] InTouch Hlth, Goleta, CA USA.
[Bryer, Alan] Groote Schuur Hosp, ZA-7925 Cape Town, South Africa.
[Bryer, Alan] Univ Cape Town, ZA-7925 Cape Town, South Africa.
[Ford, Gary A.] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Iadecola, Costantino] Weill Cornell Med Coll, New York, NY USA.
[Martins, Sheila C. O.] Hosp Clin, Porto Alegre, RS, Brazil.
[Saver, Jeff] Univ Calif Los Angeles, Los Angeles Stroke Ctr, Los Angeles, CA USA.
[Skvortsova, Veronika] Russian State Res Stroke Inst, Moscow, Russia.
[Bayley, Mark] Toronto Rehabil Inst, Toronto, ON, Canada.
[Bednar, Martin M.] Pfizer Inc, Neurosci Res Unit, Groton, CT 06340 USA.
[Duncan, Pamela; Goldstein, Larry B.] Duke Univ, Durham, NC USA.
[Enney, Lori] GlaxoSmithKline Inc, Durham, NC USA.
[Finklestein, Seth] Biotrofix Inc, Waltham, MA USA.
[Jones, Theresa A.] Univ Texas Austin, Austin, TX 78712 USA.
[Kalra, Lalit] Kings Coll London, London WC2R 2LS, England.
[Kleim, Jeff] Univ Florida, Gainesville, FL USA.
[Nitkin, Ralph] NICHHD, Natl Ctr Med Rehabil, NIH, Rockville, MD USA.
[Teasell, Robert] St Josephs Healthcare London, London, ON, Canada.
[Weiller, Cornelius] Univ Freiburg, Freiburg, Germany.
[Desai, Bhupat] Pomona Valley Hosp Med Ctr, Pomona, CA USA.
[Heiss, Wolf-Dieter] Max Planck Inst Neurol Res, Cologne, Germany.
[Saarelma, Osmo] Terveystalo Med Ctr, Helsinki, Finland.
[Shinohara, Yukito] Tachikawa Hosp, Tokyo, Japan.
[Trivedi, Bhargava] So Illinois Healthcare, Carbondale, IL USA.
[Wong, Lawrence K.] Chinese Univ Hong Kong, Sha Tin, Hong Kong, Peoples R China.
[Hakim, Antoine] Univ Ottawa, Canadian Stroke Network, Ottawa, ON, Canada.
Ottawa Hosp Res Inst, Ottawa, ON, Canada.
[Norrving, Bo] Univ Lund Hosp, S-22185 Lund, Sweden.
[Prudhomme, Stephen] Amer Heart Assoc, Dallas, TX USA.
[Bornstein, Natan M.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel.
[Davis, Stephen M.] Royal Melbourne Hosp, Melbourne, Vic, Australia.
Univ Melbourne, Melbourne, Vic, Australia.
[Goldstein, Larry B.] Durham VA Med Ctr, Durham, NC USA.
[Leys, Didier] Univ Lille Nord France, Lille, France.
[Tuomilehto, Jaakko] Univ Helsinki, Helsinki, Finland.
RP Hachinski, V (reprint author), Univ Western Ontario, Univ Hosp, 339 Windermere Rd, London, ON N6A 5A5, Canada.
EM Vladimir.Hachinski@lhsc.on.ca
RI Skolnick, Brett/B-5140-2009; Buchan, Alastair/B-9095-2009; Jones,
Theresa/F-1182-2010; Davis, Stephen/L-5260-2013; Wong, Ka Sing
Lawrence/N-3434-2015; LEYS, Didier/G-2955-2016;
OI Saver, Jeffrey/0000-0001-9141-2251; Kaste, Markku/0000-0001-6557-6412;
Schwamm, Lee/0000-0003-0592-9145; Donnan, Geoffrey/0000-0001-6324-3403;
Buchan, Alastair/0000-0002-2918-5200; Jones,
Theresa/0000-0003-0906-6439; Davis, Stephen/0000-0003-0962-2300; Wong,
Ka Sing Lawrence/0000-0002-2031-9866; LEYS, Didier/0000-0003-4408-4392;
Kivipelto, Miia/0000-0003-0992-3875; Norrving, Bo/0000-0002-8024-5096
FU Medical Research Council [G0500495]; NINDS NIH HHS [P01 NS055104, RC2
NS069335]
NR 83
TC 54
Z9 55
U1 2
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2010
VL 41
IS 6
BP 1084
EP 1099
DI 10.1161/STROKEAHA.110.586156
PG 16
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 600WK
UT WOS:000278019400006
PM 20498453
ER
PT J
AU Anderson, CD
Biffi, A
Rost, NS
Cortellini, L
Furie, KL
Rosand, J
AF Anderson, Christopher D.
Biffi, Alessandro
Rost, Natalia S.
Cortellini, Lynelle
Furie, Karen L.
Rosand, Jonathan
TI Chromosome 9p21 in Ischemic Stroke Population Structure and
Meta-Analysis
SO STROKE
LA English
DT Article
DE atherosclerosis; cardiac disease; genetics; ischemic stroke;
meta-analysis; methodology
ID CORONARY-ARTERY-DISEASE; HEART-DISEASE; GENOMEWIDE ASSOCIATION;
MYOCARDIAL-INFARCTION; GENETIC-VARIANTS; SUSCEPTIBILITY; CHINESE; LOCUS;
RISK
AB Background and Purpose-Sequence variants on chromosome 9p21.3 are implicated in coronary artery disease and myocardial infarction, but studies in ischemic stroke have produced inconsistent results. We investigated whether these conflicting findings were due to false-positive studies confounded by population stratification or false-negative studies that failed to account for effects specific to certain stroke subtypes.
Methods-After assessing for population stratification at 9p21.3 using genomewide data, we meta-analyzed 8 ischemic stroke studies. This analysis focused on 2 single nucleotide polymorphisms, rs1537378 and rs10757278, because these variants are in strong linkage disequilibrium with most single nucleotide polymorphisms analyzed in prior studies of the region.
Results-Principal component analysis of the genomewide data showed no evidence of population stratification at that locus. Meta-analysis confirmed that both rs1537378 and rs10757278 are risk factors for ischemic stroke (ORs, 1.09 [P = 0.0014] and 1.11 [P = 0.001], respectively). Subtype analysis revealed a substantial increase in the effect of each single nucleotide polymorphism for risk of large artery stroke, achieving an effect size similar to that seen in coronary artery disease/myocardial infarction.
Conclusions-Variants on 9p21.3 are associated with ischemic stroke, and restriction of analysis to large artery stroke increases effect size toward that observed in prior association studies of coronary artery disease/myocardial infarction. Previous inconsistent findings are best explained by this subtype specificity rather than any unmeasured confounding by population stratification. (Stroke. 2010; 41: 1123-1131.)
C1 [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Cortellini, Lynelle; Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Cortellini, Lynelle; Furie, Karen L.; Rosand, Jonathan] Massachusetts Gen Hosp, Stroke Serv, Boston, MA 02114 USA.
[Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Cortellini, Lynelle; Rosand, Jonathan] Broad Inst, Cambridge, MA USA.
RP Rosand, J (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA.
OI Anderson, Christopher/0000-0002-0053-2002
FU American Heart Association/Bugher Foundation Centers for Stroke
Prevention Research [0775010N]; Deane Institute for Integrative Study of
Atrial Fibrillation and Stroke; US National Institutes of Health and
National Heart, Lung, and Blood Institute [R01 HL087676]; National
Center for Research [U54 RR020278]
FX Supported by the American Heart Association/Bugher Foundation Centers
for Stroke Prevention Research (0775010N), Deane Institute for
Integrative Study of Atrial Fibrillation and Stroke, US National
Institutes of Health and National Heart, Lung, and Blood Institute's
STAMPEED genomics research program (R01 HL087676), and The National
Center for Research (U54 RR020278).
NR 20
TC 35
Z9 37
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2010
VL 41
IS 6
BP 1123
EP 1131
DI 10.1161/STROKEAHA.110.580589
PG 9
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 600WK
UT WOS:000278019400011
PM 20395606
ER
PT J
AU Zhao, XH
Zhao, Q
Chu, BC
Yang, Y
Li, FY
Zhou, XH
Cai, JM
Cai, ZL
Yuan, C
AF Zhao, Xihai
Zhao, Qian
Chu, Baocheng
Yang, Yin
Li, Feiyu
Zhou, Xiao-Hua
Cai, Jianming
Cai, Zulong
Yuan, Chun
TI Prevalence of Compositional Features in Subclinical Carotid
Atherosclerosis Determined by High-Resolution Magnetic Resonance Imaging
in Chinese Patients With Coronary Artery Disease
SO STROKE
LA English
DT Article
DE carotid artery; coronary artery disease; magnetic resonance imaging;
plaque composition; subclinical atherosclerosis
ID TRANSIENT ISCHEMIC ATTACK; INTIMA-MEDIA THICKNESS; MYOCARDIAL-ISCHEMIA;
PLAQUE COMPOSITION; MRI; CALCIFICATION; ASSOCIATION; TOMOGRAPHY; STROKE;
STENOSIS
AB Background and Purpose-Previous studies have reported that carotid atherosclerosis frequently can be seen in coronary artery disease (CAD) patients. This study sought to determine the prevalence of compositional features in subclinical carotid atherosclerosis by MRI in CAD patients.
Methods-Ninety-six subjects with suspected CAD but free of neurological symptoms underwent coronary CT angiography and carotid MRI including 3-dimensional time-of-flight, T1-weighted, T2-weighted, and proton density-weighted sequences at 3 T within a 2-week interval. The coronary artery calcium score (CACS) and degree of stenosis were measured. Areas for carotid lumen, wall, total vessel, and percent wall volume (wall volume/total vessel volume) were measured. The prevalence of carotid calcification, lipid-rich necrotic core, intraplaque hemorrhage, and surface disruption in coronary stenosis and CACS categories were determined.
Results-Carotid percent wall volume was correlated with CACS (P = 0.001). Both coronary stenosis and CACS were significantly associated with presence of carotid calcification (OR = 5.79 for 1%-49% vs 0% stenosis; OR = 10.23 for >50% vs 0% stenosis; OR = 10.65 for CACS 1-399 vs CACS 0; and OR = 20.28 for CACS >400 vs CACS 0; all P<0.05) and lipid-rich necrotic core (OR = 10.29 for 1%-49% vs 0% stenosis; OR = 4.66 for >50% vs 0% stenosis; OR = 8.23 for CACS 1-399 vs CACS 0; and OR = 11.87 for CACS >400 vs CACS 0; all P < 0.05) High prevalence of lipid-rich necrotic core was found in low-grade coronary stenosis (75.6% in 1%-49% stenosis) and CACS (73.5% in CACS 1-399).
Conclusions-Carotid plaque burden and compositional features are significantly associated with CAD severity. The finding of high prevalence of lipid-rich necrotic core in patients with low-grade coronary stenosis and CACS suggests the need for early monitoring of carotid atherosclerosis in CAD patients. (Stroke. 2010; 41: 1157-1162.)
C1 [Zhao, Xihai; Chu, Baocheng; Li, Feiyu; Yuan, Chun] Univ Washington, Dept Radiol, Seattle, WA 98109 USA.
[Yang, Yin; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Zhao, Qian; Cai, Jianming; Cai, Zulong] Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China.
[Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA USA.
RP Yuan, C (reprint author), Univ Washington, Dept Radiol, 815 Mercer St,Box 358050, Seattle, WA 98109 USA.
EM cyuan@u.washington.edu
FU National Institutes of Health [RO1 HL 56874]
FX This study is supported in part by a grant from the National Institutes
of Health (RO1 HL 56874).
NR 30
TC 9
Z9 11
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2010
VL 41
IS 6
BP 1157
EP 1162
DI 10.1161/STROKEAHA.110.580027
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 600WK
UT WOS:000278019400016
PM 20395607
ER
PT J
AU Abou-Chebl, A
Lin, R
Hussain, MS
Jovin, TG
Levy, EI
Liebeskind, DS
Yoo, AJ
Hsu, DP
Rymer, MM
Tayal, AH
Zaidat, OO
Natarajan, SK
Nogueira, RG
Nanda, A
Tian, M
Hao, Q
Kalia, JS
Nguyen, TN
Chen, M
Gupta, R
AF Abou-Chebl, Alex
Lin, Ridwan
Hussain, Muhammad Shazam
Jovin, Tudor G.
Levy, Elad I.
Liebeskind, David S.
Yoo, Albert J.
Hsu, Daniel P.
Rymer, Marilyn M.
Tayal, Ashis H.
Zaidat, Osama O.
Natarajan, Sabareesh K.
Nogueira, Raul G.
Nanda, Ashish
Tian, Melissa
Hao, Qing
Kalia, Junaid S.
Nguyen, Thanh N.
Chen, Michael
Gupta, Rishi
TI Conscious Sedation Versus General Anesthesia During Endovascular Therapy
for Acute Anterior Circulation Stroke Preliminary Results From a
Retrospective, Multicenter Study
SO STROKE
LA English
DT Article
DE acute stroke; thrombolysis; endovascular therapy; intra-arterial
therapy; sedation
ID ACUTE ISCHEMIC-STROKE; MULTIMODAL REPERFUSION THERAPY; INTRAARTERIAL
THROMBOLYSIS; PROACT II; TRIAL; RECANALIZATION; MANAGEMENT; OCCLUSION;
PATIENT; SAFETY
AB Background and Purpose-Patients undergoing intra-arterial therapy (IAT) for acute ischemic stroke receive either general anesthesia (GA) or conscious sedation. GA may delay time to treatment, whereas conscious sedation may result in patient movement and compromise the safety of the procedure. We sought to determine whether there were differences in safety and outcomes in GA patients before initiation of IAT.
Methods-A cohort of 980 patients at 12 stroke centers underwent IAT for acute stroke between 2005 and 2009. Only patients with anterior circulation strokes due to large-vessel occlusion were included in the study. A binary logistic-regression model was used to determine independent predictors of good outcome and death.
Results-The mean age was 66 +/- 15 years and median National Institutes of Health Stroke Scale score was 17 (interquartile range, 13-20). The overall recanalization rate was 68% and the symptomatic hemorrhage rate was 9.2%. GA was used in 44% of patients with no differences in intracranial hemorrhage rates when compared with the conscious sedation group. The use of GA was associated with poorer neurologic outcome at 90 days (odds ratio = 2.33; 95% CI, 1.63-3.44; P<0.0001) and higher mortality (odds ratio = 1.68; 95% CI, 1.23-2.30; P<0.0001) compared with conscious sedation.
Conclusions-Patients placed under GA during IAT for anterior circulation stroke appear to have a higher chance of poor neurologic outcome and mortality. There do not appear to be differences in hemorrhagic complications between the 2 groups. Future clinical trials with IAT can help elucidate the etiology of the differences in outcomes. (Stroke. 2010; 41: 1175-1179.)
C1 [Abou-Chebl, Alex] Univ Louisville, Med Ctr, Louisville, KY 40292 USA.
[Lin, Ridwan; Jovin, Tudor G.] Univ Pittsburgh, Med Ctr, Stroke Inst, Pittsburgh, PA USA.
[Hussain, Muhammad Shazam; Gupta, Rishi] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Levy, Elad I.; Natarajan, Sabareesh K.] SUNY Buffalo, Buffalo, NY 14260 USA.
[Liebeskind, David S.; Hao, Qing] Univ Calif Los Angeles, Los Angeles, CA USA.
[Yoo, Albert J.; Nogueira, Raul G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hsu, Daniel P.; Nanda, Ashish] Univ Hosp Case Med Ctr, Cleveland, OH USA.
[Rymer, Marilyn M.] St Lukes Brain & Stroke Inst, Kansas City, MO USA.
[Tayal, Ashis H.; Tian, Melissa] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA.
[Zaidat, Osama O.; Kalia, Junaid S.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Nguyen, Thanh N.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Chen, Michael] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Gupta, Rishi] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
RP Gupta, R (reprint author), Vanderbilt Stroke Ctr, Dept Neurol, A-0118 Med Ctr N, Nashville, TN 37232 USA.
EM rishi.gupta@vanderbilt.edu
OI Kalia, Junaid/0000-0001-7121-8638
FU National Institutes of Health; Penumbra Corp; Boston Scientific Corp;
Micrus Endovascular; Abbott Vascular; EV3
FX David Liebeskind has received significant research support from the
National Institutes of Health.; Alex Abou-Chebl, MD; Ridwan Lin, MD;
Muhammad Shazam Hussain, MD; Daniel P. Hsu, MD; Sabareesh K. Natarajan,
MD, MS; Ashish Nanda, MD; Melissa Tian, RN; Qing Hao, MD, PhD; Junaid S.
Kalia, MD; and Thanh N. Nguyen, MD, have no relevant conflicts of
interest to disclose. Albert J. Yoo has research support from Penumbra
Corp. Tudor G. Jovin, MD, is on the consultant/scientific advisory
boards for CoAxia Medical and Concentric Medical and is a consultant for
EV3. Elad I. Levy, MD, has received a research grant from Boston
Scientific Corp; research support from Micrus Endovascular, Abbott
Vascular, and EV3; has received honoraria from Intratech Medical Ltd;
has an ownership interest in Mynx/Access Closure and TheraSyn Sensors,
Inc; and is on the consultant/advisory boards for Cordis Neurovascular
and Micrus Endovascular. Marilyn M. Rymer, MD, is a speaker for
Concentric Medical and a consultant for Genentech. Ashis H. Tayal, MD,
is a speaker for Genentech and Boehringer Ingelheim. David S. Liebskind,
MD, and Raul G. Nogueira, MD, are consultants to and on the advisory
boards for Concentric Medical, EV3, and CoAxia. Osama Zaidat, MD, is on
the consultant/scientific advisory board for Boston Scientific Corp.
Michael Chen, MD, is a speaker for Concentric Medical. Rishi Gupta, MD,
is on the consultant/scientific advisory boards for Concentric Medical
and CoAxia.
NR 21
TC 146
Z9 147
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2010
VL 41
IS 6
BP 1175
EP 1179
DI 10.1161/STROKEAHA.109.574129
PG 5
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 600WK
UT WOS:000278019400019
PM 20395617
ER
PT J
AU Uppal, R
Ay, I
Dai, GP
Kim, YR
Sorensen, AG
Caravan, P
AF Uppal, Ritika
Ay, Ilknur
Dai, Guangping
Kim, Young Ro
Sorensen, A. Gregory
Caravan, Peter
TI Molecular MRI of Intracranial Thrombus in a Rat Ischemic Stroke Model
SO STROKE
LA English
DT Article
DE fibrin; gadolinium; ischemic stroke; molecular imaging; thrombus
ID MIDDLE CEREBRAL-ARTERY; TARGETED CONTRAST AGENT; TISSUE-PLASMINOGEN
ACTIVATOR; IN-VIVO; SWINE MODEL; CORONARY-THROMBOSIS; PULMONARY EMBOLI;
FIBRIN; SIGN; EP-2104R
AB Background and Purpose-Intracranial thrombus is a principal feature in most ischemic stroke, and thrombus location and size may correlate with outcome and response to thrombolytic therapy. EP-2104R is a fibrin-specific molecular MR agent that has previously been shown to enhance extracranial and venous sinus thrombi in animal models and, recently, in clinical trials. In this study, we examined whether this fibrin-specific MR probe could noninvasively characterize intracranial arterial thrombi.
Methods-Embolic stroke was induced in adult rats by occlusion of the right internal carotid artery with an aged thrombus. We used diffusion-weighted imaging, time of flight angiography, and high-resolution 3-dimensional T1-weighted MRI at 4.7 T before and after use of contrast agents EP-2104R (n = 6) and gadopentetate dimeglumine (n = 5).
Results-In all animals, MR angiography revealed a flow deficit and diffusion-weighted imaging showed hyperintensity consistent with ischemia. Using EP-2104R-enhanced MRI, we saw occlusive thrombi and vessel wall enhancement in all 6 animals with high contrast to noise relative to blood, whereas gadopentetate dimeglumine-injected animals showed no occlusive thrombus or vessel wall enhancement. The concentration of gadolinium in the thrombus after EP-2104R was 18 times that in the blood pool.
Conclusions-EP-2104R-enhanced MRI successfully identifies intracranial thrombus in a rat embolic stroke model. (Stroke. 2010; 41: 1271-1277.)
C1 Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
RP Ay, I (reprint author), Massachusetts Gen Hosp E, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St,Suite 2301, Charlestown, MA 02129 USA.
EM iay@partners.org; caravan@nmr.mgh.harvard.edu
FU National Institute of Biomedical Imaging and Bioengineering [EB009062];
Ruth L. Kirschstein National Research Service [5T32CA009502]; PHS
[NS38477]; National Center for Research Resources [P41-RR14075]; MIND
Institute
FX This study was supported by the National Institute of Biomedical Imaging
and Bioengineering (EB009062 to P. C.). I. A. was supported by a T32
Ruth L. Kirschstein National Research Service Award (5T32CA009502). A.
G. S. was supported by PHS NS38477. Partial support was also provided by
National Center for Research Resources (P41-RR14075) and the MIND
Institute.
NR 33
TC 24
Z9 26
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2010
VL 41
IS 6
BP 1271
EP 1277
DI 10.1161/STROKEAHA.109.575662
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 600WK
UT WOS:000278019400033
PM 20395615
ER
PT J
AU Ziegler, PD
Glotzer, TV
Daoud, EG
Wyse, DG
Singer, DE
Ezekowitz, MD
AF Ziegler, Paul D.
Glotzer, Taya V.
Daoud, Emile G.
Wyse, D. George
Singer, Daniel E.
Ezekowitz, Michael D.
TI Incidence of Newly Detected Atrial Arrhythmias Through Implantable
Devices in Patients With a History of Thromboembolic Events Response
SO STROKE
LA English
DT Letter
ID FIBRILLATION; ABLATION; CATHETER
C1 [Ziegler, Paul D.] Medtronic, Mt View, MN USA.
[Glotzer, Taya V.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Daoud, Emile G.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ezekowitz, Michael D.] Lankenau Inst Med Res, Wynnewood, PA USA.
RP Ziegler, PD (reprint author), Medtronic, Mt View, MN USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2010
VL 41
IS 6
BP E453
EP E454
DI 10.1161/STROKEAHA.110.584821
PG 2
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 600WK
UT WOS:000278019400050
ER
PT J
AU Bagley, SC
Munjas, B
Shekelle, P
AF Bagley, Steven C.
Munjas, Brett
Shekelle, Paul
TI A Systematic Review of Suicide Prevention Programs for Military or
Veterans
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID HEALTH; QUALITY; RISK; POPULATION; FORCE; ARMY; IRAQ; WAR
AB Military personnel and veterans have important suicide risk factors. After a systematic review of the literature on suicide prevention, seven (five in the U.S.) studies of military personnel were identified containing interventions that may reduce the risk of suicide. The effectiveness of the individual components was not assessed, and problems in methodology or reporting of data were common. Overall, multifaceted interventions for active duty military personnel are supported by consistent evidence, although of very mixed quality, and in some cases during intervals of declines in suicide rates in the general population. There were insufficient studies of U.S. Veterans to reach conclusions.
C1 [Bagley, Steven C.; Munjas, Brett; Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Bagley, Steven C.; Munjas, Brett; Shekelle, Paul] So Calif RAND Evidence Based Practice Ctr, Los Angeles, CA USA.
RP Bagley, SC (reprint author), Dept Vet Affairs, 3801 Miranda Ave, Palo Alto, CA 94304 USA.
EM steven.bagley2@va.gov
NR 27
TC 18
Z9 18
U1 1
U2 5
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0363-0234
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD JUN
PY 2010
VL 40
IS 3
BP 257
EP 265
PG 9
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 610NQ
UT WOS:000278740200005
PM 20560747
ER
PT J
AU Conrad, C
Konuk, Y
Werner, P
Cao, CG
Warshaw, A
Rattner, D
Jones, DB
Gee, D
AF Conrad, Claudius
Konuk, Yusuf
Werner, Paul
Cao, Caroline G.
Warshaw, Andrew
Rattner, David
Jones, Daniel B.
Gee, Denise
TI The effect of defined auditory conditions versus mental loading on the
laparoscopic motor skill performance of experts
SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
LA English
DT Article
DE Laparoscopy; Memory consolidation; Mental loading; Motor performance;
Music; Stress
ID NOISE-POLLUTION; MUSIC; SURGEONS; TASK
AB Music and noise are frequent occurrences in the operating room. To date, the effects of these auditory conditions on the performance of laparoscopic surgery experts have not been evaluated.
Eight internationally recognized experts were recruited for a crossover study. The experts were randomized to perform three simple tasks on a laparoscopic simulator, SurgicalSIM VR. The tasks were equal in difficulty and performed under the following conditions: silence, dichaotic music (auditory stress), classical music (auditory relaxation), and mental loading (mental arithmetic tasks). Permutations of the conditions were created to account for a learning effect. The tasks were performed twice to test for memory consolidation and to accommodate baseline variability. Time until task completion and task accuracy via instrument tip trajectory (path of the tip through space) were recorded. Performance was correlated with responses on the Brief Musical Experience Questionnaire (MEQ).
The study demonstrated that dichaotic music has a negative impact on time until task completion but not on task accuracy. In addition, memory consolidation of accuracy is negatively influenced. Classical music has a variable effect on experts' time until task completion, yet all the experts performed the tasks more accurately. Classical music had no effect on recall of a procedure. Mental loading increased time until completion, but did not affect accuracy or recall. The experience of music varied among experts and influenced how each of the conditions affected their performance.
The study demonstrated that, contrary to common belief, proficiency in surgery does not protect against stressful auditory influences or the influence of mental preoccupation. Interestingly, relaxing auditory influences such as classical music can even have a positive impact on the accuracy of experts. Previous musical experience could help to identify surgeons whose performance may be specifically affected by music or noise.
C1 [Conrad, Claudius; Konuk, Yusuf; Warshaw, Andrew; Rattner, David; Gee, Denise] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Werner, Paul] Alliant Int Univ, Calif Sch Profess Psychol, San Francisco, CA USA.
[Cao, Caroline G.] Tufts Univ, Dept Mech Engn, Medford, MA 02155 USA.
[Jones, Daniel B.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA.
RP Conrad, C (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St, Boston, MA 02114 USA.
EM Cconrad1@partners.org
NR 16
TC 19
Z9 19
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-2794
J9 SURG ENDOSC
JI Surg. Endosc.
PD JUN
PY 2010
VL 24
IS 6
BP 1347
EP 1352
DI 10.1007/s00464-009-0772-0
PG 6
WC Surgery
SC Surgery
GA 596VO
UT WOS:000277713800019
PM 20033720
ER
PT J
AU Spadea, MF
Peroni, M
Preve, E
Riboldi, M
Baroni, G
Chen, GTY
Sharp, GC
AF Spadea, Maria Francesca
Peroni, Marta
Preve, Eleonora
Riboldi, Marco
Baroni, Guido
Chen, George T. Y.
Sharp, Gregory Charles
TI Uncertainties in Lung Motion Prediction Relying on External Surrogate: A
4DCT Study in Regular vs. Irregular Breathers
SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT
LA English
DT Article
DE 4D-CT; Lung tumor; Prediction error
ID 4-DIMENSIONAL COMPUTED-TOMOGRAPHY; TUMOR MOTION; RADIATION-THERAPY;
TRACKING SYSTEM; CT; RESPIRATION; MARKERS; 4D-CT; PHASE
AB This paper examines the uncertainty in estimating lung motion from external surrogates for lung cancer patients with regular and irregular breathing 4DCT data sets were analyzed using a template matching algorithm to track the spatial movement of vessel bifurcations in 12 patients The detected internal movement of features in 3D was retrospectively synchronized with the RPM surrogate signal, and the correlation index R(2) and the prediction error were computed Patients were classified into two groups depending on the presence or not of irregularities in their breathing pattern Peak-to-peak values of feature motion in the SI direction ranged from 0 8 mm (upper lung) to 25 3 mm (lower lung) Some patients exhibited large motion also in the latero-lateral (10 6 mm) and anterior-posterior (12 2 mm) directions The median +/- quartile of R(2) in SI direction was 0 89 +/- 0 09 Prediction error values were up to 4 2 mm (95(th) percentile) with a maximum value of 4 9 mm Statistical differences between regular and irregular breathers were found for R(2), while prediction error depended only on the range of motion This study is relevant for image guided radiotherapy methods that rely on external surrogates to monitor motion
C1 [Spadea, Maria Francesca] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy.
[Spadea, Maria Francesca; Peroni, Marta; Preve, Eleonora; Riboldi, Marco; Baroni, Guido] Politecn Milano Univ, Dept Bioengn, Milan, Italy.
[Chen, George T. Y.; Sharp, Gregory Charles] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Spadea, MF (reprint author), Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy.
RI Baroni, Guido/D-3012-2011; Spadea, Maria Francesca/I-2468-2012; Riboldi,
Marco/I-2980-2014
OI Riboldi, Marco/0000-0002-2431-4966
FU CNAO Foundation (the Italian National Center of Oncological
Hadrontherapy); "Progetto Rocca" Foundation, a collaboration program
between MIT and Politecnico di Milano
FX This work was supported in part by the CNAO Foundation (the Italian
National Center of Oncological Hadrontherapy) and by the "Progetto
Rocca" Foundation, a collaboration program between MIT and Politecnico
di Milano
NR 25
TC 7
Z9 8
U1 0
U2 3
PU ADENINE PRESS
PI SCHENECTADY
PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 USA
SN 1533-0346
J9 TECHNOL CANCER RES T
JI Technol. Cancer Res. Treat.
PD JUN
PY 2010
VL 9
IS 3
BP 307
EP 315
PG 9
WC Oncology
SC Oncology
GA 600CK
UT WOS:000277961000010
PM 20441241
ER
PT J
AU Cho, AH
Arar, NH
Edelman, DE
Hartwell, PH
Oddone, EZ
Yancy, WS
AF Cho, Alex H.
Arar, Nedal H.
Edelman, David E.
Hartwell, Patricia H.
Oddone, Eugene Z.
Yancy, William S., Jr.
TI Do Diabetic Veterans Use the Internet? Self-Reported Usage, Skills, and
Interest in Using My HealtheVet Web Portal
SO TELEMEDICINE JOURNAL AND E-HEALTH
LA English
DT Article
DE veterans; medical informatics; patient preferences; diabetes; self-care;
Internet
ID GLUCOSE MONITORING-SYSTEM; CARE; MANAGEMENT
AB Objective: The Veterans Health Administration has developed My HealtheVet (MHV), a Web-based portal that links veterans to their care in the veteran affairs (VA) system. The objective of this study was to measure diabetic veterans' access to and use of the Internet, and their interest in using MHV to help manage their diabetes. Materials and Methods: Cross-sectional mailed survey of 201 patients with type 2 diabetes and hemoglobin A(1c) > 8.0% receiving primary care at any of five primary care clinic sites affiliated with a VA tertiary care facility. Main measures included Internet usage, access, and attitudes; computer skills; interest in using the Internet; awareness of and attitudes toward MHV; demographics; and socioeconomic status. Results: A majority of respondents reported having access to the Internet at home. Nearly half of all respondents had searched online for information about diabetes, including some who did not have home Internet access. More than a third obtained "some'' or "a lot'' of their health-related information online. Forty-one percent reported being "very interested'' in using MHV to help track their home blood glucose readings, a third of whom did not have home Internet access. Factors associated with being "very interested'' were as follows: having access to the Internet at home (p < 0.001), "a lot/some'' trust in the Internet as a source of health information (p = 0.002), lower age (p = 0.03), and some college (p = 0.04). Neither race (p = 0.44) nor income (p = 0.25) was significantly associated with interest in MHV. Conclusions: This study found that a diverse sample of older VA patients with sub-optimally controlled diabetes had a level of familiarity with and access to the Internet comparable to an age-matched national sample. In addition, there was a high degree of interest in using the Internet to help manage their diabetes.
C1 [Cho, Alex H.; Edelman, David E.; Oddone, Eugene Z.; Yancy, William S., Jr.] Duke Univ, Div Gen Internal Med, Durham, NC 27710 USA.
[Arar, Nedal H.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA.
[Edelman, David E.; Hartwell, Patricia H.; Oddone, Eugene Z.; Yancy, William S., Jr.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
RP Cho, AH (reprint author), Duke Univ, Div Gen Internal Med, 106 Davison Bldg,DUMC Box 3701, Durham, NC 27710 USA.
EM alex.cho@duke.edu
OI Edelman, David/0000-0001-7112-6151
FU Agency for Healthcare Research and Quality [5T32HS00079]
FX This work was supported by Grant 5T32HS00079 from Agency for Healthcare
Research and Quality.
NR 15
TC 20
Z9 20
U1 2
U2 6
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
J9 TELEMED J E-HEALTH
JI Telemed. J. e-Health
PD JUN
PY 2010
VL 16
IS 5
BP 595
EP 602
DI 10.1089/tmj.2009.0164
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 615ZW
UT WOS:000279178400011
PM 20575727
ER
PT J
AU Libby, P
Nahrendorf, M
Weissleder, R
AF Libby, Peter
Nahrendorf, Matthias
Weissleder, Ralph
TI Molecular Imaging of Atherosclerosis A Progress Report
SO TEXAS HEART INSTITUTE JOURNAL
LA English
DT Article; Proceedings Paper
CT 9th Texas Update in Cardiovascular Advancements
CY DEC 04-05, 2009
CL Houston, TX
ID IN-VIVO; PATHOPHYSIOLOGY; INFLAMMATION; MACROPHAGES; ACTIVATION; DISEASE
C1 [Libby, Peter] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
[Nahrendorf, Matthias; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
RP Libby, P (reprint author), Brigham & Womens Hosp, Div Cardiovasc Med, 77 Ave, Boston, MA 02115 USA.
EM plibby@rics.bwh.harvard.edu
FU NHLBI NIH HHS [R01 HL080472, HL080472, U01 HL080731, U01HL080731]
NR 14
TC 8
Z9 8
U1 0
U2 3
PU TEXAS HEART INST
PI HOUSTON
PA PO BOX 20345, HOUSTON, TX 77225-0345 USA
SN 0730-2347
J9 TEX HEART I J
JI Tex. Heart Inst. J.
PD JUN
PY 2010
VL 37
IS 3
BP 324
EP 327
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 607PI
UT WOS:000278517600015
PM 20548813
ER
PT J
AU Conesa, A
Fernandez-Mestre, M
Padron, D
Toro, F
Silva, N
Tassinari, P
Blanca, I
Martin, MP
Carrington, M
Layrisse, Z
AF Conesa, A.
Fernandez-Mestre, M.
Padron, D.
Toro, F.
Silva, N.
Tassinari, P.
Blanca, I.
Martin, M. P.
Carrington, M.
Layrisse, Z.
TI Distribution of killer cell immunoglobulin-like receptor genes in the
mestizo population from Venezuela
SO TISSUE ANTIGENS
LA English
DT Article
DE KIR; mestizo Venezuelan population; natural killer cells; polymerase
chain reaction-sequence-specific primers
ID IG-LIKE RECEPTOR; KIR GENE; HLA-C; T-CELLS; DIVERSITY; MOLECULES;
ADMIXTURE; CLUSTER; CLONES; BLOOD
AB This study represents the first report on the distribution of KIR genes in 205 unrelated healthy mestizo Venezuelan individuals. Genotyping analysis showed that all KIR genes are present in this population. Frequency of inhibitory killer cell immunoglobulin-like receptors (KIRs) exceeded 0.69, except for KIR2DL2 (0.29) and 2DL5 (0.37). Activating KIRs showed low frequencies (0.11-0.29), except for KIR2DS4 (0.68). Forty-five different KIR genotypes were identified, with a predominance of three genotypes found in 50.7% of the population of which 25.9% were individuals homozygous for haplotype A. The frequencies of KIR genes reflect the ethnic admixture existing in the mestizo Venezuelan population.
C1 [Fernandez-Mestre, M.; Padron, D.; Layrisse, Z.] Inst Venezolano Invest Cient, Ctr Med Expt Miguel Layrisse, Caracas 1020A, Venezuela.
[Conesa, A.; Toro, F.; Silva, N.; Tassinari, P.; Blanca, I.] Cent Univ Venezuela, Fac Med, Inst Inmunol, FOCIS Ctr Excellence, Caracas, Venezuela.
[Martin, M. P.; Carrington, M.] NCI, Canc & Inflammat Program, Expt Immunol Lab, SAIC Frederick Inc, Frederick, MD 21701 USA.
[Carrington, M.] Massachusetts Gen Hosp, Ragon Inst, MIT, Boston, MA 02114 USA.
[Carrington, M.] Harvard Univ, Boston, MA 02115 USA.
RP Fernandez-Mestre, M (reprint author), Inst Venezolano Invest Cient, Ctr Med Expt Miguel Layrisse, Kilometro 11,Carretera Panamericana,Apdo 21827, Caracas 1020A, Venezuela.
EM mfernand@ivic.ve
FU FONACIT [G-2005000395, S1-2002000504]; National Cancer Institute,
National Institutes of Health [HHSN261200800001E]; NIH, National Cancer
Institute, Center for Cancer Research
FX This research was supported in part by FONACIT grants G-2005000395 and
S1-2002000504. This project has been funded in whole or in part with
federal funds from the National Cancer Institute, National Institutes of
Health, under contract no. HHSN261200800001E. The content of this
publication does not necessarily reflect the views or policies of the
Department of Health and Human Services, nor does mention of trade
names, commercial products, or organizations imply endorsement by the
U.S. Government. This Research was supported in part by the Intramural
Research Program of the NIH, National Cancer Institute, Center for
Cancer Research. Our gratitude to the individuals who participated in
the study and to Omar Balbas for assistance with the Phylogeny Inference
Package.
NR 39
TC 1
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD JUN
PY 2010
VL 75
IS 6
BP 724
EP 729
DI 10.1111/j.1399-0039.2010.01446.x
PG 6
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 595KJ
UT WOS:000277609000012
PM 20210918
ER
PT J
AU Chin, MS
Ogawa, R
Lancerotto, L
Pietramaggiori, G
Schomacker, KT
Mathews, JC
Scherer, SS
Van Duyn, P
Prsa, MJ
Ottensmeyer, MP
Veves, A
Orgill, DP
AF Chin, Michael S.
Ogawa, Rei
Lancerotto, Luca
Pietramaggiori, Giorgio
Schomacker, Kevin T.
Mathews, Jasmine C.
Scherer, Saja S.
Van Duyn, Paul
Prsa, Michael J.
Ottensmeyer, Mark P.
Veves, Aristidis
Orgill, Dennis P.
TI In Vivo Acceleration of Skin Growth Using a Servo-Controlled Stretching
Device
SO TISSUE ENGINEERING PART C-METHODS
LA English
DT Article
ID HYDROSTATIC-PRESSURE; MECHANICAL STRETCH; TISSUE EXPANDER; HYPOXIA;
FIBROBLASTS; PROLIFERATION; BIOREACTOR; EXPRESSION; CARTILAGE; MUSCLE
AB Tension is a principal force experienced by skin and serves a critical role in growth and development. Optimal tension application regimens may be an important component for skin tissue engineering and dermatogenesis. In this study, we designed and tested a novel servo-controlled skin-stretching device to apply predetermined tension and waveforms in mice. The effects of static and cyclical stretching forces were compared in 48 mice by measuring epidermal proliferation, angiogenesis, cutaneous perfusion, and principal growth factors using immunohistochemistry, real-time reverse transcriptase-polymerase chain reaction, and hyperspectral imaging. All stretched samples had upregulated epidermal proliferation and angiogenesis. Real-time reverse transcriptase polymerase chain reaction of epidermal growth factor, transforming growth factor beta 1, and nerve growth factor demonstrated greater expression in cyclically stretched skin when compared to static stretch. Hypoxia-induced factor 1 alpha was significantly upregulated in cyclically stretched skin, but poststretch analysis demonstrated well-oxygenated tissue, collectively suggesting the presence of transient hypoxia. Waveform-specific mechanical loads may accelerate tissue growth by mechanotransduction and as a result of repeated cycles of temporary hypoxia. Further analysis of mechanotransduction signaling pathways may provide additional insight to improve skin tissue engineering methods and optimize our device.
C1 [Chin, Michael S.; Ogawa, Rei; Lancerotto, Luca; Pietramaggiori, Giorgio; Mathews, Jasmine C.; Scherer, Saja S.; Orgill, Dennis P.] Harvard Univ, Brigham & Womens Hosp, Div Plast Surg, Tissue Engn & Wound Healing Lab,Sch Med, Boston, MA 02115 USA.
[Chin, Michael S.; Mathews, Jasmine C.] Univ Massachusetts, Sch Med, Div Plast Surg, Worcester, MA USA.
[Ogawa, Rei] Nippon Med Sch, Dept Plast Reconstruct & Aesthet Surg, Tokyo 113, Japan.
[Lancerotto, Luca; Pietramaggiori, Giorgio] Univ Padua, Clin Plast Surg, I-35100 Padua, Italy.
[Schomacker, Kevin T.] HyperMed Inc, Burlington, MA USA.
[Van Duyn, Paul; Prsa, Michael J.] Wentworth Inst Technol, Boston, MA USA.
[Ottensmeyer, Mark P.] Massachusetts Gen Hosp, CIMIT, Simulat Grp, Boston, MA 02114 USA.
[Veves, Aristidis] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Joslin Beth Israel Deaconess Foot Ctr, Boston, MA 02115 USA.
[Veves, Aristidis] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Microcirculat Lab, Boston, MA 02115 USA.
RP Orgill, DP (reprint author), Harvard Univ, Brigham & Womens Hosp, Div Plast Surg, Tissue Engn & Wound Healing Lab,Sch Med, 75 Francis St, Boston, MA 02115 USA.
EM dorgill@partners.org
RI Lancerotto, Luca/A-5745-2013;
OI Lancerotto, Luca/0000-0002-2908-678X; Orgill, Dennis/0000-0002-8279-7310
FU Sean Oakes; Moore Surgical Laboratory
FX The authors would like to thank George Younan, M. D. for his excellent
technical assistance in the collection and preparation of the data.
Additionally, the authors would like to recognize the support of Sean
Oakes and the Moore Surgical Laboratory, without which this project
would not have been possible.
NR 37
TC 33
Z9 34
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3384
J9 TISSUE ENG PART C-ME
JI Tissue Eng. Part C-Methods
PD JUN
PY 2010
VL 16
IS 3
BP 397
EP 405
DI 10.1089/ten.tec.2009.0185
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA 601SJ
UT WOS:000278083900008
PM 19601702
ER
PT J
AU Blake, KD
Viswanath, K
Blendon, RJ
Vallone, D
AF Blake, Kelly D.
Viswanath, K.
Blendon, Robert J.
Vallone, Donna
TI The role of reported tobacco-specific media exposure on adult attitudes
towards proposed policies to limit the portrayal of smoking in movies
SO TOBACCO CONTROL
LA English
DT Article
ID ADOLESCENT SMOKING; UNITED-STATES; NEWS; INITIATION; BEHAVIOR
AB Objective To assess the relative, independent contribution of reported tobacco-specific media exposure (pro-tobacco advertising, anti-tobacco advertising, and news coverage of tobacco issues) to US adults' support for policy efforts that aim to regulate the portrayal of smoking in movies.
Methods Using the American Legacy Foundation's 2003 American Smoking and Health Survey (ASHES-2), multivariable logistic regression was used to model the predicted probability that US adults support movie-specific tobacco control policies, by reported exposure to tobacco-specific media messages, controlling for smoking status, education, income, race/ethnicity, age, sex, knowledge of the negative effects of tobacco and state.
Results Across most outcome variables under study, findings reveal that reported exposure to tobacco-specific media messages is associated with adult attitudes towards movie-specific policy measures. Most exposure to tobacco information in the media (with the exception of pro-tobacco advertising on the internet) contributes independently to the prediction of adult support for movie-specific policies. The direction of effect follows an expected pattern, with reported exposure to anti-tobacco advertising and news coverage of tobacco predicting supportive attitudes towards movie policies, and reported exposure to pro-tobacco advertising lessening support for some movie policies, though the medium of delivery makes a difference.
Conclusion Media campaigns to prevent tobacco use and exposure to secondhand smoke have had value beyond the intended impact of single-issue campaigns; exposure to anti-tobacco campaigns and public dialogue about the dangers of tobacco seem also to be associated with shaping perceptions of the social world related to norms about tobacco, and ideas about regulating the portrayal of smoking in movies.
C1 [Blake, Kelly D.; Viswanath, K.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Blake, Kelly D.; Viswanath, K.] Dana Farber Canc Inst Boston, Boston, MA USA.
[Blendon, Robert J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Vallone, Donna] Amer Legacy Fdn, Washington, DC USA.
RP Blake, KD (reprint author), 44 Binney St,MS LW703, Boston, MA 02115 USA.
EM kellyblake@post.harvard.edu
FU National Cancer Institute [5R25CA057711-14]; NIH
FX This study was made possible by the Harvard Education Program in Cancer
Prevention and Control, Grant 5R25CA057711-14 from the National Cancer
Institute. Other Funders: NIH.
NR 33
TC 7
Z9 7
U1 2
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-4563
J9 TOB CONTROL
JI Tob. Control
PD JUN
PY 2010
VL 19
IS 3
BP 191
EP 196
DI 10.1136/tc.2009.031260
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 600QP
UT WOS:000278002400013
PM 20008152
ER
PT J
AU Gerbino, A
Debellis, L
Caroppo, R
Curci, S
Colella, M
AF Gerbino, Andrea
Debellis, Lucantonio
Caroppo, Rosa
Curci, Silvana
Colella, Matilde
TI Cadmium inhibits acid secretion in stimulated frog gastric mucosa
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Cadmium; Gastric acid secretion; Short circuit current; Omeprazole;
H(+)/K(+)-ATPase
ID OXYNTIC CELLS; PARIETAL-CELL; SARCOPLASMIC-RETICULUM; CHLORIDE
TRANSPORT; ALKALINE SECRETION; HEAVY-METAL; CYCLIC-AMP; RECEPTOR;
CALCIUM; RAT
AB Cadmium, a toxic environmental pollutant, affects the function of different organs such as lungs, liver and kidney. Less is known about its toxic effects on the gastric mucosa. The aim of this study was to investigate the mechanisms by which cadmium impacts on the physiology of gastric mucosa. To this end, intact amphibian mucosae were mounted in Ussing chambers and the rate of acid secretion, short circuit current (I(SC)), transepithelial potential (V(t)) and resistance (R(t)) were recorded in the continuous presence of cadmium. Addition of cadmium (20 mu M to 1 mM) on the serosal but not luminal side of the mucosae resulted in inhibition of acid secretion and increase in NPPB-sensitive, chloride-dependent short circuit current. Remarkably, cadmium exerted its effects only on histamine-stimulated tissues. Experiments with TPEN, a cell-permeant chelator for heavy metals, showed that cadmium acts from the intracellular side of the acid secreting cells. Furthermore, cadmium-induced inhibition of acid secretion and increase in I(SC) cannot be explained by an action on: 1) H(2) histamine receptor, 2) Ca(2+) signalling 3) adenylyl cyclase or 4) carbonic anhydrase. Conversely, cadmium was ineffective in the presence of the H(+)/K(+)-ATPase blocker omeprazole suggesting that the two compounds likely act on the same target. Our findings suggest that cadmium affects the functionality of histamine-stimulated gastric mucosa by inhibiting the H(+)/K(+)-ATPase from the intracellular side. These data shed new light on the toxic effect of this dangerous environmental pollutant and may result in new avenues for therapeutic intervention in acute and chronic intoxication. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Gerbino, Andrea; Debellis, Lucantonio; Caroppo, Rosa; Colella, Matilde] Univ Bari, Dept Gen & Environm Physiol, I-70126 Bari, Italy.
[Curci, Silvana] Harvard Univ, Sch Med, VA Boston Healthcare Syst, W Roxbury, MA 02132 USA.
[Curci, Silvana] Harvard Univ, Sch Med, Dept Surg, W Roxbury, MA 02132 USA.
[Curci, Silvana] Brigham & Womens Hosp, W Roxbury, MA 02132 USA.
RP Gerbino, A (reprint author), Univ Bari, Dept Gen & Environm Physiol, Via Amendola 165-A, I-70126 Bari, Italy.
EM gerbino@biologia.uniba.it
RI Colella, Matilde/G-9246-2011;
OI Colella, Matilde/0000-0002-9584-7030; Debellis,
Lucantonio/0000-0002-7571-0969; CAROPPO, Rosa/0000-0002-8773-8985;
Gerbino, Andrea/0000-0002-2839-0130
FU Finanziamenti di Ateneo (Bari, Italy); Fondo per gli Investimenti della
Ricerca di Base (FIRB, Rome, Italy) [RBIN04PHZ7]
FX This work was supported by Finanziamenti di Ateneo (Bari, Italy) and
Fondo per gli Investimenti della Ricerca di Base (FIRB) grant RBIN04PHZ7
(Rome, Italy). We are grateful to Dr. Aldebaran M. Hofer (Harvard
University, MA, USA) for critical reading of the manuscript. We wish to
thank Claudia Carmone, Claudia Lippolis, Rosa Piazzolla and Michela
Sguera for excellent assistance during experiments.
NR 61
TC 2
Z9 2
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD JUN 1
PY 2010
VL 245
IS 2
BP 264
EP 271
DI 10.1016/j.taap.2010.03.010
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 601SB
UT WOS:000278083100015
PM 20307561
ER
PT J
AU Contreras, AM
Ochoa-Jimenez, RJ
Celis, A
Mendez, C
Olivares, L
Rebolledo, CE
Hernandez-Lugo, I
Aguirre-Zavala, AI
Jimenez-Mendez, R
Chung, RT
AF Contreras, Ana M.
Ochoa-Jimenez, Rodolfo J.
Celis, Alfredo
Mendez, Claudia
Olivares, Laura
Rebolledo, Claudia E.
Hernandez-Lugo, Isabel
Aguirre-Zavala, Ana I.
Jimenez-Mendez, Ricardo
Chung, Raymond T.
TI High antibody level: an accurate serologic marker of viremia in
asymptomatic people with hepatitis C infection
SO TRANSFUSION
LA English
DT Article
ID VIRUS-INFECTION; PARTIAL SEROREVERSION; COST-EFFECTIVENESS; ASSAY;
LIKELIHOOD; CLEARANCE; SAMPLES; RATIOS
AB BACKGROUND:
The screening and diagnosis of hepatitis C virus (HCV) infection is initiated by testing for antibody to HCV (anti-HCV). A positive anti-HCV test in blood donors represents ongoing infection in only a variable proportion of individuals. Because a high anti-HCV level has been associated with viremia, a study was conducted to determine whether a high antibody level is an accurate serologic marker for viremia in asymptomatic anti-HCV-positive persons.
STUDY DESIGN AND METHODS:
In a diagnostic test study, we included 856 anti-HCV-positive blood donors in a blood bank at Guadalajara, Jalisco, Mexico, between 2002 and 2007. A third-generation amplified chemiluminescence assay (ChLIA HCV) was used to detect anti-HCV. A positive result of the qualitative nucleic acid test (HCV RNA) was considered the gold standard for viremia.
RESULTS:
By receiver operating characteristic analysis, the signal-to-cutoff (S/CO) ratio of 20 or more was chosen as optimal to identify viremia and so was defined as high anti-HCV level. There was a significant difference in the proportion of viremia between subjects with high antibody level and those with lower levels (93.7% vs. 1.8%, respectively; p < 0.001). A high antibody level showed a sensitivity for viremia of 96.6% (95% confidence interval [CI], 93.8%-98.1%), a specificity of 96.6% (95% CI, 94.8%-97.8%), and a likelihood ratio of 28.6 (95% CI, 18.4%-44.6%).
CONCLUSION:
A high antibody level (S/CO ratio >= 20 by ChLIA HCV) clearly divides the viremic from the nonviremic blood donors and functions as an accurate serologic marker to guide the use of routine HCV RNA testing to confirm hepatitis C infection.
C1 [Contreras, Ana M.] Mexican Inst Social Secur, Hlth Res Council Jalisco State, Zapopan 45120, Jalisco, Mexico.
Univ Guadalajara, Med Res Unit, Dept Internal Med, Mol Diagnost Lab, Guadalajara 44430, Jalisco, Mexico.
Univ Guadalajara, Cent Blood Bank, Specialties Hosp, W Natl Med Ctr,Mexican Inst Social Secur, Guadalajara 44430, Jalisco, Mexico.
Univ Guadalajara, Dept Publ Hlth, Hlth Sci Ctr, Guadalajara 44430, Jalisco, Mexico.
Gen Hosp 1, Mexican Inst Social Secur, Dept Internal Med, Colima, Mexico.
Reg Hosp Colima, Dept Internal Med, Colima, Mexico.
Reg Hosp Colima, Clin Sexually Transmitted Dis, Colima, Mexico.
Natl Politech Inst, CINVESTAV, External Sect Pharmacol, Mexico City, DF, Mexico.
Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
RP Contreras, AM (reprint author), Mexican Inst Social Secur, Hlth Res Council Jalisco State, Pedro Alarcon 45-61, Zapopan 45120, Jalisco, Mexico.
EM acontreras53@hotmail.com
FU National Council of Science and Technology (CONACyT); Grupo Roche Syntex
de Mexico; cosHCVir [SALUD-2005-01-14158]
FX Partial grant support was provided by cosHCVir study,
SALUD-2005-01-14158, and a scholarship (Dr Ochoa-Jimenez) by the
National Council of Science and Technology (CONACyT). An unrestricted
educational grant was provided from Grupo Roche Syntex de Mexico. The
funding organizations had no role in the design and conduct of the
study; collection, management, analysis, and interpretation of the data;
or preparation, review, or approval of the manuscript.
NR 31
TC 14
Z9 15
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD JUN
PY 2010
VL 50
IS 6
BP 1335
EP 1343
DI 10.1111/j.1537-2995.2009.02571.x
PG 9
WC Hematology
SC Hematology
GA 604ZH
UT WOS:000278316500024
PM 20088833
ER
PT J
AU Wang, J
Pfleger, CM
Friedman, L
Vittorino, R
Zhao, W
Qian, XJ
Conley, L
Ho, L
Pasinetti, GM
AF Wang, Jun
Pfleger, Cathie M.
Friedman, Lauren
Vittorino, Roselle
Zhao, Wei
Qian, Xianjuan
Conley, Lindsay
Ho, Lap
Pasinetti, Giulio M.
TI POTENTIAL APPLICATION OF GRAPE DERIVED POLYPHENOLS IN HUNTINGTON'S
DISEASE
SO TRANSLATIONAL NEUROSCIENCE
LA English
DT Article
DE Neurological disorders; Motor function; Abnormal protein aggregation
Huntingtin protein; Drosophila; PC-12 cell; R6/2 mouse
AB Huntington's disease (HD) is a progressive neurodegenerative disorder associated with selective neuronal cell death. Abnormal aggregation of huntingtin protein with polyQ expansion has been shown to be causally linked to HD. Grape seed polyphenolic extract (GSPE) is a natural compound that has previously been shown to interfere with aggregations of proteins involved in neurological disorders, such as amyloid beta peptides (A beta) and Tau protein. In this study we found that GSPE treatment significantly inhibits polyQ aggregation in phaeochromocytoma (PC)-12 cell line containing an ecdysone-inducible protein comprising the first 17 amino acid of huntingtin plus 103 glutamines fused with enhanced GFP. In vivo feasibility studies using the Q93httexon1 drosophila model of HD, we extended our in vitro evidence and found that flies fed with GSPE had a significantly improved lifespan compared to the control flies. Using the R6/2 rodent model of HD, we found that oral administration of 100 mg/kg/day GSPE (equivalent to 500mg per day in human) significantly attenuated the motor skill decay as well as extended the lifespan in the R6/2 mice relative to vehicle-control mice. Collectively, our studies strongly suggest that GSPE might be able to modulate the onset and/or progression of HD.
C1 [Wang, Jun; Friedman, Lauren; Vittorino, Roselle; Zhao, Wei; Qian, Xianjuan; Conley, Lindsay; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Wang, Jun; Zhao, Wei; Qian, Xianjuan; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Pfleger, Cathie M.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
[Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA.
[Ho, Lap; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA.
RP Wang, J (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
FU Polyphenolics, Inc.
FX This work was supported by Polyphenolics, Inc. We thank Hayley Fivecoat
for assistance in the preparation of the manuscript.
NR 38
TC 7
Z9 7
U1 0
U2 2
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 2081-3856
J9 TRANSL NEUROSCI
JI Transl. Neurosci.
PD JUN
PY 2010
VL 1
IS 2
BP 95
EP 100
DI 10.2478/v10134-010-0022-y
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA V20PY
UT WOS:000208153100001
PM 21331299
ER
PT J
AU Arrieta-Cruz, I
Pavlides, C
Pasinetti, GM
AF Arrieta-Cruz, Isabel
Pavlides, Constantine
Pasinetti, Giulio Maria
TI DEEP BRAIN STIMULATION FACILITATES MEMORY IN A MODEL OF ALZHEIMER'S
DISEASE
SO TRANSLATIONAL NEUROSCIENCE
LA English
DT Article
DE Alzheimer's disease; Deep brain stimulation; Hippocampus; LTP; Neuronal
transmission Synaptic plasticity; Memory; TgCRND8 mice; Thalamus
AB Based on evidence suggesting that deep brain stimulation (DBS) may promote certain cognitive processes, we have been interested in developing DBS as a means of mitigating memory and learning impairments in Alzheimer's disease (AD). In this study we used an animal model of AD (TgCRND8 mice) to determine the effects of high-frequency stimulation (HFS) on non-amyloidogenic a-secretase activity and DBS in short-term memory. We tested our hypothesis using hippocampal slices (in vitro studies) from TgCRND8 mice to evaluate whether HFS increases a-secretase activity (non-amyloidogenic pathway) in the CA1 region. In a second set of experiments, we performed in vivo studies to evaluate whether DBS in midline thalamic region re-establishes hippocampal dependent short-term memory in TgCRND8 mice. The results showed that application of HFS to isolated hippocampal slices significantly increased synaptic plasticity in the CA1 region and promoted a 2-fold increase of non-amyloidogenic a-secretase activity, in comparison to low frequency stimulated controls from TgCRND8 mice. In the in vivo studies, DBS treatment facilitated acquisition memory in TgCRND8 mice, in comparison to their own baseline before treatment. These results provide evidence that DBS could enhance short-term memory in a mouse model of AD by increasing synaptic transmission and a-secretase activity in the C A1 region of hippocampus.
C1 [Arrieta-Cruz, Isabel; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Pavlides, Constantine] Rockefeller Univ, Neuroendocrinol Lab, New York, NY 10065 USA.
[Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA.
RP Arrieta-Cruz, I (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
NR 14
TC 0
Z9 0
U1 1
U2 6
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 2081-3856
J9 TRANSL NEUROSCI
JI Transl. Neurosci.
PD JUN
PY 2010
VL 1
IS 2
BP 170
EP 176
DI 10.2478/v10134-010-0026-7
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA V20PY
UT WOS:000208153100010
ER
PT J
AU Ahmad, M
Graham, SH
AF Ahmad, Muzamil
Graham, Steven H.
TI Inflammation After Stroke: Mechanisms and Therapeutic Approaches
SO TRANSLATIONAL STROKE RESEARCH
LA English
DT Review
DE Stroke; Ischemia; Inflammation; Inflammatory cells; Cytokines; Cell
adhesion molecules; Eicosanoids
AB Reperfusion of ischemic brain can reduce injury and improve outcome, but secondary injury due to inflammatory mechanisms limits the efficacy and time window of such treatments for stroke. This review summarizes the cellular and molecular basis of inflammation in ischemic injury as well as possible therapeutic strategies.
C1 [Ahmad, Muzamil; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr 00 GR H, Pittsburgh, PA 15206 USA.
[Ahmad, Muzamil; Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
RP Graham, SH (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr 00 GR H, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM sgra@pitt.edu
FU NCATS NIH HHS [UL1 TR000005]; NINDS NIH HHS [R01 NS037459, R01
NS037459-04, R01 NS037459-11]
NR 178
TC 33
Z9 40
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1868-4483
EI 1868-601X
J9 TRANSL STROKE RES
JI Transl. Stroke Res.
PD JUN
PY 2010
VL 1
IS 2
BP 74
EP 84
DI 10.1007/s12975-010-0023-7
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA V23ER
UT WOS:000208326600002
PM 20976117
ER
PT J
AU Zhang, F
Xing, J
Liou, AKF
Wang, S
Gan, Y
Luo, YM
Ji, XM
Stetler, RA
Chen, J
Cao, GD
AF Zhang, Feng
Xing, Juan
Liou, Anthony Kian-Fong
Wang, Suping
Gan, Yu
Luo, Yumin
Ji, Xuming
Stetler, R. Anne
Chen, Jun
Cao, Guodong
TI Enhanced Delivery of Erythropoietin Across the Blood-Brain Barrier for
Neuroprotection Against Ischemic Neuronal Injury
SO TRANSLATIONAL STROKE RESEARCH
LA English
DT Article
DE Erythropoietin; Drug delivery system; HIV TAT protein; Blood-brain
barrier; Neuroprotection; Ischemia/brain
AB Due to limited penetration of the blood-brain barrier (BBB), many therapeutic agents in clinical use require higher doses in order to reach effective concentrations in brain. In some instances, these high doses elicit severe side effects. In the case of erythropoietin (EPO), an established neuroprotectant against ischemic brain injury, its low BBB permeability requires such a high therapeutic dose that it can induce dangerous complications such as polycythemia and secondary stroke. The purpose of this study is to generate a modified EPO that has increased facility crossing the BBB without losing its neuroprotective element. We have engineered a fusion protein (EPO-TAT) by tagging a protein transduction domain derived from HIV trans-acting activator of transcription (TAT) to the EPO protein. This sequence enhanced the capacity of EPO to cross the BBB in animals at least twofold when intraperitoneally administered and up to fivefold when intravenously administered. In vitro experiments showed that this EPO fusion protein retained all its protective properties against neuronal death elicited by oxygen-glucose deprivation and N-methyl-D-aspartate insults. The needed therapeutic dose of the EPO-TAT was decreased by similar to tenfold compared to that of regular EPO to achieve equivalent neuroprotection in terms of reducing volume of infarction induced by middle cerebral artery occlusion in mice. Our results support the approach of using a protein transduction domain coupled to therapeutic agents. In this way, not only can the therapeutic doses be lowered but also agents without BBB permeability may now be available for clinical applications.
C1 [Cao, Guodong] Univ Pittsburgh, Sch Med, Dept Neurol, BST S505, Pittsburgh, PA 15261 USA.
[Zhang, Feng; Xing, Juan; Wang, Suping; Stetler, R. Anne; Chen, Jun; Cao, Guodong] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15260 USA.
[Luo, Yumin; Ji, Xuming] Capital Univ Med Sci, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing 100053, Peoples R China.
[Zhang, Feng; Xing, Juan; Liou, Anthony Kian-Fong; Wang, Suping; Gan, Yu; Stetler, R. Anne; Chen, Jun; Cao, Guodong] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Zhang, Feng; Xing, Juan; Liou, Anthony Kian-Fong; Wang, Suping; Gan, Yu; Stetler, R. Anne; Chen, Jun; Cao, Guodong] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA.
RP Cao, GD (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, BST S505, 200 Lothrop St, Pittsburgh, PA 15261 USA.
EM caog@upmc.edu
OI Zhang, Feng/0000-0001-7275-9989
FU National Institutes of Health [NS053473, NS43802, NS45048, NS36736, NS
56118]; American Heart Association Scientist Development [06300064N];
Chinese Natural Science Foundation [30670725]
FX The project was supported by National Institutes of Health Grants
NS053473 (to G. C.), NS43802, NS45048, NS36736, and NS 56118 (to J.C.),
and the American Heart Association Scientist Development Grant 06300064N
(to G. C.). Y.L. is a recipient of the Chinese Natural Science
Foundation Grant 30670725.
NR 28
TC 19
Z9 22
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1868-4483
EI 1868-601X
J9 TRANSL STROKE RES
JI Transl. Stroke Res.
PD JUN
PY 2010
VL 1
IS 2
BP 113
EP 121
DI 10.1007/s12975-010-0019-3
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA V23ER
UT WOS:000208326600006
PM 20577577
ER
PT J
AU Avery, R
Clauss, H
Danziger-Isakov, L
Davis, J
Doucette, K
van Duin, D
Fishman, J
Gunseren, F
Humar, A
Husain, S
Isada, C
Julian, K
Kaul, D
Kumar, D
Martin, S
Michaels, M
Morris, M
Silveira, F
Subramanian, A
AF Avery, R.
Clauss, H.
Danziger-Isakov, L.
Davis, J.
Doucette, K.
van Duin, D.
Fishman, J.
Gunseren, F.
Humar, A.
Husain, S.
Isada, C.
Julian, K.
Kaul, D.
Kumar, D.
Martin, S.
Michaels, M.
Morris, M.
Silveira, F.
Subramanian, A.
TI Recommended curriculum for subspecialty training in transplant
infectious disease on behalf of the American Society of Transplantation
Infectious Diseases Community of Practice Educational Initiatives
Working Group
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE curriculum; training; subspecialty; transplant infectious disease
AB P>The American Society of Transplantation Infectious Diseases (ID) Community of Practice has established an education workgroup to identify core components of a curriculum for training specialists in transplant ID. Clinical, laboratory, and research training form the triad of components on which an additional year of ID training, dedicated to the care of solid organ and hematopoietic stem cell transplant recipients, should be based. The recommended training environment would have access to adequate numbers of transplant patients, along with qualified faculty committed to teaching specialized fellows in this area. The learning objectives for both inpatient and outpatient clinical training are presented. The laboratory component requires trainees to attain expertize in utilizing and interpreting cutting-edge diagnostics used in transplant medicine. The research component may involve basic science, and translational or clinical research individualized to the trainee. Finally, suggestions for evaluation of both the fellows and the training program are provided.
C1 [Subramanian, A.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Avery, R.; Danziger-Isakov, L.; van Duin, D.; Isada, C.] Cleveland Clin Hosp, Cleveland, OH USA.
[Clauss, H.] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA.
[Davis, J.; Martin, S.] Ohio State Univ Hosp, Columbus, OH 43210 USA.
[Doucette, K.; Humar, A.; Kumar, D.] Univ Alberta, Edmonton, AB, Canada.
[Fishman, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gunseren, F.] Akdeni Univ, Antalya, Turkey.
[Husain, S.] Toronto Gen Hosp, Toronto, ON, Canada.
[Julian, K.] Penn State Univ, Coll Med, Hershey, PA USA.
[Kaul, D.] Univ Michigan Hosp, Ann Arbor, MI 48109 USA.
[Michaels, M.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.
[Morris, M.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Silveira, F.] Univ Pittsburgh Hosp, Pittsburgh, PA USA.
RP Subramanian, A (reprint author), Johns Hopkins Univ, Transplant & Oncol Ctr, Div Infect Dis, Sch Med, 1830 E Monument St,Room 463A, Baltimore, MD 21287 USA.
EM asubra@jhmi.edu
RI Silveira, Fernanda/K-4465-2012; Martin, Stanley/E-3600-2011;
OI Doucette, Karen/0000-0002-1660-9166
NR 0
TC 4
Z9 4
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD JUN
PY 2010
VL 12
IS 3
BP 190
EP 194
DI 10.1111/j.1399-3062.2010.00510.x
PG 5
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 604YY
UT WOS:000278315600002
PM 20624259
ER
PT J
AU Neofytos, D
Fishman, JA
Horn, D
Anaissie, E
Chang, CH
Olyaei, A
Pfaller, M
Steinbach, WJ
Webster, KM
Marr, KA
AF Neofytos, D.
Fishman, J. A.
Horn, D.
Anaissie, E.
Chang, C. -H.
Olyaei, A.
Pfaller, M.
Steinbach, W. J.
Webster, K. M.
Marr, K. A.
TI Epidemiology and outcome of invasive fungal infections in solid organ
transplant recipients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE invasive fungal infection; solid organ transplant; epidemiology;
outcomes; Candida; Aspergillus; invasive candidiasis; invasive
aspergillosis
ID ORTHOTOPIC LIVER-TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL;
RISK-FACTORS; AMPHOTERICIN-B; ITRACONAZOLE PROPHYLAXIS; ANTIFUNGAL
PROPHYLAXIS; RANDOMIZED-TRIAL; DOUBLE-BLIND; FLUCONAZOLE; CANDIDEMIA
AB P>Contemporary epidemiology and outcomes of invasive fungal infections (IFIs) in solid organ transplant (SOT) recipients are not well described. From March 2004 through September 2007, proven and probable IFIs were prospectively identified in 17 transplant centers in the United States. A total 429 adult SOT recipients with 515 IFIs were identified; 362 patients received a single and 67 patients received >= 2 organs. Most IFIs were caused by Candida species (59.0%), followed by Aspergillus species (24.8%), Cryptococcus species (7.0%), and other molds (5.8%). Invasive candidiasis (IC) was the most frequently observed IFI in all groups, except for lung recipients where invasive aspergillosis (IA) was the most common IFI (P < 0.0001). Almost half of IC cases in liver, heart, and lung transplant recipients occurred during the first 100 days post transplant. Over half of IA cases in lung recipients occurred > 1 year post transplant. Overall 12-week mortality was 29.6%; liver recipients had the highest mortality (P=0.05). Organ damage, neutropenia, and administration of corticosteroids were predictors of death. These results extend our knowledge on the epidemiology of IFI in SOT recipients, emphasizing the occurrence of IC early after non-lung transplant, and late complications with molds after lung transplant. Overall survival appears to have improved compared with historical reports.
C1 [Neofytos, D.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA.
[Neofytos, D.; Horn, D.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA.
[Fishman, J. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Anaissie, E.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
[Chang, C. -H.] Info Spectrum Incorp, Markham, ON, Canada.
[Olyaei, A.] Oregon Hlth & Sci Univ, Portland, OR USA.
[Pfaller, M.] Univ Iowa Hlth Care, Iowa City, IA USA.
[Steinbach, W. J.] Duke Univ, Med Ctr, Durham, NC USA.
[Webster, K. M.] Axiom Real Time Metr Inc, Oakville, ON, Canada.
[Webster, K. M.] EBM Consulting Inc, Mississauga, ON, Canada.
RP Neofytos, D (reprint author), Johns Hopkins Univ, Sch Med, Div Infect Dis, 1830 E Monument St,Room 421, Baltimore, MD 21205 USA.
EM dneofyt1@jhmi.edu
FU Astellas Pharma US Inc. (APUS)
FX Funding sources: We would like to acknowledge Astellas Pharma US Inc.
(APUS) for their generous support, Axiom Real-Time Metrics Inc. (Axiom)
for their expertise in registry management, and the many dedicated
coordinators at each site. As the financial sponsor of the PATH
Alliance, APUS observed, but did not influence, the design of the PATH
Alliance registry by the independent Scientific Advisory Board. APUS
contracts Axiom to provide overall management services for the PATH
Alliance registry, comprising data management, site support, application
and database hosting, administrative management, and data extraction and
analysis. APUS also sponsored Axiom's services for this individual
research project; these services were comprised of data extraction,
facilitation of statistical analyses, preparation of figures, and
manuscript review. Potential conflicts of interest: D.N. has received
grant support (educational research) from Astellas and has been a
consultant and/or part of advisory boards for Pfizer. J.F. has been a
consultant to Merck Inc., Hoffman LaRoche, Astellas, and Primera, has
received grant support (educational/research) from Astellas, and has
been on the speakers' bureau for Astellas and Roche. D.H. has received
recent research funding from Astellas and past funding from Pfizer; has
served as a consultant or advisor to Astellas and Pfizer, has been on
the speaker's bureau for Pfizer and Astellas, and has received speaking
honoraria from Roche. W.S. has served as consultant to Pfizer, Astellas,
and Schering-Plough and on the speakers' bureau for Astellas, Merck,
Pfizer. E.A. has been a consultant to and on the speaker's bureau for
Astellas, Pfizer, Gilead, Merck, and Schering-Plough. A.O. has been a
speaker and served as consultant to Pfizer and Astellas. M.P. has been a
consultant to and on the speakers' bureau for Pfizer, Astellas, Merck,
and Schering-Plough. C.C. has served as a statistical consultant to
Pharmacia, Pfizer, and Eli Lilly, marketing analytics consultant to
Roche, and statistical consultant via third parties to Astellas,
Topigen, and AstraZeneca. K.W. has had contract work with Astellas.
K.A.M. has been a consultant and/or part of advisory boards for
Astellas, Basilea, Enzon, Merck, Pfizer, and Schering Plough and
received grant support from Astellas, Enzon, Merck, and Pfizer.
NR 37
TC 145
Z9 156
U1 0
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD JUN
PY 2010
VL 12
IS 3
BP 220
EP 229
DI 10.1111/j.1399-3062.2010.00492.x
PG 10
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 604YY
UT WOS:000278315600006
PM 20113459
ER
PT J
AU Liu, M
Gu, M
Xu, D
Lv, Q
Zhang, W
Wu, Y
AF Liu, M.
Gu, M.
Xu, D.
Lv, Q.
Zhang, W.
Wu, Y.
TI Protective Effects of Toll-like Receptor 4 Inhibitor Eritoran on Renal
Ischemia-Reperfusion Injury
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID INNATE IMMUNE-RESPONSE; ACUTE KIDNEY INJURY; ISCHEMIA/REPERFUSION
INJURY; PRESERVATION; INFLAMMATION; E5564; HEART
AB Background. Ischemia-reperfusion injury (I/R) has a negative effect on renal allograft survival. Using a rat model of kidney IR injury, we demonstrated inhibition of Toll-like receptor (TLR) 4 with erotoran may shed new light on I/R therapy.
Methods. All 44 Fisher rats were anesthetized with ethrane. Animals were randomly divided into the S group (sham, n = 11) that received only right kidney nephrectomy or the I/R group of right kidney nephrectomy and ichemia for 40 minutes by clamping of left renal artery (n = 11). In addition, the E group (Eritoran, n = 11) and the V group (vehicle, n = 11) received eritoran (5 mg . kg(-1)) and vehicle pretreatment, respectively. Analysis of renal histology, function, cytokine/chemokine production, as well as animal mortality was performed in parallel groups by ribonuclease protection assay (RPA).
Results. At 24 hours, the creatinine value 1.49 +/- 0.2 mg/dL in the eritoran group was significantly lower than untreated controls (2.17 +/- 0.4 mg/dL). Histological findings showed tubular loss and morphological stutus as well as animal survival post-I/R injury compared to vehicle-treated rats; the difference between the S versus E groups was significant. Eritoran administration significantly attenuated monocyte infiltration into the kidney. RPA assays showed the following fold increase over sham normalized to that of GAPDH mRNA expression of tumor necrosis factor-alpha (4.67 +/- 1.52 vs 1.37 +/- 0.05), interleukin (IL)-1 beta (5.11 +/- 1.17 vs 1.92 +/- 0.27), IL-6 (4.20 +/- 0.29 vs 1.21 +/- 0.37) and monocyte chemoattractant protein-1 (8.77 +/- 1.24 vs 2.57 +/- 1.59). GAPDH was markedly reduced by eritoran treatment (eritoran vs vehicle group).
Conclusion. These data demonstrated that inhibition of TLR4 with eritoran reduced I/R-related inflammatory responses and improved the course of kidney I/R injury.
C1 [Liu, M.; Gu, M.; Xu, D.; Lv, Q.; Zhang, W.] Nanjing Med Univ, Dept Urol & Kidney Transplantat, Affiliated Hosp 1, Nanjing 210029, Jiangsu Prov, Peoples R China.
[Wu, Y.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Gu, M (reprint author), Nanjing Med Univ, Dept Urol & Kidney Transplantat, Affiliated Hosp 1, Nanjing 210029, Jiangsu Prov, Peoples R China.
EM lancetgu@163.com
OI Liu, Min/0000-0002-8117-4808
NR 20
TC 23
Z9 25
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2010
VL 42
IS 5
BP 1539
EP 1544
DI 10.1016/j.transproceed.2010.03.133
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 616UQ
UT WOS:000279236100030
PM 20620471
ER
PT J
AU Geng, EH
Glidden, DV
Emenyonu, N
Musinguzi, N
Bwana, MB
Neilands, TB
Muyindike, W
Yiannoutsos, CT
Deeks, SG
Bangsberg, DR
Martin, JN
AF Geng, Elvin H.
Glidden, David V.
Emenyonu, Nneka
Musinguzi, Nicolas
Bwana, Mwebwesa Bosco
Neilands, Torsten B.
Muyindike, Winnie
Yiannoutsos, Constantin T.
Deeks, Steven G.
Bangsberg, David R.
Martin, Jeffrey N.
TI Tracking a sample of patients lost to follow-up has a major impact on
understanding determinants of survival in HIV-infected patients on
antiretroviral therapy in Africa
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE antiretroviral scale-up strategies; losses to follow-up; determinants of
mortality on antiretroviral therapy; sampling studies; monitoring and
evaluation; Africa
ID HIV-1-INFECTED PATIENTS; WESTERN KENYA; SCALING-UP; MORTALITY; OUTCOMES;
EXPERIENCE; SETTINGS; PROGRAMS
AB P>Objective
To date, data regarding the determinants of mortality in HIV-infected patients starting antiretroviral therapy (ART) in Africa have been primarily derived from routine clinical care settings practicing the public health approach. Losses to follow-up, however, are high in these settings and may lead to bias in understanding the determinants of mortality.
Methods
We evaluated HIV-infected adults initiating ART between January 1, 2004 and September 30th, 2007 in an ART clinic in southwestern Uganda. Clinical and demographic characteristics were obtained through routine clinical care. In evaluating determinants of mortality, a 'naive' analysis used only deaths known through routine processes. A 'sample-corrected' approach incorporated, through probability weights, outcomes from a representative sample of patients lost to follow-up whose vital status was ascertained through tracking in the community.
Results
In 3,628 patients followed for up to 3.75 years after ART initiation, the 'naive' approach identified male sex and lower pre-ART CD4 count as independent determinants of mortality. The 'sample-corrected' approach found lower pre-ART CD4 count, older age, lower weight and calendar year of ART initiation, but not male sex, to be independent determinants of mortality.
Conclusions
Analyses to identify determinants of mortality in HIV-infected patients on ART in Africa that do not account for losses to follow-up can identify spurious associations and miss actual relationships - both with the potential to mislead public health efforts. A sampling-based approach to account for losses to follow-up represents a feasible and potentially scalable method to strengthen the evidence available for implementation of ART delivery in Africa.
C1 [Geng, Elvin H.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, Dept Med, San Francisco, CA 94110 USA.
[Glidden, David V.; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Emenyonu, Nneka; Musinguzi, Nicolas; Bwana, Mwebwesa Bosco; Muyindike, Winnie; Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Neilands, Torsten B.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.
[Yiannoutsos, Constantin T.] Indiana Univ, Div Biostat, Dept Med, Indianapolis, IN USA.
[Bangsberg, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Global Hlth, Boston, MA USA.
RP Geng, EH (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, Dept Med, 995 Potrero Ave,Bldg 80, San Francisco, CA 94110 USA.
EM genge@php.ucsf.edu
FU NIAID NIH HHS [K23 AI084544, K23 AI084544-01, K23 AI084544-02, K23
AI084544-03, P30 AI027763, T32 AI060530, U01 AI069911]; NIMH NIH HHS
[R01 MH054907, K24 MH087227]
NR 24
TC 34
Z9 34
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2010
VL 15
SU 1
BP 63
EP 69
DI 10.1111/j.1365-3156.2010.02507.x
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 590DZ
UT WOS:000277205500006
PM 20586962
ER
PT J
AU Eisner, BH
Eisenberg, ML
Stoller, ML
AF Eisner, Brian H.
Eisenberg, Michael L.
Stoller, Marshall L.
TI Relationship Between Body Mass Index and Quantitative 24-Hour Urine
Chemistries in Patients With Nephrolithiasis
SO UROLOGY
LA English
DT Article
ID STONE FORMERS; KIDNEY-STONES; UNITED-STATES; RISK-FACTORS; OBESITY;
OVERWEIGHT; WEIGHT; UROLITHIASIS; PREVALENCE; EXCRETION
AB OBJECTIVES To examine the relationship between body mass index and 24-hour urine constituents in a population of stone-forming patients.
METHODS A total of 880 patients who presented to a metabolic stone clinic for initial evaluation were analyzed. Patients were stratified by gender and divided into quartiles of body mass index. Associations between body mass index (BMI) and urine parameters were explored using bivariate and multivariate linear regression.
RESULTS On bivariate analysis, increasing body mass index was associated with a significant increase in sodium, calcium, citrate, uric acid, magnesium, calcium oxalate, uric acid, and a decrease in pH in men. In women, it was associated with a significant increase in sodium, uric acid, oxalate, uric acid, and decreasing pH. On multivariate analysis, BMI was associated only with increases in sodium and calcium oxalate and decrease in pH in men. In women, multivariate analysis demonstrated positive association between BMI and urine sodium, creatinine, and phosphate and a negative relationship with urine citrate and sulfate.
CONCLUSIONS Increasing body mass index was related to several risk factors for urinary stone disease in this study, including increasing urine sodium and decreasing pH in men and increasing urine uric acid, sodium, and decreasing urine citrate in women. Just as general recommendations for patients with nephrolithiasis include high voided volumes, low dietary sodium, and low animal protein intake, perhaps weight reduction should be included as part of the counseling of stone-formers to optimize 24-hour urine parameters. UROLOGY 75: 1289-1293, 2010. (C) 2010 Elsevier Inc.
C1 [Eisner, Brian H.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.
RP Eisner, BH (reprint author), Massachusetts Gen Hosp, Dept Urol, GRB 1102,55 Fruit St, Boston, MA 02114 USA.
EM beisner@partners.org
OI Eisenberg, Michael/0000-0001-5482-0141
NR 18
TC 18
Z9 21
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
J9 UROLOGY
JI Urology
PD JUN
PY 2010
VL 75
IS 6
BP 1289
EP 1293
DI 10.1016/j.urology.2009.09.024
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 603PS
UT WOS:000278221100015
PM 20018350
ER
PT J
AU Jahn, B
Theurl, E
Siebert, U
Pfeiffer, KP
AF Jahn, Beate
Theurl, Engelbert
Siebert, Uwe
Pfeiffer, Karl-Peter
TI Tutorial in Medical Decision Modeling Incorporating Waiting Lines and
Queues Using Discrete Event Simulation
SO VALUE IN HEALTH
LA English
DT Article
DE discrete event simulation; modeling; queue; waiting time
ID ECONOMIC-EVALUATION; COST-EFFECTIVENESS; HEALTH; PHARMACOECONOMICS;
DISEASE; STENTS
AB In most decision-analytic models in health care, it is assumed that there is treatment without delay and availability of all required resources. Therefore, waiting times caused by limited resources and their impact on treatment effects and costs often remain unconsidered. Queuing theory enables mathematical analysis and the derivation of several performance measures of queuing systems. Nevertheless, an analytical approach with closed formulas is not always possible. Therefore, simulation techniques are used to evaluate systems that include queuing or waiting, for example, discrete event simulation. To include queuing in decision-analytic models requires a basic knowledge of queuing theory and of the underlying interrelationships. This tutorial introduces queuing theory. Analysts and decision-makers get an understanding of queue characteristics, modeling features, and its strength. Conceptual issues are covered, but the emphasis is on practical issues like modeling the arrival of patients. The treatment of coronary artery disease with percutaneous coronary intervention including stent placement serves as an illustrative queuing example. Discrete event simulation is applied to explicitly model resource capacities, to incorporate waiting lines and queues in the decision-analytic modeling example..
C1 [Jahn, Beate; Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Informat Syst & Hlth Technol Asses, A-6060 Hall In Tirol, IT, Austria.
[Jahn, Beate; Pfeiffer, Karl-Peter] Innsbruck Med Univ, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria.
[Theurl, Engelbert] Leopold Franzens Univ Innsbruck, Dept Publ Finance, Innsbruck, Austria.
[Siebert, Uwe] Harvard Univ, Sch Med, Inst Technol Assessment, Cardiovasc Res Program, Boston, MA USA.
[Siebert, Uwe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA.
[Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA.
[Pfeiffer, Karl-Peter] FH Johanneum Univ Appl Sci, Graz, Austria.
RP Jahn, B (reprint author), UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Informat Syst & Hlth Technol Asses, Eduard Wallnoefer Ctr 1, A-6060 Hall In Tirol, IT, Austria.
EM Beate.Jahn@umit.at
FU Medical University of Innsbruck; Leopold-Franzens-University of
Innsbruck; Canadian Study Centre Innsbruck; ONCOTYROL-Center for
Personalized Cancer Medicine (Austria); Federal Ministry for Transport
Innovation and Technology (BMVIT); Federal Ministry of Economics and
Labour; Federal Ministry of Economy, Family and Youth (BMWA/BMWFJ);
Tyrolean Future Foundation (TZS); State of Styria; UMIT-University for
Health Sciences, Medical Informatics and Technology; TILAK-Hospital
Holding Company
FX Financial support for this study was provided in part by the Medical
University of Innsbruck, Leopold-Franzens-University of Innsbruck and
the Canadian Study Centre Innsbruck, and ONCOTYROL-Center for
Personalized Cancer Medicine (Austria). ONCOTYROL is a K1-COMET Center
and funded by the Federal Ministry for Transport Innovation and
Technology (BMVIT) and the Federal Ministry of Economics and Labour/the
Federal Ministry of Economy, Family and Youth (BMWA/BMWFJ), the Tyrolean
Future Foundation (TZS), and the State of Styria, represented by the
Styrian Business Promotion Agency (SFG), and supported by
UMIT-University for Health Sciences, Medical Informatics and Technology
and TILAK-Hospital Holding Company. The funding agreement ensured the
authors' independence in designing the study, interpreting the data,
writing, and publishing the report.
NR 30
TC 6
Z9 6
U1 0
U2 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD JUN-JUL
PY 2010
VL 13
IS 4
BP 501
EP 506
DI 10.1111/j.1524-4733.2010.00707.x
PG 6
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 625DD
UT WOS:000279872300024
PM 20345550
ER
PT J
AU Liu, H
Wang, C
Chen, PH
Zhang, BS
Zheng, YL
Zhang, CX
Meng, HQ
Wang, Y
Chen, DC
Xiu, MH
Kosten, TR
Zhang, XY
AF Liu, Hong
Wang, Cui
Chen, Pin Hong
Zhang, Ben Shu
Zheng, You Lan
Zhang, Chong Xi
Meng, Hua Qing
Wang, Yu
Chen, Da Chun
Xiu, Mei Hong
Kosten, Thomas R.
Zhang, Xiang Yang
TI Association of the manganese superoxide dismutase gene Ala-9Val
polymorphism with clinical phenotypes and tardive dyskinesia in
schizophrenic patients
SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
LA English
DT Review
DE Association; Manganese superoxide dismutase; Polymorphism;
Schizophrenia; Tardive dyskinesia
ID ABNORMAL INVOLUNTARY MOVEMENTS; FREE-RADICAL PATHOLOGY;
PARKINSONS-DISEASE; OXIDATIVE STRESS; MNSOD GENES; RISK;
PHARMACOGENOMICS; METAANALYSIS; POPULATION; SOD2
AB Objective: Several recent studies that have investigated the genetic association between the manganese superoxide dismutase (MnSOD) gene Ala-9Val single-nucleotide polymorphism (SNP) and tardive dyskinesia (TD) have produced conflicting results. This study was to investigate whether this SNP was associated with clinical phenotypes and antipsychotic-induced tardive dyskinesia (TD) in schizophrenia in a genetically homogeneous Han Chinese inpatient population.
Methods: Genotyping was performed for the MnSOD gene Ala-9Val SNP in Chinese schizophrenia patients with (n = 176) and without TD (n = 346). The severity of TD was assessed using the abnormal involuntary movement scale (AIMS), and psychopathology using the Positive and Negative Syndrome Scale (PANSS).
Results: The frequencies of genotypes and alleles did not differ significantly between schizophrenic patients with and without TO (both p>0.05). Also, there was no significant difference in the AIMS total score between the Val/Val and Ala allele carrier groups (p>0.05). However, the PANSS negative symptom subscore was significantly higher in patients with Val/Val genotype (21.8 +/- 7.3) than those with Ala alleles (20.1 +/- 7.7) (t = 2.32, p = 0.03).
Conclusion: While the MnSOD gene Ala-9Val polymorphism did not play a major role in the susceptibility to TD in schizophrenic patients, it might be associated with negative symptoms of schizophrenia. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Liu, Hong; Zhang, Ben Shu; Wang, Yu] Tianjin Med Univ, Gen Hosp, Dept Neurol, Tianjin 300052, Peoples R China.
[Liu, Hong] Heping Hosp Affiliated, Changzhi Med Coll, Dept Neurol, Changzhi 046000, Shanxi Province, Peoples R China.
[Wang, Cui; Zheng, You Lan] Jilin Agr Univ, Coll Chinese Med Mat, Changchun, Peoples R China.
[Chen, Pin Hong; Meng, Hua Qing] Chongqing Med Univ, Affiliated Hosp 1, Dept Mental Hlth, Chongqing 400016, Peoples R China.
[Zhang, Chong Xi] Shandong Univ Weihai, Marine Coll, Weihai, Shandong, Peoples R China.
[Chen, Da Chun; Xiu, Mei Hong; Zhang, Xiang Yang] Beijing Huilongguan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China.
[Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Kosten, TR (reprint author), VA Med Ctr, Res Bldg 110,Room 229,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM kosten@bcm.edu; xyzhang@bcm.edu
FU Stanley Medical Research Institute [03T-459, 05T-726]; Beijing Municipal
Natural Science Foundation [ID: 7072035]; Department of Veterans Affairs
FX This study was funded by the Stanley Medical Research Institute (03T-459
and 05T-726), the Beijing Municipal Natural Science Foundation (ID:
7072035), and the Department of Veterans Affairs, VISN 16, Mental
Illness Research, Education and Clinical Center (MIRECC), United States
National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639.
NR 35
TC 10
Z9 10
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-5846
J9 PROG NEURO-PSYCHOPH
JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry
PD MAY 30
PY 2010
VL 34
IS 4
BP 692
EP 696
DI 10.1016/j.pnpbp.2010.03.026
PG 5
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 612GV
UT WOS:000278885700021
PM 20346996
ER
PT J
AU Biederman, J
Petty, CR
Evans, M
Small, J
Faraone, SV
AF Biederman, Joseph
Petty, Carter R.
Evans, Maggie
Small, Jacqueline
Faraone, Stephen V.
TI How persistent is ADHD? A controlled 10-year follow-up study of boys
with ADHD
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Longitudinal; Adult; Remission; ADHD
ID ATTENTION-DEFICIT HYPERACTIVITY; AGE-DEPENDENT DECLINE;
DEFICIT/HYPERACTIVITY DISORDER; SUBTHRESHOLD DIAGNOSES; PSYCHIATRIC
STATUS; LATE-ONSET; CHILDREN; ADULTS; DEFINITION; PREVALENCE
AB The main aim of this study was to examine the age-dependent persistence of attention-deficit hyperactivity disorder (ADHD) in boys transitioning from adolescence into early adulthood attending to different definitions of persistence. We conducted a 10-year follow-up study (mean follow-up time = 11 years) of 110 boys with ADHD and 105 non-ADHD controls. Both groups were 6-17 years of age at ascertainment. ADHD was considered persistent at follow-up if subjects met full or subthreshold (more than half of the symptoms required for a full diagnosis) Diagnostic and Statistical Manual of Mental Disorders, fourth edition. (DSM-IV) diagnostic criteria, failed to attain functional remission (Global Assessment of Functioning, GAF score <= 60) or were receiving treatment for ADHD. While 65% of children with ADHD no longer met full DSM-IV criteria for ADHD at the 10-year follow-up, 78% of subjects met at least one of our definitions of persistence. Persistence as described above was associated with more psychiatric co-morbidity, more familiality with mood disorders and higher levels of educational and interpersonal impairments than controls. This 10-year longitudinal follow-up study shows that the majority of ADHD boys experience persistent symptoms and functional impairments into early adulthood. Persistence of ADHD is associated with greater psychiatric comorbidity, familiality and functional impairments. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Biederman, Joseph] Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Dept Psychiat, Boston, MA 02114 USA.
[Biederman, Joseph; Petty, Carter R.; Evans, Maggie; Small, Jacqueline] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY USA.
RP Biederman, J (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Dept Psychiat, 55 Fruit St,YAW 6A-6900, Boston, MA 02114 USA.
EM jbiederman@partners.org
OI Faraone, Stephen/0000-0002-9217-3982
FU National Institute of Child Health and Human Development (NICHD)
[5R01HD036317-10]; Lilly Foundation; Pediatric Psychopharmacology
Philanthropic Fund
FX This work was supported, in part, by National Institute of Child Health
and Human Development (NICHD) grant 5R01HD036317-10, the Lilly
Foundation Fund, and the Pediatric Psychopharmacology Philanthropic
Fund.
NR 36
TC 143
Z9 145
U1 3
U2 25
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD MAY 30
PY 2010
VL 177
IS 3
BP 299
EP 304
DI 10.1016/j.psychres.2009.12.010
PG 6
WC Psychiatry
SC Psychiatry
GA 609MB
UT WOS:000278659600005
PM 20452063
ER
PT J
AU Herzog, DB
Thomas, JG
Kass, AE
Eddy, KT
Franko, DL
Lowe, MR
AF Herzog, David B.
Thomas, J. Graham
Kass, Andrea E.
Eddy, Kamryn T.
Franko, Debra L.
Lowe, Michael R.
TI Weight suppression predicts weight change over 5 years in bulimia
nervosa
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Eating disorders; BMI; Longitudinal
ID BODY-WEIGHT; RESTRAINT; ANOREXIA; BEHAVIOR; GAIN
AB Recent studies suggest that weight suppression (WS), defined as the discrepancy between current and highest past weight, predicts short-term weight gain in bulimia nervosa (BN) during treatment. The current study was designed to build on this preliminary work by examining the relation between WS and long-term weight change in BN. Treatment-seeking women (N=97) with DSM-IV BN participated in a naturalistic longitudinal follow-up study of eating disorders. At intake, height and weight were measured and highest past weight was assessed. Self-reported weights were collected every 6 months for 5 years. Hierarchical Linear Modeling (HLM) estimated growth curves for weight change over time. Significant inter-person variability was detected for intercepts and slopes (P<0.001) so both were treated as random effects. Participants' weights increased over the study course, moderated by baseline WS (P<0.001). such that higher WS predicted more rapid weight gain. Weight change was not associated with entry weight, height, or highest-ever weight, suggesting that WS per se predicted weight change. These findings complement previous short-term studies in BN by demonstrating that WS predicts weight gain over 5 years. Because weight gain could spur radical dieting that maintains BN, these results have important treatment implications. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Herzog, David B.; Kass, Andrea E.; Eddy, Kamryn T.; Franko, Debra L.] Massachusetts Gen Hosp, Dept Psychiat, Harris Ctr, Boston, MA 02114 USA.
[Herzog, David B.; Eddy, Kamryn T.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Thomas, J. Graham; Lowe, Michael R.] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA.
[Franko, Debra L.] Northeastern Univ, Dept Counseling & Appl Educ Psychol, Boston, MA 02115 USA.
RP Herzog, DB (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Harris Ctr, 2 Longfellow Pl,Ste 200, Boston, MA 02214 USA.
EM dherzog@partners.org
FU National Institute of Mental Health [5R01 MH 38333 05]
FX This work was supported by the National Institute of Mental Health grant
5R01 MH 38333 05 (DBH). These data were presented in part at the Eating
Disorder Research Society Annual Meeting in Montreal. Quebec (September
2008). The authors would like to thank Stephanie Ross for her assistance
in editing and preparing the final version of this manuscript.
NR 27
TC 21
Z9 21
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD MAY 30
PY 2010
VL 177
IS 3
BP 330
EP 334
DI 10.1016/j.psychres.2010.03.002
PG 5
WC Psychiatry
SC Psychiatry
GA 609MB
UT WOS:000278659600010
PM 20398944
ER
PT J
AU Saito, A
Wakao, M
Deguchi, H
Mawatari, A
Sobel, M
Suda, Y
AF Saito, Akihiro
Wakao, Masahiro
Deguchi, Hiroshi
Mawatari, Aya
Sobel, Michael
Suda, Yasuo
TI Toward the assembly of heparin and heparan sulfate oligosaccharide
libraries: efficient synthesis of uronic acid and disaccharide building
blocks
SO TETRAHEDRON
LA English
DT Article
DE Synthesis; Uronic acid; Glucuronic acid; Iduronic acid; Glucosamine;
Heparin; Heparan sulfate
ID L-IDURONIC ACID; BIOLOGICAL-ACTIVITY; PROTEIN INTERACTIONS; MODULAR
SYNTHESIS; SUGAR CHIPS; GLYCOSAMINOGLYCANS; BINDING; STRATEGY; ROUTE;
PENTASACCHARIDE
AB The monosaccharide moieties found in heparin (HP) and heparan sulfate (HS), glucosamine and two kinds of uronic acids, glucuronic and iduronic acids, were efficiently synthesized by use of glucosamine hydrochloride and glucurono-6,3-lactone as starting compounds. In the synthesis of the disaccharide building block, the key issues of preparation of uronic acids (glucuronic acid and iduronic acid moieties) were achieved in 12 steps and 15 steps, respectively, without cumbersome C-6 oxidation. The resulting monosaccharide moieties were utilized to the syntheses of HP/HS disaccharide building blocks possessing glucosamine-glucuronic acid (GlcN-GlcA) or iduronic acid (GlcN-IdoA) sequences. The disaccharide building blocks were also suitable for further modification such as glycosylation, selective deprotection, and sulfation. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Saito, Akihiro; Wakao, Masahiro; Deguchi, Hiroshi; Mawatari, Aya; Suda, Yasuo] Kagoshima Univ, Grad Sch Sci & Engn, Dept Chem Biotechnol & Chem Engn, Kagoshima 8900065, Japan.
[Sobel, Michael] VA Puget Sound Hlth Care Syst, Div Vasc Surg, Seattle, WA USA.
[Sobel, Michael] Univ Washington, Sch Med, Seattle, WA USA.
[Suda, Yasuo] SUDx Biotec Corp, Kagoshima 8900013, Japan.
RP Wakao, M (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, Dept Chem Biotechnol & Chem Engn, 1-21-40 Kohrimoto, Kagoshima 8900065, Japan.
EM wakao@eng.kagoshima-u.ac.jp; ysuda@eng.kagoshima-u.ac.jp
FU Japan Science and Technology Agency [V07-05]; Japan Ministry of Health,
Labour and Welfare (MHLW); National Institutes of Health, USA [RO1
HL079182]
FX The present work was financially supported in part by grants from Japan
Science and Technology Agency (Evolutionally-venture program V07-05 to
Y.S., CREST to Y.S.), and the Japan Ministry of Health, Labour and
Welfare (MHLW) (Nanomedicine program to Y.S.), and the National
Institutes of Health, USA (RO1 HL079182 to M.S.).
NR 55
TC 10
Z9 11
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4020
J9 TETRAHEDRON
JI Tetrahedron
PD MAY 29
PY 2010
VL 66
IS 22
BP 3951
EP 3962
DI 10.1016/j.tet.2010.03.077
PG 12
WC Chemistry, Organic
SC Chemistry
GA 603GK
UT WOS:000278196500009
PM 20473366
ER
PT J
AU Liu, XH
Manzano, G
Lovett, DH
Kim, HT
AF Liu, Xuhui
Manzano, Givenchy
Lovett, David H.
Kim, Hubert T.
TI Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2
transcriptional regulation in skeletal muscle atrophy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Matrix metalloproteinase-2; Muscle atrophy; Extracellular matrix; Gene
expression regulation; Transcription; AP-1
ID HINDLIMB IMMOBILIZATION; EXPRESSION; RECOVERY; ISCHEMIA; CELLS; MMP-2;
JUNB; YB-1; RATS; FOSB
AB Previous work has suggested that an extracellular matrix degrading enzyme matrix metalloproteinase-2 (MMP-2) plays an important role in the development of muscle atrophy. However, the transcriptional regulation mechanism of MMP-2 in skeletal muscle atrophy remains largely unknown. Using transgenic MMP-2 promoter reporter mice, we have demonstrated that AP-1 and RE-1 binding sites in the MMP-2 promoter region, coupled with increased binding of Fra-1, Fra-2 and AP-2, play a critical role in MMP-2 transcriptional regulation in muscle atrophy. Novel information gained from this study has improved our understanding of in vivo transcriptional regulation of MMP-2 in skeletal muscle atrophy. Published by Elsevier Inc.
C1 [Liu, Xuhui; Manzano, Givenchy; Lovett, David H.; Kim, Hubert T.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA.
[Liu, Xuhui; Manzano, Givenchy; Kim, Hubert T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94122 USA.
[Lovett, David H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94122 USA.
RP Kim, HT (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, 4150 Clement St 112, San Francisco, CA 94121 USA.
EM Kimh@orthosurg.ucsf.edu
FU Orthopedic Research & Education Foundation; Illinois Bone and Joint
Institute
FX This work was supported by Orthopedic Research & Education Foundation
and Illinois Bone and Joint Institute.
NR 19
TC 5
Z9 5
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 28
PY 2010
VL 396
IS 2
BP 219
EP 223
DI 10.1016/j.bbrc.2010.04.067
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 609LL
UT WOS:000278658000008
PM 20398633
ER
PT J
AU Hong, W
Chen, LF
Li, JA
Yao, Z
AF Hong, Wei
Chen, Linfeng
Li, Juan
Yao, Zhi
TI Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by
tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action
in MCF-7 cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE MAPK; Corepressor; Nuclear hormone receptor; Tamoxifen
ID BREAST-CANCER CELLS; GLUCOCORTICOID-RECEPTOR; RESPONSE ELEMENT;
CROSS-TALK; TRANSCRIPTION; RESISTANCE; GROWTH; GENE; PHOSPHORYLATION;
COACTIVATORS
AB Estrogen receptor alpha (ER alpha), a ligand controlled transcription factor, plays an important role in breast cancer growth and endocrine therapy. Tamoxifen (TAM) antagonizes ER alpha activity and has been applied in breast cancer treatment. TAM-bound ER alpha associates with nuclear receptor-corepressors. Mitogen-activated protein kinase (MAPK) has been elucidated to result in cross-talk between growth factor and ER alpha. mediated signaling. We show that activated MAPK represses interaction of TAM-bound ER alpha with silencing mediator for retinoid and thyroid hormone receptors (SMRT) and inhibits the recruitment of SMRT by ER alpha to certain estrogen target genes. Blockade of MAPK signaling cascade with MEK inhibitor U0126 promotes the interaction and subsequently inhibits ER alpha activity via enhanced recruitment of SMRT, leading to reduced expression of ER alpha target genes. The growth rate of MCF-7 cells was decelerated when treated with both TAM and U0126. Moreover, the growth of MCF-7 cells stably expressing SMRT showed a robust repression in the presence of TAM and U0126. These results suggest that activated MAPK signaling cascade attenuates antagonist-induced recruitment of SMRT to ER alpha, suggesting corepressor mediates inhibition of ER alpha trans-activation and breast cancer cell growth by antagonist. Taken together, our finding indicates combination of antagonist and MAPK inhibitor could be a helpful approach for breast cancer therapy. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Hong, Wei; Yao, Zhi] Tianjin Med Univ, Dept Immunol, Tianjin 300070, Peoples R China.
[Hong, Wei; Li, Juan] Tianjin Med Univ, Dept Lab Med, Tianjin 300070, Peoples R China.
[Chen, Linfeng] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Hong, W (reprint author), Tianjin Med Univ, Dept Immunol, Tianjin 300070, Peoples R China.
EM hongwei@tijmu.edu.cn
FU Tianjin Medical University; National Basic Research Program
[2009CB918903]
FX We thank David Fisher for critically reading the manuscript. This work
was supported by a grant for the "11-5" New Century Outstanding
Scientist from Tianjin Medical University (W.H.) and a grant of National
Basic Research Program (2009CB918903).
NR 29
TC 5
Z9 5
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 28
PY 2010
VL 396
IS 2
BP 299
EP 303
DI 10.1016/j.bbrc.2010.04.085
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 609LL
UT WOS:000278658000021
PM 20406620
ER
PT J
AU Bhasin, M
Yuan, L
Keskin, DB
Otu, HH
Libermann, TA
Oettgen, P
AF Bhasin, Manoj
Yuan, Lei
Keskin, Derin B.
Otu, Hasan H.
Libermann, Towia A.
Oettgen, Peter
TI Bioinformatic identification and characterization of human endothelial
cell-restricted genes
SO BMC GENOMICS
LA English
DT Article
ID HUMAN PROTEIN ATLAS; LYS198ASN POLYMORPHISM; ANTIBODY PROTEOMICS;
BLOOD-PRESSURE; EXPRESSION; HYPERTENSION; PROMOTER; PATHOPHYSIOLOGY;
ANGIOGENESIS; SPECIFICITY
AB Background: In this study, we used a systematic bioinformatics analysis approach to elucidate genes that exhibit an endothelial cell (EC) restricted expression pattern, and began to define their regulation, tissue distribution, and potential biological role.
Results: Using a high throughput microarray platform, a primary set of 1,191 transcripts that are enriched in different primary ECs compared to non-ECs was identified (LCB >3, FDR <2%). Further refinement of this initial subset of transcripts, using published data, yielded 152 transcripts ( representing 109 genes) with different degrees of EC-specificity. Several interesting patterns emerged among these genes: some were expressed in all ECs and several were restricted to microvascular ECs. Pathway analysis and gene ontology demonstrated that several of the identified genes are known to be involved in vasculature development, angiogenesis, and endothelial function ( P < 0.01). These genes are enriched in cardiovascular diseases, hemorrhage and ischemia gene sets ( P < 0.001). Most of the identified genes are ubiquitously expressed in many different tissues. Analysis of the proximal promoter revealed the enrichment of conserved binding sites for 26 different transcription factors and analysis of the untranslated regions suggests that a subset of the EC-restricted genes are targets of 15 microRNAs. While many of the identified genes are known for their regulatory role in ECs, we have also identified several novel EC-restricted genes, the function of which have yet to be fully defined.
Conclusion: The study provides an initial catalogue of EC-restricted genes most of which are ubiquitously expressed in different endothelial cells.
C1 [Bhasin, Manoj; Yuan, Lei; Otu, Hasan H.; Libermann, Towia A.; Oettgen, Peter] Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Bhasin, Manoj; Libermann, Towia A.] Harvard Univ, Sch Med, Div Interdisciplinary Med & Biotechnol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Yuan, Lei; Oettgen, Peter] Harvard Univ, Sch Med, Div Cardiol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Yuan, Lei; Oettgen, Peter] Harvard Univ, Sch Med, Div Mol & Vasc Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Keskin, Derin B.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
RP Oettgen, P (reprint author), Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
EM joettgen@bidmc.harvard.edu
OI Otu, Hasan/0000-0002-9253-8152; Libermann, Towia/0000-0002-4006-8179
FU NIH [HL-67219, P01 HL76540]; AHA [EIA0740012]
FX This work was supported by NIH grants HL-67219 (PO) and P01 HL76540
(PO), and AHA award EIA0740012 (PO)
NR 41
TC 19
Z9 20
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD MAY 28
PY 2010
VL 11
AR 342
DI 10.1186/1471-2164-11-342
PG 18
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 625BR
UT WOS:000279867300005
PM 20509943
ER
PT J
AU Lengner, CJ
Gimelbrant, AA
Erwin, JA
Cheng, AW
Guenther, MG
Welstead, GG
Alagappan, R
Frampton, GM
Xu, P
Muffat, J
Santagata, S
Powers, D
Barrett, CB
Young, RA
Lee, JT
Jaenisch, R
Mitalipova, M
AF Lengner, Christopher J.
Gimelbrant, Alexander A.
Erwin, Jennifer A.
Cheng, Albert Wu
Guenther, Matthew G.
Welstead, G. Grant
Alagappan, Raaji
Frampton, Garrett M.
Xu, Ping
Muffat, Julien
Santagata, Sandro
Powers, Doug
Barrett, C. Brent
Young, Richard A.
Lee, Jeannie T.
Jaenisch, Rudolf
Mitalipova, Maisam
TI Derivation of Pre-X Inactivation Human Embryonic Stem Cells under
Physiological Oxygen Concentrations
SO CELL
LA English
DT Article
ID EARLY MOUSE EMBRYOS; CHROMOSOME INACTIVATION; IN-VITRO; HUMAN
BLASTOCYSTS; HISTONE H3; XIST RNA; SELF-RENEWAL; LINES; DIFFERENTIATION;
METHYLATION
AB The presence of two active X chromosomes (XaXa) is a hallmark of the ground state of pluripotency specific to murine embryonic stem cells (ESCs). Human ESCs (hESCs) invariably exhibit signs of X chromosome inactivation (XCI) and are considered developmentally more advanced than their murine counterparts. We describe the establishment of XaXa hESCs derived under physiological oxygen concentrations. Using these cell lines, we demonstrate that (1) differentiation of hESCs induces random XCI in a manner similar to murine ESCs, (2) chronic exposure to atmospheric oxygen is sufficient to induce irreversible XCI with minor changes of the transcriptome, (3) the Xa exhibits heavy methylation of the XIST promoter region, and (4) XCI is associated with demethylation and transcriptional activation of XIST along with H3K27-me3 deposition across the Xi. These findings indicate that the human blastocyst contains pre-X-inactivation cells and that this state is preserved in vitro through culture under physiological oxygen.
C1 [Lengner, Christopher J.; Cheng, Albert Wu; Guenther, Matthew G.; Welstead, G. Grant; Alagappan, Raaji; Frampton, Garrett M.; Xu, Ping; Muffat, Julien; Santagata, Sandro; Young, Richard A.; Jaenisch, Rudolf; Mitalipova, Maisam] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Frampton, Garrett M.; Young, Richard A.; Jaenisch, Rudolf] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Cheng, Albert Wu] MIT, Dept Computat & Syst Biol, Cambridge, MA 02139 USA.
[Gimelbrant, Alexander A.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Gimelbrant, Alexander A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA.
[Erwin, Jennifer A.; Lee, Jeannie T.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
[Erwin, Jennifer A.; Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Erwin, Jennifer A.; Lee, Jeannie T.] Howard Hughes Med Inst, Ann Arbor, MI 48108 USA.
[Powers, Doug] Incept Biosyst, Ann Arbor, MI 48108 USA.
[Barrett, C. Brent] Waltham Ctr, Boston IVF, Waltham, MA 02451 USA.
RP Jaenisch, R (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
EM jaenisch@wi.mit.edu; mitalipo@wi.mit.edu
RI Young, Richard/F-6495-2012;
OI Young, Richard/0000-0001-8855-8647; Muffat, Julien/0000-0003-1889-7023;
Lengner, Christopher/0000-0002-0574-5189
FU Howard Hughes Medical Institute
NR 54
TC 205
Z9 209
U1 6
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD MAY 28
PY 2010
VL 141
IS 5
BP 872
EP 883
DI 10.1016/j.cell.2010.04.010
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 602IO
UT WOS:000278132900021
PM 20471072
ER
PT J
AU Hur, W
Sun, Z
Jiang, T
Mason, DE
Peters, EC
Zhang, DD
Luesch, H
Schultz, PG
Gray, NS
AF Hur, Wooyoung
Sun, Zheng
Jiang, Tao
Mason, Daniel E.
Peters, Eric C.
Zhang, Donna D.
Luesch, Hendrik
Schultz, Peter G.
Gray, Nathanael S.
TI A Small-Molecule Inducer of the Antioxidant Response Element
SO CHEMISTRY & BIOLOGY
LA English
DT Article
ID HUMAN NEUROBLASTOMA-CELLS; SUBSTRATE ADAPTER PROTEIN; OXIDATIVE STRESS;
TERT-BUTYLHYDROQUINONE; HISTONE DEACETYLASE; CYSTEINE RESIDUES;
SULFHYDRYL-GROUPS; ACTIVATE NRF2; KEAP1; UBIQUITINATION
AB Eukaryotic cells counteract oxidative and other environmental stress through the activation of Nrf2, the transcription factor that controls the expression of a host of protective enzymes by binding to the antioxidant response element (ARE). The electrophilic molecules that are able to activate Nrf2 and its downstream target genes have demonstrated therapeutic potential in carcinogen-induced tumor models. Using a high-throughput cellular screen, we discovered a class of ARE activator, which we named AI-1, that activates Nrf2 by covalently modifying Keap1, the negative regulator of Nrf2. Biochemical studies indicated that modification of Cys151 of Keap1 by AI-1 disrupted the ability of Keap1 to serve as an adaptor for Cul3-Keap1 ubiquitin ligase complex, thereby causing stabilization and transcriptional activation of Nrf2. Al-1 and its biotinylated derivative are useful pharmacological probes for investigating the molecular details of the cellular antioxidant response.
C1 [Luesch, Hendrik] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA.
[Hur, Wooyoung; Schultz, Peter G.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
[Sun, Zheng; Jiang, Tao; Zhang, Donna D.] Univ Arizona, Dept Pharmacol & Toxicol, Coll Pharm, Tucson, AZ 85721 USA.
[Mason, Daniel E.; Peters, Eric C.; Schultz, Peter G.] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA.
[Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
RP Luesch, H (reprint author), Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA.
EM luesch@cop.ufl.edu; schultz@scripps.edu; Nathanael_Gray@dfci.harvard.edu
RI Sun, Zheng/C-1146-2012; Zhang, Donna /B-1015-2012
OI Sun, Zheng/0000-0002-6858-0633;
FU Ellison Medical Foundation; American Heart Association; Evelyn F. and
William L. McKnight Brain Institute of the University of Florida
FX This work was supported by the Ellison Medical Foundation (P.G.S.), the
American Heart Association (H.L.), and the Evelyn F. and William L.
McKnight Brain Institute of the University of Florida (H.L.). We thank
Jonathan Kern for assistance with the screens. The authors declare no
competing financial interests.
NR 43
TC 35
Z9 36
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-5521
J9 CHEM BIOL
JI Chem. Biol.
PD MAY 28
PY 2010
VL 17
IS 5
BP 537
EP 547
DI 10.1016/j.chembiol.2010.03.013
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 611TE
UT WOS:000278845000015
PM 20534351
ER
PT J
AU Cavusoglu, E
Chopra, V
Gupta, A
Battala, VR
Poludasu, S
Eng, C
Marmur, JD
AF Cavusoglu, Erdal
Chopra, Vineet
Gupta, Amit
Battala, Venkata R.
Poludasu, Shyam
Eng, Calvin
Marmur, Jonathan D.
TI Relation between red blood cell distribution width (RDW) and all-cause
mortality at two years in an unselected population referred for coronary
angiography
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE RDW; Anemia; Coronary angiography; Prognosis
ID INDEPENDENT PREDICTOR; CHARM PROGRAM; HEART-FAILURE; CHEST-PAIN; ANEMIA;
OUTCOMES
AB Background: Red blood cell distribution width (RDW), a numerical measure of the variability in size of circulating erythrocytes, has recently been shown to be a strong predictor of adverse outcomes in patients with heart failure and in patients with prior myocardial infarction but no symptomatic heart failure at baseline, even after adjustment for hematocrit. However, there are no data in other cardiac populations, including patients with acute coronary syndromes (ACS).
Methods: The present study investigated the long-term prognostic significance of baseline RDW in a well-characterized cohort of 389 male patients who were referred to coronary angiography for a variety of indications. All patients were followed prospectively for all-cause mortality, and data regarding this endpoint was available for 97% of the population at 24 months.
Results: After controlling for a variety of baseline variables (including hemoglobin and the presence of heart failure), RDW (analyzed as a categorical variable comparing the upper tertile of baseline values to the lower two levels combined) was a strong and independent predictor of all-cause mortality using a Cox proportional hazards model [ hazard ratio (HR) 2.69, 95% confidence interval (CI) 1.50-4.84, p=0.0008]. In addition, baseline RDW was also an independent predictor of all-cause mortality in the non-anemic (HR 4.73, 95% CI 2.06-10.86, p=0.0003) and ACS (HR 2.90, 95% CI 1.32-6.38, p=0.0082) subpopulations of patients.
Conclusions: These data demonstrate that elevated RDW is a strong and independent predictor of all-cause mortality in an unselected population of male patients across a broad spectrum of risk (including ACS) referred for coronary angiography. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Cavusoglu, Erdal; Gupta, Amit; Battala, Venkata R.; Poludasu, Shyam; Marmur, Jonathan D.] Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA.
[Cavusoglu, Erdal; Chopra, Vineet; Eng, Calvin] Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA.
RP Cavusoglu, E (reprint author), Suny Downstate Med Ctr, Dept Med, Div Cardiol, 450 Clarkson Ave,Box 1257, Brooklyn, NY 11203 USA.
EM ECavusoglu@aol.com
NR 12
TC 88
Z9 98
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD MAY 28
PY 2010
VL 141
IS 2
BP 141
EP 146
DI 10.1016/j.ijcard.2008.11.187
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 597AI
UT WOS:000277727200004
PM 19144426
ER
PT J
AU Boucher, J
Tseng, YH
Kahn, CR
AF Boucher, Jeremie
Tseng, Yu-Hua
Kahn, C. Ronald
TI Insulin and Insulin-like Growth Factor-1 Receptors Act as
Ligand-specific Amplitude Modulators of a Common Pathway Regulating Gene
Transcription
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID IGF-I; MICROARRAY ANALYSIS; CYTOPLASMIC DOMAINS; SIGNAL-TRANSDUCTION;
GLUCOSE-METABOLISM; BROWN ADIPOCYTES; CELL-CULTURES; MUSCLE-CELLS; MICE;
EXPRESSION
AB Insulin and insulin-like growth factor-1 (IGF-1) act on highly homologous receptors, yet in vivo elicit distinct effects on metabolism and growth. To investigate how the insulin and IGF-1 receptors exert specificity in their biological responses, we assessed their role in the regulation of gene expression using three experimental paradigms: 1) preadipocytes before and after differentiation into adipocytes that express both receptors, but at different ratios; 2) insulin receptor (IR) or IGF1R knock-out preadipocytes that only express the complimentary receptor; and 3) IR/IGF1R double knock-out (DKO) cells reconstituted with the IR, IGF1R, or both. In wild-type preadipocytes, which express predominantly IGF1R, microarray analysis revealed similar to 500 IGF-1 regulated genes (p < 0.05). The largest of these were confirmed by quantitative PCR, which also revealed that insulin produced a similar effect, but with a smaller magnitude of response. After differentiation, when IR levels increase and IGF1R decrease, insulin became the dominant regulator of each of these genes. Measurement of the 50 most highly regulated genes by quantitative PCR did not reveal a single gene regulated uniquely via the IR or IGF1R using cells expressing exclusively IGF-1 or insulin receptors. Insulin and IGF-1 dose responses from 1 to 100 nM in WT, IRKO, IGFRKO, and DKO cells re-expressing IR, IGF1R, or both showed that insulin and IGF-1 produced effects in proportion to the concentration of ligand and the specific receptor on which they act. Thus, IR and IGF1R act as identical portals to the regulation of gene expression, with differences between insulin and IGF-1 effects due to a modulation of the amplitude of the signal created by the specific ligand-receptor interaction.
C1 Joslin Diabet Ctr, Boston, MA 02215 USA.
Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.
Harvard Univ, Sch Med, Boston, MA 02215 USA.
RP Kahn, CR (reprint author), 1 Joslin Pl, Boston, MA 02215 USA.
EM c.ronald.kahn@joslin.harvard.edu
FU National Institutes of Health [DK31036, DK33201, DK077097]; Diabetes
Genome Anatomy Project [DK60837]; Harvard Catalyst/The Harvard Clinical
and Translational Science Center [UL1 RR 025758-01]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants DK31036, DK33201, and DK077097, Diabetes Genome Anatomy
Project Grant DK60837, and Harvard Catalyst/The Harvard Clinical and
Translational Science Center Grant UL1 RR 025758-01.
NR 40
TC 39
Z9 40
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 28
PY 2010
VL 285
IS 22
BP 17235
EP 17245
DI 10.1074/jbc.M110.118620
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 600JS
UT WOS:000277982600085
PM 20360006
ER
PT J
AU Choo, AY
Kim, SG
Heiden, MGV
Mahoney, SJ
Vu, H
Yoon, SO
Cantley, LC
Blenis, J
AF Choo, Andrew Y.
Kim, Sang Gyun
Heiden, Matthew G. Vander
Mahoney, Sarah J.
Vu, Hieu
Yoon, Sang-Oh
Cantley, Lewis C.
Blenis, John
TI Glucose Addiction of TSC Null Cells Is Caused by Failed mTORC1-Dependent
Balancing of Metabolic Demand with Supply
SO MOLECULAR CELL
LA English
DT Article
ID TUBEROUS SCLEROSIS COMPLEX; GREEN TEA POLYPHENOLS; GROWTH; SURVIVAL;
GLUTAMINE; TUMOR; ACTIVATION; APOPTOSIS; CANCER; PHOSPHORYLATION
AB The mTORC1-signaling pathway integrates environmental conditions into distinct signals for cell growth by balancing anabolic and catabolic processes. Accordingly, energetic stress inhibits mTORC1 signaling predominantly through AMPK-dependent activation of TSC1/2. Thus, TSC1/2-/- cells are hypersensitive to glucose deprivation, and this has been linked to increased p53 translation and activation of apoptosis. Herein, we show that mTORC1 inhibition during glucose deprivation prevented not only the execution of death, but also induction of energetic stress. mTORC1 inhibition during glucose deprivation decreased AMPK activation and allowed ATP to remain high, which was both necessary and sufficient for protection. This effect was not due to increased catabolic activities such as autophagy, but rather exclusively due to decreased anabolic processes, reducing energy consumption. Specifically, TSC1/2-/- cells become highly dependent on glutamate dehydrogenase-dependent glutamine metabolism via the TCA cycle for survival. Therefore, mTORC1 inhibition during energetic stress is primarily to balance metabolic demand with supply.
C1 [Choo, Andrew Y.; Kim, Sang Gyun; Mahoney, Sarah J.; Vu, Hieu; Yoon, Sang-Oh; Blenis, John] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Choo, Andrew Y.; Mahoney, Sarah J.] Harvard Univ, Sch Med, Program Biol, Boston, MA 02115 USA.
[Choo, Andrew Y.; Mahoney, Sarah J.] Harvard Univ, Sch Med, Program Biomed Sci, Boston, MA 02115 USA.
[Heiden, Matthew G. Vander; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
[Heiden, Matthew G. Vander] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Heiden, Matthew G. Vander; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA.
RP Blenis, J (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
EM john_blenis@hms.harvard.edu
RI Cantley, Lewis/D-1800-2014
OI Cantley, Lewis/0000-0002-1298-7653
FU NIH [GM51405]
FX We thank members of the Blenis laboratory for critical discussions and
technical assistance. We are also grateful to D. Kwiatkowski, B.
Manning, J. Brugge, W. Kaelin, Jr., C. Walker, N. Mizushima, and K.L.
Guan for providing reagents and to S. Soltoff for advice and discussions
regarding Ne+/K+-AT-Pase assays. A.Y.C. would also
like to thank J. Brugge and L. Gehrke for discussions. This work was
funded-by the NIH Grant GM51405 to J.B.
NR 32
TC 122
Z9 126
U1 3
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD MAY 28
PY 2010
VL 38
IS 4
BP 487
EP 499
DI 10.1016/j.molcel.2010.05.007
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 606SQ
UT WOS:000278448100005
PM 20513425
ER
PT J
AU Qiao, M
Wang, YQ
Xu, XE
Lu, J
Dong, YL
Tao, WF
Stein, J
Stein, GS
Iglehart, JD
Shi, QA
Pardee, AB
AF Qiao, Meng
Wang, Yaqi
Xu, Xiaoen
Lu, Jing
Dong, Yongli
Tao, Wufan
Stein, Janet
Stein, Gary S.
Iglehart, James D.
Shi, Qian
Pardee, Arthur B.
TI Mst1 Is an Interacting Protein that Mediates PHLPPs' Induced Apoptosis
SO MOLECULAR CELL
LA English
DT Article
ID KINASE MST1; SUPRACHIASMATIC NUCLEUS; STE20-LIKE KINASE; BREAST-CANCER;
HIPPO PATHWAY; MAP KINASE; ACTIVATION; PHOSPHORYLATION; AKT;
HETEROZYGOSITY
AB PHLPP1 and PHLPP2 phosphatases exert their tumor-suppressing functions by dephosphorylation and inactivation of Akt in several breast cancer and glioblastoma cells. However, Akt, or other known targets of PHLPPs that include PKC and ERK, may not fully elucidate the physiological role of the multifunctional phosphatases, especially their powerful apoptosis induction function. Here, we show that PHLPPs induce apoptosis in cancer cells independent of the known targets of PHLPPs. We identified Mst1 as a binding partner that interacts with PHLPPs both in vivo and in vitro. PHLPPs dephosphorylate Mst1 on the 1387 inhibitory site, which activate Mst1 and its downstream effectors p38 and JNK to induce apoptosis. The same 1387 site can be phosphorylated by Akt. Thus, PHLPP, Akt, and Mst1 constitute an autoinhibitory triangle that controls the fine balance of apoptosis and proliferation that is cell type and context dependent.
C1 [Qiao, Meng; Pardee, Arthur B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA.
[Iglehart, James D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Canc Biol, Boston, MA 02115 USA.
[Iglehart, James D.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Wang, Yaqi; Xu, Xiaoen; Lu, Jing] Fudan Univ, Sch Life Sci, Shanghai 200032, Peoples R China.
[Wang, Yaqi; Xu, Xiaoen; Lu, Jing] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
[Dong, Yongli; Tao, Wufan] Fudan Univ, Inst Dev Biol, Shanghai 200032, Peoples R China.
[Stein, Janet; Stein, Gary S.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.
[Stein, Janet; Stein, Gary S.] Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA.
RP Pardee, AB (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA.
EM shiqian@fudan.edu.cn; arthur_pardee@dfci.harvard.edu
RI Dong, Yongli/K-1222-2016
FU Department of Defense [DAMD 17-02-1-0692]; Pu Jiang Project [07pj14011];
Shu Guang Project [05SG05]; Science and Technology Commission of
Shanghai Municipality [07dz19505]; NSFC [30970653]; State Key Research
Project [2008ZX10002-017, 2009ZX09301-011]; Dana-Farber/Harvard
Specialized Program of Research Excellence in Breast Cancer; Dana-Farber
FX This work was supported by Department of Defense grant DAMD 17-02-1-0692
to A.B.P. and J.D.I., and by Pu Jiang Project (07pj14011), Shu Guang
Project (05SG05), Science and Technology Commission of Shanghai
Municipality Grant (07dz19505), NSFC fund (30970653), State Key Research
Project (2008ZX10002-017, 2009ZX09301-011) to Q.S. M.Q. was sponsored by
a fellowship from Dana-Farber/Harvard Specialized Program of Research
Excellence in Breast Cancer and the Women's Cancers Program at
Dana-Farber.
NR 39
TC 60
Z9 63
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD MAY 28
PY 2010
VL 38
IS 4
BP 512
EP 523
DI 10.1016/j.molcel.2010.03.017
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 606SQ
UT WOS:000278448100007
PM 20513427
ER
PT J
AU Sharma, R
Tsuchiya, M
Skobe, Z
Tannous, BA
Bartlett, JD
AF Sharma, Ramaswamy
Tsuchiya, Masahiro
Skobe, Ziedonis
Tannous, Bakhos A.
Bartlett, John D.
TI The Acid Test of Fluoride: How pH Modulates Toxicity
SO PLOS ONE
LA English
DT Article
ID RAT INCISOR ENAMEL; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN
RESPONSE; SODIUM-FLUORIDE; SECRETORY PATHWAY; DEPENDENT EVENT;
MESSENGER-RNAS; ULTRASTRUCTURAL-CHANGES; DENTAL FLUOROSIS; RENAL
CLEARANCE
AB Background: It is not known why the ameloblasts responsible for dental enamel formation are uniquely sensitive to fluoride (F(-)). Herein, we present a novel theory with supporting data to show that the low pH environment of maturating stage ameloblasts enhances their sensitivity to a given dose of F(-). Enamel formation is initiated in a neutral pH environment (secretory stage); however, the pH can fall to below 6.0 as most of the mineral precipitates (maturation stage). Low pH can facilitate entry of F(-) into cells. Here, we asked if F(-) was more toxic at low pH, as measured by increased cell stress and decreased cell function.
Methodology/Principal Findings: Treatment of ameloblast-derived LS8 cells with F(-) at low pH reduced the threshold dose of F(-) required to phosphorylate stress-related proteins, PERK, eIF2 alpha, JNK and c-jun. To assess protein secretion, LS8 cells were stably transduced with a secreted reporter, Gaussia luciferase, and secretion was quantified as a function of F(-) dose and pH. Luciferase secretion significantly decreased within 2 hr of F(-) treatment at low pH versus neutral pH, indicating increased functional toxicity. Rats given 100 ppm F(-) in their drinking water exhibited increased stress-mediated phosphorylation of eIF2 alpha in maturation stage ameloblasts (pH<6.0) as compared to secretory stage ameloblasts (pH similar to 7.2). Intriguingly, F(-)-treated rats demonstrated a striking decrease in transcripts expressed during the maturation stage of enamel development (Klk4 and Amtn). In contrast, the expression of secretory stage genes, AmelX, Ambn, Enam and Mmp20, was unaffected.
Conclusions: The low pH environment of maturation stage ameloblasts facilitates the uptake of F 2, causing increased cell stress that compromises ameloblast function, resulting in dental fluorosis.
C1 [Sharma, Ramaswamy; Skobe, Ziedonis; Bartlett, John D.] Harvard Univ, Sch Dent Med, Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA.
[Sharma, Ramaswamy; Skobe, Ziedonis; Bartlett, John D.] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
[Tsuchiya, Masahiro] Tohoku Univ, Div Aging & Geriatr Dent, Sendai, Miyagi 980, Japan.
[Tannous, Bakhos A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Tannous, Bakhos A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
[Tannous, Bakhos A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
RP Sharma, R (reprint author), Harvard Univ, Sch Dent Med, Forsyth Inst, Dept Cytokine Biol, 188 Longwood Ave, Boston, MA 02115 USA.
EM jbartlett@forsyth.org
RI Sharma, Ramaswamy/F-8401-2012;
OI Tsuchiya, Masahiro/0000-0002-7000-4547
FU National Institute of Dental and Craniofacial Research [DE018106]
FX This work was supported by grant DE018106 from the National Institute of
Dental and Craniofacial Research (www.nidcr.nih.gov) to JDB. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 80
TC 16
Z9 17
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 28
PY 2010
VL 5
IS 5
AR e10895
DI 10.1371/journal.pone.0010895
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 603QC
UT WOS:000278222100024
PM 20531944
ER
PT J
AU Fu, J
Ghali, BW
Lozynsky, AJ
Oral, E
Muratoglu, OK
AF Fu, Jun
Ghali, Bassem W.
Lozynsky, Andrew J.
Oral, Ebru
Muratoglu, Orhun K.
TI Ultra high molecular weight polyethylene with improved plasticity and
toughness by high temperature melting
SO POLYMER
LA English
DT Article
DE High temperature melting; Wear; Total joint implants
ID UHMWPE; WEAR; RESISTANCE; DEFORMATION; DEGRADATION; OSTEOLYSIS;
DEPENDENCE; COMPONENTS; POLYMERS; DENSITY
AB Our goal was to improve the strength and toughness of ultra high molecular weight polyethylene (UHWMPE), which is the preferred polymeric bearing material in total joint implants. Based on accelerated diffusion of UHMWPE chains at high temperatures, our hypothesis was that high temperature melting could minimize the structural defects and thus improve the toughness of consolidated UHMWPE. Melting of consolidated medical-grade UHMWPE at 280, 300, and 320 degrees C in inert atmosphere improved the elongation at break, work-to-failure and impact strength, presumably due to chain scissioning and structural defect elimination through self-diffusion. An important finding of this study was that the gain in plasticity and toughness did not sacrifice the wear resistance under optimized melting conditions, which may be promising for next generation high performance UHMWPE materials for joint implant bearing surfaces. (c) 2010 Elsevier Ltd. All rights reserved.
C1 [Fu, Jun; Ghali, Bassem W.; Lozynsky, Andrew J.; Oral, Ebru; Muratoglu, Orhun K.] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA.
[Fu, Jun; Oral, Ebru; Muratoglu, Orhun K.] Harvard Univ, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA.
RP Oral, E (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Lab, GRJ 1206, Boston, MA 02114 USA.
EM eoral@partners.org
RI Fu, Jun/C-1648-2012
OI Fu, Jun/0000-0002-8723-1439
FU laboratory funds
FX The authors are grateful to Dr. Neil Hubbard, Mark Allen, and Rebecca
Field of the Orthoplastics Inc., UK for assistance in the double-notched
Izod impact strength measurements. This study was funded by laboratory
funds.
NR 28
TC 20
Z9 20
U1 2
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032-3861
J9 POLYMER
JI Polymer
PD MAY 28
PY 2010
VL 51
IS 12
BP 2721
EP 2731
DI 10.1016/j.polymer.2010.04.003
PG 11
WC Polymer Science
SC Polymer Science
GA 603DK
UT WOS:000278188500035
ER
PT J
AU Allen, JD
Coronado, GD
Williams, RS
Glenn, B
Escoffery, C
Fernandez, M
Tuff, RA
Wilson, KM
Mullen, PD
AF Allen, Jennifer D.
Coronado, Gloria D.
Williams, Rebecca S.
Glenn, Beth
Escoffery, Cam
Fernandez, Maria
Tuff, Raegan A.
Wilson, Katherine M.
Mullen, Patricia Dolan
TI A systematic review of measures used in studies of human papillomavirus
(HPV) vaccine acceptability
SO VACCINE
LA English
DT Review
DE Human papillomavirus; Vaccine; Measures; Methods; Systematic review
ID YOUNG-ADULT MEN; CERVICAL-CANCER; PARENTAL ATTITUDES; REPRESENTATIVE
SAMPLE; ADOLESCENT CHILDREN; WOMENS ATTITUDES; HEALTH-EDUCATION;
COLLEGE-STUDENTS; CLINICAL-TRIALS; RISK-FACTORS
AB Background: The recent proliferation of studies describing factors associated with HPV vaccine acceptability could inform health care providers in improving vaccine coverage and support future research. This review examined measures of HPV and HPV-vaccine knowledge, attitudes, beliefs and acceptability, described psychometric characteristics, and provided recommendations about their use.
Methods: A systematic search of Medline, CINAHL, PsychoInfo, and ERIC through May 2008 for English language reports of quantitative data from parents, young adults or adolescents yielded 79 studies. Results: The majority of studies were cross-sectional surveys (87%), self-administered (67%), conducted before prophylactic vaccines were publicly available (67%) and utilized convenience samples (65%). Most measured knowledge (80%), general attitudes about HPV vaccination (40%), and willingness to vaccinate one's daughter (26%). Two-thirds did not report reliability or validity of measures. The majority did not specify a theoretical framework.
Conclusions: Use of a theoretical framework, consistent labeling of constructs, more rigorous validation of measures, and testing of measures in more diverse samples are needed to yield measurement instruments that will produce findings to guide practitioners in developing successful community and clinical interventions. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Allen, Jennifer D.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
[Allen, Jennifer D.] Harvard Univ, Sch Med, Boston, MA USA.
[Coronado, Gloria D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Williams, Rebecca S.] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC USA.
[Glenn, Beth] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
[Glenn, Beth] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
[Escoffery, Cam] Rollins Sch Publ Hlth, Atlanta, GA USA.
[Fernandez, Maria; Mullen, Patricia Dolan] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA.
[Tuff, Raegan A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Wilson, Katherine M.] Morehouse Sch Med, Atlanta, GA 30310 USA.
RP Allen, JD (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 44 Binney St, Boston, MA 02115 USA.
EM jennifer_allen@dfci.harvard.edu
RI Escoffery, Cam/F-8030-2011; Allen, Jennifer/M-2113-2015
FU Centers for Disease Control and Prevention (CDC); National Cancer
Institute (NCI), Cancer Prevention and Control Research Networks (CPCRN)
at Emory University School of Public Health [1-U48-DP00043]; Harvard
School of Public Health/Boston School of Public Health [1-U48-DP000064];
Morehouse School of Medicine, Prevention Research Center
[1-U48-DP000056]; University of California at Los Angeles School of
Public Health [1-U48-DP000059]; University of North Carolina at Chapel
Hill, Center for Health Promotion and Disease Prevention
[1-U48-DP000056]; University of Texas School of Public Health
[1-U48-DP-000057]; University of Washington School of Public Health and
Community Medicine/Fred Hutchinson Cancer Research Center
[1-U48-DP000050]
FX Research for this publication was supported by the Centers for Disease
Control and Prevention (CDC) and the National Cancer Institute (NCI)
cooperative agreements for the Cancer Prevention and Control Research
Networks (CPCRN) at Emory University School of Public Health
(1-U48-DP00043); Harvard School of Public Health/Boston School of Public
Health (1-U48-DP000064); Morehouse School of Medicine, Prevention
Research Center (1-U48-DP000056); University of California at Los
Angeles School of Public Health (1-U48-DP000059); University of North
Carolina at Chapel Hill, Center for Health Promotion and Disease
Prevention (1-U48-DP000056); University of Texas School of Public Health
(1-U48-DP-000057); and University of Washington School of Public Health
and Community Medicine/Fred Hutchinson Cancer Research Center
(1-U48-DP000050).
NR 117
TC 59
Z9 60
U1 3
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 28
PY 2010
VL 28
IS 24
BP 4027
EP 4037
DI 10.1016/j.vaccine.2010.03.063
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 614NE
UT WOS:000279065400003
PM 20412875
ER
PT J
AU Heinrichs, S
Li, C
Look, AT
AF Heinrichs, Stefan
Li, Cheng
Look, A. Thomas
TI SNP array analysis in hematologic malignancies: avoiding false
discoveries
SO BLOOD
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; RISK MYELODYSPLASTIC SYNDROMES;
LOSS-OF-HETEROZYGOSITY; COPY NUMBER; UNIPARENTAL DISOMY; CHROMOSOMAL
LESIONS; HUMAN GENOME; GENETIC ALTERATIONS; HIGH-RESOLUTION;
CYTOGENETICS
AB Comprehensive analysis of the cancer genome has become a standard approach to identifying new disease loci, and ultimately will guide therapeutic decisions. A key technology in this effort, single nucleotide polymorphism arrays, has been applied in hematologic malignancies to detect deletions, amplifications, and loss of heterozygosity (LOH) at high resolution. An inherent challenge of such studies lies in correctly distinguishing somatically acquired, cancer-specific lesions from patient-specific inherited copy number variations or segments of homozygosity. Failure to include appropriate normal DNA reference samples for each patient in retrospective or prospective studies makes it difficult to identify small somatic deletions not evident by standard cytogenetic analysis. In addition, the lack of proper controls can also lead to vastly overestimated frequencies of LOH without accompanying loss of DNA copies, so-called copy-neutral LOH. Here we use examples from patients with myeloid malignancies to demonstrate the superiority of matched tumor and normal DNA samples (paired studies) over multiple unpaired samples with respect to reducing false discovery rates in high-resolution single nucleotide polymorphism array analysis. Comparisons between matched tumor and normal samples will continue to be critical as the field moves from high resolution array analysis to deep sequencing to detect abnormalities in the cancer genome. (Blood. 2010; 115(21): 4157-4161)
C1 [Heinrichs, Stefan; Look, A. Thomas] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Li, Cheng] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
RP Look, AT (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Mayer Bldg,Rm 630,44 Binney St, Boston, MA 02115 USA.
EM thomas_look@dfci.harvard.edu
FU National Institutes of Health [CA-108631]
FX The authors thank John Gilbert for editorial review and Donna S. Neuberg
and David P. Steensma for helpful discussions.; This work was supported
in part by the National Institutes of Health (P01 grant CA-108631).
NR 25
TC 51
Z9 55
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 27
PY 2010
VL 115
IS 21
BP 4157
EP 4161
DI 10.1182/blood-2009-11-203182
PG 5
WC Hematology
SC Hematology
GA 602DE
UT WOS:000278117900005
PM 20304806
ER
PT J
AU Weisberg, E
Choi, HG
Ray, A
Barrett, R
Zhang, JM
Sim, T
Zhou, WJ
Seeliger, M
Cameron, M
Azam, M
Fletcher, JA
Debiec-Rychter, M
Mayeda, M
Moreno, D
Kung, AL
Janne, PA
Khosravi-Far, R
Melo, JV
Manley, PW
Adamia, S
Wu, C
Gray, N
Griffin, JD
AF Weisberg, Ellen
Choi, Hwan Geun
Ray, Arghya
Barrett, Rosemary
Zhang, Jianming
Sim, Taebo
Zhou, Wenjun
Seeliger, Markus
Cameron, Michael
Azam, Mohammed
Fletcher, Jonathan A.
Debiec-Rychter, Maria
Mayeda, Mark
Moreno, Daisy
Kung, Andrew L.
Janne, Pasi Antero
Khosravi-Far, Roya
Melo, Junia V.
Manley, Paul W.
Adamia, Sophia
Wu, Catherine
Gray, Nathanael
Griffin, James D.
TI Discovery of a small-molecule type II inhibitor of wild-type and
gatekeeper mutants of BCR-ABL, PDGFR alpha, Kit, and Src kinases: novel
type II inhibitor of gatekeeper mutants
SO BLOOD
LA English
DT Article
ID GASTROINTESTINAL STROMAL TUMOR; MYELOID BLAST CRISIS; TYROSINE KINASE;
IMATINIB MESYLATE; IN-VITRO; MYELOPROLIFERATIVE DISEASE; SELECTIVE
INHIBITOR; LEUKEMIA-CELLS; T315I MUTANT; C-SRC
AB Many clinically validated kinases, such as BCR-ABL, c-Kit, PDGFR, and EGFR, become resistant to adenosine triphosphate-competitive inhibitors through mutation of the so-called gatekeeper amino acid from a threonine to a large hydrophobic amino acid, such as an isoleucine or methionine. We have developed a new class of adenosine triphosphate competitive inhibitors, exemplified by HG-7-85-01, which is capable of inhibiting T315I-BCR-ABL (clinically observed in chronic myeloid leukemia), T670I-c-Kit (clinically observed in gastrointestinal stromal tumors), and T674I/M-PDGFR alpha (clinically observed in hypereosinophilic syndrome). HG-7-85-01 is unique among all currently reported kinase inhibitors in having the ability to accommodate either a gatekeeper threonine, present in the wild-type forms of these kinases, or a large hydrophobic amino acid without becoming a promiscuous kinase inhibitor. The distinctive ability of HG-7-85-01 to simultaneously inhibit both wild-type and mutant forms of several kinases of clinical relevance is an important step in the development of the next generation of tyrosine kinase inhibitors. (Blood. 2010; 115(21): 4206-4216)
C1 [Weisberg, Ellen; Ray, Arghya; Barrett, Rosemary; Janne, Pasi Antero; Adamia, Sophia; Wu, Catherine; Griffin, James D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Choi, Hwan Geun; Zhang, Jianming; Sim, Taebo; Zhou, Wenjun; Gray, Nathanael] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA USA.
[Seeliger, Markus] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
[Seeliger, Markus] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
[Seeliger, Markus] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.
[Cameron, Michael] Scripps Florida, Translat Res Inst, Jupiter, FL USA.
[Azam, Mohammed] Cincinnati Childrens Hosp & Med Ctr, Div Pathol & Expt Hematol & Canc Pathol, Cincinnati, OH USA.
[Fletcher, Jonathan A.; Mayeda, Mark] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Debiec-Rychter, Maria] Univ Louvain, Dept Human Genet, Louvain, Belgium.
[Moreno, Daisy] Dana Farber Canc Inst, Anim Resources Facil, Boston, MA 02115 USA.
[Kung, Andrew L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Kung, Andrew L.] Childrens Hosp, Boston, MA 02115 USA.
[Khosravi-Far, Roya] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA.
[Melo, Junia V.] Inst Med & Vet Sci, Dept Haematol, Adelaide, SA 5000, Australia.
[Manley, Paul W.] Novartis Pharma AG, Basel, Switzerland.
RP Weisberg, E (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM Ellen_Weisberg@dfci.harvard.edu; Nathanael_Gray@dfci.harvard.edu
RI Seeliger, Markus/D-6409-2013
FU National Institutes of Health [5K99GM080097, CA66996, CA36167, DK50654,
R01 CA130876-01A1]; Office of Science, Office of Basic Energy Sciences,
US Department of Energy [DE-AC02-05CH11231]; Leukemia & Lymphoma Society
FX The authors thank George Q. Daley for his development and provision of
PDGFR mutant-expressing cells, Jonathan Fletcher and George Demetri for
their kind development and provision of KIT mutant-expressing cell lines
used for our studies, Jinyan Du for development and provision of the
T670I-KIT plasmid and the T681I-PDGFR beta plasmid, Tina Davis for her
help with in vivo analysis, and Jayasree Sundaram for technical
assistance.; M. S. was supported by the National Institutes of Health
(5K99GM080097). The Advanced Light Source is supported by the Director,
Office of Science, Office of Basic Energy Sciences, US Department of
Energy (contract DE-AC02-05CH11231). J.D.G is supported by the National
Institutes of Health (grants CA66996, CA36167, and DK50654) and the
Leukemia & Lymphoma Society (Specialized Center of Research Award).
N.S.G. is supported by the National Institutes of Health (grant R01
CA130876-01A1).
NR 43
TC 40
Z9 40
U1 0
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 27
PY 2010
VL 115
IS 21
BP 4206
EP 4216
DI 10.1182/blood-2009-11-251751
PG 11
WC Hematology
SC Hematology
GA 602DE
UT WOS:000278117900012
PM 20299508
ER
PT J
AU Higgins, JM
Sloan, SR
AF Higgins, John M.
Sloan, Steven R.
TI Other factors may contribute to differences between sickle cell and
non-sickle cell patients Response
SO BLOOD
LA English
DT Letter
C1 [Higgins, John M.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Higgins, John M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Higgins, John M.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
[Sloan, Steven R.] Childrens Hosp Boston, Blood Bank, Joint Program Transfus Med, Boston, MA 02115 USA.
[Sloan, Steven R.] Childrens Hosp Boston, Dept Lab Med, Boston, MA 02115 USA.
[Sloan, Steven R.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Sloan, SR (reprint author), Childrens Hosp Boston, Blood Bank, Joint Program Transfus Med, Baden 406,300 Longwood Ave, Boston, MA 02115 USA.
EM steven.sloan@childrens.harvard.edu
NR 1
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 27
PY 2010
VL 115
IS 21
BP 4315
EP 4316
PG 3
WC Hematology
SC Hematology
GA 602DE
UT WOS:000278117900026
ER
PT J
AU Frei, CR
Mortensen, EM
Copeland, LA
Attridge, RT
Pugh, MJV
Restrepo, MI
Anzueto, A
Nakashima, B
Fine, MJ
AF Frei, Christopher R.
Mortensen, Eric M.
Copeland, Laurel A.
Attridge, Russell T.
Pugh, Mary Jo V.
Restrepo, Marcos I.
Anzueto, Antonio
Nakashima, Brandy
Fine, Michael J.
TI Disparities of Care for African-Americans and Caucasians with
Community-Acquired Pneumonia: A Retrospective Cohort Study
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
ID OF-VETERANS-AFFAIRS; EMPIRIC ANTIBIOTIC-THERAPY; UNITED-STATES;
ANTIMICROBIAL THERAPY; ADMINISTRATIVE DATA; RACIAL-DIFFERENCES;
ELDERLY-PATIENTS; HOSPITAL MORTALITY; PULMONARY-DISEASE; IMPACT
AB Background: African-Americans admitted to U.S. hospitals with community-acquired pneumonia (CAP) are more likely than Caucasians to experience prolonged hospital length of stay (LOS), possibly due to either differential treatment decisions or patient characteristics.
Methods: We assessed associations between race and outcomes (Intensive Care Unit [ICU] variables, LOS, 30-day mortality) for African-American or Caucasian patients over 65 years hospitalized in the Veterans Health Administration (VHA) with CAP (2002-2007). Patients admitted to the ICU were analyzed separately from those not admitted to the ICU. VHA patients who died within 30 days of discharge were excluded from all LOS analyses. We used chi-square and Fisher's exact statistics to compare dichotomous variables, the Wilcoxon Rank Sum test to compare age by race, and Cox Proportional Hazards Regression to analyze hospital LOS. We used separate generalized linear mixed-effect models, with admitting hospital as a random effect, to examine associations between patient race and the receipt of guideline-concordant antibiotics, ICU admission, use of mechanical ventilation, use of vasopressors, LOS, and 30-day mortality. We defined statistical significance as a two-tailed p <= 0.0001.
Results: Of 40,878 patients, African-Americans (n = 4,936) were less likely to be married and more likely to have a substance use disorder, neoplastic disease, renal disease, or diabetes compared to Caucasians. African-Americans and Caucasians were equally likely to receive guideline-concordant antibiotics (92% versus 93%, adjusted OR = 0.99; 95% CI = 0.81 to 1.20) and experienced similar 30-day mortality when treated in medical wards (adjusted OR = 0.98; 95% CI = 0.87 to 1.10). African-Americans had a shorter adjusted hospital LOS (adjusted HR = 0.95; 95% CI = 0.92 to 0.98). When admitted to the ICU, African Americans were as likely as Caucasians to receive guideline-concordant antibiotics (76% versus 78%, adjusted OR = 0.99; 95% CI = 0.81 to 1.20), but experienced lower 30-day mortality (adjusted OR = 0.82; 95% CI = 0.68 to 0.99) and shorter hospital LOS (adjusted HR = 0.84; 95% CI = 0.76 to 0.93).
Conclusions: Elderly African-American CAP patients experienced a survival advantage (i.e., lower 30-day mortality) in the ICU compared to Caucasians and shorter hospital LOS in both medical wards and ICUs, after adjusting for numerous baseline differences in patient characteristics. There were no racial differences in receipt of guideline-concordant antibiotic therapies.
C1 [Frei, Christopher R.; Mortensen, Eric M.; Copeland, Laurel A.; Attridge, Russell T.; Pugh, Mary Jo V.; Restrepo, Marcos I.; Anzueto, Antonio; Nakashima, Brandy] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Frei, Christopher R.; Attridge, Russell T.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.
[Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary Jo V.; Restrepo, Marcos I.; Anzueto, Antonio; Nakashima, Brandy] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA.
[Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary Jo V.; Restrepo, Marcos I.; Nakashima, Brandy] S Texas Vet Hlth Care Syst, VERDICT Res Program, San Antonio, TX 78229 USA.
[Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
RP Mortensen, EM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM mortensene@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014;
OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563;
Copeland, Laurel/0000-0002-9478-0209
FU National Institute of Nursing Research [R01NR010828]
FX The authors would like to thank Christine Oramasionwu and Warunee
Srisupha-Olarn for their editorial review of this manuscript. The
project described herein was supported by Grant Number R01NR010828 from
the National Institute of Nursing Research. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institute of Nursing Research or the
National Institutes of Health. This material is the result of work
supported with resources and the use of facilities at the South Texas
Veterans Health Care System and The University of Texas at Austin. Dr.
Frei is supported by a Loan Repayment award from the National Institute
of Allergy and Infectious Diseases of the National Institutes of Health,
salary support from The University of Texas at Austin College of
Pharmacy, and research support from AstraZeneca, Elan, and Ortho-McNeil
Janssen. Dr Copeland is funded by Merit Review Entry Program grant
MRP-05-145 from the VA Health Services Research and Development program.
Dr. Restrepo is supported by a National Institutes of Health Grant KL2
RR025766, salary support by the South Texas Veterans Health Care System
Audie L. Murphy Division and The University of Texas Health Science
Center at San Antonio. The funding agencies had no role in conducting
the study, or role in the preparation, review, or approval of the
manuscript. The views expressed in this article are those of the authors
and do not necessarily represent the views of the Department of Veterans
Affairs. This manuscript was presented, in part, at the American
Thoracic Society International Conference, May 15-20, 2009, San Diego,
CA.
NR 60
TC 10
Z9 10
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD MAY 27
PY 2010
VL 10
AR 143
DI 10.1186/1472-6963-10-143
PG 11
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 625FB
UT WOS:000279878900005
PM 20507628
ER
PT J
AU Huang, YY
Mroz, P
Zhiyentayev, T
Sharma, SK
Balasubramanian, T
Ruzie, C
Krayer, M
Fan, DZ
Borbas, KE
Yang, EY
Kee, HL
Kirmaier, C
Diers, JR
Bocian, DF
Holten, D
Lindsey, JS
Hamblin, MR
AF Huang, Ying-Ying
Mroz, Pawel
Zhiyentayev, Timur
Sharma, Sulbha K.
Balasubramanian, Thiagarajan
Ruzie, Christian
Krayer, Michael
Fan, Dazhong
Borbas, K. Eszter
Yang, Eunkyung
Kee, Hooi Ling
Kirmaier, Christine
Diers, James R.
Bocian, David F.
Holten, Dewey
Lindsey, Jonathan S.
Hamblin, Michael R.
TI In Vitro Photodynamic Therapy and Quantitative Structure-Activity
Relationship Studies with Stable Synthetic Near-Infrared-Absorbing
Bacteriochlorin Photosensitizers
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID SUBCELLULAR-LOCALIZATION; ELECTRONIC-STRUCTURE; CELL-DEATH; MTT ASSAYS;
SUBSTITUENTS; DERIVATIVES; PORPHYRINS; MOLECULES; EFFICACY; CANCER
AB Photodynamic therapy (PDT) is a rapidly developing approach to treating cancer that combines harmless visible and near-infrared light with a nontoxic photoactivatable dye, which upon encounter with molecular oxygen generates the reactive oxygen species that are toxic to cancer cells. Bacteriochlorins are tetrapyrrole compounds with two reduced pyrrole rings in the macrocycle. These molecules are characterized by strong absorption features from 700 to > 800 nm, which enable deep penetration into tissue. This report describes testing of 12 new stable synthetic bacteriochlorins for PDT activity. The 12 compounds possess a variety of peripheral substituents and are very potent in killing cancer cells in vitro after illumination. Quantitative structure-activity relationships were derived, and subcellular localization was determined. The most active compounds have both low dark toxicity and high phototoxicity. This combination together with near-infrared absorption gives these bacteriochlorins great potential as photosensitizers for treatment of cancer.
C1 [Huang, Ying-Ying; Mroz, Pawel; Zhiyentayev, Timur; Sharma, Sulbha K.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Huang, Ying-Ying; Mroz, Pawel; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China.
[Zhiyentayev, Timur] MIT, Dept Chem, Cambridge, MA 02139 USA.
[Balasubramanian, Thiagarajan] NIRvana Pharmaceut Inc, Raleigh, NC USA.
[Ruzie, Christian; Krayer, Michael; Fan, Dazhong; Borbas, K. Eszter; Lindsey, Jonathan S.] N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA.
[Yang, Eunkyung; Kee, Hooi Ling; Kirmaier, Christine; Holten, Dewey] Washington Univ, Dept Chem, St Louis, MO 63130 USA.
[Diers, James R.; Bocian, David F.] Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St,BA R414, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
RI Lindsey, Jonathan/J-7761-2012; Huang, Ying-ying/G-3153-2011;
OI Huang, Ying-ying/0000-0003-3066-6981; Hamblin,
Michael/0000-0001-6431-4605
FU NIH [GM 36238, AI050875]; Burroughs-Wellcome; Jimmy V. NCSU Cancer
Therapeutics; National Institute of Allergy and Infectious Diseases
[R41AI072854]; Genzyme-Partners Translational Research Grant; Division
of Chemical Sciences, Geosciences and Biosciences Division, Office of
Basic Energy Sciences of the U.S. Department of Energy
[DE-FG02-05ER15660, DE-FG02-05ER15661]
FX This work was supported by the NIH (Grant GM 36238 to J.S.L. and Grant
AI050875 to M.R.H.), by a Burroughs-Wellcome fellowship (to M.K.), and
by the Jimmy V. NCSU Cancer Therapeutics Training Program. Y.-Y.H. and
T.B. were supported by Grant R41AI072854 from the National Institute of
Allergy and Infectious Diseases to NIRvana Pharmaceuticals, Inc. P.M.
was partially supported by Genzyme-Partners Translational Research
Grant. Characterization of the photophysical and redox properties of the
bacteriochlorins described herein were initially motivated by
solar-energy studies and supported by grants from the Division of
Chemical Sciences, Geosciences and Biosciences Division, Office of Basic
Energy Sciences of the U.S. Department of Energy to D.F.B. (Grant
DE-FG02-05ER15660) and D.H. (Grant DE-FG02-05ER15661).
NR 39
TC 59
Z9 60
U1 1
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 27
PY 2010
VL 53
IS 10
BP 4018
EP 4027
DI 10.1021/jm901908s
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 597OF
UT WOS:000277766900015
PM 20441223
ER
PT J
AU Baba, Y
Huttenhower, C
Nosho, K
Tanaka, N
Shima, K
Hazra, A
Schernhammer, ES
Hunter, DJ
Giovannucci, EL
Fuchs, CS
Ogino, S
AF Baba, Yoshifumi
Huttenhower, Curtis
Nosho, Katsuhiko
Tanaka, Noriko
Shima, Kaori
Hazra, Aditi
Schernhammer, Eva S.
Hunter, David J.
Giovannucci, Edward L.
Fuchs, Charles S.
Ogino, Shuji
TI Epigenomic diversity of colorectal cancer indicated by LINE-1
methylation in a database of 869 tumors
SO MOLECULAR CANCER
LA English
DT Article
ID POPULATION-BASED SAMPLE; NORMAL COLONIC-MUCOSA; MICROSATELLITE
INSTABILITY; DNA METHYLATION; PHENOTYPE CIMP; CHROMOSOMAL INSTABILITY;
EPIGENETIC INSTABILITY; L1 RETROTRANSPOSON; PIK3CA MUTATION;
HYPOMETHYLATION
AB Background: Genome-wide DNA hypomethylation plays a role in genomic instability and carcinogenesis. LINE-1 (L1 retrotransposon) constitutes a substantial portion of the human genome, and LINE-1 methylation correlates with global DNA methylation status. LINE-1 hypomethylation in colon cancer has been strongly associated with poor prognosis. However, whether LINE-1 hypomethylators constitute a distinct cancer subtype remains uncertain. Recent evidence for concordant LINE-1 hypomethylation within synchronous colorectal cancer pairs suggests the presence of a non-stochastic mechanism influencing tumor LINE-1 methylation level. Thus, it is of particular interest to examine whether its wide variation can be attributed to clinical, pathologic or molecular features.
Design: Utilizing a database of 869 colorectal cancers in two prospective cohort studies, we constructed multivariate linear and logistic regression models for LINE-1 methylation (quantified by Pyrosequencing). Variables included age, sex, body mass index, family history of colorectal cancer, smoking status, tumor location, stage, grade, mucinous component, signet ring cells, tumor infiltrating lymphocytes, CpG island methylator phenotype (CIMP), microsatellite instability, expression of TP53 (p53), CDKN1A (p21), CTNNB1 (beta-catenin), PTGS2 (cyclooxygenase-2), and FASN, and mutations in KRAS, BRAF, and PIK3CA.
Results: Tumoral LINE-1 methylation ranged from 23.1 to 90.3 of 0-100 scale (mean 61.4; median 62.3; standard deviation 9.6), and distributed approximately normally except for extreme hypomethylators [LINE-1 methylation < 40; N = 22 (2.5%), which were far more than what could be expected by normal distribution]. LINE-1 extreme hypomethylators were significantly associated with younger patients (p = 0.0058). Residual plot by multivariate linear regression showed that LINE-1 extreme hypomethylators clustered as one distinct group, separate from the main tumor group. The multivariate linear regression model could explain 8.4% of the total variability of LINE-1 methylation (R-square = 0.084). Multivariate logistic regression models for binary LINE-1 hypomethylation outcomes (cutoffs of 40, 50 and 60) showed at most fair predictive ability (area under receiver operator characteristics curve < 0.63).
Conclusions: LINE-1 extreme hypomethylators appear to constitute a previously-unrecognized, distinct subtype of colorectal cancers, which needs to be confirmed by additional studies. Our tumor LINE-1 methylation data indicate enormous epigenomic diversity of individual colorectal cancers.
C1 [Baba, Yoshifumi; Nosho, Katsuhiko; Tanaka, Noriko; Shima, Kaori; Fuchs, Charles S.; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Baba, Yoshifumi; Nosho, Katsuhiko; Tanaka, Noriko; Shima, Kaori; Hazra, Aditi; Schernhammer, Eva S.; Hunter, David J.; Giovannucci, Edward L.; Fuchs, Charles S.; Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA USA.
[Huttenhower, Curtis; Tanaka, Noriko] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Hazra, Aditi; Schernhammer, Eva S.; Hunter, David J.; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Hazra, Aditi; Schernhammer, Eva S.; Hunter, David J.; Giovannucci, Edward L.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Schernhammer, Eva S.] Ludwig Boltzmann Inst Appl Canc Res, Vienna, Austria.
[Schernhammer, Eva S.] Appl Canc Res Inst Translat Res, Vienna, Austria.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Ogino, S (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM shuji_ogino@dfci.harvard.edu
OI Huttenhower, Curtis/0000-0002-1110-0096
FU U.S. National Institute of Health [P01 CA87969, P01 CA55075, P50
CA127003, K07 CA122826]; Bennett Family Fund for Targeted Therapies
Research; Entertainment Industry Foundation National Colorectal Cancer
Research Alliance; Japan Society for the Promotion of Science
FX This work was supported by U.S. National Institute of Health [P01
CA87969 (to S. Hankinson), P01 CA55075 (to W. Willett), P50 CA127003 (to
C.S.F.), K07 CA122826 (to S.O.)]; the Bennett Family Fund for Targeted
Therapies Research; and the Entertainment Industry Foundation National
Colorectal Cancer Research Alliance. K.N. was supported by a fellowship
grant from the Japan Society for the Promotion of Science. The content
is solely the responsibility of the authors and does not necessarily
represent the official views of NCI or NIH. Funding agencies did not
have any role in the design of the study; the collection, analysis, or
interpretation of the data; the decision to submit the manuscript for
publication; or the writing of the manuscript.
NR 69
TC 79
Z9 81
U1 1
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 27
PY 2010
VL 9
AR 125
DI 10.1186/1476-4598-9-125
PG 17
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 617KE
UT WOS:000279278800002
PM 20507599
ER
PT J
AU Medoff, BD
Abbott, GF
Louissaint, A
AF Medoff, Benjamin D.
Abbott, Gerald F.
Louissaint, Abner, Jr.
TI A Man with a Cough and Pain in the Left Shoulder Langerhans'-cell
histiocytosis of bone and lung.
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ERDHEIM-CHESTER-DISEASE; DENDRITIC CELLS; PULMONARY; LESIONS;
MANIFESTATIONS; CLASSIFICATION; MELIOIDOSIS; INVOLVEMENT; SARCOIDOSIS;
TUMORS
C1 [Medoff, Benjamin D.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
[Abbott, Gerald F.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Louissaint, Abner, Jr.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Medoff, Benjamin D.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Abbott, Gerald F.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Louissaint, Abner, Jr.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Medoff, BD (reprint author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
NR 36
TC 1
Z9 1
U1 1
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 27
PY 2010
VL 362
IS 21
BP 2013
EP 2022
DI 10.1056/NEJMcpc1002114
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 601JI
UT WOS:000278054000011
PM 20505181
ER
PT J
AU Sloss, CM
Wang, F
Palladino, MA
Cusack, JC
AF Sloss, C. M.
Wang, F.
Palladino, M. A.
Cusack, J. C., Jr.
TI Activation of EGFR by proteasome inhibition requires HB-EGF in
pancreatic cancer cells
SO ONCOGENE
LA English
DT Article
DE proteasome inhibition; NPI-0052; EGFR; HB-EGF; pancreatic cancer
ID EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; EXPRESSION; BORTEZOMIB;
RESISTANCE; P38; CHEMOTHERAPY; CONTRIBUTES; SENSITIVITY; ERLOTINIB
AB Resistance to drug treatments underlies the high lethality of pancreatic ductal adenocarcinoma. Along with others, we have recently identified that proteasome inhibition is a promising therapeutic option in this highly refractory disease. The pleiotropic effects of proteasome inhibition include the activation of apoptotic signaling pathways and also antiapoptotic signaling pathways such as EGFR, AKT and the MAP kinases that reduce the apoptotic potential of this class of drug. In this study, we sought to determine the mechanism behind the activation of EGFR in response to proteasome inhibition in pancreatic cancer cells. We found that the second-generation proteasome inhibitor NPI-0052 induced the mRNA transcription of several EGFR family ligands (EGF, HB-EGF and epiregulin), however only increases in HB-EGF were detected at the protein level. Using both pharmacological inhibitors and lentiviral-mediated shRNA knockdown of EGFR ligand expression, we discovered that ligand cleavage by MMP/ADAMs and HB-EGF expression is required for activation of EGFR in response to proteasome inhibition. Furthermore, we discover that induction of HB-EGF is dependent on reactive oxygen species and p38-MAPK signaling but not ERK and that the transcription factor SP-1 is involved in NPI-0052-induced HB-EGF transcription. Together, these results indicate that stress signaling leading to induction of HB-EGF expression and increases in MMP/ADAM-dependent HB-EGF cleavage are responsible for proteasome inhibitor-induced activation of EGFR in pancreatic cancer cells. Oncogene (2010) 29, 3146-3152; doi: 10.1038/onc.2010.52; published online 8 March 2010
C1 [Sloss, C. M.; Wang, F.; Cusack, J. C., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol,Dept Surg, Boston, MA 02114 USA.
[Palladino, M. A.] Nereus Pharmaceut, San Diego, CA USA.
RP Cusack, JC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol,Dept Surg, Yawkey Bldg 7th Floor,55 Fruit St, Boston, MA 02114 USA.
EM jcusack@partners.org
FU NIH [CA98871]
FX This study was supported by NIH Grant no. CA98871 (JC Cusack).
NR 30
TC 9
Z9 11
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAY 27
PY 2010
VL 29
IS 21
BP 3146
EP 3152
DI 10.1038/onc.2010.52
PG 7
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 602IQ
UT WOS:000278133100011
PM 20208558
ER
PT J
AU Porcheray, F
DeVito, J
Yeap, BY
Xue, LJ
Dargon, I
Paine, R
Girouard, TC
Saidman, SL
Colvin, RB
Wong, WC
Zorn, E
AF Porcheray, Fabrice
DeVito, Julie
Yeap, Beow Y.
Xue, Lijuan
Dargon, Ian
Paine, Rosemary
Girouard, Timothy C.
Saidman, Susan L.
Colvin, Robert B.
Wong, Waichi
Zorn, Emmanuel
TI Chronic Humoral Rejection of Human Kidney Allografts Associates With
Broad Autoantibody Responses
SO TRANSPLANTATION
LA English
DT Article
DE Chronic humoral rejection; Autoantibodies; Human
ID RENAL-TRANSPLANT RECIPIENTS; CORONARY-ARTERY DISEASE; ANTIPHOSPHOLIPID
ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; CARDIAC TRANSPLANTATION;
ORGAN-TRANSPLANTATION; ENDOTHELIAL-CELLS; TARGETS; SERA; CAPILLARIES
AB Background. Chronic humoral rejection (CHR) is a major complication after kidney transplantation. The cause of CHR is currently unknown. Autoantibodies have often been reported in kidney transplant recipients alongside anti-donor human leukocyte antigen antibodies. Yet, the lack of comprehensive studies has limited our understanding of this autoimmune component in the pathophysiology of CHR.
Methods. By using a series of ELISA and immunocytochemistry assays, we assessed the development of autoantibodies in 25 kidney transplant recipients with CHR and 25 patients with stable graft function. We also compared the reactivity of five CHR and five non-CHR patient sera with 8027 recombinant human proteins using protein microarrays.
Results. We observed that a majority of CHR patients, but not non-CHR control patients, had developed antibody responses to one or several autoantigens at the time of rejection. Protein microarray assays revealed a burst of autoimmunity at the time of CHR. Remarkably, microarray analysis showed minimal overlap between profiles, indicating that each CHR patient had developed autoantibodies to a unique set of antigenic targets.
Conclusion. The breadth of autoantibody responses, together with the absence of consensual targets, suggests that these antibody responses result from systemic B-cell deregulation.
C1 [Porcheray, Fabrice; DeVito, Julie; Xue, Lijuan; Dargon, Ian; Paine, Rosemary; Zorn, Emmanuel] Harvard Univ, Sch Med, Dept Surg, Transplantat Biol Res Ctr,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Yeap, Beow Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA USA.
[Xue, Lijuan] Jilin Univ, Hosp 1, Urol Dept 2, Changchun 130023, Jilin, Peoples R China.
[Girouard, Timothy C.; Saidman, Susan L.; Colvin, Robert B.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Wong, Waichi] Harvard Univ, Sch Med, Dept Med, Renal Unit,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Zorn, E (reprint author), MGH E, Transplantat Biol Res Ctr, Bldg 149-5102,13th St, Charlestown, MA 02129 USA.
EM emmanuel.zorn@tbrc.mgh.harvard.edu
RI porcheray, fabrice/B-9505-2012
FU Fahd and Nadia Alireza's Research Fund
FX This work was supported by the Fahd and Nadia Alireza's Research Fund.
NR 36
TC 32
Z9 34
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD MAY 27
PY 2010
VL 89
IS 10
BP 1239
EP 1246
DI 10.1097/TP.0b013e3181d72091
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 605HZ
UT WOS:000278339900010
PM 20445487
ER
PT J
AU Hamm, JP
Dyckman, KA
Ethridge, LE
McDowell, JE
Clementz, BA
AF Hamm, Jordan P.
Dyckman, Kara A.
Ethridge, Lauren E.
McDowell, Jennifer E.
Clementz, Brett A.
TI Preparatory Activations across a Distributed Cortical Network Determine
Production of Express Saccades in Humans
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID VISUALLY GUIDED SACCADES; FRONTAL EYE FIELD; SUPERIOR COLLICULUS;
REACTION-TIMES; ATTENTION; EEG; MONKEY; BRAIN; OSCILLATIONS; MOVEMENTS
AB Reaction time variability across trials to identical stimuli may arise from both ongoing and transient neural processes occurring before trial onset. These processes were examined with dense-array EEG as humans completed saccades in a "gap" paradigm known to elicit bimodal variability in response times, including separate populations of "express" and regular reaction time saccades. Results indicated that express reaction time trials could be differentiated from regular reaction time trials by (1) pretrial phase synchrony of occipital cortex oscillations in the 8-9 Hz (low alpha) frequency range (lower phase synchrony preceding express trials), (2) subsequent mid-and late-gap period cortical activities across a distributed occipital-parietal network (stronger activations preceding express trials), and (3) posttarget parietal activations locked to response generation (weaker preceding express trials). A post hoc path analysis suggested that the observed cortical activations leading to express saccades are best understood as an interdependent chain of events that affect express saccade production. These results highlight the importance of a distributed posterior cortical network, particularly in right hemisphere, that prepares the saccade system for rapid responding.
C1 [Hamm, Jordan P.; Ethridge, Lauren E.; McDowell, Jennifer E.; Clementz, Brett A.] Univ Georgia, Dept Psychol, Athens, GA 30602 USA.
[Hamm, Jordan P.; Ethridge, Lauren E.; McDowell, Jennifer E.; Clementz, Brett A.] Univ Georgia, Dept Neurosci, BioImaging Res Ctr, Athens, GA 30602 USA.
[Dyckman, Kara A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02129 USA.
RP Clementz, BA (reprint author), Univ Georgia, Dept Psychol, Psychol Bldg,Baldwin St, Athens, GA 30602 USA.
EM clementz@uga.edu
OI Hamm, Jordan/0000-0002-9868-6121; Ethridge, Lauren/0000-0003-0601-6911
FU National Institutes of Health [MH076998, MH082514]
FX This work was supported by National Institutes of Health Grants MH076998
and MH082514. We thank Noah Duncan and Emily Leonard Parks for their
help with data collection.
NR 58
TC 22
Z9 22
U1 0
U2 3
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 26
PY 2010
VL 30
IS 21
BP 7350
EP 7357
DI 10.1523/JNEUROSCI.0785-10.2010
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 601XZ
UT WOS:000278102600024
PM 20505102
ER
PT J
AU Brown, TI
Ross, RS
Keller, JB
Hasselmo, ME
Stern, CE
AF Brown, Thackery I.
Ross, Robert S.
Keller, Joseph B.
Hasselmo, Michael E.
Stern, Chantal E.
TI Which Way Was I Going? Contextual Retrieval Supports the Disambiguation
of Well Learned Overlapping Navigational Routes
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID MEDIAL TEMPORAL-LOBE; BILATERAL HIPPOCAMPAL-LESIONS; ORBITOFRONTAL
CORTEX; PREFRONTAL CORTICES; SPATIAL CONTEXT; EPISODIC MEMORY;
WORKING-MEMORY; SEQUENCES; PARAHIPPOCAMPAL; CONNECTIONS
AB Groundbreaking research in animals has demonstrated that the hippocampus contains neurons that distinguish between overlapping navigational trajectories. These hippocampal neurons respond selectively to the context of specific episodes despite interference from overlapping memory representations. The present study used functional magnetic resonance imaging in humans to examine the role of the hippocampus and related structures when participants need to retrieve contextual information to navigate well learned spatial sequences that share common elements. Participants were trained outside the scanner to navigate through 12 virtual mazes from a ground-level first-person perspective. Six of the 12 mazes shared overlapping components. Overlapping mazes began and ended at distinct locations, but converged in the middle to share some hallways with another maze. Non-overlapping mazes did not share any hallways with any other maze. Successful navigation through the overlapping hallways required the retrieval of contextual information relevant to the current navigational episode. Results revealed greater activation during the successful navigation of the overlapping mazes compared with the non-overlapping mazes in regions typically associated with spatial and episodic memory, including the hippocampus, parahippocampal cortex, and orbitofrontal cortex. When combined with previous research, the current findings suggest that an anatomically integrated system including the hippocampus, parahippocampal cortex, and orbitofrontal cortex is critical for the contextually dependent retrieval of well learned overlapping navigational routes.
C1 [Brown, Thackery I.; Ross, Robert S.; Hasselmo, Michael E.; Stern, Chantal E.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Brown, Thackery I.; Ross, Robert S.; Keller, Joseph B.; Hasselmo, Michael E.; Stern, Chantal E.] Boston Univ, Silvio O Conte Ctr Memory & Brain, Boston, MA 02215 USA.
[Brown, Thackery I.; Keller, Joseph B.; Hasselmo, Michael E.; Stern, Chantal E.] Boston Univ, Ctr Excellence Learning Educ Sci & Technol, Boston, MA 02215 USA.
[Brown, Thackery I.; Ross, Robert S.; Stern, Chantal E.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
RP Stern, CE (reprint author), Boston Univ, Ctr Memory & Brain, 2 Cummington St, Boston, MA 02215 USA.
EM chantal@bu.edu
OI Ross, Robert/0000-0002-3987-881X; Hasselmo, Michael/0000-0002-9925-6377
FU Silvio O. Conte Center National Institutes of Health [P50 MH071702];
Center of Excellence for Learning in Education, Science and Technology
National Science Foundation Science of Learning Center [NSF
SBE-0354378]; National Center for Research Resources [P41RR14075]
FX This work was supported by the Silvio O. Conte Center National
Institutes of Health Grant P50 MH071702; Center of Excellence for
Learning in Education, Science and Technology National Science
Foundation Science of Learning Center Grant NSF SBE-0354378; and
National Center for Research Resources Grant P41RR14075. Research was
conducted at the Cognitive Neuroimaging Laboratory, Center for Memory
and Brain, Boston University (Boston, MA), and the Athinoula A. Martinos
Center for Biomedical Imaging, Massachusetts General Hospital, Harvard
Medical School (Charlestown, MA). We thank R. Newmark for his technical
assistance during data collection.
NR 56
TC 57
Z9 57
U1 1
U2 10
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 26
PY 2010
VL 30
IS 21
BP 7414
EP 7422
DI 10.1523/JNEUROSCI.6021-09.2010
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 601XZ
UT WOS:000278102600030
PM 20505108
ER
PT J
AU Kim, BW
Kennedy, DN
Lehar, J
Lee, MJ
Blood, AJ
Lee, S
Perlis, RH
Smoller, JW
Morris, R
Fava, M
Breiter, HC
AF Kim, Byoung Woo
Kennedy, David N.
Lehar, Joseph
Lee, Myung Joo
Blood, Anne J.
Lee, Sang
Perlis, Roy H.
Smoller, Jordan W.
Morris, Robert
Fava, Maurizio
Breiter, Hans C.
CA Phenotype Genotype Project Addicti
TI Recurrent, Robust and Scalable Patterns Underlie Human Approach and
Avoidance
SO PLOS ONE
LA English
DT Article
ID OPPONENT-PROCESS THEORY; MEDIAL FRONTAL-CORTEX; DECISION-MAKING;
PROSPECT-THEORY; NEURAL SYSTEMS; REWARD VALUE; INFORMATION-THEORY;
EXPECTED VALUE; POWER FUNCTION; HUMAN BRAIN
AB Background: Approach and avoidance behavior provide a means for assessing the rewarding or aversive value of stimuli, and can be quantified by a keypress procedure whereby subjects work to increase (approach), decrease (avoid), or do nothing about time of exposure to a rewarding/aversive stimulus. To investigate whether approach/avoidance behavior might be governed by quantitative principles that meet engineering criteria for lawfulness and that encode known features of reward/aversion function, we evaluated whether keypress responses toward pictures with potential motivational value produced any regular patterns, such as a trade-off between approach and avoidance, or recurrent lawful patterns as observed with prospect theory.
Methodology/Principal Findings: Three sets of experiments employed this task with beautiful face images, a standardized set of affective photographs, and pictures of food during controlled states of hunger and satiety. An iterative modeling approach to data identified multiple law-like patterns, based on variables grounded in the individual. These patterns were consistent across stimulus types, robust to noise, describable by a simple power law, and scalable between individuals and groups. Patterns included: (i) a preference trade-off counterbalancing approach and avoidance, (ii) a value function linking preference intensity to uncertainty about preference, and (iii) a saturation function linking preference intensity to its standard deviation, thereby setting limits to both.
Conclusions/Significance: These law-like patterns were compatible with critical features of prospect theory, the matching law, and alliesthesia. Furthermore, they appeared consistent with both mean-variance and expected utility approaches to the assessment of risk. Ordering of responses across categories of stimuli demonstrated three properties thought to be relevant for preference-based choice, suggesting these patterns might be grouped together as a relative preference theory. Since variables in these patterns have been associated with reward circuitry structure and function, they may provide a method for quantitative phenotyping of normative and pathological function (e.g., psychiatric illness).
C1 [Kim, Byoung Woo; Lee, Myung Joo; Blood, Anne J.; Lee, Sang; Morris, Robert; Breiter, Hans C.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, MENC, Boston, MA 02114 USA.
[Kim, Byoung Woo; Kennedy, David N.; Lee, Myung Joo; Blood, Anne J.; Lee, Sang; Perlis, Roy H.; Smoller, Jordan W.; Morris, Robert; Fava, Maurizio; Breiter, Hans C.] Harvard Univ, Sch Med, Boston, MA USA.
[Kim, Byoung Woo; Lee, Myung Joo; Blood, Anne J.; Lee, Sang; Breiter, Hans C.] Massachusetts Gen Hosp, Dept Psychiat, Lab Neuroimaging & Genet, Boston, MA 02114 USA.
[Kennedy, David N.] Massachusetts Gen Hosp, Dept Neurol, Ctr Morphometr Anal, Boston, MA 02114 USA.
[Lehar, Joseph] Boston Univ, Dept Bioinformat, Boston, MA 02215 USA.
[Blood, Anne J.; Breiter, Hans C.] Massachusetts Gen Hosp, Dept Psychiat, Mood & Motor Control Lab, Boston, MA 02114 USA.
[Perlis, Roy H.; Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin, Boston, MA 02114 USA.
[Perlis, Roy H.; Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Res Program, Boston, MA 02114 USA.
[Perlis, Roy H.; Smoller, Jordan W.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
RP Kim, BW (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, MENC, Boston, MA 02114 USA.
EM hbreiter@partners.org
RI Kennedy, David/H-3627-2012;
OI Lauwereyns, Jan/0000-0003-0551-2550
FU National Institute on Drug Abuse [14118, 026002, 026104]; Office of
National Drug Control Policy - Counterdrug Technology Assessment Center,
Washington, D.C.; MGH Department of Radiology; National Center for
Research Resources [P41RR14075]; National Institute of Neurological
Disorders and Stroke [34189, 052368]; [DABK39-03-0098];
[DABK39-03-C-0098]
FX This work was supported by grants to HCB (#14118, 026002, 026104) from
the National Institute on Drug Abuse, and grants (DABK39-03-0098 &
DABK39-03-C-0098; The MGH Phenotype Genotype Project in Addiction and
Mood Disorder) from the Office of National Drug Control Policy -
Counterdrug Technology Assessment Center, Washington, D.C. Further
support, in part, was provided to HCB by the MGH Department of
Radiology, and the National Center for Research Resources (P41RR14075).
Other support was provided to DNK by the National Institute of
Neurological Disorders and Stroke (#34189), and to SJB by the National
Institute of Neurological Disorders and Stroke (#052368). The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 151
TC 7
Z9 7
U1 2
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 26
PY 2010
VL 5
IS 5
AR e10613
DI 10.1371/journal.pone.0010613
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 603PW
UT WOS:000278221500002
PM 20532247
ER
PT J
AU Lewis, GD
Farrell, L
Wood, MJ
Martinovic, M
Arany, Z
Rowe, GC
Souza, A
Cheng, S
McCabe, EL
Yang, E
Shi, X
Deo, R
Roth, FP
Asnani, A
Rhee, EP
Systrom, DM
Semigran, MJ
Vasan, RS
Carr, SA
Wang, TJ
Sabatine, MS
Clish, CB
Gerszten, RE
AF Lewis, Gregory D.
Farrell, Laurie
Wood, Malissa J.
Martinovic, Maryann
Arany, Zoltan
Rowe, Glenn C.
Souza, Amanda
Cheng, Susan
McCabe, Elizabeth L.
Yang, Elaine
Shi, Xu
Deo, Rahul
Roth, Frederick P.
Asnani, Aarti
Rhee, Eugene P.
Systrom, David M.
Semigran, Marc J.
Vasan, Ramachandran S.
Carr, Steven A.
Wang, Thomas J.
Sabatine, Marc S.
Clish, Clary B.
Gerszten, Robert E.
TI Metabolic Signatures of Exercise in Human Plasma
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID STRENUOUS PHYSICAL-EXERCISE; ISCHEMIC-HEART-DISEASE; RAT
SKELETAL-MUSCLE; CARDIOVASCULAR-DISEASE; ADIPOSE-TISSUE; RESISTANCE
EXERCISE; VITAMIN-E; ACID; MORTALITY; LIPOLYSIS
AB Exercise provides numerous salutary effects, but our understanding of how these occur is limited. To gain a clearer picture of exercise-induced metabolic responses, we have developed comprehensive plasma metabolite signatures by using mass spectrometry to measure >200 metabolites before and after exercise. We identified plasma indicators of glycogenolysis (glucose-6-phosphate), tricarboxylic acid cycle span 2 expansion (succinate, malate, and fumarate), and lipolysis (glycerol), as well as modulators of insulin sensitivity (niacinamide) and fatty acid oxidation (pantothenic acid). Metabolites that were highly correlated with fitness parameters were found in subjects undergoing acute exercise testing and marathon running and in 302 subjects from a longitudinal cohort study. Exercise-induced increases in glycerol were strongly related to fitness levels in normal individuals and were attenuated in subjects with myocardial ischemia. A combination of metabolites that increased in plasma in response to exercise (glycerol, niacinamide, glucose-6-phosphate, pantothenate, and succinate) up-regulated the expression of nur77, a transcriptional regulator of glucose utilization and lipid metabolism genes in skeletal muscle in vitro. Plasma metabolic profiles obtained during exercise provide signatures of exercise performance and cardiovascular disease susceptibility, in addition to highlighting molecular pathways that may modulate the salutary effects of exercise.
C1 [Lewis, Gregory D.; Farrell, Laurie; Wood, Malissa J.; Martinovic, Maryann; Cheng, Susan; Deo, Rahul; Asnani, Aarti; Semigran, Marc J.; Wang, Thomas J.; Gerszten, Robert E.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Lewis, Gregory D.; Farrell, Laurie; Wood, Malissa J.; Martinovic, Maryann; Cheng, Susan; Deo, Rahul; Asnani, Aarti; Semigran, Marc J.; Wang, Thomas J.; Gerszten, Robert E.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Lewis, Gregory D.; Asnani, Aarti; Gerszten, Robert E.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
[Lewis, Gregory D.; Sabatine, Marc S.; Gerszten, Robert E.] Harvard Univ, Sch Med, Donald W Reynolds Cardiovasc Clin Res Ctr Atheros, Boston, MA 02115 USA.
[Lewis, Gregory D.; Souza, Amanda; Yang, Elaine; Shi, Xu; Rhee, Eugene P.; Carr, Steven A.; Clish, Clary B.; Gerszten, Robert E.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Arany, Zoltan; Rowe, Glenn C.] Beth Israel Deaconess Med Ctr, Cardiovasc Inst, Boston, MA 02215 USA.
[Arany, Zoltan; Rowe, Glenn C.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Cheng, Susan; McCabe, Elizabeth L.; Vasan, Ramachandran S.; Wang, Thomas J.] Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA.
[Cheng, Susan; Sabatine, Marc S.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
[Deo, Rahul; Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Rhee, Eugene P.] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
[Systrom, David M.] Massachusetts Gen Hosp, Div Pulm & Crit Care, Boston, MA 02114 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Epidemiol Sect, Boston, MA 02118 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Sect Prevent Med, Boston, MA 02118 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA.
RP Lewis, GD (reprint author), Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
EM glewis@partners.org; rgerszten@partners.org
RI Roth, Frederick/H-6308-2011;
OI Systrom, David/0000-0002-9610-6330; Ramachandran,
Vasan/0000-0001-7357-5970; Roth, Frederick/0000-0002-6628-649X; Rowe,
Glenn/0000-0002-8195-9605
FU NIH [K23HL091106, R01 HL072872, U01HL083141, R01DK081572]; Donald W.
Reynolds Foundation; Fondation Leducq; American Heart Association
Fellow-to-Faculty Award; Established Investigator Award; National Heart,
Lung and Blood Institute [N01-HC-25195]; Sarnoff Cardiovascular Research
Foundation; NIH-National Human Genome Research Institute [HG003224,
HG0017115, NS054052, HG004233]; Keck Foundation
FX Funding: NIH grants K23HL091106 (G. D. L.), R01 HL072872 (R. E. G. and
M. S. S.), U01HL083141 (R. E. G., M. S. S., and F. P. R.), and
R01DK081572 (R. E. G.); Donald W. Reynolds Foundation (R. E. G. and M.
S. S.); Fondation Leducq (R. E. G.); American Heart Association
Fellow-to-Faculty Award (G. D. L.); and Established Investigator Award
(R. E. G.). This work was also supported by the National Heart, Lung and
Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195). A.
A. was supported by a predoctoral award from the Sarnoff Cardiovascular
Research Foundation. F. P. R. was also supported in part by NIH-National
Human Genome Research Institute grants HG003224, HG0017115, NS054052,
and HG004233 and by the Keck Foundation.
NR 62
TC 97
Z9 101
U1 4
U2 40
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 26
PY 2010
VL 2
IS 33
AR 33ra37
DI 10.1126/scitranslmed.3001006
PG 13
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 601SV
UT WOS:000278085300003
PM 20505214
ER
PT J
AU Rasmussen, RA
Lakhashe, SK
Ruprecht, RM
AF Rasmussen, Robert A.
Lakhashe, Samir K.
Ruprecht, Ruth M.
TI Bimodal AIDS vaccine approach: Induction of cellular as well as humoral
immunity can protect from systemic infection
SO VACCINE
LA English
DT Article
DE HIV clade C; Vaccine; R5 SHIV; Animal model; Protein immunization;
Multimeric gp160
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CLADE-C ENV; NEUTRALIZING ANTIBODIES;
HIV-1 INFECTION; CORE ANTIGENS; ENVELOPE; MACAQUES; TYPE-1;
IMMUNOGENICITY; IMMUNIZATION
AB HIV clade C ( HIV-C) strains comprise similar to 56% of all HIV infections worldwide, and AIDS vaccines intended for global use must protect against this subtype. Our vaccine strategy has been to induce balanced antiviral immunity consisting of both neutralizing antibody and cell-mediated immune responses, an approach we tested in primates. As reported earlier, after isolating recently transmitted HIV-C strains from Zambian infants, we used env from one such virus. HIV1084i. to generate a multimeric gp160 immunogen. From another virus, isolated from a different child of the same mother-infant cohort, we cloned env to generate a recombinant simian-human immunodeficiency virus (SHIV), which was adapted to rhesus monkeys to yield SHIV-1157ip. Infant macaques were immunized with recombinant viral proteins, including multimeric HIV-C Env 1084i. To test whether cross-protection could be achieved, we mismatched HIV-C Env immunogens and challenge virus cite. All vaccinated and control monkeys were exposed orally to low-dose SHIV-1157ip. Animals with no or only transient infection were rechallenged intrarectally with a high dose of R5 SHIV-1157ipd3N4, a "late", animal-evolved variant of SHIV-1157ip. Compared to controls, the vaccinees had significantly lower peak viral RNA loads, and one vaccinee remained completely virus-free, even in lymphoid tissues. Data from our novel heterologous mucosal challenge model and our protein-only immunogens imply that significant protection against heterologous viruses circulating in the local community may be achievable with a strategy that seeks to simultaneously induce cellular immunity as well as neutralizing antibody responses. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Rasmussen, Robert A.; Lakhashe, Samir K.; Ruprecht, Ruth M.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Rasmussen, Robert A.; Lakhashe, Samir K.; Ruprecht, Ruth M.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Ruprecht, RM (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.
EM ruth_ruprecht@dfci.harvard.edu
RI Lakhashe, Samir/F-1150-2014
FU NCRR NIH HHS [RR-00165, P51 RR000165]; NIAID NIH HHS [P01 AI048240, P01
AI48240]
NR 28
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAY 26
PY 2010
VL 28
SU 2
BP B25
EP B31
DI 10.1016/j.vaccine.2009.10.131
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 613ZI
UT WOS:000279023600006
PM 20510739
ER
PT J
AU Kveiborg, B
Hermann, TS
Major-Pedersen, A
Christiansen, B
Rask-Madsen, C
Raunso, J
Kober, L
Torp-Pedersen, C
Dominguez, H
AF Kveiborg, Britt
Hermann, Thomas S.
Major-Pedersen, Atheline
Christiansen, Buris
Rask-Madsen, Christian
Raunso, Jakob
Kober, Lars
Torp-Pedersen, Christian
Dominguez, Helena
TI Metoprolol compared to carvedilol deteriorates insulin-stimulated
endothelial function in patients with type 2 diabetes - a randomized
study
SO CARDIOVASCULAR DIABETOLOGY
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; CHRONIC HEART-FAILURE; EUROPEAN TRIAL COMET;
BETA-BLOCKING-AGENTS; OXIDATIVE STRESS; NITRIC-OXIDE; INTRAVENOUS
PROPRANOLOL; HYPERTENSIVE PATIENTS; PLASMA ADIPONECTIN; MELLITUS
AB Aim: Studies of beta blockade in patients with type 2 diabetes have shown inferiority of metoprolol treatment compared to carvedilol on indices of insulin resistance. The aim of this study was to examine the effect of metoprolol versus carvedilol on endothelial function and insulin-stimulated endothelial function in patients with type 2 diabetes.
Method: 24 patients with type 2 diabetes were randomized to receive either 200 mg metoprolol succinate or 50 mg carvedilol daily. Endothelium-dependent vasodilation was assessed by using venous occlusion plethysmography with increasing doses of intra-arterial infusions of the agonist serotonin. Insulin-stimulated endothelial function was assessed after co-infusion of insulin for sixty minutes. Vaso-reactivity studies were done before and after the two-month treatment period.
Results: Insulin-stimulated endothelial function was deteriorated after treatment with metoprolol, the percentage change in forearm blood-flow was 60.19% +/- 17.89 (at the highest serotonin dosages) before treatment and -33.80% +/- 23.38 after treatment (p = 0.007). Treatment with carvedilol did not change insulin-stimulated endothelial function. Endothelium-dependent vasodilation without insulin was not changed in either of the two treatment groups.
Conclusion: This study shows that vascular insulin sensitivity was preserved during treatment with carvedilol while blunted during treatment with metoprolol in patients with type 2 diabetes.
C1 [Kveiborg, Britt; Christiansen, Buris] Naestved Hosp, Dept Med, Naestved, Denmark.
[Hermann, Thomas S.; Raunso, Jakob; Torp-Pedersen, Christian] Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark.
[Rask-Madsen, Christian] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Kober, Lars] Rigshosp, Ctr Heart, Dept Cardiol, DK-2100 Copenhagen, Denmark.
[Dominguez, Helena] Herlev Hosp, Dept Cardiol, DK-2730 Herlev, Denmark.
[Major-Pedersen, Atheline] Gentofte Univ Hosp, Dept Internal Med, Hellerup, Denmark.
RP Kveiborg, B (reprint author), Naestved Hosp, Dept Med, Naestved, Denmark.
EM BRIKVE01@geh.regionh.dk
RI Torp-Pedersen, Christian/E-5931-2013;
OI DOMINGUEZ, HELENA/0000-0002-7089-2636
FU Danish Heart Foundation; Bispebjerg Hospital Research Foundation
FX Grant has been provided for Britt Kveiborg from The Danish Heart
Foundation and Bispebjerg Hospital Research Foundation.
NR 36
TC 13
Z9 15
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2840
J9 CARDIOVASC DIABETOL
JI Cardiovasc. Diabetol.
PD MAY 25
PY 2010
VL 9
AR 21
DI 10.1186/1475-2840-9-21
PG 11
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism
GA 626FF
UT WOS:000279950900001
PM 20500877
ER
PT J
AU Katritsis, D
Merchant, FM
Mela, T
Singh, JP
Heist, EK
Armoundas, AA
AF Katritsis, Demosthenes
Merchant, Faisal M.
Mela, Theofanie
Singh, Jagmeet P.
Heist, E. Kevin
Armoundas, Antonis A.
TI Catheter Ablation of Atrial Fibrillation The Search for Substrate-Driven
End Points
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Review
DE atrial fibrillation; catheter ablation; substrate modification
ID PULMONARY VEIN ISOLATION; DOUBLE-LASSO TECHNIQUE; LONG-TERM;
CIRCUMFERENTIAL ABLATION; RADIOFREQUENCY ABLATION; GANGLIONATED PLEXI;
SPECTRAL-ANALYSIS; ANATOMIC APPROACH; FOLLOW-UP; ELECTROGRAMS
AB Indications for catheter ablation of atrial fibrillation (AF) have expanded to include increasingly complex cases, such as long-standing persistent AF and structural heart disease. Although pulmonary vein isolation remains essential for most ablation procedures, the role of substrate modification has taken on increasing importance. Despite the various ablation strategies available, single-procedure efficacy remains suboptimal among patients with structural heart disease or long-standing persistent AF, where recurrence rates may exceed 50% after a single procedure. These high rates of AF recurrence support the notion that currently available procedural end points are ineffective in identifying which patients are most likely to benefit from substrate modification and defining when that substrate has been sufficiently modified such that additional ablation is unnecessary. In order to improve outcomes, the next generation of procedural end points should seek to define specific properties of the underlying atrial electrical substrate and characterize the impact of catheter ablation on those electrophysiologic properties. The use of substrate-driven end points would be a major step in the process of moving from empiric ablation lesions to a customized ablation strategy based on atrial physiology. In this article, we review current approaches to catheter ablation of AF and discuss specific procedural end points as they pertain to each ablation strategy. We also provide a paradigm for the future development of novel substrate-driven procedural end points. (J Am Coll Cardiol 2010;55:2293-8) (C) 2010 by the American College of Cardiology Foundation
C1 [Armoundas, Antonis A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
[Katritsis, Demosthenes] Athens Euroclin, Dept Cardiol, Athens, Greece.
[Merchant, Faisal M.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA USA.
[Mela, Theofanie; Singh, Jagmeet P.; Heist, E. Kevin] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA USA.
RP Armoundas, AA (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.
EM aarmoundas@partners.org
FU American Heart Association [0635127N]; Center for Integration of
Medicine and Innovative Technology; Deane Institute for Integrative
Research in Atrial Fibrillation and Stroke; Cardiovascular Research
Society; Johnson Johnson; Medtronic; Boston Scientific; Biotronik;
Boston Scientific, Medtronic; Sorin Group; St. Jude Medical
FX From the *Department of Cardiology, Athens Euroclinic, Athens, Greece;
dagger Cardiology Division and Cardiac Arrhythmia Service, Massachusetts
General Hospital, Boston, Massachusetts; and the Cardiovascular Research
Center, Massachusetts General Hospital, Charlestown, Massachusetts. This
work was supported by a Scientist Development Grant (#0635127N) from the
American Heart Association and grants from the Center for Integration of
Medicine and Innovative Technology, the Deane Institute for Integrative
Research in Atrial Fibrillation and Stroke, and the Cardiovascular
Research Society. Dr. Katritsis has received research grants from
Johnson & Johnson, Medtronic, and Boston Scientific. Dr. Mela has
received lecture honoraria from Boston Scientific, Medtronic, St. Jude
Medical, and Biotronik. Dr. Singh has received lecture honoraria and
research grants from Biotronik, Boston Scientific, Medtronic, Sorin
Group, and St. Jude Medical, and has done consulting for sanofi-aventis.
Dr. Heist has received research support from and been a speaker for
Biotronik, Boston Scientific, Medtronic, and Sorin/ELA and has been a
consultant and speaker for and received research support from St. Jude
Medical. Drs. Katritsis and Merchant contributed equally to this work.
NR 64
TC 19
Z9 22
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 25
PY 2010
VL 55
IS 21
BP 2293
EP 2298
DI 10.1016/j.jacc.2010.03.016
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 598BB
UT WOS:000277805800001
PM 20488298
ER
PT J
AU Ahmadiyeh, N
Pomerantz, MM
Grisanzio, C
Herman, P
Jia, L
Almendro, V
He, HH
Brown, M
Liu, XS
Davis, M
Caswell, JL
Beckwith, CA
Hills, A
MacConaill, L
Coetzee, GA
Regan, MM
Freedman, ML
AF Ahmadiyeh, Nasim
Pomerantz, Mark M.
Grisanzio, Chiara
Herman, Paula
Jia, Li
Almendro, Vanessa
He, Housheng Hansen
Brown, Myles
Liu, X. Shirley
Davis, Matt
Caswell, Jennifer L.
Beckwith, Christine A.
Hills, Adam
MacConaill, Laura
Coetzee, Gerhard A.
Regan, Meredith M.
Freedman, Matthew L.
TI 8q24 prostate, breast, and colon cancer risk loci show tissue-specific
long-range interaction with MYC
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE chromosome conformation capture; epigenetic; genetics
ID GENOME-WIDE ASSOCIATION; COLORECTAL-CANCER; GENE-EXPRESSION; ACTIVE
CHROMATIN; CHROMOSOME 8Q24; SUSCEPTIBILITY; ENHANCERS; VARIANT;
RS6983267; SCAN
AB The 8q24 gene desert contains risk loci for multiple epithelial cancers, including colon, breast, and prostate. Recent evidence suggests these risk loci contain enhancers. In this study, data are presented showing that each risk locus bears epigenetic marks consistent with enhancer elements and forms a long-range chromatin loop with the MYC proto-oncogene located several hundred kilobases telomeric and that these interactions are tissue-specific. We therefore propose that the 8q24 risk loci operate through a common mechanism-as tissue-specific enhancers of MYC.
C1 [Ahmadiyeh, Nasim; Pomerantz, Mark M.; Grisanzio, Chiara; Herman, Paula; Almendro, Vanessa; He, Housheng Hansen; Brown, Myles; Liu, X. Shirley; Davis, Matt; Caswell, Jennifer L.; Beckwith, Christine A.; Hills, Adam; MacConaill, Laura; Freedman, Matthew L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[He, Housheng Hansen; Liu, X. Shirley; Regan, Meredith M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Ahmadiyeh, Nasim] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Jia, Li] Washington Univ, Sch Med, Dept Internal Med, Ctr Pharmacogenom, St Louis, MO 63110 USA.
[Coetzee, Gerhard A.] Univ So Calif, Norris Canc Ctr, Dept Urol, Los Angeles, CA 90033 USA.
[Freedman, Matthew L.] Eli & Edythe L Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
RP Freedman, ML (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM freedman@broadinstitute.org
RI He, Housheng/G-9614-2011; Davis, Matt/F-9045-2012;
OI Brown, Myles/0000-0002-8213-1658; Caswell-Jin,
Jennifer/0000-0002-5711-8355
FU Doris Duke Clinical Scientist Development Award; National Institutes of
Health [R01 CA129435]; Mayer Foundation; H.L. Snyder Medical Foundation;
Dana-Farber/Harvard Cancer Center Prostate Cancer SPORE (National Cancer
Institute) [5P50CA90381]; Emerald Foundation, Inc.; National Cancer
Institute [R01 CA 109147, R01 CA 136924, CA089393]; William L. Edwards
Prostate Cancer Foundation
FX We thank Keluo Yao and Sarah Kehoe from Center for Cancer Genome
Discovery, Dana-Farber Cancer Center, for running Sequenom Chips. M. L.
F. is a Howard Hughes Medical Institute Physician-Scientist Early Career
Awardee and is a recipient of a 2006 Doris Duke Clinical Scientist
Development Award. This work was supported by grants from the National
Institutes of Health (R01 CA129435 to M. L. F.), the Mayer Foundation
(to M. L. F.), the H.L. Snyder Medical Foundation (to M. L. F.), the
Dana-Farber/Harvard Cancer Center Prostate Cancer SPORE (National Cancer
Institute Grant 5P50CA90381), the Emerald Foundation, Inc. (to M. L.
F.), National Cancer Institute R01 CA 109147 and National Cancer
Institute R01 CA 136924 (to G. A. C.), and by the Dana-Farber/Harvard
SPORE in breast cancer from the National Cancer Institute (CA089393). M.
P. is the recipient of the William L. Edwards Prostate Cancer Foundation
Young Investigator Award.
NR 30
TC 167
Z9 174
U1 1
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 25
PY 2010
VL 107
IS 21
BP 9742
EP 9746
DI 10.1073/pnas.0910668107
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 601JP
UT WOS:000278054700049
PM 20453196
ER
PT J
AU Tong, YR
Yamaguchi, H
Giaime, E
Boyle, S
Kopan, R
Kelleher, RJ
Shen, J
AF Tong, Youren
Yamaguchi, Hiroo
Giaime, Emilie
Boyle, Scott
Kopan, Raphael
Kelleher, Raymond J., III
Shen, Jie
TI Loss of leucine-rich repeat kinase 2 causes impairment of protein
degradation pathways, accumulation of alpha-synuclein, and apoptotic
cell death in aged mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE Parkinson's disease; knockout; autophagy; ubiquitin-proteasome system;
aging
ID CAUSES NEURODEGENERATIVE DISEASE; PARKINSONS-DISEASE; NEURONAL TOXICITY;
TRANSGENIC MICE; AUTOPHAGY; LRRK2; MUTATIONS; GENE; EXPRESSION; SYSTEM
AB Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease. LRRK2is a large protein containing a small GTPase domain and a kinase domain, but its physiological role is unknown. To identify the normal function of LRRK2 in vivo, we generated two independent linesofgerm-line deletion mice. The dopaminergic system of LRRK2(-/-) mice appears normal, and numbers of dopaminergic neurons and levels of striatal dopamine are unchanged. However, LRRK2-/- kidneys, which suffer the greatest loss of LRRK compared with other organs, develop striking accumulation and aggregation of alpha-synuclein and ubiquitinated proteins at 20 months of age. The autophagy-lysosomal pathway is also impaired in the absence of LRRK2, as indicated by accumulation of lipofuscin granules as well as altered levels of LC3-II and p62. Furthermore, loss of LRRK2 dramatically increases apoptotic cell death, inflammatory responses, and oxidative damage. Collectively, our findings show that LRRK2 plays an essential and unexpected role in the regulation of protein homeostasis during aging, and suggest that LRRK2 mutations may cause Parkinson's disease and cell death via impairment of protein degradation pathways, leading to alpha-synuclein accumulation and aggregation over time.
C1 [Tong, Youren; Yamaguchi, Hiroo; Giaime, Emilie; Shen, Jie] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis,Dept Neurol,Program Neurosci, Boston, MA 02115 USA.
[Boyle, Scott; Kopan, Raphael] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
[Kelleher, Raymond J., III] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res,Dept Neurol,Program Neurosci, Boston, MA 02115 USA.
RP Shen, J (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis,Dept Neurol,Program Neurosci, Boston, MA 02115 USA.
EM jshen@rics.bwh.harvard.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
FX We thank Huailong Zhao and Lan Wang for technical assistance. This work
was supported by grants from the National Institute of Neurological
Disorders and Stroke and the Michael J. Fox Foundation (to J.S.) and
grants from the National Institute of Diabetes and Digestive and Kidney
Diseases (to R.K. and S.B.).
NR 38
TC 209
Z9 210
U1 1
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 25
PY 2010
VL 107
IS 21
BP 9879
EP 9884
DI 10.1073/pnas.1004676107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 601JP
UT WOS:000278054700072
PM 20457918
ER
PT J
AU Poliseno, L
Salmena, L
Riccardi, L
Fornari, A
Song, MS
Hobbs, RM
Sportoletti, P
Varmeh, S
Egia, A
Fedele, G
Rameh, L
Loda, M
Pandolfi, PP
AF Poliseno, Laura
Salmena, Leonardo
Riccardi, Luisa
Fornari, Alessandro
Song, Min Sup
Hobbs, Robin M.
Sportoletti, Paolo
Varmeh, Shorheh
Egia, Ainara
Fedele, Giuseppe
Rameh, Lucia
Loda, Massimo
Pandolfi, Pier Paolo
TI Identification of the miR-106b similar to 25 MicroRNA Cluster as a
Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene
MCM7 in Transformation (vol 3, artn ra29, 2010)
SO SCIENCE SIGNALING
LA English
DT Correction
ID MAINTENANCE PROTEIN MCM7; PROSTATE-CANCER; CELLULAR-TRANSFORMATION;
TUMOR SUPPRESSION; MYC PROTEIN; EXPRESSION; NEUROBLASTOMA;
TUMORIGENESIS; SPECIFICITY; ACTIVATION
AB PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a tumor suppressor that antagonizes signaling through the phosphatidylinositol-3-kinase-Akt pathway. We have demonstrated that subtle decreases in PTEN abundance can have critical consequences for tumorigenesis. Here, we used a computational approach to identify miR-22, miR-25, and miR-302 as three PTEN-targeting microRNA (miRNA) families found within nine genomic loci. We showed that miR-22 and the miR-106b similar to 25 cluster are aberrantly overexpressed in human prostate cancer, correlate with abundance of the miRNA processing enzyme DICER, and potentiate cellular transformation both in vitro and in vivo. We demonstrated that the intronic miR-106b similar to 25 cluster cooperates with its host gene MCM7 in cellular transformation both in vitro and in vivo, so that the concomitant overexpression of MCM7 and the miRNA cluster triggers prostatic intraepithelial neoplasia in transgenic mice. Therefore, the MCM7 gene locus delivers two simultaneous oncogenic insults when amplified or overexpressed in human cancer. Thus, we have uncovered a proto-oncogenic miRNA-dependent network for PTEN regulation and defined the MCM7 locus as a critical factor in initiating prostate tumorigenesis.
C1 [Poliseno, Laura; Salmena, Leonardo; Riccardi, Luisa; Song, Min Sup; Hobbs, Robin M.; Sportoletti, Paolo; Varmeh, Shorheh; Egia, Ainara; Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr,Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med & Pathol, Boston, MA 02215 USA.
[Fornari, Alessandro; Fedele, Giuseppe; Loda, Massimo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Fornari, Alessandro] Univ Turin, Dept Biomed Sci & Human Oncol, Molinette Hosp, I-10126 Turin, Italy.
[Fedele, Giuseppe; Loda, Massimo] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Rameh, Lucia] Boston Biomed Res Inst, Watertown, MA 02472 USA.
RP Pandolfi, PP (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr,Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med & Pathol, Boston, MA 02215 USA.
EM ppandolf@bidmc.harvard.edu
OI Poliseno, Laura/0000-0001-6557-955X
NR 1
TC 1
Z9 1
U1 3
U2 5
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD MAY 25
PY 2010
VL 3
IS 123
AR er6
DI 10.1126/scisignal.3123er6
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 601BC
UT WOS:000278032000006
ER
PT J
AU Han, LH
Wu, SM
Condit, JC
Kemp, NJ
Milner, TE
Feldman, MD
Chen, SC
AF Han, Li-Hsin
Wu, Shaomin
Condit, J. Christopher
Kemp, Nate J.
Milner, Thomas E.
Feldman, Marc D.
Chen, Shaochen
TI Light-powered micromotor driven by geometry-assisted, asymmetric
photon-heating and subsequent gas convection
SO APPLIED PHYSICS LETTERS
LA English
DT Article
DE convection; gold; micromotors; molecular dynamics method; nanoparticles;
nanoporous materials; polymers
AB We report on the design, fabrication, and analysis of a light-driven micromotor. The micromotor was created from a nanoporous polymer with close-packed gold nanoparticles which generate heat by absorbing light. The blades of the micromotor were curved, forming convex and concave sides. Upon lateral irradiation, by geometric effect the convex side transfers more photon-generated heat to the surrounding gas molecules, causing a convective motion of gas and leading to the rotation of the micromotor. The light-driven motions of gas molecules were analyzed using molecular dynamics modeling. (C) 2010 American Institute of Physics. [doi:10.1063/1.3431741]
C1 [Han, Li-Hsin; Wu, Shaomin; Chen, Shaochen] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA.
[Condit, J. Christopher; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA.
[Kemp, Nate J.] Volcano Corp, Billerica, MA 01821 USA.
[Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Feldman, Marc D.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Chen, SC (reprint author), Univ Texas Austin, Dept Mech Engn, C2200, Austin, TX 78712 USA.
EM scchen@mail.utexas.edu
RI Han, Li-Hsin/C-5440-2015
OI Han, Li-Hsin/0000-0002-0135-2863
FU Office of Naval Research [N00014-07-1-0609]; National Science Foundation
[CMMI 0555275]
FX This work is supported by grants from the Office of Naval Research
N00014-07-1-0609 and the National Science Foundation CMMI 0555275 to
S.C. We appreciate the donation of the DMD tool kit from Texas
Instruments. We also thank the computer support from Intel's High
Education Program.
NR 20
TC 7
Z9 7
U1 2
U2 11
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
MELVILLE, NY 11747-4501 USA
SN 0003-6951
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD MAY 24
PY 2010
VL 96
IS 21
AR 213509
DI 10.1063/1.3431741
PG 3
WC Physics, Applied
SC Physics
GA 603BP
UT WOS:000278183200085
ER
PT J
AU Ho, PM
Zeng, C
Tavel, HM
Selby, JV
O'Connor, PJ
Margolis, KL
Magid, DJ
AF Ho, P. Michael
Zeng, Chan
Tavel, Heather M.
Selby, Joe V.
O'Connor, Patrick J.
Margolis, Karen L.
Magid, David J.
TI Trends in First-line Therapy for Hypertension in the Cardiovascular
Research Network Hypertension Registry, 2002-2007
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Letter
ID JOINT NATIONAL COMMITTEE; LIPID-LOWERING TREATMENT; HIGH BLOOD-PRESSURE;
7TH REPORT; PREVENTION
C1 [Ho, P. Michael; Zeng, Chan; Tavel, Heather M.; Magid, David J.] Inst Hlth Res, Denver, CO USA.
[Ho, P. Michael] Vet Affairs Med Ctr, Denver Dept, Denver, CO USA.
[Ho, P. Michael] Univ Colorado, Dept Med, Denver, CO USA.
[Magid, David J.] Univ Colorado, Dept Emergency Med, Denver, CO 80202 USA.
[Selby, Joe V.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[O'Connor, Patrick J.; Margolis, Karen L.] HealthPartners Res Fdn, Minneapolis, MN USA.
RP Ho, PM (reprint author), Denver VA Med Ctr, 1055 Clermont St 111B, Denver, CO 80220 USA.
FU NHLBI NIH HHS [U19HL091179]
NR 6
TC 10
Z9 10
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 24
PY 2010
VL 170
IS 10
BP 912
EP 913
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 599LO
UT WOS:000277914400012
PM 20498420
ER
PT J
AU Hellman, A
Chess, A
AF Hellman, Asaf
Chess, Andrew
TI Extensive sequence-influenced DNA methylation polymorphism in the human
genome
SO EPIGENETICS & CHROMATIN
LA English
DT Article
ID INHERITANCE; LOCUS; GENE
AB Background: Epigenetic polymorphisms are a potential source of human diversity, but their frequency and relationship to genetic polymorphisms are unclear. DNA methylation, an epigenetic mark that is a covalent modification of the DNA itself, plays an important role in the regulation of gene expression. Most studies of DNA methylation in mammalian cells have focused on CpG methylation present in CpG islands (areas of concentrated CpGs often found near promoters), but there are also interesting patterns of CpG methylation found outside of CpG islands.
Results: We compared DNA methylation patterns on both alleles between many pairs (and larger groups) of related and unrelated individuals. Direct observation and simulation experiments revealed that around 10% of common single nucleotide polymorphisms (SNPs) reside in regions with differences in the propensity for local DNA methylation between the two alleles. We further showed that for the most common form of SNP, a polymorphism at a CpG dinucleotide, the presence of the CpG at the SNP positively affected local DNA methylation in cis.
Conclusions: Taken together with the known effect of DNA methylation on mutation rate, our results suggest an interesting interdependence between genetics and epigenetics underlying diversity in the human genome.
C1 [Hellman, Asaf] Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel.
[Chess, Andrew] Harvard Univ, Ctr Human Genet Res, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Chess, Andrew] Harvard Univ, Dept Med, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Chess, Andrew] Broad Inst, Cambridge, MA USA.
RP Hellman, A (reprint author), Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel.
EM asafh@ekmd.huji.ac.il; chess@chgr.mgh.harvard.edu
FU National Institutes of Health; Simons Foundation; Israel Science
Foundation
FX We are grateful to H. Cedar, M. Daly, J. Hutchinson, L. Merriam, T.
Mitchison, V. Mootha and R. Mostoslavsky for discussions and comments,
and to A. Kirby for discussions and analyses of polymorphisms. We thank
J. Smoller for DNA samples. This work was supported by the National
Institutes of Health (to A.C.), the Simons Foundation (to A.C.) and from
the Israel Science Foundation (to A.H).
NR 14
TC 47
Z9 47
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-8935
J9 EPIGENET CHROMATIN
JI Epigenetics Chromatin
PD MAY 24
PY 2010
VL 3
AR 11
DI 10.1186/1756-8935-3-11
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 674UH
UT WOS:000283775100001
PM 20497546
ER
PT J
AU Razansky, RN
Rosenthal, A
Mallas, G
Razansky, D
Jaffer, FA
Ntziachristos, V
AF Razansky, R. Nika
Rosenthal, Amir
Mallas, George
Razansky, Daniel
Jaffer, Farouc A.
Ntziachristos, Vasilis
TI Near-infrared fluorescence catheter system for two-dimensional
intravascular imaging in vivo
SO OPTICS EXPRESS
LA English
DT Article
ID INDOCYANINE GREEN; VULNERABLE PLAQUE; PLASMA-VOLUME; ATHEROSCLEROTIC
PLAQUE; CARDIOVASCULAR-DISEASE; INFLAMMATION; TOMOGRAPHY; MODALITIES;
MODEL; RISK
AB Detection of high-risk coronary arterial plaques prior to rupture remains an unmet clinical challenge, in part due to the stringent resolution and sensitivity requirements for in vivo human coronary arterial imaging. To address this need, we have developed a near-infrared (NIR) fluorescence imaging catheter system for intra-vascular molecular imaging of atherosclerosis in coronary artery-sized vessels, capable of resolving two-dimensional fluorescence activity in hollow organs, such as blood vessels. Based on a rotational fiber design, the catheter system illuminates and detects perpendicular to the rotational axis, while an automated pullback mechanism enables visualization along blood vessels with a scan speed of up to 1.5 mm/sec. We demonstrate the previously undocumented capacity to produce intravascular NIR fluorescence images of hollow organs in vivo and showcase the performance metrics of the system developed using blood vessel mimicking phantoms. This imaging approach is geared toward in vivo molecular imaging of atherosclerotic biomarkers and is engineered to allow seamless integration into the cardiac catheterization laboratory. (C) 2010 Optical Society of America
C1 [Razansky, R. Nika; Rosenthal, Amir; Razansky, Daniel; Ntziachristos, Vasilis] Tech Univ Munich, Chair Biol Imaging, Munich, Germany.
[Razansky, R. Nika; Rosenthal, Amir; Razansky, Daniel; Ntziachristos, Vasilis] Helmholtz Zentrum Munchen, Inst Biol & Med Imaging, Munich, Germany.
[Rosenthal, Amir; Mallas, George; Jaffer, Farouc A.] Harvard Univ, Sch Med, Boston, MA USA.
[Rosenthal, Amir; Mallas, George; Jaffer, Farouc A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Rosenthal, Amir; Mallas, George; Jaffer, Farouc A.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Razansky, RN (reprint author), Tech Univ Munich, Chair Biol Imaging, Munich, Germany.
EM 1nika.razansky@tum.de
RI Rosenthal, Amir/C-8650-2014;
OI Jaffer, Farouc/0000-0001-7980-384X; Razansky, Daniel/0000-0001-8676-0964
FU MOBITUM project; German Federal Ministry of Education and Research
(BMBF)
FX This work was funded in part by the MOBITUM project, the German Federal
Ministry of Education and Research (BMBF). The authors acknowledge the
great help of Ion Botnar MD, Adam Mauskapf BS, and J. Luis Guerrero BS
with in vivo experimentation and the help of Alexander Lang with the
technical support.
NR 25
TC 16
Z9 16
U1 0
U2 4
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD MAY 24
PY 2010
VL 18
IS 11
BP 11372
EP 11381
DI 10.1364/OE.18.011372
PG 10
WC Optics
SC Optics
GA 607OB
UT WOS:000278512300052
PM 20588998
ER
PT J
AU Ha, JY
Shishkov, M
Colice, M
Oh, WY
Yoo, H
Liu, L
Tearney, GJ
Bouma, BE
AF Ha, J. Y.
Shishkov, M.
Colice, M.
Oh, W. Y.
Yoo, H.
Liu, L.
Tearney, G. J.
Bouma, B. E.
TI Compensation of motion artifacts in catheter-based optical frequency
domain imaging
SO OPTICS EXPRESS
LA English
DT Article
ID COHERENCE TOMOGRAPHY; PERFORMANCE; MICROSCOPY
AB A novel heterodyne Doppler interferometer method for compensating motion artifacts caused by cardiac motion in intracoronary optical frequency domain imaging (OFDI) is demonstrated. To track the relative motion of a catheter with regard to the vessel, a motion tracking system is incorporated with a standard OFDI system by using wavelength division multiplexing (WDM) techniques. Without affecting the imaging beam, dual WDM monochromatic beams are utilized for tracking the relative radial and longitudinal velocities of a catheter-based fiber probe. Our results demonstrate that tracking instantaneous velocity can be used to compensate for distortion in the images due to motion artifacts, thus leading to accurate reconstruction and volumetric measurements with catheter-based imaging. (C) 2010 Optical Society of America
C1 [Ha, J. Y.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Ha, JY (reprint author), Harvard Univ, Sch Med, 50 Blossom St,BAR 7, Boston, MA 02114 USA.
EM bouma@helix.mgh.harvard.edu
RI Oh, Wang-Yuhl/C-2055-2011; Yoo, Hongki/B-6421-2013
OI Yoo, Hongki/0000-0001-9819-3135
FU National Institutes of Health [R33 CA125560, R01 HL076398]; Terumo
Medical Corporation
FX This research was supported in part by the National Institutes of Health
(grants R33 CA125560 and R01 HL076398), and Terumo Medical Corporation.
M. Colice is currently with Hamilton Brook Smith Reynolds P. C., 530
Virginia Rd, Concord MA 01742.
NR 15
TC 11
Z9 11
U1 0
U2 3
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD MAY 24
PY 2010
VL 18
IS 11
BP 11418
EP 11427
DI 10.1364/OE.18.011418
PG 10
WC Optics
SC Optics
GA 607OB
UT WOS:000278512300056
PM 20589002
ER
PT J
AU Kabbarah, O
Nogueira, C
Feng, B
Nazarian, RM
Bosenberg, M
Wu, M
Scott, KL
Kwong, LN
Xiao, YH
Cordon-Cardo, C
Granter, SR
Ramaswamy, S
Golub, T
Duncan, LM
Wagner, SN
Brennan, C
Chin, L
AF Kabbarah, Omar
Nogueira, Cristina
Feng, Bin
Nazarian, Rosalynn M.
Bosenberg, Marcus
Wu, Min
Scott, Kenneth L.
Kwong, Lawrence N.
Xiao, Yonghong
Cordon-Cardo, Carlos
Granter, Scott R.
Ramaswamy, Sridhar
Golub, Todd
Duncan, Lyn M.
Wagner, Stephan N.
Brennan, Cameron
Chin, Lynda
TI Integrative Genome Comparison of Primary and Metastatic Melanomas
SO PLOS ONE
LA English
DT Article
ID NUCLEOTIDE POLYMORPHISM ARRAYS; HUMAN HEPATOCELLULAR-CARCINOMA;
PROTEIN-KINASE PATHWAY; COPY NUMBER ANALYSIS; MALIGNANT-MELANOMA; CELL
CARCINOMAS; CUTANEOUS MELANOMA; UVEAL MELANOMA; BREAST-CANCER;
LUNG-CANCER
AB A cardinal feature of malignant melanoma is its metastatic propensity. An incomplete view of the genetic events driving metastatic progression has been a major barrier to rational development of effective therapeutics and prognostic diagnostics for melanoma patients. In this study, we conducted global genomic characterization of primary and metastatic melanomas to examine the genomic landscape associated with metastatic progression. In addition to uncovering three genomic subclasses of metastastic melanomas, we delineated 39 focal and recurrent regions of amplification and deletions, many of which encompassed resident genes that have not been implicated in cancer or metastasis. To identify progressionassociated metastasis gene candidates, we applied a statistical approach, Integrative Genome Comparison (IGC), to define 32 genomic regions of interest that were significantly altered in metastatic relative to primary melanomas, encompassing 30 resident genes with statistically significant expression deregulation. Functional assays on a subset of these candidates, including MET, ASPM, AKAP9, IMP3, PRKCA, RPA3, and SCAP2, validated their pro-invasion activities in human melanoma cells. Validity of the IGC approach was further reinforced by tissue microarray analysis of Survivin showing significant increased protein expression in thick versus thin primary cutaneous melanomas, and a progression correlation with lymph node metastases. Together, these functional validation results and correlative analysis of human tissues support the thesis that integrated genomic and pathological analyses of staged melanomas provide a productive entry point for discovery of melanoma metastases genes.
C1 [Kabbarah, Omar; Nogueira, Cristina; Wu, Min; Scott, Kenneth L.; Kwong, Lawrence N.; Golub, Todd; Chin, Lynda] Dana Faber Canc Inst, Dept Med Oncol, Boston, MA USA.
[Kabbarah, Omar; Nogueira, Cristina; Wu, Min; Scott, Kenneth L.; Kwong, Lawrence N.; Golub, Todd; Chin, Lynda] Harvard Med Sch, Boston, MA USA.
[Nogueira, Cristina; Xiao, Yonghong] Univ Porto, Inst Mol Pathol & Immunol, Oporto, Portugal.
[Feng, Bin; Xiao, Yonghong; Chin, Lynda] Dana Faber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA.
[Nazarian, Rosalynn M.; Duncan, Lyn M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol,Dermatopathol Unit, Boston, MA USA.
[Bosenberg, Marcus] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT USA.
[Cordon-Cardo, Carlos] Columbia Univ, Dept Pathol, New York, NY USA.
[Granter, Scott R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA.
[Ramaswamy, Sridhar] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA.
[Golub, Todd] MIT, Braod Inst, Boston, MA USA.
[Wagner, Stephan N.] Med Univ Vienna, Dept Dermatol, DIAID, Vienna, Austria.
[Wagner, Stephan N.] Austrian Acad Sci, Ctr Mol Med, Vienna, Austria.
[Brennan, Cameron] Memorial Sloan Kettering Canc Ctr, Dept Neurosurg, HOPP, New York, NY USA.
[Chin, Lynda] Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA.
RP Kabbarah, O (reprint author), Dana Faber Canc Inst, Dept Med Oncol, Boston, MA USA.
EM cbrennan@mskcc.org; lynda_chin@dfci.harvard.edu
RI Nogueira, Cristina/N-4574-2015;
OI Nogueira, Cristina/0000-0002-0853-5304; Brennan,
Cameron/0000-0003-4064-8891; Wagner, Stephan/0000-0003-4941-7029;
Nazarian, Rosalynn/0000-0003-4003-7193
FU National Institutes of Health [T32 AR07098, UO1 CA84313, RO1 CA93947,
P50 CA93683]; Foundation for Science and Technology [PRAXIS/BD/21794/99]
FX National Institutes of Health training grant (T32 AR07098) to O. K.
Fellowship from the Foundation for Science and Technology (Fundacao para
a Ciencia e Tecnologia , PRAXIS/BD/21794/99) to C. N. National
Institutes of Health grants UO1 CA84313, RO1 CA93947, and P50 CA93683 to
L. C. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript
NR 55
TC 61
Z9 61
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 24
PY 2010
VL 5
IS 5
AR e10770
DI 10.1371/journal.pone.0010770
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 601CC
UT WOS:000278034600003
PM 20520718
ER
PT J
AU Nitta, M
Kozono, D
Kennedy, R
Stommel, J
Ng, K
Zinn, PO
Kushwaha, D
Kesari, S
Furnari, F
Hoadley, KA
Chin, L
DePinho, RA
Cavenne, WK
D'Andrea, A
Chen, CC
AF Nitta, Masayuki
Kozono, David
Kennedy, Richard
Stommel, Jayne
Ng, Kimberly
Zinn, Pascal O.
Kushwaha, Deepa
Kesari, Santosh
Furnari, Frank
Hoadley, Katherine A.
Chin, Lynda
DePinho, Ronald A.
Cavenee, Webster K.
D'Andrea, Alan
Chen, Clark C.
TI Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in
Glioblastoma Therapy
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; DNA-DAMAGE RESPONSE; INTEGRATED GENOMIC
ANALYSIS; ERROR-PRONE REPAIR; REACTIVE OXYGEN; HUMAN CANCERS;
POLY(ADP-RIBOSE) POLYMERASE; RAS ONCOGENE; CELLS; INSTABILITY
AB Despite the critical role of Epidermal Growth Factor Receptor (EGFR) in glioblastoma pathogenesis [1,2], EGFR targeted therapies have achieved limited clinical efficacy [3]. Here we propose an alternate therapeutic strategy based on the conceptual framework of non-oncogene addiction [4,5]. A directed RNAi screen revealed that glioblastoma cells overexpressing EGFRvIII [6], an oncogenic variant of EGFR, become hyper-dependent on a variety of DNA repair genes. Among these, there was an enrichment of Base Excision Repair (BER) genes required for the repair of Reactive Oxygen Species (ROS)-induced DNA damage, including poly-ADP ribose polymerase 1 (PARP1). Subsequent studies revealed that EGFRvIII overexpression in glioblastoma cells caused increased levels of ROS, DNA strand break accumulation, and genome instability. In a panel of primary glioblastoma lines, sensitivity to PARP1 inhibition correlated with the levels of EGFR activation and oxidative stress. Gene expression analysis indicated that reduced expression of BER genes in glioblastomas with high EGFR expression correlated with improved patient survival. These observations suggest that oxidative stress secondary to EGFR hyperactivation necessitates increased cellular reliance on PARP1 mediated BER, and offer critical insights into clinical trial design.
C1 [Nitta, Masayuki; Kozono, David; Ng, Kimberly; Zinn, Pascal O.; Kushwaha, Deepa; D'Andrea, Alan; Chen, Clark C.] Dana-Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA.
[Kozono, David] Harvard Radiat Oncol Program, Boston, MA USA.
[Kennedy, Richard] Almac Diagnost, Craigavon, North Ireland.
[Stommel, Jayne; Chin, Lynda; DePinho, Ronald A.] Dana-Farber Canc Inst, Belfer Inst Appl Canc Sci, Dept Med Oncol, Boston, MA USA.
[Kesari, Santosh] Univ Calif San Diego, Dept Neurol, Moores UCSD Canc Ctr, La Jolla, CA USA.
[Furnari, Frank; Cavenee, Webster K.] Ludwig Inst Canc Res, La Jolla, CA USA.
[Hoadley, Katherine A.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Chen, Clark C.] Beth Israel Deaconess Med Ctr, Div Neurosurg, Boston, MA USA.
RP Nitta, M (reprint author), Dana-Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA.
EM clark_chen@dfci.harvard.edu
RI Chen, Clark/C-8714-2013; Kesari, Santosh/E-8461-2013
OI Chen, Clark/0000-0001-6258-9277;
FU Burroughs Wellcome Fund [CAMS 1006775.01]; National Brain Tumor
Foundation; ABC2 Foundation
FX CCC was supported by an award from the Burroughs Wellcome Fund (CAMS
1006775.01), National Brain Tumor Foundation, and ABC2 Foundation. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 33
TC 34
Z9 36
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 24
PY 2010
VL 5
IS 5
AR e10767
DI 10.1371/journal.pone.0010767
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 601CC
UT WOS:000278034600002
PM 20532243
ER
PT J
AU Susa, M
Iyer, AK
Ryu, K
Choy, E
Hornicek, FJ
Mankin, H
Milane, L
Amiji, MM
Duan, Z
AF Susa, Michiro
Iyer, Arun K.
Ryu, Keinosuke
Choy, Edwin
Hornicek, Francis J.
Mankin, Henry
Milane, Lara
Amiji, Mansoor M.
Duan, Zhenfeng
TI Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate
Delivery System to Overcome Drug Resistance in Osteosarcoma
SO PLOS ONE
LA English
DT Article
ID P-GLYCOPROTEIN EXPRESSION; MULTIDRUG-RESISTANCE; OVARIAN-CARCINOMA;
CYCLOSPORINE-A; CANCER CELLS; SOLID TUMOR; STEM-CELLS; REVERSAL;
DOXORUBICIN; GENE
AB Background: The use of neo-adjuvant chemotherapy in treating osteosarcoma has improved patients' average 5 year survival rate from 20% to 70% in the past 30 years. However, for patients who progress after chemotherapy, its effectiveness diminishes due to the emergence of multi-drug resistance (MDR) after prolonged therapy.
Methodology/Principal Findings: In order to overcome both the dose-limiting side effects of conventional chemotherapeutic agents and the therapeutic failure resulting from MDR, we designed and evaluated a novel drug delivery system for MDR1 siRNA delivery. Novel biocompatible, lipid-modified dextran-based polymeric nanoparticles were used as the platform for MDR1 siRNA delivery; and the efficacy of combination therapy with this system was evaluated. In this study, multi-drug resistant osteosarcoma cell lines (KHOS(R2) and U-2OS(R2)) were treated with the MDR1 siRNA nanocarriers and MDR1 protein (P-gp) expression, drug retention, and immunofluoresence were analyzed. Combination therapy of the MDR1 siRNA loaded nanocarriers with increasing concentrations of doxorubicin was also analyzed. We observed that MDR1 siRNA loaded dextran nanoparticles efficiently suppresses P-gp expression in the drug resistant osteosarcoma cell lines. The results also demonstrated that this approach may be capable of reversing drug resistance by increasing the amount of drug accumulation in MDR cell lines.
Conclusions/Significance: Lipid-modified dextran-based polymeric nanoparticles are a promising platform for siRNA delivery. Nanocarriers loaded with MDR1 siRNA are a potential treatment strategy for reversing MDR in osteosarcoma.
C1 [Susa, Michiro; Ryu, Keinosuke; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA USA.
[Susa, Michiro; Ryu, Keinosuke; Choy, Edwin; Hornicek, Francis J.; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA USA.
[Iyer, Arun K.; Milane, Lara; Amiji, Mansoor M.] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA USA.
RP Susa, M (reprint author), Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA USA.
EM zduan@partners.org
RI Susa, Michiro/L-2291-2013; Amiji, Mansoor/A-4365-2014;
OI Amiji, Mansoor/0000-0001-6170-881X; Choy, Edwin/0000-0001-9896-8084;
Iyer, Arun/0000-0002-4428-0222
FU National Cancer Institute, National Institutes of Health (Nanotechnology
Platform Partnership) [R01-CA119617]; Sarcoma Foundation of America;
Gattegno and Wechsler funds
FX This project was supported, in part, by a grant from the National Cancer
Institute, National Institutes of Health (Nanotechnology Platform
Partnership), R01-CA119617. Dr. Duan is supported, in part, through a
grant from Sarcoma Foundation of America. Support has also been provided
by the Gattegno and Wechsler funds. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 48
TC 70
Z9 77
U1 5
U2 36
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 24
PY 2010
VL 5
IS 5
AR e10764
DI 10.1371/journal.pone.0010764
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 601CC
UT WOS:000278034600001
PM 20520719
ER
PT J
AU Jespersen, S
Sogaard, OS
Schonheyder, HC
Fine, MJ
Ostergaard, L
AF Jespersen, Sanne
Sogaard, Ole S.
Schonheyder, Henrik C.
Fine, Michael J.
Ostergaard, Lars
TI Clinical features and predictors of mortality in admitted patients with
community- and hospital-acquired legionellosis: A Danish historical
cohort study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID LEGIONNAIRES-DISEASE; PROGNOSTIC-FACTORS; PNEUMONIA; VALIDATION;
MORBIDITY; THERAPY; TRENDS
AB Background: Legionella is a common cause of bacterial pneumonia. Community-acquired [CAL] and hospital-acquired legionellosis [HAL] may have different presentations and outcome. We aimed to compare clinical characteristics and examine predictors of mortality for CAL and HAL.
Methods: We identified hospitalized cases of legionellosis in 4 Danish counties from January 1995 to December 2005 using the Danish national surveillance system and databases at departments of clinical microbiology. Clinical and laboratory data were retrieved from medical records; vital status was obtained from the Danish Civil Registration System. We calculated 30- and 90-day case fatality rates and identified independent predictors of mortality using logistic regression analyses.
Results: We included 272 cases of CAL and 60 cases of HAL. Signs and symptoms of HAL were less pronounced than for CAL and time from in-hospital symptoms to legionellosis diagnosis was shorter for CAL than for HAL (5.5 days vs. 12 days p < 0.001). Thirty-day case fatality was 12.9% for CAL and 33.3% for HAL; similarly 90-day case fatalities in the two groups were 15.8% and 55.0%, respectively. In a logistic regression analysis (excluding symptoms and laboratory tests) age > 65 years (OR = 2.6, 95% CI: 1.1-5.9) and Charlson comorbidty index = 2 (OR = 2.7, 95% CI: 1.1-6.5) were associated with an increased risk of death in CAL. We identified no statistically significant predictors of 30-day mortality in HAL.
Conclusions: Signs and symptoms were less pronounced in HAL compared to CAL. Conversely, 30-day case fatality was almost 3 times higher. Clinical awareness is important for the timely diagnosis and treatment especially of HAL. There is a need for further studies of prognostic factors in order to improve the therapeutic approach to legionellosis and potentially reduce mortality.
C1 [Jespersen, Sanne; Sogaard, Ole S.; Ostergaard, Lars] Aarhus Univ Hosp, Dept Infect Dis, DK-8200 Aarhus N, Denmark.
[Schonheyder, Henrik C.] Aarhus Univ Hosp, Dept Clin Microbiol, DK-9000 Aalborg, Denmark.
[Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Med, UPMC Montefiore Hosp, Pittsburgh, PA 15213 USA.
RP Jespersen, S (reprint author), Aarhus Univ Hosp, Dept Infect Dis, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark.
EM sanne.jespersen@ki.au.dk
RI Sogaard, Ole/P-6058-2016
FU Beckett-fonden
FX We would like to acknowledge Statens Serum Institut for making the
microbiological data available to us and Beckett-fonden for financial
support.
NR 20
TC 12
Z9 14
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAY 21
PY 2010
VL 10
AR 124
DI 10.1186/1471-2334-10-124
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA 605XP
UT WOS:000278382100001
PM 20492639
ER
PT J
AU Owens, RM
Gu, XL
Shin, MR
Springer, TA
Jin, MM
AF Owens, Roisin M.
Gu, Xiaoling
Shin, Miran
Springer, Timothy A.
Jin, Moonsoo M.
TI Engineering of Single Ig Superfamily Domain of Intercellular Adhesion
Molecule 1 (ICAM-1) for Native Fold and Function
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN RHINOVIRUS; CRYSTAL-STRUCTURE; CELL-SURFACE; TRANSENDOTHELIAL
MIGRATION; IMMUNOGLOBULIN SUPERFAMILY; DIRECTED EVOLUTION;
COXSACKIEVIRUS A21; RECEPTOR MOLECULE; ANTIGEN-1 LFA-1; IN-VIVO
AB The immunoglobulin (Ig) superfamily is one of the largest families in the vertebrate genome, found most frequently in cell surface molecules. Intercellular adhesion molecule-1 (ICAM-1) contains five extracellular Ig superfamily domains (D1-D5) of which the first domain, D1, is the binding site for the integrin lymphocyte function-associated antigen-1 (LFA-1) and human rhinovirus. Despite the modular nature of many Ig superfamily domains with respect to domain folding and ligand recognition, D1 does not fold on its own due to the loss of its interaction with the second domain. The goal of this study was to engineer ICAM-1D1 by introducing mutations that would stabilize the Ig superfamily domain fold while retaining its ability to bind to LFA-1 and rhinovirus. First, with a directed evolution approach, we isolated mutations in D1 that showed binding to conformation-specific antibodies and the ligand binding domain of LFA-1 called the inserted, or I, domain. Then, with a rational design approach we introduced mutations that contributed to the stability of ICAM-1 D1 in solution. The mutations that restored native folding of D1 in isolation were those that would convert hydrogen bond networks in buried regions into hydrophobic contacts. Notably, for most mutations, identical or similar types of substitutions were found in ICAM-1 molecules of different species and other ICAM family members. The systematic approach demonstrated in this study to engineer a single Ig superfamily fold in ICAM-1 can be broadly applicable to the engineering of modular Ig superfamily domains in other cell surface molecules.
C1 [Springer, Timothy A.; Jin, Moonsoo M.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA.
[Owens, Roisin M.; Gu, Xiaoling; Shin, Miran; Jin, Moonsoo M.] Cornell Univ, Dept Biomed Engn, Ithaca, NY 14853 USA.
RP Springer, TA (reprint author), Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA.
EM springer@idi.harvard.edu; mj227@cornell.edu
RI Jin, Moonsoo/D-6128-2011;
OI Owens, Roisin/0000-0001-7856-2108
FU National Institutes of Health [CA31798, AI079532]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants CA31798 and AI079532.
NR 50
TC 7
Z9 7
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 21
PY 2010
VL 285
IS 21
BP 15906
EP 15915
DI 10.1074/jbc.M110.104349
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 596WJ
UT WOS:000277715900028
PM 20304924
ER
PT J
AU Smith, KJ
Twal, WO
Soodavar, F
Virella, G
Lopes-Virella, MF
Hammad, SM
AF Smith, Kent J.
Twal, Waleed O.
Soodavar, Farzan
Virella, Gabriel
Lopes-Virella, Maria F.
Hammad, Samar M.
TI Heat Shock Protein 70B ' (HSP70B ') Expression and Release in Response
to Human Oxidized Low Density Lipoprotein Immune Complexes in
Macrophages
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID U937 MONOCYTIC CELLS; SPHINGOSINE KINASE; CYTOKINE PRODUCTION;
PLASMA-MEMBRANE; STRESS-PROTEINS; LDL; HEAT-SHOCK-PROTEIN-70; SURVIVAL;
PATHWAY; ATHEROSCLEROSIS
AB Heat shock proteins (HSPs) have been implicated in the activation and survival of macrophages. This study examined the role of HSP70B', a poorly characterized member of the HSP70 family, in response to oxidatively modified LDL (oxLDL) and immune complexes prepared with human oxLDL and purified human antibodies to oxLDL (oxLDL-IC) in monocytic and macrophage cell lines. Immunoblot analysis of cell lysates and conditioned medium from U937 cells treated with oxLDL alone revealed an increase in intracellular HSP70B' protein levels accompanied by a concomitant increase in HSP70B' extracellular levels. Fluorescence immunohistochemistry and confocal microscopy, however, demonstrated that oxLDL-IC stimulated the release of HSP70B', which co-localized with cell-associated oxLDL-IC. In HSP70B'-green fluorescent protein-transfected mouse RAW 264.7 cells, oxLDL-IC-induced HSP70B' co-localized with membrane-associated oxLDL-IC as well as the lipid moiety of internalized oxLDL-IC. Furthermore, the data demonstrated that HSP70B' is involved in cell survival, and this effect could be mediated by sphingosine kinase 1 (SK1) activation. An examination of regularly implicated cytokines revealed a significant relationship between HSP70B' and the release of the anti-inflammatory cytokine interleukin-10 (IL-10). Small interfering RNA knockdown of HSP70B' resulted in a corresponding decrease in SK1 mRNA levels and SK1 phosphorylation as well as increased release of IL-10. In conclusion, these findings suggest that oxLDL-IC induce the synthesis and release of HSP70B', and once stimulated, HSP70B' binds to the cell-associated and internalized lipid moiety of oxLDL-IC. The data also implicate HSP70B' in key cellular functions, such as regulation of SK1 activity and release of IL-10, which influence macrophage activation and survival.
C1 [Smith, Kent J.; Twal, Waleed O.; Soodavar, Farzan; Hammad, Samar M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
[Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Lopes-Virella, Maria F.] Med Univ S Carolina, Div Endocrinol, Dept Med, Charleston, SC 29425 USA.
[Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Hammad, SM (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, 114 Doughty St,630B,POB 250776, Charleston, SC 29425 USA.
EM hammadsm@musc.edu
FU National Institutes of Health (NIH) [HL079274]; NIH (American Recovery
and Investment Act (ARRA)) [R01 HL079274-04S1]; NIH (National Center for
Research Resources) [P20 RR17677]; NIH [P01 HL55782, R01 DK081352, R01
DK081352-02S1]; Department of Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health (NIH) Grant HL079274 and NIH (American Recovery and Investment
Act (ARRA)) Grant R01 HL079274-04S1 (to S. M. H.); NIH (National Center
for Research Resources) Grant P20 RR17677 (South Carolina Center of
Biomedical Research Excellence in Lipidomics and Pathobiology) (to S. M.
H.); and NIH Grants P01 HL55782, R01 DK081352, and R01 DK081352-02S1
(ARRA) (to M. F. L.-V.). This work was also supported by funding from
the Department of Veterans Affairs (to M. F. L.-V.).
NR 58
TC 14
Z9 14
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 21
PY 2010
VL 285
IS 21
BP 15985
EP 15993
DI 10.1074/jbc.M110.113605
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 596WJ
UT WOS:000277715900036
PM 20348092
ER
PT J
AU Okuhira, K
Fitzgerald, ML
Tamehiro, N
Ohoka, N
Suzuki, K
Sawada, J
Naito, M
Nishimaki-Mogami, T
AF Okuhira, Keiichiro
Fitzgerald, Michael L.
Tamehiro, Norimasa
Ohoka, Nobumichi
Suzuki, Kazuhiro
Sawada, Jun-ichi
Naito, Mikihiko
Nishimaki-Mogami, Tomoko
TI Binding of PDZ-RhoGEF to ATP-binding Cassette Transporter A1 (ABCA1)
Induces Cholesterol Efflux through RhoA Activation and Prevention of
Transporter Degradation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NUCLEOTIDE EXCHANGE FACTOR; HIGH-DENSITY-LIPOPROTEIN;
LEUKEMIA-ASSOCIATED RHO; HETEROTRIMERIC G-PROTEINS; TANGIER-DISEASE;
APOA-I; CELLULAR CHOLESTEROL; ABCA1-DEFICIENT MACROPHAGES; P115 RHOGEF;
RECEPTOR
AB ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux to apolipoprotein A1 (apoA-I) initiates the biogenesis of high density lipoprotein. Here we show that the Rho guanine nucleotide exchange factors PDZ-RhoGEF and LARG bind to the C terminus of ABCA1 by a PDZ-PDZ interaction and prevent ABCA1 protein degradation by activating RhoA. ABCA1 is a protein with a short half-life, and apoA-I stabilizes ABCA1 protein; however, depletion of PDZ-RhoGEF/LARG by RNA interference suppressed the apoA-I stabilization of ABCA1 protein in human primary fibroblasts. Exogenous PDZ-RhoGEF expression activated RhoA and increased ABCA1 protein levels and cholesterol efflux activity. Likewise, forced expression of a constitutively active RhoA mutant significantly increased ABCA1 protein levels, whereas a dominant negative RhoA mutant decreased them. The constitutively active RhoA retarded ABCA1 degradation, thus accounting for its ability to increase ABCA1 protein. Moreover, stimulation with apoA-I transiently activated RhoA, and the pharmacological inhibition of RhoA or the dominant negative RhoA blocked the ability of apoA-I to stabilize ABCA1. Finally, depletion of RhoA or RhoGEFs/RhoA reduces the cholesterol efflux when transcriptional regulation via PPAR gamma is eliminated. Taken together, our results have identified a novel physical and functional interaction between ABCA1 and PDZ-RhoGEF/LARG, which activates RhoA, resulting in ABCA1 stabilization and cholesterol efflux activity.
C1 [Okuhira, Keiichiro; Ohoka, Nobumichi; Suzuki, Kazuhiro; Sawada, Jun-ichi; Naito, Mikihiko; Nishimaki-Mogami, Tomoko] Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588511, Japan.
[Fitzgerald, Michael L.; Tamehiro, Norimasa] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lipid Metab Unit, Boston, MA 02114 USA.
[Fitzgerald, Michael L.; Tamehiro, Norimasa] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
RP Okuhira, K (reprint author), Natl Inst Hlth Sci, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588511, Japan.
EM okuhira@nihs.go.jp
FU National Institutes of Health [HL-074136]; Japan Society for the
Promotion of Science; Japan Health Sciences Foundation; Takeda Science
Foundation; American Heart Association [09GRNT2260352]
FX This work was supported by National Institutes of Health Grant HL-074136
(to M. L. F.). This work was also supported by grants-in-aid for
scientific research from the Japan Society for the Promotion of Science,
by a research fund from Japan Health Sciences Foundation, by a Takeda
Science Foundation grant (to K. O.), and by American Heart Association
Grant 09GRNT2260352 (to M. L. F.).
NR 55
TC 24
Z9 25
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 21
PY 2010
VL 285
IS 21
BP 16369
EP 16377
DI 10.1074/jbc.M109.061424
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 596WJ
UT WOS:000277715900073
PM 20348106
ER
PT J
AU Athar, BS
Bednarz, B
Seco, J
Hancox, C
Paganetti, H
AF Athar, Basit S.
Bednarz, Bryan
Seco, Joao
Hancox, Cindy
Paganetti, Harald
TI Comparison of out-of-field photon doses in 6 MV IMRT and neutron doses
in proton therapy for adult and pediatric patients
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID MODULATED RADIATION-THERAPY; MONTE-CARLO SIMULATIONS; 2ND CANCERS; RISK;
IRRADIATION; PHANTOMS; BEAMS; MODEL
AB The purpose of this study was to assess lateral out-of-field doses in 6MV IMRT (intensity modulated radiation therapy) and compare them with secondary neutron equivalent dose contributions in proton therapy. We simulated out-of-field photon doses to various organs as a function of distance, patient's age, gender and treatment volumes based on 3, 6, 9 cm field diameters in the head and neck and spine region. The out-of-field photon doses to organs near the field edge were found to be in the range of 2, 5 and 10 mSv Gy(-1) for 3 cm, 6 cm and 9 cm diameter IMRT fields, respectively, within 5 cm of the field edge. Statistical uncertainties calculated in organ doses vary from 0.2% to 40% depending on the organ location and the organ volume. Next, a comparison was made with previously calculated neutron equivalent doses from proton therapy using identical field arrangements. For example, out-of-field doses for IMRT to lung and uterus (organs close to the 3 cm diameter spinal field) were computed to be 0.63 and 0.62 mSv Gy(-1), respectively. These numbers are found to be a factor of 2 smaller than the corresponding out-of-field doses for proton therapy, which were estimated to be 1.6 and 1.7 mSv Gy(-1) (RBE), respectively. However, as the distance to the field edge increases beyond approximately 25 cm the neutron equivalent dose from proton therapy was found to be a factor of 2-3 smaller than the out-of-field photon dose from IMRT. We have also analyzed the neutron equivalent doses from an ideal scanned proton therapy (assuming not significant amount of absorbers in the treatment head). Out-of-field doses were found to be an order of magnitude smaller compared to out-of-field doses in IMRT or passive scattered proton therapy. In conclusion, there seem to be three geometrical areas when comparing the out-of-target dose from IMRT and (passive scattered) proton treatments. Close to the target (in-field, not analyzed here) protons offer a distinct advantage due to the lower integral dose. Out-of-field, but within approximately 25 cm from the field edge, the scattered photon dose in IMRT turned out to be roughly a factor of 2 lower than the neutron equivalent dose from proton therapy for the fields considered in this study. At larger distances to the field (beyond similar to 25 cm), protons offer an advantage, resulting in doses that are roughly a factor of 2-3 lower.
C1 [Athar, Basit S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Athar, BS (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
EM bathar@partners.org; bbednarz@partners.org; jseco@partners.org;
chancox@partners.org; hpaganetti@partners.org
RI Seco, Joao/J-4451-2012
FU Department of Radiation Oncology at Massachusetts General Hospital
(MGH); NIH/NCI [CO6-CA059267]
FX This work was supported by institutional funds (ECOR award by Partners
Health Care Inc., Ira Spiro award for translational research by the
Department of Radiation Oncology at Massachusetts General Hospital
(MGH)) and an NIH/NCI grant (CO6-CA059267).
NR 21
TC 24
Z9 24
U1 1
U2 8
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD MAY 21
PY 2010
VL 55
IS 10
BP 2879
EP 2891
DI 10.1088/0031-9155/55/10/006
PG 13
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 590HI
UT WOS:000277215700006
PM 20427856
ER
PT J
AU Nickerson, ML
Kostiha, BN
Brandt, W
Fredericks, W
Xu, KP
Yu, FS
Gold, B
Chodosh, J
Goldberg, M
Lu, DW
Yamada, M
Tervo, TM
Grutzmacher, R
Croasdale, C
Hoeltzenbein, M
Sutphin, J
Malkowicz, SB
Wessjohann, L
Kruth, HS
Dean, M
Weiss, JS
AF Nickerson, Michael L.
Kostiha, Brittany N.
Brandt, Wolfgang
Fredericks, William
Xu, Ke-Ping
Yu, Fu-Shin
Gold, Bert
Chodosh, James
Goldberg, Marc
Lu, Da Wen
Yamada, Masakazu
Tervo, Timo M.
Grutzmacher, Richard
Croasdale, Chris
Hoeltzenbein, Maria
Sutphin, John
Malkowicz, S. Bruce
Wessjohann, Ludger
Kruth, Howard S.
Dean, Michael
Weiss, Jayne S.
TI UBIAD1 Mutation Alters a Mitochondrial Prenyltransferase to Cause
Schnyder Corneal Dystrophy
SO PLOS ONE
LA English
DT Article
ID ESCHERICHIA-COLI; CRYSTALLINE DYSTROPHY; TOPOLOGY PREDICTION; PROTEIN
STRUCTURES; CHOLESTEROL; GENE; MEMBRANE; TRANSFERASE; METABOLISM;
BLADDER
AB Background: Mutations in a novel gene, UBIAD1, were recently found to cause the autosomal dominant eye disease Schnyder corneal dystrophy (SCD). SCD is characterized by an abnormal deposition of cholesterol and phospholipids in the cornea resulting in progressive corneal opacification and visual loss. We characterized lesions in the UBIAD1 gene in new SCD families and examined protein homology, localization, and structure.
Methodology/Principal Findings: We characterized five novel mutations in the UBIAD1 gene in ten SCD families, including a first SCD family of Native American ethnicity. Examination of protein homology revealed that SCD altered amino acids which were highly conserved across species. Cell lines were established from patients including keratocytes obtained after corneal transplant surgery and lymphoblastoid cell lines from Epstein-Barr virus immortalized peripheral blood mononuclear cells. These were used to determine the subcellular localization of mutant and wild type protein, and to examine cholesterol metabolite ratios. Immunohistochemistry using antibodies specific for UBIAD1 protein in keratocytes revealed that both wild type and N102S protein were localized sub-cellularly to mitochondria. Analysis of cholesterol metabolites in patient cell line extracts showed no significant alteration in the presence of mutant protein indicating a potentially novel function of the UBIAD1 protein in cholesterol biochemistry. Molecular modeling was used to develop a model of human UBIAD1 protein in a membrane and revealed potentially critical roles for amino acids mutated in SCD. Potential primary and secondary substrate binding sites were identified and docking simulations indicated likely substrates including prenyl and phenolic molecules.
Conclusions/Significance: Accumulating evidence from the SCD familial mutation spectrum, protein homology across species, and molecular modeling suggest that protein function is likely down-regulated by SCD mutations. Mitochondrial UBIAD1 protein appears to have a highly conserved function that, at least in humans, is involved in cholesterol metabolism in a novel manner.
C1 [Nickerson, Michael L.; Kostiha, Brittany N.; Gold, Bert; Dean, Michael] NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA.
[Nickerson, Michael L.] NIH, Grad Partnership Program, Bethesda, MD 20892 USA.
[Nickerson, Michael L.] George Washington Univ, Inst Biomed Sci, Program Mol Med, Washington, DC USA.
[Kostiha, Brittany N.] Hood Coll, Biomed Sci Grad Program, Frederick, MD 21701 USA.
[Brandt, Wolfgang; Wessjohann, Ludger] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Halle, Saale, Germany.
[Fredericks, William; Malkowicz, S. Bruce] Univ Penn, Dept Surg, Div Urol, Philadelphia, PA 19104 USA.
[Fredericks, William; Malkowicz, S. Bruce] Vet Affairs Med Ctr, Philadelphia, PA USA.
[Xu, Ke-Ping; Yu, Fu-Shin; Weiss, Jayne S.] Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA.
[Xu, Ke-Ping; Yu, Fu-Shin; Weiss, Jayne S.] Wayne State Univ, Sch Med, Dept Ophthalmol, Detroit, MI 48201 USA.
[Chodosh, James] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Howe Lab, Cambridge, MA 02138 USA.
[Goldberg, Marc] Inst Eye, Tulsa, OK USA.
[Lu, Da Wen] Triserv Gen Hosp, Taipei, Taiwan.
[Yamada, Masakazu] Natl Tokyo Med Ctr, Natl Inst Sensory Organs, Tokyo, Japan.
[Tervo, Timo M.] Univ Helsinki, Hosp Eye, Helsinki, Finland.
[Grutzmacher, Richard] Grutzmacher Lewis & Sierra, Sacramento, CA USA.
[Croasdale, Chris] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
[Hoeltzenbein, Maria] Max Planck Inst Mol Genet, Berlin, Germany.
[Sutphin, John] Univ Kansas, Med Ctr, Dept Ophthalmol, Prairie Village, KS USA.
[Kruth, Howard S.] NHLBI, Sect Expt Atherosclerosis, NIH, Bethesda, MD 20892 USA.
[Weiss, Jayne S.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.
RP Nickerson, ML (reprint author), NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA.
EM nickersonml@mail.nih.gov; jweiss@med.wayne.edu
RI Dean, Michael/G-8172-2012; Hoeltzenbein, Maria/B-1134-2016
OI Dean, Michael/0000-0003-2234-0631; Hoeltzenbein,
Maria/0000-0002-2451-4247
FU National Eye Institute [EY12972]; Eye Bank Association of America (JSW);
Midwest Eye Banks; National Cancer Institute, National Institutes of
Health [HHSN261200800001E]
FX This work was supported in part by a grant from the National Eye
Institute (grant EY12972 to J.S.W.) and by funding from the Eye Bank
Association of America (JSW), and the Midwest Eye Banks (J.S.W. and
K.-P.X.). This project has been funded in part with federal funds from
the National Cancer Institute, National Institutes of Health, under
Contract No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the U.S. Government. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 34
TC 29
Z9 32
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2010
VL 5
IS 5
AR e10760
DI 10.1371/journal.pone.0010760
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 600VQ
UT WOS:000278017400016
PM 20505825
ER
PT J
AU Roccaro, AM
Sacco, A
Aujay, M
Ngo, HT
Azab, AK
Azab, F
Quang, P
Maiso, P
Runnels, J
Anderson, KC
Demo, S
Ghobrial, IM
AF Roccaro, Aldo M.
Sacco, Antonio
Aujay, Monette
Ngo, Hai T.
Azab, Abdel Kareem
Azab, Feda
Quang, Phong
Maiso, Patricia
Runnels, Judith
Anderson, Kenneth C.
Demo, Susan
Ghobrial, Irene M.
TI Selective inhibition of chymotrypsin-like activity of the
immunoproteasome and constitutive proteasome in Waldenstrom
macroglobulinemia
SO BLOOD
LA English
DT Article
ID MULTIPLE-MYELOMA CELLS; ENDOPLASMIC-RETICULUM STRESS; IN-VITRO; KAPPA-B;
PATHWAY; BORTEZOMIB; TARGET; CYTOTOXICITY; SURVIVAL; THERAPY
AB Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has been successfully tested in clinical trials. Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-target effects. Selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive proteasome 20S (c20S) and immunoproteasome 20S (i20S) represents a sufficient and successful strategy to induce antineoplastic effect in hematologic tumors. We therefore studied ONX0912, a novel selective, irreversible inhibitor of the CT-L activity of i20S and c20S. Primary WM cells express higher level of i20S compared with c20S, and that ONX0912 inhibited the CT-L activity of both i20S and c20S, leading to induction of toxicity in primary WM cells, as well as of apoptosis through c-Jun N-terminal kinase activation, nuclear factor kappa B (NF-kappa B) inhibition, caspase cleavage, and initiation of the unfolded protein response. Importantly, ONX0912 exerted toxicity in WM cells, by reducing bone marrow (BM)derived interleukin-6 (IL-6) and insulinlike growth factor 1 (IGF-1) secretion, thus inhibiting BM-induced p-Akt and phosphorylated extracellular signal-related kinase (p-ERK) activation in WM cells. These findings suggest that targeting i20S and c20S CT-L activity by ONX0912 represents a valid antitumor therapy in WM. (Blood. 2010; 115(20): 4051-4060)
C1 [Roccaro, Aldo M.; Sacco, Antonio; Ngo, Hai T.; Azab, Abdel Kareem; Azab, Feda; Quang, Phong; Maiso, Patricia; Runnels, Judith; Anderson, Kenneth C.; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Roccaro, Aldo M.; Sacco, Antonio; Ngo, Hai T.; Azab, Abdel Kareem; Azab, Feda; Quang, Phong; Maiso, Patricia; Runnels, Judith; Anderson, Kenneth C.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Boston, MA USA.
[Aujay, Monette; Demo, Susan] Onyx Pharmaceut, Emeryville, CA USA.
RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, 44 Binney St,Mayer 548A, Boston, MA 02115 USA.
EM irene_ghobrial@dfci.harvard.edu
RI Sacco, Antonio/K-4681-2016;
OI Sacco, Antonio/0000-0003-2945-9416; Maiso, Patricia/0000-0003-3745-1924;
Roccaro, Aldo/0000-0002-1872-5128
FU International Waldenstrom Macroglobulinemia Foundation (IWMF); [R21
1R21CA126119-01]
FX This study was supported in part by R21 1R21CA126119-01 and the
International Waldenstrom Macroglobulinemia Foundation (IWMF). This work
was supported by the Michelle and Steven Kirsch laboratory for
Waldenstrom and the Heje fellowship for Waldenstrom.
NR 32
TC 44
Z9 45
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 20
PY 2010
VL 115
IS 20
BP 4051
EP 4060
DI 10.1182/blood-2009-09-243402
PG 10
WC Hematology
SC Hematology
GA 599OS
UT WOS:000277923600010
PM 20110419
ER
PT J
AU Schulz, C
Leuschen, NV
Frohlich, T
Lorenz, M
Pfeiler, S
Gleissner, CA
Kremmer, E
Kessler, M
Khandoga, AG
Engelmann, B
Ley, K
Massberg, S
Arnold, GJ
AF Schulz, Christian
Leuschen, Nina V.
Froehlich, Thomas
Lorenz, Michael
Pfeiler, Susanne
Gleissner, Christian A.
Kremmer, Elisabeth
Kessler, Mirjam
Khandoga, Alexander G.
Engelmann, Bernd
Ley, Klaus
Massberg, Steffen
Arnold, Georg J.
TI Identification of novel downstream targets of platelet glycoprotein VI
activation by differential proteome analysis: implications for thrombus
formation
SO BLOOD
LA English
DT Article
ID ALDOSE REDUCTASE INHIBITOR; ACTIN-RELATED PROTEIN; RECEPTOR GAMMA-CHAIN;
COLLAGEN RECEPTOR; DISULFIDE-ISOMERASE; GEL-ELECTROPHORESIS;
ENDOTHELIAL-CELLS; IN-VIVO; PHOSPHORYLATION; AGGREGATION
AB Platelets play a key role in hemostasis and various diseases including arterial thrombosis. Glycoprotein VI (GPVI) mediates adhesion to collagen structures exposed at sites of vascular injury and subsequent platelet activation. We determined the effects of specific activation of GPVI on the human platelet proteome. Isolated human platelets were stimulated with an activating monoclonal antibody specific for GPVI. Platelet proteins were analyzed by 2-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry. We identified 8 differentially abundant proteins associated with cell signaling, metabolism, organization and rearrangement of the cytoskeleton, and membrane trafficking. Differentially abundant proteins included aldose reductase (AR), beta-centractin, charged multivesicular body protein 3, Src substrate cortactin, ERp57, and pleckstrin. Importantly, GPVI-modulated protein abundance was functionally relevant. Correspondingly, AR enzyme activity significantly increased upon GPVI activation and inhibition of AR resulted in reduced platelet aggregation. Furthermore, ERp57 was re-leased upon ligation of platelet GPVI and increased the activity of tissue factor, a major initiator of blood coagulation. In summary, GPVI activation results in differential changes in abundance of platelet proteins, including AR and ERp57, which support platelet aggregation and platelet-dependent coagulation. These results provide further insight into the mechanisms that underlie platelet activation through the GPVI receptor and may help to identify novel pharmacologic targets. (Blood. 2010; 115(20): 4102-4110)
C1 [Schulz, Christian; Leuschen, Nina V.; Lorenz, Michael; Kessler, Mirjam; Khandoga, Alexander G.; Massberg, Steffen] Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany.
[Leuschen, Nina V.] Univ Cologne, Inst Genet, Dept Mouse Genet & Metab, D-5000 Cologne, Germany.
[Froehlich, Thomas; Arnold, Georg J.] Univ Munich, LAFUGA, Gene Ctr, Munich, Germany.
[Pfeiler, Susanne; Engelmann, Bernd] Univ Munich, Inst Klin Chem, Munich, Germany.
[Gleissner, Christian A.; Ley, Klaus] La Jolla Inst Allergy & Immunol, Div Inflammat Biol, La Jolla, CA USA.
[Gleissner, Christian A.] Heidelberg Univ, Dept Cardiol Angiol & Pneumonol, Heidelberg, Germany.
[Kremmer, Elisabeth] Helmholtz Zentrum Munchen, Inst Mol Immunol, Munich, Germany.
[Massberg, Steffen] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
[Massberg, Steffen] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Schulz, C (reprint author), Tech Univ Munich, Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.
EM schulz@dhm.mhn.de
RI Schulz, Christian/J-8545-2012; Frohlich, Thomas/C-6735-2011
OI Schulz, Christian/0000-0003-3878-7833;
FU German Foundation of Heart Research; Dr Helmut Legerlotz-Stiftung;
Deutsche Forschungsgemeinschaft (DFG) [Ma2186-3/1, Ma2186-4/1]
FX This study was supported by grants of the German Foundation of Heart
Research and the Dr Helmut Legerlotz-Stiftung (C. S.), and grants from
the Deutsche Forschungsgemeinschaft (DFG; Ma2186-3/1 and Ma2186-4/1; S.
M.). S. M. is a Heisenberg fellow of the DFG.
NR 52
TC 33
Z9 35
U1 1
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 20
PY 2010
VL 115
IS 20
BP 4102
EP 4110
DI 10.1182/blood-2009-07-230268
PG 9
WC Hematology
SC Hematology
GA 599OS
UT WOS:000277923600015
PM 20107233
ER
PT J
AU Brown, JA
Stevenson, K
Kim, HT
Cutler, C
Ballen, K
McDonough, S
Reynolds, C
Herrera, M
Liney, D
Ho, V
Kao, G
Armand, P
Koreth, J
Alyea, E
McAfee, S
Attar, E
Dey, B
Spitzer, T
Soiffer, R
Ritz, J
Antin, JH
Boussiotis, VA
AF Brown, Julia A.
Stevenson, Kristen
Kim, Haesook T.
Cutler, Corey
Ballen, Karen
McDonough, Sean
Reynolds, Carol
Herrera, Maria
Liney, Deborah
Ho, Vincent
Kao, Grace
Armand, Philippe
Koreth, John
Alyea, Edwin
McAfee, Steve
Attar, Eyal
Dey, Bimalangshu
Spitzer, Thomas
Soiffer, Robert
Ritz, Jerome
Antin, Joseph H.
Boussiotis, Vassiliki A.
TI Clearance of CMV viremia and survival after double umbilical cord blood
transplantation in adults depends on reconstitution of thymopoiesis
SO BLOOD
LA English
DT Article
ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; IMMUNE
RECONSTITUTION; UNRELATED DONORS; T-LYMPHOCYTES; PERIPHERAL-BLOOD;
CYTOMEGALOVIRUS-INFECTION; HEMATOLOGIC MALIGNANCIES; THYMIC FUNCTION;
RECIPIENTS
AB Umbilical cord blood grafts are increasingly used as sources of hematopoietic stem cells in adults. Data regarding the outcome of this approach in adults are consistent with delayed and insufficient immune reconstitution resulting in high infection-related morbidity and mortality. Using cytomegalovirus (CMV)-specific immunity as a paradigm, we evaluated the status, mechanism, and clinical implications of immune reconstitution in adults with hematologic malignancies undergoing unrelated double unit cord blood transplantation. Our data indicate that CD8(_) T cells capable of secreting interferon-gamma (IFN-gamma) in a CMV-specific enzyme-linked immunosorbent spot (ELISpot) assay are detectable at 8 weeks after transplantation, before reconstitution of thymopoiesis, but fail to clear CMV viremia. Clearance of CMV viremia occurs later and depends on the recovery of CD4(+)CD45RA(+) T cells, reconstitution of thymopoiesis, and attainment of T-cell receptor rearrangement excision circle (TREC) levels of 2000 or more copies/mu g DNA. In addition, overall survival was significantly higher in patients who displayed thymic regeneration and attainment of TREC levels of 2000 or more copies/mu g DNA (P = .005). These results indicate that reconstitution of thymopoiesis is critical for long-term clinical outcome in adult recipients of umbilical cord blood transplant. The trial was prospectively registered at http://www.clinicaltrials.gov (NCT00133367). (Blood. 2010; 115(20): 4111-4119)
C1 [Brown, Julia A.; Boussiotis, Vassiliki A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol & Canc Biol, Boston, MA 02215 USA.
[Stevenson, Kristen; Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA.
[Stevenson, Kristen; Kim, Haesook T.] Dana Farber Canc Inst, Dept Computat Biol, Boston, MA 02115 USA.
[Cutler, Corey; McDonough, Sean; Reynolds, Carol; Herrera, Maria; Liney, Deborah; Ho, Vincent; Kao, Grace; Armand, Philippe; Koreth, John; Alyea, Edwin; Soiffer, Robert; Ritz, Jerome; Antin, Joseph H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ballen, Karen; McAfee, Steve; Attar, Eyal; Dey, Bimalangshu; Spitzer, Thomas] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA.
RP Boussiotis, VA (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol & Canc Biol, 330 Brookline Ave, Boston, MA 02215 USA.
EM vboussio@bidmc.harvard.edu
OI Ritz, Jerome/0000-0001-5526-4669
FU National Institutes of Health [CA123855, AI43552, CA104596, HL087870,
T32CA081156, AI029530, CA142106]
FX This work was supported by grants from the National Institutes of
Health: CA123855, AI43552, CA104596, HL087870 (V. A. B.), T32CA081156
(J.B.), AI029530 and CA142106 (H. T. K., K. S.), and CA142106 (J.H.A.).
NR 49
TC 52
Z9 52
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 20
PY 2010
VL 115
IS 20
BP 4111
EP 4119
DI 10.1182/blood-2009-09-244145
PG 9
WC Hematology
SC Hematology
GA 599OS
UT WOS:000277923600016
PM 20107229
ER
PT J
AU Cheung, WY
Neville, BA
Earle, CC
AF Cheung, Winson Y.
Neville, Bridget A.
Earle, Craig C.
TI Associations Among Cancer Survivorship Discussions, Patient and
Physician Expectations, and Receipt of Follow-Up Care
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; BREAST-CANCER; HEALTH;
OUTCOMES; OLDER; SATISFACTION; TRENDS
AB Purpose
To explore the associations among cancer survivorship discussions, patient-physician expectations, and receipt of follow-up care in cancer survivors.
Patients and Methods
We surveyed cancer survivors about various aspects of their care, including expectations of their providers' roles, whether discussions with a physician had occurred, and self-reported patterns of follow-up. Primary care providers (PCPs) and oncologists were also surveyed for their own perceived roles. We developed a scoring system to evaluate the level of agreement in expectations between patients and physicians and between PCPs and oncologists (where 0 = most discordant and 4 = most concordant). Regression and stratified analyses were conducted to examine the relationships among expectations, discussions, and follow-up.
Results
In total, 535 patients (54%) and 378 physicians (62%) responded. Survivorship care expectations were most discrepant between PCPs and oncologists (mean score, 1.78), moderate between patients and oncologists (mean score, 1.97), and most similar between patients and PCPs (mean score, 2.82). Having a conversation specifically about cancer follow-up was associated with better concordance between patients and oncologists, but not for patients and their PCPs or between physicians. Better concordance in patient-oncologist expectations also correlated with greater odds of receiving certain aspects of follow-up care, such as influenza vaccinations and physical examinations, but only if a discussion about cancer follow-up had occurred.
Conclusion
A discussion about cancer follow-up may affect survivorship care through its primary influence on patient-oncologist expectations. Further work is required to clarify the aspects of survivorship discussions that are important for optimal cancer survivorship care planning.
C1 [Earle, Craig C.] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada.
British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA.
RP Earle, CC (reprint author), Inst Clin Evaluat Sci, 2075 Bayview Ave,Rm G-106, Toronto, ON M4N 3M5, Canada.
EM craig.earle@ices.on.ca
FU Perini Family Cancer Survivors' Center; Canadian Association of Medical
Oncologists; National Cancer Institute of Canada
FX Supported by funds from the Perini Family Cancer Survivors' Center, an
award from the Canadian Association of Medical Oncologists, and a grant
from the National Cancer Institute of Canada.
NR 22
TC 27
Z9 27
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
BP 2577
EP 2583
DI 10.1200/JCO.2009.26.4549
PG 7
WC Oncology
SC Oncology
GA 598JO
UT WOS:000277832400014
PM 20406932
ER
PT J
AU Peppercorn, J
Shapira, I
Collyar, D
Deshields, T
Lin, N
Krop, I
Grunwald, H
Friedman, P
Partridge, AH
Schilsky, RL
Bertagnolli, MM
AF Peppercorn, Jeffrey
Shapira, Iuliana
Collyar, Deborah
Deshields, Teresa
Lin, Nancy
Krop, Ian
Grunwald, Hans
Friedman, Paula
Partridge, Ann H.
Schilsky, Richard L.
Bertagnolli, Monica M.
TI Ethics of Mandatory Research Biopsy for Correlative End Points Within
Clinical Trials in Oncology
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CHRONIC MYELOID-LEUKEMIA; LOW-DOSE CYTARABINE; CELL LUNG-CANCER;
BREAST-CANCER; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; MOLECULAR
SUBTYPES; ANTICANCER AGENTS; PROSTATE-CANCER; GENE-MUTATIONS
AB Clinical investigators in oncology are increasingly interested in using molecular analysis of cancer tissue to understand the biologic bases of response or resistance to novel interventions and to develop prognostic and predictive biomarkers that will guide clinical decision making. Some scientific questions of this nature can only be addressed, or may best be addressed, through the conduct of a clinical trial in which research biopsies are obtained from all participants. However, trial designs with mandatory research biopsies have raised ethical concerns related to the risk of harm to participants, the adequacy of voluntary informed consent, and the potential for misunderstanding among research participants when access to an experimental intervention is linked to the requirement to undergo a research biopsy. In consideration of the ethical and scientific issues at stake in this debate, the Cancer and Leukemia Group B Ethics Committee proposes guidelines for clinical trials involving mandatory research biopsies. Any cancer clinical trial that requires research biopsies of participants must be well designed to address the scientific question, obtain the biopsy in a way that minimizes risk, and ensure that research participants are fully informed of the risks, rationale, and requirements of the study, as well as of treatment alternatives. Further guidelines and discussions of this issue are specified in this position paper. We feel that if these principles are respected, an informed adult with cancer can both understand and voluntarily consent to participation in a clinical trial involving mandatory research biopsy for scientific end points.
C1 [Peppercorn, Jeffrey] Duke Univ, Med Ctr, Div Med Oncol, Duke Comprehens Canc Ctr, Durham, NC 27710 USA.
N Shore Univ Hosp, Manhasset, NY USA.
Mt Sinai Queens Hosp Ctr, Jamaica, NY USA.
Patient Advocates Res, Danville, CA USA.
Washington Univ, Sch Med, St Louis, MO USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Canc & Leukemia Grp B Cent Off, Chicago, IL USA.
RP Peppercorn, J (reprint author), Duke Univ, Med Ctr, Div Med Oncol, Duke Comprehens Canc Ctr, Box 3446, Durham, NC 27710 USA.
EM jeffrey.peppercorn@duke.edu
FU American Society of Clinical Oncology Foundation; Breast Cancer Research
Foundation; Greenwall Foundation
FX Supported by the American Society of Clinical Oncology Foundation
(J.P.), Breast Cancer Research Foundation (J.P.), and the Greenwall
Foundation Faculty Scholars Program in Bioethics (J.P.).
NR 46
TC 33
Z9 33
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
BP 2635
EP 2640
DI 10.1200/JCO.2009.27.2443
PG 6
WC Oncology
SC Oncology
GA 598JO
UT WOS:000277832400021
PM 20406927
ER
PT J
AU Abel, GA
Neville, BA
Weeks, JC
Stone, RM
AF Abel, G. A.
Neville, B. A.
Weeks, J. C.
Stone, R. M.
TI Assessment of performance measures for patients with the myclodysplastic
syndrome (MDS) in the United States
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Abel, G. A.; Neville, B. A.; Weeks, J. C.; Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6002
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004281
ER
PT J
AU Abou-Nassar, K
Stevenson, K
Antin, JH
Freedman, A
AF Abou-Nassar, K.
Stevenson, K.
Antin, J. H.
Freedman, A.
TI (90)y-ibritumomab tiuxetan followed by reduced-intensity conditioning
(RIC) and allogeneic stem-cell transplantation (SCT) in patients with
high-risk relapsed, refractory, or transformed follicular lymphoma (FL).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Partners Canc Care, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6538
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004474
ER
PT J
AU Alsina, M
Lonial, S
Weber, DM
Coutre, SE
Kang, BP
Glynos, T
Warsi, G
Snodgrass, SM
Richardson, PG
AF Alsina, M.
Lonial, S.
Weber, D. M.
Coutre, S. E.
Kang, B. P.
Glynos, T.
Warsi, G.
Snodgrass, S. M.
Richardson, P. G.
TI PANORAMA 2: A phase II study of panobinostat (LBH589) in combination
with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed
and BTZ-refractory multiple myeloma (MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS308
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002308
ER
PT J
AU Anand, A
Scher, HI
Beer, TM
Higano, CE
Danila, DC
Taplin, M
Efstathiou, E
Hirmand, M
Sawyers, CL
Heller, G
AF Anand, A.
Scher, H. I.
Beer, T. M.
Higano, C. E.
Danila, D. C.
Taplin, M.
Efstathiou, E.
Hirmand, M.
Sawyers, C. L.
Heller, G.
CA Prostate Canc Clin Trials
TI Circulating tumor cells (CTC) and prostate specific antigen (PSA) as
response indicator biomarkers in chemotherapy-naive patients with
progressive castration-resistant prostate cancer(CRPC) treated with
MDV3100.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Univ Washington, Sch Med, Seattle, WA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Medivation Inc, San Francisco, CA USA.
RI Anand, Aseem/P-1214-2014; Sawyers, Charles/G-5327-2016
OI Anand, Aseem/0000-0002-3606-540X;
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4546
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003669
ER
PT J
AU Anaya, DA
Richardson, PA
Albo, D
Artinyan, A
Petersen, NJ
Awad, SS
Berger, DH
Cormier, JN
AF Anaya, D. A.
Richardson, P. A.
Albo, D.
Artinyan, A.
Petersen, N. J.
Awad, S. S.
Berger, D. H.
Cormier, J. N.
TI Treatment patterns in patients with colorectal liver metastasis: A
cohort study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3628
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003440
ER
PT J
AU Anderson, KC
Weller, E
Lonial, S
Jakubowiak, AJ
Jagannath, S
Raje, NS
Avigan, D
Knight, RD
Esseltine, D
Richardson, PG
AF Anderson, K. C.
Weller, E.
Lonial, S.
Jakubowiak, A. J.
Jagannath, S.
Raje, N. S.
Avigan, D.
Knight, R. D.
Esseltine, D.
Richardson, P. G.
TI Lenalidomide, bortezomib, and dexamethasone in patients with newly
diagnosed multiple myeloma (MM): Final results of a multicenter phase
I/II study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
St Vincent Catholic Med Ctr, New York, NY USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Celgene Corp, Summit, NJ USA.
Millennium Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8016
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005036
ER
PT J
AU Anderson, KS
Wong, J
Posner, MR
Riemer, AB
Lorch, JH
Haddad, RI
Bryan, J
Mclean, M
Kelsey, K
AF Anderson, K. S.
Wong, J.
Posner, M. R.
Riemer, A. B.
Lorch, J. H.
Haddad, R. I.
Bryan, J.
Mclean, M.
Kelsey, K.
TI Detection of antibodies to the HPV16 proteome in head and neck cancer
patient sera
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Merck & Co Inc, West Point, PA USA.
Boston Univ, Sch Publ Hlth, Boston, MA USA.
Brown Univ, Providence, RI 02912 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5545
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004222
ER
PT J
AU Avigan, D
Rosenblatt, J
Vasir, B
Atkins, MB
McDermott, DF
Somaiya, P
Mills, H
Fitzgerald, D
Dombagoda, D
Kufe, DW
AF Avigan, D.
Rosenblatt, J.
Vasir, B.
Atkins, M. B.
McDermott, D. F.
Somaiya, P.
Mills, H.
Fitzgerald, D.
Dombagoda, D.
Kufe, D. W.
TI Vaccination with DC/RCC fusions following cytoreductive nophrectomy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2511
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003103
ER
PT J
AU Azzi, GR
Schutz, FA
Je, Y
Choueiri, TK
AF Azzi, G. R.
Schutz, F. A.
Je, Y.
Choueiri, T. K.
TI Bevacizumab (BEV) and the risk of arterial thromboembolic evets (ATE) in
patients with renal cell carcinoma and other cancers: A large
comprehensive meta-analysis of more than 13,000 patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4609
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003732
ER
PT J
AU Baer, MR
George, SL
Sanford, BL
Stone, RM
Marcucci, G
Mayer, RJ
Larson, RA
AF Baer, M. R.
George, S. L.
Sanford, B. L.
Stone, R. M.
Marcucci, G.
Mayer, R. J.
Larson, R. A.
TI Treatment of older patients with de novo acute myeloid leukemia (AML)
with one or more postremission chemotherapy courses: Analysis of four
CALGB studies.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
Canc & Leukemia Grp B, Chicago, IL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6531
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004468
ER
PT J
AU Balboni, TA
Paulk, ME
Balboni, MJ
Phelps, AC
Vanderweele, T
Wright, AA
Block, S
Prigerson, HG
AF Balboni, T. A.
Paulk, M. E.
Balboni, M. J.
Phelps, A. C.
Vanderweele, T.
Wright, A. A.
Block, S.
Prigerson, H. G.
TI Contrasting effects of religious/spiritual support front religious
communities versus medical teams on advanced cancer patient end-of-life
care
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9012
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005279
ER
PT J
AU Bardia, A
Huang, P
Zhang, Z
Sokoll, L
Ingle, JN
Carey, LA
Lin, NU
Nanda, R
Viswanathan, K
Wolff, AC
AF Bardia, A.
Huang, P.
Zhang, Z.
Sokoll, L.
Ingle, J. N.
Carey, L. A.
Lin, N. U.
Nanda, R.
Viswanathan, K.
Wolff, A. C.
CA Translational Breast Canc Res Cons
TI Circulating tumor cell (CTC) and CA2729 as predictors of outcome in
patients with metastatic breast cancer (MBC) in the prospective TBCRC
005 biomarker study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA.
Mayo Clin Rochester, Rochester, MN USA.
Univ N Carolina, Chapel Hill, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 1001
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002520
ER
PT J
AU Bartolomeo, J
Norden, AD
Drappatz, J
Ciampa, AS
Doherty, LM
LaFrankie, DC
Quant, EC
Beroukhim, R
Wen, PY
AF Bartolomeo, J.
Norden, A. D.
Drappatz, J.
Ciampa, A. S.
Doherty, L. M.
LaFrankie, D. C.
Quant, E. C.
Beroukhim, R.
Wen, P. Y.
TI Safety of concurrent bevacizumab therapy and anticoagulation in
high-grade glioma patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Bartolomeo, J.; Norden, A. D.; Drappatz, J.; Ciampa, A. S.; Doherty, L. M.; LaFrankie, D. C.; Quant, E. C.; Beroukhim, R.; Wen, P. Y.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2043
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003038
ER
PT J
AU Basch, EM
Reeve, BB
Cleeland, CS
Sloan, JA
Mendoza, TR
Abemethy, AP
Bruner, D
Minasian, LM
Burke, LB
Schrag, D
AF Basch, E. M.
Reeve, B. B.
Cleeland, C. S.
Sloan, J. A.
Mendoza, T. R.
Abemethy, A. P.
Bruner, D.
Minasian, L. M.
Burke, L. B.
Schrag, D.
CA PRO-CTCAE Investigators
TI Development of the patient-reported version of the common terminology
criteria for adverse events (PRO-CTCAE)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NCI, Bethesda, MD 20892 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Mayo Clin Rochester, Rochester, MN USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
US FDA, Silver Spring, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e19605
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852001668
ER
PT J
AU Batchu, RB
Semaan, A
Seward, SM
Qazi, A
Chamala, S
Bryant, CS
Steffes, C
Kumar, S
Shammas, MA
Weaver, DW
AF Batchu, R. B.
Semaan, A.
Seward, S. M.
Qazi, A.
Chamala, S.
Bryant, C. S.
Steffes, C.
Kumar, S.
Shammas, M. A.
Weaver, D. W.
TI Relationship of miR-101 and targeted epigenetic silencing of EzH2 on
cell growth and invasiveness in ovarian cancer cells.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Wayne State Univ, Dept Surg, Detroit, MI USA.
Wayne State Univ, Detroit, MI USA.
Detroit Med Ctr, Detroit, MI USA.
Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e15538
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852001189
ER
PT J
AU Beadling, C
Heinrich, MC
Schuff, K
Druker, BJ
Corless, CL
AF Beadling, C.
Heinrich, M. C.
Schuff, K.
Druker, B. J.
Corless, C. L.
TI Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a
personalized cancer medicine registry
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10503
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005611
ER
PT J
AU Beer, TM
Rademacher, BL
Geng, H
Pittsenbarger, J
Garzotto, M
Nelson, P
Higano, CS
Qian, DZ
AF Beer, T. M.
Rademacher, B. L.
Geng, H.
Pittsenbarger, J.
Garzotto, M.
Nelson, P.
Higano, C. S.
Qian, D. Z.
TI Effect of ID1 expression change following chemotherapy on chemotherapy
sensitivity.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Washington, Sch Med, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4548
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003671
ER
PT J
AU Berlin, J
Catalano, PJ
Feng, Y
Lowy, AM
Blackstock, AW
Philip, PA
McWilliams, RR
Abbruzzese, JL
Benson, AB
AF Berlin, J.
Catalano, P. J.
Feng, Y.
Lowy, A. M.
Blackstock, A. W.
Philip, P. A.
McWilliams, R. R.
Abbruzzese, J. L.
Benson, A. B.
TI ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or
bevacizumab (B) in combination with gemcitabine (G) and in combination
with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx)
for patients (pts) with completely resected pancreatic adenocarcinoma
(PC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calif San Diego, San Diego Moores Canc Ctr, San Diego, CA 92103 USA.
Wake Forest Univ, Winston Salem, NC 27109 USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Mayo Clin, Rochester, MN USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
NR 0
TC 1
Z9 1
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4034
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003500
ER
PT J
AU Bhowmik, S
Lu, W
Rosenthal, DS
AF Bhowmik, S.
Lu, W.
Rosenthal, D. S.
TI Effects of Chinese herbal medicine on cytochrome P450, a systematic
review
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Osher Res Ctr, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e13150
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000364
ER
PT J
AU Blakeley, JO
Ye, X
Grossman, SA
Mikkelsen, T
Rosenfeld, MR
Bradley, CR
Eichler, AF
Nabors, LB
Desideri, S
Supko, JG
AF Blakeley, J. O.
Ye, X.
Grossman, S. A.
Mikkelsen, T.
Rosenfeld, M. R.
Bradley, C. R.
Eichler, A. F.
Nabors, L. B.
Desideri, S.
Supko, J. G.
CA Adult Brain Tumor Consortium
TI Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination
with temozolomide (TMZ) in malignant glioma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Johns Hopkins Univ, Baltimore, MD USA.
Johns Hopkins Comprehens Canc Ctr, Baltimore, MD USA.
Henry Ford Hlth Syst, Detroit, MI USA.
Univ Penn, Philadelphia, PA 19104 USA.
BiPar Sci, San Francisco, CA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2012
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003007
ER
PT J
AU Blaszkowsky, LS
Abrams, TA
Miksad, RA
Zheng, H
Meyerhardt, JA
Schrag, D
Kwak, EL
Fuchs, C
Ryan, DP
Zhu, AX
AF Blaszkowsky, L. S.
Abrams, T. A.
Miksad, R. A.
Zheng, H.
Meyerhardt, J. A.
Schrag, D.
Kwak, E. L.
Fuchs, C.
Ryan, D. P.
Zhu, A. X.
TI Phase I/II study of everolimus in patients with advanced hepatocellular
carcinoma (HCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e14542
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000673
ER
PT J
AU Bradbury, AR
Patrick-Miller, LJ
Tuchman, L
Moore, C
Rauch, P
Sands, CB
Schmidheiser, H
Daly, MB
AF Bradbury, A. R.
Patrick-Miller, L. J.
Tuchman, L.
Moore, C.
Rauch, P.
Sands, C. B.
Schmidheiser, H.
Daly, M. B.
TI Knowledge and perceptions of breast cancer risk in adolescent girls at
high risk and population risk for breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Canc Inst New Jersey, New Brunswick, NJ USA.
Childrens Natl Med Ctr, Washington, DC 20010 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e12037
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000165
ER
PT J
AU Brawer, MK
Smith, MR
Malkowicz, SB
Hancock, ML
Morton, RA
Steiner, MS
AF Brawer, M. K.
Smith, M. R.
Malkowicz, S. B.
Hancock, M. L.
Morton, R. A.
Steiner, M. S.
TI Effect of toremifene on fracture risk in men younger than age 80 on
androgen-deprivation therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 GTx Inc, Memphis, TN USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Hosp Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4676
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004045
ER
PT J
AU Buckle, GC
Werner, L
Oh, WK
Bubley, G
Hayes, JH
Weckstein, D
Elfiky, A
Sims, DM
Kantoff, P
Taplin, M
AF Buckle, G. C.
Werner, L.
Oh, W. K.
Bubley, G.
Hayes, J. H.
Weckstein, D.
Elfiky, A.
Sims, D. M.
Kantoff, P.
Taplin, M.
TI Phase II trial of RAD001 (R) and bicalutamide (B) for
castration-resistant prostrate cancer (CPRC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Biostat & Computat Blol, Boston, MA 02115 USA.
Mt Sinai Sch Med, New York, NY USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
New Hampshre Oncol Hematol PA, Hooksett, NH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4660
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004029
ER
PT J
AU Bullock, AJ
Zhang, L
O'Neill, AM
Percy, A
Sukhatme, V
Mier, JW
Atkins, MB
Bhatt, RS
AF Bullock, A. J.
Zhang, L.
O'Neill, A. M.
Percy, A.
Sukhatme, V.
Mier, J. W.
Atkins, M. B.
Bhatt, R. S.
TI Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell
carcinoma (RCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 9
Z9 9
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4630
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003753
ER
PT J
AU Campbell, A
Reckamp, KL
Camidge, DR
Giaccone, G
Gadgeel, SM
Khuri, FR
Engelman, JA
Denis, LJ
O'Connell, JP
Janne, PA
AF Campbell, A.
Reckamp, K. L.
Camidge, D. R.
Giaccone, G.
Gadgeel, S. M.
Khuri, F. R.
Engelman, J. A.
Denis, L. J.
O'Connell, J. P.
Janne, P. A.
TI PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy
in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer
(NSCLC): A phase (P) II trial in advanced NSCLC after failure of
chemotherapy (CT) and erlotinib (E)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Pfizer Inc, New London, CT USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Univ Colorado Denver, Aurora, CO USA.
NCI, Bethesda, MD 20892 USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 20
Z9 20
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7596
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004729
ER
PT J
AU Capelletti, M
Wang, XF
Gu, L
Graziano, SL
Kratzke, RA
Strauss, GM
Maddaus, M
Green, MR
Vokes, EE
Janne, PA
AF Capelletti, M.
Wang, X. F.
Gu, L.
Graziano, S. L.
Kratzke, R. A.
Strauss, G. M.
Maddaus, M.
Green, M. R.
Vokes, E. E.
Janne, P. A.
TI Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in
surgically resected stage IB NSCLC: CALGB 9633.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Canc & Leukemia Grp B Stat Ctr, Durham, NC USA.
SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
Univ Minnesota, Minneapolis, MN USA.
Tufts Med Ctr, Boston, MA USA.
Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA.
Xcenda, Palm Harbor, FL USA.
Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 1
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7008
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004552
ER
PT J
AU Cassier, PA
Stacchiotti, S
Gelderblom, H
Thomas, DM
Van der Graaf, W
Seddon, BM
Julien, D
Wagner, AJ
Blay, J
AF Cassier, P. A.
Stacchiotti, S.
Gelderblom, H.
Thomas, D. M.
Van der Graaf, W.
Seddon, B. M.
Julien, D.
Wagner, A. J.
Blay, J.
TI Imatinib mesylate for the treatment of locally advanced and/or
metastatic pigmented villonodular synovitis/tenosynovial giant cell
tumor (PVNS/TGCT).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Hop Edouard Herriot, Lyon, France.
Ist Nazl Tumori, I-20133 Milan, Italy.
Leiden Univ, Dept Clin Oncol, Med Ctr, Leiden, Netherlands.
Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
Univ Coll London Hosp, London, England.
Inst Gustave Roussy, Villejuif, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Lyon 1, F-69365 Lyon, France.
RI van der Graaf, Winette/A-5006-2014; Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10012
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005521
ER
PT J
AU Cercek, A
Weiser, MR
Goodman, KA
Reidy, DL
Wong, WD
Guillem, JG
Temple, LK
Schrag, D
Paty, P
Saltz, L
AF Cercek, A.
Weiser, M. R.
Goodman, K. A.
Reidy, D. L.
Wong, W. D.
Guillem, J. G.
Temple, L. K.
Schrag, D.
Paty, P.
Saltz, L.
TI Complete pathologic response in the primary of rectal or colon cancer
treated with FOLFOX without radiation.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003460
ER
PT J
AU Chan, JA
Mayer, RJ
Jackson, N
Malinowski, P
Regan, E
Kulke, M
AF Chan, J. A.
Mayer, R. J.
Jackson, N.
Malinowski, P.
Regan, E.
Kulke, M.
TI Phase I study of sorafenib in combination with everolimus (RAD001) in
patients with advanced neuroendocrine tumors (NET)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Chan, J. A.; Mayer, R. J.; Jackson, N.; Malinowski, P.; Regan, E.; Kulke, M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e14597
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000720
ER
PT J
AU Chen, AB
Neville, BA
Schrag, D
AF Chen, A. B.
Neville, B. A.
Schrag, D.
TI Adoption of CT-based simulation and outcomes following radiation for
stage III non-small cell lung cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Chen, A. B.; Neville, B. A.; Schrag, D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6007
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004286
ER
PT J
AU Chen, Y
Kolesar, J
Huang, W
DiPaola, RS
Pins, M
Carducci, MA
Stein, MN
Bubiey, G
Wilding, G
Liu, G
AF Chen, Y.
Kolesar, J.
Huang, W.
DiPaola, R. S.
Pins, M.
Carducci, M. A.
Stein, M. N.
Bubiey, G.
Wilding, G.
Liu, G.
TI Phase II trial of lapatinib in patients in stage D0 prostate cancer
(E5803): Effect of Kras and EGFR status on clinical outcome
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Canc Inst New Jersey, New Brunswick, NJ USA.
Univ Illinois, Coll Med, Chicago, IL USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4668
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004037
ER
PT J
AU Chiorean, EG
Matei, D
Younger, A
Funke, JM
Waddell, MJ
Jones, DR
Hahn, NM
Perkins, SM
Sandrasegaran, K
Sweeney, C
AF Chiorean, E. G.
Matei, D.
Younger, A.
Funke, J. M.
Waddell, M. J.
Jones, D. R.
Hahn, N. M.
Perkins, S. M.
Sandrasegaran, K.
Sweeney, C.
TI Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P)
in patients (pts) with refractory solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
Hoosier Oncol Grp, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3043
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003248
ER
PT J
AU Choueiri, TK
Xie, W
Kollmannsberger, CK
Rini, BI
McDermott, DF
Knox, JJ
Heng, DY
AF Choueiri, T. K.
Xie, W.
Kollmannsberger, C. K.
Rini, B. I.
McDermott, D. F.
Knox, J. J.
Heng, D. Y.
TI The impact of body mass index (HMI) and body surface area (RSA) on
treatment outcome to vascular endothelial growth factor (VEGF)-targeted
therapy in metastatic renal cell carcinoma: Results from a large
international collaboration
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada.
Cleveland Clin, Cleveland, OH 44106 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4524
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003647
ER
PT J
AU Choy, E
Cao, Y
Hornicek, F
Wood, KB
Schwab, JH
Liu, X
Mankin, H
Duan, Z
AF Choy, E.
Cao, Y.
Hornicek, F.
Wood, K. B.
Schwab, J. H.
Liu, X.
Mankin, H.
Duan, Z.
TI Effect of histone deacetylase inhibitor (HDACI) PCI-24781 on
chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell
lines.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Choy, E.; Cao, Y.; Hornicek, F.; Wood, K. B.; Schwab, J. H.; Liu, X.; Mankin, H.; Duan, Z.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10089
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005598
ER
PT J
AU Clancy, MS
Cleary, JM
Mani, S
Choy, E
Wolf, M
Silverman, MH
Gad, SC
Parkman, MH
Shapiro, G
Dezube, BJ
AF Clancy, M. S.
Cleary, J. M.
Mani, S.
Choy, E.
Wolf, M.
Silverman, M. H.
Gad, S. C.
Parkman, M. H.
Shapiro, G.
Dezube, B. J.
TI Novel tubulin inhibitors ALB 109564(a) in patients with solid tumurs: A
phase I trail
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Montefiore Med Ctr, Bronx, NY 10467 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Albany Mol Res Inc, Albany, NY USA.
Aptuit Consulting Inc, Lexington, MA USA.
Gad Consulting Serv, Cary, NC USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e13119
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000338
ER
PT J
AU Cleary, JM
Heath, EI
Kwak, EL
Dezube, BJ
Gandhi, L
Zack, C
Bradley, R
Vukovic, VM
Shapiro, G
LoRusso, P
AF Cleary, J. M.
Heath, E. I.
Kwak, E. L.
Dezube, B. J.
Gandhi, L.
Zack, C.
Bradley, R.
Vukovic, V. M.
Shapiro, G.
LoRusso, P.
TI A phase I dose-escalation study of the Hsp90 inhibitor STA-9090
administered twice weekly in patients with solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Karmanos Canc Inst, Detroit, MI USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Synta Pharmaceut Corp, Lexington, MA USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3083
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003288
ER
PT J
AU Cohen, RB
Janne, PA
Engelman, JA
Martinez, P
Nishida, Y
Gendreau, S
Wu, B
Felip, E
AF Cohen, R. B.
Janne, P. A.
Engelman, J. A.
Martinez, P.
Nishida, Y.
Gendreau, S.
Wu, B.
Felip, E.
TI A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2
inhibitor XL765 (SAR245409) in combination with erlotinib (E) in
patients (pts) with advanced solid fumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
Exelixis, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3015
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003220
ER
PT J
AU Corless, CL
Ballman, KV
Antonescu, C
Blanke, CD
Blackstein, ME
Demetri, GD
von Mehren, M
Maki, RG
Pisters, PW
DeMatteo, RP
AF Corless, C. L.
Ballman, K. V.
Antonescu, C.
Blanke, C. D.
Blackstein, M. E.
Demetri, G. D.
von Mehren, M.
Maki, R. G.
Pisters, P. W.
DeMatteo, R. P.
CA Amer Coll Surg Oncology Grp
TI Relation of tumor pathologic and molecular features to outcome after
surgical resection of localized primary gastrointestinal stromal tumor
(GIST): Results of the intergroup phase III trial ACOSOG Z9001.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Mayo Clin Rochester, Rochester, MN USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ British Columbia, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada.
Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
Harvard Canc Ctr, Ludwig Ctr, Dana Farber Canc Inst, Boston, MA USA.
Sarcoma Ctr, Boston, MA USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 16
Z9 19
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10006
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005515
ER
PT J
AU Cranmer, LD
Chawla, SP
Rushing, DA
Butrynski, JE
Okuno, SH
Adkins, D
Langmuir, VK
Lorente, GA
Kroll, S
Ganjoo, KN
AF Cranmer, L. D.
Chawla, S. P.
Rushing, D. A.
Butrynski, J. E.
Okuno, S. H.
Adkins, D.
Langmuir, V. K.
Lorente, G. A.
Kroll, S.
Ganjoo, K. N.
TI Phase I/III study of TH-302 combined with doxorubicin in soft tissue
sarcoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA.
Sarcoma Oncol Ctr, Santa Monica, CA USA.
Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin, Rochester, MN USA.
Washington Univ, Sch Med, St Louis, MO USA.
Threshold Pharmaceut, Redwood City, CA USA.
Stanford Univ, Palo Alto, CA 94304 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10036
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005545
ER
PT J
AU Da Grace, DI
Yellapragada, S
Yasin, Z
Arce-Lara, CE
AF Da Grace, D. I.
Yellapragada, S.
Yasin, Z.
Arce-Lara, C. E.
TI Retrospective analysis of multiple myeloma survival outcomes in
veterans: Focus on racial differences, age, and novel therapies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Da Grace, D. I.; Yellapragada, S.; Yasin, Z.; Arce-Lara, C. E.] Baylor Coll Med, Dan L Duncan Canc Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8127
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005147
ER
PT J
AU Dandamudi, UB
Ghebremichael, MS
Sosman, JA
Regan, MM
Atkins, MB
Clark, J
Dutcher, JP
Curti, BD
Vaishampayan, UN
Ernstoff, MS
AF Dandamudi, U. B.
Ghebremichael, M. S.
Sosman, J. A.
Regan, M. M.
Atkins, M. B.
Clark, J.
Dutcher, J. P.
Curti, B. D.
Vaishampayan, U. N.
Ernstoff, M. S.
CA Cytokine Working Grp
TI A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in
patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine
Working Group Study (CWGS)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
Montefiore Med Ctr, North Div, New York, NY USA.
Earle A Chiles Res Inst, Portland, OR USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4530
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003653
ER
PT J
AU DeAngelo, DJ
Tefferi, A
Mesa, RA
Paley, CS
Wadleigh, M
Snyder, D
Ondovik, MS
Rine, J
Bhalla, KN
AF DeAngelo, D. J.
Tefferi, A.
Mesa, R. A.
Paley, C. S.
Wadleigh, M.
Snyder, D.
Ondovik, M. S.
Rine, J.
Bhalla, K. N.
TI A phase II trial of oral panobinostat (LBH589), a no deacetylase
inhibitor (DACi) in patients with primary myelofibrosis (PMF),
post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia
vera (PV) myelofibrosis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin Rochester, Rochester, MN USA.
Mayo Clin Arizona, Scottsdale, AZ USA.
Novartis Pharmaceut, E Hanover, NJ USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS283
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002283
ER
PT J
AU del Campo, J
Ciuleanu, T
Sessa, C
Westermann, AM
Roszak, A
Chan, S
Hogberg, T
Zintl, P
Park, YC
Krasner, CN
AF del Campo, J.
Ciuleanu, T.
Sessa, C.
Westermann, A. M.
Roszak, A.
Chan, S.
Hogberg, T.
Zintl, P.
Park, Y. C.
Krasner, C. N.
TI Trabectedin (Tr) as single agent in relapsed ovarian cancer (ROC)
patients (pts) with a platinum-free interval (PFI) of 6 to 12 months
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Vall dHebron Hosp, Barcelona, Spain.
Inst Oncol 1 Chiricuta, Cluj Napoca, Romania.
Osped Reg Bellinzona & Valli, Oncol Inst Southern Switzerland, Bellinzona, Switzerland.
Ctr Dept Med Oncol, Amsterdam, Zuidoost, Netherlands.
Wielkopolsica Ctr Oncol, Poznan, Poland.
Univ Nottingham Hosp, Nottingham NG7 2UH, England.
Nord Soc Gynaecol Oncol, Lund, Sweden.
PharmaMar, Colmenar Vlejo, Madrid, Spain.
Johnson & Johnson Pharmaceut Res & Dev, Titusville, NJ USA.
Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5060
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004116
ER
PT J
AU Demetri, GD
Blay, J
Schoffski, P
Maki, RG
Yovine, AJ
Judson, IR
Casali, PG
Gomez, J
Bayever, E
Le Cesne, A
AF Demetri, G. D.
Blay, J.
Schoffski, P.
Maki, R. G.
Yovine, A. J.
Judson, I. R.
Casali, P. G.
Gomez, J.
Bayever, E.
Le Cesne, A.
TI Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS)
treated in clinical trials (CTs) versus expanded access programs (EAPs):
A decade of experience with single-agent trabectedin (Tr).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Ludwig Ctr, Harvard Canc Ctr, Boston, MA 02115 USA.
Sarcoma Ctr, Boston, MA USA.
Univ Lyon 1, F-69365 Lyon, France.
Catholic Univ Louvain, Leuven Canc Inst, B-3000 Louvain, Belgium.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
PharmaMar, Madrid, Spain.
Canc Res UK Ctr Canc Therapeut, London, England.
Ist Nazl Tumori, I-20133 Milan, Italy.
Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
Inst Gustave Roussy, Villejuif, France.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10029
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005538
ER
PT J
AU Dodgion, CM
Neville, BA
Lipsitz, SR
Schrag, D
Greenberg, CC
AF Dodgion, C. M.
Neville, B. A.
Lipsitz, S. R.
Schrag, D.
Greenberg, C. C.
TI Do older Americans tindrgo stoma reversal following low anterior
resection for rectal cancer?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3656
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003467
ER
PT J
AU Dolly, S
Wagner, AJ
Bendell, JC
Yan, Y
Ware, JA
Mazina, KE
Holden, SN
Derynck, MK
De Bono, JS
Burris, HA
AF Dolly, S.
Wagner, A. J.
Bendell, J. C.
Yan, Y.
Ware, J. A.
Mazina, K. E.
Holden, S. N.
Derynck, M. K.
De Bono, J. S.
Burris, H. A., III
TI A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor
GDC-0980 administered QD in patients with advanced solid tumors or
non-Hodgkin's lymphoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Royal Marsden Hosp, London SW3 6JJ, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Genentech Inc, San Francisco, CA 94080 USA.
Royal Marsden NHS Fdn Trust, Drug Dev Unit, Sutton, Surrey, England.
Inst Canc Res, Sutton, Surrey, England.
Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
NR 0
TC 11
Z9 11
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3079
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003284
ER
PT J
AU Drappatz, J
Brenner, AJ
Rosenfeld, S
Groves, MD
Mikkelsen, T
Schiff, D
Sarantopoulos, J
Wong, E
Wen, PY
Castaigne, J
AF Drappatz, J.
Brenner, A. J.
Rosenfeld, S.
Groves, M. D.
Mikkelsen, T.
Schiff, D.
Sarantopoulos, J.
Wong, E.
Wen, P. Y.
Castaigne, J.
TI ANG1005: Results of a phase I study in patients with recurrent malignant
glioma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA.
Columbia Univ, Med Ctr, New York, NY USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Henry Ford Hlth Syst, Detroit, MI USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Angiochem Inc, Montreal, PQ, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2009
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003004
ER
PT J
AU Drouin, MA
Kollmannsberger, CK
Uronis, HE
Martell, RE
Wang, J
Dubay, M
Dupont, I
Besterman, JM
Hurwitz, H
Shapiro, G
AF Drouin, M. A.
Kollmannsberger, C. K.
Uronis, H. E.
Martell, R. E.
Wang, J.
Dubay, M.
Dupont, I.
Besterman, J. M.
Hurwitz, H.
Shapiro, G.
TI Daily administration of MGCD265 to patients with solid tumors in a
dose-escalation phase 1 study (study 265-101)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 MethylGene Inc, Montreal, PQ, Canada.
BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada.
Duke Univ, Med Ctr, Durham, NC USA.
Tufts Med Ctr, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3106
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003311
ER
PT J
AU Duda, GD
Ancukiewicz, M
Clark, JW
Miksad, RA
Fuchs, C
Ryan, DP
Jain, RK
Zhu, AX
AF Duda, G. D.
Ancukiewicz, M.
Clark, J. W.
Miksad, R. A.
Fuchs, C.
Ryan, D. P.
Jain, R. K.
Zhu, A. X.
TI Early toxicity of sunitinib as a potential predictive biomarker in
advanced hepatocellular carcinoma (HCC) patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4081
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003546
ER
PT J
AU Dumont, AG
Rink, L
Miettinen, M
Joensuu, H
Strosberg, JR
Gronchi, A
Corless, CL
Lazar, AJ
Lev, D
von Mehren, M
AF Dumont, A. G.
Rink, L.
Miettinen, M.
Joensuu, H.
Strosberg, J. R.
Gronchi, A.
Corless, C. L.
Lazar, A. J.
Lev, D.
von Mehren, M.
TI Coexistence of gastrointestinal stromal tumor (GIST) with desmoid tumor
(DT): Case series of 22 patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Armed Forces Inst Pathol, Washington, DC 20306 USA.
Helsinki Univ Cent Hosp, Helsinki, Finland.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Ist Nazl Tumori, I-20133 Milan, Italy.
Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10052
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005561
ER
PT J
AU Edelman, G
Bedell, C
Shapiro, G
Pandya, SS
Kwak, EL
Scheffold, C
Nguyen, LT
Laird, A
Baselga, J
Rodon, J
AF Edelman, G.
Bedell, C.
Shapiro, G.
Pandya, S. S.
Kwak, E. L.
Scheffold, C.
Nguyen, L. T.
Laird, A.
Baselga, J.
Rodon, J.
TI A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor
administered orally to patients (pts) with advanced malignancies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Texas Oncol, Irving, TX USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Exelixis, San Francisco, CA USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
NR 0
TC 18
Z9 18
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3004
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003209
ER
PT J
AU Egloff, AM
Lee, J
Vaezi, AE
Langer, CJ
Forastiere, AA
Quon, H
Burtness, B
Grandis, JR
AF Egloff, A. M.
Lee, J.
Vaezi, A. E.
Langer, C. J.
Forastiere, A. A.
Quon, H.
Burtness, B.
Grandis, J. R.
TI Tumor molecular correlates of unresectable, locally advanced head and
neck squamous cell carcinoma (SCCHN) response to concurrent radiation
(RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG
3303)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Johns Hopkins Univ, Baltimore, MD USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Pittsburgh, Inst Eye & Ear, Pittsburgh, PA 15213 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5537
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004214
ER
PT J
AU Eichler, AF
Kahle, KT
Wang, DL
Joshi, VA
Engelman, JA
Sequist, LV
AF Eichler, A. F.
Kahle, K. T.
Wang, D. L.
Joshi, V. A.
Engelman, J. A.
Sequist, L. V.
TI EGFR mutation status and survival after diagnosis of brain metastasis in
non-small cell lung cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7542
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004675
ER
PT J
AU Eichler, AF
Shih, HA
Sequist, LV
Wen, PY
Jain, RK
Sorensen, AG
Batchelor, T
AF Eichler, A. F.
Shih, H. A.
Sequist, L. V.
Wen, P. Y.
Jain, R. K.
Sorensen, A. G.
Batchelor, T.
TI A phase I study of cediranib plus whole-brain radiation therapy in
patients with brain metastases from non-small cell lung cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS177
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002179
ER
PT J
AU Engelstaedter, V
Cristea, MC
Garber, JE
Neuhausen, SL
Frankel, PH
Sand, S
Steele, L
Matulonis, U
Liu, J
Weitzel, J
AF Engelstaedter, V.
Cristea, M. C.
Garber, J. E.
Neuhausen, S. L.
Frankel, P. H.
Sand, S.
Steele, L.
Matulonis, U.
Liu, J.
Weitzel, J.
TI Clinical characteristics and outcomes of BRCA-associated ovarian cancer
(OC): Genotype and survival
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
City Hope Natl Med Ctr, Duarte, CA 91010 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5017
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004075
ER
PT J
AU Enzinger, PC
Burtness, B
Hollis, D
Niedzwiecki, D
Ilson, D
Benson, AB
Mayer, RJ
Goldberg, RM
AF Enzinger, P. C.
Burtness, B.
Hollis, D.
Niedzwiecki, D.
Ilson, D.
Benson, A. B.
Mayer, R. J.
Goldberg, R. M.
TI A randomized phase II study of three standard chemotherapy regimens
(ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE
junction cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
CALGB Stat Ctr, Durham, NC USA.
Duke Univ, Durham, NC USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
Univ N Carolina, Chapel Hill, NC USA.
NR 0
TC 2
Z9 2
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4006
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003476
ER
PT J
AU Esserman, L
Chu, B
Chung, R
Ozanne, E
Yau, C
Tsing, P
Baehner, FL
Tutt, AN
Moore, DH
Benz, C
AF Esserman, L.
Chu, B.
Chung, R.
Ozanne, E.
Yau, C.
Tsing, P.
Baehner, F. L.
Tutt, A. N.
Moore, D. H.
Benz, C.
TI Risk partitioning model shows need to address time dependence of breast
cancer recurrence.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Buck Inst Age Res, Novato, CA USA.
Guys Hosp, London SE1 9RT, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10605
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005711
ER
PT J
AU Ewer, M
Suter, TM
Lenihan, DJ
Niculescu, L
Breazna, A
Motzer, RJ
Demetri, GD
AF Ewer, M.
Suter, T. M.
Lenihan, D. J.
Niculescu, L.
Breazna, A.
Motzer, R. J.
Demetri, G. D.
TI Sunitinib (SU)-related hypertension in a randomieed placebo
(P)-controlled trial of GIST patients (pts)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Hosp Bern, CH-3010 Bern, Switzerland.
Vanderbilt Heart, Nashville, TN USA.
Pfizer Inc, New York, NY USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Ludwig Ctr, Harvard Canc Ctr, Boston, MA 02115 USA.
Sarcoma Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10059
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005568
ER
PT J
AU Fink, K
Mikkelsen, T
Nabors, LE
Ravin, P
Plotkin, SR
Schiff, D
Hicking, C
Picard, M
Reardon, DA
AF Fink, K.
Mikkelsen, T.
Nabors, L. E.
Ravin, P.
Plotkin, S. R.
Schiff, D.
Hicking, C.
Picard, M.
Reardon, D. A.
TI Long-term effects of cilengitide, a novel integrin inhibitor, in
recurrent glioblastoma: A randomized phase IIa study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Baylor Res Inst, Dallas, TX USA.
Henry Ford Hlth Syst, Detroit, MI USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Univ Massachusetts, Dept Neurol, Worcester, MA 01605 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
Merck KGaA, Darmstadt, Germany.
Duke Univ, Med Ctr, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2010
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003005
ER
PT J
AU Fisch, M
Lee, J
Chang, VT
Wagner, LI
Cella, D
Minasian, LM
McCaskill-Stevens, WJ
Weiss, M
Smith, M
Cleeland, CS
AF Fisch, M.
Lee, J.
Chang, V. T.
Wagner, L. I.
Cella, D.
Minasian, L. M.
McCaskill-Stevens, W. J.
Weiss, M.
Smith, M.
Cleeland, C. S.
TI A prospective evaluation of symptom change over 4 weeks for outpatients
with common solid tumors: Results from E2Z02 (the SOAPP study)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
VA New Jersey Hlth Care Syst, E Orange, NJ USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
Northwestern Univ, Chicago, IL 60611 USA.
NCI, Bethesda, MD 20892 USA.
Minocqua Ctr, Marshfield Clin, Minocqua, WI USA.
Res Advocacy Network, Naperville, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9120
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005385
ER
PT J
AU Flaherty, KT
Lee, SJ
Schuchter, LM
Flaherty, LE
Wright, JJ
Leming, PD
Kirkwood, JM
AF Flaherty, K. T.
Lee, S. J.
Schuchter, L. M.
Flaherty, L. E.
Wright, J. J.
Leming, P. D.
Kirkwood, J. M.
TI Final results of E2603: A double-blind, randomized phase III trial
comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S)
in metastatic melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Wayne State Univ, Detroit, MI USA.
NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA.
Cincinnati Hematol Oncol Inc, Cincinnati, OH USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
NR 0
TC 5
Z9 5
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8511
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005182
ER
PT J
AU Foss, FM
Sjak-Shie, NN
Goy, A
Advani, R
Jacobsen, ED
AF Foss, F. M.
Sjak-Shie, N. N.
Goy, A.
Advani, R.
Jacobsen, E. D.
TI Phase II study of denileukin diftitox with CHOP chemotherapy in
newly-diagnosed PTCL: CONCEPT trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Yale Canc Ctr, New Haven, CT USA.
Ctr Canc Care & Res, St Louis, MO USA.
Hackensack Univ, Med Ctr, Hackensack, NJ USA.
Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8045
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005065
ER
PT J
AU Freedman, RA
Virgo, KS
He, Y
Pavluck, A
Winer, EP
Ward, EM
Keating, NL
AF Freedman, R. A.
Virgo, K. S.
He, Y.
Pavluck, A.
Winer, E. P.
Ward, E. M.
Keating, N. L.
TI Do socioeconomic factors and insurance explain racial/ethnic disparities
in receipt of recommended breast cancer care?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Amer Canc Soc, Atlanta, GA 30329 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 574
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002408
ER
PT J
AU Furman, RR
Byrd, JC
Flinn, IW
Coutre, SE
Benson, DM
Brown, JR
Kahl, BS
WagnerJohnston, ND
Giese, NA
Yu, AS
AF Furman, R. R.
Byrd, J. C.
Flinn, I. W.
Coutre, S. E.
Benson, D. M., Jr.
Brown, J. R.
Kahl, B. S.
WagnerJohnston, N. D.
Giese, N. A.
Yu, A. S.
TI Interim results from a phase I study of CAL-101, a selective oral
inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients
with relapsed or refractory hematologic malignancies.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Weill Cornell Med Coll, New York, NY USA.
Ohio State Univ, Columbus, OH 43210 USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Wisconsin, Madison, WI USA.
Washington Univ, Sch Med, St Louis, MO USA.
Calistoga Pharmaceut Inc, Seattle, WA USA.
NR 0
TC 5
Z9 5
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3032
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003237
ER
PT J
AU Garzotto, M
Hung, A
Beer, TM
Farris, PE
AF Garzotto, M.
Hung, A.
Beer, T. M.
Farris, P. E.
TI Phase I/II study of preoperative intensity-modulated radiation therapy
(IMRT) and docetaxel for high-risk prostate cancer: A platform for
radiosensitizer development
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS250
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002250
ER
PT J
AU Geoerger, B
Kieran, MW
Grupp, S
Blaney, S
Perek, D
Clancy, J
Krygowski, M
Boni, J
Berkenblit, A
Spunt, SL
AF Geoerger, B.
Kieran, M. W.
Grupp, S.
Blaney, S.
Perek, D.
Clancy, J.
Krygowski, M.
Boni, J.
Berkenblit, A.
Spunt, S. L.
TI Phase II study of temsirolimus in children with high-grade glioma,
neuroblastoma, and rhabdomyosarcoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Inst Gustave Roussy, Villejuif, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Childrens Hosp, Philadelphia, PA 19104 USA.
Texas Childrens Canc Ctr, Houston, TX USA.
Ctr Zdowia Dziecka, Inst Pomnik, Warsaw, Poland.
Pfizer Inc, Cambridge, MA USA.
Pfizer Inc, Collegeville, PA USA.
St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9541
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005470
ER
PT J
AU Gerstner, ER
Chen, Q
Batchelor, T
Sorensen, AG
AF Gerstner, E. R.
Chen, Q.
Batchelor, T.
Sorensen, A. G.
TI Use of FLAIR MRI in determining glioblastoma response to cediranib
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Martinos Ctr Biomed Res, Charlestown, MA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2063
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003058
ER
PT J
AU Gibney, G
Eifiky, A
Bussom, S
Hoimes, CJ
Burns, A
McDonough, JA
Rowen, E
Cheng, YC
Kelly, WK
AF Gibney, G.
Eifiky, A.
Bussom, S.
Hoimes, C. J.
Burns, A.
McDonough, J. A.
Rowen, E.
Cheng, Y. C.
Kelly, W. K.
TI A phase II study of oral phenoxodiol in castrate and noncastrate
prostate cancer patients with associated cytokine changes
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Yale Univ, Sch Med, New Haven, CT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Yale Canc Ctr, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4661
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004030
ER
PT J
AU Gibney, G
Elfiky, A
Holmes, CJ
Burns, A
Rowen, E
McDonough, JA
Lampert, R
Gross, C
Kelly, WK
AF Gibney, G.
Elfiky, A.
Holmes, C. J.
Burns, A.
Rowen, E.
McDonough, J. A.
Lampert, R.
Gross, C.
Kelly, W. K.
TI Assessing cardiae risk using heart rate variability in a phase II study
of androgen-deprivation therapy and bevacizumab in noncastrate
metastatic prostate cancer patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Yale Univ, Sch Med, New Haven, CT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Yale Canc Ctr, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS244
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002244
ER
PT J
AU Gibson, MK
Catalano, PJ
Kleinberg, L
Staley, CA
Montgomery, E
Song, W
Mulcahy, MF
Leichman, LP
Benson, AB
AF Gibson, M. K.
Catalano, P. J.
Kleinberg, L.
Staley, C. A.
Montgomery, E.
Song, W.
Mulcahy, M. F.
Leichman, L. P.
Benson, A. B.
TI E2205: A phase II study to measure response rate and toxicity of
neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional
5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative
docetaxel (DT) and C in patients with operable adenocarcinoma of the
esophagus
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Univ, Baltimore, MD USA.
Emory Clin, Atlanta, GA 30322 USA.
Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA.
Pottstown Canc Ctr, Pottstown, PA USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
Desert Reg Med Ctr, Ctr Comprehens Canc, Palm Springs, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4064
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003530
ER
PT J
AU Gollob, J
Infante, JR
Shapiro, G
LoRusso, P
Dezube, BJ
Heymach, J
Cehelsky, J
Falzone, R
Vaishnaw, A
Burris, HA
AF Gollob, J.
Infante, J. R.
Shapiro, G.
LoRusso, P.
Dezube, B. J.
Heymach, J.
Cehelsky, J.
Falzone, R.
Vaishnaw, A.
Burris, H. A., III
TI Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi
therapeutic for solid tumors with liver involvement.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Alnylam Pharmaceut, Cambridge, MA USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Tennessee Oncol, Nashville, TN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3042
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003247
ER
PT J
AU Gramza, AW
Patterson, J
Peters, J
Kaufman, M
Wise, S
Flynn, D
AF Gramza, A. W.
Patterson, J.
Peters, J.
Kaufman, M.
Wise, S.
Flynn, D.
TI Activity of novel RET inhibitors against RET genotypes associated with
medullary thyroid cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Deciphera Pharmaceut, Lawrence, KS USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5559
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004236
ER
PT J
AU Guo, J
Si, L
Kong, Y
Xu, XW
Flaherty, KT
Corless, CL
Zhu, YY
Li, L
Li, HF
AF Guo, J.
Si, L.
Kong, Y.
Xu, X. W.
Flaherty, K. T.
Corless, C. L.
Zhu, Y. Y.
Li, L.
Li, H. F.
TI A phase II study of imatinib for advanced melanoma patients with KIT
aberrations
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Beijing Canc Hosp, Beijing, Peoples R China.
Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8527
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005197
ER
PT J
AU Haddad, RI
Tishler, RB
Adkins, D
Khuri, FR
Clark, J
Lorch, JH
Wirth, LJ
Sarlis, NJ
Jaffa, Z
Posner, MR
AF Haddad, R. I.
Tishler, R. B.
Adkins, D.
Khuri, F. R.
Clark, J.
Lorch, J. H.
Wirth, L. J.
Sarlis, N. J.
Jaffa, Z.
Posner, M. R.
CA Paradigm Study Grp
TI The PARADIGM trial: A phase III study comparing sequential therapy (ST)
to concurrent chemoradiotherapy (CRT) in locally advanced head and neck
cancer (LAHNC): Preliminary toxicity report
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
Washington Univ, Sch Med, St Louis, MO USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Sanofi Aventis US, Bridgewater, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5563
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004240
ER
PT J
AU Hahn, NM
Stadler, WM
Zon, R
Waterhouse, DM
Picus, J
Nattam, SR
Johnson, CS
Perkins, SM
Waddell, MJ
Sweeney, C
AF Hahn, N. M.
Stadler, W. M.
Zon, R.
Waterhouse, D. M.
Picus, J.
Nattam, S. R.
Johnson, C. S.
Perkins, S. M.
Waddell, M. J.
Sweeney, C.
TI Mature results from Hoosier Oncology Group GU04-75 phase II trial of
cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line
chemotherapy for metastatic urothelial carcinoma (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
Univ Chicago, Chicago, IL 60637 USA.
Michiana Hematol Oncol PC, South Bend, IN USA.
Oncol Hematol Care Inc, Cincinnati, OH USA.
Washington Univ, Sch Med, St Louis, MO USA.
Ft Wayne Med Oncol & Hematol, Ft Wayne, IN USA.
Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
Hoosier Oncol Grp, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4541
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003664
ER
PT J
AU Hamann, HA
Lee, J
Schiller, JH
Horn, L
Cleeland, CS
Manola, J
Wagner, LI
Chang, VT
Fisch, M
AF Hamann, H. A.
Lee, J.
Schiller, J. H.
Horn, L.
Cleeland, C. S.
Manola, J.
Wagner, L. I.
Chang, V. T.
Fisch, M.
TI Clinician perceptions of care difficulty and quality of life for lung
cancer patients: Results from the ECOG SOAP? study (E2Z02)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
VA New Jersey Hlth Care Syst, E Orange, NJ USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9102
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005367
ER
PT J
AU Hassett, MJ
Niland, JC
Hughes, ME
Theriault, RL
Blayney, DW
Wong, Y
Hudis, C
Marcom, PK
Laronga, C
Weeks, JC
AF Hassett, M. J.
Niland, J. C.
Hughes, M. E.
Theriault, R. L.
Blayney, D. W.
Wong, Y.
Hudis, C.
Marcom, P. K.
Laronga, C.
Weeks, J. C.
TI Gene expression profile testing for breast cancer: Patterns and
predictors of use and impact on chemotherapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 566
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002400
ER
PT J
AU Hay, J
Atkinson, TM
Mendoza, TR
Reeve, BB
Willis, G
Gagne, JJ
Abernethy, AP
Cleeland, CS
Schrag, D
Basch, EM
AF Hay, J.
Atkinson, T. M.
Mendoza, T. R.
Reeve, B. B.
Willis, G.
Gagne, J. J.
Abernethy, A. P.
Cleeland, C. S.
Schrag, D.
Basch, E. M.
TI Refinement of the patient-reported outcomes version of the common
terminology criteria for adverse events (PRO-CTCAE) via cognitive
interviewing.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NCI, Bethesda, MD 20892 USA.
Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9060
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005326
ER
PT J
AU Hayes, JH
Ollendorf, DA
Barry, MJ
Pearson, SD
McMahon, PM
AF Hayes, J. H.
Ollendorf, D. A.
Barry, M. J.
Pearson, S. D.
McMahon, P. M.
TI Therapeutic options for low-risk prostate cancer: A cost-effectiveness
analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Inst Clin & Econ Review, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6012
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004291
ER
PT J
AU Heinrich, MC
Wise, S
Hood, M
Smith, B
Kaufman, M
Lu, W
Wang, Y
Griffith, D
Flynn, D
Fletcher, JA
AF Heinrich, M. C.
Wise, S.
Hood, M.
Smith, B.
Kaufman, M.
Lu, W.
Wang, Y.
Griffith, D.
Flynn, D.
Fletcher, J. A.
TI In vitro activity of novel KIT/PDGFRA switch pocket kinase inhibitors
against mutations associated with drug-resistant GI stromal tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Deciphera Pharmaceut, Lawrence, KS USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10007
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005516
ER
PT J
AU Heist, RS
Duda, GD
Sahani, D
Pennell, NA
Neal, JW
Ancukiewicz, M
Engelman, JA
Lynch, TJ
Jain, RK
AF Heist, R. S.
Duda, G. D.
Sahani, D.
Pennell, N. A.
Neal, J. W.
Ancukiewicz, M.
Engelman, J. A.
Lynch, T. J.
Jain, R. K.
TI In vivo assessment of the effects of bevacizumab in advanced non-small
cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Yale Canc Ctr, New Haven, CT USA.
Smilow Canc Hosp, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7612
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004744
ER
PT J
AU Henderson, TO
Whitton, J
Leisenring, W
Neglia, JP
Meadows, AT
Oeffinger, KC
Diller, L
Armstrong, GT
Robison, LL
Nathan, PC
AF Henderson, T. O.
Whitton, J.
Leisenring, W.
Neglia, J. P.
Meadows, A. T.
Oeffinger, K. C.
Diller, L.
Armstrong, G. T.
Robison, L. L.
Nathan, P. C.
TI Gastrointestinal malignancies as a subsequent malignant neoplasm in
survivors of childhood cancer: A report from the Childhood Cancer
Survivor Study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Minnesota, Minneapolis, MN USA.
Childrens Hosp, Philadelphia, PA 19104 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9520
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005449
ER
PT J
AU Heng, DY
Xie, W
Bjarnason, GA
Vaishampayan, UN
Donskov, F
Wood, L
Knox, JJ
Tan, M
Kollmannsberger, CK
Rini, BI
Choueiri, TK
AF Heng, D. Y.
Xie, W.
Bjarnason, G. A.
Vaishampayan, U. N.
Donskov, F.
Wood, L.
Knox, J. J.
Tan, M.
Kollmannsberger, C. K.
Rini, B. I.
Choueiri, T. K.
TI A unified prognostic model for first- and second-line targeted therapy
in metastatic renal cell carcinoma (mRCC): Results from a large
international study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
Queen Elizabeth II Heath Sci Ctr, Halifax, NS, Canada.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
Natl Canc Ctr Singapore, Singapore, Singapore.
BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada.
Cleveland Clin, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4523
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003646
ER
PT J
AU Hensley, ML
Wathen, K
Maki, RG
Araujo, DM
Sutton, G
Priebat, DA
George, S
Baker, LH
AF Hensley, M. L.
Wathen, K.
Maki, R. G.
Araujo, D. M.
Sutton, G.
Priebat, D. A.
George, S.
Baker, L. H.
TI Adjuvant treatment of high-risk primary uterine Ieiomyosarcoma with
gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of
phase II multicenter trial SARC005.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
St Vincents Hosp & Hlth Serv, Indianapolis, IN USA.
Washington Hosp Ctr, Washington, DC 20010 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10021
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005530
ER
PT J
AU Heon, S
Yeap, BY
Britt, GJ
Rabin, MS
Jackman, DM
Johnson, BE
AF Heon, S.
Yeap, B. Y.
Britt, G. J.
Rabin, M. S.
Jackman, D. M.
Johnson, B. E.
TI Rates of CNS progression in patients with advanced NSCLC harboring
somatic EGFR mutations and treated with gefitinib or erlotinib
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7543
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004676
ER
PT J
AU Higano, CS
Small, EJ
Schellhammer, PF
Kantoff, P
Redfern, CH
Nemunaitis, JJ
Nabhan, C
Xu, Y
Whitmore, JB
Frohlich, MW
AF Higano, C. S.
Small, E. J.
Schellhammer, P. F.
Kantoff, P.
Redfern, C. H.
Nemunaitis, J. J.
Nabhan, C.
Xu, Y.
Whitmore, J. B.
Frohlich, M. W.
TI Predictors of outcome and subgroup results from the integrated analysis
of sipulencel-T trials in metastatic castration-resistant prostate
cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Washington, Sch Med, Seattle, WA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Urol Virginia, Norfolk, VA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Oncol Associates San Diego, San Diego, CA USA.
Mary Crowley Canc Res Ctr, Dallas, TX USA.
Oncol Specialists SC, Park Ridge, IL USA.
Dendreon Corp, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4550
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003673
ER
PT J
AU Higgins, MJ
Prowell, TM
Blackford, A
Slater, S
Argani, P
Green, H
Khouri, N
Blumenthal, R
Garber, JE
Stearns, V
AF Higgins, M. J.
Prowell, T. M.
Blackford, A.
Slater, S.
Argani, P.
Green, H.
Khouri, N.
Blumenthal, R.
Garber, J. E.
Stearns, V.
TI A short-term biomarker modulation prevention study of simvastatin in
women at increased risk for breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
US FDA, Silver Spring, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Sch Med, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 1505
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002678
ER
PT J
AU Hirte, HW
McGuire, WP
Edwards, RP
Husain, A
Hoskins, P
Michels, JE
Matulonis, U
Sexton, C
Fox, JA
Michelson, G
AF Hirte, H. W.
McGuire, W. P., III
Edwards, R. P.
Husain, A.
Hoskins, P.
Michels, J. E.
Matulonis, U.
Sexton, C.
Fox, J. A.
Michelson, G.
TI Final results of a phase II study of voreloxin in women with
platinum-resistant ovarian cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Juravinski Canc Ctr, Hamilton, ON, Canada.
Franklin Sq Hosp Ctr, Harry & Jeanette Weinberg Canc Inst, Baltimore, MD USA.
Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Pittsburgh, PA 15213 USA.
Stanford Univ, Sch Med, Stanford, CA 94305 USA.
BC Canc Agcy, Vancouver, BC, Canada.
BC Canc Agcy, Vancouver Isl Ctr, Victoria, BC, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Sunesis Pharmaceut Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5002
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004062
ER
PT J
AU Hodi, FS
O'Day, S
McDermott, DF
Haanen, JB
Robert, C
Zhu, X
Yellin, MJ
Ibrahim, RA
Hoos, A
Wolchok, JD
AF Hodi, F. S.
O'Day, S.
McDermott, D. F.
Haanen, J. B.
Robert, C.
Zhu, X.
Yellin, M. J.
Ibrahim, R. A.
Hoos, A.
Wolchok, J. D.
TI Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of
both from a phase III, randomized, double-blind, multicenter study of
previously treated patients with unresectable stage III or IV melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands.
Inst Gustave Roussy, Villejuif, France.
Medarex Inc, Bloomsbury, NJ USA.
Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8509
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005180
ER
PT J
AU Holloway, RW
Roche, M
DeMars, L
Williams, JA
Enke, A
Klein, A
Linke, RG
Krasner, CN
AF Holloway, R. W.
Roche, M.
DeMars, L.
Williams, J. A., Jr.
Enke, A.
Klein, A.
Linke, R. G.
Krasner, C. N.
TI Immunotherapy with intraperitoneal catumaxomab in patients with advanced
ovarian cancer after a complete response to chemotherapy: A phase II
study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Florida Hosp Canc Inst, Orlando, FL USA.
Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA.
Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
South Carolina Oncol Associates, Columbia, SC USA.
Fresenius Biotech N Amer, Waltham, MA USA.
Fresenius Biotech GmbH, Munich, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5015
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004073
ER
PT J
AU Hong, TS
Tsai, HK
Coen, J
Blaszkowsky, LS
Hartshorn, KL
Kwak, EL
Willins, J
Ryan, DP
Kachnic, LA
AF Hong, T. S.
Tsai, H. K.
Coen, J.
Blaszkowsky, L. S.
Hartshorn, K. L.
Kwak, E. L.
Willins, J.
Ryan, D. P.
Kachnic, L. A.
TI Dose-painted intensity-modulated radiation therapy for anal cancer: A
multi-institutional report of acute toxicity and response to therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Harvard Radiat Oncol Program, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Boston Univ, Sch Med, Boston, MA 02118 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Boston Med Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4144
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003609
ER
PT J
AU Hu, Y
Weeks, CM
In, H
Dodgion, CM
Golshan, M
Chun, YS
Hassett, MJ
Gu, X
Lipsitz, SR
Greenberg, CC
AF Hu, Y.
Weeks, C. M.
In, H.
Dodgion, C. M.
Golshan, M.
Chun, Y. S.
Hassett, M. J.
Gu, X.
Lipsitz, S. R.
Greenberg, C. C.
TI Impact of neoadjuvant chemotherapy on breast reconstruction.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6135
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004414
ER
PT J
AU Hughes, KS
Schnaper, LA
Cirrincione, C
Berry, DA
McCormick, B
Muss, HB
Shank, B
Hudis, C
Winer, EP
Smith, BL
AF Hughes, K. S.
Schnaper, L. A.
Cirrincione, C.
Berry, D. A.
McCormick, B.
Muss, H. B.
Shank, B.
Hudis, C.
Winer, E. P.
Smith, B. L.
CA CALGB
ECOG
RTOG
TI Lumpectomy plus tamoxifen with or without irradiation in women age 70 or
older with early breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Greater Baltimore Med Ctr, Baltimore, MD USA.
Duke Univ, Durham, NC USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
Doctors Med Ctr, San Pablo, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 25
Z9 25
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 507
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002347
ER
PT J
AU Hunter, ZR
Yang, G
Ioakimidis, LI
Hanzis, CA
Manning, RJ
Patterson, CJ
Sheehy, PS
Gong, P
Xu, L
Treon, SP
AF Hunter, Z. R.
Yang, G.
Ioakimidis, L. I.
Hanzis, C. A.
Manning, R. J.
Patterson, C. J.
Sheehy, P. S.
Gong, P.
Xu, L.
Treon, S. P.
TI Association of CR/VGPR with progression-free survival in rituximab-naive
WM patients undergoing rituximab-based therapy, as predicted by
polymorphisms in Fc gamma RIIIA-158
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Hunter, Z. R.; Yang, G.; Ioakimidis, L. I.; Hanzis, C. A.; Manning, R. J.; Patterson, C. J.; Sheehy, P. S.; Gong, P.; Xu, L.; Treon, S. P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8108
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005128
ER
PT J
AU Huober, JB
Gelber, S
Thurlimann, E
Regan, MM
Price, KN
Goldhirsch, A
Coates, AS
Viale, G
Oehischiegei, C
AF Huober, J. B.
Gelber, S.
Thuerlimann, El.
Regan, M. M.
Price, K. N.
Goldhirsch, A.
Coates, A. S.
Viale, G.
Oehischiegei, C.
TI Prognosis of medullary breast cancer: Analyses of 13 International
Breast Cancer Study Group (IBCSG) trials.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Int Breast Canc Study Grp, Bern, Switzerland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 630
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002464
ER
PT J
AU Infante, JR
Fecher, LA
Nallapareddy, S
Gordon, MS
Flaherty, KT
Cox, DS
DeMarini, DJ
Morris, SR
Burris, HA
Messersmith, WA
AF Infante, J. R.
Fecher, L. A.
Nallapareddy, S.
Gordon, M. S.
Flaherty, K. T.
Cox, D. S.
DeMarini, D. J.
Morris, S. R.
Burris, H. A.
Messersmith, W. A.
TI Safety and efficacy results from the first-in-human study of the oral
MEK 1/2 inhibitor GSK1120212
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Sarah Cannon Res Inst, Nashville, TN USA.
Tennessee Oncol, Nashville, TN USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Premiere Oncol Arizona, Scottsdale, AZ USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC USA.
NR 0
TC 30
Z9 32
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2503
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003095
ER
PT J
AU Ioakimidis, LI
Hanzis, CA
Manning, RJ
Patterson, CJ
Soumerai, JD
Hunter, ZR
Brodsky, PS
Sheehy, PS
Turnbull, B
Treon, SP
AF Ioakimidis, L. I.
Hanzis, C. A.
Manning, R. J.
Patterson, C. J.
Soumerai, J. D.
Hunter, Z. R.
Brodsky, P. S.
Sheehy, P. S.
Turnbull, B.
Treon, S. P.
TI Association of maintenance rituximab with clinical outcome in
rituximab-naive patients with Waldenstrom's macroglobulinemia (WM) who
respond to a rituximab containing regimen
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Biobridges, Needham, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8107
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005127
ER
PT J
AU Isakoff, SJ
Overmoyer, B
Tung, NM
Gelman, RS
Giranda, VL
Bernhard, KM
Habin, KR
Ellisen, LW
Winer, EP
Goss, PE
AF Isakoff, S. J.
Overmoyer, B.
Tung, N. M.
Gelman, R. S.
Giranda, V. L.
Bernhard, K. M.
Habin, K. R.
Ellisen, L. W.
Winer, E. P.
Goss, P. E.
TI A phase II trial of the PARP inhibitor veliparib (ABT888) and
temozolomide for metastatic breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Abbott Labs, Abbott Pk, IL 60064 USA.
NR 0
TC 9
Z9 9
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 1019
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002534
ER
PT J
AU Jacobus, SJ
Van Wier, SA
Ahmann, GJ
Henderson, KJ
Callander, NS
Williams, ME
Siegel, DS
Greipp, PR
Rajkumar, SV
Fonseca, R
AF Jacobus, S. J.
Van Wier, S. A.
Ahmann, G. J.
Henderson, K. J.
Callander, N. S.
Williams, M. E.
Siegel, D. S.
Greipp, P. R.
Rajkumar, S. V.
Fonseca, R.
TI Impact high-risk classification by FISH on overall survival in myeloma:
An Eastern Cooperative Oncology Group (ECOG) study E4A03
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin Scottsdale, Scottsdale, AZ USA.
Mayo Clin, Rochester, MN USA.
Univ Wisconsin, Madison, WI USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
Hackensack Univ, Med Ctr, Hackensack, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10546
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005654
ER
PT J
AU Jagannath, S
Siegel, DS
Hajek, R
Dimopoulos, MA
Yoon, S
Lonial, S
Graef, T
Lupinacci, L
Reiser, D
Anderson, KC
AF Jagannath, S.
Siegel, D. S.
Hajek, R.
Dimopoulos, M. A.
Yoon, S.
Lonial, S.
Graef, T.
Lupinacci, L.
Reiser, D.
Anderson, K. C.
TI Update on vantage program to assess combined vorinostol (V) and
bortezomib (B) in patients (pts) with relapsed and/or refractory (RR)
multiple myeloma (MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 St Vincent Catholic Med Ctr, New York, NY USA.
Hackensack Univ Med Ctr, Hackensack, NJ USA.
Fac Med MU, Brno, Czech Republic.
Univ Hosp Brno, Brno, Czech Republic.
Univ Athens, Sch Med, Dept Therapeut, GR-11527 Athens, Greece.
Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Merck & Co Inc, Upper Gwynedd, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8133
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005153
ER
PT J
AU Jakubowiak, AJ
Benson, DM
Bensinger, W
Siegel, DS
Zimmerman, TM
Mohrbacher, A
Richardson, PG
Afar, D
Singhal, AK
Anderson, KC
AF Jakubowiak, A. J.
Benson, D. M., Jr.
Bensinger, W.
Siegel, D. S.
Zimmerman, T. M.
Mohrbacher, A.
Richardson, P. G.
Afar, D.
Singhal, A. K.
Anderson, K. C.
CA Multiple Myeloma Res Consortium
TI Elotuzumab in combination with bortezomib in patients with
relapsed/refractory multiple myeloma: A phase I study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Michigan, Ann Arbor, MI 48109 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Hackensack Univ, Med Ctr, Hackensack, NJ USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ So Calif, Los Angeles, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Facet Biotech Inc, Redwood City, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8003
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005023
ER
PT J
AU James, DF
Brown, JR
Werner, L
Wierda, WG
Rai, KR
Gould, J
Castro, JE
Rassenti, L
Neuberg, DS
Kipps, TJ
AF James, D. F.
Brown, J. R.
Werner, L.
Wierda, W. G.
Rai, K. R.
Gould, J.
Castro, J. E.
Rassenti, L.
Neuberg, D. S.
Kipps, T. J.
TI Lenalidomide and rituximab for the initial treatment of chronic
lymphocytic leukemia: Report of an ongoing study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Calif San Diego, Chron Lymphocyt Leukemia Res Consortium, Moores Canc Ctr, La Jolla, CA 92093 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA.
Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6583
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004519
ER
PT J
AU Janeway, KA
Kim, S
Lodish, M
Nose, V
Dahia, P
Rustin, P
Demetri, GD
Fletcher, JA
Helman, LJ
Stratakis, CA
AF Janeway, K. A.
Kim, S.
Lodish, M.
Nose, V.
Dahia, P.
Rustin, P.
Demetri, G. D.
Fletcher, J. A.
Helman, L. J.
Stratakis, C. A.
CA Consortium Pediat Wildtype GIST
TI Succinate dehydrogenase in KIT/PDGFRA wild-type gastrointestinal stromal
tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
NCI, Bethesda, MD 20892 USA.
NIH, Bethesda, MD 20892 USA.
Univ Miami, Sch Med, Miami, FL USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
Hop Robert Debre, F-75019 Paris, France.
Harvard Canc Ctr, Ludwig Ctr, Dana Farber Canc Inst, Boston, MA USA.
Sarcoma Ctr, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10008
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005517
ER
PT J
AU Janne, PA
Wang, XF
Socinski, MA
Crawford, J
Capelletti, M
Edelman, MJ
Villalona-Calero, MA
Kratzke, RA
Vokes, EE
Miller, VA
AF Janne, P. A.
Wang, X. F.
Socinski, M. A.
Crawford, J.
Capelletti, M.
Edelman, M. J.
Villalona-Calero, M. A.
Kratzke, R. A.
Vokes, E. E.
Miller, V. A.
TI Randomized phase II trial of erlotinib (E) alone or in combination with
carboplatin/parclitaxel (CP) in never or light former smokers with
advanced lung adenocarinoma: CALGB 30406
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Ctr Stat, Canc & Leukemia Grp B, Durham, NC USA.
Univ N Carolina, Chapel Hill, NC USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
Univ Minnesota, Minneapolis, MN USA.
Univ Chicago, Chicago, IL 60637 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 9
Z9 13
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7503
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004643
ER
PT J
AU Johnson, BE
Ryan, AJ
Heymach, J
Stephens, C
Kennedy, SJ
Langmuir, PB
Herbst, RS
AF Johnson, B. E.
Ryan, A. J.
Heymach, J.
Stephens, C.
Kennedy, S. J.
Langmuir, P. B.
Herbst, R. S.
TI Tumor biomarker analyses from the phase III ZODIAC study of docetaxel
(D) plus or minus vandetanib (VAN) in second-line advanced NSCLC
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
AstraZeneca, Macclesfield, Cheshire, England.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
AstraZeneca, Wilmington, DE USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7516
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004652
ER
PT J
AU Judson, IR
Blay, J
Chawla, SP
Radford, JA
Le Cesne, A
Verweij, J
von Mehren, M
Pontes, J
Bayever, E
Demetri, GD
AF Judson, I. R.
Blay, J.
Chawla, S. P.
Radford, J. A.
Le Cesne, A.
Verweij, J.
von Mehren, M.
Pontes, J.
Bayever, E.
Demetri, G. D.
TI Trabecteding (Tr) in the treatment of advanced uterine leiomyosarcomas
(U-LMS): Results of a pooled analysis of five single-agent phase II
studies using the recommended dose.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Canc Res UK Ctr Canc Therapeut, London, England.
Univ Lyon 1, F-69365 Lyon, France.
Sarcoma Oncol Ctr, Santa Monica, CA USA.
Univ Manchester, Manchester, Lancs, England.
Christie NHS Fdn Trust, Manchester, Lancs, England.
Inst Gustave Roussy, Villejuif, France.
Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Rotterdam, Netherlands.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
PharmaMar, Madrid, Spain.
Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
Dana Farber Canc Inst, Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA.
Sarcoma Ctr, Boston, MA USA.
RI Radford, John/N-1331-2015; Blay, Jean-Yves/N-3966-2016
OI Radford, John/0000-0001-7898-2786; Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10028
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005537
ER
PT J
AU Kabbinavar, FF
Miller, VA
Johnson, BE
O'Connor, PG
Soh, C
AF Kabbinavar, F. F.
Miller, V. A.
Johnson, B. E.
O'Connor, P. G.
Soh, C.
CA ATLAS Investigators
TI Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab
(B) therapy with or without erlotinib (E) after completion of
chemotherapy (chemo) with B for first-line treatment of locally
advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Genentech Inc, San Francisco, CA 94080 USA.
NR 0
TC 8
Z9 8
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7526
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004661
ER
PT J
AU Kalinsky, K
Lee, SJ
Lawrence, DP
Kirkwood, JM
AF Kalinsky, K.
Lee, S. J.
Lawrence, D. P.
Kirkwood, J. M.
TI A phase II trial of dasatinib in patients with unresectable locally
advanced or stage IV mucosal, acral, and solar melanomas: An Eastern
Cooperative Oncology Group study (E2607)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Columbia Univ, Med Ctr, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS312
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002312
ER
PT J
AU Kantoff, P
Petrylak, DP
Pomerantz, M
Israel, RJ
Olson, WC
Ramakrishna, T
Morris, S
AF Kantoff, P.
Petrylak, D. P.
Pomerantz, M.
Israel, R. J.
Olson, W. C.
Ramakrishna, T.
Morris, S.
TI First-in-human phase I trial of prostate-specific membrane antigen
antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Columbia Univ, Med Ctr, New York, NY USA.
Progen Pharmaceut Inc, Tarrytown, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS245
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002245
ER
PT J
AU Katz, ML
Archer, L
Peppercorn, JM
Kereakoglow, S
Collyar, D
Burstein, HJ
Schilsky, RL
Partridge, AH
AF Katz, M. L.
Archer, L.
Peppercorn, J. M.
Kereakoglow, S.
Collyar, D.
Burstein, H. J.
Schilsky, R. L.
Partridge, A. H.
TI The role of patient advocates in clinical trials: Perspectives from
investigators and advocates in the Cancer and Leukemia Group B (CALGB).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Ohio State Univ, Columbus, OH 43210 USA.
Canc & Leukemia Grp B, Ctr Stat, Durham, NC USA.
Duke Univ, Med Ctr, Durham, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Canc & Leukemia Grp B, Daville, CA USA.
Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6148
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004427
ER
PT J
AU Keefe, SM
Moyneur, E
Meyers, S
Barghout, V
Flaherty, KT
AF Keefe, S. M.
Moyneur, E.
Meyers, S.
Barghout, V.
Flaherty, K. T.
TI Dose reductions and delays in patients (pts) with renal cell carcinoma
(RCC) treated with sorafenib (SR) or sunitinib (SU): Retrospective
analysis of two large US health care claims databases
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Hosp Univ Penn, Philadelphia, PA 19104 USA.
StatLog Consulting Inc, Lange Gardien, PQ, Canada.
Bayer Healthcare Pharmaceut, Wayne, NJ USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6090
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004369
ER
PT J
AU Kelly, K
Hwang, JJ
Shapiro, G
Mani, S
Cotreau, MM
Credi, M
Al-Adhami, M
Bhargava, P
AF Kelly, K.
Hwang, J. J.
Shapiro, G.
Mani, S.
Cotreau, M. M.
Credi, M.
Al-Adhami, M.
Bhargava, P.
TI Phase I study of AV-412, a novel, irreversible EGER inhibitor,
administered intermittently in patients with advanced solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Kansas, Med Ctr, Westwood, KS USA.
Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Montefiore Med Ctr, Bronx, NY 10467 USA.
AVEO Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3103
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003308
ER
PT J
AU Khan, N
Dicker, D
Flaherty, KT
Lerner, J
El-Deiry, W
AF Khan, N.
Dicker, D.
Flaherty, K. T.
Lerner, J.
El-Deiry, W.
TI Hyperspectral imaging: A noninvasive in vivo method of imaging melanoma
lesions in a patient being treated with a novel B-RAF inhibitor
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
LightForm Inc, Hillsborough, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e19019
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852001557
ER
PT J
AU Kim, E
Sharko, J
Drohan, B
Roche, C
Specht, M
Gadd, M
Smith, BL
Hughes, KS
AF Kim, E.
Sharko, J.
Drohan, B.
Roche, C.
Specht, M.
Gadd, M.
Smith, B. L.
Hughes, K. S.
TI Breast cancer and high-risk diagnosis in core biopsies stratified by
ethnicity
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Kim, E.; Sharko, J.; Drohan, B.; Roche, C.; Specht, M.; Gadd, M.; Smith, B. L.; Hughes, K. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 1584
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002751
ER
PT J
AU Kindelberger, D
Daniels, K
Kantoff, E
Atkinson, T
Liu, J
Campos, SM
Berlin, ST
Cibas, E
Matulonis, U
AF Kindelberger, D.
Daniels, K.
Kantoff, E.
Atkinson, T.
Liu, J.
Campos, S. M.
Berlin, S. T.
Cibas, E.
Matulonis, U.
TI Predictive value of circulating tumor cells for response to therapy in
women with recurrent epithelial ovarian cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5111
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004166
ER
PT J
AU Kindler, HL
Richards, DA
Stephenson, J
Garbo, LE
Lima, CSR
Safran, H
Wiezorek, JS
Feigal, EG
Bray, S
Fuchs, C
AF Kindler, H. L.
Richards, D. A.
Stephenson, J.
Garbo, L. E.
Lima, C. S. Rocha
Safran, H.
Wiezorek, J. S.
Feigal, E. G.
Bray, S.
Fuchs, C.
TI A placebo-controlled, randomized phase II study of conatumumab (C) or
AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with
metastatic pancreatic cancer (mPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Chicago, Chicago, IL 60637 USA.
Texas Oncol, Tyler, TX USA.
Oncol Res Inst, Greenville, SC USA.
Canc Treatment Ctr, Greenville, SC USA.
New York Oncol Hematol, Albany, NY USA.
Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA.
Brown Univ, Oncol Grp, Providence, RI 02912 USA.
Amgen Inc, Thousand Oaks, CA USA.
Amgen Inc, Cambridge, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4035
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003501
ER
PT J
AU Kozyreva, ON
Chi, D
Theall, KP
Zhu, AX
AF Kozyreva, O. N.
Chi, D.
Theall, K. P.
Zhu, A. X.
TI A multicenter retrospective study on clinical features and outcome in
elderly patients with hepatocellular carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Tufts Med Ctr, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e14569
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000696
ER
PT J
AU Krajewski, KM
Heng, DY
Pedrosa, I
Ramaiya, NH
Jagannathan, JP
Van den Abbeeie, AD
Atkins, MB
McDermott, DF
Schutz, FA
Choueiri, TK
AF Krajewski, K. M.
Heng, D. Y.
Pedrosa, I.
Ramaiya, N. H.
Jagannathan, J. P.
Van den Abbeeie, A. D.
Atkins, M. B.
McDermott, D. F.
Schutz, F. A.
Choueiri, T. K.
TI Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage,
radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in
advanced renal cell carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4526
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003649
ER
PT J
AU Krasner, CN
Seiden, M
Roche, M
Morgan, MA
Matulonis, U
Wolf, J
Drescher, C
Alvarez, RD
Armstrong, DK
Supko, JG
AF Krasner, C. N.
Seiden, M.
Roche, M.
Morgan, M. A.
Matulonis, U.
Wolf, J.
Drescher, C.
Alvarez, R. D.
Armstrong, D. K.
Supko, J. G.
TI Tolerability and pharmacokinetics of intraperitoneal carboplatin and
paclitaxel with intravenous bevacizumab
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5037
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004093
ER
PT J
AU Kraveka, JM
Weitzman, SS
Smith, L
Lynch, JC
Chang, M
Kinney, M
Perkins, SL
Laver, JH
Gross, TG
Weinstein, HJ
AF Kraveka, J. M.
Weitzman, S. S.
Smith, L.
Lynch, J. C.
Chang, M.
Kinney, M.
Perkins, S. L.
Laver, J. H.
Gross, T. G.
Weinstein, H. J.
CA Children's Oncology Grp
TI Advanced-stage anaplastic large-cell lymphoma in children and
adolescents: Results of ANHL0131, a randomized phase III trail with
standard APO (doxorubicin, prednisone, vincristine) versus consolidation
with a regimen including vinblastine: A report from the Children's
Oncology Group
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Med Univ S Carolina, Hollings Canc Ctr, Div Pediat Hematol Oncol, Charleston, SC 29425 USA.
Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
COG Stat & Data Ctr, Omaha, NE USA.
Univ Nebraska Med Ctr, Omaha, NE USA.
COG Stat & Data Ctr, Gainesville, FL USA.
Univ Florida, Gainesville, FL USA.
Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
Univ Utah Hlth Sci, Dept Pathol, Salt Lake City, UT USA.
ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA.
St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
Nationwide Childrens Hosp, Dept Pediat Hematol Oncol, Columbus, OH USA.
Massachusetts Gen Hosp, Div Pediat Hematol Oncol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9511
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005440
ER
PT J
AU Kroetz, DL
Baldwin, RM
Owzar, K
Jiang, C
Zembutsu, H
Kubo, M
Nakamura, Y
Shulman, LN
Retain, MJ
AF Kroetz, D. L.
Baldwin, R. M.
Owzar, K.
Jiang, C.
Zembutsu, H.
Kubo, M.
Nakamura, Y.
Shulman, L. N.
Retain, M. J.
CA Canc Leukemia Grp B
TI Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel
(P)-induced peripheral neuropathy (PN): Results from a genome-wide
association study (GWAS) in CALGB 40101.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ Tokyo, Tokyo, Japan.
RIKEN, Ctr Genom Med, Yokohama, Kanagawa, Japan.
Univ Tokyo, Inst Med Sci, Tokyo, Japan.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Chicago, Chicago, IL 60637 USA.
RI Kubo, Michiaki/N-7947-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3021
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003226
ER
PT J
AU Krop, IE
Flores, L
Tuck, DP
Ryan, PD
Partridge, AH
Morganstern, D
Najita, J
Iezon-Geyda, K
Winer, EP
Harris, L
AF Krop, I. E.
Flores, L.
Tuck, D. P.
Ryan, P. D.
Partridge, A. H.
Morganstern, D.
Najita, J.
Iezon-Geyda, K.
Winer, E. P.
Harris, L.
TI Phase II trial of preoperative vinorelbine/trastuzumab (VH) or
docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer
with analysis of resistance mechanisms.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Faulkner Hosp, Dana Farber Canc Inst, Boston, MA USA.
Yale Univ, Sch Med, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 549
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002383
ER
PT J
AU Kumar, S
Crowley, J
Klein, SK
Lahuerta, JJ
Lee, J
Moreau, P
Morgan, G
Richardson, PG
Siegel, DS
Durie, BG
AF Kumar, S.
Crowley, J.
Klein, S. K.
Lahuerta, J. J.
Lee, J.
Moreau, P.
Morgan, G.
Richardson, P. G.
Siegel, D. S.
Durie, B. G.
CA IMWG
TI Treatment patterns and outcome among patients with multiple myeloma
relapsing and or refractory to bortezomib and immunomodulatory drugs: A
multicenter International Myeloma Working Group study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mayo Clin, Rochester, MN USA.
Canc Res & Biostat, Seattle, WA USA.
Erasmus Univ, Med Ctr, Rotterdam, Netherlands.
Hosp Univ 12 Octubre, Madrid, Spain.
Gachon Univ Gil Hosp, Inchon, South Korea.
Univ Hosp, Nantes, France.
Royal Marsden Hosp, London SW3 6JJ, England.
Royal Marsden Hosp, Surrey, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Hackensack Univ, Med Ctr, Hackensack, NJ USA.
Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA.
RI Kumar, Shaji/A-9853-2008; richard, chrystelle/K-8595-2015
OI Kumar, Shaji/0000-0001-5392-9284;
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8125
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005145
ER
PT J
AU Lacouture, ME
McArthur, GA
Chapman, PB
Ribas, A
Flaherty, KT
Lee, RJ
Nolop, KB
Kim, KB
Duvic, M
Sosman, JA
AF Lacouture, M. E.
McArthur, G. A.
Chapman, P. B.
Ribas, A.
Flaherty, K. T.
Lee, R. J.
Nolop, K. B.
Kim, K. B.
Duvic, M.
Sosman, J. A.
CA Dermatology Working Grp
TI PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and
histologic characteristics of therapy-associated cutaneous neoplasms in
a phase I trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
Univ Calif Los Angeles, Los Angeles, CA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Roche, Nutley, NJ USA.
Plexxikon Inc, Berkeley, CA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8592
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005262
ER
PT J
AU Lawrence, DP
Hamid, O
McDermott, DF
Puzanov, I
Sznol, M
Clark, J
Logan, T
Hodi, FS
Heller, KN
Margolin, KA
AF Lawrence, D. P.
Hamid, O.
McDermott, D. F.
Puzanov, I.
Sznol, M.
Clark, J.
Logan, T.
Hodi, F. S.
Heller, K. N.
Margolin, K. A.
TI Phase II trial of ipilimumab monotherapy in melanoma patients with brain
metastases
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Angeles Clin & Res Inst, Santa Monica, CA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Yale Canc Ctr, New Haven, CT USA.
Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Bristol Myers Squibb Co, Plainsboro, NJ USA.
Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8523
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005193
ER
PT J
AU Lawson, DH
Lee, SJ
Tarhini, AA
Margolin, KA
Ernstoff, MS
Kirkwood, JM
AF Lawson, D. H.
Lee, S. J.
Tarhini, A. A.
Margolin, K. A.
Ernstoff, M. S.
Kirkwood, J. M.
TI E4697: Phase III cooperative group studt of yeast-derived granulocyte
macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant
treatment of patients with completely resected stage III-IV melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Univ Washington, Seattle, WA 98195 USA.
Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8504
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005176
ER
PT J
AU Leavey, P
Bender, JLG
Mascarenhas, L
Granowetter, L
Anderson, M
Krailo, MD
Gorlick, RG
Marina, N
AF Leavey, P.
Bender, J. L. Glade
Mascarenhas, L.
Granowetter, L.
Anderson, M.
Krailo, M. D.
Gorlick, R. G.
Marina, N.
TI Feasibility of bevacizumab (NSC 704865, BB-IN D# 7921) combined with
vincristine, topotecan, and cyclophosphamide in patients with first
recurrent Ewing sarcoma (EWS): A Children's Oncology Group (COG) study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Columbia Univ, New York, NY USA.
Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA.
Columbia Univ, CHONY, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Childrens Hosp, Boston, MA 02115 USA.
Childrens Oncol Grp, Arcadia, CA USA.
Childrens Hosp, Bronx, NY USA.
Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9552
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005481
ER
PT J
AU Leighl, NB
Soria, J
Bennouna, J
Blais, N
Traynor, AM
Papadimitrakopoulou, V
Klimovsky, J
Jappe, A
Jehl, V
Johnson, BE
AF Leighl, N. B.
Soria, J.
Bennouna, J.
Blais, N.
Traynor, A. M.
Papadimitrakopoulou, V.
Klimovsky, J.
Jappe, A.
Jehl, V.
Johnson, B. E.
TI Phase II study of everolimus plus erlotinib in previously treated
patients with advanced non-small cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada.
Inst Gustave Roussy, Villejuif, France.
Ctr Rene Gauducheau, F-44035 Nantes, France.
CHUM Hop Notre Dame, Montreal, PQ, Canada.
Univ Wisconsin Carbone Canc Ctr, Madison, WI USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Novartis Oncol, E Hanover, NJ USA.
Novartis Pharma AG, Basel, Switzerland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI bennouna, jaafar/K-9350-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7524
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004659
ER
PT J
AU Leijen, S
Schellens, JH
Shapiro, G
Pavlick, AC
Tibes, R
Demuth, T
Viscusi, J
Cheng, JD
Xu, Y
Oza, AM
AF Leijen, S.
Schellens, J. H.
Shapiro, G.
Pavlick, A. C.
Tibes, R.
Demuth, T.
Viscusi, J.
Cheng, J. D.
Xu, Y.
Oza, A. M.
TI A phase I pharmacological and pharmacodynamic study of MK-1775, a Weel
tyrosine kinase inhibitor, in monotherapy and combination with
gemcitabine, cisplatin, or carboplatin in patients with advanced solid
tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Netherlands Canc Inst, Amsterdam, Netherlands.
Univ Utrecht, Dept Pharmaceut Sci, Fac Sci, Utrecht, Netherlands.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NYU, Med Ctr, New York, NY 10016 USA.
Scottsdale Healthcare & TGen, Virginia G Piper Canc Ctr, Scottsdale, AZ USA.
Merck & Co Inc, N Wales, PA USA.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3067
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003272
ER
PT J
AU Lennes, IT
Temel, JS
Hoedt, C
Saylor, PJ
Ortiz, TM
Admane, S
Lamont, EB
AF Lennes, I. T.
Temel, J. S.
Hoedt, C.
Saylor, P. J.
Ortiz, T. M.
Admane, S.
Lamont, E. B.
TI Predictors of patient misunderstanding of the goals of care at
initiation of chemotheraphy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
SUNY Buffalo, Buffalo, NY 14260 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9038
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005304
ER
PT J
AU Li, J
Liu, R
Wang, J
Rabkin, SD
AF Li, J.
Liu, R.
Wang, J.
Rabkin, S. D.
TI Cytotoxicity of oncolytic herpes simplex virus vector of breast cancer
stem cells.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Sun Yat Sen Univ, Affiliated Hosp 3, Breast Canc Ctr, Guangzhou 510275, Guangdong, Peoples R China.
Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurosurg Lab, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e13637
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000487
ER
PT J
AU Lim, ZD
Choueiri, TK
Hirsch, MS
Jonasch, E
Vaishampayan, UN
Tamboli, P
Corn, PG
Hang, DY
Tannir, NM
AF Lim, Z. Dubauskas
Choueiri, T. K.
Hirsch, M. S.
Jonasch, E.
Vaishampayan, U. N.
Tamboli, P.
Corn, P. G.
Hang, D. Y.
Tannir, N. M.
TI Vascular endothelial growth factor (VEGF)-targeted therapy for the
treatment of adult metastatic Xp11 translocation renal cell carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4606
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003729
ER
PT J
AU Lin, NU
Ramakrishna, N
Younger, WJ
Storniolo, AM
Come, SE
Gelman, RS
Eisenberg, E
Winer, EP
AF Lin, N. U.
Ramakrishna, N.
Younger, W. J.
Storniolo, A. M.
Come, S. E.
Gelman, R. S.
Eisenberg, E.
Winer, E. P.
TI Phase I study of lapatinib(L) in combination with whole-brain radiation
therapy (WBRT) in patients (pts) with brain metastases from
HER2-positive breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
MD Anderson Canc Ctr Orlando, Orlando, FL USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Indiana Univ Simon Canc Ctr, Indianapolis, IN USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 1154
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002669
ER
PT J
AU Lin, NU
Mayer, IA
Hobday, TJ
Falkson, CI
Dees, EC
Nanda, R
Krop, IE
Rimawi, MF
Wolff, AC
Winer, EP
AF Lin, N. U.
Mayer, I. A.
Hobday, T. J.
Falkson, C. I.
Dees, E. C.
Nanda, R.
Krop, I. E.
Rimawi, M. F.
Wolff, A. C.
Winer, E. P.
CA TBCRC
TI TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in
patients (pts) with HER2+metastatic breast cancer (MBC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Mayo Clin, Rochester, MN USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
Univ Chicago, Chicago, IL 60637 USA.
Baylor Coll Med, Houston, TX 77030 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS132
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002135
ER
PT J
AU Lipshultz, SE
Lipsitz, SR
Miller, TL
Neuberg, DS
Dahlberg, SE
Colan, SD
Silverman, LB
Cushman, LL
Henkel, JM
Sallan, SE
AF Lipshultz, S. E.
Lipsitz, S. R.
Miller, T. L.
Neuberg, D. S.
Dahlberg, S. E.
Colan, S. D.
Silverman, L. B.
Cushman, L. L.
Henkel, J. M.
Sallan, S. E.
CA Acute Lymphoblastic Leukemia
TI Late cardiac status in long-term survivors of childhood high-risk ALL 8
years after continuous or bolus infusion of doxorubicin: The DFCI
Childhood ALL 91-01 randomized trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9513
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005442
ER
PT J
AU Liu, R
Wang, J
Li, J
Rabkin, SD
AF Liu, R.
Wang, J.
Li, J.
Rabkin, S. D.
TI Treatment of human breast tumors by oncolytic herpes simplex virus.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China.
Sun Yat Sen Univ, Affiliated Hosp 3, Breast Canc Ctr, Guangzhou 510275, Guangdong, Peoples R China.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurosurg Lab, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e13605
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000459
ER
PT J
AU Loggers, ET
Soto, E
Desanto-Madeya, S
Wright, AA
Stieglitz, H
Paulk, ME
Prigerson, HG
AF Loggers, E. T.
Soto, E.
Desanto-Madeya, S.
Wright, A. A.
Stieglitz, H.
Paulk, M. E.
Prigerson, H. G.
TI The role of acculturation in end-of-life outcomes for Latino advanced
cancer patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Harvard Univ, Sch Med, Mt Auburn Hosp, Dept Med, Cambridge, MA 02138 USA.
Univ Massachusetts, Boston, MA 02125 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas Southwestern, Dallas, TX USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6117
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004396
ER
PT J
AU Lorch, JH
Posner, MR
Goloubeva, O
Cullen, KJ
Sarlis, NJ
Tishler, RB
Haddad, RI
AF Lorch, J. H.
Posner, M. R.
Goloubeva, O.
Cullen, K. J.
Sarlis, N. J.
Tishler, R. B.
Haddad, R. I.
CA TAX 324 Study Grp
TI Long-term results from TAX324: A phase III trial of sequential therapy
comparing TPF to PF in locally advanced (LA) squamous cell cancer of the
head and neck (HNC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
Sanofi Aventis, Bridgewater, NJ USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5512
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004189
ER
PT J
AU LoRusso, P
Krop, IE
Burris, HA
Vukelja, SJ
Miller, K
Zheng, M
Chu, Y
Lu, M
Amler, LC
Rugo, HS
AF LoRusso, P.
Krop, I. E.
Burris, H. A., III
Vukelja, S. J.
Miller, K.
Zheng, M.
Chu, Y.
Lu, M.
Amler, L. C.
Rugo, H. S.
TI Quantitative assessment of diagnostic markers and correlations with
efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients
(pts) with metastatic breast cancer (MBC) who had progressed on prior
HER2-directed therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
Texas Oncol, Tyler, TX USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Genentech Inc, San Francisco, CA 94080 USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 1016
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002532
ER
PT J
AU Lu, KH
Skates, S
Bevers, TB
Newland, W
Moore, RG
Leeds, L
Harris, S
Adeyinka, OW
Fritsche, HA
Bast, RC
AF Lu, K. H.
Skates, S.
Bevers, T. B.
Newland, W.
Moore, R. G.
Leeds, L.
Harris, S.
Adeyinka, O. W.
Fritsche, H. A.
Bast, R. C.
TI A prospective US ovarian cancer screening study using the risk of
ovarian cancer algorithm (ROCA)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Iowa Clin, Des Moines, IA USA.
Brown Univ, Women & Infants Hosp, Providence, RI USA.
Obstet & Gynecol Associates, Houston, TX USA.
Baylor Sammons Breast Ctr, Dallas, TX USA.
Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
RI Bast, Robert/E-6585-2011
OI Bast, Robert/0000-0003-4621-8462
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5003
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004063
ER
PT J
AU Lu, W
Lorch, JH
Balboni, TA
Sher, DJ
Goguen, LA
Norris, CM
Tishler, RB
Posner, MR
Rosenthal, DS
Haddad, RI
AF Lu, W.
Lorch, J. H.
Balboni, T. A.
Sher, D. J.
Goguen, L. A.
Norris, C. M., Jr.
Tishler, R. B.
Posner, M. R.
Rosenthal, D. S.
Haddad, R. I.
TI Acupuncture for dysphagia after chemoradialion therapy in head and neck
cancer: An ongoing pilot, randomized, sham-controlled trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Osher Res Ctr, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Surg, Div Otolaryngol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS270
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002270
ER
PT J
AU Lu-Emerson, C
Norden, AD
Drappatz, J
Quant, EC
Ciampa, AS
Doherty, LM
LaFrankie, DC
Wen, PY
AF Lu-Emerson, C.
Norden, A. D.
Drappatz, J.
Quant, E. C.
Ciampa, A. S.
Doherty, L. M.
LaFrankie, D. C.
Wen, P. Y.
TI Retrospective study of dasatinib in recurrent high-grade glioma (HGG)
patients who failed bevacizumab.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Lu-Emerson, C.; Norden, A. D.; Drappatz, J.; Quant, E. C.; Ciampa, A. S.; Doherty, L. M.; LaFrankie, D. C.; Wen, P. Y.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e12525
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000214
ER
PT J
AU Mahindra, AK
Richardson, PG
Hari, P
Laubach, J
Ghobrial, IM
Schlossman, RL
Weller, E
Munshi, NC
Anderson, KC
Raje, NS
AF Mahindra, A. K.
Richardson, P. G.
Hari, P.
Laubach, J.
Ghobrial, I. M.
Schlossman, R. L.
Weller, E.
Munshi, N. C.
Anderson, K. C.
Raje, N. S.
TI Results of a phase I study of RAD001 in combination with lenalidomide in
patients with relapsed or refractory multiple mycloma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8032
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005052
ER
PT J
AU Mak, RH
Doran, E
Muzikansky, A
Kang, J
Choi, NC
Willers, H
Jackman, DM
Sequist, LV
AF Mak, R. H.
Doran, E.
Muzikansky, A.
Kang, J.
Choi, N. C.
Willers, H.
Jackman, D. M.
Sequist, L. V.
TI Thoracic radiation therapy in locally advanced NSCLC patients (pts) with
EGFR mutations.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7016
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004560
ER
PT J
AU Margalit, DN
Heckman, K
Chen, Y
Catalano, PJ
Vivenzio, T
Nissen, K
Mauch, P
Ng, AK
AF Margalit, D. N.
Heckman, K.
Chen, Y.
Catalano, P. J.
Vivenzio, T.
Nissen, K.
Mauch, P.
Ng, A. K.
TI Technologic advancements and error rates in ratiation therapy (RT)
delivery.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Canc Consortium, Harvard Radiat Oncol Program, Boston, MA USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Dept Radiat Oncol, Sch Med, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6141
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004420
ER
PT J
AU Matulonis, U
Pereira, L
Lee, H
Campos, SM
Liu, J
Lee, J
Whalen, C
Atkinson, T
Hill, M
Berlin, ST
AF Matulonis, U.
Pereira, L.
Lee, H.
Campos, S. M.
Liu, J.
Lee, J.
Whalen, C.
Atkinson, T.
Hill, M.
Berlin, S. T.
TI Sequential angiogenic blockade for the treatment of recurrent ovarian
cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5083
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004138
ER
PT J
AU Mayer, EL
Nohria, A
Miller, K
Rugo, HS
Carey, LA
Ryabin, N
Gelman, RS
Winer, EP
Burstein, HJ
AF Mayer, E. L.
Nohria, A.
Miller, K.
Rugo, H. S.
Carey, L. A.
Ryabin, N.
Gelman, R. S.
Winer, E. P.
Burstein, H. J.
TI Cardiovascular safety of adjuvant bevacizumab for breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA.
Univ N Carolina, Chapel Hill, NC USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 571
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002405
ER
PT J
AU Mayer, EL
Ligibel, JA
Burstein, HJ
Miller, K
Carey, LA
Rugo, HS
Ryabin, N
Gelman, RS
Winer, EP
Wolff, AC
AF Mayer, E. L.
Ligibel, J. A.
Burstein, H. J.
Miller, K.
Carey, L. A.
Rugo, H. S.
Ryabin, N.
Gelman, R. S.
Winer, E. P.
Wolff, A. C.
TI TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab,
metronomic chemotherapy (CM), diet and exercise after preoperative
chemotherapy for breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Univ N Carolina, Chapel Hill, NC USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS103
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002106
ER
PT J
AU McArthur, GA
Puzanov, I
Ribas, A
Chapman, PB
Kim, KB
Sosman, JA
Lee, RJ
Nolop, KB
Flaherty, KT
Hicks, R
AF McArthur, G. A.
Puzanov, I.
Ribas, A.
Chapman, P. B.
Kim, K. B.
Sosman, J. A.
Lee, R. J.
Nolop, K. B.
Flaherty, K. T.
Hicks, R.
TI Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Roche, Nutley, NJ USA.
Plexxikon Inc, Berkeley, CA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Canc Trials Australia, Melbourne, Vic, Australia.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8529
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005199
ER
PT J
AU McCarthy, PL
Owzar, K
Anderson, KC
Hofmeister, CC
Hassoun, H
Hurd, DD
Stadtmauer, EA
Giralt, S
Hars, V
Linker, CA
AF McCarthy, P. L.
Owzar, K.
Anderson, K. C.
Hofmeister, C. C.
Hassoun, H.
Hurd, D. D.
Stadtmauer, E. A.
Giralt, S.
Hars, V.
Linker, C. A.
CA CALGB
ECOG
BMT-CTN
TI Phase III intergroup study of lenalfdomide versus placebo maintenance
therapy following single autologous stem cell transplant (ASCT) for
multiple myeloma (MM): CALGB 100104
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Wake Forest Univ, Winston Salem, NC 27109 USA.
Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8017
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005037
ER
PT J
AU McDermott, DF
Hebremichael, MS
Signoretti, S
Margolin, KA
Clark, J
Sosman, JA
Dutcher, JP
Logan, T
Figlin, RA
Atkins, MB
AF McDermott, D. F.
Hebremichael, M. S.
Signoretti, S.
Margolin, K. A.
Clark, J.
Sosman, J. A.
Dutcher, J. P.
Logan, T.
Figlin, R. A.
Atkins, M. B.
CA Cytokine Working Grp
TI The high-dose aldesleukin (HD IL-2) 'SELECT" trial in patients with
metastatic renal cell carcinoma (mRCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Washington, Seattle, WA 98195 USA.
Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Monash Med Ctr, North Div, New York, NY USA.
Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA.
City Hope Natl Med Ctr, Duarte, CA 91010 USA.
NR 0
TC 16
Z9 16
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4514
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003640
ER
PT J
AU McMillin, DW
Hunter, ZR
Delmore, J
Smith, P
Birner, A
Richardson, PG
Anderson, KC
Treon, SP
Mitsiades, CS
AF McMillin, D. W.
Hunter, Z. R.
Delmore, J.
Smith, P.
Birner, A.
Richardson, P. G.
Anderson, K. C.
Treon, S. P.
Mitsiades, C. S.
TI Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma
and Waldenstrom's macroglobulinemia, and effect on miRNA expression
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Takeda Oncol Co, Millennium Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8110
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005130
ER
PT J
AU Meier, FE
Beck, D
Niessner, H
Flaherty, KT
Sinnberg, T
Schadendorf, D
Kulms, D
Garbe, C
AF Meier, F. E.
Beck, D.
Niessner, H.
Flaherty, K. T.
Sinnberg, T.
Schadendorf, D.
Kulms, D.
Garbe, C.
TI Effect of mTOR inhibitors on sorafenib-induced endoplasnic reticulum
stress and apoptosis in melanoma cells
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Tubingen, Dept Dermatol & Oncol, Tubingen, Germany.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Univ Hosp Essen, Essen, Germany.
Univ Stuttgart, Inst Cell Biol & Immunol, D-70174 Stuttgart, Germany.
Univ Tubingen, Dept Dermatol, Tubingen, Germany.
RI Kulms, Dagmar/H-1653-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e19027
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852001565
ER
PT J
AU Mercado, RC
Hempel, H
Mopala, R
Kastrinos, F
Steyerberg, EW
Balmana, J
Cohn, DE
Backes, FJ
De La Chapelle, A
Syngal, S
AF Mercado, R. C.
Hempel, H.
Mopala, R.
Kastrinos, F.
Steyerberg, E. W.
Balmana, J.
Cohn, D. E.
Backes, F. J.
De La Chapelle, A.
Syngal, S.
CA CCFR
TI Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch
syndrome among endometrial cancer cases
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA.
Ohio State Univ, Div Human Genet, Columbus, OH 43210 USA.
Columbia Univ, Herbert Irving Comprehens Canc Ctr, Div Digest & Liver Dis, Med Ctr, New York, NY USA.
Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.
Univ Autonoma Barcelona, Hosp Vall dHebron, Dept Med, E-08193 Barcelona, Spain.
Ohio State Univ, Div Gynecol Oncol, Columbus, OH 43210 USA.
Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5024
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004081
ER
PT J
AU Meyerhardt, JA
Schrag, D
Kulke, M
Enzinger, PC
Chan, JA
Blaszkowsky, LS
Goldstein, M
Allen, B
Regan, E
Abrams, TA
AF Meyerhardt, J. A.
Schrag, D.
Kulke, M.
Enzinger, P. C.
Chan, J. A.
Blaszkowsky, L. S.
Goldstein, M.
Allen, B.
Regan, E.
Abrams, T. A.
TI Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) in
previously treated metastatic colorectal cancer (mCRC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e14055
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000563
ER
PT J
AU Michaelson, D
McDermott, DF
Atkins, MB
Cho, DC
Olivier, KM
Schwarzberg, AB
Choueiri, TK
AF Michaelson, D.
McDermott, D. F.
Atkins, M. B.
Cho, D. C.
Olivier, K. M.
Schwarzberg, A. B.
Choueiri, T. K.
TI Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid
and/or poor-risk metastatic renal cell carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Canc Ctr South Florida, Lake Worth, FL USA.
Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e15076
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852001084
ER
PT J
AU Millenson, MM
Lee, J
Hanna, NH
Langer, CJ
Hoang, T
Graham, DL
Okuno, SH
Schiller, JH
AF Millenson, M. M.
Lee, J.
Hanna, N. H.
Langer, C. J.
Hoang, T.
Graham, D. L.
Okuno, S. H.
Schiller, J. H.
TI Pemetrexed (Pem) plus gemcitabine (Gem) or carboplatin (Carbo) in
patients (pts) with advanced malignant mesothelioma (MPM): A randomized
phase II trial, E1B03
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Indiana Univ, Indianapolis, IN 46204 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Univ Wisconsin, Madison, WI USA.
Carle Clin Associates, Urbana, IL USA.
Mayo Clin Rochester, Rochester, MN USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e18053
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852001391
ER
PT J
AU Mita, AC
Heist, RS
Aren, O
Mainwaring, PN
Bazhenova, L
Gadgeel, SM
Blum, RH
Polikoff, J
Biswas, J
Spear, MA
AF Mita, A. C.
Heist, R. S.
Aren, O.
Mainwaring, P. N.
Bazhenova, L.
Gadgeel, S. M.
Blum, R. H.
Polikoff, J.
Biswas, J.
Spear, M. A.
TI Phase II study of docetaxel with or without plinabulin (NPI-2358) in
patients with non-small cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Inst Nacl Canc Oncol, Santiago, Chile.
Mater Misericordiae Adult Hosp, Brisbane, Australia.
Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Bendigo Hlth Care Grp, Bendigo, Australia.
Kaiser Hosp San Diego, San Diego, CA USA.
Chittaranjan Natl Canc Inst, Kolkata, India.
Nereus Pharmaceut, San Diego, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7592
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004725
ER
PT J
AU Mok, T
Spigel, DR
Park, K
Socinski, MA
Tung, SY
Kim, D
Borzillo, G
Zhang, H
O'Connell, JP
Janne, PA
AF Mok, T.
Spigel, D. R.
Park, K.
Socinski, M. A.
Tung, S. Y.
Kim, D.
Borzillo, G.
Zhang, H.
O'Connell, J. P.
Janne, P. A.
TI Efficacy and safety of PF-00299804 (PF299). an oral, irreversible,
part-human epidermal growth factor receptor (pan-HER) tyrosine kinase
inhibitor (TKI), as first-line treatment (tx) of selected patients (pts)
with advanced (adv) non-small cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea.
Univ N Carolina, Chapel Hill, NC USA.
Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China.
Seoul Natl Univ Hosp, Seoul 110744, South Korea.
Pfizer Inc, New London, CT USA.
Pfizer Res & Dev Co Ltd, Shanghai, Peoples R China.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 10
Z9 10
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7537
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004670
ER
PT J
AU Morrow, PH
Wulf, GM
Booser, DJ
Moore, JA
Flores, PR
Krop, IE
Winer, EP
Hortobagyi, GN
Yu, D
Esteva, FJ
AF Morrow, P. H.
Wulf, G. M.
Booser, D. J.
Moore, J. A.
Flores, P. R.
Krop, I. E.
Winer, E. P.
Hortobagyi, G. N.
Yu, D.
Esteva, F. J.
TI Phase I/II trail of everoiimus (RAD001) and trastuzumab in patients with
trastuzumab-resistant, HER2-overexpressing breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 1014
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002530
ER
PT J
AU Mullen, JT
Kobayashi, W
Harmon, DC
Choy, E
Hornicek, F
Gebhardt, MC
Springfield, DS
Rosenberg, AE
Spiro, IJ
DeLaney, TF
AF Mullen, J. T.
Kobayashi, W.
Harmon, D. C.
Choy, E.
Hornicek, F.
Gebhardt, M. C.
Springfield, D. S.
Rosenberg, A. E.
Spiro, I. J.
DeLaney, T. F.
TI Long-term follow-up of patients treated with neoadjuvant chemotherapy
and radiotherapy for large extremity soft tissue sarcomas.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10022
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005531
ER
PT J
AU Munshi, NC
Lee, S
Roodman, GD
Behler, C
Kambhampati, S
Rose, MG
Brophy, MT
Houranieh, A
Esseltine, D
Lichtenstein, A
AF Munshi, N. C.
Lee, S.
Roodman, G. D.
Behler, C.
Kambhampati, S.
Rose, M. G.
Brophy, M. T.
Houranieh, A.
Esseltine, D.
Lichtenstein, A.
TI Phase II multisite study to evaluate efficacy and safety of single
weekly administration of bortezomib (BZ) and dexmethasone (dex) in newly
diagnosed multiple myeloma (NDMM) patients (pts)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Boston VA Healthcare Syst, West Roxbury, MA USA.
VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
Kansas City Vet Affairs Med Ctr, Kansas City, MO USA.
VA Connecticut Healthcare Syst, West Haven, CT USA.
Millennium Pharmaceut Inc, Cambridge, MA USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS307
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002307
ER
PT J
AU Nakabayashi, M
Oh, WK
Werner, L
Xie, W
Regan, MM
McKearn, TJ
Kantoff, P
Pomerantz, M
AF Nakabayashi, M.
Oh, W. K.
Werner, L.
Xie, W.
Regan, M. M.
McKearn, T. J.
Kantoff, P.
Pomerantz, M.
TI Association of genetic polymorphisms in ERCC1 gene with PSA response to
carboplatin chemotherapy in men with metastatic castration-resistant
prostate cancer (CRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mt Sinai Sch Med, New York, NY USA.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Agennix Inc, Princeton, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4639
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004009
ER
PT J
AU Nannini, M
Pantaleo, MA
Astolfi, A
Maleddu, A
Heinrich, MC
Corless, CL
di Battista, M
Catena, F
Santini, D
Biasco, G
AF Nannini, M.
Pantaleo, M. A.
Astolfi, A.
Maleddu, A.
Heinrich, M. C.
Corless, C. L.
di Battista, M.
Catena, F.
Santini, D.
Biasco, G.
TI Identification of oncogenic events in gastrointestinal stromal tumors
(GISTs) by combined gene expression and copy number analysis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Bologna, Bologna, Italy.
Univ Bologna, Seragnoli Dept, Bologna, Italy.
Univ Bologna, GIST Study Grp, Bologna, Italy.
Interdept Ctr Canc Res, Bologna, Italy.
Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Univ Bologna, S Orsola Malpighi Hosp, Emergency Surg & Transplant Dept, Bologna, Italy.
St Orsola Marcello Malpighi Hosp, Pathol Unit, Bologna, Italy.
RI nannini, margherita/J-9866-2016
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10039
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005548
ER
PT J
AU Neal, JW
Pennell, NA
Goodgame, BW
Lanuti, M
Heist, RS
Shaw, AT
Temel, JS
Janne, PA
Azzoli, CG
Sequist, LV
AF Neal, J. W.
Pennell, N. A.
Goodgame, B. W.
Lanuti, M.
Heist, R. S.
Shaw, A. T.
Temel, J. S.
Janne, P. A.
Azzoli, C. G.
Sequist, L. V.
TI A multicenter phase II trial of adjuvant erlotinib in patients with
resected non-small cell lung cancer (NSCLC) and mutations in the
epidermal growth factor receptor (EGFR): Toxicity evaluation.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Washington Univ, St Louis, MO USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7078
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004621
ER
PT J
AU Nghiemphu, PL
Omuro, AM
Cloughesy, T
Mellinghoff, IK
Norden, AG
Nguyen, LT
Rajangam, K
Wen, PY
AF Nghiemphu, P. L.
Omuro, A. M.
Cloughesy, T.
Mellinghoff, I. K.
Norden, A. G.
Nguyen, L. T.
Rajangam, K.
Wen, P. Y.
TI A Phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel
PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in
patients (pts) with newly diagnosed malignant glioma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Calif Los Angeles, Neurooncol Program, Los Angeles, CA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Exelixis, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3085
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003290
ER
PT J
AU O'Regan, KN
Ramaiya, NH
Jagannathan, JP
Dipiro, P
Van den Abbeele, AD
Hodi, FS
AF O'Regan, K. N.
Ramaiya, N. H.
Jagannathan, J. P.
Dipiro, P.
Van den Abbeele, A. D.
Hodi, F. S.
TI Patterns of disease spread in metastatic mucosal melanoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [O'Regan, K. N.; Ramaiya, N. H.; Jagannathan, J. P.; Dipiro, P.; Van den Abbeele, A. D.; Hodi, F. S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8583
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005253
ER
PT J
AU O'Shaughnessy, J
Miles, D
Gray, RJ
Dieras, V
Perez, EA
Zon, R
Cortes, J
Zhou, X
Phan, S
Miller, K
AF O'Shaughnessy, J.
Miles, D.
Gray, R. J.
Dieras, V.
Perez, E. A.
Zon, R.
Cortes, J.
Zhou, X.
Phan, S.
Miller, K.
TI A meta-analysis of overall survival data from three randomized trials of
bevacizumab (BV) and first-line chemotherapy as treatment for patients
with metastatic breast cancer (MBC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Baylor Sammons Canc Ctr, Dallas, TX USA.
Mt Vernon Canc Ctr, Northwood, Middx, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Inst Curie, Paris, France.
Mayo Clin Florida, Jacksonville, FL USA.
Michiana Hematol Oncol PC, South Bend, IN USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
Genentech Inc, San Francisco, CA 94080 USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
NR 0
TC 16
Z9 16
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 1005
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002523
ER
PT J
AU Ottmann, OG
Fenaux, P
Lubbert, M
DeAngelo, DJ
Garcia-Manero, G
Bhalla, KN
Sekeres, MA
Ludicke, F
Weber, HJ
Winiger, IJ
AF Ottmann, O. G.
Fenaux, P.
Luebbert, M.
DeAngelo, D. J.
Garcia-Manero, G.
Bhalla, K. N.
Sekeres, M. A.
Luedicke, F.
Weber, H. J.
Winiger, I. J.
TI A phase Ib study of oral panobinostat (LBH589) administered with
5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS),
chronic myeloid leukemia (AML)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Hosp Frankfurt, Frankfurt, Germany.
Hop Avicenne, F-93009 Bobigny, France.
Univ Hosp Freiburg, Freiburg, Germany.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA.
Cleveland Clin, Taussig Canc Inst, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA.
Novertis Pharma AG, Basel, Switzerland.
RI Ottmann, Oliver/D-5007-2016
OI Ottmann, Oliver/0000-0001-9559-1330
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS282
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002282
ER
PT J
AU Pandalai, PK
Hornick, JL
Wang, Q
Morgan, JA
George, S
Baldini, EH
Devlin, PM
Raut, CP
AF Pandalai, P. K.
Hornick, J. L.
Wang, Q.
Morgan, J. A.
George, S.
Baldini, E. H.
Devlin, P. M.
Raut, C. P.
TI Cutaneous angiosarcoma of the head and neck.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10067
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005576
ER
PT J
AU Partridge, AH
Hughes, ME
Wong, Y
Edge, SB
Theriault, RL
Blayney, DW
Niland, JC
Winer, EP
Weeks, JC
Tamimi, RM
AF Partridge, A. H.
Hughes, M. E.
Wong, Y.
Edge, S. B.
Theriault, R. L.
Blayney, D. W.
Niland, J. C.
Winer, E. P.
Weeks, J. C.
Tamimi, R. M.
TI The effect of age on delay in diagnosis and stage of breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 1580
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002747
ER
PT J
AU Patil, S
Figlin, RA
Hutson, TE
Michaelson, D
Negrier, S
Kim, ST
Huang, X
Motzer, RJ
AF Patil, S.
Figlin, R. A.
Hutson, T. E.
Michaelson, D.
Negrier, S.
Kim, S. T.
Huang, X.
Motzer, R. J.
TI TWiST analysis to estimate overall benefit for metastatic renal cell
carcinoma (mRCC) patients (pts) treated in a phase III trial of
sunitinib versus interferon-alfa (IFN-alpha)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Ctr Leon Berard, Serv Cancerol Med, F-69373 Lyon, France.
Pfizer Inc, La Jolla, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4594
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003717
ER
PT J
AU Peled, N
Hakim, M
Haick, H
Bunn, PA
Miller, YE
Kennedy, TC
Mitchell, JD
Weyant, MJ
Hirsch, FR
AF Peled, N.
Hakim, M.
Haick, H.
Bunn, P. A.
Miller, Y. E.
Kennedy, T. C.
Mitchell, J. D.
Weyant, M. J.
Hirsch, F. R.
TI Use of a nanoparticle-based artificial olfactory system, NaNose, to
distinguish malignant from benign pulmonary nodules
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Colorado Denver Canc Ctr, Aurora, CO USA.
Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel.
Russell Berrie Nanotechnol Inst, Haifa, Israel.
Denver Vet Affairs Med Ctr, Denver, CO USA.
Univ Colorado Denver, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10521
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005629
ER
PT J
AU Petricoin, E
Ross, MM
Zhou, W
Tamburro, D
Luchini, A
Liotta, LA
Scully, RE
Miller, TL
Sallan, SE
Lipshultz, SE
AF Petricoin, E.
Ross, M. M.
Zhou, W.
Tamburro, D.
Luchini, A.
Liotta, L. A.
Scully, R. E.
Miller, T. L.
Sallan, S. E.
Lipshultz, S. E.
TI Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in
pediatric acute lymphoblastic leukemia assessed by nanopartice-capture
mass spectrometry.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 George Mason Univ, Manassas, VA USA.
George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA USA.
Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy.
Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.
Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
RI Luchini, Alessandra/M-5340-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9528
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005457
ER
PT J
AU Phan, AT
Yao, JC
Fogelman, DR
Hess, KR
Ng, CS
Bullock, SA
Malinowski, P
Regan, E
Kulke, M
AF Phan, A. T.
Yao, J. C.
Fogelman, D. R.
Hess, K. R.
Ng, C. S.
Bullock, S. A.
Malinowski, P.
Regan, E.
Kulke, M.
TI A prospective, multi-institutional phase II study of GW786034
(pozopanib) and depot octreotide (sandostatin LAR) in advanced low-grade
neuroendocrine carcinoma (LGNEC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 22
Z9 22
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4001
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003471
ER
PT J
AU Pindyck, T
Spurgeon, SE
Okada, CY
Epner, EE
AF Pindyck, T.
Spurgeon, S. E.
Okada, C. Y.
Epner, E. E.
TI Cladribine plus rituximab for the initial treatment of mantle cell
lymphoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA.
Penn State Hershey Canc Inst, Hershey, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8099
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005119
ER
PT J
AU Pirl, WF
Greer, J
Bemis, H
Heist, RS
Gallagher, E
Sequist, LV
Engelman, JA
Traeger, L
Lennes, IT
Temel, JS
AF Pirl, W. F.
Greer, J.
Bemis, H.
Heist, R. S.
Gallagher, E.
Sequist, L. V.
Engelman, J. A.
Traeger, L.
Lennes, I. T.
Temel, J. S.
TI Depression and EGFR mutation status in stage IV non-small cell lung
cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9086
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005351
ER
PT J
AU Pishvalan, MJ
Cotarla, I
Wagner, AJ
Deeken, JF
He, AR
Hwang, JJ
Demetri, GD
Halim, A
Copigneaux, C
Marshall, J
AF Pishvalan, M. J.
Cotarla, I.
Wagner, A. J.
Deeken, J. F.
He, A. R.
Hwang, J. J.
Demetri, G. D.
Halim, A.
Copigneaux, C.
Marshall, J.
TI Final reporting of a phase I clinical trial of the oral PPAR-gamma
against, CS-7017, in patients with advanced malignancies.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Georgetown Univ, Med Ctr, Washington, DC 20007 USA.
Harvard Canc Ctr, Dana Farber Canc Inst, Ludwig Ctr, Boston, MA USA.
Sarcoma Ctr, Boston, MA USA.
Daiichi Sankyo Pharma Dev, Edison, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2526
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003118
ER
PT J
AU Posner, MR
Lorch, JH
Goloubeva, O
Tan, M
Schumaker, L
Sartis, NJ
Haddad, RI
Cullen, KJ
AF Posner, M. R.
Lorch, J. H.
Goloubeva, O.
Tan, M.
Schumaker, L.
Sartis, N. J.
Haddad, R. I.
Cullen, K. J.
TI Oropharyax cancer (OPC) in TAX 324: Human papillomavirus (HPV) and
survival
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Univ Maryland, Marlene & Stewart Greertebaum Canc Ctr, Baltimore, MD 21201 USA.
Sanofi Eventis US, Bridgewater, NJ USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5525
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004202
ER
PT J
AU Pulsifer, MB
Delgado, I
Tarbell, N
Kuhlthau, K
MacDonald, SM
Yock, TI
AF Pulsifer, M. B.
Delgado, I.
Tarbell, N.
Kuhlthau, K.
MacDonald, S. M.
Yock, T. I.
TI Neurocognitive outcomes after proton radiation for pediatric brain
tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9508
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005437
ER
PT J
AU Punglia, RS
Wong, JS
Burstein, HJ
Weeks, JC
AF Punglia, R. S.
Wong, J. S.
Burstein, H. J.
Weeks, J. C.
TI Decision analysis: Excision alone versus excision plus radiation therapy
for ductal carcinoma in situ
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Punglia, R. S.; Wong, J. S.; Burstein, H. J.; Weeks, J. C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 577
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002411
ER
PT J
AU Quek, RH
Morgan, JA
Shapiro, G
Butrynski, JE
Wang, Q
Huftalen, T
Jederlinic, N
Wagner, AJ
Demetri, GD
George, S
AF Quek, R. H.
Morgan, J. A.
Shapiro, G.
Butrynski, J. E.
Wang, Q.
Huftalen, T.
Jederlinic, N.
Wagner, A. J.
Demetri, G. D.
George, S.
TI Combination mTOR plus IGF-IR inhibition: Phase I trial of everolimus and
CP-751871 in patients (pts) with advanced sarcomas and other solid
tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Canc Ctr, Dana Farber Canc Inst, Ludwig Ctr, Boston, MA USA.
Sarcoma Ctr, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10002
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005511
ER
PT J
AU Raje, NS
Munshi, NC
Mahindra, AK
Pozzi, S
Richardson, PG
Laubach, J
Ghobrial, IM
Schlossman, RL
Anderson, KC
AF Raje, N. S.
Munshi, N. C.
Mahindra, A. K.
Pozzi, S.
Richardson, P. G.
Laubach, J.
Ghobrial, I. M.
Schlossman, R. L.
Anderson, K. C.
TI Bone marker assessment as a guide to chronic use of aminobisphosphonates
in multiple myeloma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Pozzi, Samantha/A-7617-2012
OI Pozzi, Samantha/0000-0001-7917-1774
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8140
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005160
ER
PT J
AU Ramalingam, SS
Lee, J
Belani, CP
Aisner, SC
Kolesar, J
Howe, CW
Velasco, MR
Schiller, JH
AF Ramalingam, S. S.
Lee, J.
Belani, C. P.
Aisner, S. C.
Kolesar, J.
Howe, C. W.
Velasco, M. R.
Schiller, J. H.
TI Cetuximab for the treatment of advanced bronchioloalveolar carcinoma
(BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Penn State Hershey Canc Inst, Hershey, PA USA.
Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA.
Univ Wisconsin Carbone Canc Ctr, Madison, WI USA.
Minnesota Oncol Hematol PA, St Paul, MN USA.
Canc Care Specialists, Decatur, GA USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7522
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004658
ER
PT J
AU Ramanathan, RK
Rosen, PJ
Wagner, AJ
Sahasrabudhe, S
Weiss, GJ
Lee, P
Fuerst, M
Robbins, P
Litka, P
Von Hoff, DD
AF Ramanathan, R. K.
Rosen, P. J.
Wagner, A. J.
Sahasrabudhe, S.
Weiss, G. J.
Lee, P.
Fuerst, M.
Robbins, P.
Litka, P.
Von Hoff, D. D.
TI A phase I pharmacodynamic and pharmacokinetic study of a Ras inhibitor,
PRLX 93936, in patients with advanced solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Virginia G Piper Canc Ctr, Scottsdale, AZ USA.
TGen, Scottsdale, AZ USA.
Tower Canc Res Fdn, Beverly Hills, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Prolexys Pharmaceut Inc, Salt Lake City, UT USA.
Scottsdale Healthcare, Virginia G Piper Canc Ctr, Scottsdale, AZ USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e13042
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000279
ER
PT J
AU Raut, CP
Morgan, JA
Quek, RH
Boucher, Y
Duda, GD
Lahdenranta, J
Ancukiewicz, M
Eder, JP
Jain, RK
Demetri, GD
AF Raut, C. P.
Morgan, J. A.
Quek, R. H.
Boucher, Y.
Duda, G. D.
Lahdenranta, J.
Ancukiewicz, M.
Eder, J. P.
Jain, R. K.
Demetri, G. D.
TI Measurement of interstitial fluid pressure (IF P) and circulating
biomarkers in soft tissue sarcoma (STS): An exploratory phase II
clinical and correlative study of sorafenib (SOR) in patients with
refractory STS (NCI Protocol 6948).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
AstraZeneca, Waltham, MA USA.
Harvard Canc Ctr, Dana Farber Canc Inst, Ludwig Ctr, Boston, MA USA.
Sarcoma Ctr, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10091
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005600
ER
PT J
AU Reichardt, P
Blay, J
Gelderblom, H
Schlemmer, M
Demetri, GD
Bin Bui, N
McArthur, GA
Yazji, S
Hsu, Y
Rutkowski, P
AF Reichardt, P.
Blay, J.
Gelderblom, H.
Schlemmer, M.
Demetri, G. D.
Bin Bui, N.
McArthur, G. A.
Yazji, S.
Hsu, Y.
Rutkowski, P.
TI Phase III trial of nilotinib in patients with advanced gastrointestinal
stromal tumor (GIST): First results from ENEST g3.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 HELIOS Klinikum Bad Saarow, Berlin, Germany.
Univ Lyon 1, F-69365 Lyon, France.
Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands.
Univ Munich, Univ Hosp Grosshadem, Dept Internal Med 3, Munich, Germany.
Dana Farber Canc Inst, Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA.
Sarcoma Ctr, Boston, MA USA.
Inst Bergonie, Bordeaux, France.
Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
Novartis Pharmaceut, Florham Pk, NJ USA.
M Sklodowska Curie Mem Canc Ctr, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland.
Inst Oncol, Warsaw, Poland.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 8
Z9 9
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10017
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005526
ER
PT J
AU Ribi, K
Aldridge, J
Phillips, K
Sun, Z
Thompson, AM
Harvey, VJ
Thurlimann, B
Cardoso, F
Coates, AS
Bernhard, J
AF Ribi, K.
Aldridge, J.
Phillips, K.
Sun, Z.
Thompson, A. M.
Harvey, V. J.
Thuerlimann, B.
Cardoso, F.
Coates, A. S.
Bernhard, J.
TI Changes in cognitive function in postmenopausal women 1 year after
completing adjuvant letrozole or tamoxifen in the Breast International
Group (BIG) 1-98 trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Int Beast Canc Study Grp, Bern, Switzerland.
Dana Farber Canc Inst, Int Beast Canc Study Grp Stat Ctr, Boston, MA 02115 USA.
Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
Univ Dundee, Dundee, Scotland.
Auckland Hosp, Auckland, New Zealand.
Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland.
Inst Jules Bordet, B-1000 Brussels, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 527
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002363
ER
PT J
AU Richardson, PG
Weber, DM
Mitsiades, CS
Dimopoulos, MA
Harousseau, J
Howe, J
Graef, T
Byrne, C
Anderson, KC
Siegel, DS
AF Richardson, P. G.
Weber, D. M.
Mitsiades, C. S.
Dimopoulos, M. A.
Harousseau, J.
Howe, J.
Graef, T.
Byrne, C.
Anderson, K. C.
Siegel, D. S.
TI Phase I study of combined vorinostat (V), lenalidomide (L), and
dexamethasone (D) in patients (pts) with relapsed or refractory multiple
myeloma (MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Athens, Sch Med, Dept Therapeut, GR-11527 Athens, Greece.
Ctr Rene Gauducheau, St Herblain, France.
Merck & Co Inc, Upper Gwynedd, PA USA.
Celgene Corp, Summit, NJ USA.
Hackensack Univ, Med Ctr, Hackensack, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8031
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005051
ER
PT J
AU Rosenberg, JE
Drabkin, HA
Lara, P
Harzstark, AL
Figlin, RA
Smith, GW
Erlandsson, F
Laber, DA
AF Rosenberg, J. E.
Drabkin, H. A.
Lara, P., Jr.
Harzstark, A. L.
Figlin, R. A.
Smith, G. W.
Erlandsson, F.
Laber, D. A.
TI A phase II, single-arm study of AS1411 in metastatic renal cell
carcinoma (RCC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Med Univ S Carolina, Charleston, SC 29425 USA.
Univ Calif Davis, Sacramento, CA 95817 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
St Francis Hosp, Beech Grove, IN USA.
Antisoma Res Ltd, London, England.
Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4590
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003713
ER
PT J
AU Rosenzweig, MQ
Giblin, JM
Mickle, M
Morse, A
Sheehy, PS
Sommer, V
AF Rosenzweig, M. Q.
Giblin, J. M.
Mickle, M.
Morse, A.
Sheehy, P. S.
Sommer, V.
TI Knowledge needs of nurse practitioners new to oncology care.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.
Emory Clin, Atlanta, GA 30322 USA.
Northwestern Mem Fac Fdn, Chicago, IL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Kansas City Canc Ctr, Kansas City, KS USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e16532
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852001274
ER
PT J
AU Ruddy, KJ
Gelber, S
Tamimi, RM
Schapira, L
Come, SE
Meyer, ME
Winer, EP
Partridge, AH
AF Ruddy, K. J.
Gelber, S.
Tamimi, R. M.
Schapira, L.
Come, S. E.
Meyer, M. E.
Winer, E. P.
Partridge, A. H.
TI Coping strategies in young women with breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9159
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005423
ER
PT J
AU Rudin, CM
Oliveira, MR
Garon, EB
Bonomi, P
Camidge, DR
Nolan, C
Busman, T
Krivoshik, A
Humerickhouse, R
Gandhi, L
AF Rudin, C. M.
Oliveira, M. R.
Garon, E. B.
Bonomi, P.
Camidge, D. R.
Nolan, C.
Busman, T.
Krivoshik, A.
Humerickhouse, R.
Gandhi, L.
TI A phase IIa study of ABT-263 in patients with relapsed small-cell lung
cancer (SCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
NorthWest Med Specia, Tacoma, WA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Rush Univ, Med Ctr, Chicago, IL 60612 USA.
Univ Colorado Denver, Aurora, CO USA.
Abbott Labs, Abbott Pk, IL 60064 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7046
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004590
ER
PT J
AU Rueda, BR
McCann, C
Growdon, WB
Foster, R
Curley, MD
Ross, RW
Proctor, J
MacDougall, J
AF Rueda, B. R.
McCann, C.
Growdon, W. B.
Foster, R.
Curley, M. D.
Ross, R. W.
Proctor, J.
MacDougall, J.
TI Significance of the hedgehog (Hh) pathway in ovarian cancer xenograft
growth.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Infin Pharmaceut, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5058
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004114
ER
PT J
AU Ryan, CJ
Smith, MR
Logothetis, C
Koepfgen, K
Taplin, M
Harzstark, AL
Kantoff, P
Khooh, TS
Molina, A
Small, EJ
AF Ryan, C. J.
Smith, M. R.
Logothetis, C.
Koepfgen, K.
Taplin, M.
Harzstark, A. L.
Kantoff, P.
Khooh, T. S.
Molina, A.
Small, E. J.
TI Median time to progression in chemotherapy (chemo)-naive patients with
castration-resistant prostate cancer (CRPC) treated with abiraterone at
and low-dose prednisone (Pred).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Cougar Biotechnol, Los Angeles, CA USA.
Ortho Biotech Oncol Res & Dev, Los Angeles, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4671
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004040
ER
PT J
AU Samuel, TA
Sessa, C
Britten, C
Milligan, KS
Mita, MM
Banerji, U
Pluard, TJ
Stiegler, P
Quad, C
Shapiro, G
AF Samuel, T. A.
Sessa, C.
Britten, C.
Milligan, K. S.
Mita, M. M.
Banerji, U.
Pluard, T. J.
Stiegler, P.
Quad, C.
Shapiro, G.
TI AUY922, a novel HSP90 inhibitor: Final results of a First-in-human study
in patients with advanced solid malignancies.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Med Coll Georgia, Augusta, GA 30912 USA.
Osped Reg Bellinzona & Valli, Oncol Inst Southern Switzerland, Bellinzona, Switzerland.
Univ Calif Los Angeles, Clin Res Unit, Los Angeles, CA USA.
Nevada Canc Inst, Las Vegas, NV USA.
Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA.
Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England.
Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Novartis Pharmaceut, Basel, Switzerland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 8
Z9 8
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2528
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003119
ER
PT J
AU Samuels, BL
Tap, WD
Patel, S
von Mehren, M
Hamm, JT
Kaiser, PE
Schuetze, S
Li, J
Bayever, E
Demetri, GD
AF Samuels, B. L.
Tap, W. D.
Patel, S.
von Mehren, M.
Hamm, J. T.
Kaiser, P. E.
Schuetze, S.
Li, J.
Bayever, E.
Demetri, G. D.
TI Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS)
failing standard of care: Interim analysis of 1,400 patients (pts) in an
expanded access program study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Kootenai Canc Ctr, Post Falls, ID USA.
Univ Calif Los Angeles, Santa Monica, CA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Norton Hlth Care, Louisville, KY USA.
Oncol Specialists, Niles, IL USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA.
Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
Dana Farber Canc Inst, Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA.
Sarcoma Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10027
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005536
ER
PT J
AU San-Miguel, JF
Sezer, O
Siegel, DS
Guenther, A
Blade, J
Prosser, IW
Bengoudifa, B
Klebsattel, M
Bourquelot, PM
Anderson, KC
AF San-Miguel, J. F.
Sezer, O.
Siegel, D. S.
Guenther, A.
Blade, J.
Prosser, I. W.
Bengoudifa, B.
Klebsattel, M.
Bourquelot, P. M.
Anderson, K. C.
TI Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib
in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref)
multiple myeloma (MM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Hosp Univ Salamanca, Salamanca, Spain.
Wuerzburg Univ Hosp, Wurzburg, Germany.
Hackensack Univ, Med Ctr, Hackensack, NJ USA.
Univ Kiel, Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany.
Hosp Clin Barcelona, Barcelona, Spain.
Canberra Hosp, Canberra, ACT, Australia.
Novartis Pharma AG, Basel, Switzerland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8001
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005021
ER
PT J
AU Schiff, D
Reardon, DA
Kesari, S
Mikkelsen, T
De Groot, JF
Fichtel, L
Coyle, TE
Wong, E
Eaton, C
Silver, B
AF Schiff, D.
Reardon, D. A.
Kesari, S.
Mikkelsen, T.
De Groot, J. F.
Fichtel, L.
Coyle, T. E.
Wong, E.
Eaton, C.
Silver, B.
TI Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based
on a domain of human fibronectin, in recurrent glioblastoma (rGBM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Virginia, Med Ctr, Charlottesville, VA USA.
Duke Univ, Med Ctr, Durham, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Henry Ford Hlth Syst, Detroit, MI USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
South Texas Oncol & Hematol, San Antonio, TX USA.
SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Adnexus, Waltham, MA USA.
RI Kesari, Santosh/E-8461-2013
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2011
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003006
ER
PT J
AU Schoenfeld, A
Nielsen, GP
Hornicek, F
Duan, Z
Ferrone, S
Schwab, JH
AF Schoenfeld, A.
Nielsen, G. P.
Hornicek, F.
Duan, Z.
Ferrone, S.
Schwab, J. H.
TI CSPG4 and B7-H3 as prognostic biomarkers in chordonta
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10050
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005559
ER
PT J
AU Schrag, D
Weiser, MR
Goodman, KA
Gonen, M
Cercek, A
Reidy, DL
Temple, LK
Wong, WD
Paty, P
Saltz, L
AF Schrag, D.
Weiser, M. R.
Goodman, K. A.
Gonen, M.
Cercek, A.
Reidy, D. L.
Temple, L. K.
Wong, W. D.
Paty, P.
Saltz, L.
TI Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal
cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 17
Z9 17
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3511
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003323
ER
PT J
AU Schuetze, S
Wathen, K
Choy, E
Samuels, BL
Ganjoo, KN
Staddon, AP
von Mehren, M
Chow, WA
Trent, JC
Baker, LH
AF Schuetze, S.
Wathen, K.
Choy, E.
Samuels, B. L.
Ganjoo, K. N.
Staddon, A. P.
von Mehren, M.
Chow, W. A.
Trent, J. C.
Baker, L. H.
TI Results of a Sarcoma Alliance for Research through Collaboration (SARC)
phase II trial of dasatinib in previously treated, high-grade, advanced
sarcoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Michigan, Ann Arbor, MI 48109 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Kootenai Canc Ctr, Post Falls, ID USA.
Stanford Univ, Palo Alto, CA 94304 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10009
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005518
ER
PT J
AU Schutz, FA
Je, Y
Azzi, GR
Choueiri, TK
AF Schutz, F. A.
Je, Y.
Azzi, G. R.
Choueiri, T. K.
TI Risk of congestive heart failure with VEGF-targeted therapy. A
systematic review and meta-analysis of clinical trials.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4602
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003725
ER
PT J
AU Sequist, LV
Natale, RB
Senzer, NN
Martins, R
Lilenbaum, R
Gray, JE
Borger, DR
Paez, G
Grayzel, DS
Gettinger, SN
AF Sequist, L. V.
Natale, R. B.
Senzer, N. N.
Martins, R.
Lilenbaum, R.
Gray, J. E.
Borger, D. R.
Paez, G.
Grayzel, D. S.
Gettinger, S. N.
TI Association between anaplastic lymphoma kinase rearrangements (rALK) and
the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel
Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA USA.
Mary Crowley Canc Res Ctr, Dallas, TX USA.
Seattle Canc Care Alliance, Seattle, WA USA.
Mt Sinai Comprehens Canc Ctr, Miami Beach, FL USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Massachusetts Gen Hosp, Translat Res Lab, Boston, MA 02114 USA.
Infin Pharmaceut, Cambridge, MA USA.
Yale Univ Sch Med, New Haven, CT USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7517
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004653
ER
PT J
AU Shannon, J
Lieberman, S
Maxcy, C
Thuillier, P
Peters, L
Garzotto, M
AF Shannon, J.
Lieberman, S.
Maxcy, C.
Thuillier, P.
Peters, L.
Garzotto, M.
TI Fish oil, green tea, and prostate cancer prevention
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Kaiser Permanente Northwest, Portland, OR USA.
Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS140
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002143
ER
PT J
AU Shapiro, G
Kwak, EL
Dezube, BJ
Lawrence, DP
Cleary, JM
Lewis, S
Squires, M
Lock, V
Lyons, JF
Yule, M
AF Shapiro, G.
Kwak, E. L.
Dezube, B. J.
Lawrence, D. P.
Cleary, J. M.
Lewis, S.
Squires, M.
Lock, V.
Lyons, J. F.
Yule, M.
TI Phase I pharmacokinetic and pharmacodynamic study of the heat shock
protein 90 inhibitor AT13387 in patients with refractory solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Astex Therapeut, Cambridge, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3069
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003274
ER
PT J
AU Shaw, AT
Yeap, B
Costa, DB
Solomon, BJ
Kwak, EL
Nguyen, AT
Bergethon, K
Engelman, JA
Iafrate, AJ
AF Shaw, A. T.
Yeap, B.
Costa, D. B.
Solomon, B. J.
Kwak, E. L.
Nguyen, A. T.
Bergethon, K.
Engelman, J. A.
Iafrate, A. J.
TI Prognostic versus predictive value of EML4-ALK translocation in
metastatic non-small cell lung cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
Canc Trials Australia, Melbourne, Vic, Australia.
Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Translat Res Lab, Boston, MA 02114 USA.
NR 0
TC 5
Z9 6
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7606
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004739
ER
PT J
AU Sher, DJ
Neville, BA
Tishler, RB
Schrag, D
AF Sher, D. J.
Neville, B. A.
Tishler, R. B.
Schrag, D.
TI Changing rates of organ-preservation therapy over time for head and neck
cancer: A SEER-Medicare analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6063
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004342
ER
PT J
AU Shonka, NA
Gilbert, MR
Yung, WA
Paio, Y
Liu, J
Bekele, BN
Wen, PY
Chen, AP
Heymach, J
De Groot, JF
AF Shonka, N. A.
Gilbert, M. R.
Yung, W. A.
Paio, Y.
Liu, J.
Bekele, B. N.
Wen, P. Y.
Chen, A. P.
Heymach, J.
De Groot, J. F.
TI Use of cytokines to predict on-target in patients with recurrent
glioblastoma treated with aflibercept
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NCI, Bethesda, MD 20892 USA.
RI Gilbert, Mark/J-7494-2016
OI Gilbert, Mark/0000-0003-2556-9722
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e12507
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000199
ER
PT J
AU Shustov, AR
Pro, B
Horwitz, SM
Jacobsen, ED
Boyd, A
Fruchtman, SM
O'Connor, O
AF Shustov, A. R.
Pro, B.
Horwitz, S. M.
Jacobsen, E. D.
Boyd, A.
Fruchtman, S. M.
O'Connor, O.
TI Pralatrexate in patients with relapsed/refractory peripheral T-cell
lymphoma (PTCL): Relationship between response and survival
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Seattle Canc Care Alliance, Seattle, WA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Alios Therapeut, Westminster, CO USA.
Alios Therapeut, Princeton, NJ USA.
NYU, Inst Canc, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8054
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005074
ER
PT J
AU Sikov, WM
Perou, CM
Golshan, M
Collyar, D
Berry, DA
Hahn, OM
Singh, B
Hudis, C
Winer, EP
AF Sikov, W. M.
Perou, C. M.
Golshan, M.
Collyar, D.
Berry, D. A.
Hahn, O. M.
Singh, B.
Hudis, C.
Winer, E. P.
CA Canc Leukemia Grp B
North Amer Intergrp
TI Randomized phase II trial of adding carboplatin and/or bevacizumab to
neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative
breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Canc & Leukemia Grp B, Daville, CA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Chicago, Chicago, IL 60637 USA.
NYU Med Ctr, Tisch Hosp, New York, NY 10016 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS110
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002113
ER
PT J
AU Slingluff, CL
Lee, SJ
Chianese-Bullock, KA
Olson, WC
Butterfield, LH
Leming, PD
Kirkwood, JM
AF Slingluff, C. L.
Lee, S. J.
Chianese-Bullock, K. A.
Olson, W. C.
Butterfield, L. H.
Leming, P. D.
Kirkwood, J. M.
TI First report of a randomized phase II trial of multi-epitope vaccination
with melanoma peptides for cytotoxic T cells and helper T cells in
patients with metastatic melanoma: An Eastern Cooperative Oncology Group
Study (E1602)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Virginia, Charlottesville, VA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Cincinnati Hematol Oncol Inc, Cincinnati, OH USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8508
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005179
ER
PT J
AU Small, EJ
Beer, TM
Weinberg, VK
Higano, CS
Nordquist, LT
Rosenberg, JE
Alumkal, JJ
Yu, EY
Sun, J
Lin, AM
AF Small, E. J.
Beer, T. M.
Weinberg, V. K.
Higano, C. S.
Nordquist, L. T.
Rosenberg, J. E.
Alumkal, J. J.
Yu, E. Y.
Sun, J.
Lin, A. M.
TI Intermittent chemotherapy (ICh) for metastatic castration-resistant
prostate cancer (mCRPC): Results of a prospective randomized phase II
trial of the DoD Prostate Cancer Clinical Trials Consortium.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Univ Washington, Sch Med, Seattle, WA USA.
Oncol Hematol West PC, Omaha, NE USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4684
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004053
ER
PT J
AU Smith, MR
Cook, RJ
Nelson, JB
AF Smith, M. R.
Cook, R. J.
Nelson, J. B.
TI Natural history of castration-resistant nonmetastatic prostate cancer:
Secondary analyses of a multicenter randomized controlled trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Waterloo, Waterloo, ON N2L 3G1, Canada.
Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4653
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004022
ER
PT J
AU Soumerai, JD
Hunter, LR
Boxer, M
Kahl, BS
Ioakimidis, LI
Patterson, CJ
Treon, SP
AF Soumerai, J. D.
Hunter, L. R.
Boxer, M.
Kahl, B. S.
Ioakimidis, L. I.
Patterson, C. J.
Treon, S. P.
TI Long-term follow-up of patients with lymphoplasmacylic lymphoma
(Waldenstronls macroglobulinemia) who were treated with alemtuzumab
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Arizona Oncol Associates, Tucson, AZ USA.
Univ Wisconsin, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8109
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005129
ER
PT J
AU Sperduto, PW
Xu, Z
Sneed, P
Luo, X
Roberge, D
Bhatt, AK
Jensen, AW
Shih, HA
Kirkpatrick, J
Gaspar, LE
AF Sperduto, P. W.
Xu, Z.
Sneed, P.
Luo, X.
Roberge, D.
Bhatt, A. K.
Jensen, A. W.
Shih, H. A.
Kirkpatrick, J.
Gaspar, L. E.
CA Graded Prognostic Assessment GPA
TI A graded prognostic assessment (GPA) for women with breast cancer and
brain metastases.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Minnesota, Gamma Knife Ctr, Waconia, MN USA.
Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Minnesota, Div Biostat, Minneapolis, MN USA.
McGill Univ, Dept Radiat Oncol, Ctr Hlth, Montreal, PQ H3A 2T5, Canada.
Univ Wisconsin Hosp, Dept Radiat Oncol, Madison, WI USA.
Mayo Clin, Dept Radiat Oncol, Rochester, MN USA.
Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ Colorado Denver, Aurora, CO USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 1028
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002543
ER
PT J
AU Spurgeon, SE
Okada, CY
Huang, J
Phillips, J
Epner, EE
AF Spurgeon, S. E.
Okada, C. Y.
Huang, J.
Phillips, J.
Epner, E. E.
TI Targeting the epigenome: A phase I/II study of vorinostat (SAHA),
cladribine (2-CdA), and rituximab in relapsed B-cell malignancies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA.
Univ Utah, Salt Lake City, UT USA.
Penn State Hershey Canc Inst, Hershey, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS301
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002301
ER
PT J
AU Stein, MN
Chen, Y
Hudes, GR
Carducci, MA
Tan, W
DiPaola, RS
AF Stein, M. N.
Chen, Y.
Hudes, G. R.
Carducci, M. A.
Tan, W.
DiPaola, R. S.
TI ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients
(pts) with metastatic castration-resistant prostate cancer (CRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Canc Inst New Jersey, New Brunswick, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Mayo Clin Jacksonville, Jacksonville, FL 32224 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4556
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003679
ER
PT J
AU Stuart, RK
Kashani, FR
Cripe, LD
Maris, MB
Cooper, MA
Dakhil, SR
Stone, RM
Turturro, F
Fox, JA
Michelson, G
AF Stuart, R. K.
Kashani, F. Ravandi
Cripe, L. D.
Maris, M. B.
Cooper, M. A.
Dakhil, S. R.
Stone, R. M.
Turturro, F.
Fox, J. A.
Michelson, G.
TI Voreloxin single-agent treatment of older patients (60 years or older)
with previously untreated acute myeloid leukemia: Final results from a
phase II study with three schedules.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Med Univ S Carolina, Charleston, SC 29425 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA.
Rocky Mt Blood & Marrow Transplant Program, Denver, CO USA.
St Francis Hosp, Indianapolis, IN USA.
Canc Ctr Kansas, Wichita, KS USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71105 USA.
Sunesis Pharmaceut Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6525
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004462
ER
PT J
AU Sullivan, RJ
Frankenthaler, A
Wang, W
Seery, VJ
Lee, M
Koon, HB
Atkins, MB
AF Sullivan, R. J.
Frankenthaler, A.
Wang, W.
Seery, V. J.
Lee, M.
Koon, H. B.
Atkins, M. B.
TI A retrospective comparison of 12 weeks versus 52 weeks of adjuvant
interferon for patients with stage HB, HC, and IHA (IIB-IIA) melanoma
(Mel)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Hosp Case Med Ctr, Cleveland, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 19013
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852001551
ER
PT J
AU Sweeney, C
Dugan, WM
Dreicer, R
Chu, F
Parks, G
Baker, K
Reed, D
Jansz, K
Zadra, J
Yiannoutsos, CT
AF Sweeney, C.
Dugan, W. M., II
Dreicer, R.
Chu, F.
Parks, G.
Baker, K.
Reed, D.
Jansz, K.
Zadra, J.
Yiannoutsos, C. T.
TI A randomized placebo-controlled trial of daily high-dose oral
risedronate in men with metastatic prostate cancer commencing androgen
deprivation therapy (ADT)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Hoosier Oncol Grp, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Community Canc Care, Indianapolis, IN USA.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
San Bernadino Urol Associates, San Bernardino, CA USA.
Kansas City Urol Care, Overland Pk, KS USA.
Madigan Army Med Ctr, Urol Serv, Tacoma, WA 98431 USA.
David Reed, Seattle, WA USA.
Burlington Profess Ctr, Burlington, ON, Canada.
Male Female Hlth & Res, Barrie, ON, Canada.
Indiana Univ, Hoosier Oncol Grp, Indianapolis, IN 46204 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e15000
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852001017
ER
PT J
AU Sznol, M
Powderly, JD
Smith, DC
Brahmer, JR
Drake, CG
McDermott, DF
Lawrence, DP
Wolchok, JD
Topalian, SL
Lowy, I
AF Sznol, M.
Powderly, J. D.
Smith, D. C.
Brahmer, J. R.
Drake, C. G.
McDermott, D. F.
Lawrence, D. P.
Wolchok, J. D.
Topalian, S. L.
Lowy, I.
TI Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1,
BMS-936558/ONO-4538) in patients with advanced refractory malignancies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Yale Canc Ctr, New Haven, CT USA.
Carolina BioOnco Inst, Huntersville, NC USA.
Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA.
Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Medarex Inc, Bloomsbury, NJ USA.
NR 0
TC 30
Z9 32
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2506
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003098
ER
PT J
AU Tai, WD
Phoon, HP
Tan, S
Koo, Y
Quek, RH
Tao, M
Lim, S
AF Tai, W. D.
Phoon, H. P.
Tan, S.
Koo, Y.
Quek, R. H.
Tao, M.
Lim, S.
TI Primary mediastinal large B-cell lymphoma: Otimal therapy and prognostic
factors in 40 consecutive Asian patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Natl Canc Ctr Singapore, Singapore, Singapore.
Natl Canc Ctr, Singapore, Singapore.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8074
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005094
ER
PT J
AU Tan, W
Wilner, KD
Bang, Y
Kwak, EL
Maki, RG
Camidge, DR
Solomon, BJ
Ou, SI
Salgia, R
Clark, JW
AF Tan, W.
Wilner, K. D.
Bang, Y.
Kwak, E. L.
Maki, R. G.
Camidge, D. R.
Solomon, B. J.
Ou, S. I.
Salgia, R.
Clark, J. W.
TI Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after
multiple oral doses to advanced cancer patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Pfizer Inc, San Diego, CA USA.
Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Colorado Denver, Aurora, CO USA.
Peter MacCallum Canc Ctr & Canc Trials Australia, Melbourne, Vic, Australia.
Univ Calif Irvine, Med Ctr, Chao Family Comprehens Canc Ctr, Orange, CA USA.
Univ Chicago, Dept Med, Chicago, IL 60637 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 18
Z9 19
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2596
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003187
ER
PT J
AU Tannir, NM
Wong, Y
Kollmannsberger, CK
Ernstoff, MS
Perry, DJ
Appleman, LJ
Posadas, EM
Qian, J
Ricker, JL
Michaelson, D
AF Tannir, N. M.
Wong, Y.
Kollmannsberger, C. K.
Ernstoff, M. S.
Perry, D. J.
Appleman, L. J.
Posadas, E. M.
Qian, J.
Ricker, J. L.
Michaelson, D.
TI Phase II trial of linifanib in patients with advanced renal cell cancer
(RCC) after sunitinib failure
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada.
Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
Washington Hosp Ctr, Washington, DC 20010 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Univ Chicago, Chicago, IL 60637 USA.
Abbott Labs, Abbott Pk, IL 60064 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4527
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003650
ER
PT J
AU Tap, WD
Demetri, GD
Barnette, P
Desai, J
Kavan, P
Tozer, R
Friberg, GR
Deng, H
McCaffery, I
Tolcher, AW
AF Tap, W. D.
Demetri, G. D.
Barnette, P.
Desai, J.
Kavan, P.
Tozer, R.
Friberg, G. R.
Deng, H.
McCaffery, I.
Tolcher, A. W.
TI AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or
desmoplastic small round cell tumors (DSRCT): Phase II results
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Calif, Los Angeles Med Hematol Oncol, Santa Monica, CA USA.
Harvard Canc Ctr, Ludwig Ctr, Dana Farber Canc Inst, Boston, MA USA.
Sarcoma Ctr, Boston, MA USA.
Primary Childrens Med Ctr, Salt Lake City, UT 84103 USA.
Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
McGill Univ, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada.
Juravinski Canc Ctr, Hamilton, ON, Canada.
Amgen Inc, Thousand Oaks, CA USA.
START Ctr Canc Care, San Antonio, TX USA.
NR 0
TC 4
Z9 5
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10001
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005510
ER
PT J
AU Taplin, M
Nakabayashi, A
Werner, L
Yang, M
Xie, W
Sun, T
Pomerantz, M
Freedman, M
Lee, GM
Kantoff, P
AF Taplin, M.
Nakabayashi, A.
Werner, L.
Yang, M.
Xie, W.
Sun, T.
Pomerantz, M.
Freedman, M.
Lee, G. M.
Kantoff, P.
TI Association between genetic polymorphisms in SLCO1B3 gene and response
to ketoconazole (K) in men with castration-resistant prostate cancer
(CRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4557
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003680
ER
PT J
AU Temel, JS
Greer, J
Gallagher, E
Admane, S
Pirl, WF
Jackson, V
Dahlin, C
Muzikansky, A
Jacobsen, J
Lynch, TJ
AF Temel, J. S.
Greer, J.
Gallagher, E.
Admane, S.
Pirl, W. F.
Jackson, V.
Dahlin, C.
Muzikansky, A.
Jacobsen, J.
Lynch, T. J.
TI Effect of early palliative care (PC) on quality of life (QOL),
aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC
patients: Results of a phase III randomized trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
SUNY Buffalo, Buffalo, NY 14260 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Yale Canc Ctr, New Haven, CT USA.
Smilow Canc Hosp, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7509
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004648
ER
PT J
AU Temple, LK
Patil, S
Paty, P
Weiser, MR
Nash, G
Guillem, JG
Goodman, KA
Wong, WD
Schrag, D
AF Temple, L. K.
Patil, S.
Paty, P.
Weiser, M. R.
Nash, G.
Guillem, J. G.
Goodman, K. A.
Wong, W. D.
Schrag, D.
TI Bowel dysfunction after sphincter-preserving surgery
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3657
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003468
ER
PT J
AU Ter-Minassian, M
Frauenhoffer, CS
Hooshmand, SM
Asomaning, K
Lin, X
Chan, JA
Christiani, DC
Kulke, M
AF Ter-Minassian, M.
Frauenhoffer, C. S.
Hooshmand, S. M.
Asomaning, K.
Lin, X.
Chan, J. A.
Christiani, D. C.
Kulke, M.
TI Prospective analysis of clinical outcomes and prognostic factors in
patients with ne 11 neuroendocrine tumors (NETs)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4044
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003510
ER
PT J
AU Tevaarwerk, A
Lee, J
Sesto, MC
Buhr, KA
Cleeland, CS
Manola, J
Wagner, LI
Chang, VT
Fisch, M
AF Tevaarwerk, A.
Lee, J.
Sesto, M. C.
Buhr, K. A.
Cleeland, C. S.
Manola, J.
Wagner, L. I.
Chang, V. T.
Fisch, M.
TI Predictors of employment (empl) outcomes in outpatients (pts) with
common solid tumors: A secondary analysis from E2Z02 (ECOG's SOAPP
study)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Wisconsin, Madison, WI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
VA New Jersey Hlth Care Syst, E Orange, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 9118
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005383
ER
PT J
AU Tolcher, AW
Mikulski, SM
Messersmith, WA
Kwak, EL
Gibbon, D
Boylan, J
Xu, ZX
DeMario, M
Wheler, JJ
AF Tolcher, A. W.
Mikulski, S. M.
Messersmith, W. A.
Kwak, E. L.
Gibbon, D.
Boylan, J.
Xu, Z. X.
DeMario, M.
Wheler, J. J.
TI A phase I study of RO4929097, a novel gamma secretase inhibitor, in
patients with advanced solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 START Ctr Canc Care, San Antonio, TX USA.
Hoffmann La Roche, Nutley, NJ USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Canc Inst New Jersey, New Brunswick, NJ USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 5
Z9 5
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2502
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003094
ER
PT J
AU Treon, SP
Hanzis, CA
Ioakimidis, LI
Patterson, CJ
Hunter, ZR
Brodsky, PS
Sheehy, PS
Manning, RJ
AF Treon, S. P.
Hanzis, C. A.
Ioakimidis, L. I.
Patterson, C. J.
Hunter, Z. R.
Brodsky, P. S.
Sheehy, P. S.
Manning, R. J.
TI Clinical characteristics and treatment outcome of disease-related
peripheral neuropathy in Waldenstom's macroglobulinemia (WM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Treon, S. P.; Hanzis, C. A.; Ioakimidis, L. I.; Patterson, C. J.; Hunter, Z. R.; Brodsky, P. S.; Sheehy, P. S.; Manning, R. J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8114
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005134
ER
PT J
AU Vaezi, AE
Wang, X
Buch, SC
Farrow, D
Weaver, DT
D'Andrea, AD
Seethala, RR
Romkes, M
Niedernhofer, LJ
Grandis, JR
AF Vaezi, A. E.
Wang, X.
Buch, S. C.
Farrow, D.
Weaver, D. T.
D'Andrea, A. D.
Seethala, R. R.
Romkes, M.
Niedernhofer, L. J.
Grandis, J. R.
TI Use of XPF expression in tumors and XPF single nucleotide polymorphisms
to predict clinical outcome in head and neck cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Pittsburgh, Pittsburgh, PA USA.
On Q Ity, Waltham, MA USA.
Univ Pittsburgh, Div Clin Pharmacol, Pittsburgh, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Pittsburgh, Inst Eye & Ear, Pittsburgh, PA 15213 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5520
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004197
ER
PT J
AU Vandergrift, JL
Mamet, R
Zornosa, C
Reid, ME
Rabin, MS
Ettinger, DS
Kalemkerian, GP
Otterson, GA
Niland, JC
Pisters, K
AF Vandergrift, J. L.
Mamet, R.
Zornosa, C.
Reid, M. E.
Rabin, M. S.
Ettinger, D. S.
Kalemkerian, G. P.
Otterson, G. A.
Niland, J. C.
Pisters, K.
CA NCCN Oncology Outcomes Database
TI First-line systemic therapy in metastatic non-small cell lung cancer
(mNSCLC) patients treated at National Comprehensive Cancer Network
(NCCN) institutions: An analysis from the NCCN Oncology Outcomes
Database Project.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Natl Comprehens Canc Network, Ft Washington, PA USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
Arthur G James Canc Hosp, Columbus, OH USA.
Solove Res Inst, Columbus, OH USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7634
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005014
ER
PT J
AU Von Hoff, DD
LoRusso, P
Tibes, R
Shapiro, G
Weiss, GJ
Ware, JA
Fredrickson, J
Mazina, KE
Levy, GG
Wagner, AJ
AF Von Hoff, D. D.
LoRusso, P.
Tibes, R.
Shapiro, G.
Weiss, G. J.
Ware, J. A.
Fredrickson, J.
Mazina, K. E.
Levy, G. G.
Wagner, A. J.
TI A first-in-human phase I study to evaluate the pan-PI3K inhibitor
GDC-0941 administered QD or BID in patients with advanced solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Virginia G Piper Canc Ctr, Scottsdale, AZ USA.
TGen, Scottsdale, AZ USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Scottsdale Healthcare, Virginia G Piper Canc Ctr, Scottsdale, AZ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Genentech Inc, San Francisco, CA 94080 USA.
NR 0
TC 7
Z9 7
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2541
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003132
ER
PT J
AU Wakelee, HA
Gettinger, SN
Engelman, JA
Janne, PA
West, HJ
Subramaniam, DS
Leach, JW
Wax, MB
Yaron, Y
Lara, P
AF Wakelee, H. A.
Gettinger, S. N.
Engelman, J. A.
Janne, P. A.
West, H. J.
Subramaniam, D. S.
Leach, J. W.
Wax, M. B.
Yaron, Y.
Lara, P., Jr.
TI A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E)
in patients (pts) with non-small cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Stanford Univ, Sch Med, Stanford, CA 94305 USA.
Yale Univ, Sch Med, New Haven, CT USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Swedish Canc Inst, Seattle, WA USA.
Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
Pk Nicollet Inst, St Louis Pk, MN USA.
Summit Med Grp, Summit, NJ USA.
Exelixis, San Francisco, CA USA.
Univ Calif Davis, Sacramento, CA 95817 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3017
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003222
ER
PT J
AU Waltman, BA
Dias-Santagata, D
Cosper, AK
Mino-Kenudson, M
Borger, DR
Fidias, P
Shaw, AT
Iafrate, AJ
Engelman, JA
Sequist, LV
AF Waltman, B. A.
Dias-Santagata, D.
Cosper, A. K.
Mino-Kenudson, M.
Borger, D. R.
Fidias, P.
Shaw, A. T.
Iafrate, A. J.
Engelman, J. A.
Sequist, L. V.
TI SNaPshot multigene assay to detect mechanisms of acquired resistance to
EGFR tyrosine kinase inhibitors (TKIs)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Translat Res Lab, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7554
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004687
ER
PT J
AU Wanebo, HJ
Ghebremichael, MS
Burtness, B
Ridge, JA
Spencer, S
Rosen, FR
Hancock, MR
Tolba, KA
Forastiere, AA
AF Wanebo, H. J.
Ghebremichael, M. S.
Burtness, B.
Ridge, J. A.
Spencer, S.
Rosen, F. R.
Hancock, M. R.
Tolba, K. A.
Forastiere, A. A.
TI Phase II induction cetuximab (C25), paclitaxel (P), and carboplatin (C)
followed by chemoradiation with C255, P, C, and RT 68-72Gy for stage
III/IV head and neck squamous cancer: Primary site organ preservation
and disease control at 2 years (ECOG, E2303)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Landmark Med Ctr, Woonsocket, RI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Alabama Birmingham, Birmingham, AL USA.
John H Stroger Jr Hosp Cook Cty, Chicago, IL USA.
St Mary Canc Ctr, Grand Junction, CO USA.
Univ Miami, Sch Med, Miami, FL USA.
Johns Hopkins Univ, Baltimore, MD USA.
NR 0
TC 8
Z9 8
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5513
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004190
ER
PT J
AU Wang, J
Dang, P
Pandalai, PK
Raut, CP
Maduekwe, UN
Yoon, SS
AF Wang, J.
Dang, P.
Pandalai, P. K.
Raut, C. P.
Maduekwe, U. N.
Yoon, S. S.
TI Comparison of the 2010 AJCC TNM staging system with a modified lymph
node ratio staging system in 7,233 gastric cancer patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4023
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003489
ER
PT J
AU Wen, PY
Prados, M
Schiff, D
Reardon, DA
Cloughesy, T
Mikkelsen, T
Batchelor, T
Drappatz, J
Chamberlain, MC
De Groot, JF
AF Wen, P. Y.
Prados, M.
Schiff, D.
Reardon, D. A.
Cloughesy, T.
Mikkelsen, T.
Batchelor, T.
Drappatz, J.
Chamberlain, M. C.
De Groot, J. F.
TI Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and
RET, in patients (pts) with progressive glioblastoma (GB)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
Henry Ford Hlth Syst, Detroit, MI USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Seattle Canc Care Alliance, Seattle, WA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 2006
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003002
ER
PT J
AU Wood, ME
Kingsley, F
Ellerton, JA
Atkins, JN
Grubbs, SS
Muss, HB
Garber, JE
AF Wood, M. E.
Kingsley, F.
Ellerton, J. A.
Atkins, J. N.
Grubbs, S. S.
Muss, H. B.
Garber, J. E.
TI A randomized trial of atorvastatin versus placebo in women at high risk
for breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Vermont, Coll Med, Fletcher Allen Hlth Care, Burlington, VT USA.
Univ Vermont, Coll Med, Burlington, VT USA.
Canc Consultants, Las Vegas, NV USA.
Southeastern Med Ctr, Winston Salem, NC USA.
Med Oncol Hematol Consultants PA, Newark, DE USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS141
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002144
ER
PT J
AU Wright, AA
Pereira, L
Nilsson, ME
Gibson, C
Campos, SM
Roche, M
Berlin, ST
Krasner, CN
Penson, RT
Matulonis, U
AF Wright, A. A.
Pereira, L.
Nilsson, M. E.
Gibson, C.
Campos, S. M.
Roche, M.
Berlin, S. T.
Krasner, C. N.
Penson, R. T.
Matulonis, U.
TI Associations between age and quality of life in advanced ovarian cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5085
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004140
ER
PT J
AU Yang, G
Gong, P
Xu, L
Hunter, ZR
Zhou, Y
Liu, X
Cao, Y
Ciccarelli, B
Patterson, CJ
Treon, SP
AF Yang, G.
Gong, P.
Xu, L.
Hunter, Z. R.
Zhou, Y.
Liu, X.
Cao, Y.
Ciccarelli, B.
Patterson, C. J.
Treon, S. P.
TI Activity of the CD20-directed monoclonal antibody GA101 relative to
rituximab in Waldenstrom's macroglobulinemia (WM), and applicability to
patients expressing Fc gamma RIIIA-158 F/F
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Yang, G.; Gong, P.; Xu, L.; Hunter, Z. R.; Zhou, Y.; Liu, X.; Cao, Y.; Ciccarelli, B.; Patterson, C. J.; Treon, S. P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8112
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005132
ER
PT J
AU Yeo, W
Riely, GJ
Yeap, B
Lau, MW
Warner, J
Bodio, KA
Kris, MG
Pao, W
Kobayashi, S
Costa, DB
AF Yeo, W.
Riely, G. J.
Yeap, B.
Lau, M. W.
Warner, J.
Bodio, K. A.
Kris, M. G.
Pao, W.
Kobayashi, S.
Costa, D. B.
TI Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with
EGFR mutations
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Natl Univ Singapore Hosp, Singapore 117548, Singapore.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7572
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004705
ER
PT J
AU Yonesaka, K
Okamoto, I
Satoh, T
Takeda, K
Takada, M
Nishio, K
Fukuoka, M
Saijo, N
Janne, PA
Nakagawa, K
AF Yonesaka, K.
Okamoto, I.
Satoh, T.
Takeda, K.
Takada, M.
Nishio, K.
Fukuoka, M.
Saijo, N.
Janne, P. A.
Nakagawa, K.
TI Heregulin as a novel cetuximab-resistace factor in colorectal cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Kinki Univ, Sch Med, Osaka 589, Japan.
Osaka City Gen Hosp, Osaka, Japan.
Kinki Univ, Sch Med, Sakai Hosp, Osaka 589, Japan.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Kinki Univ Hosp, Osaka, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA e14044
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852000554
ER
PT J
AU Yoon, SS
Chen, Y
Karl, D
Choy, E
Harmon, DC
Kambadakone, A
Sahani, D
Duda, DG
Jain, RK
DeLaney, TF
AF Yoon, S. S.
Chen, Y.
Karl, D.
Choy, E.
Harmon, D. C.
Kambadakone, A.
Sahani, D.
Duda, D. G.
Jain, R. K.
DeLaney, T. F.
TI A phase II study of neoadjuvant bevacizumab and radiation therapy for
resectable soft tissue sarcomas.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Yoon, S. S.; Chen, Y.; Karl, D.; Choy, E.; Harmon, D. C.; Kambadakone, A.; Sahani, D.; Duda, D. G.; Jain, R. K.; DeLaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10023
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005532
ER
PT J
AU Zeliadt, SB
Sekaran, NK
Slatore, CG
Au, DH
Wu, DY
Crawford, J
Lyman, GH
Dale, DC
AF Zeliadt, S. B.
Sekaran, N. K.
Slatore, C. G.
Au, D. H.
Wu, D. Y.
Crawford, J.
Lyman, G. H.
Dale, D. C.
TI Comparison of the Veterans Affairs Oncology Registry and the SEER Cancer
Registry among patients with lung cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 VA Puget Sound Healthcare Syst, HSR&D Northwest Ctr Excellence, Seattle, WA USA.
VA Puget Sound, Seattle, WA USA.
Univ Washington, Sch Med, Seattle, WA USA.
Portland VAMC Hlth Serv Res & Dev, Portland, OR USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
VA Puget Sound Healthcare Syst, Seattle, WA USA.
Duke Univ, Med Ctr, Durham, NC USA.
Duke Univ, Durham, NC USA.
Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6056
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004335
ER
PT J
AU Zhang, W
Lee, J
Schiller, JH
Carbone, DP
Chung, CH
Lenz, H
AF Zhang, W.
Lee, J.
Schiller, J. H.
Carbone, D. P.
Chung, C. H.
Lenz, H.
TI Use of germline polymorphisms in VEGF to predict tumor response and
progression-free survival in non-small cell lung cancer (NSCLC) patients
treated with sorafenib: Subset pharmacogenetic analysis of Eastern
Cooperative Oncology Group (ECOG) trial E2501
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Vanderbilt Univ, Nashville, TN 37235 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7607
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004740
ER
PT J
AU Zhu, AX
Finn, RS
Mulcahy, MF
Gurtler, JS
Sun, W
Schwartz, JD
Rojas, P
Dontabhaktuni, A
Youssoufian, H
Stuart, KE
AF Zhu, A. X.
Finn, R. S.
Mulcahy, M. F.
Gurtler, J. S.
Sun, W.
Schwartz, J. D.
Rojas, P.
Dontabhaktuni, A.
Youssoufian, H.
Stuart, K. E.
TI A phase II study of ramucirumab as first-line monotherapy in patients
(pts) with advanced hepatocellular carcinoma (HCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
East Jefferson Gen Hosp, Metairie, LA USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
ImClone Syst, Branchburg, NJ USA.
Tufts Univ, Sch Med, Lahey Clin Med Ctr, Burlington, MA USA.
NR 0
TC 8
Z9 10
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4083
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003548
ER
PT J
AU Zornosa, C
Mamet, R
Reid, ME
Ettinger, DS
Otterson, GA
Rabin, MS
Hayman, J
Niland, JC
Pisters, K
AF Zornosa, C.
Mamet, R.
Reid, M. E.
Ettinger, D. S.
Otterson, G. A.
Rabin, M. S.
Hayman, J.
Niland, J. C.
Pisters, K.
CA NCCN Oncology Outcomes Database
TI Utilization of adjuvant therapy among completely resected non-small cell
lung cancer (NSCLC) patients in the National Comprehensive Cancer
Network (NCCN) Outcomes Database Project.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Natl Comprehens Canc Network, Ft Washington, PA USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
Arthur G James Canc Hosp, Columbus, OH USA.
Sotove Res Inst, Columbus, OH USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 7017
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004561
ER
PT J
AU Guiguemde, WA
Shelat, AA
Bouck, D
Duffy, S
Crowther, GJ
Davis, PH
Smithson, DC
Connelly, M
Clark, J
Zhu, FY
Jimenez-Diaz, MB
Martinez, MS
Wilson, EB
Tripathi, AK
Gut, J
Sharlow, ER
Bathurst, I
El Mazouni, F
Fowble, JW
Forquer, I
McGinley, PL
Castro, S
Angulo-Barturen, I
Ferrer, S
Rosenthal, PJ
DeRisi, JL
Sullivan, DJ
Lazo, JS
Roos, DS
Riscoe, MK
Phillips, MA
Rathod, PK
Van Voorhis, WC
Avery, VM
Guy, RK
AF Guiguemde, W. Armand
Shelat, Anang A.
Bouck, David
Duffy, Sandra
Crowther, Gregory J.
Davis, Paul H.
Smithson, David C.
Connelly, Michele
Clark, Julie
Zhu, Fangyi
Jimenez-Diaz, Maria B.
Martinez, Maria S.
Wilson, Emily B.
Tripathi, Abhai K.
Gut, Jiri
Sharlow, Elizabeth R.
Bathurst, Ian
El Mazouni, Farah
Fowble, Joseph W.
Forquer, Isaac
McGinley, Paula L.
Castro, Steve
Angulo-Barturen, Inigo
Ferrer, Santiago
Rosenthal, Philip J.
DeRisi, Joseph L.
Sullivan, David J., Jr.
Lazo, John S.
Roos, David S.
Riscoe, Michael K.
Phillips, Margaret A.
Rathod, Pradipsinh K.
Van Voorhis, Wesley C.
Avery, Vicky M.
Guy, R. Kiplin
TI Chemical genetics of Plasmodium falciparum
SO NATURE
LA English
DT Article
ID DIHYDROOROTATE DEHYDROGENASE; SCREENING LIBRARIES; DRUG DISCOVERY;
MALARIA; IDENTIFICATION; DISRUPTION; RESISTANCE; SURVIVAL; GROWTH
AB Malaria caused by Plasmodium falciparum is a disease that is responsible for 880,000 deaths per year worldwide. Vaccine development has proved difficult and resistance has emerged for most antimalarial drugs. To discover new antimalarial chemotypes, we have used a phenotypic forward chemical genetic approach to assay 309,474 chemicals. Here we disclose structures and biological activity of the entire library-many of which showed potent in vitro activity against drug-resistant P. falciparum strains-and detailed profiling of 172 representative candidates. A reverse chemical genetic study identified 19 new inhibitors of 4 validated drug targets and 15 novel binders among 61 malarial proteins. Phylochemogenetic profiling in several organisms revealed similarities between Toxoplasma gondii and mammalian cell lines and dissimilarities between P. falciparum and related protozoans. One exemplar compound displayed efficacy in a murine model. Our findings provide the scientific community with new starting points for malaria drug discovery.
C1 [Guiguemde, W. Armand; Shelat, Anang A.; Bouck, David; Smithson, David C.; Connelly, Michele; Clark, Julie; Zhu, Fangyi; Guy, R. Kiplin] St Jude Childrens Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA.
[Duffy, Sandra; Avery, Vicky M.] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Brisbane, Qld 4111, Australia.
[Crowther, Gregory J.; Van Voorhis, Wesley C.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Davis, Paul H.; Roos, David S.] Univ Penn, Penn Genome Frontiers Inst, Philadelphia, PA 19104 USA.
[Davis, Paul H.; Roos, David S.] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.
[Jimenez-Diaz, Maria B.; Martinez, Maria S.; Angulo-Barturen, Inigo; Ferrer, Santiago] GlaxoSmithKline Inc, Dis Developing World, Tres Cantos 28760, Spain.
[Wilson, Emily B.; DeRisi, Joseph L.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA.
[Tripathi, Abhai K.; Sullivan, David J., Jr.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
[Gut, Jiri; Rosenthal, Philip J.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA.
[Sharlow, Elizabeth R.; Lazo, John S.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA.
[Bathurst, Ian] Med Malaria Venture, CH-1215 Geneva, Switzerland.
[El Mazouni, Farah; Phillips, Margaret A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
[Fowble, Joseph W.; Rathod, Pradipsinh K.] Univ Washington, Dept Chem, Seattle, WA 98195 USA.
[Forquer, Isaac; Riscoe, Michael K.] Portland VA Med Ctr, Expt Chemotherapy Lab, Portland, OR 97239 USA.
[McGinley, Paula L.; Castro, Steve] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.
RP Guy, RK (reprint author), St Jude Childrens Hosp, Dept Chem Biol & Therapeut, 332 N Lauderdale St, Memphis, TN 38105 USA.
EM kip.guy@stjude.org
RI Avery, Vicky/A-5449-2010; Davis, Paul/J-6141-2012; Shelat, Anang
/J-4995-2013; Guy, Rodney/J-7107-2013; duffy, sandra/B-8479-2017;
OI Davis, Paul/0000-0002-0526-3841; Guy, Rodney/0000-0002-9638-2060; duffy,
sandra/0000-0002-2814-1193; Crowther, Gregory/0000-0003-0530-9130
FU American Lebanese Syrian Associated Charities (ALSAC); St Jude
Children's Research Hospital (SJCRH); Medicines for Malaria Venture;
National Institute of Allergy and Infectious Diseases [AI772682,
AI075517, AI067921, AI080625, AI28724, AI53862, AI35707, AI053680,
AI075594, AI082617, AI045774]; National Cancer Institute [CA78039];
Welch Foundation [I-1257]; Doris Duke Charitable Foundation; Ellison
Medical Foundation
FX This work was supported by the American Lebanese Syrian Associated
Charities (ALSAC) and St Jude Children's Research Hospital (SJCRH, R. K.
G.), the Medicines for Malaria Venture (W. C. V. V. and V. M. A.),
National Institute of Allergy and Infectious Diseases (AI772682 (P. H.
D.), AI075517 (R. K. G.), AI067921 (W. C. V. V.) and AI080625 (W. C. V.
V.), AI28724 (D. S. R.), AI53862 (J.L.D.), AI35707 (P.J.R.), AI053680
(M. A. P. and P. K. R.), AI075594 (M. A. P., P. K. R. and I. B.),
AI082617 (P. K. R.) and AI045774 (D.J.S.)), the National Cancer
Institute (CA78039 (J.S.L.)), the Welch Foundation (I-1257 (M. A. P.)),
the Doris Duke Charitable Foundation (P.J.R.), and the Ellison Medical
Foundation (D. S. R.). We acknowledge A. B. Vaidya for providing the
parasite strain D10_yDHOD. We acknowledge M. Sigal for assistance in the
early leads project coordination, the SJCRH High Throughput Screening
Center, particularly J. Cui; the SJCRH Lead Discovery Informatics
Center, and the SJCRH High Throughput Analytical Chemistry Center,
particularly C. Nelson and A. Lemoff; at UW, F. Buckner, W. Hol and A.
Napuli (AI067921, W. Hol); S. Wei and W. Hao in the UT Southwestern HTS
Center; and the Australian Red Cross Blood Service for the provision of
O+ erythrocytes to Griffith University.
NR 27
TC 286
Z9 289
U1 2
U2 55
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 20
PY 2010
VL 465
IS 7296
BP 311
EP 315
DI 10.1038/nature09099
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 598IO
UT WOS:000277829200032
PM 20485428
ER
PT J
AU Wu, XW
Nguyen, BC
Dziunycz, P
Chang, S
Brooks, Y
Lefort, K
Hofbauer, GFL
Dotto, GP
AF Wu, Xunwei
Nguyen, Bach-Cuc
Dziunycz, Piotr
Chang, Sungeun
Brooks, Yang
Lefort, Karine
Hofbauer, Guenther F. L.
Dotto, G. Paolo
TI Opposing roles for calcineurin and ATF3 in squamous skin cancer
SO NATURE
LA English
DT Article
ID TRANSFORMED PHENOTYPE; CELLULAR SENESCENCE; TUMOR SUPPRESSION; INHIBITOR
DSCR1; STEM-CELLS; C-MYC; GROWTH; DIFFERENTIATION; PROLIFERATION;
CARCINOMA
AB Calcineurin inhibitors such as cyclosporin A (CsA) are the mainstay of immunosuppressive treatment for organ transplant recipients. Squamous cell carcinoma (SCC) of the skin is a major complication of treatment with these drugs, with a 65 to 100-fold higher risk than in the normal population(1). By contrast, the incidence of basal cell carcinoma (BCC), the other major keratinocyte-derived tumour of the skin, of melanoma and of internal malignancies increases to a significantly lesser extent(1). Here we report that genetic and pharmacological suppression of calcineurin/nuclear factor of activated T cells (NFAT) function promotes tumour formation in mouse skin and in xenografts, in immune compromised mice, of H-ras(V12) (also known as Hras1)-expressing primary human keratinocytes or keratinocyte-derived SCC cells. Calcineurin/NFAT inhibition counteracts p53 (also known as TRP53)-dependent cancer cell senescence, thereby increasing tumorigenic potential. ATF3, a member of the 'enlarged' AP-1 family, is selectively induced by calcineurin/NFAT inhibition, both under experimental conditions and in clinically occurring tumours, and increased ATF3 expression accounts for suppression of p53-dependent senescence and enhanced tumorigenic potential. Thus, intact calcineurin/NFAT signalling is critically required for p53 and senescence-associated mechanisms that protect against skin squamous cancer development.
C1 [Wu, Xunwei; Nguyen, Bach-Cuc; Chang, Sungeun; Brooks, Yang; Dotto, G. Paolo] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
[Dziunycz, Piotr; Hofbauer, Guenther F. L.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland.
[Lefort, Karine; Dotto, G. Paolo] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland.
RP Dotto, GP (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
EM gian-paolo.dotto@unil.ch
RI Hofbauer, Gunther/B-2671-2010
OI Hofbauer, Gunther/0000-0003-0542-7989
FU NIH [AR054856, AR39190]; Swiss National Foundation [311003A-122281/1];
Oncosuisse [OCS-02361-02-2009]; European Union [LSHB-CT-2005-019067];
Korean Government Foundation [KRF-2007-013-E00044];
Olga-Mayenfisch-Stiftung
FX We thank P. Khavari, S. Kitajima, N. Clipstone and G. Crabtree for gift
of retroviruses, W. Austen for human skin material, C. Brisken and C.
Missero for careful reading of the manuscript, and E. Castillo for
sequencing of the ras and p53 genes. This work was supported by grants
from NIH (AR054856 and AR39190), the Swiss National Foundation
(311003A-122281/1), Oncosuisse (OCS-02361-02-2009), the European Union
(Epistem, Sixth Framework Program, LSHB-CT-2005-019067) and, in part, by
a grant to S. C. by the Korean Government Foundation
(KRF-2007-013-E00044) and to G. F. L. H. by the
Olga-Mayenfisch-Stiftung.
NR 37
TC 111
Z9 111
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 20
PY 2010
VL 465
IS 7296
BP 368
EP U130
DI 10.1038/nature08996
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 598IO
UT WOS:000277829200045
PM 20485437
ER
PT J
AU D'Andrea, AD
AF D'Andrea, Alan D.
TI MECHANISMS OF DISEASE Susceptibility Pathways in Fanconi's Anemia and
Breast Cancer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Review
ID DNA-DAMAGE RESPONSE; CROSS-LINK REPAIR; ACUTE MYELOID-LEUKEMIA;
HOMOLOGOUS RECOMBINATION REPAIR; SHARED GENETIC SUSCEPTIBILITY;
PANCREATIC-CANCER; POLY(ADP-RIBOSE) POLYMERASE; CORE COMPLEX; BRCA
PATHWAY; GERMLINE MUTATIONS
C1 [D'Andrea, Alan D.] Childrens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[D'Andrea, Alan D.] Childrens Hosp, Dept Pediat, Dana Farber Canc Inst, Boston, MA 02115 USA.
[D'Andrea, Alan D.] Harvard Univ, Sch Med, Boston, MA USA.
RP D'Andrea, AD (reprint author), Childrens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM alan_dandrea@dfci.harvard.edu
FU National Institutes of Health [RO1DK43889, R01HL52725, PO1CA092584,
U19A1067751]
FX Supported by grants (RO1DK43889, R01HL52725, PO1CA092584, and
U19A1067751) from the National Institutes of Health.
NR 117
TC 156
Z9 158
U1 1
U2 21
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 20
PY 2010
VL 362
IS 20
BP 1909
EP 1919
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 598EI
UT WOS:000277815600009
PM 20484397
ER
PT J
AU Muss, HB
D'Alessandro, HA
Brachtel, EF
AF Muss, Hyman B.
D'Alessandro, Helen Anne
Brachtel, Elena F.
TI A Woman with Mammographically Detected Early Breast Cancer Invasive
ductal carcinoma of the breast, grade 3 of 3, positive for estrogen
receptors, progesterone receptors, and HER2
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIALS; GERIATRIC ASSESSMENT;
AMERICAN-SOCIETY; 15-YEAR SURVIVAL; PROGNOSTIC INDEX; OLDER WOMEN; AGE;
TRASTUZUMAB; COMORBIDITY
C1 [Muss, Hyman B.] Univ N Carolina, Dept Med, Div Hematol & Oncol, Chapel Hill, NC 27515 USA.
[Muss, Hyman B.] Univ N Carolina, Dept Med, Coll Med, Chapel Hill, NC USA.
[D'Alessandro, Helen Anne] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Brachtel, Elena F.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[D'Alessandro, Helen Anne] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Brachtel, Elena F.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Muss, HB (reprint author), Univ N Carolina, Dept Med, Div Hematol & Oncol, Chapel Hill, NC 27515 USA.
NR 40
TC 1
Z9 1
U1 0
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 20
PY 2010
VL 362
IS 20
BP 1921
EP 1928
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 598EI
UT WOS:000277815600013
PM 20484399
ER
PT J
AU Isselbacher, EM
AF Isselbacher, Eric M.
TI A Man with Abdominal and Flank Pain REPLY
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID DISEASE
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Isselbacher, EM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 20
PY 2010
VL 362
IS 20
BP 1944
EP 1945
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 598EI
UT WOS:000277815600034
ER
PT J
AU Moncaster, JA
Pineda, R
Moir, RD
Lu, SQ
Burton, MA
Ghosh, JG
Ericsson, M
Soscia, SJ
Mocofanescu, A
Folkerth, RD
Robb, RM
Kuszak, JR
Clark, JI
Tanzi, RE
Hunter, DG
Goldstein, LE
AF Moncaster, Juliet A.
Pineda, Roberto
Moir, Robert D.
Lu, Suqian
Burton, Mark A.
Ghosh, Joy G.
Ericsson, Maria
Soscia, Stephanie J.
Mocofanescu, Anca
Folkerth, Rebecca D.
Robb, Richard M.
Kuszak, Jer R.
Clark, John I.
Tanzi, Rudolph E.
Hunter, David G.
Goldstein, Lee E.
TI Alzheimer's Disease Amyloid-beta Links Lens and Brain Pathology in Down
Syndrome
SO PLOS ONE
LA English
DT Article
ID PROTEIN-PRECURSOR; EXPRESSION; DEPOSITION; DEMENTIA; LOCUS; HYPOTHESIS;
CRYSTALLIN; CATARACTS; PEOPLE; CDNA
AB Down syndrome (DS, trisomy 21) is the most common chromosomal disorder and the leading genetic cause of intellectual disability in humans. In DS, triplication of chromosome 21 invariably includes the APP gene (21q21) encoding the Alzheimer's disease (AD) amyloid precursor protein (APP). Triplication of the APP gene accelerates APP expression leading to cerebral accumulation of APP-derived amyloid-beta peptides (A beta), early-onset AD neuropathology, and age-dependent cognitive sequelae. The DS phenotype complex also includes distinctive early-onset cerulean cataracts of unknown etiology. Previously, we reported increased A beta accumulation, co-localizing amyloid pathology, and disease-linked supranuclear cataracts in the ocular lenses of subjects with AD. Here, we investigate the hypothesis that related AD-linked A beta pathology underlies the distinctive lens phenotype associated with DS. Ophthalmological examinations of DS subjects were correlated with phenotypic, histochemical, and biochemical analyses of lenses obtained from DS, AD, and normal control subjects. Evaluation of DS lenses revealed a characteristic pattern of supranuclear opacification accompanied by accelerated supranuclear A beta accumulation, co-localizing amyloid pathology, and fiber cell cytoplasmic A beta aggregates (similar to 5 to 50 nm) identical to the lens pathology identified in AD. Peptide sequencing, immunoblot analysis, and ELISA confirmed the identity and increased accumulation of A beta in DS lenses. Incubation of synthetic A beta with human lens protein promoted protein aggregation, amyloid formation, and light scattering that recapitulated the molecular pathology and clinical features observed in DS lenses. These results establish the genetic etiology of the distinctive lens phenotype in DS and identify the molecular origin and pathogenic mechanism by which lens pathology is expressed in this common chromosomal disorder. Moreover, these findings confirm increased A beta accumulation as a key pathogenic determinant linking lens and brain pathology in both DS and AD.
C1 [Moncaster, Juliet A.; Lu, Suqian; Burton, Mark A.; Ghosh, Joy G.; Mocofanescu, Anca; Goldstein, Lee E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Mol Aging & Dev Lab,Dept Surg, Boston, MA 02115 USA.
[Pineda, Roberto] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Moir, Robert D.; Soscia, Stephanie J.; Tanzi, Rudolph E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Res Unit,Dept Neurol, Charlestown, MA USA.
[Ericsson, Maria] Harvard Univ, Dept Cell Biol, Sch Med, Elect Microscopy Facil, Boston, MA USA.
[Folkerth, Rebecca D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Robb, Richard M.; Hunter, David G.] Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
[Kuszak, Jer R.] Rush Univ, Med Ctr, Dept Ophthalmol, Chicago, IL 60612 USA.
[Kuszak, Jer R.] Rush Univ, Dept Pathol, Med Ctr, Chicago, IL 60612 USA.
[Clark, John I.] Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA.
[Clark, John I.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
RP Moncaster, JA (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Mol Aging & Dev Lab,Dept Surg, Boston, MA 02115 USA.
EM LGOLD@BU.EDU
OI Moncaster, Juliet/0000-0002-7849-4325; Hunter,
David/0000-0002-4587-4794; Goldstein, Lee/0000-0001-8419-9800
FU National Institutes of Health, Bethesda, MD [R01GM75986, K23AG024792];
American Federation for Aging Research, New York, NY; Alzheimer's
Association, Chicago, IL; American Health Assistance Foundation,
Clarksburg, MD; Cure Alzheimer's Fund, Wellesley Hills, MA; Boston
University School of Medicine, Boston, MA; Boston University Alzheimer's
Disease Center, Boston, MA (NIH ADCC) [P30AG13846]
FX Funding: National Institutes of Health, Bethesda, MD (R01GM75986 and
K23AG024792, LEG); American Federation for Aging Research, New York, NY
(LEG); Alzheimer's Association, Chicago, IL (LEG); American Health
Assistance Foundation, Clarksburg, MD (LEG); Anonymous Foundation (LEG);
Cure Alzheimer's Fund, Wellesley Hills, MA (RDM); Boston University
School of Medicine, Boston, MA (LEG); and Boston University Alzheimer's
Disease Center, Boston, MA (NIH ADCC grant P30AG13846). The funding
sponsors had no role in study design, data collection, data analysis,
data interpretation, or writing of the report. The senior corresponding
author (LEG) has full access to all study data and takes final
responsibility for the decision to submit the results of the study for
publication.
NR 50
TC 49
Z9 50
U1 2
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2010
VL 5
IS 5
AR e10659
DI 10.1371/journal.pone.0010659
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 600VP
UT WOS:000278017300002
PM 20502642
ER
PT J
AU Van Cleave, J
Gortmaker, SL
Perrin, JM
AF Van Cleave, Jeanne
Gortmaker, Steven L.
Perrin, James M.
TI Chronic Health Conditions and Obesity Among Children and Youth Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Van Cleave, Jeanne; Perrin, James M.] MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, Boston, MA USA.
[Gortmaker, Steven L.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
RP Van Cleave, J (reprint author), MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, Boston, MA USA.
NR 4
TC 0
Z9 0
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 19
PY 2010
VL 303
IS 19
BP 1915
EP 1916
DI 10.1001/jama.2010.586
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 597NJ
UT WOS:000277764500012
ER
PT J
AU Piacentini, J
Woods, DW
Scahill, L
Wilhelm, S
Peterson, AL
Chang, S
Ginsburg, GS
Deckersbach, T
Dziura, J
Levi-Pearl, S
Walkup, JT
AF Piacentini, John
Woods, Douglas W.
Scahill, Lawrence
Wilhelm, Sabine
Peterson, Alan L.
Chang, Susanna
Ginsburg, Golda S.
Deckersbach, Thilo
Dziura, James
Levi-Pearl, Sue
Walkup, John T.
TI Behavior Therapy for Children With Tourette Disorder A Randomized
Controlled Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID TIC DISORDERS; HABIT REVERSAL; RISPERIDONE; SEVERITY; ADOLESCENTS;
PREVALENCE; REDUCTION; PIMOZIDE; MODEL; SCALE
AB Context Tourette disorder is a chronic and typically impairing childhood-onset neurologic condition. Antipsychotic medications, the first-line treatments for moderate to severe tics, are often associated with adverse effects. Behavioral interventions, although promising, have not been evaluated in large-scale controlled trials.
Objective To determine the efficacy of a comprehensive behavioral intervention for reducing tic severity in children and adolescents.
Design, Setting, and Participants Randomized, observer-blind, controlled trial of 126 children recruited from December 2004 through May 2007 and aged 9 through 17 years, with impairing Tourette or chronic tic disorder as a primary diagnosis, randomly assigned to 8 sessions during 10 weeks of behavior therapy (n=61) or a control treatment consisting of supportive therapy and education (n=65). Responders received 3 monthly booster treatment sessions and were reassessed at 3 and 6 months following treatment.
Intervention Comprehensive behavioral intervention.
Main Outcome Measures Yale Global Tic Severity Scale (range 0-50, score >15 indicating clinically significant tics) and Clinical Global Impressions-Improvement Scale (range 1 [very much improved] to 8 [very much worse]).
Results Behavioral intervention led to a significantly greater decrease on the Yale Global Tic Severity Scale (24.7 [95% confidence interval {CI}, 23.1-26.3] to 17.1 [95% CI, 15.1-19.1]) from baseline to end point compared with the control treatment (24.6 [95% CI, 23.2-26.0] to 21.1 [95% CI, 19.2-23.0]) (P<.001; difference between groups, 4.1; 95% CI, 2.0-6.2) (effect size=0.68). Significantly more children receiving behavioral intervention compared with those in the control group were rated as being very much improved or much improved on the Clinical Global Impressions-Improvement scale (52.5% vs 18.5%, respectively; P<.001; number needed to treat=3). Attrition was low (12/126, or 9.5%); tic worsening was reported by 4% of children (5/126). Treatment gains were durable, with 87% of available responders to behavior therapy exhibiting continued benefit 6 months following treatment.
Conclusion A comprehensive behavioral intervention, compared with supportive therapy and education, resulted in greater improvement in symptom severity among children with Tourette and chronic tic disorder.
C1 [Piacentini, John] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[Woods, Douglas W.] Univ Wisconsin, Milwaukee, WI 53201 USA.
[Scahill, Lawrence; Dziura, James] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA.
[Wilhelm, Sabine; Deckersbach, Thilo] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Ginsburg, Golda S.; Walkup, John T.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA.
[Levi-Pearl, Sue] Tourette Syndrome Assoc, Bayside, NY USA.
RP Piacentini, J (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,Room 68-251, Los Angeles, CA 90024 USA.
EM jpiacentini@mednet.ucla.edu
RI Piacentini, John/C-4645-2011;
OI Scahill, Lawrence/0000-0001-5073-1707
FU NIMH; Seaside Therapeutics; Shire Pharmaceuticals; National Institutes
of Health (NIH); Janssen; Forest Research Institute; Shire Development
Inc; Medtronic; Cyberonics; Northstar; Eli Lilly; JAZZ Pharmaceuticals;
CMP Media; Medical Education Reviews; McMahon Group; DiMedix; Tourette
Syndrome Association; National Institute of Mental Health [R01MH070802];
National Center for Research Resources, NIH [UL1 RR024139]
FX Drs Piacentini, Woods, Scahill, Wilhelm, Peterson, Chang, Ginsburg,
Deckersbach, and Walkup report receiving royalties from Oxford
University Press for treatment manuals on tic disorders. Drs Piacentini,
Woods, Scahill, Wilhelm, Peterson, Chang, and Walkup report receiving
honoraria for CME presentations from the Tourette Syndrome Association.
Drs Piacentini, Woods, and Walkup receive royalties from Guilford Press
for a book on Tourette disorder. Dr Piacentini reports receiving
royalties from Oxford University Press for treatment manuals on child
obsessive-compulsive disorder and APA Books for other books on child
mental health, speaking honoraria from Janssen-Cilag, and support in the
form of free medication and matching placebo from Pfizer for clinical
trials funded by NIMH. Dr Woods reports receiving book royalties from
New Harbinger and Springer Publications. Dr Scahill reports receiving
royalties from Oxford University Press for a textbook on pediatric
psychopharmacology; serving as a consultant for Janssen Pharmaceuticals,
Bristol-Myers Squibb, Neuropharm, Supernus, and Shire Pharmaceuticals;
receiving research support from Seaside Therapeutics and Shire
Pharmaceuticals; and receiving support in the form of free medication
and matching placebo from Janssen Pharmaceuticals and Shire
Pharmaceuticals for clinical trials funded by NIMH. Dr Wilhelm reports
receiving support in the form of free medication and matching placebo
from Forest Laboratories for clinical trials funded by the National
Institutes of Health (NIH) and receiving book royalties from Guilford
Publications, New Harbinger Publications, and Oxford University Press
and speaking honoraria from PRIMEDIA Healthcare, a publicly traded
company working as a logistics collaborator for the MGH Psychiatry
Academy (the education programs conducted by the MGH Psychiatry Academy
were supported through Independent Medical Education grants from
pharmaceutical companies cosupporting the overall program, along with
participant tuition). Dr Deckersbach reports receiving consulting fees
from the Constella Group for serving as a reviewer for the
Congressionally Directed Medical Research Program. He also reports
receiving honoraria, consulting fees, and/or royalties from Medacorp,
MGH Psychiatry Academy, BrainCells Inc, Systems Research and
Applications Corp, Boston University, the Catalan Agency for Health
Technology Assessment and Research, and National Association of Social
Workers-Massachusetts. He reports participating in research funded by
Janssen, Forest Research Institute, Shire Development Inc, Medtronic,
Cyberonics, and Northstar. Dr Walkup reports receiving consulting fees
from Eli Lilly and JAZZ Pharmaceuticals and lecture fees from CMP Media,
Medical Education Reviews, McMahon Group, DiMedix, and the Tourette
Syndrome Association. He reports receiving free drug and matching
placebo from Pfizer and Lilly and free drugs from Abbott for NIMH-funded
clinical trials. He reports receiving fees for consultation with defense
counsel and submission of written reports in litigation involving
GlaxoSmithKline. No other disclosures relevant to this article were
reported.; Funding/Support: This work was supported by grant R01MH070802
from the National Institute of Mental Health to Dr Piacentini, with
subcontracts to Drs Woods, Scahill, Wilhelm, Peterson, and Walkup. Drs
Scahill and Dziura receive support from the Yale University Clinical and
Translational Sciences Award grant UL1 RR024139 from the National Center
for Research Resources, NIH.
NR 49
TC 192
Z9 195
U1 8
U2 31
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 19
PY 2010
VL 303
IS 19
BP 1929
EP 1937
DI 10.1001/jama.2010.607
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 597NJ
UT WOS:000277764500019
PM 20483969
ER
PT J
AU Al-Swailem, AM
Shehata, MM
Abu-Duhier, FM
Al-Yamani, EJ
Al-Busadah, KA
Al-Arawi, MS
Al-Khider, AY
Al-Muhaimeed, AN
Al-Qahtani, FH
Manee, MM
Al-Shomrani, BM
Al-Qhtani, SM
Al-Harthi, AS
Akdemir, KC
Inan, MS
Otu, HH
AF Al-Swailem, Abdulaziz M.
Shehata, Maher M.
Abu-Duhier, Faisel M.
Al-Yamani, Essam J.
Al-Busadah, Khalid A.
Al-Arawi, Mohammed S.
Al-Khider, Ali Y.
Al-Muhaimeed, Abdullah N.
Al-Qahtani, Fahad H.
Manee, Manee M.
Al-Shomrani, Badr M.
Al-Qhtani, Saad M.
Al-Harthi, Amer S.
Akdemir, Kadir C.
Inan, Mehmet S.
Otu, Hasan H.
TI Sequencing, Analysis, and Annotation of Expressed Sequence Tags for
Camelus dromedarius
SO PLOS ONE
LA English
DT Article
ID IMMUNOGLOBULIN HEAVY-CHAIN; FATTY-ACID COMPOSITION; CONSTANT-REGION
GENES; ALPHA-GENES; STRESS; ORGANIZATION; P27(KIP1); ALIGNMENT; GLUCOSE;
BLOOD
AB Despite its economical, cultural, and biological importance, there has not been a large scale sequencing project to date for Camelus dromedarius. With the goal of sequencing complete DNA of the organism, we first established and sequenced camel EST libraries, generating 70,272 reads. Following trimming, chimera check, repeat masking, cluster and assembly, we obtained 23,602 putative gene sequences, out of which over 4,500 potentially novel or fast evolving gene sequences do not carry any homology to other available genomes. Functional annotation of sequences with similarities in nucleotide and protein databases has been obtained using Gene Ontology classification. Comparison to available full length cDNA sequences and Open Reading Frame (ORF) analysis of camel sequences that exhibit homology to known genes show more than 80% of the contigs with an ORF>300 bp and similar to 40% hits extending to the start codons of full length cDNAs suggesting successful characterization of camel genes. Similarity analyses are done separately for different organisms including human, mouse, bovine, and rat. Accompanying web portal, CAGBASE (http://camel.kacst.edu.sa/), hosts a relational database containing annotated EST sequences and analysis tools with possibility to add sequences from public domain. We anticipate our results to provide a home base for genomic studies of camel and other comparative studies enabling a starting point for whole genome sequencing of the organism.
C1 [Al-Swailem, Abdulaziz M.; Shehata, Maher M.; Abu-Duhier, Faisel M.; Al-Yamani, Essam J.; Al-Arawi, Mohammed S.; Al-Khider, Ali Y.; Al-Muhaimeed, Abdullah N.; Al-Qahtani, Fahad H.; Manee, Manee M.; Al-Shomrani, Badr M.; Al-Qhtani, Saad M.; Al-Harthi, Amer S.; Inan, Mehmet S.; Otu, Hasan H.] King Abdulaziz City Sci & Technol, Biotechnol Res Ctr, Nat Resources & Environm Res Inst, Riyadh, Saudi Arabia.
[Al-Busadah, Khalid A.] King Faisal Univ, Fac Vet Med & Anim Resources, Al Hasa, Saudi Arabia.
[Akdemir, Kadir C.; Otu, Hasan H.] Harvard Univ, Sch Med, Dept Med, BIDMC Genom Ctr, Boston, MA USA.
RP Al-Swailem, AM (reprint author), King Abdulaziz City Sci & Technol, Biotechnol Res Ctr, Nat Resources & Environm Res Inst, Riyadh, Saudi Arabia.
EM hotu@bidmc.harvard.edu
FU King Abdulaziz City for Science and Technology (KACST); Natural
Resources and Environment Research Institute (NRERI), Riyadh, Saudi
Arabia; Dubai-Harvard Foundation for Medical Research
FX This project was supported by a grant from King Abdulaziz City for
Science and Technology (KACST), Natural Resources and Environment
Research Institute (NRERI), Riyadh, Saudi Arabia
(http://www.kacst.edu.sa). HHO is partially supported by Dubai-Harvard
Foundation for Medical Research (http://www.dhfmr.hms.harvard.edu). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 50
TC 14
Z9 14
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 19
PY 2010
VL 5
IS 5
AR e10720
DI 10.1371/journal.pone.0010720
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 598NT
UT WOS:000277845400022
PM 20502665
ER
PT J
AU Sykiotis, GP
Pitteloud, N
Seminara, SB
Kaiser, UB
Crowley, WF
AF Sykiotis, Gerasimos P.
Pitteloud, Nelly
Seminara, Stephanie B.
Kaiser, Ursula B.
Crowley, William F., Jr.
TI Deciphering Genetic Disease in the Genomic Era: The Model of GnRH
Deficiency
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Review
ID IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM;
GONADOTROPIN-RELEASING-HORMONE; ADRENAL HYPOPLASIA CONGENITA;
KALLMANN-SYNDROME; OLFACTORY-BULB; CANDIDATE GENE; MUTATIONS; RECEPTOR;
DIAGNOSIS; OBESITY
AB Isolated gonadotropin-releasing hormone (GnRH) deficiency is a treatable albeit rare form of reproductive failure that has revealed physiological mechanisms controlling human reproduction, but despite substantial progress in discovering pathogenic single-gene defects, most of the genetic basis of GnRH deficiency remains uncharted. Although unbiased genetic investigations of affected families have identified mutations in previously unsuspected genes as causes of this disease in some cases, their application has been severely limited because of the negative effect of GnRH deficiency on fertility; moreover, relatively few of the many candidate genes nominated because of biological plausibility from in vitro or animal model experiments were subsequently validated in patients. With the advent of exciting technological platforms for sequencing, homozygosity mapping, and detection of structural variation at the whole-genome level, human investigations are again assuming the leading role for gene discovery. Using human GnRH deficiency as a paradigm and presenting original data from the screening of numerous candidate genes, we discuss the emerging model of patient-focused clinical genetic research and its complementarities with basic approaches in the near future.
C1 [Sykiotis, Gerasimos P.; Pitteloud, Nelly; Seminara, Stephanie B.; Kaiser, Ursula B.; Crowley, William F., Jr.] Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA.
[Sykiotis, Gerasimos P.; Pitteloud, Nelly; Seminara, Stephanie B.; Crowley, William F., Jr.] Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02114 USA.
[Kaiser, Ursula B.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA.
RP Crowley, WF (reprint author), Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA.
EM crowley.william@mgh.harvard.edu
RI PITTELOUD, Nelly/K-2709-2014;
OI Sykiotis, Gerasimos/0000-0002-9565-4941
FU NICHD NIH HHS [U54 HD028138-19S1, HD056264-02S1, R01 HD015788, R01
HD015788-23, R01 HD043341, R01 HD056264, U54 HD028138]
NR 58
TC 13
Z9 13
U1 0
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 19
PY 2010
VL 2
IS 32
AR 32rv2
DI 10.1126/scitranslmed.3000288
PG 10
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 598KK
UT WOS:000277835400005
PM 20484732
ER
PT J
AU Parker, BD
Schurgers, LJ
Brandenburg, VM
Christenson, RH
Vermeer, C
Ketteler, M
Shlipak, MG
Whooley, MA
Ix, JH
AF Parker, Benjamin D.
Schurgers, Leon J.
Brandenburg, Vincent M.
Christenson, Robert H.
Vermeer, Cees
Ketteler, Markus
Shlipak, Michael G.
Whooley, Mary A.
Ix, Joachim H.
TI The Associations of Fibroblast Growth Factor 23 and Uncarboxylated
Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart
and Soul Study
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; FETUIN-A LEVELS; CARDIOVASCULAR MORTALITY; SERUM
PHOSPHORUS; MYOCARDIAL-INFARCTION; DIALYSIS PATIENTS; VASCULAR
CALCIFICATION; GLYCOPROTEIN/FETUIN-A; PHOSPHATE LEVELS; RISK
AB Background: Fibroblast growth factor 23 (FGF23), uncarboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibitors of vascular calcification. Whether circulating levels of each are associated with cardiovascular disease (CVD) events or mortality in populations without end-stage renal disease is unknown.
Objective: To evaluate the associations of FGF23, ucMGP, and fetuin-A with mortality and CVD events.
Design: Observational study.
Setting: 12 outpatient clinics in the San Francisco Bay area.
Patients: 833 outpatients with stable coronary artery disease (CAD), recruited from 11 September 2000 to 20 December 2002.
Measurements: Fibroblast growth factor 23, ucMGP, and fetuin-A concentrations were measured at baseline. Participants were followed until 1 December 2008 for mortality and CVD events.
Results: During a median follow-up of 6.0 years, 220 participants died and 182 had CVD events. Compared with participants with FGF-23 levels in the lowest tertile, those in the highest tertile had 2-fold greater risk for mortality (hazard ratio [HR], 2.15 [95% CI, 1.43 to 3.24]) and CVD events (HR, 1.83 [CI, 1.15 to 2.91]) after adjustment for traditional CVD risk factors, C-reactive protein levels, and kidney function. The highest ucMGP tertile was associated with lower mortality risk (HR, 0.48 [CI, 0.31 to 0.75]) and showed a nonsignificant trend toward lower CVD event risk by tertile analysis (HR, 0.65 [CI, 0.40 to 1.05])-an association that was significant when modeled continuously (P = 0.029). No significant association of fetuin-A with mortality (HR, 0.84 [CI, 0.55 to 1.27]) or CVD events (HR, 0.99 [CI, 0.64 to 1.55]) was observed.
Limitation: Participants had prevalent CAD.
Conclusion: In outpatients with stable CAD, higher FGF23 and lower ucMGP levels are independently associated with mortality and CVD events.
C1 [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA.
Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
Maastricht Univ, Cardiovasc Res Inst, Maastricht, Netherlands.
VitaK, Maastricht, Netherlands.
Rhein Westfal TH Aachen, Univ Hosp, Aachen, Germany.
Klinikum Coburg, Coburg, Germany.
Univ Maryland, Baltimore, MD 21201 USA.
RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA.
EM joeix@ucsd.edu
OI Vermeer, Cees/0000-0002-2300-8561
FU National Heart, Lung, and Blood Institute (NHLBI) [T32 HL007261,
R01HL096851, R01 HL079235]; American Heart Association; Department of
Veterans Epidemiology Merit Review Program; Department of Veterans
Affairs Health Services Research and Development service; American
Federation for Aging Research; Robert Wood Johnson Foundation; Ischemia
Research and Education Foundation
FX Grant Support: By a Hypertension Training Grant (T32 HL007261) through
the National Heart, Lung, and Blood Institute (NHLBI) (Dr. Parker), an
American Heart Association Fellow-to-Faculty transition grant, and the
NHLBI (grant R01HL096851, Dr. Ix). The Heart and Soul Study was
supported by the Department of Veterans Epidemiology Merit Review
Program; the Department of Veterans Affairs Health Services Research and
Development service; the NHLBI (grant R01 HL079235); the American
Federation for Aging Research (Paul Beeson Scholars Program); the Robert
Wood Johnson Foundation (Generalist Physician Faculty Scholars Program);
and the Ischemia Research and Education Foundation. Dr. Ix had full
access to all of the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis.
NR 56
TC 234
Z9 242
U1 0
U2 14
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 18
PY 2010
VL 152
IS 10
BP 640
EP +
DI 10.1059/0003-4819-152-10-201005180-00004
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 598RJ
UT WOS:000277855500003
PM 20479029
ER
PT J
AU Drews, RE
Shulman, LN
AF Drews, Reed E.
Shulman, Lawrence N.
TI Update in Hematology and Oncology
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID CHRONIC KIDNEY-DISEASE; ANEMIA; CANCER
C1 [Drews, Reed E.] Harvard Univ, Div Hematol Oncol, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Drews, RE (reprint author), Harvard Univ, Div Hematol Oncol, Beth Israel Deaconess Med Ctr, Sch Med, E-RA-430,330 Brookline Ave, Boston, MA 02215 USA.
EM rdrews@bidmc.harvard.edu
NR 5
TC 4
Z9 4
U1 1
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 18
PY 2010
VL 152
IS 10
BP 655
EP W229
DI 10.1059/0003-4819-152-10-201005180-00244
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 598RJ
UT WOS:000277855500005
PM 20410447
ER
PT J
AU Zhang, B
Strauss, AC
Chu, S
Li, M
Ho, YW
Shiang, KD
Snyder, DS
Huettner, CS
Shultz, L
Holyoake, T
Bhatia, R
AF Zhang, Bin
Strauss, Adam C.
Chu, Su
Li, Min
Ho, Yinwei
Shiang, Keh-Dong
Snyder, David S.
Huettner, Claudia S.
Shultz, Leonard
Holyoake, Tessa
Bhatia, Ravi
TI Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells
by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
SO CANCER CELL
LA English
DT Article
ID CHRONIC MYELOID-LEUKEMIA; COMPLETE CYTOGENETIC REMISSION; BCR-ABL;
TYROSINE KINASE; CD34(+) CELLS; BLAST-CRISIS; HEMATOPOIETIC PROGENITORS;
DASATINIB BMS-354825; CHRONIC-PHASE; PRIMARY CML
AB Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients but does not eliminate leukemia stem cells (LSCs), which remain a potential source of relapse. Here we investigated the ability of HDAC inhibitors (HDACis) to target CML stem cells. Treatment with HDACis combined with IM effectively induced apoptosis in quiescent CML progenitors resistant to elimination by IM alone, and eliminated CML stem cells capable of engrafting immunodeficient mice. In vivo administration of HDACis with IM markedly diminished LSCs in a transgenic mouse model of CML. The interaction of IM and HDACis inhibited genes regulating hematopoietic stem cell maintenance and survival. HDACi treatment represents an effective strategy to target LSCs in CML patients receiving tyrosine kinase inhibitors.
C1 [Zhang, Bin; Strauss, Adam C.; Chu, Su; Ho, Yinwei; Shiang, Keh-Dong; Bhatia, Ravi] City Hope Natl Med Ctr, Div Hematopoiet Stem Cell & Leukemia Res, Duarte, CA 91010 USA.
[Li, Min; Shiang, Keh-Dong] City Hope Natl Med Ctr, Dept Informat Sci, Duarte, CA 91010 USA.
[Snyder, David S.] City Hope Natl Med Ctr, Dept Hematol & HCT, Duarte, CA 91010 USA.
[Huettner, Claudia S.] Dana Farber Canc Inst, Beffer Inst Appl Canc Sci, Boston, MA 02445 USA.
[Shultz, Leonard] Jackson Lab, Bar Harbor, ME 04609 USA.
[Holyoake, Tessa] Univ Glasgow, Canc Div, Sect Expt Haematol, Glasgow G12 OYN, Lanark, Scotland.
RP Bhatia, R (reprint author), City Hope Natl Med Ctr, Div Hematopoiet Stem Cell & Leukemia Res, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM rbhatia@coh.org
OI holyoake, tessa/0000-0002-0608-6066
FU National Institutes of Health [R01 CA95684, R01 HL77847, CA34196];
Leukemia and Lymphoma Society; General clinical Research Center [5M01
RR00043]; Novartis
FX This work was supported by the National Institutes of Health (grants R01
CA95684 and R01 HL77847, and grant CA34196 to the Jackson Laboratory),
the Leukemia and Lymphoma Society (Translational research Grant to
R.B.), and the General clinical Research Center (grant #5M01 RR00043).
We acknoweldge the excellent technical support of the COHNMC Analytical
Cytometry, Functional Genomics and Bioinformatics cores, and the Animal
Resources Center. We thank Allen Lin and UK Hematologies for assistance
with obtaining samples, StemCyte for their generous gift of CB samples,
Elisabeth Buchdunger and Peter Atadja from Novartis Pharmaceuticals for
supplying IM, LAQ, and Jeff Taur for assistance with NSG mouse studies.
R.B. is a Novartis advisory board member. T.H. is a Novartis advisory
board member and has received research funding form Novartis.
NR 44
TC 130
Z9 137
U1 1
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD MAY 18
PY 2010
VL 17
IS 5
BP 427
EP 442
DI 10.1016/j.ccr.2010.03.011
PG 16
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 598UC
UT WOS:000277863300006
PM 20478526
ER
PT J
AU Zheng, HW
Ying, HQ
Wiedemeyer, R
Yan, HY
Quayle, SN
Ivanova, EV
Paik, JH
Zhang, HL
Xiao, YH
Perry, SR
Hu, J
Vinjamoori, A
Gan, BY
Sahin, E
Chheda, MG
Brennan, C
Wang, YA
Hahn, WC
Chin, L
DePinho, RA
AF Zheng, Hongwu
Ying, Haoqiang
Wiedemeyer, Ruprecht
Yan, Haiyan
Quayle, Steven N.
Ivanova, Elena V.
Paik, Ji-Hye
Zhang, Hailei
Xiao, Yonghong
Perry, Samuel R.
Hu, Jian
Vinjamoori, Anant
Gan, Boyi
Sahin, Ergun
Chheda, Milan G.
Brennan, Cameron
Wang, Y. Alan
Hahn, William C.
Chin, Lynda
DePinho, Ronald A.
TI PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem
Cells and Gliomas
SO CANCER CELL
LA English
DT Article
ID TUMOR-INITIATING CELLS; BETA-CATENIN; HUMAN GLIOBLASTOMA; SELF-RENEWAL;
SPORADIC MEDULLOBLASTOMAS; PATHWAY ACTIVATION; PROGENITOR CELLS;
BRAIN-TUMORS; CANCER-CELLS; DISEASE
AB A hallmark feature of glioblastoma is its strong self-renewal potential and immature differentiation state, which contributes to its plasticity and therapeutic resistance. Here, integrated genomic and biological analyses identified PLAGL2 as a potent protooncogene targeted for amplification/gain in malignant gliomas. Enhanced PLAGL2 expression strongly suppresses neural stem cell (NSC) and glioma-initiating cell differentiation while promoting their self-renewal capacity upon differentiation induction. Transcriptome analysis revealed that these differentiation-suppressive activities are attributable in part to PLAGL2 modulation of Wnt/beta-catenin signaling. Inhibition of Wnt signaling partially restores PLAGL2-expressing NSC differentiation capacity. The identification of PLAGL2 as a glioma oncogene highlights the importance of a growing class of cancer genes functioning to impart stem cell-like characteristics in malignant cells.
C1 [Zheng, Hongwu; Ying, Haoqiang; Wiedemeyer, Ruprecht; Yan, Haiyan; Quayle, Steven N.; Ivanova, Elena V.; Paik, Ji-Hye; Zhang, Hailei; Xiao, Yonghong; Perry, Samuel R.; Hu, Jian; Gan, Boyi; Sahin, Ergun; Wang, Y. Alan; Chin, Lynda; DePinho, Ronald A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA.
[Zheng, Hongwu; Ying, Haoqiang; Wiedemeyer, Ruprecht; Yan, Haiyan; Quayle, Steven N.; Ivanova, Elena V.; Paik, Ji-Hye; Zhang, Hailei; Xiao, Yonghong; Perry, Samuel R.; Hu, Jian; Vinjamoori, Anant; Gan, Boyi; Sahin, Ergun; Chheda, Milan G.; Wang, Y. Alan; Hahn, William C.; Chin, Lynda; DePinho, Ronald A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Zheng, Hongwu; Ying, Haoqiang; Quayle, Steven N.; Paik, Ji-Hye; Hu, Jian; Gan, Boyi; Sahin, Ergun; Chheda, Milan G.; Hahn, William C.; Chin, Lynda; DePinho, Ronald A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Zheng, Hongwu; Ying, Haoqiang; Quayle, Steven N.; Paik, Ji-Hye; Hu, Jian; Gan, Boyi; Sahin, Ergun; Chin, Lynda; DePinho, Ronald A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Chin, Lynda] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA.
[Chheda, Milan G.] Massachusetts Gen Hosp, Dept Neurooncol, Boston, MA 02129 USA.
[Chheda, Milan G.; Hahn, William C.; Chin, Lynda] Harvard & Massachusetts Inst Technol, Broad Inst, Cambridge, MA 02142 USA.
[Brennan, Cameron] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA.
[Brennan, Cameron] Weill Cornell Med Coll, Dept Neurosurg, New York, NY 10065 USA.
RP DePinho, RA (reprint author), Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA.
EM ron_depinho@dfci.harvard.edu
OI Zheng, Hongwu/0000-0002-5823-4913; Brennan, Cameron/0000-0003-4064-8891
FU Helen Hay Whitney Foundation; American Brain Tumor Association; Damon
Runyon Cancer Research Foundation; Mildred Scheel Fellowship (Deutsche
Krebshilfe); Canadian Institutes of Health Research; Goldhirsh
Foundation; Multiple Myeloma Research Foundation; National Institutes of
Health [RO1CA99041, 5P01CA95616, 1RC2CA148268-01, 1RC2CA148222-01];
Renee E. Belfer Foundation for Innovative Cancer Science; Ben and
Catherine Ivy Foundation
FX We thank S. Zhou and S. Jiang for excellent mouse husbandry and care.
H.Z. was supported by the Helen Hay Whitney Foundation. H.Y. is
supported by the American Brain Tumor Association. J.H.P was supported
by the Damon Runyon Cancer Research Foundation. R.W. is supported by a
Mildred Scheel Fellowship (Deutsche Krebshilfe), and S.N.Q. is supported
by a fellowship from the Canadian Institutes of Health Research. Grant
support comes from the Goldhirsh Foundation (R.A.D.), the Ben and
Catherine Ivy Foundation (W.C.H., L.C., and R.A.D.), the Multiple
Myeloma Research Foundation (YAW.), and National Institutes of Health
grants RO1CA99041 (L.C.), 5P01CA95616 (W.C.H., L.C., and R.A.D.),
1RC2CA148268-01 (W.C.H., L.C., and R.A.D.), and 1RC2CA148222-01 (BAD.).
R.A.D. is an American Cancer Society Research Professor and is supported
by the Robert A. and Renee E. Belfer Foundation for Innovative Cancer
Science.
NR 69
TC 98
Z9 101
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD MAY 18
PY 2010
VL 17
IS 5
BP 497
EP 509
DI 10.1016/j.ccr.2010.03.020
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 598UC
UT WOS:000277863300011
PM 20478531
ER
PT J
AU Noushmehr, H
Weisenberger, DJ
Diefes, K
Phillips, HS
Pujara, K
Berman, BP
Pan, F
Pelloski, CE
Sulman, EP
Bhat, KP
Verhaak, RGW
Hoadley, KA
Hayes, DN
Perou, CM
Schmidt, HK
Ding, L
Wilson, RK
Van Den Berg, D
Shen, H
Bengtsson, H
Neuvial, P
Cope, LM
Buckley, J
Herman, JG
Baylin, SB
Laird, PW
Aldape, K
AF Noushmehr, Houtan
Weisenberger, Daniel J.
Diefes, Kristin
Phillips, Heidi S.
Pujara, Kanan
Berman, Benjamin P.
Pan, Fei
Pelloski, Christopher E.
Sulman, Erik P.
Bhat, Krishna P.
Verhaak, Roel G. W.
Hoadley, Katherine A.
Hayes, D. Neil
Perou, Charles M.
Schmidt, Heather K.
Ding, Li
Wilson, Richard K.
Van Den Berg, David
Shen, Hui
Bengtsson, Henrik
Neuvial, Pierre
Cope, Leslie M.
Buckley, Jonathan
Herman, James G.
Baylin, Stephen B.
Laird, Peter W.
Aldape, Kenneth
CA Canc Genome Atlas Res Network
TI Identification of a CpG Island Methylator Phenotype that Defines a
Distinct Subgroup of Glioma
SO CANCER CELL
LA English
DT Article
ID INTEGRATED GENOMIC ANALYSIS; CODON 132 MUTATION; HIGH-GRADE GLIOMA; DNA
METHYLATION; GLIOBLASTOMA-MULTIFORME; PROSTATE-CANCER; RETINOIC ACID;
COLORECTAL-CANCER; PROMOTER HYPERMETHYLATION; PROFILING REVEALS
AB We have profiled promoter DNA methylation alterations in 272 glioblastoma tumors in the context of The Cancer Genome Atlas (TCGA). We found that a distinct subset of samples displays concerted hypermethylation at a large number of loci, indicating the existence of a glioma-CpG island methylator phenotype (G-CIMP). We validated G-CIMP in a set of non-TCGA glioblastomas and low-grade gliomas. G-CIMP tumors belong to the proneural subgroup, are more prevalent among lower-grade gliomas, display distinct copy-number alterations, and are tightly associated with IDH1 somatic mutations. Patients with G-CIMP tumors are younger at the time of diagnosis and experience significantly improved outcome. These findings identify G-CIMP as a distinct subset of human gliomas on molecular and clinical grounds.
C1 [Noushmehr, Houtan; Weisenberger, Daniel J.; Berman, Benjamin P.; Pan, Fei; Van Den Berg, David; Shen, Hui; Buckley, Jonathan; Laird, Peter W.] Univ So Calif, USC Epigenome Ctr, Los Angeles, CA 90033 USA.
[Diefes, Kristin; Bhat, Krishna P.; Aldape, Kenneth] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
[Phillips, Heidi S.; Pujara, Kanan] Genentech Inc, Dept Tumor Biol & Angiogenesis, San Francisco, CA 94080 USA.
[Pelloski, Christopher E.; Sulman, Erik P.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
[Verhaak, Roel G. W.] MIT, Eli & Edythe L Broad Inst, Cambridge, MA 02142 USA.
[Verhaak, Roel G. W.] Harvard Univ, Cambridge, MA 02142 USA.
[Verhaak, Roel G. W.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Hoadley, Katherine A.; Hayes, D. Neil; Perou, Charles M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Hoadley, Katherine A.; Hayes, D. Neil; Perou, Charles M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Schmidt, Heather K.; Ding, Li; Wilson, Richard K.] Washington Univ, Sch Med, Genome Ctr, Dept Genet, St Louis, MO 63108 USA.
[Bengtsson, Henrik; Neuvial, Pierre] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA.
[Cope, Leslie M.; Herman, James G.; Baylin, Stephen B.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21231 USA.
[Buckley, Jonathan] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
RP Laird, PW (reprint author), Univ So Calif, USC Epigenome Ctr, Los Angeles, CA 90033 USA.
EM plaird@usc.edu
RI Noushmehr, Houtan/C-9692-2013; Berman, Benjamin/D-5942-2014; Waha,
Andreas/J-2950-2014; Laird, Peter/G-8683-2012;
OI Noushmehr, Houtan/0000-0003-4051-8114; Hayes, D.
Neil/0000-0001-6203-7771; Perou, Charles/0000-0001-9827-2247
FU NIH/NCI [U24 CA126561, U24 CA143882-01, P50CA127001]; M.D. Anderson
Center for Cancer Epigenetics; Brain Tumor Funders' Collaborative; V
Foundation; Rose Foundation
FX This work was supported by NIH/NCI grants U24 CA126561 and U24
CA143882-01 (P.W.L. and S.B.B.), grants from the M.D. Anderson Center
for Cancer Epigenetics, the Brain Tumor Funders' Collaborative, the V
Foundation, and the Rose Foundation, and SPORE grant P50CA127001 from
NIH/NCI (K.A.). We thank Dennis Maglinte and members of the USC
Epigenome Center for helpful discussions, Andreana Rivera for technical
assistance, and Marisol Guerrero for editorial assistance. P.W.L. is a
shareholder, consultant, and scientific advisory board member of
Epigenomics, AG, which has a commercial interest in DNA methylation
markers. This work was not supported by Epigenomics, AG. K.A. is a
consultant and scientific advisory board member for Castle Biosciences,
which has a commercial interest in molecular diagnostics. This work was
not supported by Castle Biosciences.
NR 64
TC 867
Z9 890
U1 6
U2 71
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD MAY 18
PY 2010
VL 17
IS 5
BP 510
EP 522
DI 10.1016/j.ccr.2010.03.017
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 598UC
UT WOS:000277863300012
PM 20399149
ER
PT J
AU Enhorning, S
Wang, TJ
Nilsson, PM
Almgren, P
Hedblad, B
Berglund, G
Struck, J
Morgenthaler, NG
Bergmann, A
Lindholm, E
Groop, L
Lyssenko, V
Orho-Melander, M
Newton-Cheh, C
Melander, O
AF Enhorning, Sofia
Wang, Thomas J.
Nilsson, Peter M.
Almgren, Peter
Hedblad, Bo
Berglund, Goran
Struck, Joachim
Morgenthaler, Nils G.
Bergmann, Andreas
Lindholm, Eero
Groop, Leif
Lyssenko, Valeria
Orho-Melander, Marju
Newton-Cheh, Christopher
Melander, Olle
TI Plasma Copeptin and the Risk of Diabetes Mellitus
SO CIRCULATION
LA English
DT Article
DE arginine vasopressin; copeptin; diabetes mellitus; epidemiology; risk
factors
ID TERMINAL PROVASOPRESSIN COPEPTIN; ACUTE MYOCARDIAL-INFARCTION;
VASOPRESSIN RECEPTOR; ARGININE-VASOPRESSIN; INSULIN-RESISTANCE;
CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; HEART-FAILURE; ANTAGONIST;
CLONING
AB Background-Animal studies suggest that the arginine vasopressin system may play a role in glucose metabolism, but data from humans are limited.
Methods and Results-We analyzed plasma copeptin (copeptin), a stable C-terminal fragment of the arginine vasopressin prohormone. Using baseline and longitudinal data from a Swedish population-based sample (n=4742; mean age, 58 years; 60% women) and multivariable logistic regression, we examined the association of increasing quartiles of copeptin (lowest quartile as reference) with prevalent diabetes mellitus at baseline, insulin resistance (top quartile of fasting plasma insulin among nondiabetic subjects), and incident diabetes mellitus on long-term follow-up. New-onset diabetes mellitus was ascertained through 3 national and regional registers. All models were adjusted for clinical and anthropometric risk factors, cystatin C, and C-reactive protein. In cross-sectional analyses, increasing copeptin was associated with prevalent diabetes mellitus (P=0.04) and insulin resistance (P < 0.001). During 12.6 years of follow-up, 174 subjects (4%) developed new-onset diabetes mellitus. The odds of developing diabetes mellitus increased across increasing quartiles of copeptin, even after additional adjustment for baseline fasting glucose and insulin (adjusted odds ratios, 1.0, 1.37, 1.79, and 2.09; P for trend=0.004). The association with incident diabetes mellitus remained significant in analyses restricted to subjects with fasting whole blood glucose < 5.4 mmol/L at baseline (adjusted odds ratios, 1.0, 1.80, 1.92, and 3.48; P=0.001).
Conclusions-Elevated copeptin predicts increased risk for diabetes mellitus independently of established clinical risk factors, including fasting glucose and insulin. These findings could have implications for risk assessment, novel antidiabetic treatments, and metabolic side effects from arginine vasopressin system modulation. (Circulation. 2010; 121: 2102-2108.)
C1 [Enhorning, Sofia; Nilsson, Peter M.; Almgren, Peter; Hedblad, Bo; Berglund, Goran; Lindholm, Eero; Groop, Leif; Lyssenko, Valeria; Orho-Melander, Marju; Melander, Olle] Lund Univ, Dept Clin Sci, SE-20502 Malmo, Sweden.
[Enhorning, Sofia; Nilsson, Peter M.; Melander, Olle] Malmo Univ Hosp, Dept Internal Med, Malmo, Sweden.
[Newton-Cheh, Christopher] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA.
[Wang, Thomas J.; Newton-Cheh, Christopher] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA USA.
[Newton-Cheh, Christopher] Harvard & MIT, Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Struck, Joachim; Morgenthaler, Nils G.; Bergmann, Andreas] BRAHMS AG, Res Dept, Hennigsdorf, Germany.
[Wang, Thomas J.; Newton-Cheh, Christopher] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
RP Melander, O (reprint author), Lund Univ, Dept Clin Sci, Clin Res Ctr, Malmo Univ Hosp, Entrance 72,Bldg 91,Floor 12, SE-20502 Malmo, Sweden.
EM olle.melander@med.lu.se
FU Swedish Medical Research Council; Swedish Heart and Lung Foundation;
Medical Faculty of Lund University; Malmo University Hospital; Albert
Pahlsson Research Foundation; Crafoord Foundation; Ernhold Lundstroms
Research Foundation; Region Skane; Hulda and Conrad Mossfelt Foundation;
King Gustaf V and Queen Victoria Foundation; Lennart Hanssons Memorial
Fund; Wallenberg Foundation; NIH [K23-HL-080025, R01-HL-086875,
R01-HL-083197, R01-DK-081572]; Doris Duke Charitable Foundation;
Burroughs Wellcome Fund; American Heart Association
FX Drs Enhorning and Melander were supported by grants from the Swedish
Medical Research Council, the Swedish Heart and Lung Foundation, the
Medical Faculty of Lund University, Malmo University Hospital, the
Albert Pahlsson Research Foundation, the Crafoord Foundation, the
Ernhold Lundstroms Research Foundation, the Region Skane, the Hulda and
Conrad Mossfelt Foundation, the King Gustaf V and Queen Victoria
Foundation, the Lennart Hanssons Memorial Fund, and the Wallenberg
Foundation. Dr Newton-Cheh was supported by NIH K23-HL-080025, a Doris
Duke Charitable Foundation Clinical Scientist Development Award, and a
Burroughs Wellcome Fund Career Award for Medical Scientists. Dr Wang was
supported by NIH grants R01-HL-086875, R01-HL-083197, and R01-DK-081572
and a grant from the American Heart Association. We also thank Brahms
and Dade-Behring for their support of assay measurements.
NR 37
TC 93
Z9 97
U1 5
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAY 18
PY 2010
VL 121
IS 19
BP 2102
EP U51
DI 10.1161/CIRCULATIONAHA.109.909663
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 597PF
UT WOS:000277769900004
PM 20439785
ER
PT J
AU Stewart, RA
Sanda, T
Widlund, HR
Zhu, SZ
Swanson, KD
Hurley, AD
Bentires-Alj, M
Fisher, DE
Kontaridis, MI
Look, AT
Neel, BG
AF Stewart, Rodney A.
Sanda, Takaomi
Widlund, Hans R.
Zhu, Shizhen
Swanson, Kenneth D.
Hurley, Aeron D.
Bentires-Alj, Mohamed
Fisher, David E.
Kontaridis, Maria I.
Look, A. Thomas
Neel, Benjamin G.
TI Phosphatase-Dependent and -Independent Functions of Shp2 in Neural Crest
Cells Underlie LEOPARD Syndrome Pathogenesis
SO DEVELOPMENTAL CELL
LA English
DT Article
ID PROTEIN-TYROSINE-PHOSPHATASE; CAUSE NOONAN-SYNDROME; MUTATIONS CAUSE
NOONAN; OF-FUNCTION MUTATIONS; DNA-DAMAGE; STEM-CELLS; ZEBRAFISH;
PTPN11; GERMLINE; DIFFERENTIATION
AB The tyrosine phosphatase SHP2 (PTPN11) regulates cellular proliferation, survival, migration, and differentiation during development. Germ line mutations in PTPN11 cause Noonan and LEOPARD syndromes, which have overlapping clinical features. Paradoxically, Noonan syndrome mutations increase SHP2 phosphatase activity, while LEOPARD syndrome mutants are catalytically impaired, raising the possibility that SHP2 has phosphatase-independent roles. By comparing shp2-deficient zebrafish embryos with those injected with mRNA encoding LEOPARD syndrome point mutations, we identify a phosphatase- and Erk-dependent role for Shp2 in neural crest specification and migration. We also identify an unexpected phosphatase- and Erk-independent function, mediated through its SH2 domains, which is evolutionarily conserved and prevents p53-mediated apoptosis in the brain and neural crest. Our results indicate that previously enigmatic aspects of LEOPARD syndrome pathogenesis can be explained by the combined effects of loss of Shp2 catalytic function and retention of an SH2 domain-mediated role that is essential for neural crest cell survival.
C1 [Stewart, Rodney A.; Sanda, Takaomi; Zhu, Shizhen; Hurley, Aeron D.; Fisher, David E.; Look, A. Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Stewart, Rodney A.] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA.
[Widlund, Hans R.; Hurley, Aeron D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA.
[Swanson, Kenneth D.; Bentires-Alj, Mohamed; Kontaridis, Maria I.; Neel, Benjamin G.] Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA 02115 USA.
RP Stewart, RA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.
EM rodney.stewart@hci.utah.edu; thomas_look@dfci.harvard.edu;
bneel@uhnres.utoronto.ca
RI Mohamed, Bentires-Alj/F-4484-2015;
OI Mohamed, Bentires-Alj/0000-0001-6344-1127; Stewart,
Rodney/0000-0003-1220-1830
FU NIH/NINDS [R00 NS058608]; Friends for Life, DFCI; Children's Leukemia
Research Association research; NIH/NHLBI [R00 HL088514]; [R01
HL083271]; [R37 CA49152]; [R01 CA104605]
FX We thank P. Henion, J. Amatruda, R. Halaban, R. George, and C. Levi for
reagents; T. Buyal, R. Solovyev and Y. Ahn for technical assistance; K.
Kotredes, J. Kanki, and B. Baker for zebrafish maintenance; and C. Jette
and members of the Look and Neel labs for helpful discussions. This work
was supported by grants R01 HL083271 and R37 CA49152 (B.G.N) and R01
CA104605 (A.T.L.). R.A.S is supported by NIH/NINDS award R00 NS058608.
S.Z. is supported by a fellowship from Friends for Life, DFCI. T.S. is
supported by Children's Leukemia Research Association research grant.
M.K. is supported by NIH/NHLBI grant R00 HL088514.
NR 50
TC 50
Z9 50
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1534-5807
J9 DEV CELL
JI Dev. Cell
PD MAY 18
PY 2010
VL 18
IS 5
BP 750
EP 762
DI 10.1016/j.devcel.2010.03.009
PG 13
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 602CI
UT WOS:000278115500011
PM 20493809
ER
PT J
AU Scharf, JM
Mathews, CA
AF Scharf, Jeremiah M.
Mathews, Carol A.
TI Copy number variation in Tourette syndrome Another case of
neurodevelopmental generalist genes?
SO NEUROLOGY
LA English
DT Editorial Material
ID DISEASE
C1 [Scharf, Jeremiah M.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Dept Neurol, Boston, MA 02114 USA.
[Scharf, Jeremiah M.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Dept Psychiat, Boston, MA 02114 USA.
[Scharf, Jeremiah M.] Brigham & Womens Hosp, Div Cognit & Behav Neurol, Dept Neurol, Boston, MA 02115 USA.
[Mathews, Carol A.] Univ Calif San Francisco, Langley Porter Psychiat Inst, Dept Psychiat, San Francisco, CA 94143 USA.
RP Scharf, JM (reprint author), Massachusetts Gen Hosp, Psychiat Neurodev Genet Unit, Ctr Human Genet Res, 185 Cambridge St,6th Floor, Boston, MA 02114 USA.
EM jscharf@partners.org
FU NIMH NIH HHS [K23 MH085057, K23 MH085057-02, K23 MH085057-03, R25
MH060482]; NINDS NIH HHS [R01 NS037484, R01 NS048376, U01 NS040024]
NR 10
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD MAY 18
PY 2010
VL 74
IS 20
BP 1564
EP 1565
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 597OG
UT WOS:000277767000002
PM 20427746
ER
PT J
AU Frohlich, LF
Mrakovcic, M
Steinborn, R
Chung, UI
Bastepe, M
Juppner, H
AF Froehlich, Leopold F.
Mrakovcic, Maria
Steinborn, Ralf
Chung, Ung-Il
Bastepe, Murat
Jueppner, Harald
TI Targeted deletion of the Nesp55 DMR defines another Gnas imprinting
control region and provides a mouse model of autosomal dominant PHP-Ib
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE genomic imprinting; Gsa; pseudohypoparathyroidism; parathyroid hormone;
hormonal resistance
ID PSEUDOHYPOPARATHYROIDISM-TYPE-IB; HORMONE RESISTANCE; EPIGENETIC
CHANGES; CONTROL ELEMENT; ALPHA-SUBUNIT; G-PROTEINS; LOCUS; METHYLATION;
GENE; IDENTIFICATION
AB Approximately 100 genes undergo genomic imprinting. Mutations in fewer than 10 imprinted genetic loci, including GNAS, are associated with complex human diseases that differ phenotypically based on the parent transmitting the mutation. Besides the ubiquitously expressed Gsa, which is of broad biological importance, GNAS gives rise to an antisense transcript and to several Gsa variants that are transcribed from the nonmethylated parental allele. We previously identified two almost identical GNAS microdeletions extending from exon NESP55 to antisense (AS) exon 3 (delNESP55/delAS3-4). When inherited maternally, both deletions are associated with erasure of all maternal GNAS methylation imprints and autosomal-dominant pseudohypoparathyroidism type Ib, a disorder characterized by parathyroid hormone-resistant hypocalcemia and hyperphosphatemia. As for other imprinting disorders, the mechanisms resulting in abnormal GNAS methylation are largely unknown, in part because of a paucity of suitable animal models. We now showed in mice that deletion of the region equivalent to delNESP55/delAS3-4 on the paternal allele (Delta Nesp55(p)) leads to healthy animals without Gnas methylation changes. In contrast, mice carrying the deletion on the maternal allele (Delta Nesp55(m)) showed loss of all maternal Gnas methylation imprints, leading in kidney to increased 1A transcription and decreased Gsa mRNA levels, and to associated hypocalcemia, hyperphosphatemia, and secondary hyperparathyroidism. Besides representing a murine autosomal-dominant pseudohypoparathyroidism type Ib model and one of only few animal models for imprinted human disorders, our findings suggest that the Nesp55 differentially methylated region is an additional principal imprinting control region, which directs Gnas methylation and thereby affects expression of all maternal Gnas-derived transcripts.
C1 [Froehlich, Leopold F.; Chung, Ung-Il; Bastepe, Murat; Jueppner, Harald] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA.
[Froehlich, Leopold F.; Chung, Ung-Il; Bastepe, Murat; Jueppner, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Froehlich, Leopold F.; Mrakovcic, Maria] Univ Vet Med, Inst Pathophysiol, A-1210 Vienna, Austria.
[Froehlich, Leopold F.] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria.
[Steinborn, Ralf] Univ Vet Med, VetOMICS Ctr, A-1210 Vienna, Austria.
[Chung, Ung-Il] Univ Tokyo, Grad Sch Engn, Dept Bioengn, Tokyo 1130033, Japan.
[Chung, Ung-Il] Univ Tokyo, Grad Sch Med, Dept Bioengn, Tokyo 1130033, Japan.
[Jueppner, Harald] Massachusetts Gen Hosp, Dept Pediat, Pediat Nephrol Unit, Boston, MA 02114 USA.
RP Juppner, H (reprint author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA.
EM jueppner@helix.mgh.harvard.edu
FU National Institute of Diabetes and Digestive and Kidney
Diseases/National Institutes of Health [R01DK46718, R01DK073911]
FX We thank Dr. En Li (Massachusetts General Hospital) for J1 ES cells; G.
Bounoutas for help with the electroporation of ES cells; T. Doetschman
for the 129Sv library; K.R. Thomas for the pACN vector; M. Stuerzl for
the pAL41 plasmid; and I.H. Maxwell for the DT-A cassette. This work was
supported by grants from National Institute of Diabetes and Digestive
and Kidney Diseases/National Institutes of Health Grants R01DK46718 (to
H.J.) and R01DK073911 (to M.B.).
NR 34
TC 32
Z9 35
U1 1
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 18
PY 2010
VL 107
IS 20
BP 9275
EP 9280
DI 10.1073/pnas.0910224107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 598GH
UT WOS:000277822600047
PM 20427744
ER
PT J
AU Suwanai, H
Wilcox, MA
Mathis, D
Benoist, C
AF Suwanai, Hirotsugu
Wilcox, Martha Angela
Mathis, Diane
Benoist, Christophe
TI A defective Il15 allele underlies the deficiency in natural killer cell
activity in nonobese diabetic mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE type 1 diabetes; gene mapping; cytotoxicity; genetic variation
ID NOD MICE; IN-VIVO; NK; IL-15; MOUSE; ASSOCIATION; COMPLEX; CLUSTER; BETA
AB The nonobese diabetic (NOD) mouse strain has a genetic deficiency in natural killer (NK) cells. This defect underlies this strain's utility in several experimental settings; in particular, it promotes engraftment of human tissue in NOD hosts during the generation of "humanized" mouse models. We have mapped the major NK-cell defect in the NOD vs. C57BL/6 (B6) strain to an inadequately expressed Il15 allele. Treatment of NOD mice with a reagent that specifically enhances interleukin (IL)-15 bioavailability normalized NK-cell numbers and activity in the absence of nonspecific stimulation. These findings raise the possibility of exploiting reagents that impact the IL-15 receptor pathway to facilitate construction of humanized mouse models on non-NOD genetic backgrounds.
C1 [Suwanai, Hirotsugu; Wilcox, Martha Angela; Mathis, Diane; Benoist, Christophe] Joslin Diabet Ctr, Sect Immunol & Immunogenet, Boston, MA 02215 USA.
[Wilcox, Martha Angela; Mathis, Diane; Benoist, Christophe] Harvard Univ, Dept Pathol, Sch Med, Broad Inst, Boston, MA 02115 USA.
[Wilcox, Martha Angela; Mathis, Diane; Benoist, Christophe] Harvard Stem Cell Inst, Boston, MA 02115 USA.
RP Benoist, C (reprint author), Joslin Diabet Ctr, Sect Immunol & Immunogenet, Boston, MA 02215 USA.
EM cbdm@hms.harvard.edu
FU Alexander and Margaret Stewart Trust; National Institutes of Health [R01
DK59658]; American Diabetes Association
FX We thank Dr. A. Goldrath for advice on IL-15 complexes, K. Hattori and
J. Pagan for assistance with mice, and J. LaVecchio and G. Buruzula for
help with flow cytometry. This work was supported by grants from the
Alexander and Margaret Stewart Trust and from the National Institutes of
Health (R01 DK59658). H.S. was supported by a mentor-based postdoctoral
fellowship from the American Diabetes Association.
NR 23
TC 15
Z9 16
U1 0
U2 0
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 18
PY 2010
VL 107
IS 20
BP 9305
EP 9310
DI 10.1073/pnas.1004492107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 598GH
UT WOS:000277822600052
PM 20439722
ER
PT J
AU Biller, BMK
Colao, A
Petersenn, S
Bonert, VS
Boscaro, M
AF Biller, Beverly M. K.
Colao, Annamaria
Petersenn, Stephan
Bonert, Vivien S.
Boscaro, Marco
TI Prolactinomas, Cushing's disease and acromegaly: debating the role of
medical therapy for secretory pituitary adenomas
SO BMC ENDOCRINE DISORDERS
LA English
DT Review
ID ACTING SOMATOSTATIN ANALOG; CARDIAC-VALVE REGURGITATION; GAMMA-KNIFE
RADIOSURGERY; VALVULAR HEART-DISEASE; LONG-TERM TREATMENT;
HORMONE-RECEPTOR ANTAGONIST; GROWTH-FACTOR-I; OCTREOTIDE-LAR; DOPAMINE
AGONISTS; TUMOR SHRINKAGE
AB Pituitary adenomas are associated with a variety of clinical manifestations resulting from excessive hormone secretion and tumor mass effects, and require a multidisciplinary management approach. This article discusses the treatment modalities for the management of patients with a prolactinoma, Cushing's disease and acromegaly, and summarizes the options for medical therapy in these patients.
First-line treatment of prolactinomas is pharmacotherapy with dopamine agonists; recent reports of cardiac valve abnormalities associated with this class of medication in Parkinson's disease has prompted study in hyperprolactinemic populations. Patients with resistance to dopamine agonists may require other treatment. First-line treatment of Cushing's disease is pituitary surgery by a surgeon with experience in this condition. Current medical options for Cushing's disease block adrenal cortisol production, but do not treat the underlying disease. Pituitary-directed medical therapies are now being explored. In several small studies, the dopamine agonist cabergoline normalized urinary free cortisol in some patients. The multi-receptor targeted somatostatin analogue pasireotide (SOM230) shows promise as a pituitary-directed medical therapy in Cushing's disease; further studies will determine its efficacy and safety. Radiation therapy, with medical adrenal blockade while awaiting the effects of radiation, and bilateral adrenalectomy remain standard treatment options for patients not cured with pituitary surgery. In patients with acromegaly, surgery remains the first-line treatment option when the tumor is likely to be completely resected, or for debulking, especially when the tumor is compressing neurovisual structures. Primary therapy with somatostatin analogues has been used in some patients with large extrasellar tumors not amenable to surgical cure, patients at high surgical risk and patients who decline surgery. Pegvisomant is indicated in patients who have not responded to surgery and other medical therapy, although there are regional differences in when it is prescribed. In conclusion, the treatment of patients with pituitary adenomas requires a multidisciplinary approach. Dopamine agonists are an effective first-line medical therapy in most patients with a prolactinoma, and somatostatin analogues can be used as first-line therapy in selected patients with acromegaly. Current medical therapies for Cushing's disease primarily focus on adrenal blockade of cortisol production, although pasireotide and cabergoline show promise as pituitary-directed medical therapy for Cushing's disease; further long-term evaluation of efficacy and safety is important.
C1 [Biller, Beverly M. K.] Massachusetts Gen Hosp, Neuroendocrine Clin Ctr, Boston, MA 02114 USA.
[Colao, Annamaria] Univ Naples Federico II, Dipartimento Endocrinol & Oncol Mol & Clin, Naples, Italy.
[Petersenn, Stephan] Univ Duisburg Essen, Div Endocrinol, Essen, Germany.
[Bonert, Vivien S.] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90095 USA.
[Boscaro, Marco] Polytech Univ Marche, Inst Internal Med, Div Endocrinol, Ancona, Italy.
RP Biller, BMK (reprint author), Massachusetts Gen Hosp, Neuroendocrine Clin Ctr, Boston, MA 02114 USA.
EM bbiller@partners.org
OI BOSCARO, MARCO/0000-0003-2596-1652
FU Novartis; Ipsen; Italfarmaco; Pfizer; Novartis Pharmaceuticals
Corporation
FX MB declares no competing interests. VB has research studies ongoing with
support from Novartis, and speaker honoraria also from Novartis. BMKB
has received research grants and/or consulting honoraria from Ipsen,
Novartis and Pfizer. AC has received unrestricted grants by Ipsen,
Italfarmaco, Novartis, and Pfizer for research programs in acromegaly,
received lectures fees by Ipsen, Italfarmaco, Novartis, and Pfizer and
has been a member of the Scientific Boards of Novartis and Ipsen. SP has
received consulting fees from Novartis, and lecture honoraria from
Novartis and Ipsen.; The authors thank Keri Wellington, PhD, Mudskipper
Bioscience, for medical editorial assistance with this manuscript.
Financial support for medical editorial assistance was provided by
Novartis Pharmaceuticals Corporation. The content of this review was not
influenced by the pharmaceutical industry, and represents the content of
an independent CME symposium at the 89th Annual Meeting of the Endocrine
Society.
NR 128
TC 28
Z9 28
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6823
J9 BMC ENDOCR DISORD
JI BMC Endocr. Disord.
PD MAY 17
PY 2010
VL 10
AR 10
DI 10.1186/1472-6823-10-10
PG 14
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 851LS
UT WOS:000297272300002
PM 20478050
ER
PT J
AU Rugge, M
de Boni, M
Pennelli, G
de Bona, M
Giacomelli, L
Fassan, M
Basso, D
Plebani, M
Graham, DY
AF Rugge, M.
de Boni, M.
Pennelli, G.
de Bona, M.
Giacomelli, L.
Fassan, M.
Basso, D.
Plebani, M.
Graham, D. Y.
TI Gastritis OLGA-staging and gastric cancer risk: a twelve-year
clinico-pathological follow-up study
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID HELICOBACTER-PYLORI ERADICATION; RANDOMIZED CONTROLLED-TRIAL; ATROPHIC
GASTRITIS; INTESTINAL METAPLASIA; SERUM PEPSINOGEN; CLASSIFICATION;
SYSTEM; PATHOGENESIS; METAANALYSIS; POPULATION
AB P>Background
Intestinal-type gastric cancer (GC) still ranks among the high-incidence, highly lethal malignancies. Atrophic gastritis is the cancerization field in which GC develops. The current histological reporting formats for gastritis do not include any (atrophy-based) ranking of GC risk.
Aim
To test the gastritis OLGA-staging (Operative Link for Gastritis Assessment) in prognosticating neoplastic progression.
Methods
Ninety-three Italian patients were followed up for more than 12 years (range: 144-204 months). Clinical examinations, pepsinogen serology, endoscopy and histology (also assessing Helicobacter pylori status) were performed both at enrolment (T1) and at the end of the follow-up (T2).
Results
All invasive or intra-epithelial gastric neoplasia were consistently associated with high-risk (III/IV) OLGA stages. There was a significant inverse correlation between the mean pepsinogen ratio and the OLGA stage (test for trend; P < 0.001). OLGA-staging at T1 predicted both the OLGA stage (Kaplan-Maier log-rank test, P = 0.001) and the neoplasia at T2 (Kaplan-Maier log-rank test, P = 0.001).
Conclusions
This long-term follow-up study provides the first evidence that gastritis OLGA-staging conveys relevant information on the clinico-pathological outcome of gastritis and therefore for patient management. According to OLGA-staging and H. pylori-status, gastritis patients could be confidently stratified and managed according to their different cancer risks.
C1 [Rugge, M.] Univ Padua, Cattedra Anat Patol, Ist Oncol Veneto IOV IRCCS, I-35121 Padua, Italy.
[Rugge, M.; Pennelli, G.; Fassan, M.] Univ Padua, Dept Diagnost Med Sci & Special Therapies, Pathol Unit, I-35121 Padua, Italy.
[de Boni, M.; de Bona, M.] Feltre Hosp, Dept Gastroenterol, Feltre, Italy.
[Giacomelli, L.] Azienda Osped Padova, Dept Pathol, Padua, Italy.
[Basso, D.; Plebani, M.] Univ Padua, Dept Diagnost Med Sci & Special Therapies, Clin Biochem Unit, I-35121 Padua, Italy.
[Graham, D. Y.] Baylor Coll Med, Vet Adm Hosp, Div Digest Dis, Houston, TX 77030 USA.
RP Rugge, M (reprint author), Univ Padua, Cattedra Anat Patol, Ist Oncol Veneto IOV IRCCS, Via Aristide Gabelli 61, I-35121 Padua, Italy.
EM massimo.rugge@unipd.it
RI Fassan, Matteo/F-5152-2012; Basso, Daniela/J-7855-2016; Rugge,
Massimo/K-7525-2016;
OI Fassan, Matteo/0000-0001-6515-5482; Basso, Daniela/0000-0001-8745-6171;
PENNELLI, GIANMARIA/0000-0003-0210-165X
FU Office of Research and Development Medical Research Service, Department
of Veterans Affairs; Public Health Service [DK56338]; Texas Medical
Center Digestive Diseases Center [R01 CA116845]; 'Arianna' Association
ONLUS (Feltre); AIRC; 'Guido Berlucchi' Foundation; 'Morgagni'
Association for Oncological Research (Padova)
FX Declaration of personal interests: Guarantor of the article: Dr Rugge
had full access to all the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data analysis.
Specific author contributions: Massimo Rugge - Pathological assessment
and clinico-pathological correlations. Michele de Boni - Patient
recruitment, clinical examination and endoscopy assessment. Gianmaria
Pennelli and Matteo Fassan - Pathological assessment. Manuela de Bona -
patient recruitment. Luciano Giacomelli - Biostatistician. Daniela Basso
and Mario Plebani - Serology study. David Y Graham -
Clinico-pathological correlations. All authors have read and approved
the final manuscript draft submitted. The authors would like to thank G.
Bonet, MD, general practitioner of the Vanoi valley residents: without
his enthusiastic, highly professional and dedicated co-operation, the
present study would not have been possible. Special thanks to the Head
of the Department of Pathology at Feltre Hospital, Dr. R. Barbazza, who
kindly provided the histological material for this study. The authors
are indebted to A. Bellumat, MD and F. Valiante, MD (of the
Gastroenterology Department at Feltre Hospital), who were involved in
the endoscopic procedures, to M. Tollardo, MD, who helped in preliminary
data collection, and to Dr. M. Guido, MD, for her critical review of the
manuscript. Dr. Graham is supported in part by the Office of Research
and Development Medical Research Service, Department of Veterans
Affairs, and by a Public Health Service grant (DK56338), which funds the
Texas Medical Center Digestive Diseases Center, and R01 CA116845. The
contents are solely the responsibility of the authors and do not
necessarily represent the official views of the VA or NIH. In the last 2
years, Dr. Graham has received small sums as grants from Meretek and
BioHit for investigator-initiated and completely investigator-controlled
research. Dr. Graham is also a paid consultant for Otsuka
Pharmaceuticals (a manufacturer of the 13C-urea breath test). None of
the other authors have any potential conflicts of interest. Declaration
of funding interests: This research was supported in part by the
'Arianna' Association ONLUS (Feltre); the AIRC grant Veneto Region,
2009; the 'Guido Berlucchi' Foundation and the 'Morgagni' Association
for Oncological Research (Padova). The funding agencies had no role in
the design and conduct of the study.
NR 37
TC 89
Z9 93
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD MAY 15
PY 2010
VL 31
IS 10
BP 1104
EP 1111
DI 10.1111/j.1365-2036.2010.04277.x
PG 8
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 586NL
UT WOS:000276917100006
PM 20180784
ER
PT J
AU Gebregziabher, M
Egede, LE
Lynch, CP
Echols, C
Zhao, YM
AF Gebregziabher, Mulugeta
Egede, Leonard E.
Lynch, Cheryl P.
Echols, Carrae
Zhao, Yumin
TI Effect of Trajectories of Glycemic Control on Mortality in Type 2
Diabetes: A Semiparametric Joint Modeling Approach
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE cohort studies; diabetes mellitus; type 2; hemoglobin A; glycosylated;
mortality; retrospective studies; veterans
ID OF-VETERANS-AFFAIRS; EVENT TIME DATA; CARDIOVASCULAR MORTALITY;
MEDICATION ADHERENCE; HEMOGLOBIN A(1C); GLUCOSE CONTROL; ALL-CAUSE;
ASSOCIATION; DISEASE; POPULATION
AB Data on the effect of trajectories in long-term glycemia and all-cause mortality are lacking. The authors studied the effect of trajectories in long-term glycemic control on all-cause mortality in patients with type 2 diabetes. A cohort of 8,812 veterans with type 2 diabetes was assembled retrospectively using Veterans Affairs registry data. For each veteran in the cohort, a 3-month person-period data set was created from April 1997 to May 2006. The average duration of follow-up was 4.5 years. The overall mortality rate was 15.3%. Using a novel approach for joint modeling of time to death and longitudinal measurements of hemoglobin A1c (HbA1c) level, after adjustment for all significant baseline covariates, baseline HbA1c was found to be significantly associated with mortality (hazard ratio = 2.1, 95% confidence interval: 1.3, 3.6) (i.e., a 1% increase in baseline HbA1c level was associated with an average 2-fold increase in mortality risk). Similarly, the slope of the HbA1c trajectory was marginally significantly associated with mortality (hazard ratio = 7.3, 95% confidence interval: 0.9, 57.1) after adjustment for baseline covariates (i.e., a 1% increase in HbA1c level over 3 months was associated with a 22% increase in mortality risk). The authors conclude that a positive trajectory of long-term hyperglycemia is associated with increased mortality.
C1 [Egede, Leonard E.; Lynch, Cheryl P.; Zhao, Yumin] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta; Egede, Leonard E.; Lynch, Cheryl P.; Echols, Carrae] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
[Egede, Leonard E.; Lynch, Cheryl P.; Zhao, Yumin] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA.
EM egedel@musc.edu
OI Gebregziabher, Mulugeta/0000-0002-4826-481X
FU Center for Disease Prevention and Health Interventions for Diverse
Populations [REA 08-261]; Department of Veterans Affairs Health Services
Research and Development Service
FX This study was supported by grant REA 08-261 from the Center for Disease
Prevention and Health Interventions for Diverse Populations, which is
funded by the Department of Veterans Affairs Health Services Research
and Development Service (Principal Investigator, Leonard E. Egede).
NR 38
TC 8
Z9 8
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAY 15
PY 2010
VL 171
IS 10
BP 1090
EP 1098
DI 10.1093/aje/kwq070
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 597AU
UT WOS:000277728400005
PM 20427326
ER
PT J
AU Spragg, RG
Bernard, GR
Checkley, W
Curtis, JR
Gajic, O
Guyatt, G
Hall, J
Israel, E
Jain, M
Needham, DM
Randolph, AG
Rubenfeld, GD
Schoenfeld, D
Thompson, BT
Ware, LB
Young, D
Harabin, AL
AF Spragg, Roger G.
Bernard, Gordon R.
Checkley, William
Curtis, J. Randall
Gajic, Ognjen
Guyatt, Gordon
Hall, Jesse
Israel, Elliott
Jain, Manu
Needham, Dale M.
Randolph, Adrienne G.
Rubenfeld, Gordon D.
Schoenfeld, David
Thompson, B. Taylor
Ware, Lorraine B.
Young, Duncan
Harabin, Andrea L.
TI Beyond Mortality Future Clinical Research in Acute Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE clinical trials; acute respiratory distress syndrome; pulmonary
diseases; edema; inflammation
ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL;
QUALITY-OF-LIFE; PULMONARY-ARTERY; MECHANICAL VENTILATION; OUTCOMES;
ARDS; SURVIVORS; RISK; INFLAMMATION
AB Mortality in National Heart, Lung and Blood Institute sponsored clinical trials of treatments for acute lung injury (ALI) has decreased dramatically during the past two decades. As a consequence, design of such trials based on a mortality outcome requires ever-increasing numbers of patients. Recognizing that advances in clinical trial design might be applicable to these trials and might allow trials with fewer patients, the National Heart, Lung and Blood Institute convened a workshop of extramural experts from several disciplines. The workshop assessed the current state of clinical research addressing ALI, identified research needs, and recommended: (1) continued performance of trials evaluating treatments of patients with ALI; (2) development of strategies to perform ALI prevention trials; (3) observational studies of patients without ALI undergoing prolonged mechanical ventilation; and (4) development of a standardized format for reporting methods, endpoints, and results of ALI trials.
C1 [Harabin, Andrea L.] NHLBI, Div Lung Dis, NIH, Bethesda, MD 20892 USA.
[Spragg, Roger G.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
[Bernard, Gordon R.; Ware, Lorraine B.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.
[Checkley, William; Needham, Dale M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA.
[Curtis, J. Randall] Univ Washington, Harborview Med Ctr, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98104 USA.
[Gajic, Ognjen] Mayo Clin, Div Pulm & Crit Care, Rochester, MN USA.
[Guyatt, Gordon] McMaster Univ, Dept Epidemiol & Biostat, Hamilton, ON, Canada.
[Guyatt, Gordon] McMaster Univ, Dept Med, Hamilton, ON, Canada.
[Hall, Jesse] Univ Chicago, Med Ctr, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA.
[Israel, Elliott] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Jain, Manu] Northwestern Univ, Div Pulm & Crit Care Med, Chicago, IL 60611 USA.
[Randolph, Adrienne G.] Childrens Hosp Boston, Boston, MA USA.
[Rubenfeld, Gordon D.] Univ Toronto, Dept Med, Toronto, ON, Canada.
[Schoenfeld, David] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Thompson, B. Taylor] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA.
[Young, Duncan] John Radcliffe Hosp, Oxford OX3 9DU, England.
RP Harabin, AL (reprint author), NHLBI, Div Lung Dis, NIH, 6701 Rockledge Dr, Bethesda, MD 20892 USA.
EM Harabin@nih.gov
OI Randolph, Adrienne/0000-0002-3084-3071
FU National Heart, Lung and Blood Institute, National Institutes of Health
FX Supported by National Heart, Lung and Blood Institute, National
Institutes of Health.
NR 53
TC 122
Z9 126
U1 1
U2 8
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAY 15
PY 2010
VL 181
IS 10
BP 1121
EP 1127
DI 10.1164/rccm.201001-0024WS
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 596ME
UT WOS:000277688400016
PM 20224063
ER
PT J
AU Banerjee, I
Maiti, S
Parashurama, N
Yarmush, M
AF Banerjee, Ipsita
Maiti, Spandan
Parashurama, Natesh
Yarmush, Martin
TI An integer programming formulation to identify the sparse network
architecture governing differentiation of embryonic stem cells
SO BIOINFORMATICS
LA English
DT Article
ID TRANSCRIPTIONAL REGULATORY NETWORKS; ENGINEERING GENE NETWORKS;
PANCREATIC DEVELOPMENT; EXPRESSION; PERTURBATIONS; SPECIFICATION;
NEUROGENIN3; CORTEX
AB Motivation: Primary purpose of modeling gene regulatory networks for developmental process is to reveal pathways governing the cellular differentiation to specific phenotypes. Knowledge of differentiation network will enable generation of desired cell fates by careful alteration of the governing network by adequate manipulation of cellular environment.
Results: We have developed a novel integer programming-based approach to reconstruct the underlying regulatory architecture of differentiating embryonic stem cells from discrete temporal gene expression data. The network reconstruction problem is formulated using inherent features of biological networks: (i) that of cascade architecture which enables treatment of the entire complex network as a set of interconnected modules and (ii) that of sparsity of interconnection between the transcription factors. The developed framework is applied to the system of embryonic stem cells differentiating towards pancreatic lineage. Experimentally determined expression pro. le dynamics of relevant transcription factors serve as the input to the network identification algorithm. The developed formulation accurately captures many of the known regulatory modes involved in pancreatic differentiation. The predictive capacity of the model is tested by simulating an in silico potential pathway of subsequent differentiation. The predicted pathway is experimentally verified by concurrent differentiation experiments. Experimental results agree well with model predictions, thereby illustrating the predictive accuracy of the proposed algorithm.
Contact: ipb1@pitt.edu
Supplementary information: Supplementary data are available at Bioinformatics online.
C1 [Banerjee, Ipsita; Parashurama, Natesh; Yarmush, Martin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Hosp Children,Ctr Engn Med, Boston, MA 02114 USA.
[Banerjee, Ipsita] Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA.
[Maiti, Spandan] Michigan Technol Univ, Dept Mech Engn Engn Mech, Houghton, MI 49931 USA.
RP Banerjee, I (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Hosp Children,Ctr Engn Med, 51 Blossom St, Boston, MA 02114 USA.
EM ipb1@pitt.edu
FU NIH [DP2-116520]; University of Pittsburgh
FX This work was partly supported by NIH (DP2-116520) and start-up funds
from University of Pittsburgh to IB.
NR 31
TC 6
Z9 6
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
J9 BIOINFORMATICS
JI Bioinformatics
PD MAY 15
PY 2010
VL 26
IS 10
BP 1332
EP 1339
DI 10.1093/bioinformatics/btq139
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Computer Science, Interdisciplinary Applications; Mathematical &
Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Computer Science; Mathematical & Computational Biology; Mathematics
GA 593IP
UT WOS:000277447500008
PM 20363729
ER
PT J
AU Wynn, JK
Sugar, C
Horan, WP
Kern, R
Green, MF
AF Wynn, Jonathan K.
Sugar, Catherine
Horan, William P.
Kern, Robert
Green, Michael F.
TI Mismatch Negativity, Social Cognition, and Functioning in Schizophrenia
Patients
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Functioning; mismatch negativity; schizophrenia; social cognition
ID EVENT-RELATED POTENTIALS; NEUROCOGNITIVE DEFICITS; PERCEPTION;
REDUCTION; MATRICS; MEMORY; ERP
AB Background: Cognition and social cognition have been found to influence functional outcome in schizophrenia patients. However, little is known about the underlying neural substrates that are associated with social cognition or daily functioning. Prior studies found associations between mismatch negativity (MMN), an event-related potential response indexing early auditory processing, and functioning in schizophrenia patients.
Methods: In this study, we examined MMN, social cognition (social perception and theory of mind), and four domains of functioning (work, independent living, social networks, and family networks) in 33 schizophrenia patients and 42 demographically comparable healthy control subjects.
Results: Schizophrenia patients exhibited reduced MMN activity at frontocentral electrode sites compared with healthy control subjects. Within the schizophrenia sample, greater MMN activity at frontocentral sites correlated with better work and independent living (but not social or family networks) and with better social perception.
Conclusions: These results suggest that MMN activity is more closely tied to some outcome domains (work and independent living) than others. Mismatch negativity has been previously shown to be associated with basic cognition and functional outcome in schizophrenia, but these findings are the first, to our knowledge, to show MMN associations with social cognition. These results are consistent with cascade models of information processing in which deficits in early perceptual processing have a downstream impact on higher order social cognition and community functioning.
C1 [Wynn, Jonathan K.] Univ Calif Los Angeles, Los Angeles & VA Greater Los Angeles Healthcare S, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA.
[Sugar, Catherine] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90073 USA.
[Wynn, Jonathan K.; Horan, William P.; Kern, Robert; Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
RP Wynn, JK (reprint author), Univ Calif Los Angeles, Los Angeles & VA Greater Los Angeles Healthcare S, Dept Psychiat & Biobehav Sci, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jkwynn@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
FU National Institutes of Mental Health [MH-43292]; Veterans Affairs Career
Development Award
FX This work was supported by a National Alliance fir Research on
Schizophrenia and Depression Young Investigator Award to JKW and Grant
MH-43292 from the National Institutes of Mental Health to MFG. JKW was
supported by a Veterans Affairs Career Development Award while preparing
the manuscript for publication.
NR 45
TC 58
Z9 58
U1 2
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 15
PY 2010
VL 67
IS 10
BP 940
EP 947
DI 10.1016/j.biopsych.2009.11.024
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 595RK
UT WOS:000277629900007
PM 20074704
ER
PT J
AU Schonberger, M
Leggett, C
Kim, SW
Hooker, JM
AF Schoenberger, Matthias
Leggett, Carmine
Kim, Sung Won
Hooker, Jacob M.
TI Synthesis of [C-11]SSR149415 and preliminary imaging studies using
positron emission tomography
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Positron emission tomography; Vasopressin; SSR149415; Carbon-11
ID V-1B RECEPTOR ANTAGONIST; STRESS-RELATED DISORDERS; VASOPRESSIN
ANTAGONISTS; ANXIOLYTIC-LIKE; V1B RECEPTOR; SSR149415; RODENT; SYSTEM;
RAT
AB SSR149415 was the first non-peptide vasopressin-(V-1b) receptor antagonist reported. It has been used to probe the role of V-1b receptors in animal models of depression, aggression, and stress-anxiety, and was progressed to clinical trials for the treatment of depression. Due to the interest in V-1b receptors as a therapeutic target and the growing use of SSR149415 in preclinical research, we developed a method to label SSR145419 with carbon-11 and have studied its pharmacokinetics in non-human primates using positron emission tomography. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Schoenberger, Matthias; Kim, Sung Won; Hooker, Jacob M.] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA.
[Schoenberger, Matthias] Johannes Gutenberg Univ Mainz, Dept Nucl Chem, D-55128 Mainz, Germany.
[Leggett, Carmine] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA.
[Hooker, Jacob M.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Hooker, Jacob M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
RP Hooker, JM (reprint author), Brookhaven Natl Lab, Dept Med, Bldg 555, Upton, NY 11973 USA.
EM hooker@nmr.mgh.harvard.edu
OI Hooker, Jacob/0000-0002-9394-7708
FU Brookhaven National Laboratory with the U. S. Department of Energy
[DE-AC02-98CH10886]; Study Foundation of the German People
FX This study was supported by Brookhaven National Laboratory under
contract DE-AC02-98CH10886 with the U. S. Department of Energy,
supported by its Office of Biological and Environmental Research.
Funding for M. S. was provided by the Study Foundation of the German
People. The authors are grateful to Dr. Michael Schueller for cyclotron
operation and the PET radiochemistry, the imaging team at BNL (Youwen
Xu, Colleen Shea, Lisa Muench, David Alexoff, Pauline Carter, Payton
King, and Don Warner) for carrying out primate imaging experiments, and
to Dr. Joanna Fowler for scientific input and guidance. M. S.
acknowledges Prof. Dr. Frank Rosch for advice and support during this
work.
NR 24
TC 14
Z9 14
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 15
PY 2010
VL 20
IS 10
BP 3103
EP 3106
DI 10.1016/j.bmcl.2010.03.108
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 590RY
UT WOS:000277246300018
PM 20400305
ER
PT J
AU Weingart, SN
Toro, J
Spencer, J
Duncombe, D
Gross, A
Bartel, S
Miransky, J
Partridge, A
Shulman, LN
Connor, M
AF Weingart, Saul N.
Toro, Julio
Spencer, Justin
Duncombe, Deborah
Gross, Anne
Bartel, Sylvia
Miransky, Jeremy
Partridge, Ann
Shulman, Lawrence N.
Connor, Maureen
TI Medication Errors Involving Oral Chemotherapy
SO CANCER
LA English
DT Article
DE oral chemotherapy; incident reports; medication errors; adverse drug
events
ID ADVERSE DRUG EVENTS; REPORTING SYSTEM; BREAST-CANCER; INPATIENTS;
ATTITUDES; CHILDREN; THERAPY; WOMEN; US
AB BACKGROUND: Given the expanding use of oral chemotherapies, the authors set out to examine errors in the prescribing, dispensing, administration, and monitoring of these drugs. METHODS: Reports were collected of oral chemotherapy-associated medication errors from a medical literature and Internet search and review of reports to the Medication Errors Reporting Program and MEDMARX The authors solicited incident reports from 14 comprehensive cancer centers, and also collected incident reports, pharmacy interventions, and prompted clinician reports from their own center They classified the type of incident, severity, stage in the medication use process, and type of medication error They examined the yield of the various reporting methods to identify oral chemotherapy-related medication errors RESULTS: The authors identified 99 adverse drug events, 322 near misses, and 87 medical errors with low risk of harm Of the 99 adverse drug events, 20 were serious or life-threatening, 52 were significant, and 25 were minor The most common medication errors involved wrong dose (38 8%), wrong drug (13 6%), wrong number of days supplied (11 0%), and missed dose (10 0%) The majority of errors resulted in a near miss, however, 39 3% of reports involving the wrong number of days supplied resulted in adverse drug events Incidents derived from the literature search and hospital incident reporting system included a larger percentage of adverse drug events (731% and 58 8%, respectively) compared with other sources CONCLUSIONS: Ensuring oral chemotherapy safety requires improvements in the way these drugs are ordered, dispensed, administered, and monitored Cancer 2010;116:2455-64. (C) 2010 American Cancer Society
C1 [Weingart, Saul N.; Spencer, Justin; Duncombe, Deborah; Gross, Anne; Bartel, Sylvia; Partridge, Ann; Shulman, Lawrence N.; Connor, Maureen] Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA.
[Weingart, Saul N.; Partridge, Ann; Shulman, Lawrence N.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Toro, Julio; Gross, Anne] Brigham & Womens Hosp, Dept Nursing, Boston, MA 02115 USA.
[Toro, Julio; Gross, Anne] Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA 02125 USA.
[Miransky, Jeremy] Mem Sloan Kettering Canc Ctr, Dept Qual Assessment, New York, NY 10021 USA.
RP Weingart, SN (reprint author), Dana Farber Canc Inst, Ctr Patient Safety, 44 Binney St, Boston, MA 02115 USA.
FU US Agency for Healthcare Research and Quality [P20 HS17123-01]
FX This study was funded by the US Agency for Healthcare Research and
Quality, grant P20 HS17123-01
NR 27
TC 25
Z9 25
U1 0
U2 10
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2010
VL 116
IS 10
BP 2455
EP 2464
DI 10.1002/cncr.25027
PG 10
WC Oncology
SC Oncology
GA 588ZC
UT WOS:000277112300023
PM 20225328
ER
PT J
AU Passer, BJ
Cheema, T
Zhou, BS
Wakimoto, H
Zaupa, C
Razmjoo, M
Sarte, J
Wu, SL
Wu, CL
Noah, JW
Li, QJ
Buolamwini, JK
Yen, Y
Rabkin, SD
Martuza, RL
AF Passer, Brent J.
Cheema, Tooba
Zhou, Bingsen
Wakimoto, Hiroaki
Zaupa, Cecile
Razmjoo, Mani
Sarte, Jason
Wu, Shulin
Wu, Chin-Lee
Noah, James W.
Li, Qianjun
Buolamwini, John K.
Yen, Yun
Rabkin, Samuel D.
Martuza, Robert L.
TI Identification of the ENT1 Antagonists Dipyridamole and Dilazep as
Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication
SO CANCER RESEARCH
LA English
DT Article
ID RIBONUCLEOTIDE REDUCTASE; MITOMYCIN; VECTORS; GLIOMA; CELLS
AB Oncolytic herpes simplex virus-1 (oHSV) vectors selectively replicate in tumor cells, where they kill through oncolysis while sparing normal cells. One of the drawbacks of oHSV vectors is their limited replication and spread to neighboring cancer cells. Here, we report the outcome of a high-throughput chemical library screen to identify small-molecule compounds that augment the replication of oHSV G47 Delta. Of the 2,640-screened bioactives, 6 compounds were identified and subsequently validated for enhanced G47 Delta replication. Two of these compounds, dipyridamole and dilazep, interfered with nucleotide metabolism by potently and directly inhibiting the equilibrative nucleoside transporter-1 (ENT1). Replicative amplification promoted by dipyridamole and dilazep were dependent on HSV mutations in ICP6, the large subunit of ribonucleotide reductase. Our results indicate that ENT1 antagonists augment oHSV replication in tumor cells by increasing cellular ribonucleoside activity. Cancer Res; 70(10); 3890-5. (C) 2010 AACR.
C1 [Passer, Brent J.] Massachusetts Gen Hosp, Dept Neurosurg, Brain Tumor Res Ctr, Boston, MA 02114 USA.
[Wu, Shulin; Wu, Chin-Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Zhou, Bingsen; Yen, Yun] City Hope Natl Med Ctr, Dept Clin & Mol Pharmacol, Duarte, CA 91010 USA.
[Noah, James W.; Li, Qianjun] So Res Inst, Birmingham, AL 35255 USA.
[Buolamwini, John K.] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN USA.
RP Passer, BJ (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Brain Tumor Res Ctr, Simches Res Bldg,CRPZN 3800,185 Cambridge St, Boston, MA 02114 USA.
EM bpasser@partners.org
RI rabkin, samuel/C-2443-2012
OI rabkin, samuel/0000-0003-2344-2795
FU [R01 CA10139]; [NS032677]; [R03 MH083258]; [P30 NS045776]
FX Grant Support; Grants R01 CA10139 and NS032677 (R. L. Martuza), R03
MH083258 (B.J. Passer), and P30 NS045776 (S. D. Rabkin) for the
real-time PCR core.
NR 20
TC 17
Z9 18
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2010
VL 70
IS 10
BP 3890
EP 3895
DI 10.1158/0008-5472.CAN-10-0155
PG 6
WC Oncology
SC Oncology
GA 607GE
UT WOS:000278486300006
PM 20424118
ER
PT J
AU Davies, JK
Singh, H
Huls, H
Yuk, D
Lee, DA
Kebriaei, P
Champlin, RE
Nadler, LM
Guinan, EC
Cooper, LJN
AF Davies, Jeff K.
Singh, Harjeet
Huls, Helen
Yuk, Dongin
Lee, Dean A.
Kebriaei, Partow
Champlin, Richard E.
Nadler, Lee M.
Guinan, Eva C.
Cooper, Laurence J. N.
TI Combining CD19 Redirection and Alloanergization to Generate
Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell
Malignancies
SO CANCER RESEARCH
LA English
DT Article
ID BONE-MARROW-TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-VIVO
PERSISTENCE; ADOPTIVE IMMUNOTHERAPY; CYTOMEGALOVIRUS-INFECTION; IMMUNE
RECONSTITUTION; ANTITUMOR-ACTIVITY; CENTRAL MEMORY; LYMPHOCYTES;
RECEPTOR
AB Allogeneic hematopoietic stem-cell transplantation can cure some patients with high-risk B-cell malignancies, but disease relapse following transplantation remains a significant problem. One approach that could be used to augment the donor T-cell-mediated antitumor effect is the infusion of allogeneic donor-derived T cells expressing a chimeric antibody receptor (CAR) specific to the B-cell antigen CD19. However, the use of such cells might result in toxicity in the form of graft-versus-host disease mediated by CD19-specific (CD19-CAR) T cells possessing alloreactive endogenous T-cell receptors. We therefore investigated whether nonalloreactive tumor-specific human T cells could be generated from peripheral blood mononuclear cells of healthy donors by the combination of CD19 redirection via CAR expression and subsequent alloanergization by allostimulation and concomitant blockade of CD28-mediated costimulation. Alloanergization of CD19-CAR T cells resulted in efficient and selective reduction of alloresponses in both CD4(+) and CD8(+) T cells, including allospecific proliferation and cytokine secretion. Importantly, T-cell effector functions including CAR-dependent proliferation and specific target cytolysis and cytokine production were retained after alloanergization. Our data support the application of CD19 redirection and subsequent alloanergization to generate allogeneic donor T cells for clinical use possessing increased antitumor activity but limited capacity to mediate graft-versus-host disease. Immunotherapy with such cells could potentially reduce disease relapse after allogeneic transplantation without increasing toxicity, thereby improving the outcome of patients undergoing allogeneic transplantation for high-risk B-cell malignancies. Cancer Res; 70(10); 3915-24. (C) 2010 AACR.
C1 [Cooper, Laurence J. N.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Unit 907, Houston, TX 77030 USA.
[Davies, Jeff K.; Yuk, Dongin; Nadler, Lee M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Guinan, Eva C.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Guinan, Eva C.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Lee, Dean A.; Cooper, Laurence J. N.] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA.
RP Cooper, LJN (reprint author), Univ Texas MD Anderson Canc Ctr, Div Pediat, Unit 907, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM ljncooper@mdanderson.org
OI Lee, Dean/0000-0001-6693-5392
FU DOD [PR064229]; Alex Lemonade Stand Foundation; Alliance for Cancer Gene
Therapy; Burroughs Wellcome Fund; Department of Veterans Affairs;
Gillson Longenbaugh Foundation; Leukemia and Lymphoma Society; Lymphoma
Research Foundation; Miller Foundation; National Foundation for Cancer
Research; Pediatric Cancer Research Foundation; National Marrow Donor
Program; William Lawrence and Blanche Hughes Foundation; [CA100265];
[CA16672]; [CA124782]; [CA120956]; [CA129390]; [CA116127];
[CA137645]
FX Grant Support; PO1 (CA100265), CCSG (CA16672), RO1s (CA124782,
CA120956), R21s (CA129390, CA116127, CA137645), DOD (PR064229), Alex
Lemonade Stand Foundation, Alliance for Cancer Gene Therapy, Burroughs
Wellcome Fund, Department of Veterans Affairs, Gillson Longenbaugh
Foundation, Leukemia and Lymphoma Society, Lymphoma Research Foundation,
Miller Foundation, National Foundation for Cancer Research, Pediatric
Cancer Research Foundation, National Marrow Donor Program, and William
Lawrence and Blanche Hughes Foundation.
NR 48
TC 24
Z9 26
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2010
VL 70
IS 10
BP 3915
EP 3924
DI 10.1158/0008-5472.CAN-09-3845
PG 10
WC Oncology
SC Oncology
GA 607GE
UT WOS:000278486300009
PM 20424114
ER
PT J
AU Hernandez, L
Hsu, SC
Davidson, B
Birrer, MJ
Kohn, EC
Annunziata, CM
AF Hernandez, Lidia
Hsu, Sarah C.
Davidson, Ben
Birrer, Michael J.
Kohn, Elise C.
Annunziata, Christina M.
TI Activation of NF-KB Signaling by Inhibitor of NF-KB Kinase beta
Increases Aggressiveness of Ovarian Cancer
SO CANCER RESEARCH
LA English
DT Article
ID KAPPA-B; IKK-BETA; CARCINOMA; GROWTH; MANAGEMENT; ONCOGENE; INVASION;
SYSTEM
AB The NF-kappa B family of transcription factors has been implicated in the propagation of ovarian cancer, but the significance of constitutive NF-kappa B signaling in ovarian cancer is unknown. We hypothesized that constitutive NF-kappa B signaling defines a subset of ovarian cancer susceptible to therapeutic targeting of this pathway. We investigated the biological relevance of NF-kappa B in ovarian cancer using a small-molecule inhibitor of inhibitor of NF-kappa B kinase beta (IKK beta) and confirmed with RNA interference toward IKK beta. We developed a gene expression signature of IKK beta signaling in ovarian cancer using both pharmacologic and genetic manipulation of IKK beta. The expression of IKK beta protein itself and the nine-gene ovarian cancer-specific IKK beta signature were related to poor outcome in independently collected sets of primary ovarian cancers (P = 0.02). IKK beta signaling in ovarian cancer regulated the transcription of genes involved in a wide range of cellular effects known to increase the aggressive nature of the cells. We functionally validated the effect of IKK beta signaling on proliferation, invasion, and adhesion. Downregulating IKK beta activity, either by a small-molecule kinase inhibitor or by short hairpin RNA depletion of IKK beta, blocked all of these cellular functions, reflecting the negative regulation of the target genes identified. The diversity of functions controlled by IKK beta in ovarian cancer suggests that therapeutic blockade of this pathway could be efficacious if specific IKK beta inhibitor therapy is focused to patients whose tumors express a molecular profile suggestive of dependence on IKK beta activity. Cancer Res; 70(10); 4005-14. (C) 2010 AACR.
C1 [Hernandez, Lidia; Hsu, Sarah C.; Kohn, Elise C.; Annunziata, Christina M.] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Davidson, Ben] Univ Oslo, Fac Med, Oslo Univ Hosp, Fac Div,Radiumhosp,Norwegian Radium Hosp,Div Path, Oslo, Norway.
[Birrer, Michael J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Annunziata, CM (reprint author), NCI, Med Oncol Branch, Ctr Canc Res, 10 Ctr Dr,Room 12N226, Bethesda, MD 20892 USA.
EM annunzic@mail.nih.gov
RI Annunziata, Christina/L-3219-2016
OI Annunziata, Christina/0000-0003-2033-6532
FU Center for Cancer Research, NCI; Marsha Rivkin Foundation for Ovarian
Cancer Research; Norwegian Cancer Society and Health Region of
South-Eastern Norway
FX Grant Support; Intramural Program of the Center for Cancer Research, NCI
(C. M. Annunziata and E. C. Kohn); Marsha Rivkin Foundation for Ovarian
Cancer Research (C. M. Annunziata); and Norwegian Cancer Society and
Health Region of South-Eastern Norway (B. Davidson).
NR 26
TC 60
Z9 62
U1 2
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2010
VL 70
IS 10
BP 4005
EP 4014
DI 10.1158/0008-5472.CAN-09-3912
PG 10
WC Oncology
SC Oncology
GA 607GE
UT WOS:000278486300018
PM 20424119
ER
PT J
AU Torres-Arzayus, MI
Zhao, J
Bronson, R
Brown, M
AF Torres-Arzayus, Maria I.
Zhao, Jin
Bronson, Roderick
Brown, Myles
TI Estrogen-Dependent and Estrogen-Independent Mechanisms Contribute to
AIB1-Mediated Tumor Formation
SO CANCER RESEARCH
LA English
DT Article
ID MAMMARY-GLAND DEVELOPMENT; RECEPTOR-ALPHA; OVARIECTOMIZED RATS;
COACTIVATOR; MICE; AIB1; 17-BETA-ESTRADIOL; AROMATASE; ONCOGENE;
IMPLANTS
AB We have previously reported the oncogenic properties of the gene amplified in breast cancer 1 (AIB1), a member of the p160 family of hormone receptor coactivators. In a transgenic mouse model, AIB1 overexpression resulted in a high incidence of tumors in various tissues, including mammary gland, uterus, lung, and pituitary. To determine whether the AIB1 oncogenicity in this model depended on its function as an estrogen receptor ( ER) coactivator, we abolished ER signaling through two independent approaches, by performing ovariectomy on AIB1 transgenic (AIB1-tg) mice to prevent gonadal estrogen production and by crossing AIB1-tg mice with ER alpha-null mutant mice. Ovariectomized (ovx) mice, but not AIB1 x ER alpha-/- mice, still developed mammary gland hyperplasia and ductal carcinoma in situ. Both approaches, however, completely prevented the development of invasive mammary tumors, indicating that invasive mammary tumor formation is strictly estrogen dependent. Once developed, AIB1-induced mammary tumors can subsequently lose their dependence on estrogen: Injection of ER alpha(+)tumor cell lines derived from such tumors into ovx or untreated wild-type mice resulted in a similar rate of tumor growth in both groups. Surprisingly, however, ovx mice had an similar to 4-fold higher rate of metastasis formation, suggesting that estrogen provided some protection from metastasis formation. Lastly, our experiments identified oncogenic functions of AIB1 that are independent of its ER coactivation, as both approaches, ovariectomy and ER-/- crosses, still resulted in a high incidence of tumors in the lung and pituitary. We therefore conclude that AIB1 can exert its oncogenicity through tissue-specific estrogen-dependent and estrogen-independent functions. Cancer Res; 70(10); 4102-11. (C) 2010 AACR.
C1 [Torres-Arzayus, Maria I.; Zhao, Jin; Brown, Myles] Dana Farber Canc Inst, Div Mol & Cellular Oncol, Dept Med Oncol, Boston, MA 02115 USA.
[Bronson, Roderick] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Brown, M (reprint author), Dana Farber Canc Inst, Div Mol & Cellular Oncol, Dept Med Oncol, 44 Binney St,D730, Boston, MA 02115 USA.
EM myles_brown@dfci.harvard.edu
OI Brown, Myles/0000-0002-8213-1658
FU NIH [P01 CA8011105, P50C89393]; DF/HCC Breast Cancer Spore; National
Institute of Mental Health, the National Institute of Allergy and
Infectious Diseases, the National Institute of Child Health and Human
Development, and the National Institutes of Health Office of the
Director [K12 HD051959]
FX NIH grants P01 CA8011105 and P50C89393 and the DF/HCC Breast Cancer
Spore grant. M.I. Torres-Arzayus received research funding from the
Building Interdisciplinary Research in Women's Health (K12 HD051959,
supported by the National Institute of Mental Health, the National
Institute of Allergy and Infectious Diseases, the National Institute of
Child Health and Human Development, and the National Institutes of
Health Office of the Director).
NR 33
TC 26
Z9 28
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2010
VL 70
IS 10
BP 4102
EP 4111
DI 10.1158/0008-5472.CAN-09-4080
PG 10
WC Oncology
SC Oncology
GA 607GE
UT WOS:000278486300028
PM 20442283
ER
PT J
AU Mostoslavsky, R
Esteller, M
Vaquero, A
AF Mostoslavsky, Raul
Esteller, Manel
Vaquero, Alejandro
TI At the crossroad of lifespan, calorie restriction, chromatin and disease
Meeting on sirtuins
SO CELL CYCLE
LA English
DT Article
DE sirtuins; NAD(+) deacetylases; chromatin; metabolism; cancer; aging
ID SMALL-MOLECULE INHIBITOR; REMODELING COMPLEX NORC; DNA
METHYLTRANSFERASE-1; GENOMIC STABILITY; HUMAN CANCER; HUMAN SIRT1;
IN-VIVO; HISTONE; ACETYLATION; RNA
AB Longevity, lifespan, cancer, cellular transformation, energy, calorie restriction, diabetes. what can tie together such a diversity of hot topics in biomedical research? Emerging findings suggest that the answer lies in understanding the functions of the recently discovered family of proteins known as Sirtuins. Barcelona hosted the first scientific meeting completely focused on these evolutionary conserved protein deacetylases, bringing together experts in the biochemistry to cellular biology, mice models, drug targeting and pathophysiology of these molecules. Their work, summarized here, establishes the Sirtuins as major players in cellular homeostasis and human diseases that act through a whole range of biochemical substrates and physiological processes. Undoubtedly, this is an increasingly expanding field that it is here to stay and growth.
C1 [Mostoslavsky, Raul] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02115 USA.
[Esteller, Manel] Canc Epigenet Grp, Barcelona, Catalonia, Spain.
[Esteller, Manel; Vaquero, Alejandro] ICREA, Barcelona, Catalonia, Spain.
[Vaquero, Alejandro] Bellvitge Biomed Res Inst IDIBELL, Chromatin Biol Grp, PEBC, Barcelona, Catalonia, Spain.
RP Mostoslavsky, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02115 USA.
EM rmostoslavsky@mgh.harvard.edu; mes-teller@iconcologia.net;
avaquero@idibell.cat
RI Vaquero, Alejandro/I-9845-2014; Esteller, Manel/L-5956-2014
OI Vaquero, Alejandro/0000-0002-8735-4156; Esteller,
Manel/0000-0003-4490-6093
FU Sidney Kimmel Research Foundation; V Foundation; AFAR; Massachusetts
Life Sciences Center; NIH; European Union [HEALTH-F2-2007-200620,
LSHG-CT-2006-037415]; Health Department of the Catalan Government
(Generalitat); Spanish Ministry of Science and Innovation (MICINN);
ICREA; Institut Catala d'Oncologia (ICO); Generalitat de Catalunya;
Fundacion Sandra Ibarra; [FIS PI08 1345]; [Consolider MEC09-05]
FX We apologize to the colleagues whose work could not be cited in this
review due to space limitations. We thank Nabeel Bardeesy for critically
reading the manuscript. R. M. work is supported by the Sidney Kimmel
Research Foundation, the V Foundation, AFAR, The Massachusetts Life
Sciences Center and NIH. M. E. work is supported by the European Union
Grants FP7 CANCERDIP (HEALTH-F2-2007-200620) and SMARTER
(LSHG-CT-2006-037415), the FIS PI08 1345 and Consolider MEC09-05 Spanish
Grants and the Health Department of the Catalan Government
(Generalitat). M. E. is an Institucio Catalana de Recerca i Estudis
Avancats (ICREA) Research Professor. A. V. work is supported by the
Spanish Ministry of Science and Innovation (MICINN), ICREA, the Institut
Catala d'Oncologia (ICO), The Generalitat de Catalunya and the Fundacion
Sandra Ibarra.
NR 38
TC 13
Z9 13
U1 0
U2 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAY 15
PY 2010
VL 9
IS 10
BP 1907
EP 1912
PG 6
WC Cell Biology
SC Cell Biology
GA 600VB
UT WOS:000278015900017
PM 20458180
ER
PT J
AU Xu, L
Czito, BG
Willett, CG
AF Xu, Lei
Czito, Brian G.
Willett, Christopher G.
TI Epigenetic Markers in Rectal Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID DNA METHYLATION; IRRADIATED PATIENTS; RADIOTHERAPY; CARCINOMA
AB DNA methylation changes in rectal cancer may serve as a new screening marker and a tool for monitoring recurrence. Importantly, these changes may also function as a predictive marker to allow appropriate exclusion of (neo)adjuvant therapies in patients at low risk for disease recurrence, sparing them from potential treatment-related morbidities. Clin Cancer Res; 16(10); 2699-701. (C) 2010 AACR.
C1 [Czito, Brian G.; Willett, Christopher G.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.
[Xu, Lei] Massachusetts Gen Hosp, Steele Lab, Boston, MA 02114 USA.
RP Willett, CG (reprint author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.
EM christopher.willett@duke.edu
NR 12
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2010
VL 16
IS 10
BP 2699
EP 2701
DI 10.1158/1078-0432.CCR-10-0559
PG 3
WC Oncology
SC Oncology
GA 608PH
UT WOS:000278597600001
PM 20460492
ER
PT J
AU Zhang, WD
Choi, J
Zeng, WY
Rogers, SA
Alyea, EP
Rheinwald, JG
Canning, CM
Brusic, V
Sasada, T
Reinherz, EL
Ritz, J
Soiffer, RJ
Wu, CJ
AF Zhang, Wandi
Choi, Jaewon
Zeng, Wanyong
Rogers, Shelby A.
Alyea, Edwin P.
Rheinwald, James G.
Canning, Christine M.
Brusic, Vladimir
Sasada, Tetsuro
Reinherz, Ellis L.
Ritz, Jerome
Soiffer, Robert J.
Wu, Catherine J.
TI Graft-versus-Leukemia Antigen CML66 Elicits Coordinated B-Cell and
T-Cell Immunity after Donor Lymphocyte Infusion
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW-TRANSPLANTATION;
MULTIPLE-MYELOMA; DENDRITIC CELLS; TUMOR-IMMUNITY; MEMORY; RESPONSES;
IMMUNOTHERAPY; PEPTIDE; CANCER
AB Purpose: The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized.
Experimental Design: We examined responses developing against CML66, an immunogenic antigen preferentially expressed in myeloid progenitor cells identified from a patient with chronic myelogenous leukemia who attained long-lived remission following CD4+ donor lymphocyte infusion (DLI).
Results: From this patient, CML66-reactive CD8+ T-cell clones were detected against an endogenously presented HLA-B*4403-restricted epitope (HDVDALLW). Neither CML66-specific antibody nor T-cell responses were detectable in peripheral blood before DLI. However, by 1 month after DLI, CD8+ T cells were present in peripheral blood and at 10-fold higher frequency in marrow. Subsequently, plasma antibody to CML66 developed in association with disease remission. Donor-derived CML66-reactive T cells were detected at low levels in vivo in marrow before DLI by ELISpot and by a nested PCR-based assay to detect clonotypic T-cell receptor sequences but not in blood of the patient pre-DLI nor of the graft donor.
Conclusions: CD4+ DLI results in rapid expansion of preexisting marrow-resident leukemia-specific donor CD8+ T cells, followed by a cascade of antigen-specific immune responses detectable in blood. Our single-antigen analysis thus shows that durable posttransplant tumor immunity is directed in part against nonpolymorphic overexpressed leukemia antigens that elicit coordinated cellular and humoral immunity. Clin Cancer Res; 16(10); 2729-39. (C) 2010 AACR.
C1 [Wu, Catherine J.] Harvard Inst Med, Dana Farber Canc Inst, Cancer Vaccine Ctr, Boston, MA 02115 USA.
[Rogers, Shelby A.; Alyea, Edwin P.; Canning, Christine M.; Sasada, Tetsuro; Reinherz, Ellis L.; Ritz, Jerome; Soiffer, Robert J.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Rheinwald, James G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Harvard Skin Dis Res Ctr, Boston, MA USA.
[Alyea, Edwin P.; Sasada, Tetsuro; Reinherz, Ellis L.; Ritz, Jerome; Soiffer, Robert J.; Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Wu, CJ (reprint author), Harvard Inst Med, Dana Farber Canc Inst, Cancer Vaccine Ctr, Room 416B,77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM cwu@partners.org
FU Dana-Farber Cancer Institute Pasquarello Tissue Bank; Dana-Farber Cancer
Institute (Boston); NIAMS [P30 AR42689]; Department of Defense
[W81XWH-07-1-0080]; NCI [5R21CA115043-2]; Howard Hughes Medical
Institute; Damon-Runyon Cancer Research Foundation [CI-38-07]
FX We thank the Dana-Farber Cancer Institute Pasquarello Tissue Bank and
the clinical transplant teams at Dana-Farber Cancer Institute (Boston)
for their generous support; Linyun Chen, Sean McDonough, and Patricia
Barron for excellent technical help; and Zach Herbert, Alicja
Piechoka-Trocha, and Dr. Christian Brander for invaluable advice and
assistance.; J.G. Rheinwald and Cell Culture Core of Harvard Skin
Disease Research Center were supported by NIAMS grant P30 AR42689. C.J.
Wu was supported by Department of Defense grant W81XWH-07-1-0080, Miles
and Eleanor Shore Award, NCI grant 5R21CA115043-2, and Early Career
Physician-Scientist Award of the Howard Hughes Medical Institute and is
a Damon-Runyon Clinical Investigator supported in part by Damon-Runyon
Cancer Research Foundation grant CI-38-07.
NR 44
TC 17
Z9 18
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2010
VL 16
IS 10
BP 2729
EP 2739
DI 10.1158/1078-0432.CCR-10-0415
PG 11
WC Oncology
SC Oncology
GA 608PH
UT WOS:000278597600005
PM 20460482
ER
PT J
AU Chi, RC
Rock, MT
Neuzil, KM
AF Chi, Ru-Chien
Rock, Michael T.
Neuzil, Kathleen M.
TI Immunogenicity and Safety of Intradermal Influenza Vaccination in
Healthy Older Adults
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID CELLULAR IMMUNE-RESPONSES; RANDOMIZED CONTROLLED-TRIAL;
ANTIBODY-RESPONSES; ELDERLY-PEOPLE; MORTALITY BENEFITS; SEASONAL
INFLUENZA; T-CELLS; EFFICACY; IMMUNIZATION; PROTECTION
AB Background. Influenza vaccine immunogenicity is suboptimal in older persons. Intradermal (ID) vaccination may be a promising alternative to intramuscular (IM) vaccination.
Methods. This randomized trial compared the immunogenicity of 60% dose ID influenza vaccination to standard IM vaccination of full-dose or 60% dose vaccine. Pre- and postvaccination measurements in the hemagglutination inhibition antibody titer were compared. Participants who received reduced-dose vaccine were revaccinated with full-dose IM vaccine.
Results. 257 healthy adults aged >= 65 years received 1 of the following trivalent inactivated influenza vaccines: standard-dose (15 mu g each of 3 hemagglutinin vaccine antigens in 0.5 mL) IM injection, reduced-dose (9 mu g, 0.3 mL) IM injection, reduced-dose ( 9 mu g, 0.3 mL) ID injection, or 2 reduced-dose (4.5 mu g, 0.15 mL) ID injections. Respective seroprotection rates were 65.6%, 57.8%, 68.9%, and 67.2% against A/H1N1; 76.6%, 75.0%, 75.4%, and 75.0% against A/H3N2; and 26.6%, 17.2%, 16.4%, and 25.0% against influenza B. Subsequent full-dose IM vaccination of participants randomized to reduced-dose vaccine by either IM or ID routes did not improve seroprotection rates. Local reactions of redness, swelling, and itching were significantly more frequent among recipients of ID injections.
Conclusion. Influenza vaccine at 60% dose by either IM or ID route elicited antibody responses generally similar to full-dose IM vaccination among healthy elderly persons (ClinicalTrials. gov identifier: NCT00504231).
C1 [Chi, Ru-Chien] Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Neuzil, Kathleen M.] Univ Washington, Dept Global Hlth, Seattle, WA 98108 USA.
[Chi, Ru-Chien] Univ Washington, Dept Med, Seattle, WA 98108 USA.
[Neuzil, Kathleen M.] PATH, Seattle, WA USA.
[Rock, Michael T.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
RP Chi, RC (reprint author), Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-182, Seattle, WA 98108 USA.
EM rchi@u.washington.edu
FU Research and Development Medical Research Service, Department of
Veterans Affairs; World Health Organization; Fondation Merieux entitled
"Intradermal Immunization: An Alternative Route for Vaccine
Administration" in Annecy, France
FX This material is based on work supported by the Research and Development
Medical Research Service, Department of Veterans Affairs. The views in
this article do not necessarily represent the views of the Department of
Veterans Affairs.; Presented in part: a conference sponsored by the
World Health Organization and Fondation Merieux entitled "Intradermal
Immunization: An Alternative Route for Vaccine Administration" in
Annecy, France, 8 April 2008, and 2 American Geriatrics Society annual
meetings, 2 May 2008 and 30 April 2009.
NR 43
TC 24
Z9 24
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2010
VL 50
IS 10
BP 1331
EP 1338
DI 10.1086/652144
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 584PO
UT WOS:000276764900001
PM 20377407
ER
PT J
AU Bassett, IV
Walensky, RP
AF Bassett, Ingrid V.
Walensky, Rochelle P.
TI Integrating HIV Screening into Routine Health Care in Resource-Limited
Settings
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID TO-CHILD TRANSMISSION; TESTING OPT-OUT; SOUTH-AFRICA; ANTIRETROVIRAL
THERAPY; MISSED OPPORTUNITIES; SEXUAL-BEHAVIOR; DEVELOPING-COUNTRIES;
DISCORDANT COUPLES; RANDOMIZED-TRIAL; ANTENATAL CARE
AB United Nations is committed to achieving universal access to human immunodeficiency virus (HIV) care, treatment, and prevention. Although the gateway to HIV care and secondary prevention is knowledge of serostatus, use of voluntary counseling and testing in resource-limited settings with the highest burden of HIV infection and AIDS has been limited. On the basis of evidence of increased patient uptake and the opportunity to avoid missed HIV testing opportunities in health care facilities, in 2007, the World Health Organization recommended provider-initiated HIV testing as a standard part of medical care in settings with generalized HIV epidemics. Although provider-initiated testing has shown promise, optimal implementation strategies that ensure broad coverage, while preserving human rights, remain an active area of research. We review the benefits of knowledge of HIV serostatus and evidence from multiple countries surrounding the successes and pitfalls of provider-initiated testing in health care and home-based settings.
C1 [Bassett, Ingrid V.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Bassett, Ingrid V.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Walensky, Rochelle P.] Harvard Ctr AIDS Res, Boston, MA USA.
RP Bassett, IV (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 50 Staniford St,9th Fl, Boston, MA 02114 USA.
EM ibassett@partners.org
OI Walensky, Rochelle P./0000-0002-8795-379X
FU National Institute of Allergy and Infectious Disease [K23AI068458];
National Institute of Mental Health [R01 MH073445, R01 MH65869]; Doris
Duke Charitable Foundation; Center for Global Health Policy; Infectious
Diseases Society of America; HIV Medicine Association, through the Bill
& Melinda Gates Foundation
FX Financial support. National Institute of Allergy and Infectious Disease
(K23AI068458 to I. V. B.), National Institute of Mental Health (R01
MH073445 to R. P. W. and R01 MH65869 to R. P. W.), and the Doris Duke
Charitable Foundation, Clinical Scientist Development Award (to R. P.
W.).; Supplement sponsorship. This article is part of a supplement
entitled "Synergistic Pandemics: Confronting the Global HIV and
Tuberculosis Epidemics," which was sponsored by the Center for Global
Health Policy, a project of the Infectious Diseases Society of America
and the HIV Medicine Association, through a grant from the Bill &
Melinda Gates Foundation.
NR 81
TC 36
Z9 36
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2010
VL 50
SU 3
BP S77
EP S84
DI 10.1086/651477
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 584PV
UT WOS:000276765600003
PM 20397960
ER
EF